(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 1 August 2002 (01.08.2002)

PCT

(10) International Publication Number WO 02/059377 A2

(51) International Patent Classification7:

_ _ _

(21) International Application Number: PCT/US02/02242

(22) International Filing Date: 24 January 2002 (24.01.2002)

(25) Filing Language:

English

C12Q 1/68

(26) Publication Language:

English

(30) Priority Data:

60/263,965	24 January 2001 (24.01.2001)	US
60/265,928	2 February 2001 (02.02.2001)	US
09/829,472	9 April 2001 (09.04.2001)	US
60/282,698	9 April 2001 (09.04.2001)	US
60/288,590	4 May 2001 (04.05.2001)	US
60/294,443	29 May 2001 (29.05.2001)	US

- (71) Applicant: EOS BIOTECHNOLOGY, INC. [US/US]; 225Λ Gateway Boulevard, South San Francisco, CA 94080-7019 (US).
- (72) Inventors: MACK, David, H.; 2076 Monterey Avenue, Menlo Park, CA 94025 (US). GISH, Kurt, C.; 40 Perego Terrace #2, San Francisco, CA 94131 (US). AFAR, Daniel; 435 Visitacion Avenue, Brisbane, CA 94005 (US).

- (74) Agents: BASTIAN, Kevin, L. et al.; Townsend and Townsend and Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

(57) Abstract: Described herein are genes whose expression are up-regulated or down-regulated in breast cancer. Related methods and compositions that can be used for diagnosis and treatment of breast cancer are disclosed. Also described herein are methods that can be used to identify modulators of breast cancer.

METHODS OF DIAGNOSIS OF BREAST CANCER, COMPOSITIONS AND METHODS OF SCREENING FOR MODULATORS OF BREAST CANCER

5

10

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims priority to USSN 60/263,965, filed January 24, 2001; USSN 60/265,928, filed February 2, 2001; USSN 09/829,472 filed April 9, 2001; USSN 60/282,698, filed April 9, 2001; USSN 60/288,590, filed May 4, 2001; and USSN 60/294,443, filed May 29, 2001, all of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in breast cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis and therapy of breast cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit breast cancer.

20

25

15

BACKGROUND OF THE INVENTION

Breast cancer is one of the most frequently diagnosed cancers and the second leading cause of female cancer death in North America and northern Europe, with lung cancer being the leading cause. Lifetime incidence of the disease in the United States is one-in-eight, with a 1-in-29 lifetime risk of dying from breast cancer. Early detection of breast cancer, using mammography, clinical breast examination, and self breast examination, has dramatically improved the treatment of the disease, although sensitivity is still major concern, as mammographic sensitivity has been estimated at only 60%–90%. Treatment of breast cancer consists largely of surgical lumpectomy or mastectomy, radiation therapy, anti-

hormone therapy, and/or chemotherapy. Although many breast cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life. Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons et al., 2000, Arch. Pathol. Lab. Med. 124:966-978; Hamilton and Piccart, 2000, Ann. Oncol. 11:647-663), including genetic predispostion markers BRCA-1 and BRCA-2 (Robson, 2000, J. Clin. Oncol. 18:113sup-118sup).

5

10

15

20

25

Imaging of breast cancer for diagnosis has been problematic and limited. In addition, dissemination of tumor cells (metastases) to locoregional lymph nodes is an important prognostic factor; five year survival rates drop from 80 percent in patients with no lymph node metastases to 45 to 50 percent in those patients who do have lymph node metastases. A recent report showed that micrometastases can be detected from lymph nodes using reverse transcriptase-PCR methods based on the presence of mRNA for carcinoembryonic antigen, which has previously been shown to be present in the vast majority of breast cancers but not in normal tissues. Liefers et al., New England J. of Med. 339(4):223 (1998).

The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies. Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monclonal antibodies directed to Her2/neu (Herceptin®/trastuzumab) are currently in use for the treatment of metastatic breast cancer (Ross and Fletcher, 1998, Stem Cells 16:413-428). Similarly, anti-CD20 monoclonal antibodies (Rituxin®/rituximab) are used to effectively treat non-Hodgekin's lymphoma (Maloney et al., 1997, Blood 90:2188-2195; Leget and Czuczman, 1998, Curr. Opin. Oncol. 10:548-551).

Other potential immunotherapeutic targets have been identified for breast cancer. One such target is polymorphic epithelial mucin (MUC1). MUC1 is a transmembrane

protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in breast cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target (Gilewski et al., 2000, Clin. Cancer Res. 6:1693-1701; Scholl et al., 2000, J. Immunother. 23:570-580). The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the 5 tumor marker, CA 15-3 (Bon et al., 1997, Clin. Chem. 43:585-593). However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease. Many other genes have been reported to be overexpressed in breast cancer, such as EGFR (Sainsbury et al., 1987, Lancet 1(8547):1398-1402), c-erbB3 (Naidu et al., 1988, Br. J. Cancer 78:1385-1390), FGFR2 10 (Penault-Llorca et al., 1991, Int. J. Cancer 61:170-176), PKW (Preiherr et al., 2000, Anticancer Res. 20:2255-2264), MTA1 (Nawa et al., 2000, J. Cell Biochem. 79:202-212), breast cancer associated gene 1 (Kurt et al., 2000, Breast Cancer Res. Treat. 59:41-48). Although monoclonal antibodies to the protein products of some of these overexpressed genes have been reported (for review, see Green et al., 2000, Cancer Treat. Rev. 26:269-286), 15 none are currently approved for breast cancer therapy in the US.

Disclosures of certain genes and ESTs described as being expressed in breast cancer are found in international patent applications WO-99/33869, WO-97/25426, WO-97/02280 and WO-00/55173, WO-98/45328 and WO-00/22130. Similarly, genes and ESTs described as being expressed in breast cancer are disclosed in US Patent Nos. 5,759,776 and 5,693,522. The utility of such genes is described in each of these publications, and their disclosures are incorporated herein in their entirety.

20

25

30

While industry and academia have identified novel sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of breast cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in breast and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of breast cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate breast cancer.

SUMMARY OF THE INVENTION

The present invention therefore provides nucleotide sequences of genes that are up- and down-regulated in breast cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate breast cancer, such as hormones or antibodies. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

5

10

15

20

25

In one aspect, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the present invention provides a method of determining the level of a breast cancer associated transcript in a cell from a patient.

In one embodiment, the present invention provides a method of detecting a breast cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25.

In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-25.

In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.

In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.

In one embodiment, the polynucleotide is immobilized on a solid surface.

In one embodiment, the patient is undergoing a therapeutic regimen to treat breast cancer. In another embodiment, the patient is suspected of having metastatic breast cancer.

In one embodiment, the patient is a human.

In one embodiment, the breast cancer associated transcript is mRNA.

In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of breast cancer, the method comprising the steps of: (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of a breast cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic breast cancer. In a further embodiment, the patient has a drug resistant form of breast cancer.

In one embodiment, the method further comprises the step of: (iii) comparing the level of the breast cancer-associated transcript to a level of the breast cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.

10

15

20

25

Additionally, provided herein is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-25.

In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-25.

In one embodiment, an expression vector or cell comprises the isolated nucleic acid.

In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-25.

In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.

In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.

5

10

15

20

25

30

In one aspect, the present invention provides a method of detecting a breast cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.

In another aspect, the present invention provides a method of detecting antibodies specific to breast cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-25.

In another aspect, the present invention provides a method for identifying a compound that modulates a breast cancer-associated polypeptide, the method comprising the steps of: (i) contacting the compound with a breast cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25; and (ii) determining the functional effect of the compound upon the polypeptide.

In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.

In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.

In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.

In another aspect, the present invention provides a method of inhibiting proliferation of a breast cancer-associated cell to treat breast cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.

In one embodiment, the compound is an antibody.

In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having breast cancer

or to a cell sample isolated therefrom; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of breast cancer.

5

10

15

20

25

30

In one embodiment, the control is a mammal with breast cancer or a cell sample therefrom that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal.

In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.

In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-25 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.

In another aspect, the present invention provides a method for treating a mammal having breast cancer comprising administering a compound identified by the assay described herein.

In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having breast cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.

In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in a breast cancer. In one embodiment, a gene is selected from Tables 1-25. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.

In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of

expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.

5

10

15

20

25

30

Also provided is a method of evaluating the effect of a candidate breast cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the breast cancer modulatory protein, or an animal lacking the breast cancer modulatory protein, for example as a result of a gene knockout.

Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-25, wherein the biochip comprises fewer than 1000 nucleic acid probes. Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.

Furthermore, a method of diagnosing a disorder associated with breast cancer is provided. The method comprises determining the expression of a gene of Tables 1-25, preferably a gene of Table 25, in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with breast cancer.

In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in breast cancer.

In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of a breast cancer modulating protein (breast cancer modulatory protein) or a fragment thereof and an antibody which binds to said breast cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining a breast cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said breast cancer modulatory protein or fragment thereof. The method further includes determining the binding of said breast cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist. Preferably, the agent inhibits breast cancer.

Also provided herein are methods of eliciting an immune response in an individual. In one embodiment a method provided herein comprises administering to an individual a composition comprising a breast cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

5

10

15

20

25

30

Further provided herein are compositions capable of eliciting an immune response in an individual. In one embodiment, a composition provided herein comprises a breast cancer modulating protein, preferably encoded by a nucleic acid of Tables 1-25, more preferably of Table 25, or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding a breast cancer modulating protein, preferably selected from the nucleic acids of Tables 1-25, and a pharmaceutically acceptable carrier.

Also provided are methods of neutralizing the effect of a breast cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-25.

In another aspect of the invention, a method of treating an individual for breast cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of a breast cancer modulating protein. In another embodiment, the method comprises administering to a patient having breast cancer an antibody to a breast cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for breast cancer (PC), including metastatic breast cancer, as well as methods for screening for compositions which modulate breast cancer. Also provided are methods for treating breast cancer.

Tables 1-24B provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in breast cancer

samples. Tables 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 18, 19, 20, 21, and 22 list those genes that are up-regulated in breast cancer cells. Table 14 lists those genes that are highly upregulated in breast cancer cells. Table 1, 2, 3, 15, and 23 list genes that are down-regulated in breast cancer cells and Table 16, lists genes that are highly down-regulated in breast cancer genes. The Tables also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.

Definitions

5

10

15

20

25

The term "breast cancer protein" or "breast cancer polynucleotide" or "breast cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-25; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-25 and conservatively modified variants thereof or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-25. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human; rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. A "breast cancer polypeptide" and a "breast cancer polynucleotide," include both naturally occurring or recombinant forms.

A "full length" breast cancer protein or nucleic acid refers to a breast cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurring, wild type breast cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.

5

10

15

20

25

30

"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of a breast cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish.

"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention *in vivo*. Archival tissues, having treatment or outcome history, will be particularly useful.

The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to

be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

10

15

20

25

30

A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Current Protocols in Molecular Biology (Ausubel et al., eds. 1995 supplement)).

Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms,

which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

10

15

20

25

30

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a

nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

5

10

15

20

25

30

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.

A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells *in vivo*, and the like. Host cells may be prokaryotic cells such as *E. coli*, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells such as CHO, HeLa, and the like (*see, e.g.*, the American Type Culture Collection catalog or web site, www.atcc.org).

The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Preferably, it means that the nucleic acid or protein is at least 85% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means

removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.

The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.

10

15

20

25

30

Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino

acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.

10

15

20

25

30

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.

Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5)

Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).

Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts et al., Molecular Biology of the Cell (3rd ed., 1994) and Cantor & Schimmel, Biophysical Chemistry Part I: The Conformation of Biological Macromolecules (1980). "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains. Domains are portions of a polypeptide that

often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of β -sheet and α -helices. "Tertiary structure" refers to the complete three dimensional structure of a polypeptide monomer. "Quaternary structure" refers to the three dimensional structure formed, usually by the noncovalent association of independent tertiary units. Anisotropic terms are also known as energy terms.

5

30

"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together. Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more 10 nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have alternate backbones, comprising, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages (see Eckstein, 15 Oligonucleotides and Analogues: A Practical Approach, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, Sanghui & 20 Cook, eds.. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g. to increase the stability and half-life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid 25 analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.

A variety of references disclose such nucleic acid analogs, including, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al, Chem. Lett. 805

(1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 91986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphophoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and 5 linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; 10 Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 15 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp 169-176). Several nucleic acid analogs 20 are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference.

Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids. This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (T_m) for mismatched versus perfectly matched basepairs. DNA and RNA typically exhibit a 2-4°C drop in T_m for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9°C. Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is

25

30

relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.

5

10

15

20

25

30

The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside" includes non-naturally occurring analog structures. Thus, e.g. the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.

A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include ³²P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to detect antibodies specifically reactive with the peptide. The labels may be incorporated into the breast cancer nucleic acids, proteins and antibodies at any position. Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter et al., Nature, 144:945 (1962); David et al., Biochemistry, 13:1014 (1974); Pain et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including

radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.

A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe. Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.

5

10

15

20

25

30

As used herein a "nucleic acid probe or oligonucleotide" is defined as a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled as with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.

The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed

or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e., using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as depicted above.

The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a

promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.

5

10

15

20

25

30

The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).

The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength pH. The T_m is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T_m, 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotides) and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is at least two times

background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50% formamide, 5x SSC, and 1% SDS, incubating at 42°C, or, 5x SSC, 1% SDS, incubating at 65°C, with wash in 0.2x SSC, and 0.1% SDS at 65°C. For PCR, a temperature of about 36°C is typical for low stringency amplification, although annealing temperatures may vary between about 32°C and 48°C depending on primer length. For high stringency PCR amplification, a temperature of about 62°C is typical, although high stringency annealing temperatures can range from about 50°C to about 65°C, depending on the primer length and specificity. Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90°C - 95°C for 30 sec - 2 min., an annealing phase lasting 30 sec. - 2 min., and an extension phase of about 72°C for 1 - 2 min. Protocols and guidelines for low and high stringency amplification reactions are provided, e.g., in Innis et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, Inc. N.Y.).

5

10

15

20

25

Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37°C, and a wash in 1X SSC at 45°C. A positive hybridization is at least twice background. Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., and Current Protocols in Molecular Biology, ed. Ausubel, et al.

The phrase "functional effects" in the context of assays for testing compounds that modulate activity of a breast cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the breast cancer protein or nucleic acid, e.g., a functional, physical, or chemical effect, such as the ability to decrease breast cancer. It includes ligand binding activity; cell growth on soft agar; anchorage dependence; contact

inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis *in vivo*; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. "Functional effects" include *in vitro*, *in vivo*, and *ex vivo* activities.

5

10

15

20

25

30

By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of a breast cancer protein sequence, e.g., functional, enzymatic, physical and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the breast cancer protein; measuring binding activity or binding assays, e.g. binding to antibodies or other ligands, and measuring cellular proliferation. Determination of the functional effect of a compound on breast cancer can also be performed using breast cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence; tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of breast cancer cells. The functional effects can be evaluated by many means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for breast cancer-associated sequences, measurement of RNA stability, identification of downstream or reporter gene expression (CAT, luciferase, β -gal, GFP and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.

"Inhibitors", "activators", and "modulators" of breast cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using *in vitro* and *in vivo* assays of breast cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block

activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of breast cancer proteins, e.g., antagonists. Antisense nucleic acids may seem to inhibit expression and subsequent function of the protein. "Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate breast cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of breast cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules and the like. Such assays for inhibitors and activators include, e.g., expressing the breast cancer protein *in vitro*, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of breast cancer can also be identified by incubating breast cancer cells with the test compound and determining increases or decreases in the expression of 1 or more breast cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50 or more breast cancer proteins, such as breast cancer proteins encoded by the sequences set out in Tables 1-25.

Samples or assays comprising breast cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably 50%, more preferably 25-0%. Activation of a breast cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 150%, more preferably 200-500% (i.e., two to five fold higher relative to the control), more preferably 1000-3000% higher.

The phrase "changes in cell growth" refers to any change in cell growth and proliferation characteristics *in vitro* or *in vivo*, such as formation of foci, anchorage independence, semi-solid or soft agar growth, changes in contact inhibition and density limitation of growth, loss of growth factor or serum requirements, changes in cell morphology, gaining or losing immortalization, gaining or losing tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or

immortalization of the cell. See, e.g., Freshney, Culture of Animal Cells a Manual of Basic Technique pp. 231-241 (3rd ed. 1994).

5

10

15

20

25

30

"Tumor cell" refers to precancerous, cancerous, and normal cells in a tumor.

"Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene. Transformation is associated with phenotypic changes, such as immortalization of cells, aberrant growth control, nonmorphological changes, and/or malignancy (see, Freshney, Culture of Animal Cells a Manual of Basic Technique (3rd ed. 1994)).

"Antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See Paul, Fundamental Immunology.

An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (V_L) and variable heavy chain (V_H) refer to these light and heavy chains respectively.

Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'₂, a dimer of Fab which itself is a light chain joined to V_H-C_H1 by a disulfide bond. The F(ab)'₂

may be reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'₂ dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region (see Fundamental Immunology (Paul ed., 3d ed. 1993). While various antibody fragments are defined in terms of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries (see, e.g., McCafferty et al., Nature 348:552-554 (1990))

For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many technique known in the art can be used (see, e.g., Kohler & Milstein, Nature 256:495-497 (1975); Kozbor et al., Immunology Today 4:72 (1983); Cole et al., pp. 77-96 in Monoclonal Antibodies and Cancer Therapy (1985); Coligan, Current Protocols in Immunology (1991); Harlow & Lane, Antibodies, A Laboratory Manual (1988); and Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986)). Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens (see, e.g., McCafferty et al., Nature 348:552-554 (1990); Marks et al., Biotechnology 10:779-783 (1992)).

A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.

10

15

20

25

Identification of breast cancer-associated sequences

5

10

15

20

25

In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal breast or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the breast, or breast cancer tissue or metastatic breast cancerous tissue can be compared with tissue samples of breast and other tissues from surviving cancer patients. By comparing expression profiles of tissue in known different breast cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained.

The identification of sequences that are differentially expressed in breast cancer versus non-breast cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate breast cancer, and thus tumor growth or recurrence, in a particular patient. Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of breast cancer in the tissue. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the breast cancer expression profile. This may be done by making biochips comprising sets of the important breast cancer genes, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the breast cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the breast cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense nucleic acids, or the breast cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.

Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in breast cancer, herein termed "breast cancer sequences." As outlined below, breast cancer sequences include those that are up-regulated (i.e., expressed at a higher level) in breast cancer, as well as those that are down-regulated (i.e., expressed at a lower level). In a preferred embodiment, the breast cancer sequences are from humans; however, as will be appreciated by those in the art, breast cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other breast cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets, e.g., (dogs, cats, etc.). Breast cancer sequences from other organisms may be obtained using the techniques outlined below.

5

10

15

20

25

30

Breast cancer sequences can include both nucleic acid and amino acid sequences. As will be appreciated by those in the art and is more fully outlined below, breast cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids, as well as screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the breast cancer sequences can be generated.

A breast cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the breast cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions.

For identifying breast cancer-associated sequences, the breast cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs. non metastatic tissue. Other suitable tissue comparisons include comparing breast cancer samples with metastatic cancer samples from other cancers, such as lung, breast, gastrointestinal cancers, ovarian, etc. Samples of different stages of breast cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes. The samples are first microdissected, if applicable, and treated as is known in the art

for the preparation of mRNA. Suitable biochips are commercially available, e.g. from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.

In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal breast, but also including, and not limited to lung, heart, brain, liver, breast, kidney, muscle, colon, small intestine, large intestine, spleen, bone and placenta. In a preferred embodiment, those genes identified during the breast cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, this is not necessary. That is, when screening for drugs, it is usually preferable that the target be disease specific, to minimize possible side effects.

In a preferred embodiment, breast cancer sequences are those that are upregulated in breast cancer; that is, the expression of these genes is higher in the breast cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. All unigene cluster identification numbers and accession numbers herein are for the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, DA, et al., Nucleic Acids Research 26:1-7 (1998) and http://www.ncbi.nlm.nih.gov/. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). U.S. Patent Application N. 09/687,576, with the same assignee as the present application, further discloses related sequences, compositions, and methods of diagnosis and treatment of

In another preferred embodiment, breast cancer sequences are those that are down-regulated in the breast cancer; that is, the expression of these genes is lower in breast cancer tissue as compared to non-cancerous tissue (see, e.g., Tables 1,2, 3, 15, 16 etc...). "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred.

breast cancer is hereby expressly incorporated by reference.

5

10

15

20

25

Informatics

10

15

20

25

30

The ability to identify genes that are over or under expressed in breast cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. For example, the expression profiles can be used in diagnostic or prognostic evaluation of patients with breast cancer. Or as another example, subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson, Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA (June 11-12, 1998)). Subcellular toxicological information can also be utilized in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).

Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in substantially any form in which data can be maintained and transmitted, but is preferably an electronic database. The electronic database of the invention can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.

The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.

The compositions and methods for identifying and/or quantitating the relative and/or absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing breast cancer, i.e., the identification of breast cancer-associated sequences described herein, provide an abundance of information, which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring,

gene-disease causal linkages, identification of correlates of immunity and physiological status, among others. Although the data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, prior data processing using high-speed computers is utilized.

5

10

15

20

25

30

An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S. Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of-fit measure. U.S. Patent 5,926,818 discloses a multidimensional database comprising a functionality for multi-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S. Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.

See also Mount et al., Bioinformatics (2001); Biological Sequence Analysis:

Probabilistic Models of Proteins and Nucleic Acids (Durbin et al., eds., 1999);

Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins (Baxevanis & Oeullette eds., 1998)); Rashidi & Buehler, Bioinformatics: Basic Applications in Biological Science and Medicine (1999); Introduction to Computational Molecular Biology (Setubal et

al., eds 1997); Bioinformatics: Methods and Protocols (Misener & Krawetz, eds, 2000); Bioinformatics: Sequence, Structure, and Databanks: A Practical Approach (Higgins & Taylor, eds., 2000); Brown, Bioinformatics: A Biologist's Guide to Biocomputing and the Internet (2001); Han & Kamber, Data Mining: Concepts and Techniques (2000); and Waterman, Introduction to Computational Biology: Maps, Sequences, and Genomes (1995).

5

10

15

20

25

The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.

In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for breast cancer. In another variation, the assay records cross-tabulate one or more of the following parameters for each target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic coordinates); (2) sample source; and (3) absolute and/or relative quantity of the target species present in the sample.

The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGRAM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers for at least 10 target data records cross-tabulated with target source.

When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.

The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.

10

15

20

25

30

The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or 10BaseT), telephone line, ISDN line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) and/or charge domains (e.g., an array of DRAM cells) composing a bit pattern encoding data acquired from an assay of the invention.

The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.

In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the

assay results. Data for a query target is entered into the central processor via an I/O device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.

The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIPS 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O device.

The invention also preferably provides the use of a computer system, such as that described above, which comprises: (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by the methods of the invention, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Characteristics of breast cancer-associated proteins

5

10

15

20

25

30

Breast cancer proteins of the present invention may be classified as secreted proteins, transmembrane proteins or intracellular proteins. In one embodiment, the breast cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes (see, e.g., Molecular

Biology of the Cell (Alberts, ed., 3rd ed., 1994). For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity and the like. Intracellular proteins also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are involved in maintaining the structural integrity of organelles.

5

10

15

20

25

30

An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more motifs for which defined functions have been attributed. In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of primary sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule and/or molecules with which the protein may associate. One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains. Versions are available via the internet from Washington University in St. Louis, the Sanger Center in England, and the Karolinska Institute in Sweden (see, e.g., Bateman et al., Nuc. Acids Res. 28:263-266 (2000); Sonnhammer et al., Proteins 28:405-420 (1997); Bateman et al., Nuc. Acids Res. 27:260-262 (1999); and Sonnhammer et al., Nuc. Acids Res. 26:320-322-(1998)).

In another embodiment, the breast cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell. They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described

for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.

5

10

15

20

25

30

Transmembrane proteins may contain from one to many transmembrane domains. For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain. However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 20 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g. PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g. IL-1 receptor, IL-2 receptor,

The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like. For example, growth factors such as EGF, FGF and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include

cytokines, mitogenic factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules. In this respect, they mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPI) anchor, or may themselves be transmembrane proteins. Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.

Breast cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins.

It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods. Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.

In another embodiment, the breast cancer proteins are secreted proteins; the secretion of which can be either constitutive or regulated. These proteins have a signal peptide or signal sequence that targets the molecule to the secretory pathway. Secreted proteins are involved in numerous physiological events; by virtue of their circulating nature, they serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor) or an endocrine manner (acting on cells at a distance). Thus secreted molecules find use in modulating or altering numerous aspects of physiology. Breast cancer proteins that are secreted proteins are particularly preferred in the present invention as they serve as good targets for diagnostic markers, e.g., for blood, plasma, serum, or stool tests.

Use of breast cancer nucleic acids

5

10

15

20

25

30

As described above, breast cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the breast cancer

sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA are found on the same molecule.

5

10

15

20

25

30

The breast cancer nucleic acid sequences of the invention, e.g., the sequences in Tables 1-25, can be fragments of larger genes, i.e., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions. Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the breast cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/UniGene/).

Once the breast cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire breast cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant breast cancer nucleic acid can be further-used as a probe to identify and isolate other breast cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant breast cancer nucleic acids and proteins.

The breast cancer nucleic acids of the present invention are used in several ways. In a first embodiment, nucleic acid probes to the breast cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, and/or antisense applications.

Alternatively, the breast cancer nucleic acids that include coding regions of breast cancer proteins can be put into expression vectors for the expression of breast cancer proteins, again for screening purposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to breast cancer nucleic acids (both the nucleic acid sequences outlined in the figures and/or the complements thereof) are

made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the breast cancer nucleic acids, *i.e.* the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.

20

5

10

15

In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used. That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (i.e., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.

25

30

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of electrostatic,

hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.

In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

10

15

20

25

The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silicabased materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. A preferred substrate is described in copending application entitled Reusable Low Fluorescent Plastic Biochip, U.S. Application Serial No. 09/270,214, filed March 15, 1999, herein incorporated by reference in its entirety.

Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize

sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

5

10

15

20

30

In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g. using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affimetrix GeneChipTM technology.

Often, amplification-based assays are performed to measure the expression level of breast cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, a breast cancer-associated nucleic acid

sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of breast cancer-associated RNA. Methods of quantitative amplification are well known to those of skill in the art. Detailed protocols for quantitative PCR are provided, e.g., in Innis et al., PCR Protocols, A Guide to Methods and Applications (1990).

In some embodiments, a TaqMan based assay is used to measure expression. TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).

Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR) (see Wu & Wallace, Genomics 4:560 (1989), Landegren et al., Science 241:1077 (1988), and Barringer et al., Gene 89:117 (1990)), transcription amplification (Kwoh et al., Proc. Natl. Acad. Sci. USA 86:1173 (1989)), self-sustained sequence replication (Guatelli et al., Proc. Nat. Acad. Sci. USA 87:1874 (1990)), dot PCR, and linker adapter PCR, etc.

Expression of breast cancer proteins from nucleic acids

10

15

20

25

30

In a preferred embodiment, breast cancer nucleic acids, e.g., encoding breast cancer proteins are used to make a variety of expression vectors to express breast cancer proteins which can then be used in screening assays, as described below. Expression vectors and recombinant DNA technology are well known to those of skill in the art (see, e.g., Ausubel, supra, and Gene Expression Systems (Fernandez & Hoeffler, eds, 1999)) and are used to express proteins. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these

expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the breast cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism. Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the breast cancer protein. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

10

15

20

25

In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g. in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art (e.g., Fernandez & Hoeffler, *supra*).

5

10

15

20

25

30

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

The breast cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a breast cancer protein, under the appropriate conditions to induce or cause expression of the breast cancer protein. Conditions appropriate for breast cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Saccharomyces cerevisiae* and other yeasts, *E. coli, Bacillus subtilis*, Sf9 cells, C129 cells, 293 cells, *Neurospora*, BHK, CHO, COS, HeLa cells, HUVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.

In a preferred embodiment, the breast cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include

retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter (see, e.g., Fernandez & Hoeffler, supra). Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenlyation signals include those derived form SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.

Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, breast cancer proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. The expression vector may also include a signal peptide sequence that provides for secretion of the breast cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which

render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others (e.g., Fernandez & Hoeffler, *supra*). The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, breast cancer proteins are produced in insect cells.

Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, breast cancer protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.

15

20

25

30

The breast cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the breast cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the breast cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the breast cancer protein is a breast cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the breast cancer protein is purified or isolated after expression. Breast cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the breast cancer protein may be purified using a standard anti-breast cancer protein antibody column. Ultrafiltration

and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, *Protein Purification* (1982). The degree of purification necessary will vary depending on the use of the breast cancer protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the breast cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.

Variants of breast cancer proteins

5

10

15

20

25

30

In one embodiment, the breast cancer proteins are derivative or variant breast cancer proteins as compared to the wild-type sequence. That is, as outlined more fully below, the derivative breast cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion or deletion may occur at any residue within the breast cancer peptide.

Also included within one embodiment of breast cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the breast cancer protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant breast cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the breast cancer protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to

optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed breast cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of breast cancer protein activities.

5

10

15

20

25

30

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the breast cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the breast cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the breast cancer protein is altered. For example, glycosylation sites may be altered or removed.

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue

having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

5

10

15

20

25

Covalent modifications of breast cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a breast cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of a breast cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking breast cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-breast cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.

Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl, threonyl or tyrosyl residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (Creighton, *Proteins: Structure and Molecular Properties*, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the breast cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence breast cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence breast cancer polypeptide. Glycosylation patterns can be altered in many ways. For example the use of different cell types to express breast cancer-associated sequences can result in different glycosylation patterns.

Addition of glycosylation sites to breast cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence breast cancer polypeptide (for O-linked glycosylation sites). The breast cancer amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the breast cancer polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

5

10

15

20

25

30

Another means of increasing the number of carbohydrate moieties on the breast cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330, and in Aplin & Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the breast cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of breast cancer comprises linking the breast cancer polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Breast cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules comprising a breast cancer polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a breast cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the breast cancer polypeptide. The presence of such epitope-tagged forms of a breast cancer polypeptide can be detected using

an antibody against the tag polypeptide. Also, provision of the epitope tag enables the breast cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a breast cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; HIS6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field et al., Mol. Cell. Biol. 8:2159-2165 (1988)); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., Molecular and Cellular Biology 5:3610-3616 (1985)); and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky et al., Protein Engineering 3(6):547-553 (1990)). Other tag polypeptides include the Flag-peptide (Hopp et al., BioTechnology 6:1204-1210 (1988)); the KT3 epitope peptide (Martin et al., Science 255:192-194 (1992)); tubulin epitope peptide (Skinner et al., J. Biol. Chem. 266:15163-15166 (1991)); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA 87:6393-6397 (1990)).

Also included are other breast cancer proteins of the breast cancer family, and breast cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related breast cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the breast cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR Protocols, *supra*).

Antibodies to breast cancer proteins

5

10

15

20

25

30

In a preferred embodiment, when the breast cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the breast cancer protein

should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller breast cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.

Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, *supra*; and Harlow & Lane, *supra*). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

10

15

20

25

30

The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler & Milstein, *Nature* 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-25 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene

glycol, to form a hybridoma cell (Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103 (1986)). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

5

10

15

20

25

30

In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens or that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded by a nucleic acid Tables 1-25 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.

In a preferred embodiment, the antibodies to breast cancer protein are capable of reducing or eliminating a biological function of a breast cancer protein, as is described below. That is, the addition of anti-breast cancer protein antibodies (either polyclonal or preferably monoclonal) to breast cancer tissue (or cells containing breast cancer) may reduce or eliminate the breast cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

In a preferred embodiment the antibodies to the breast cancer proteins are humanized antibodies (e.g., Xenerex Biosciences, Mederex, Inc., Abgenix, Inc., Protein Design Labs, Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include

5

10

15

20

25

30

human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a nonhuman species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992)). Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a nonhuman species.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries (Hoogenboom & Winter, J. Mol. Biol. 227:381 (1991); Marks et al., J. Mol. Biol. 222:581 (1991)). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, p. 77 (1985) and Boerner et al., J. Immunol. 147(1):86-95 (1991)). Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all

WO 02/059377 PCT/US02/0224:

respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, e.g., in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology 10:779-783 (1992); Lonberg et al., Nature 368:856-859 (1994); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996); Neuberger, Nature Biotechnology 14:826 (1996); Lonberg & Huszar, Intern. Rev. Immunol. 13:65-93 (1995).

5

10

15

20

25

30

By immunotherapy is meant treatment of breast cancer with an antibody raised against breast cancer proteins. As used herein, immunotherapy can be passive or active. Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the antigen may be provided by injecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.

In a preferred embodiment the breast cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted breast cancer protein.

In another preferred embodiment, the breast cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the breast cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane breast cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the breast cancer protein. The antibody is also an antagonist of the breast cancer protein. Further, the antibody prevents activation of the transmembrane breast cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the breast cancer

protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-α, TNF-β, IL-1, INF-γ and IL-2, or chemotherapeutic agents including 5FU, vinblastine, actinomycin D, cisplatin, methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, breast cancer is treated by administering to a patient antibodies directed against the transmembrane breast cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.

In another preferred embodiment, the antibody is conjugated to an effector moiety. The effector moiety can be any number of molecules, including labelling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the breast cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the breast cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with breast cancer.

In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to breast cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with breast cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against breast cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane breast cancer proteins not only serves to increase the local concentration of therapeutic moiety in the breast cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the therapeutic moiety.

In another preferred embodiment, the breast cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the breast cancer protein can be targeted within a cell, i.e., the nucleus, an antibody thereto contains a signal for that target localization, i.e., a nuclear localization signal.

5

10

15

20

25

30

The breast cancer antibodies of the invention specifically bind to breast cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a K_d of at least about 0.1 mM, more usually at least about 1 μ M, preferably at least about 0.1 μ M or better, and most preferably, 0.01 μ M or better. Selectivity of binding is also important.

Detection of breast cancer sequence for diagnostic and therapeutic applications

In one aspect, the RNA expression levels of genes are determined for different cellular states in the breast cancer phenotype. Expression levels of genes in normal tissue (i.e., not undergoing breast cancer) and in breast cancer tissue (and in some cases, for varying severities of breast cancer that relate to prognosis, as outlined below) are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint" of the state. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.

"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can

5

10

15

20

25

qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus breast cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type, but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is increased or decreased; i.e., gene expression is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, Nature Biotechnology 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis and RNase protection. As outlined above, preferably the change in expression (i.e., upregulation or downregulation) is at least about 50%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000% being especially preferred.

Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the breast cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to breast cancer genes, i.e., those identified as being important in a breast cancer phenotype, can be evaluated in a breast cancer diagnostic test.

In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes. Multiple protein expression monitoring can be performed as well. Similarly, these assays may be performed on an individual basis as well.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in

a particular cell. The assays are further described below in the example. PCR techniques can be used to provide greater sensitivity.

In a preferred embodiment nucleic acids encoding the breast cancer protein are detected. Although DNA or RNA encoding the breast cancer protein may be detected, of particular interest are methods wherein an mRNA encoding a breast cancer protein is detected. Probes to detect mRNA can be a nucleotide/deoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding a breast cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3indoyl phosphate.

10

15

20

25

30

In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.

As described and defined herein, breast cancer proteins, including intracellular, transmembrane or secreted proteins, find use as markers of breast cancer.

Detection of these proteins in putative breast cancer tissue allows for detection or diagnosis

of breast cancer. In one embodiment, antibodies are used to detect breast cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the breast cancer protein is detected, e.g., by immunoblotting with antibodies raised against the breast cancer protein. Methods of immunoblotting are well known to those of ordinary skill in the art.

In another preferred method, antibodies to the breast cancer protein find use in in situ imaging techniques, e.g., in histology (e.g., Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993)). In this method cells are contacted with from one to many antibodies to the breast cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the breast cancer protein(s) contains a detectable label, e.g. an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of breast cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.

10

15

20

25

30

In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.

In another preferred embodiment, antibodies find use in diagnosing breast cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of breast cancer proteins.

Antibodies can be used to detect a breast cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE technology and the like. Conversely, the presence of

In a preferred embodiment, *in situ* hybridization of labeled breast cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including

antibodies may indicate an immune response against an endogenous breast cancer protein.

breast cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in prognosis assays. As above, gene expression profiles can be generated that correlate to breast cancer, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of genes being preferred. As above, breast cancer probes may be attached to biochips for the detection and quantification of breast cancer sequences in a tissue or patient. The assays proceed as outlined above for diagnosis. PCR method may provide more sensitive and accurate quantification.

Assays for therapeutic compounds

5

10

15

20

25

30

In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing breast cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent (e.g., Zlokarnik, et al., Science 279:84-8 (1998); Heid, Genome Res 6:986-94, 1996).

In a preferred embodiment, the breast cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified breast cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the breast cancer phenotype or an identified physiological function of a breast cancer protein. As above, this can be done on an individual gene level or

by evaluating the effect of drug candidates on a "gene expression profile". In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent, see Zlokarnik, *supra*.

5

10

15

20

25

Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in breast cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the breast cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing breast cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in breast cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in breast cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.

The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the breast cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.

In a preferred embodiment, gene expression or protein monitoring of a number of entities, i.e., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.

In this embodiment, the breast cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of breast cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.

Expression monitoring can be performed to identify compounds that modify the expression of one or more breast cancer-associated sequences, e.g., a polynucleotide sequence set out in Table 17. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate breast cancer, modulate breast cancer proteins, bind to a breast cancer protein, or interfere with the binding of a breast cancer protein and an antibody or other binding partner.

The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the breast cancer phenotype or the expression of a breast cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses a breast cancer phenotype, e.g. to a normal tissue fingerprint. In another embodiment, a modulator induced a breast cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

In one aspect, a modulator will neutralize the effect of a breast cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.

In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to a breast cancer polypeptide or to modulate activity. Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.

10

15

20

25

30

In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.

A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks (Gallop *et al.*, *J. Med. Chem.* 37(9):1233-1251 (1994)).

Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175, Furka, Pept. Prot. Res. 37:487-493 (1991), Houghton et al., Nature, 354:84-88 (1991)), peptoids (PCT Publication No WO 91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT Publication WO 92/00091), benzodiazepines (U.S. Pat. No. 5,288,514), diversomers such as

hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc. Nat. Acad. Sci. USA 90:6909-6913 (1993)), vinylogous polypeptides (Hagihara et al., J. Amer. Chem. Soc. 114:6568 (1992)), nonpeptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann et al., J. Amer. Chem. Soc. 114:9217-9218 (1992)), analogous organic syntheses of small compound libraries (Chen et al., J. Amer. Chem. Soc. 116:2661 (1994)), oligocarbamates (Cho, et al., Science 261:1303 (1993)), and/or peptidyl phosphonates (Campbell et al., J. Org. Chem. 59:658 (1994)). See, generally, Gordon et al., J. Med. Chem. 37:1385 (1994), nucleic acid libraries (see, e.g., Strategene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn et al., Nature Biotechnology 14(3):309-314 (1996), and PCT/US96/10287), carbohydrate libraries (see, e.g., Liang et al., Science 274:1520-1522 (1996), and U.S. Patent No. 5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, Baum, C&EN, Jan 18, page 33 (1993); isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No. 5,288,514; and the like).

5

10

15

20

25

Devices for the preparation of combinatorial libraries are commercially available (*see*, *e.g.*, 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).

A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis,

MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

The assays to identify modulators are amenable to high throughput screening. Preferred assays thus detect enhancement or inhibition of breast cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.

High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art. Similarly, binding assays and reporter gene assays are similarly well known. Thus, e.g., U.S. Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (i.e., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.

10

15

20

25

In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.). These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.

In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially

preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.

In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

5

10

15

20

25

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

Modulators of breast cancer can also be nucleic acids, as defined above.

As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.

After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques. For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate. For example, an *in vitro* transcription with labels covalently attached to the nucleotides is performed. Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.

5

10

15

20

25

30

In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.

As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702, 5,597,909, 5,545,730, 5,594,117, 5,591,584, 5,571,670, 5,580,731, 5,571,670, 5,591,584, 5,624,802, 5,635,352, 5,594,118, 5,359,100, 5,124,246 and 5,681,697, all of which are hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.

A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to,

temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.

These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.

5

10

15

20

25

30

The reactions outlined herein may be accomplished in a variety of ways. Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.

The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.

Screens are performed to identify modulators of the breast cancer phenotype. In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.

In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress a breast cancer expression pattern leading to a normal expression pattern, or to modulate a single breast cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically

modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated breast cancer tissue reveals genes that are not expressed in normal tissue or breast cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for breast cancer genes or proteins.

In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated breast cancer tissue sample.

5

10

15

20

25

30

Thus, in one embodiment, a test compound is administered to a population of breast cancer cells, that have an associated breast cancer expression profile. By "administration" or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (i.e., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97/01019. Regulatable gene therapy systems can also be used.

Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.

Thus, e.g., breast cancer tissue may be screened for agents that modulate, e.g., induce or suppress the breast cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on breast cancer activity. By defining such a signature for the breast cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.

In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of

either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "breast cancer proteins" or a "breast cancer modulatory protein". The breast cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the breast cancer modulatory protein is a fragment. In a preferred embodiment, the breast cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of Table 25. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of Table 25. In another embodiment, the sequences are sequence variants as further described herein.

5

10

15

20

25

Preferably, the breast cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment. Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In one embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, i.e., to cysteine.

In one embodiment the breast cancer proteins are conjugated to an immunogenic agent as discussed herein. In one embodiment the breast cancer protein is conjugated to BSA.

Measurements of breast cancer polypeptide activity, or of breast cancer or the breast cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the breast cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of breast cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second

messengers such as cGMP. In the assays of the invention, mammalian breast cancer polypeptide is typically used, e.g., mouse, preferably human.

5

10

15

Assays to identify compounds with modulating activity can be performed *in vitro*. For example, a breast cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 48 hours. In one embodiment, the breast cancer polypeptide levels are determined *in vitro* by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the breast cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.

Alternatively, a reporter gene system can be devised using the breast cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or β -gal. The reporter construct is typically transfected into a cell. After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.

In a preferred embodiment, as outlined above, screens may be done on
individual genes and gene products (proteins). That is, having identified a particular
differentially expressed gene as important in a particular state, screening of modulators of the
expression of the gene or the gene product itself can be done. The gene products of
differentially expressed genes are sometimes referred to herein as "breast cancer proteins."
The breast cancer protein may be a fragment, or alternatively, be the full length protein to a
fragment shown herein.

In one embodiment, screening for modulators of expression of specific genes is performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate

differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.

In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present. Alternatively, cells comprising the breast cancer proteins can be used in the assays.

5

10

15

20

25

30

Thus, in a preferred embodiment, the methods comprise combining a breast cancer protein and a candidate compound, and determining the binding of the compound to the breast cancer protein. Preferred embodiments utilize the human breast cancer protein, although other mammalian proteins may also be used, e.g. for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative breast cancer proteins may be used.

Generally, in a preferred embodiment of the methods herein, the breast cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflonTM, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving

areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

In a preferred embodiment, the breast cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the breast cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

5

10

15

20

25

30

The determination of the binding of the test modulating compound to the breast cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the breast cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as appropriate.

In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., ¹²⁵I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.

In one embodiment, the binding of the test compound is determined by competitive binding assay. The competitor is a binding moiety known to bind to the target molecule (i.e., a breast cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are typically optimized, e.g., to facilitate rapid high throughput

screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the breast cancer protein and thus is capable of binding to, and potentially modulating, the activity of the breast cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.

5

10

15

20

25

In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the breast cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the test compound is capable of binding to the breast cancer protein.

In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the breast cancer proteins. In this embodiment, the methods comprise combining a breast cancer protein and a competitor in a first sample. A second sample comprises a test compound, a breast cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the breast cancer protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the breast cancer protein.

Alternatively, differential screening is used to identify drug candidates that bind to the native breast cancer protein, but cannot bind to modified breast cancer proteins. The structure of the breast cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of a

breast cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

5

10

15

20

25

30

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.

In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of a breast cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising breast cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes a breast cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g. hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.

In this way, compounds that modulate breast cancer agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the breast cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.

In one embodiment, a method of inhibiting breast cancer cell division is provided. The method comprises administration of a breast cancer inhibitor. In another embodiment, a method of inhibiting breast cancer is provided. The method comprises administration of a breast cancer inhibitor. In a further embodiment, methods of treating cells or individuals with breast cancer are provided. The method comprises administration of a breast cancer inhibitor.

In one embodiment, a breast cancer inhibitor is an antibody as discussed above. In another embodiment, the breast cancer inhibitor is an antisense molecule.

5

10

15

20

25

30

A variety of cell growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.

Soft agar growth or colony formation in suspension

Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate. For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected with tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of breast cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft.

Techniques for soft agar growth or colony formation in suspension assays are described in Freshney, *Culture of Animal Cells a Manual of Basic Technique* (3rd ed., 1994), herein incorporated by reference. *See also*, the methods section of Garkavtsev *et al.* (1996), *supra*, herein incorporated by reference.

Contact inhibition and density limitation of growth

Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a

higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (³H)-thymidine at saturation density can be used to measure density limitation of growth. See Freshney (1994), supra. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.

In this assay, labeling index with (³H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with a breast cancer-associated sequence and are grown for 24 hours at saturation density in non-limiting medium conditions. The percentage of cells labeling with (³H)-thymidine is determined autoradiographically. *See*, Freshney (1994), *supra*.

Growth factor or serum dependence

5

10

15

20

25

30

Transformed cells have a lower serum dependence than their normal counterparts (see, e.g., Temin, J. Natl. Cancer Insti. 37:167-175 (1966); Eagle et al., J. Exp. Med. 131:836-879 (1970)); Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.

Tumor specific markers levels

Tumor cells release an increased amount of certain factors (hereinafter "tumor specific markers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985)). Similarly, Tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman, Angiogenesis and Cancer, Sem Cancer Biol. (1992)).

Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkless et al., J. Biol. Chem. 249:4295-4305 (1974); Strickland & Beers, J. Biol. Chem. 251:5694-5702 (1976); Whur et al., Br. J. Cancer 42:305-

312 (1980); Gullino, Angiogenesis, tumor vascularization, and potential interference with tumor growth. in Biological Responses in Cancer, pp. 178-184 (Mihich (ed.) 1985); Freshney Anticancer Res. 5:111-130 (1985).

Invasiveness into Matrigel

5

10

15

20

25

30

The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate breast cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.

Techniques described in Freshney (1994), *supra*, can be used. Briefly, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent. Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by prelabeling the cells with ¹²⁵I and counting the radioactivity on the distal side of the filter or bottom of the dish. *See, e.g.*, Freshney (1984), *supra*.

Tumor growth in vivo

Effects of breast cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the breast cancer gene is disrupted or in which a breast cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous breast cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous breast cancer gene with a mutated version of the breast cancer gene, or by mutating the endogenous breast cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice

that possess germ cells partially derived from the mutant cell line. Therefore, by breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion (see, e.g., Capecchi et al., Science 244:1288 (1989)). Chimeric targeted mice can be derived according to Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual, Cold Spring Harbor Laboratory (1988) and Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed., IRL Press, Washington, D.C., (1987).

Alternatively, various immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella et al., J. Natl. Cancer Inst. 52:921 (1974)), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley et al., Br. J. Cancer 38:263 (1978); Selby et al., Br. J. Cancer 41:52 (1980)) can be used as a host. Transplantable tumor cells (typically about 10⁶ cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing a breast cancer-associated sequences are injected subcutaneously. After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.

Polynucleotide modulators of breast cancer

5

10

15

20

25

30

Antisense Polynucleotides

In certain embodiments, the activity of a breast cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, *i.e.*, a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA nucleic acid sequence, e.g., a breast cancer protein mRNA, or a subsequence thereof. Binding of the antisense polynucleotide to the mRNA reduces the translation and/or stability of the mRNA.

In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other

sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the breast cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.

Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized *in vitro*. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.

Antisense molecules as used herein include antisense or sense oligonucleotides. Sense oligonucleotides can, e.g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA (antisense) sequences for breast cancer molecules. A preferred antisense molecule is for a breast cancer sequences in Tables 1-25, or for a ligand or activator thereof. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, e.g., Stein & Cohen (Cancer Res. 48:2659 (1988 and van der Krol et al. (BioTechniques 6:958 (1988)).

20 Ribozymes

5

10

15

25

30

In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of breast cancer-associated nucleotide sequences. A ribozyme is an RNA molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto et al., Adv. in Pharmacology 25: 289-317 (1994) for a general review of the properties of different ribozymes).

The general features of hairpin ribozymes are described, e.g., in Hampel et al., Nucl. Acids Res. 18:299-304 (1990); European Patent Publication No. 0 360 257; U.S. Patent No. 5,254,678. Methods of preparing are well known to those of skill in the art (see, e.g.,

WO 94/26877; Ojwang et al., Proc. Natl. Acad. Sci. USA 90:6340-6344 (1993); Yamada et al., Human Gene Therapy 1:39-45 (1994); Leavitt et al., Proc. Natl. Acad. Sci. USA 92:699-703 (1995); Leavitt et al., Human Gene Therapy 5:1151-120 (1994); and Yamada et al., Virology 205: 121-126 (1994)).

5

10

15

20

25

Polynucleotide modulators of breast cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of breast cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.

Thus, in one embodiment, methods of modulating breast cancer in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell an anti-breast cancer antibody that reduces or eliminates the biological activity of an endogenous breast cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding a breast cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g. when the breast cancer sequence is down-regulated in breast cancer, such state may be reversed by increasing the amount of breast cancer gene product in the cell. This can be accomplished, e.g., by overexpressing the endogenous breast cancer gene or administering a gene encoding the breast cancer sequence, using known gene-therapy techniques, e.g.. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g. as described in PCT/US93/03868, hereby incorporated by reference in its entirety. Alternatively, e.g. when the breast cancer

sequence is up-regulated in breast cancer, the activity of the endogenous breast cancer gene is decreased, e.g. by the administration of a breast cancer antisense nucleic acid.

In one embodiment, the breast cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to breast cancer proteins. Similarly, the breast cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify breast cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to a breast cancer protein; that is, the antibodies show little or no cross-reactivity to other proteins. The breast cancer antibodies may be coupled to standard affinity chromatography columns and used to purify breast cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the breast cancer protein.

Methods of identifying variant breast cancer-associated sequences

5

10

15

20

25

30

Without being bound by theory, expression of various breast cancer sequences is correlated with breast cancer. Accordingly, disorders based on mutant or variant breast cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant breast cancer genes, e.g., determining all or part of the sequence of at least one endogenous breast cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the breast cancer genotype of an individual, e.g., determining all or part of the sequence of at least one breast cancer gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced breast cancer gene to a known breast cancer gene, i.e., a wild-type gene.

The sequence of all or part of the breast cancer gene can then be compared to the sequence of a known breast cancer gene to determine if any differences exist. This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the breast cancer gene of

the patient and the known breast cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the breast cancer genes are used as probes to determine the number of copies of the breast cancer gene in the genome.

In another preferred embodiment, the breast cancer genes are used as probes to determine the chromosomal localization of the breast cancer genes. Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the breast cancer gene locus.

10

15

20

25

30

5

Administration of pharmaceutical and vaccine compositions

In one embodiment, a therapeutically effective dose of a breast cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (e.g., Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery; Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992), Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations (1999)). As is known in the art, adjustments for breast cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application N. 09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in breast cancer is hereby expressly incorporated by reference.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.

The administration of the breast cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the breast cancer proteins and modulators may be directly applied as a solution or spray.

5

10

15

20

25

The pharmaceutical compositions of the present invention comprise a breast cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.

The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges. It is recognized that breast cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecule(s) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecule(s) in an appropriately resistant carrier, such as a liposome or a protection barrier. Means of protecting agents from digestion are well known in the art.

10

15

20

25

30

The compositions for administration will commonly comprise a breast cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs (e.g., *Remington's Pharmaceutical Science* (15th ed., 1980) and Goodman & Gillman, *The Pharmacologial Basis of Therapeutics* (Hardman *et al.*, eds., 1996)).

Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art, e.g., Remington's Pharmaceutical Science and Goodman and Gillman, The Pharmacologial Basis of Therapeutics, supra.

The compositions containing modulators of breast cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose." The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc. Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer.

5

10

15

20

25

30

It will be appreciated that the present breast cancer protein-modulating compounds can be administered alone or in combination with additional breast cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.

In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-25, such as antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of breast cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.

The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use

of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell (see, e.g., Berger & Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology volume 152 (Berger), Ausubel et al., eds., Current Protocols (supplemented through 1999), and Sambrook et al., Molecular Cloning - A Laboratory Manual (2nd ed., Vol. 1-3, 1989).

5

10

15

20

25

30

In a preferred embodiment, breast cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, breast cancer genes (including both the full-length sequence, partial sequences, or regulatory sequences of the breast cancer coding regions) can be administered in a gene therapy application. These breast cancer genes can include antisense applications, either as gene therapy (i.e. for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.

Breast cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, A. et al., J. Clin. Invest. 95:341 (1995)), peptide compositions encapsulated in poly(DL-lactide-co-glycolide) ("PLG") microspheres (see, e.g., Eldridge, et al., Molec. Immunol. 28:287-294, (1991); Alonso et al., Vaccine 12:299-306 (1994); Jones et al., Vaccine 13:675-681 (1995)), peptide compositions contained in immune stimulating complexes (ISCOMS) (see, e.g., Takahashi et al., Nature 344:873-875 (1990); Hu et al., Clin Exp Immunol. 113:235-243 (1998)), multiple antigen peptide systems (MAPs) (see, e.g., Tam, Proc. Natl. Acad. Sci. U.S.A. 85:5409-5413 (1988); Tam, J. Immunol. Methods 196:17-32 (1996)), peptides formulated as multivalent peptides; peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., In: Concepts in vaccine development (Kaufmann, ed., p. 379, 1996); Chakrabarti, et al., Nature 320:535 (1986); Hu et al., Nature 320:537 (1986); Kieny, et al., AIDS Bio/Technology 4:790 (1986); Top et al., J. Infect. Dis. 124:148 (1971); Chanda et al., Virology 175:535 (1990)), particles of viral or synthetic origin (see, e.g., Kofler et al., J. Immunol. Methods. 192:25 (1996); Eldridge et al., Sem. Hematol. 30:16 (1993); Falo et al., Nature Med. 7:649 (1995)), adjuvants (Warren et al., Annu. Rev. Immunol. 4:369 (1986);

Gupta et al., Vaccine 11:293 (1993)), liposomes (Reddy et al., J. Immunol. 148:1585 (1992); Rock, Immunol. Today 17:131 (1996)), or, naked or particle absorbed cDNA (Ulmer, et al., Science 259:1745 (1993); Robinson et al., Vaccine 11:957 (1993); Shiver et al., In: Concepts in vaccine development (Kaufmann, ed., p. 423, 1996); Cease & Berzofsky, Annu. Rev. Immunol. 12:923 (1994) and Eldridge et al., Sem. Hematol. 30:16 (1993)). Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.

Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, *Bortadella pertussis* or *Mycobacterium tuberculosis* derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A. Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.

10

15

20

25

30

Vaccines can be administered as nucleic acid compositions wherein DNA or RNA encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient. This approach is described, for instance, in Wolff *et. al.*, *Science* 247:1465 (1990) as well as U.S. Patent Nos. 5,580,859; 5,589,466; 5,804,566; 5,739,118; 5,736,524; 5,679,647; WO 98/04720; and in more detail below. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (*see, e.g.*, U.S. Patent No. 5,922,687).

For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of

vaccinia virus, e.g., as a vector to express nucleotide sequences that encode breast cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S.

Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al., Nature 351:456-460 (1991). A wide variety of other vectors useful for therapeutic administration or immunization e.g. adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent to those skilled in the art from the description herein (see, e.g., Shata et al., Mol Med Today 6:66-71 (2000); Shedlock et al., J Leukoc Biol 68:793-806 (2000); Hipp et al., In Vivo 14:571-85 (2000)).

10

15

20

25

30

Methods for the use of genes as DNA vaccines are well known, and include placing a breast cancer gene or portion of a breast cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in a breast cancer patient. The breast cancer gene used for DNA vaccines can encode full-length breast cancer proteins, but more preferably encodes portions of the breast cancer proteins including peptides derived from the breast cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a breast cancer gene. For example, breast cancer-associated genes or sequence encoding subfragments of a breast cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the breast cancer polypeptide encoded by the DNA vaccine. Additional or alternative adjuvants are available.

In another preferred embodiment breast cancer genes find use in generating animal models of breast cancer. When the breast cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed

to the breast cancer gene will also diminish or repress expression of the gene. Animal models of breast cancer find use in screening for modulators of a breast cancer-associated sequence or modulators of breast cancer. Similarly, transgenic animal technology including gene knockout technology, e.g. as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the breast cancer protein. When desired, tissue-specific expression or knockout of the breast cancer protein may be necessary.

It is also possible that the breast cancer protein is overexpressed in breast cancer. As such, transgenic animals can be generated that overexpress the breast cancer protein. Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene. Animals generated by such methods find use as animal models of breast cancer and are additionally useful in screening for modulators to treat breast cancer.

15

20

25.

10

5

Kits for Use in Diagnostic and/or Prognostic Applications

For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, breast cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, antisense polynucleotides, ribozymes, dominant negative breast cancer polypeptides or polynucleotides, small molecules inhibitors of breast cancer-associated sequences *etc*. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.

In addition, the kits may include instructional materials containing directions (i.e., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such. Any medium capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the

like. Such media may include addresses to internet sites that provide such instructional materials.

The present invention also provides for kits for screening for modulators of breast cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: a breast cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing breast cancer-associated activity. Optionally, the kit contains biologically active breast cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products. The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

15 EXAMPLES

5

10

20

25

30

Example 1: Tissue Preparation, Labeling Chips, and Fingerprints

Purifying total RNA from tissue sample using TRIzol Reagent

The sample weight is first estimated. The tissue samples are homogenized in 1 ml of TRIzol per 50 mg of tissue using a homogenizer (e.g., Polytron 3100). The size of the generator/probe used depends upon the sample amount. A generator that is too large for the amount of tissue to be homogenized will cause a loss of sample and lower RNA yield. A larger generator (e.g., 20 mm) is suitable for tissue samples weighing more than 0.6 g. Fill tubes should not be overfilled. If the working volume is greater than 2 ml and no greater than 10 ml, a 15 ml polypropylene tube (Falcon 2059) is suitable for homogenization.

Tissues should be kept frozen until homogenized. The TRIzol is added directly to the frozen tissue before homogenization. Following homogenization, the insoluble material is removed from the homogenate by centrifugation at 7500 x g for 15 min. in a Sorvall superspeed or 12,000 x g for 10 min. in an Eppendorf centrifuge at 4°C. The cleared

homogenate is then transferred to a new tube(s). Samples may be frozen and stored at -60 to -70°C for at least one month or else continue with the purification.

The next process is phase separation. The homogenized samples are incubated for 5 minutes at room temperature. Then, 0.2 ml of chloroform per 1ml of TRIzol reagent is added to the homogenization mixture. The tubes are securely capped and shaken vigorously by hand (do not vortex) for 15 seconds. The samples are then incubated at room temp. for 2-3 minutes and next centrifuged at 6500 rpm in a Sorvall superspeed for 30 min. at 4oC.

5

10

15

20

25

The next process is RNA Precipitation. The aqueous phase is transferred to a fresh tube. The organic phase can be saved if isolation of DNA or protein is desired. Then 0.5 ml of isopropyl alcohol is added per 1ml of TRIzol reagent used in the original homogenization. Then, the tubes are securely capped and inverted to mix. The samples are then incubated at room temp. for 10 minutes an centrifuged at 6500 rpm in Sorvall for 20 min. at 4°C.

The RNA is then washed. The supernatant is poured off and the pellet washed with cold 75% ethanol. 1 ml of 75% ethanol is used per 1 ml of the TRIzol reagent used in the initial homogenization. The tubes are capped securely and inverted several times to loosen pellet without vortexing . They are next centrifuged at $<8000\,$ rpm ($<7500\,$ x g) for 5 minutes at 4° C.

The RNA wash is decanted. The pellet is carefully transferred to an Eppendorf tube (sliding down the tube into the new tube by use of a pipet tip to help guide it in if necessary). Tube(s) sizes for precipitating the RNA depending on the working volumes. Larger tubes may take too long to dry. Dry pellet. The RNA is then resuspended in an appropriate volume (e.g., 2 -5 ug/ul) of DEPC H₂0. The absorbance is then measured.

The poly A+ mRNA may next be purified from total RNA by other methods such as Qiagen's RNeasy kit. The poly A + mRNA is purified from total RNA by adding the oligotex suspension which has been heated to 37°C and mixing prior to adding to RNA.

The Elution Buffer is incubated at 70°C. If there is precipitate in the buffer, warm up the 2 x Binding Buffer at 65°C. The the total RNA is mixed with DEPC-treated water, 2 x Binding

Buffer, and Oligotex according to Table 2 on page 16 of the Oligotex Handbook and next incubated for 3 minutes at 65°C and 10 minutes at room temperature.

The preparation is centrifuged for 2 minutes at 14,000 to 18,000 g, preferably, at a "soft setting," The supernatant is removed without disturbing Oligotex pellet. A little bit of solution can be left behind to reduce the loss of Oligotex. The supernatant is saved until satisfactory binding and elution of poly A⁺ mRNA has been found.

Then, the preparation is gently resuspended in Wash Buffer OW2 and pipetted onto the spin column and centrifuged at full speed (soft setting if possible) for 1 minute.

Next, the spin column is transferred to a new collection tube and gently resuspended in Wash Buffer OW2 and centrifuged as described herein.

10

15

20

25

Then, the spin column is transferred to a new tube and eluted with 20 to 100 ul of preheated (70°C) Elution Buffer. The Oligotex resin is gently resuspended by pipetting up and down. The centrifugation is repeated as above and the elution repeated with fresh elution buffer or first eluate to keep the elution volume low.

The absorbance is next read to determine the yield, using diluted Elution Buffer as the blank.

Before proceeding with cDNA synthesis, the mRNA is precipitated before proceeding with cDNA synthesis, as components leftover or in the Elution Buffer from the Oligotex purification procedure will inhibit downstream enzymatic reactions of the mRNA. 0.4 vol. of 7.5 M NH4OAc + 2.5 vol. of cold 100% ethanol is added and the preparation precipitated at -20°C 1 hour to overnight (or 20-30 min. at -70°C), and centrifuged at 14,000-16,000 x g for 30 minutes at 4°C. Next, the pellet is washed with 0.5 ml of 80% ethanol (-20°C) and then centrifuged at 14,000-16,000 x g for 5 minutes at room temperature. The 80% ethanol wash is then repeated. The last bit of ethanol from the pellet is then dried without use of a speed vacuum and the pellet is then resuspended in DEPC H₂0 at 1ug/ul concentration.

Alternatively the RNA may be purified using other methods (e.g., Qiagen's RNeasy kit).

No more than 100 ug is added to the RNeasy column. The sample volume is adjusted to 100 ul with RNase-free water. 350 ul Buffer RLT and then 250 ul ethanol (100%) are added to the sample. The preparation is then mixed by pipetting and applied to an RNeasy mini spin column for centrifugation (15 sec at >10,000 rpm). If yield is low, reapply the flowthrough to the column and centrifuge again.

Then, transfer column to a new 2 ml collection tube and add 500 ul Buffer RPE and centrifuge for 15 sec at >10,000 rpm. The flowthrough is discarded. 500 ul Buffer RPE and is then added and the preparation is centriuged for 15 sec at >10,000 rpm. The flowthrough is discarded. and the column membrane dried by centrifuging for 2 min at maximum speed. The column is transferred to a new 1.5-ml collection tube. 30-50 ul of RNase-free water is applied directly onto column membrane. The column is then centrifuged for 1 min at >10,000 rpm and the elution step repeated.

The absorbance is then read to determine yield. If necessary, the material may be ethanol precipitated with ammonium acetate and 2.5X volume 100% ethanol.

15

20

30

10

5

First Strand cDNA Synthesis

The first strand can be make using using Gibco's "SuperScript Choice System for cDNA Synthesis" kit. The starting material is 5 ug of total RNA or 1 ug of polyA+ mRNAl. For total RNA, 2 ul of SuperScript RT is used; for polyA+ mRNA, 1 ul of SuperScript RT is used. The final volume of first strand synthesis mix is 20 ul. The RNA should be in a volume no greater than 10 ul. The RNA is incubated with 1 ul of 100 pmol T7-T24 oligo for 10 min at 70°C followed by addition on ice of 7 ul of: 4ul 5X 1st Strand Buffer, 2 ul of 0.1M DTT, and 1 ul of 10mM dNTP mix. The preparation is then incubated at 37°C for 2 min before addition of the SuperScript RT followed by incubation at 37°C for 1

25 hour.

Second Strand Synthesis

For the second strand synthesis, place 1st strand reactions on ice and add: 91 ul DEPC H₂0; 30 ul 5X 2nd Strand Buffer; 3 ul 10mM dNTP mix; 1 ul 10 U/ul E.coli DNA Ligase; 4 ul 10 U/ul E.coli DNA Polymerase; and 1 ul 2 U/ul RNase H. Mix and incubate 2

hours at 16°C. Add 2 ul T4 DNA Polymerase. Incubate 5 min at 16°C. Add 10 ul of 0.5M EDTA.

Cleaning up cDNA

The cDNA is purified using Phenol:Chloroform:Isoamyl Alcohol (25:24:1) and Phase-Lock gel tubes. The PLG tubes are centrifuged for 30 sec at maximum speed. The cDNA mix is then transferred to PLG tube. An equal volume of phenol:chloroform:isamyl alcohol is then added, the preparation shaken vigorously (no vortexing), and centrifuged for 5 minutes at maximum speed. The top aqueous solution is transferred to a new tube and ethanol precipitated by adding 7.5X 5M NH4OAc and 2.5X volume of 100% ethanol. Next, it is centrifuged immediately at room temperature for 20 min, maximum speed. The supernatant is removed, and the pellet washed with 2X with cold 80% ethanol. As much ethanol wash as possible should be removed before air drying the pellet; and resuspending it in 3 ul RNase-free water.

15

20

25

30

10

5

In vitro Transcription (IVT) and labeling with biotin

In vitro Transcription (IVT) and labeling with biotin is performed as follows: Pipet 1.5 ul of cDNA into a thin-wall PCR tube. Make NTP labeling mix by combining 2 ul T7 10xATP (75 mM) (Ambion); 2 ul T7 10xGTP (75 mM) (Ambion); 1.5 ul T7 10xCTP (75 mM) (Ambion); 1.5 ul T7 10xUTP (75 mM) (Ambion); 3.75 ul 10 mM Bio-11-UTP (Boehringer-Mannheim/Roche or Enzo); 3.75 ul 10 mM Bio-16-CTP (Enzo); 2 ul 10x T7 transcription buffer (Ambion); and 2 ul 10x T7 enzyme mix (Ambion). The final volume is 20 ul. Incubate 6 hours at 37°C in a PCR machine. The RNA can be furthered cleaned. Clean-up follows the previous instructions for RNeasy columns or Qiagen's RNeasy protocol handbook. The cRNA often needs to be ethanol precipitated by resuspension in a volume compatible with the fragmentation step.

Fragmentation is performed as follows. 15 ug of labeled RNA is usually fragmented. Try to minimize the fragmentation reaction volume; a 10 ul volume is recommended but 20 ul is all right. Do not go higher than 20 ul because the magnesium in the fragmentation buffer contributes to precipitation in the hybridization buffer. Fragment

RNA by incubation at 94 C for 35 minutes in 1 x Fragmentation buffer (5 x Fragmentation buffer is 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc). The labeled RNA transcript can be analyzed before and after fragmentation. Samples can be heated to 65°C for 15 minutes and electrophoresed on 1% agarose/TBE gels to get an approximate idea of the transcript size range

For hybridization, 200 ul (10 ug cRNA) of a hybridization mix is put on the chip. If multiple hybridizations are to be done (such as cycling through a 5 chip set), then it is recommended that an initial hybridization mix of 300 ul or more be made. The hybridization mix is: fragment labeled RNA (50 ng/ul final conc.); 50 pM 948-b control oligo; 1.5 pM BioB; 5 pM BioC; 25 pM BioD; 100 pM CRE; 0.1 mg/ml herring sperm DNA; 0.5 mg/ml acetylated BSA; and 300 ul with 1xMES hyb buffer.

The hybridization reaction is conducted with non-biotinylated IVT (purified by RNeasy columns) (see example 1 for steps from tissue to IVT): The following mixture is prepared:

15 IVT antisense RNA; 4 μg: μ l Random Hexamers (1 μg/μl): 4 μl H₂O: μ l 14 μl

10

25

Incubate the above 14 µl mixture at 70°C for 10 min.; then put on ice.

The Reverse transcription procedure uses the following mixture:

0.1 M DTT: 3 μl
50X dNTP mix: 0.6 μl
H₂O: 2.4 μl
Cy3 or Cy5 dUTP (1mM): 3 μl
SS RT II (BRL): 1 μl

The above solution is added to the hybridization reaction and incubated for 30 min., 42°C. Then, 1 µl SSII is added and incubated for another hour before being placed on ice.

16 µl

The 50X dNTP mix contains 25mM of cold dATP, dCTP, and dGTP, 10mM of dTTP and is made by adding 25 μl each of 100mM dATP, dCTP, and dGTP; 10 μl of 100mM dTTP to 15 μl H₂O.]

RNA degradation is performed as follows. Add 86 µl H₂O, 1.5 µl 1M NaOH/2 mM EDTA and incubate at 65°C, 10 min.. For U-Con 30, 500 µl TE/sample spin at 7000 g for 10 min, save flow through for purification. For Qiagen purification, suspend u-con recovered material in 500 µl buffer PB and proceed using Qiagen protocol. For DNAse digestion, add 1 ul of 1/100 dilution of DNAse/30 ul Rx and incubate at 37°C for 15 min. Incubate at 5 min 95°C to denature the DNAse.

10

15

5

Sample preparation

For sample preparation, add Cot-1 DNA, 10 μ l; 50X dNTPs, 1 μ l; 20X SSC, 2.3 μ l; Na pyro phosphate, 7.5 μ l; 10 mg/ml Herring sperm DNA; 1 ul of 1/10 dilution to 21.8 final vol. Dry in speed vac. Resuspend in 15 μ l H₂0. Add 0.38 μ l 10% SDS. Heat 95°C, 2 min and slow cool at room temp. for 20 min. Put on slide and hybridize overnight at 64°C. Washing after the hybridization: 3X SSC/0.03% SDS: 2 min., 37.5 ml 20X SSC+0.75ml 10% SDS in 250ml H₂O; 1X SSC: 5 min., 12.5 ml 20X SSC in 250ml H₂O; 0.2X SSC: 5 min., 2.5 ml 20X SSC in 250ml H₂O. Dry slides and scan at appropriate PMT's and channels.

TABLE 1: Figure 1 from BRCA 001 US

Table 1 shows genes, (incorporated in their entirety here and throughout the application where primekeys are provided), downregulated in tumor tissue compared to normal breast tissue.

10							
			Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number				
	ExAccn: Unigene		jene number	ion number, Gendank accession number			
	Unigene		jene gene title	9			
15	R1:			reast tissue to tumor			
				5			
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1		
20	100 170	500004	LI 4000	to be to the second behavior	-		
20		D90084 T51986	Hs.1023	pyruvate dehydrogenase (lipoamide) alpha	5 10		
		M55405	HS.200100	hemoglobin, gamma G qb:Homo sapiens mucin (MUC-3) mRNA, part	5		
		BE142019	Hs 222056	Homo sapiens cDNA FLJ11572 fis, clone HE	10		
		X52078		transcription factor 3 (E2A immunoglobul	5		
25		BE259039		Ewing sarcoma breakpoint region 1	5		
		X16841		neural cell adhesion molecule 1	5		
		A03758		NM_000477*:Homo sapiens albumin (ALB), m	10		
		L27065		gb:Human neurofibromatosis 2 (NF2) mRNA,	5		
		M60832	Hs.249239	collagen, type VIII, alpha 2	5		
30		BE379727	Hs.83213		10		
	101125	AJ250562	Hs.82749	transmembrane 4 superfamily member 2	5		
	101166	M90424	Hs.2099	lipocalin 1 (protein migrating faster th	5		
	101184	NM_001674	Hs.460	activating transcription factor 3	10		
~ -		NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10		
35		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10		
		M21305		gb:Human alpha satellite and satellite 3	10		
		N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10		
		M27826		endogenous retroviral protease	10		
40		AV650262	Hs.75765		5		
40		M74447	Hs.502	transporter 2, ATP-binding cassette, sub	10		
		U22961	U- 4000C0	gb:Human mRNA clone with similarity to L	10		
		NM_001504		G protein-coupled receptor 9	5 10		
		U48251	Hs.75871	protein kinase C binding protein 1 tenascin XB	10		
45		U89337 U60115		four and a half LIM domains 1	5		
73		AA313538	115.235005	gb:EST185419 Colon carcinoma (HCC) cell	10		
		NM_006744	Hs.76461	retinol-binding protein 4, interstitial	10		
		AA829286		serum amyloid A1	10		
		X98085	Hs.54433	tenascin R (restrictin, janusin)	5		
50		AA081995	, , , , , , , , , , , , , , , , , , , ,	gb:zn26d06.r1 Stratagene neuroepithelium	10		
-		AA126129		gb:zm78c07.r1 Stratagene neuroepithelium	5		
		AA137107	Hs.326391	Homo sapiens, clone MGC:16638, mRNA, com	10		
		AA326216	Hs.8719	hypothetical protein MGC1136	5		
		AB041036	Hs.57771	••• • • • • • • • • • • • • • • • • • •	5		
55		R50727	Hs,336970	ESTS	10		
	104106	AA422123		gb:zv26h12.r1 Soares_NhHMPu_S1 Homo sapi	5		
		AL353957	Hs.284181	hypothetical protein DKFZp434P0531	10		
	104250	F06638	Hs.12440		10		
		AA426189		gb:zw11e09.r1 Soares_NhHMPu_S1 Horno sapi	5		
60	104492	N73185	Hs.94285		10		
		N91071	Hs.109650		10		
		N99542	Hs.572	orosomucoid 1	5		
	104532	AI498763	Hs.203013	hypothetical protein FLJ12748	10		

104536 R24024 Hs.158101 Homo sapiens cDNA FLJ14673 fis, done NT Hs.104639 AW899769 Hs.105201 ESTS Hs.105201 ESTS 104711 AA017245 Hs.190380 ESTS 104731 AA019304 Hs.190380 ESTS 105005 AA103904 Hs.125070 ESTS, Moderately similar to I54374 gene Hs.28065 ESTS 105005 AA10390 Hs.28065 ESTS 105005 AA10390 Hs.28065 ESTS 105036 AA10390 Hs.28065 ESTS 105231 AW970043 Hs.28061 hypothetical protein FLJ20988 Hs.28061 hypothetical protein FLJ1090 gbz:20f12.71 Stratagene NT2 neuronal pr Hs.1919 ESTS, Weakly similar to T25731 hypothetic 106194 AW976171 Hs.286194 hypothetical protein FLJ1159 ESTS, Highly similar to T00391 hypothetic 106194 AW976171 Hs.286194 hypothetical protein FLJ22233 Hs.19160 ESTS 106393 AD224069 Hs.25522 klAA1808 protein Hs.191608 ESTS 106391 AA135688 Hs.1083 Hs.25522 klAA1808 protein Hs.3776 106762 AW054886 Hs.25521 hrom sapiens, clone IMAGE:4139786, mRNA, 18.26530 106870 A9803730 Hs.26530 106870 A980342 Hs.26530 Serum deprivation response (phosphatidyl hypothetical protein in MGC2605 Hs.25692 107144 AF127026 Hs.26530 Serum deprivation response (phosphatidyl hypothetical protein in MGC2605 107214 AF127026 Hs.23420 Hs.33430 ESTS 107313 AW95985 Hs.11805 ESTS 107331 AW95985 Hs.154015 hypothetical protein in MGC2605 Hs.26500 Hypothetical protein in MGC2605 Hs.26620 Hypothetical protein in MGC2605 Hs.26500 Hypothetical protein in MGC2605 Hypothetical protein in MGC2605 Hypothetical protein in MGC2605 Hypothet
104659 AW969769 Hs. 105201 ESTs 104677 AA009764 Hs. 190302 ESTs 104731 AA017245 Hs. 32794 ESTs 104731 AA019300 Hs. 125070 ESTs, Moderately similar to I54374 gene 105036 AA103930 Hs. 25845 ESTs 105036 AA103090 Hs. 25849 hypothetical protein FLJ20898 hypothetical protein FLJ20898 hypothetical protein FLJ22838 hypothetical protein FLJ21898 ESTs, Weakly similar to 125731 hypothetil hypothetical protein FLJ11199 gestoff for the first protein FLJ21893 hypothetical protein FLJ21838 hypothetical protein FLJ22233 hypothetical protein FLJ2233 hypothetical protein
104677 AA009764
104711 AA017245
104731 AA019300
104731 AA019300
105005 Al299208
105005 Al298208
105036 AA130390
10 105105 R61532
105231 AW970043
105239 AA21036
105921 AA421973 105927 BE242857 Hs.169119 ESTs, Weakly similar to T25731 hypothetil hypothetical protein FLJ11159 106052 N79885 Hs.6382 ESTs, Highly similar to T00391 hypothetil Hs.191608 ESTs, Highly similar to T00391 hypothetil Hs.191608 ESTs hypothetical protein FLJ22233 Hs.286194 hypothetical protein FLJ22233 Hs.19021 bkFzP434N061 protein Hs.19021 bkFzP434N061 protein Hs.19021 bkFzP434N061 protein Hs.313182 ESTs Homo sapiens, clone IMAGE:4139786, mRNA, zinc finger protein 216 Homo sapiens mRNA for KIAA1863 protein, gb:tk04g09.x1 NCI_CGAP_Lu24 Homo sapiens serum deprivation response (phosphatidyl hypothetical protein MGC2605 indolethylamine N-methyltransferase hypothetical protein Hs.30127 hypothetical protein ESTs, Highly similar to CYA5_HUMAN ADENY RecQ protein-like 4 Hs.26632 Hs.334305 GS1999full myosin IA INA065032 Hs.11805 ESTs Highly similar to ALU8_HUMAN A PTEN induced putative kinase 1 hypothetical protein PGC2389 hypothetical protein PGC2389 hypothetical protein FLJ14529 Empirically selected from AFFX single pr Hs.47623 ESTs Homo AFFX single pr Hs.47623 ESTs
105957 BE242857 Hs.27021 hypothetical protein FLJ11159
15 106052 N79885
106119 AL359624 Hs.11387 KIAA1453 protein
106181 Al803651
106194 AW976171 Hs.286194 hypothetical protein FLJ22233 106283 Al085846 Hs.25522 KlAA1808 protein 106491 AV235928 Hs.313182 ESTs 106491 AA135688 Hs.10083 Hs.0083 106700 AA906434 Hs.3776 zinc finger protein 216 106870 Al983730 Hs.25682 Hs.25682 Hs.25682 Hs.26530 serum deprivation response (phosphatidyl 106892 Al347578 Hs.124015 hypothetical protein MGC2605 hypothetical protein FLJ14529 fypithetical protein FLJ14529 hypothetical protein
106283 Al085846 Hs.25522 KlAA1808 protein 106379 AL042069 Hs.119021 DKFZP434N061 protein 106451 AW235928 Hs.1083 Homo sapiens, clone IMAGE:4139786, mRNA, 106700 AA906434 Hs.3776 zinc finger protein 216 106851 Al458623 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 106870 Al983730 Hs.26530 serum deprivation response (phosphatidyl 106892 Al347578 Hs.124015 hypothetical protein MGC2605 106892 AF128847 Hs.204038 indolethylamine N-methyltransferase 106991 AJ223811 Hs.30127 hypothetical protein 107103 Al446183 Hs.9572 ESTs, Highly similar to CYA5_HUMAN ADENY 107124 AB006532 Hs.33405 GS1999full 107214 AF127026 Hs.5394 myosin IA 107424 AB020672 Hs.175411 KlAA0865 protein 107331 Al905985 Hs.111805 ESTs 107331 US1704 Hs.232428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 hypothetical protein MGC11308 107467 W28516 Hs.19210 hypothetical protein MCC11308 107451 AL042425 Hs.283976 hypothetical protein FL014529 Empirically selected from AFFX single pr 107683 N53167 Hs.220687 ESTs 107754 AA017462 Hs.26087 ESTs
20
106451 AW235928 Hs.313182 ESTs 106491 AA135688 Hs.10083 Homo sapiens, clone IMAGE:4139786, mRNA, 106702 AW054886 Hs.25682 Homo sapiens protein 216 106851 Al458623 Hs.25682 Homo sapiens mRNA for KIAA1863 protein, 106870 Al983730 Hs.26530 serum deprivation response (phosphatidyl 106892 Al347578 Hs.124015 hypothetical protein MGC2605 106954 AF128847 Hs.204038 indolethylamine N-methyltransferase 106991 AJ223811 Hs.9572 ESTs, Highly similar to CYA5_HUMAN ADENY 107124 AB006532 Hs.31442 RecQ protein-like 4 107124 AB006532 Hs.334305 GS1999full 107214 AF127026 Hs.5394 myosin IA 107242 AB020672 Hs.175411 KIAA0865 protein 107331 Al905985 Hs.11805 ESTs 107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107453 Al092790 Hs.334703 hypothetical protein FL04529 Empirically selected from AFFX single pr 107683 N53167 Hs.269244 ESTs
106491 AA135688 Hs. 10083 Homo sapiens, clone IMAGE:4139786, mRNA, 106700 AA906434 Hs. 3776 zinc finger protein 216 Hs. 25682 Homo sapiens mRNA for KIAA 1863 protein, gb:tk04909.x1 NCI_CGAP_Lu24 Homo sapiens serum deprivation response (phosphatidyl hypothetical protein MGC2605 106851 AI458623 Hs. 26530 serum deprivation response (phosphatidyl hypothetical protein MGC2605 106954 AF128847 Hs. 204038 hs. 124015 hypothetical protein MGC2605 107991 AJ223811 Hs. 30127 hypothetical protein MGC2605 107103 AI446183 Hs. 30127 hypothetical protein GC2605 107124 AB006532 Hs. 31442 RecQ protein-like 4 107124 AB006532 Hs. 334305 GS1999full myosin IA 107214 AF127026 Hs. 175411 KIAA0865 protein 107242 AB020672 Hs. 175411 KIAA0865 protein 107331 AI905985 Hs. 111805 ESTs 107351 U51704 Hs. 323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs. 6163 PTEN induced putative kinase 1 107447 W28516 Hs. 19210 hypothetical protein MGC11308 107451 AL042425 Hs. 283976 hypothetical protein FL014529 Empirically selected from AFFX single pr 107683 N53167 Hs. 220687 ESTs 107754 AA017462 Hs. 26084 ESTs
106491 AA135688
106700 AA906434
106782 AW054886
25 106851 Al458623
106870 Al983730 Hs.26530 serum deprivation response (phosphatidyl hypothetical protein MGC2605 hypothetical protein MGC2605 hs.204038 indolethylamine N-methyltransferase hypothetical protein hypothetical hypothetical hy
106892 Al347578
106954 AF128847 Hs.204038 indolethylamine N-methyltransferase hypothetical protein 106991 AJ223811 Hs.9572 ESTs, Highly similar to CYA5_HUMAN ADENY 107104 AB006532 Hs.31442 RecQ protein-like 4 107148 A1005036 Hs.334305 GS1999full myosin IA 107214 AF127026 Hs.5394 myosin IA 107242 AB020672 Hs.175411 KIAA0865 protein 107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein FL14529 107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
106991 AJ223811 Hs.30127 hypothetical protein 107103 Al446183 Hs.39572 ESTs, Highly similar to CYA5_HUMAN ADENY 107124 AB006532 Hs.31442 RecQ protein-like 4 107124 AF127026 Hs.5394 myosin IA 107242 AB020672 Hs.175411 KIAA0865 protein 107331 Al905985 Hs.111805 ESTs 107331 U51704 Hs.6163 Hs.111805 ESTs 10747 W28516 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hyphetical protein FL02389 107459 W38002 Hs.334703 hypothetical protein FL014529 Empirically selected from AFFX single pr 107683 N53167 Hs.47623 ESTs 107754 AA017462 Hs.269244 ESTs
107103 Al446183
107124 AB006532 Hs.31442 RecQ protein-like 4 107214 AF127026 Hs.334305 GS1999full 107214 AF127026 Hs.5394 myosin IA 107242 AB020672 Hs.175411 KIAA0865 protein 35 107331 AI905985 Hs.11805 ESTs 107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein PRO2389 107452 W38002 ESTS 107711 W96141 Hs.220687 ESTS 107754 AA017462 Hs.269244 ESTS
107148 Al005036 Hs.334305 GS1999full myosin IA 107214 AF127026 Hs.5394 myosin IA 107242 AB020672 Hs.175411 KIAA0865 protein 107331 Al905985 Hs.11805 ESTs 107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein PRO2389 107459 W38002 Hs.334703 hypothetical protein FL14529 Empirically selected from AFFX single pr 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
107214 AF127026 Hs.5394 myosin IA 107242 AB020672 Hs.175411 KIAA0865 protein 107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.66163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein PRO2389 107459 W38002 Hs.334703 hypothetical protein FL14529 Empirically selected from AFFX single pr 107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
35 107242 AB020672 Hs.175411 KiAA0865 protein 107331 Al905985 Hs.111805 ESTs 107351 U51704 Hs.2323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein PRO2389 40 107453 Al092790 Hs.334703 hypothetical protein FLJ14529 Empirically selected from AFFX single pr 107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
107331 Al905985 Hs.111805 ESTs 107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107451 AL042425 Hs.9210 hypothetical protein MGC11308 107453 Al092790 Hs.334703 hypothetical protein PRO2389 107459 W38002 107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220667 ESTs 107754 AA017462 Hs.269244 ESTs
107351 U51704 Hs.323428 ESTs, Moderately similar to ALU8_HUMAN A 107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypthetical protein PRO2389 107459 W38002 Hs.334703 hypothetical protein FLJ14529 Empirically selected from AFFX single pr 107711 W96141 Hs.220667 ESTs 107754 AA017462 Hs.269244 ESTs
107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein PRO2389 107459 W38002 Hs.334703 hypothetical protein FLJ14529 Empirically selected from AFFX single pr 107741 W96141 Hs.220667 ESTs 107754 AA017462 Hs.269244 ESTs
107423 W26652 Hs.6163 PTEN induced putative kinase 1 107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein PRO2389 107459 W38002 Hs.334703 hypothetical protein FLJ14529 Empirically selected from AFFX single pr 107741 W96141 Hs.220667 ESTs 107754 AA017462 Hs.269244 ESTs
107447 W28516 Hs.19210 hypothetical protein MGC11308 107451 AL042425 Hs.283976 hypothetical protein PRO2389 107452 W38002 Hs.334703 hypothetical protein FL14529 Empirically selected from AFFX single pr 107741 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
107451 AL042425 Hs.283976 hypthetical protein PRO2389 107453 Al092790 Hs.334703 hypothetical protein FLJ14529 Empirically selected from AFFX single pr 107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
40 107453 Al092790 Hs.334703 hypothetical protein FLJ14529 107459 W38002 Empirically selected from AFFX single pr 107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
107459 W38002 Empirically selected from AFFX single pr 107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
107683 N53167 Hs.47623 ESTs 107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
107711 W96141 Hs.220687 ESTs 107754 AA017462 Hs.269244 ESTs
107754 AA017462 Hs.269244 ESTs
45 107/57 BE621721 Hs.280792 hypothetical protein Ftb 12367 similar to
400004 44000000 11-04040 EOT-
107864 AA025060 Hs.61246 ESTs
107872 BE271708 Hs.95110 ESTs, Weakly similar to A55943 1-phospha
107888 AA025836 Hs.191637 ESTs
107997 AL049176 Hs.82223 chordin-like
50 108056 AA043675 Hs.62633 ESTs .
108081 AA093668 Hs.28578 muscleblind (Drosophila)-like
108113 AA012881 Hs.72531 hypothetical protein FLJ11838
108238 AA059473 Hs.66783 EST
108257 AA677927 Hs.144269 ESTs
55 108335 AA070500 gb:zm70h03.s1 Stratagene neuroepithelium
108351 AA071193 gb:zf79b12.s1 Soares_pineal_gland_N3HPG
108382 NM_006770 Hs.67726 macrophage receptor with collagenous str
108392 AA075124 gb:zm86a01.s1 Stratagene ovarian cancer
100002 70010 124 gb:2110000 1:31 0 to to to go in o station of the
409441 AA070070 gb:zm07c09 s1 Stratagene colon HT29 (937
108441 AA079079 gb:zm97c09.s1 Stratagene colon HT29 (937
60 108446 AA085383 gb:zn13q03.s1 Stratagene hNT neuron (937
60 108446 AA085383 gb:zn13g03.s1 Stratagene hNT neuron (937 108497 AA074897 gb:zm85a05.r1 Stratagene ovarian cancer
60 108446 AA085383 gb:zn13g03.s1 Stratagene hNT neuron (937 gb:zm85a05.r1 Stratagene ovarian cancer 108604 AA934589 Hs.49696 ESTs
60 108446 AA085383 gb:zn13g03.s1 Stratagene hNT neuron (937 gb:zm85a05.r1 Stratagene ovarian cancer 108604 AA934589 Hs.49696 ESTs 108662 AF117646 Hs.156637 Cas-Br-M (murine) ectropic retroviral tr
108446 AA085383 gb:zn13g03.s1 Stratagene hNT neuron (937 gb:zm85a05.r1 Stratagene ovarian cancer 108604 AA934589 Hs.49696 ESTs 108662 AF117646 Hs.156637 Cas-Br-M (murine) ectropic retroviral tr KIAA0842 protein
60 108446 AA085383 gb:zn13g03.s1 Stratagene hNT neuron (937 gb:zm85a05.r1 Stratagene en hNT neuron (937 gb:zm85a05.r1 Stratagene ovarian cancer ESTs
108446 AA085383 gb:zn13g03.s1 Stratagene hNT neuron (937 gb:zm85a05.r1 Stratagene ovarian cancer 108604 AA934589 Hs.49696 ESTs 108662 AF117646 Hs.156637 Cas-Br-M (murine) ectropic retroviral tr KIAA0842 protein

	109389	AA101325	Hs.86154	hypothetical protein FLJ12457	10
		F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	5
		R40604		ESTs, Weakly similar to MCAT_HUMAN MITOC	10
5		A1094674	Hs.30524	ring finger protein 24	10
3		H46749	Hs.31540	ESTs	10
		W22165	Hs.22586		5 10
		AW294162 H51276	Hs.13526	UDP-N-acetyl-alpha-D-galactosamine:polyp hypothetical protein FLJ12688	10
	110455	H52576	113.13020	gb:yt85e08.r1 Soares_pineal_gland_N3HPG	5
10		H72639	Hs.167608		5
		H60593	Hs.124990		10
	110976	AL044174	Hs.159526	patched (Drosophila) homolog	10
	110987	AI753316	Hs.26034	ESTs	5
1.5		N66616	Hs.138629	H.sapiens mRNA for subtelomeric repeat s	5
15		AI798376		gb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10
		AJ224864	Hs.9688	leukocyte membrane antigen	5 5
		AA641636	Hs.37477		10
		R00144 Al168511	Hs.189771	gb:ow90h09.s1 Soares_fetal_liver_spleen_	10
20		R16733	Hs.20499	ESTs	10
		R26065	110.20100	gb:yh39d03.s1 Soares placenta Nb2HP Homo	5
		AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
		R42333	Hs.302292		10
		AL117490	Hs.47225		10
25		NM_006668	Hs.25121		10
		R51889	Hs.24990	ESTs	5
		R31094	Hs.24378	ESTs	10 10
		R77302 BE618629	Hs.268809	gb:yi75h08.s1 Soares placenta Nb2HP Homo	5
30		T98628	Hs.191290		5
50		AI057205	Hs.14584		5
		AA581428	Hs.5021	EST	10
		T16837	Hs.4241	ESTs	5
	113149	T51588	1	gb:yb27e06.s1 Stratagene fetal spleen (9	10
35		T54659		Homo sapiens cDNA FLJ11465 fis, clone HE	5
		AA743563	Hs.10305		5
		AW207424	Hs.332594		10 10
		N92359 R16763	Hs.14518 Hs.268679	ESTs, Moderately similar to A48752 B-cel	5
40		AA913635		Homo sapiens cDNA FLJ20812 fis, clone AD	10
-10		R06874		ESTs, Moderately similar to ALU1_HUMAN A	5
		AI791905	Hs.95549	hypothetical protein	10
		AI244311	Hs.26912	ESTs	10
		W07586	Hs.8045	ESTs	3
45		W86195		gb:zh54e05.s1 Soares_fetal_liver_spleen_	· 10
		Z39319	Hs.27347	EST	10
		AB018263	Hs.180338 Hs.28273	tumor necrosis factor receptor superfami ESTs	5 5
		AA745978 AA020736	115.20213	gb:ze63b11.s1 Soares retina N2b4HR Homo	5
50		AA034378	Hs.267319	endogenous retroviral protease	5
		AA065096		gb:zrr50a02.s1 Stratagene fibroblast (937	5
		AA081507		gb:zn05b10.r1 Stratagene hNT neuron (937	5
	114844	AA234826	Hs.87386	EST	5
		AA234462	Hs.87350	ESTs	5
55		AK000725	Hs.50579	hypothetical protein FLJ20718	3
		AF173081		Vertebrate LIN7 homolog 1, Tax interacti	5 5
		AB020649 AA398841	Hs.74569	KIAA0842 protein hypothetical protein FLJ20517	10
		AI478427	Hs.39850 Hs.43125	esophageal cancer related gene 4 protein	10
60	116107	AL133916		hypothetical protein FLJ20093	10
55		AA463902	Hs.13522	ESTs, Weakly similar to I38022 hypotheti	5
		AW968703	Hs.30085	hypothetical protein FLJ23186	5
	116291	AW410377	Hs.41502	hypothetical protein FLJ21276	5
		AW194253	Hs.68607	ESTs	10
65	116659	BE314852		Homo sapiens clone 23763 unknown mRNA, p	5 5
		F10528 AW801806	Hs.70001	ESTs, Moderately similar to JC6169 nucle gb:lL5-UM0070-110400-062-g07 UM0070 Homo	5 5
	11/000	VAA00 1000		go.is-dividoro-110400-002-gor dividoro Hollio	3

		AI803656	Hs.42373	ESTs	5
		N20468		gb:yx39b10.s1 Soares melanocyte 2NbHM Ho	10
		AI472863	Hs.43387	ESTs	5
_		N34417	Hs.44584	ESTs	3
5		N26627	Hs.82364	ESTs, Weakly similar to JC4124 pregnancy	5
		N40551		Homo sapiens Ets-1 binding protein (E1B)	10
		N49285	Hs.182391		10
		AW263476	Hs.44268	, , ,	10 5
10		BE222341	Hs.279472		3
10		N53145 AW955696	Hs.90960	gb:yv55f09.s1 Soares fetal liver spleen ESTs	10
		A1078236	Hs.49688	ESTS	5
		N70907	Hs.230619		· 10
		AL122040		Homo sapiens mRNA; cDNA DKFZp434G1972 (f	3
15		AA993527		hypothetical protein FLJ23403	5
		AI160570		pregnancy specific beta-1-glycoprotein 6	3
	119159	AF142419	Hs.15020		5
	119216	AA514422	Hs.221849	ESTs	5
	119317	AK002001	Hs.51305	v-maf musculoaponeurotic fibrosarcoma (a	10
20	119366	T77892		gb:yd20f04.s1 Soares fetal liver spleen	5
		T81824	Hs.90949	EST	5
		W38051		Empirically selected from AFFX single pr	10
		AL049798	Hs.80552	dermatopontin	3
26		AF086332	Hs.58314	ESTs	10
25		AF088061	Hs.159690		5
		AF086429	Hs.58429	ESTs	5 5
		AW803308 U34249	Hs.62954	femitin, heavy polypeptide 1 Human putative zinc finger protein (ZNFB	5
		AL042725	DS.33/401	gb:DKFZp434B1822_r1 434 (synonym: htes3)	10
30		AW136934	Hs.97162	ESTs	5
50		AA907743	Hs.142373		5
		AA401695	Hs.97334	ESTs	5
		AA405763		Homo sapiens cDNA FLJ20470 fis, clone KA	5
	121764	AA421452		ESTs, Weakly similar to KIAA0926 protein	5
35	122034	AK000229	Hs.98017	Homo sapiens cDNA FLJ20222 fis, clone CO	10
-	122441	AA447555	Hs.99116	EST	10
		AA458945	Hs.95898	ESTs	10
		AW135093	Hs.97282	ESTs, Highly similar to G100_HUMAN 110 K	5
40		AA609122		Homo sapiens mRNA; cDNA DKFZp434D2472 (f	5
40		AI024595	Hs.97508	a disintegrin and metalloproteinase doma	5
		AA621529		gb:af47a02.s1 Soares_total_fetus_Nb2HF8_	10 5
		H62570 H83465		gb:yr44a01.r1 Soares fetal liver spleen gb:ys91a11.s1 Soares retina N2b5HR Homo	5
		AK001527	He 163053	hypothetical protein FLJ10665	5
45		NM_014312		cortic al thymocyte receptor (X. laevis	10
		T98199	Hs.48403	hypothetical protein FLJ10847	10
		BE299567		ESTs, Moderately similar to ALU8_HUMAN A	5
		NM_002666	Hs.103253		10
		BE256206	Hs.17775	p75NTR-associated cell death executor; o	5
50	128484	AA485421	Hs.270503	ESTs, Weakly similar to ALU7_HUMAN ALU S	10
	128511	NM_002250	Hs.10082	potassium intermediate/small conductance	10
		R44214	Hs.101189		5
		C16161		hypothetical protein PRO2543	5
<i>5 5</i>		AA193106		chromosome 11 open reading frame 23	10
55		H39537	Hs.75309	eukaryotic translation elongation factor	10 10
		AW150717		STAT induced STAT inhibitor 3 Homo sapiens cDNA FLJ12965 fis, clone NT	10
		N62889 AA443323		BPOZ protein	5
		AA056483		Human Chromosome 16 BAC clone CIT987SK-A	5
60		NM_013403	Hs.108665		10
50		AL117472		SH3-domain protein 5 (ponsin)	5
		A1146494		ESTs, Weakly similar to IRX2 HUMAN IROQU	3
		U40714		tyrosyl-tRNA synthetase	5
		AA530892		dual specificity phosphatase 1	5
65		BE617015	Hs.11006	ESTs, Moderately similar to T17372 plasm	10
		AF110141		WAS protein family, member 2	10
	129368	NM_003877	Hs.110776	STAT induced STAT inhibitor-2	5

	129371	X06828	Hs 110802	von Willebrand factor	5
		AW245805		claudin 5 (transmembrane protein deleted	10
		W37944	Hs.4007	Sarcolemmal-associated protein	5
		BE061069		KIAA0467 protein	10
5		AF020038	Hs.11223	•	10
		BE222078	Hs.113069		10
	129684	BE622468	Hs.11924	ESTs, Weakly similar to I38022 hypotheti	5
		Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	5
	129778	AK001676	Hs.12457	hypothetical protein FLJ10814	10
10		AK000956	Hs.13209		5
		Al338993	Hs.134535		5
		AJ251760		guanine nucleotide binding protein (G pr	5
	129977	NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	5
15		NM_001158	Hs.143102	amine oxidase, copper containing 2 (reti	5
13		M62402		Insulin-like growth factor binding prote	10 5
		AA452006	Hs.333199		5
		W80711 D88435		Homo saplens mRNA for KIAA1727 protein,	10
		Al241084		cyclin G associated kinase nonselective sodium potassium/proton exc	5
20		AA435746	113,134303	gb:zt79e03.s1 Soares_testis_NHT Homo sap	5
20		V00517	Hs 283108	hemoglobin, gamma G	10
		NM_001928		D component of complement (adipsin)	10
		X72308		small inducible cytokine A7 (monocyte ch	5
		BE222978	Hs.15760		10
25		AW390834	Hs.75874	pregnancy-associated plasma protein A	5
	130563	BE270472	Hs.279900	HSPC015 protein	10
	130589	AL110226	Hs.16441	DKFZP434H204 protein	10
•		AI652143		hypothetical protein FLJ13111	5
20		Al769067		ESTs, Weakly similar to T28770 hypotheti	3
30		AA993269	Hs.17872		10
		NM_006691	Hs.17917	extracellular link domain-containing 1	10
		AA232075	Hs. 18259	XPA binding protein 1; putative ATP(GTP)	5
		AF263462	Hs. 18376	KIAA1319 protein	10
35		N41322 M81349	Hs.18441 Hs.1955	ESTs serum amyloid A4, constitutive	5 10
55		BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
		AB040935	Hs.23954	cerebral cell adhesion molecule	10
		AA360419		inositol(myo)-1(or 4)-monophosphatase 1	10
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
40		AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
		AK000393	Hs.25817		5
	131341	AF110908	Hs.297660	TNF receptor-associated factor 3	5
	131406	H83294	Hs.284122	Wnt inhibitory factor-1	5
4.5		BE394648	Hs.27414	hypothetical protein	5
45		AW966881	Hs.41639	programmed cell death 2	10
		BE559681	Hs.30736		5
		AA829286		serum amyloid A1	10
		AA443966	Hs.31595		10
50		H69342	Hs.26320	TRABID protein	10 5
50		AA021258 BE244961	Hs.32753	ESTs FE65-LIKE 2	5
		AJ000263		keratin, hair, basic, 6 (monilethrix)	10
		AW294659	Hs.34054	Homo sapiens cDNA: FLJ22488 fis, clone H	5
		AJ003112	Hs.34780	doublecortex; lissencephaly, X-linked (d	5
55		AK000010		hypothetical protein FLJ20003	10
		H81604		KIAA0798 gene product	5
		X80818		glutamate receptor, metabotropic 4	5
	132296	AA467752	Hs.195161	ESTs	5
	132426	AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
60	132477	S68874		prostaglandin E receptor 3 (subtype EP3)	5
	132675	Al291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
	132796	NM_006283		transforming, acidic coiled-coil contain	10
		W28548	Hs.224829		10
65	132905	NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
65		BE175645		LBP protein 32	5 5
	133116	BE563966 NM_003278	Hs.6529 Hs.65424	ESTs, Weakly similar to I78885 serine/th tetranectin (plasminogen-binding protein	10
	133 120	1414[_003210	115.03424	renancent (higanitiodet-muonid hiorent	10

	133130	AF052138	Hs.6580	Homo saplens cDNA: FLJ23227 fis, clone C	5	
		AA668224	Hs.6634		5	
		AW956781			5	
		NM_002776	Hs.69423		5	
5		AA207059		gb:zq80h09.s1 Stratagene hNT neuron (937	5	
	133407	AF017987	Hs.7306		5	
	133552	H21497	Hs.7471	BBP-like protein 1	5	
	133702	L02321	Hs.75652	glutathione S-transferase M5	5	
	133719	H26904	Hs.75736		5	
10		N71725			10	
	133789		Hs.76239	hypothetical protein FLJ20608	5	
		AF072441	Hs.7840	calcineurin binding protein 1	10	
	134055			ES1 (zebrafish) protein, human homolog o	10	
1.5		AI372588	Hs.8022	TU3A protein	10	
15		AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	10	
		BE243319	Hs.79672	KIAA0652 gene product	5 10	
		AW905827	Hs.81454	ketohexokinase (fructokinase)	5	
		BE549343	Hs.82208	acyl-Coenzyme A dehydrogenase, very long	5	
20		AF207664	Hs.8230	a disintegrin-like and metalloprotease (5	
20	134449	AI190413	Hs.83450 Hs.8373	laminin, alpha 3 (nicein (150kD), kalini ESTs	10	
		M64936	U8'0913	gb:Homo sapiens retinoic acid-inducible	10	
		NM_002757	He 250870	mitogen-activated protein kinase kinase	10	
		M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	10	
25		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	5	
		U73394		killer cell immunoglobulin-like receptor	5	
		AL008583		dynein, axonemal, light polypeptide 4	5	
,		D10216		POU domain, class 1, transcription facto	5	
		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	10	
30	134786	T29618	Hs.89640	TEK tyrosine kinase, endothelial (venous	10	
	134912	T87521	Hs.261457	ESTs	5	
	134963	NM_003394	Hs.91985	wingless-type MMTV integration site fami	10	
		H22570		hypothetical protein FLJ20093	5	
0.5		AA302517		KIAA1444 protein	5	
35		X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10	
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	10	
		U76456		tissue inhibitor of metalloproteinase 4	5	
		AB002361	Hs.96633	KIAA0363 protein	5 5	
40	135250		Hs.97203	small inducible cytokine subfamily A (Cy	5	
40		AA416829	Hs.191597 Hs.9905	ESTs, Weakly similar to unnamed protein	3	
	135337	AA905406	Hs.99975	cholinergic receptor, nicotinic, delta p	10	
	101367		Hs.4	alcohol dehydrogenase 1B (class I), beta	5 .	
	128870		Hs.75309	eukaryotic translation elongation factor	5	
45		AW245805		claudin 5 (transmembrane protein deleted	5	
		M62402		insulin-like growth factor binding prote	5	-
		NM_006691	Hs.17917	extracellular link domain-containing 1	10	
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	3	
		AF017987	Hs.7306	secreted frizzled-related protein 1	5	
50	133731	N71725	Hs.272572	hemoglobin, alpha 2	5	
	134369	AF207664	Hs.8230	a disintegrin-like and metalloprotease (5	
	135066	X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10	
		AL036557	Hs.95910	putative lymphocyte G0/G1 switch gene	5	
		AK001852	Hs.274151	•	5	
55		AW580227	Hs.47860	neurotrophic tyrosine klnase, receptor, type 2	10	
		AW377752	Hs.83341	AXL receptor tyrosine kinase	5	
	427458		Hs.29283	ESTs, Weakly similar to LKHU proteoglycan link	5	
	446674			solute carrier family 4 (anion exchanger), memb	10	
60	449820	U85642	Hs.138506		5 200	10
UU		RC_H15814_s YEL024w/RIP		Human apM1 mRNA for GS3109 (novel adipose specific colla EST - YEL024w/RIP1	3	10
		- LLUZ4W/INIP	•	COLUMN TIPE I	•	

TABLE 1A

Table 1 A shows the accession numbers for those pkeys lacking unigeneID's for Table 1. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

(1
11

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number

Genbank accession numbers

15

Accession:

	Pkey	CAT Number	Accessions
20	108446 108497	112224_1 110079_2	AA085383 AA126091 AA074174 AA075373 AA079120 AA070831 AA075978 AA075372 AA128503 AA074897 AA113914 AA064871 AA079329 AA071309 AA084710 AA129030 AA075042 AA074794 AA071453 AA078803 AA148628 AA122204 AA074159 AA126185 AA079117 AA127089 AA070912 AA079280 AA131372 AA078833 AA071087 AA076131 AA071047 AA079401 AA083070 AA102076 AA115163 AA074198 AA134725 AA113889 AA121103 AA075041 AA065148 AA071310 AA101144 AA079659 AA078931 AA079209 AA070928 AA068994 AA069817 AA076187 AA069053
25			AA131489 AA071308 AA063317 AA070156 AA071430 AA076056 AA075684 AA070053 AA126283 AA126078 AA075895 AA079208 AA074583 AA071086 AA079623 AA070627 AA078802 AA076622 AA065051 AA079143 AA071110 AA079434 AA148748 AA079230 AA085188 AA074485 AA070580 AA076151 AA083166 AA085118 AA079450 AA085044 AA120938 AA079200 AA100188 AA081472 AA122355 AA129031 AA085362 AA069220 AA070940 AA075968 AA074563 AA084027 AA115929
30	124215 117058 110455 111168	1597154_1 1219924_1 46874_1 38585_1	H62570 H59063 AW801806 H90434 BE086530 H52576 AF085971 H52172 AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567
35		55555_1	AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 Al267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 Al829309 AW991957 N66951 AA527374 H66215 AA045564 Al694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703
40	111498 104340 103747 134496	411008_1 46289_10 117944_1 46501_1	AW817659 BE081531 H59570 Al168511 Al022712 AA700366 R07371 R07324 AA426189 F15201 AA081995 AA101099 M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311
4.5	Al684569 A		Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514
45	103750 105239	118365_1 34624_1	AA126129 AA126033 AA082561 AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904 C16859
50	120379	34624_3	AL042725 BE063316 AW975610 AA457591 BE062092 AI655202 AA714296 AI267264 AI075321 AA223286 AA071122 AA227849 AA216700 AI696002 AA101867 AA099426 AA135997 AL041698 T02815 T51824 AA207189 T59230 T51868 AA663341 BE165757 AW818104 AW392886 AA584918 AA099408 AW856396 AW861859 AA053045
55	114624 106851 108392 100545 100654	111686_1 322947_1 113549_1 22955_11 tgr_HT2969	AA081507 AA070071 AA070840 AA084362 Al458623 AA639708 AA485409 R22065 AA485570 AA075124 AA075208 M55405 AW752552 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495
60	100702 102208	tigr_HT3413 6735_9	X51363 X51364 X51365 L27065 U22961 AA203623 AA503337 A 174733 A 192802 C06092 AA035357 A 190619 A 199244 A 828450 AA602296 A 378195 A 209170 A 186653 A 127795 A 183846 H77389 A 589465 AA629390 H94306 A 018388 R68584 AA027196 A 745413 A 685092 A 093426 A 623873 A 074570 N50096 AA047486 N25060 AA327614 A 042512 A 383957 AA156873 A 333101

N70806 Al141254 Al383191 Al401237 Al080709 Al093400 W84549 T90806 R00012 W01413 AA630557 Al378348 Al559265 AA877103 W84464 AA625146 R68379 Al133207 Al1332980 Al133214 Al064826 Al061615 Al133473 Al174852 Al133404 A1133272 V00494 M12523 M12523 A1207526 A1133120 A1064802 A1174993 A1114729 A1061645 A1064716 A1064959 H77388 T85706 AF075298 AI110799 D17107 NM_000477 AF190168 R50724 AI248416 AI207432 AI133684 AI133345 AI174710 5 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 AI174748 AI114663 AI133104 AI132999 AI133100 AI064925 AI064979 AI133063 AA343347 T69091 AA233989 T39772 AI444620 T52290 D16931 T40012 T48403 T58926 T69195 AI133061 T50850 AI400677 AI091136 AA334608 T57411 Z20979 10 N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T74820 AF075316 Al110818 T40121 T57381 Al114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786 Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 AI065020 T90925 T50889 D17029 AI133703 AA333805 AI133040 AI133017 AI064857 AI110730 AF074637 AI207567 15 H71080 T73217 AA343950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 Al114710 T51776 AA343213 Al114714 T58102 Al110809 R28984 Al174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 20 A1189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 Al114720 Al433289 AA046980 AI823482 AI114536 AA860651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 Al935509 Al150977 T62890 T71374 T68294 Al174774 T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111 AA0250505 T73330 25 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158 T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 30 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864 AA621529 genbank_AA621529 123941 118049 genbank_N53145 N53145 102800 14782 20 AA313538 U88895 U88902 35 AA422123_i_atAA422123_i 104106 111738 genbank_R26065 R26065 113149 genbank_T51588 T51588 genbank_W86195 genbank_AA070500 113958 W86195 108335 AA070500 genbank_AA071193 40 AA071193 108351 108441 genbank_AA079079 AA079079 124276 genbank_H83465 H83465 101447 entrez_M21305 M21305 117226 genbank_N20468 N20468 45 genbank_AA207059 AA207059,AA207241 133379 119366 genbank_T77892 T77892 W38051 119528 NOT_FOUND_entrez_W38051 112588 genbank_R77302 R77302 genbank AA020736 114449 AA020736 genbank_AA065096 50 114576 AA065096 107459 W38002_s_at W38002_s -AA435746 130339 genbank_AA435746

PCT/US02/02242 WO 02/059377

TABLE 2: Figure 2 from BRCA 001 US

Table 2 shows genes downregulated in tumor tissue compared to normal breast tissue. 5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number

Pkey: ExAccn: UnigenelD: Unigene Title: 10

Unigene gene title Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UnigenelD	Unigene Tittle	R1
	100/00	T51986	Hs.283108	hemoglobin, gamma G	10
		BE142019	Hs.222056	Homo saplens cDNA FLJ11572 fls, clone HE	10
		A03758	110.222000	NM_000477*:Homo sapiens albumin (ALB), m	10
20		BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	10
		NM_001674	Hs.460	activating transcription factor 3	10
		NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
		M21305		gb:Human alpha satellite and satellite 3	10
25		N98569	Hs.76422	phospholipase A2, group IIA (platelets,	10
	101511	M27826	Hs.267319	endogenous retroviral protease	10
	101736	M74447	Hs.502	transporter 2, ATP-binding cassette, sub-famil	10
	102208	U22961		gb:Human mRNA clone with similarity to L	10
	102450	U48251	Hs.75871	protein kinase C binding protein 1	10
30	102800	AA313538		gb:EST185419 Colon carcinoma (HCC) cell	10
	102857	NM_006744	Hs.76461	retinol-binding protein 4, interstitial	10
	102990	AA829286	Hs.332053	serum amyloid A1	10
		AA081995		gb:zn26d06.r1 Stratagene neuroepithelium	10
~ ~		AA137107	Hs.326391	Homo sapiens, clone MGC:16638, mRNA, com	10
35		R50727	Hs.336970	ESTs	10
		AL353957	Hs.284181	hypothetical protein DKFZp434P0531	10
		F06638	Hs.12440	Homo sapiens clone 24734 mRNA sequence	10
		N73185	Hs.94285	EST	10
40		N91071	Hs.109650	ESTs	10
40		A1498763	Hs.203013	hypothetical protein FLJ12748	10
		AA009764	Hs.190380	ESTs	10
		AA017245	Hs.32794	ESTs	10
		AA019300	Hs.125070	ESTs, Moderately similar to I54374 gene	10
45		A1298208	Hs.28805	ESTs	10
45		AA130390	Hs.25549	hypothetical protein FLJ20898	10
		AA221036	110 6202	gb:zr03f12.r1 Stratagene NT2 neuronal pr	10 10
		N79885 Al803651	Hs.6382 Hs.191608	EŞTs, Highly similar to T00391 hypothetl ESTs	10
		A1003651 A1085846	Hs.25522	KIAA1808 protein	10
50		AL042069	Hs.119021	DKFZP434N061 protein	10
50		AW235928	Hs.313182	ESTs	10
		AA135688	Hs.10083	Homo sapiens, clone IMAGE:4139786, mRNA,	10
		AW054886	Hs.25682	Homo sapiens mRNA for KIAA1863 protein,	10
		AB006532	Hs.31442	RecQ protein-like 4	10
55		A1005036	Hs.334305	GS1999full	10
55		AF127026	Hs.5394	myosin IA	10
		AB020672	Hs.175411	KIAA0865 protein	10
		A1905985	Hs.111805	ESTs	10
		W28516	Hs.19210	hypothetical protein MGC11308	10
60		AL042425	Hs.283976	hypthetical protein PRO2389	10
		BE271708	Hs.95110	ESTs, Weakly similar to A55943 1-phospha	10
		AA071193		gb:zf79b12.s1 Soares_pineal_gland_N3HPG	10
		F01449	Hs.26954	Homo sapiens mRNA; cDNA DKFZp762G123 (fr	10
		AW294162	Hs.301062	UDP-N-acetyl-alpha-D-galactosamine:polyp	10
65		AL044174	Hs.159526	patched (Drosophila) homolog	5
~ -					

	444400			1.400.00 4.101.00.00 0.0011	40
	111168	A1798376		gb:tr34b07.x1 NCl_CGAP_Ov23 Homo sapiens	10
		R16733	Hs.20499	ESTs	10
		AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10
_		AA034378	Hs.267319	endogenous retroviral protease	10
5		NM_002666	Hs.103253	perllipin	10
		AA193106	Hs.180817	chromosome 11 open reading frame 23	5
		AW150717	Hs.296176	STAT induced STAT inhibitor 3	10
		AF110141	Hs.288908	WAS protein family, member 2	10
10		AW245805	Hs.110903	claudin 5 (transmembrane protein deleted	10
10		AF020038	Hs.11223	isocitrate dehydrogenase 1 (NADP+), solu	10
		BE222078	Hs.113069	ESTs	10
		M62402	Hs.274313	insulin-like growth factor binding prote	10
		D88435	Hs.153227	cyclin G associated kinase	10
		V00517	Hs.283108	hemoglobin, gamma G	10
15	130436	NM_001928	Hs.155597	D component of complement (adipsin)	10
	130563	BE270472	Hs.279900	HSPC015 protein	10
	130589	AL110226	Hs.16441	DKFZP434H204 protein	10
		AA993269	Hs.17872	Homo sapiens, clone IMAGE:3875012, mRNA	10
	130689	NM_006691	Hs.17917	extracellular link domain-containing 1	10
20	130689	AA046747	Hs.17917	extracellular link domain-containing 1	10
	130718	N70196	Hs.18376	KIAA1319 protein	10
	130798	M81349	Hs.1955	serum amyloid A4, constitutive	10
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10
	131184	AB040935	Hs.23954	cerebral cell adhesion molecule	10
25	131282	X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	10
	131328	AW939251	Hs.25647	v-fos FBJ murine osteosarcoma viral onco	10
		AW966881	Hs.41639	programmed cell death 2	10
		AA829286	Hs.332053	serum amyloid A1	10
••	131785	H69342	Hs.26320	TRABID protein	10
30	131828	AJ000263	Hs.278658	keratin, hair, basic, 6 (monilethrix)	10
	132426	AW118072	Hs.89981	diacylglycerol kinase, zeta (104kD)	10
		Al291496	Hs.5476	Homo sapiens, clone IMAGE:3530123, mRNA,	10
	132898	W28548	Hs.224829	ESTs	10
	132905	NM_004235	Hs.7934	Kruppel-like factor 4 (gut)	10
35	133120	NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	10
		AF017987	Hs.7306	secreted frizzled-related protein 1	10
	133719	H26904	Hs.75736	apolipoprotein D	10
		AF072441	Hs.7840	calcineurin binding protein 1	10
4.0		D86062	Hs.182423	ES1 (zebrafish) protein, human homolog o	10
40		Al372588	Hs.8022	TU3A protein	5
		AA081846	Hs.7921	Homo sapiens mRNA; cDNA DKFZp566E183 (fr	5
		BE243319	Hs.79672	KIAA0652 gene product	10
		AF207664	Hs.8230	a disintegrin-like and metalloprotease (10
	134496	M64936		gb:Homo sapiens retinoic acid-inducible	10
45		NM_002757	Hs.250870	mitogen-activated protein kinase kinase	10
		M26315	Hs.85258	CD8 antigen, alpha polypeptide (p32)	5
		NM_000078	Hs.89538	cholesteryl ester transfer protein, plas	5
		NM_003394	Hs.91985	wingless-type MMTV integration site fami	10
		X04430	Hs.93913	interleukin 6 (interferon, beta 2)	10
50		AW580227	Hs.47860	neurotrophic tyrosine kinase, receptor, type 2	10
	446674	AA563892	Hs.306000	solute carrier family 4 (anion exchanger), memb	10

TABLE 2A

Table 2A shows the accession numbers for those pkeys lacking unigenelD's for Table 2. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	
-	Pkey:

5

Unique Eos probeset identifier number

CAT number: Gene cluster number
Accession: Genbank accession numbers

15	Pkey	CAT number	r Accessions
20	111168	38585_1	A1798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 A1267168 AA157718 AA1577719 AA10472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053524 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 A1829309 AW991957 N66951 AA527374 H66215 AA045564 A1694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
25	103747 134496	117944_1 46501_1	AA081995 AA101099 M64936 Al025512 Al382987 BE061777 AA089966 BE169930 T41176 AW594624 BE502415 AA121893 Al269283 T40311 Al684569 AA257011 Al079277 Al241318 BE327710 AW975215 AW896268 AA884990 BE327514
30	105239	34624_1	AA221036 R87170 BE537068 BE544757 C18935 AW812058 T92565 AA227415 AA233942 AA223237 AA668403 AA601627 AW869639 BE061833 BE000620 AW961170 AW847519 AA308542 AW821833 AW945688 C04699 AA205504 AA377241 AW821667 AA055720 AW817981 AW856468 AA155719 AA179928 T03007 AW754298 AA227407 AA113928 AA307904
	100654	tigr_HT2969	C16859 A03758 A06977 A15293 D17029 D17107 D17171 L00132 L00133 M12523 M13075 M13076 M92816 U22961 V00494 V00495 X51363 X51364 X51365
35	102208	6735_9	U22961 AA203623 AA503337 AI174733 AI192802 C06092 AA035357 AI190619 AI199244 AI828450 AA602296 AI378195 AI209170 AI186653 AI127795 AI183846 H77389 AI589465 AA629390 H94306 AI018388 R68584 AA027196 AI745413 AI685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101 N70806 AI141254 AI383191 AI401237 AI080709 AI093400 W84549 T90806 R00012 W01413 AA630557 AI378348 AI559265 AA877103 W84464 AA625146 R68379 AI133207 AI132980 AI133214 AI064826 AI061615 AI133473 AI174852 AI133404
40		•	Al133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM_000477 AF190168 R50724 Al248416 Al207432 Al133684 Al133345 Al174710 Al133290 Al133304 Al174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al114498 Al114759 Al207568 Al064960 Al174753 Al114666 R69184 R00011 Al064997 T60501 Al207701 T71735 AA385318 H73569 T60496 H94399 Al133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701
45			Al174748 Al113663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T774820 AF075316 Al110818 T40121 T57381 Al114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 Al174786
50			Al132926 R09237 Al064838 Al133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 Al065049 T84512 T55918 Al207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 Al114676 Al064778 AA035710 W52763 Al114786
55			T83564 AA341859 T81684 T55769 A1114710 T51776 AA343213 A1114714 T58102 A1110809 R28984 A1174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 A1114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 A1203974 A1189471 AA005147 A1478102 A1207662 A1192792 A1768421 A1064737 AW051713 AA936693 A1133117 A1766232 A1913646 T83962 A1065112 A1207689 A1174684 A1207702 T81475 A1133325 A1032512 AA701169 A1936354 A1114720 A1433289
60			AAQA6980 AI823482 AI114536 AA860651 AW242644 R07469 AW300438 AI133416 AW271670 AI991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AI174774 T67411 T68318 AI064689 T56624 T69010 T68982 T68302 AI332829 T72908 AI064819 AI205880 T62895 T69430 T95111 AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 AI336158

T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

102800 14782_20 AA313538 U88895 U88902 108351 genbank_AA071193 AA071193 101447 entrez_M21305 M21305

5

TABLE 3: Figure 3 from BRCA 001 US

Table 3 shows genes downregulated in tumor tissue compared to normal breast tissue.

5

10	Pkey: ExAccn: UnigeneID: Unigene Title: R1:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of normal breast tissue to tumor
----	---	--

15					
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	101336	NM_006732	Hs.75678	FBJ murine osteosarcoma viral oncogene h	10.0
	102208	U22961		gb:Human mRNA clone with similarity to L	10.0
20	102990	AA829286	Hs.332053	serum amyloid A1	10.0
	111168	A1798376		qb:tr34b07.x1 NCI_CGAP_Ov23 Homo sapiens	10.0
	111803	AA593731	Hs.325823	ESTs, Moderately similar to ALU5_HUMAN A	10.0
	130085	M62402	Hs.274313	insulin-like growth factor binding prote	10.0
	130840	BE048821	Hs.20144	small inducible cytokine subfamily A (Cy	10.0
25	131543	AW966881	Hs.41639	programmed cell death 2	10.0
	133120	NM 003278	Hs.65424	tetranectin (plasminogen-binding protein	10.0
		NM 000078	Hs 89538	cholesteryl ester transfer protein, plas	10.0

TABLE 3A

Table 3A shows the accession numbers for those pkeys lacking unigeneID's for Table 3. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:
	CAT number:

Pkey

15

30

35

40

45

50

55

Unique Eos probeset identifier number

Gene duster number

CAT number Accessions

Accession:

Genbank accession numbers

20	111168 38585_1	AI798376 S46400 AW811617 AW811616 W00557 BE142245 AW858232 AW861851 AW858362 AA232351 AA218567 AA055556 AW858231 AW857541 AW814172 H66214 AW814398 AF134164 AA243093 AA173345 AA199942 AA223384 AA227092 AA227080 T12379 AA092174 T61139 AA149776 AA699829 AW879188 AW813567 AW813538 AI267168 AA157718 AA157719 AA100472 AA100774 AA130756 AA157705 AA157730 AA157715 AA053324 AW849581 AW854566 C05254 AW882836 T92637 AW812621 AA206583 AA209204 BE156909 AA226824 AI829309 AW991957 N66951 AA527374 H66215 AA045564 AI694265 H60808 AA149726 AW195620 BE081333 BE073424 AW817662 AW817705 AW817703 AW817659 BE081531 H59570
25	1022086735_9	U22961 AA203623 AA503337 A1174733 A1192802 C06092 AA035357 A1190619 A1199244 A1828450 AA602296 A1378195 A1209170 A1186653 A1127795 A1183846 H77389 A1589465 AA629390 H94306 A1018388 R68584 AA027196 A1745413 A1685092

6 AI378195 Al209170 Al186653 Al127795 Al183846 H77389 Al589465 AA629390 H94306 Al018388 R68584 AA027196 Al745413 Al685092 AI093426 AI623873 AI074570 N50096 AA047486 N25060 AA327614 AI042512 AI383957 AA156873 AI333101 N70806 AI141254 Al383191 Al401237 Al080709 Al093400 W84549 T90806 R00012 W01413 AA630557 Al378348 Al559265 AA877103 W84464 AA625146 R68379 AI133207 AI132980 AI133214 AI064826 AI061615 AI133473 AI174852 AI133404 AI133272 V00494 M12523 M12523 Al207526 Al133120 Al064802 Al174993 Al114729 Al061645 Al064716 Al064959 H77388 T85706 AF075298 Al110799 D17107 NM_000477 AF190168 R50724 AI248416 AI207432 AI133684 AI133345 AI174710 AI133290 AI133304 AI174948 Al207484 Al110717 AF074624 Al114515 AF063516 Al110642 Al114559 Al1114498 Al114759 Al207568 Al064960 Al174753 A1114666 R69184 R00011 AI064997 T60501 AI207701 T71735 AA385318 H73569 T60496 H94399 AI133158 T74675 AA484750 T73413 T55909 R50261 T72061 N80533 T51189 T74936 Al207490 Al132925 Al064701 Al174748 Al114663 Al133104 Al132999 Al133100 Al064925 Al064979 Al133063 AA343347 T69091 AA233989 T39772 Al444620 T52290 D16931 T40012 T48403 T58926 T69195 Al133061 T50850 Al400677 Al091136 AA334608 T57411 Z20979 N56507 T87485 Al133622 AA343370 T40075 T69671 T53849 T74820 AF075316 Al110818 T40121 T57381 Al114468 AA332728 T51362 Al114589 R06691 Al110629 AF063503 Al140543 AA334661 AA332720 AA343262 T73513 T86549 Al114840 T57284 T39981 T61407 T72757 T51749 T56630 AA343125 T72126 R94135 T83028 T39972 T39896 AI174786 AI132926 R09237 AI064838 AI133660 T60398 T88753 T55930 T92126 Al444602 T60996 Al114792 H93911 Al133106 R10779 Al065020 T90925 T50889 D17029 Al133703 AA333805 Al133040 Al133017 Al064857 Al110730 AF074637 Al207567 H71080 T73217 AA343950 Al174743 AA334224 AA334281 R06692 T64739 T40163 T60628 T81661 T73179 R01842 AA501730 T39931 T39662 T40136 AA334904 T71425 H77784 R00874 AI065049 T84512 T55918 AI207595 T39951 AA005016 T60361 T69176 T73356 T58795 T61233 T39955 T60612 AI114676 AI064778 AA035710 W52763 AI114786 T83564 AA341859 T81684 T55769 AI114710 T51776 AA343213 AI114714 T58102 AI110809 R28984 AI174854 AA305675 AA343592 T53836 T46869 T64721 T55508 W05241 T54019 T57945 T60513 T48364 AF075308 W86731 T82851 T48269 H54053 T73211 Al114590 T48317 T55965 T74857 R84226 T56552 T52231 T74946 T76976 R02576 T95666 Al203974 Al189471 AA005147 Al478102 Al207662 Al192792 Al768421 Al064737 AW051713 AA936693 Al133117 Al766232 Al913646 T83962 Al065112 Al207689 Al174684 Al207702 T81475 Al133325 Al032512 AA701169 Al936354 A1114720 A1433289 AA046980 A1823482 A1114536 AA860651 AW242644 R07469 AW300438 A1133416 AW271670 A1991363 T78943 AI823481 AA845518 AA719124 AA883454 T68850 T69115 AI935509 AI150977 T62890 T71374 T68294 AI174774 T67411 T68318 Al064689 T56624 T69010 T68982 T68302 Al332829 T72908 Al064819 Al205880 T62895 T69430 T95111

AA025050 T73330 W52657 T71984 T69118 W92684 AI114860 T62093 T61797 AI522333 T73322 H92981 T56018 T61811 T57232 Al336158 T61821 T69457 T62900 T62912 T72917 T46885 Al702448 T57212 T57203 R94581 T71311 T61819 T89358 T67708 T70918 T59166 Al187111 T64308 T62071 T69427 Al114750 T60430 R09734 T69033 T69141 T69453 T67908 R16809 T69394 Al207729 T55839 T90273 T73339 AW194909 T75486 T71850 T71305 T71287 T53877 T73452 T68852 N75290 Al312890 T67751 Al174983 T51679 T54851 H69880 N73734 AA443453 T73466 H69672 N53869 T68447 D11809 D12412 T64300 T28321 T55864

TABLE 4: Figure 4 from BRCA 001 US

Table 4 shows genes upregulated in tumor tissue compared to normal breast tissue.

Pkey: Unique Eos probeset Identifier number ExAcon: Exemplar Accession number, Genbank accession number Unigene Itile: Unigene gene title R1: Ratio of tumor to normal breast tissue

15	Pkey	ExAccn	UnigeneID	Unigene Title	R1
•	100113	NM_001269	9Hs.84746	chromosome condensation 1	2.3
		X02308	Hs.82962		2.9
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodiesterase 1	1.9
20		BE185499		KIAA0020 gene product	1.9
		D13666		osteoblast specific factor 2 (fasciclin I-like) (periostin)	7.5
		H60720	Hs.81892		9.2
		W44671		gene predicted from cDNA with a complete coding sequence	1.6
			Hs.217493		2.0
25		D38521		KIAA0077 protein	1.5
				\$100 calcium-binding protein A11 (calgizzarin)	13.5
				KIAA0090 protein	5.1
		D50920		KIAA0130 gene product	1.9
	100335	AW247529	Hs.6793	platelet-activating factor acetylhydrolase, isoform lb, gamma subunit (29kD)	2.7
30	100364	NM 00434	1Hs.154868	carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase	2.0
				KIAA0175 gene product	2.6
		D84145	Hs.39913		3.2
	100400	AW954324	Hs.75790	phosphatidylinositol glycan, class C	1.5
	100418	D86978	Hs.84790	KIAA0225 protein	2.0
35		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein A/B	2.9
	100518	NM_00441		desmoplakin (DPI, DPII)	1.9
	100666	L05424	Hs.169610	CD44 antigen (homing function and Indian blood group system)	5.7
	100667	L05424		CD44 antigen (homing function and Indian blood group system)	9.0
		L05424		CD44 antigen (homing function and Indian blood group system)	7.6
40	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	100685	AA328229	Hs.184582	ribosomal protein L24	1.8
		AA383256		estrogen receptor 1	1.6
				general transcription factor IIH, polypeptide 2 (44kD subunit)	5.9
				cathepsin B	1.7
45				S164 protein	1.7
				ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)	1.5
		AA157634		solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5	6.3
		AK000405		ubiquitin-like 4	11.4
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5 reductase)	1.6
50		J05070	Hs.151738		8.2
		J05614		gb:Human proliferating cell nuclear antigen (PCNA) gene, promoter region.	5.0
		N99692	Hs.75227	Empirically selected from AFFX single probeset	2.6
		L06419	Hs.75093	procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase, Ehlers-Danlos syndrome ty	pe vi) 1.4
<i></i>		NM_00626		peripherin	16.9 2.0
55				core-binding factor, beta subunit	1.8
	101216	AA284166	HS.84113	cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase)	1.7
	101228	AA333387	HS.82916	chaperonin containing TCP1, subunit 6A (zeta 1)	1.7
	101247	AA132666		glycogen synthase kinase 3 beta	1.5
60		L18964	Hs.1904	protein kinase C, iota	5.2
60	101332	J04088		topoisomerase (DNA) II alpha (170kD)	3.4
	101332	J04088		topoisomerase (DNA) II alpha (170kD)	6.3
	101352	AI494299	FIS. 1029/	COX17 (yeast) homolog, cytochrome c oxidase assembly protein	4.2
	101396	BE267931	08801.80	proliferaling cell nuclear antigen gb:Human Alu repeats in the region 5' to the small nuclear rib	1.9
CF	101445	M21259	CHC 101C	gurruman Alu repeats in the region of to the small modelar no	1.6
65	1014/0	NM_00054	UITS. 1040	tumor protein p53 (Li-Fraumeni syndrome)	1.0

	101478	NM_002890	Hs.758		2.5
	101483	M24486	Hs.76768	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide l	5.5
	101540	J04977	Hs.84981	X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoin	ing 2.1
_	101573	AW248421	Hs.250758	proteasome (prosome, macropain) 26S subunit, ATPase, 3	1.6
5	101580	NM_012151	IHs.83363	coagulation factor VIII-associated (intronic transcript)	5.7
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G protein), beta polypeptide 2	1.8
	101592	AF064853	Hs.91299	guanine nucleotide binding protein (G pr	5.6
	101621	BE391804	Hs.62661	guanylate binding protein 1, interferon-inducible, 67kD	2.4
	101702	AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), alpha isoform	1.3
10		M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacement protein)	2.1
	101759	M80244	Hs.184601	solute carrier family 7 (cationic amino acid transporter, y+system), member 5	5.0
	101767			carboxypeptidase B1 (tissue)	14.4
	101782	AA306495	Hs.1869	phosphoglucomutase 1	5.2
	101805	AW409747	Hs.75612	stress-Induced-phosphoprotein 1 (Hsp70/Hsp90-organizing protein)	8.6
15	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psoriasin 1)	8.9
	101810	NM_000318	3Hs.180612	peroxisomal membrane protein 3 (35kD, Zellweger syndrome)	3.2
	101879	AA176374	Hs.243886	nuclear autoantigenic sperm protein (histone-binding)	1.6
				glycoprotein hormones, alpha polypeptide	31.3
	101920	AF182645	Hs.8024	IK cytokine, down-regulator of HLA II	1.8
20	101973	U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T	1) 2.4
	101983	Al904232	Hs.75323	prohibitin	8.4
	102009	BE245149	Hs.82643	protein tyrosine kinase 9	1.3
	102036	BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevisiae, homolog)	2.0
	102083	T35901	Hs.75117	Interleukin enhancer binding factor 2, 45kD	1.6
25	102083	T35901	Hs.75117	Interleukin enhancer binding factor 2, 4	1.3
	102107	BE258602	Hs.182366	heat shock protein 75	1.4
		NM_001809		centromere protein A (17kD)	1.8
				death associated protein 3	4.6
		AW950852			4.3
30		AA829978			6.7
		U24389	Hs.65436		4.3
	102234	AW163390		heterochromatin-like protein 1	1.9
	102260	AL039104	Hs.159557	karyopherin alpha 2 (RAG cohort 1, importin alpha 1)	4.4
	102302	AA306342	Hs.69171	protein kinase C-like 2	2.7
35		BE298063		chromobox homolog 1 (Drosophila HP1 beta)	1.5
		BE378432		cyclin-dependent kinase 4	2.3
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member B2	2.0
	102349	AU077055	Hs.289107	baculoviral IAP repeat-containing 2	3.2
	102369	U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	2.0
40	102374	U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2
	102391	AA296874		deoxyguanosine kinase	1.5
	102455	U48705	Hs.75562	discoidin domain receptor family, member 1	6.9
		NM_001359		2,4-dienoyl CoA reductase 1, mitochondrial	1.8
		U50939	Hs.61828	amyloid beta precursor protein-binding protein 1, 59kD	1.5
45		AL080116	Hs.74420	origin recognition complex, subunit 3 (yeast homolog)-like	3.3
	102494	AI188137	Hs.75193	COP9 homolog	2.1
	102501	AF217197	Hs.74562	siah binding protein 1; FBP interacting repressor, pyrimidine tract binding splicing	3.2
	102522	BE250944	Hs.183556	solute carrier family 1 (neutral amino acid transporter), member 5	2.8
			Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolog	5.7
50	102564	U59423	Hs.79067	MAD (mothers against decapentaplegic, Drosophila) homolog 1	2.3
	102568	W81489	Hs.223025	RAB31, member RAS oncogene family	5.3
	102580	U60808	Hs.152981	CDP-dlacylglycerol synthase (phosphatidate cytidylyltransferase) 1	2.1
	102581	AU077228	Hs.77256	enhancer of zeste (Drosophila) homolog 2	1.6
	102582	U61232	Hs.32675	tubulin-specific chaperone e	2.1
55	102617	AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5	1.8
	102618	AL037672	Hs.81071	extracellular matrix protein 1	5.8
				zinc finger protein 184 (Kruppel-like)	1.3
				karyopherin (importin) beta 2	1.8
				putative protein	2.3
60		NM_007019	9Hs.93002	ubiquitin carrier protein E2-C	4.3
		U96132		hydroxyacyl-Coenzyme A dehydrogenase, type II	6.0
		BE540274		forkhead box M1	4.2
		AU077058		BRCA1 associated RING domain 1	1.9
		T97490	Hs.50002	small inducible cytokine subfamily A (Cys-Cys), member 19	2.3
65		AB014460			1.2
-		BE252241			6.4
				high-mobility group (nonhistone chromosomal) protein 17-like 3	1.6

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (beta)	5.6
	102831	AA262170	Hs.80917	adaptor-related protein complex 3, sigma 1 subunit	2.0
	102844	AV653790	Hs.324275	WW domain-containing protein 1	1.3
_	102868	X02419	Hs.77274	plasminogen activator, urokinase	4.4
5	102925	BE440142	Hs.2943	signal recognition particle 19kD	1.9
	102935	BE561850	Hs.80506	small nuclear ribonucleoprotein polypeptide A'	2.4
	102968	AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase (NAD+ dependent), methenyltetrahydrofolate cyc	clohydrolase2.7
	102983	BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A) expressed in	3.1
	102985	U95742	Hs.2707	G1 to S phase transition 1	5.2
10	103023	AW500470	Hs.117950	multifunctional polypeptide similar to SAICAR synthetase and AIR carboxylase	1.6
				CDC28 protein kinase 1	2.5
	103060	NM_005940)Hs.155324	matrix metalloproteinase 11 (MMP11; stromelysin 3)	4.5
		AU077231		cyclin D1 (PRAD1: parathyroid adenomatosis 1)	3.1
	103089	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaphyseal chondrodysplasia)	2.4
15	103177	BE244377	Hs.48876	famesyl-diphosphate famesyltransferase 1	3.5
	103178	AA205475	Hs.275865	ribosomal protein S18	9.9
	103179	NM_001777		CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	1.3
	103181	X69636	Hs.334731	Homo sapiens, clone IMAGE:3448306, mRNA, partial cds	2.0
	103185	NM_006825	5Hs.74368	transmembrane protein (63kD), endoplasmic reticulum/Golgì intermediate compartment	1.6
20	103191	AA401039	Hs.2903	protein phosphatase 4 (formerly X), catalytic subunit	2.5
	103193	NM_004766	6Hs.75724	coatomer protein complex, subunit beta 2 (beta prime)	2.2
	103194	NM_004939	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 1	6.3
	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8
	103223	BE275607	Hs.1708	chaperonin containing TCP1, subunit 3 (gamma)	3.0
25	103232	X75962	Hs.129780	tumor necrosis factor receptor superfamily, member 4	1.8
	103238	Al369285	Hs.75189	death-associated protein	5.6
	103297	NM_001545	5Hs.9078	Immature colon carcinoma transcript 1	1.9
	103330	A1803447	Hs.77496	small nuclear ribonucleoprotein polypeptide G	2.5
		X89059		gb:H.saptens mRNA for unknown protein expressed in macrophage	1.6
30	103376	AL036166	Hs.323378	coated vesicle membrane protein	1.8
			Hs.114366	pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase)	2.3
	103392	X94563		gb:H.saplens dbl/acbp gene exon 1 & 2.	4.0
		BE564090		translocase of inner mitochondrial membrane 17 (yeast) homolog A	1.3
	103491	AF264750	Hs.288971	myeloid/lymphoid or mlxed-lineage leukemia 3	5.6
35	103505	AL031224	Hs.33102	transcription factor AP-2 beta (activating enhancer-binding protein 2 beta)	5.1
	103547	A1376722	Hs.180062	proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctional protease 7)	9.7
	103588	NM_006218	3Hs.85701	phosphoinositide-3-kinase, catalytic, alpha polypeptide	2.0
		NM_000346		SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal)	1.3
40				polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	2.0
40				membrane component, chromosome 11, surface marker 1	2.3
	103727	AI878883	Hs.296381	growth factor receptor-bound protein 2	1.3
	103749	AL135301	Hs.8768	hypothetical protein FLJ10849	1.8
				Homo sapiens mRNA; cDNA DKFZp586l2022 (from clone DKFZp586l2022)	1.3
				hypothetical 43.2 Kd protein	7.5
45		H26531	Hs.7367	Homo sapiens BTB domain protein (BDPL) mRNA, partial cds	1.2
		AA080912		gb:zn04d03.r1 Stratagene hNT neuron (937233) Homo sapiens cDNA clone 5' similar	1.5
				CGI-120 protein	1.5
				hypothetical protein FLJ10330	1.5
				hypothetical protein FLJ10416 similar to constitutive photomorphogenic protein 1	6.5
50		NM_002407		mammaglobin 2	2.9
		AA251242			1.4
	104174	AA478984	Hs.6451	PRO0659 protein	5,6
	104227	AB002343	Hs.98938	protocadherin alpha 9	1.6
	104275	A1751970	Hs.101067	GCN5 (general control of amino-acid synthesis, yeast, homolog)-like 2	5.4
55				polymerase (RNA) II (DNA directed) polypeptide K (7.0kD)	6.3
		AA324597		Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	1.6
	104423	R83113	Hs.1432	protein kinase C substrate 80K-H	5.2
		AB037762		myelin gene expression factor 2	1.2
C C	104532	A1498763		hypothetical protein FLJ12748	2.1
60				DKFZP434F1735 protein	1,2
			Hs.30098		1.3
	104757	AI694413		olfactory receptor, family 2, subfamily 1, member 6	2.3
	104804	AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapiens]	1.3
	104806	AB023175	Hs.22982	KIAA0958 protein	2.3
65	104827	AW052006	Hs.8551	PRP4/STK/WD splicing factor	10.9
	104846	Al250789	Hs.32478	ESTs	5.6
	104854	AA041276	Hs.154729	3-phosphoinositide dependent protein klnase-1	12.3

	104867	AA278898	Hs.225979	hypothetical protein similar to small G proteins, especially RAP-2A	2.0
		T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (from clone DKFZp564O2364)	1.3
	104896	AW015318	Hs.23165	ESTs	17.7
	104909	AW408164	Hs.249184	transcription factor 19 (SC1)	5.0
5	104916	AW958157	Hs.155489	NS1-associated protein 1	1.7
	104919	AA026880	Hs.25252	prolactin receptor	1.4
		AF043467		neurexophilin 2	2.2
	104973	NM_015310)Hs.6763	KIAA0942 protein	5.0
	104974	Y12059	Hs.278675	bromodomain-containing 4	1.4
10	104975	AL136877	Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	2.4
	104975	AL136877	Hs.50758	SMC4 (structural maintenance of chromoso	2.3
	104978	Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010317E24 gene, clone IMAGE:3502019, mRNA, partial	cds 7.2
	104979	AA937934	Hs.321062	ESTs	1.3
	104994	A1499930	Hs.334885	mitochondrial GTP binding protein	3.5
15	105009	BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protein glycosyltransferase	5.5
	105012	AF098158	Hs.9329	chromosome 20 open reading frame 1	3.3
	105028	AI050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2
	105032	AA127818		gb:zl12a02.s1 Soares_pregnant_uterus_NbHPU Homo saplens cDNA clone IMAGE:501674 3'	6.8
••	105039	AA907305	Hs.36475	ESTs	2.5
20	105041	AB037716	Hs.26204	KIAA1295 protein	2.2
	105045	BE242899	Hs.129951	speckle-type POZ protein	3.8
	105079	AA151342	Hs.12677	CGI-147 protein	9.5
	105087	AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HEMBA 1002716	5.6
0.5	105088	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
25	105095	Z78407	Hs.27023	vesicle transport-related protein	2.2
	105110	BE387350	Hs.33122	KIAA1160 protein	1.6
	105126	AW975433	Hs.36288	ESTs	6.3
	105127	AA045648	Hs.301957	nudix (nucleoside diphosphate linked molely X)-type motif 5	2.1
	105141	AA164687	Hs.177576	mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isoenzyme A	2.7
30				hypothetical protein NUF2R	1.9
	105169	BE245294	Hs.180789	S164 protein	1.7
		AA191512		Homo saplens cDNA FLJ11309 fis, clone PLACE1010076	4.8
		AA071276		KIAA0859 protein	1.9
		AA263143		RAD51-interacting protein	2.8
35		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	1.9
		AA700122		sentrin-specific protease	8.0
				KIAA0779 protein	1.8
		NM_01601		CGI-68 protein	8.2
40				hypothetical protein FLJ21918	5.0
40			Hs.32356		2.5
				hypothetical protein FLJ10326	2.2 2.3
				membrane protein CH1	5.4
				interleukin enhancer binding factor 3, 90kD	1.6
15				Npw38-binding protein NpwBP	1.6
45			Hs.65648	RNA binding motif protein 8A	
		AA252395		gb:zs12g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA done IMAGE:685026 3', mRNA sequence	1.6
				CCR4-NOT transcription complex, subunit 7	1.3
			Hs.32471		3.4
50		AB023179		KIAA0962 protein	9.3
50			Hs.27445		1.4
				hypothetical protein FLJ14299	10.9
		AA579535		hypothetical protein FLJ20452	2.9
				splicing factor 3b, subunit 1, 155kD	1.7
F				hypothetical protein FLJ12475	1.4
55		AA280072		fetal Alzheimer antigen	1.7
		AK000892		glucocorticoid modulatory element binding protein 1	5.5
				casein kinase 1, gamma 2	9.4
				hypothetical protein FLJ20059	2.0
60		AW499988	HS.Z/801	zinc finger protein 278	1.7
60		R26944		Homo sapiens mRNA; cDNA DKFZp564M0264 (from clone DKFZp564M0264) sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short	2.6
		BE246502			1.5
		AW151952		hypothetical protein FLJ20739	1.3
	105/59	AI123118	IIS, 10 109	chemokine-like factor, alternatively spliced synovial sarcoma, translocated to X chromosome	1.6
65	100//1	MIZU//ZU	175.1332Z1	transcriptional unit N143	2.2
65				E3 ubiquitin figase SMURF2	1.3
			Hs.12653		2.4
	103030	71202100	113, 12000	LUIG	

	105858	AF151066	Hs.281428	hypothetical protein	2.9
		AK001708		hypothetical protein FLJ10846	1.4
		AF016371		peptidyl prolyl isomerase H (cyclophilin H)	5.2
		AW194426		ESTs	1.7
5				LOIS	2.8
J		AW081202		Tionic daplone, done in to Eleasons in the first transfer	1.4
		AA477956		2013	1.4
		AL157441			
		AA130158		ESTs, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	1.0
		AA533491		11/postcada proteiri Editioni	6.8
10	106140	AB006624	Hs.14912		1.6
	106271	AA251393	Hs.289052	Homo sapiens, Similar to RIKEN cDNA 5430429M05 gene, done MGC:13155, mRNA, complete ∞	is 10.
		AB037742		KIAA1321 protein	1.3
		Y10043	Hs.19114	high-mobility group (nonhistone chromosomal) protein 4	3.6
		AL043114		ESTs, Weakly similar to A54849 collagen alpha 1(VII) chain precursor [H.sapiens]	5.4
15		AK001404			5.7
10		AW390282		transmembrane 7 superfamily member 2	6.3
		AB040916			6.5
				TARTITOO PIONAT	2.2
		AW748420		Tono acpiona act and ever for help of the	2.7
20		AF119256		Ento migor proton Ero	2.3
20		D63078		Traine Supreme Service Leaders and Linear Li	1.6
		AA454036		2013	
	106586	AA243837	Hs.57787	E015	1.6
	106589	AK000933	Hs.28661	FIGHIO Supports Object Earder Hoj Sierie Harrist Ho	2.4
	106610	AA458882	Hs.79732		7.9
25	106624	NM_003595	5Hs.26350		7.7
	106650	AL049951	Hs.22370		1.8
	106669	AV657117	Hs.184164	ESTs, Moderately similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	1.3
				hypothetical protein FLJ12549	4.5
				TIA1 cytoloxic granule-associated RNA-binding protein	1.3
30		BE388094			1.6
50	106705	ΔE17//97	He 203753	Bcl-2-related ovarian killer protein-like	5.7
		AW959893		DOI E TOTALCO OTALIANT KINOT PROTOIN INCO	16.2
				Hypothenodi promiti cononno diffindi de l'illa e	1.5
		BE564871		centrin, EF-hand protein, 3 (CDC31 yeast homolog)	2.2
25		AB037744		145 t 1020 protein	1.3
35			HS.300631	hypothetical protein	16.8
		N49809		Homo sapiens, clone IMAGE:3343149, mRNA, partial ods	1.5
		W79171	Hs.9567	GL002 protein	
				Ballodipson ractor bire tee	2,2
					3.3
40	106945	AK000511	Hs.6294	hypothetical protein DKFZp434L1435 similar to valyl tRNA synthetase	6.8
	106973	BE156256	Hs.11923	hypothetical protein	6.6
	106977	AL043152	Hs.50421	KIAA0203 gene product	4.8
		AW631480		ESTs	6.0
				hypothetical protein FLJ20727	1.3
45	107029	AF264750	Hs 288971	myeloid/lymphoid or mixed-lineage leukemia 3	1.8
,,,		AW385224		ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative function)	1.7
		AK000733		GTPase activating protein	2.5
		AK000512		hypothetical protein FLJ20505	1.7
		AV661958		GK001 protein	4.6
50					3.3
50		AV661958		GK001 protein	2.0
		AK001455		Down syndrome critical region gene 2	6.3
		AW378065		ESTs	33.5
		AW391927		KIAA1288 protein	
	107174	BE122762		ESTs	5.2
55	107197	W15477	Hs.64639	glioma pathogenesis-related protein	6.1
	107221	AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (stathmin)	17.4
	107243	BE219716	Hs.34727	ESTs, Moderately similar to 138759 zinc finger/leucine zipper protein [H.sapiens]	7.4
	107248	AW263124	Hs.315111	nuclear receptor co-repressor/HDAC3 complex subunit	1.8
		D60341	Hs.21198	translocase of outer mitochondrial membrane 70 (yeast) homolog A	6.6
60		BE379594		ESTs. Moderately similar to ALU7. HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.5
50		N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL HYPOTHETICAL 63.5 KD PROTEIN ZK353.1 IN	2.5
	107200	N95657	Hs.6820	ESTs, Moderately similar to YOU1_CAEEL H	1.7
				hypothetical protein MGC4606	3.2
		BE277457	175.JU00 I	Homo sapiens mRNA; cDNA DKFZp586I0324 (from done DKFZp586I0324)	2.0
65		T63174			5.0
65	107354	NM_00629	3HS.30448	zinc finger protein 193	1,2
	107392	AVVZ99900	HS.20/032	TATA element modulatory factor 1	1,2

	107529	BE515065	Hs.296585	nucleolar protein (KKE/D repeat)	3.0
	107554	AA001386	Hs.59844	ESTs	1.3
	107681	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	2.2
	107772	AA018587	Hs.303055	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	2.1
5			Hs.47584	potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3	8.4
	107901	L42612	Hs.335952		2.5
	107901		Hs.335952		1.6
				Ig superfamily receptor LNIR	2.2
	107974	AW956103	Hs.61712	pyruvate dehydrogenase kinase, isoenzyme 1	6.7
10	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member	1 1.5
			Hs.59847		1.3
				F-box only protein 5	7.1
		N31256	Hs.161623		2.5
			Hs.339659		3.5
15				Homo sapiens cDNA FLJ12758 fis, clone NT2RP2001328	3.4
			Hs.182685		1.6
			Hs.69507		1.7
				homeo box C10	9.8
				KIAA1077 protein	7.2
20				hypothetical protein FLJ20516	1.3
20			Hs.9071	progesterone membrane binding protein	2.7
				DKFZP564O0463 protein	1.8
			Hs.178904		1.5
		H06720		endosulfine alpha	2.1
25			Hs.48480		5.3
<i>_J</i>		AK001431		hypothetical protein FLJ10569	4.0
	100094	ANDU 1431	HS.3103	Homo sapiens amino acid transport system N2 (SN2) mRNA, complete cds	5.6
				homeo box (expressed in ES cells) 1	1.6
				hypothetical protein FLJ10633	6.2
30			Hs.23467 Hs.72134	KIAA1064 protein	1.7
50				ESTs	1.4
		AA157811	Hs.72127	gb:zo35d07.s1 Stratagene colon (937204) Homo sapiens cDNA clone 3' similar to contains Alu rep	
			Un 705/5		2.9
			Hs.72545		1.6
35			Hs.52184	hypothetical protein FLJ20618	3.2
33				hypothetical protein FLJ13782	1.7
				hypothetical protein FLJ22104	2.6
				zinc finger protein 281	2.9
			Hs.73625	RAB6 interacting, kinesin-like (rabkinesin 6)	2.0
40			Hs.58169	highly expressed in cancer, rich in leucine heptad repeats	5.3
40			3Hs.82035	potential nuclear protein C5ORF5; GAP-like protein	5.7
			Hs.189998		5.3
				nucleoporin 214kD (CAIN) ESTs, Weakly similar to AF126743 1 DNAJ domain-containing protein MCJ [H.sapiens]	1.4
	109270	N99673	Hs.3585	Library series money only british by the containing protein wood in sapients	2.9
45				Homo sapiens mRNA; cDNA DKFZp586F1822 (from clone DKFZp586F1822)	1.3
43				C2H2 (Kruppel-type) zinc finger protein	2.9
	109341	AA213506	Hs.115099	EST VIA A0030	1.5
				KIAA0929 protein Msx2 interacting nuclear target (MINT) homolog	2.2
		H83603	Hs.40408	homeo box C9	3.0
50		N30531	Hs.42215	protein phosphatase 1, regulatory subunit 6	1.9
50		Al160029		ESTS	1.8
			Hs.189915		3,7
				KIAA1143 protein	3.2
		NM_01531		KIAA0942 protein	
			Hs.87134		2.0
55		L40027		glycogen synthase kinase 3 alpha	2.1
		F02614	Hs.27319	ESTs	1.4
		R71264	Hs.16798		1.3
	110039	H11938	Hs.21907	histone acetyltransferase	2.0
				matrix Gla protein	2.5
60			Hs.29956		1.7
	110110	T07353	Hs.7948	ESTs	2.9
	110129	R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	1.7
	110154	NM_01452	1Hs.17667	SH3-domain binding protein 4	4.2
	110240	A1668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOCHROME P450 4A11 PRECURSOR [H.sapiens]	4.2
65	110242	N41744	Hs.19978	CGI-30 protein	1.3
	110259	H28428	Hs.32406	ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	2.2
	440040	DEDECOOR	Un 44906	hypothetical protein EL 149/190	7.1

5.3

		Al288666	Hs.16621	DKFZP434I116 protein	6.2
	110501	H55748		gb:yq94a01.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA done IMAGE:203400 3*	6.1
	110504	H55915	Hs.210859	hypothetical protein FLJ11016	6.1
_	110525	H57330	Hs.37430	EST	6.3
5	110568	AK001160	Hs.5999	hypothetical protein FLJ10298	1.3
	110699	T97586	Hs.18090	ESTs	1.8
	110705	AB007902	Hs,32168	KIAA0442 protein	1.6
	110742	AW190338	Hs.28029	hypothetical protein MGC11256	7.6
	110761	AL138077	Hs.16157	hypothetical protein FLJ12707	2.5
10	110762	BE044245	Hs.30011	hypothetical protein MGC2963	9.3
	110765	AK000322	Hs.18457	hypothetical protein FLJ20315	5.5
	110769	BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 fis, done HEMBA1006364	2.1
	110799	AI089660	Hs.323401	dpy-30-like protein	1.5
	110805	T25829	Hs.24048	FK506 binding protein precursor	6.6
15	110813	AA767373	Hs.35669	ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	5.7
	110820	R33261	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 precursor, intestinal [H.sapiens]	3.4
	110840	N31598	Hs.12727	hypothetical protein FLJ21610	1.7
	110844	Al740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2 (beta)	1.7
	110854	BE612992		hypothetical protein FLJ10607 similar to glucosamine-phosphate N-acetyltransferase	4.7
20		AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo saplens cDNA clone 3' similar to contains element	2.3
		BE384447	Hs.16034	hypothetical protein MGC13186	3.5
		AL117430		DKFZP434D156 protein	2.2
		BE092285			2.6
		H04360	Hs.24283	ESTs, Moderately similar to reduced expression in cancer [H.sapiens]	1.9
25		NM_005864		signal transduction protein (SH3 containing)	6.7
		AK002180			2.0
		AK001980		ADP-ribosyltransferase (NAD+; poly(ADP-ribose) polymerase)-like 2	1.3
				UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T	
		N63823		ESTs, Moderately similar to Z195_HUMAN ZINC FINGER PROTEIN 195 [H.sapiens]	3.6
30				hypothetical protein	2.1
20		N46180		Homo saplens cDNA FLJ13289 fis, clone OVARC1001170	2.3
		R67419		Homo sapiens cDNA FLJ12900 fis, clone NT2RP2004321	3.7
		AL050166			7.5
				asportin (LRR class 1)	7.1
35				Homo sapiens cDNA FLJ20738 fis, clone HEP08257	6.7
		AI815486		Homo sapiens cDNA FLJ20738 fis, clone HE	3.3
		N67603		ESTs, Weakly similar to S65824 reverse transcriptase homolog [H.sapiens]	3.6
		AW139408			1.5
				KIAA1361 protein	2.6
40				KIAA1866 protein	4.6
		N90956	Hs.17230		7.9
		AA778711		eukaryotic translation initiation factor 1A	6.9
				KIAA1265 protein	5.0
		Al523913			3.8
45		T99755	Hs.334728		1.2
-10				LIS1-interacting protein NUDE1, rat homolog	5.1
		H58589		Homo sapiens cDNA FLJ11027 fis, clone PLACE1004114	2.2
		AJ478658	Hs.94631		2.8
		N94606		HSCARG protein	2.2
50				oxidation resistance 1	2.1
50				sialyltransferase 9 (CMP-NeuAc:lactosylceramide alpha-2,3-sialyltransferase; GM3 synthase)	5.1
		W46342		Homo sapiens, done IMAGE:3659680, mRNA, partial cds	8.4
		R02354	Hs.15999		2.7
		Al051194			6.5
55	111400	W90638	Hs.221310	ESTs, Moderately similar to ZRF1_HUMAN ZUOTIN RELATED FACTOR-1 (M-PHASE	1.4
J J					1.6
		R10720	Hs.20670		
•	11102/	R52656 AB037834	Hs.21691	ESTS Hama parions mDNA for KIAA1412 amtoin, partial ada	1.6
				Homo sapiens mRNA for KIAA1413 protein, partial cds	2.4
60		BE298665		Homo sapiens mRNA; cDNA DKFZp564D016 (from done DKFZp564D016)	10.6
60		AW083791		suppressor of potassium transport defect 3	6.6
		NM_015310		KIAA0942 protein	5.1
		R41823	Hs.7413	ESTs; calsyntenin-2	2.8
		AB029000			14.6
<i>(</i>	112388	R46071	MS.301693	Homo sapiens, clone IMAGE:3638994, mRNA, partial cds	9.0
65				A kinase (PRKA) anchor protein 11	1.4
		AW007287		Homo saplens cDNA: FLJ21086 fis, clone CAS03272	1.4
	112506	A1742756	ris.200/9	ESTs	3.2

		R68425	Hs.13809	hypothetical protein FLJ10648	2.0	
	112752	AK001635	Hs.14838	hypothetical protein FLJ10773	1.8	
	112884	AK000004	Hs.5013		6.6	
_	112923	T10258	Hs.5037	EST	1.5	
5	112936	AW970826	Hs.6185	KIAA1557 protein	3.2	
	112958	R61388	Hs.6724	ESTs	6.0	
	112966	Z44718	Hs.102548	glucocorficoid receptor DNA binding factor 1	6.4	
	112978	AK000272	Hs.7099	hypothetical protein FLJ20265	1.2	
	112995	AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYKI protein [M.musculus]	5.6	
10	112996	BE276112	Hs.7165	zinc finger protein 259	2.0	
	113047	AI571940	Hs.7549	ESTs	1.9	
	113049	AW965190	Hs.7560	Homo sapiens mRNA for KIAA1729 protein, partial cds	2.4	
		T40707	Hs.270862	ESTs	1.3	
		T57317		gb:yb51a03.s1 Stratagene fetal spleen (937205) Homo saplens cDNA clone IMAGE:74668 3',	1.7	
15		T63857		gb:yc16e01.s1 Stratagene lung (937210) Homo sapiens cDNA clone 3', mRNA sequence	2.8	
			Hs.11449	DKFZP564O123 protein	1.3	
				protein (peptidyl-prolyl cis/trans isomerase) NIMA-Interacting, 4 (parvulin)	3.2	
			Hs.179808		1.2	
		AI467908		ESTs .	5.9	
20		H59588	Hs.15233		2.0	
			Hs.142442		3.6	
	113647	AA813887	Hs 188173	Homo sapiens cDNA FLJ12187 fis, clone MAMMA1000831	1.3	
		T97307		gb:ye53h05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121497 3',	4.4	
			Hs.184411		1.3	
25		AW499665		SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member		
23				zinc finger protein 313	13.4	
		AL359588		hypothetical protein DKFZp762B226	1.7	
				chitobiase, di-N-acetyl-	1.3	
		W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone COL01832	3.3	
30		BE207480		Homo sapiens cDNA: FLJ22044 fis, clone HEP09141	3.1	
50		H13325		hypothetical protein DKFZp761O17121	3.2	
					2.3	
				hypothetical protein FLJ10826	11.3	
		T26483	Hs.6059	EGF-containing fibulin-like extracellular matrix protein 2	2.7	
35		W57902	Hs.90744	proteasome (prosome, macropain) 26S subunit, non-ATPase, 11	6.1	
33			Hs.16537	hypothetical protein, similar to (U06944) PRAJA1	6.6	
			Hs.21732			
		AW953484		hypothetical protein FLJ22041 similar to FK506 binding proteins	1.9	
		W87544	Hs.268828		1.2	
40				Homo sapiens cDNA FLJ11562 fis, clone HEMBA1003197	5.4	
40				hypothetical protein FLJ21939 similar to 5-azacytidine induced gene 2	9.4	
		AB029551		RING1 and YY1 binding protein	1.8	
				fucose-1-phosphate guanylyltransferase	1.5	
	114226	AB028968	Hs.7989	KIAA1045 protein	1.8	0.0
40	114253	BE149866	Hs.14831	Homo sapiens, Similar to zinc finger protein 136 (done pHZ-20), done MGC:10647, mRNA, compl	ete cus	2.3
45		AL117518		KIAA0978 protein	1.4	
				KIAA0306 protein	15.8	
				fatty acid desaturase 2	1.9	
	114309	AA332453	Hs,20824	CGI-85 protein	2.4	
	114392	AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-rich protein M14 precursor - mouse [M.musculus]	1.8	
50				Homo sapiens mRNA; cDNA DKFZp434B0425 (from clone DKFZp434B0425)	1.2	
		H37908		ESTs, Weakly similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE	5.5	
	114463	AL120247	Hs.40109	KIAA0872 protein	5.2	
	114464	AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110012M11 gene, clone IMAGE:3688605, mRNA, partial	ods 1.2	
	114471	AA028074	Hs.104613	RP42 homolog	1.8	
55	114480	BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T	6) 13.4	
	114671	AA766268	Hs.266273	hypothetical protein FLJ13346	1.9	
	114698	AA476966	Hs.110857	polymerase (RNA) III (DNA directed) polypeptide K (12.3 kDa)	3.5	
	114730	Al373544	Hs.331328	intermediate filament protein syncollin	3.8	
	114767	AI859865	Hs.154443	minichromosome maintenance deficient (S. cerevisiae) 4	1.6	
60				CGI-76 protein	3.1	
		AA159181		serologically defined colon cancer antigen 1	3.5	
		AL157545		bromodomain and PHD finger containing, 3	4.3	
	114895	AA236177	Hs.76591		7.1	
	114896	BE539101	Hs.5324	hypothetical protein	1.3	
65		AA236672		gb:zt29f02.s1 Soares ovary tumor NbHOT Homo sapiens cDNA done IMAGE:723771 3', mRNA s		1.5
J.J.	11/030	AA237022	Hs.188717	ËSTs	2.0	
			Hs.58384		2.9	

		AI733881 AF102546		BMP-R1B dachshund (Drosophila) homolog	2.3 1.3
		AA252360		toll-like receptor 9	1.6
		AI751438		Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1913076	11.8
5				LIM protein (similar to rat protein kina	1.5
		A1670847		hypothetical protein	1.5
			Hs.88155	ESTs	2.8
			Hs.186572		2.5 1.5
10		AW365434		hypothetical protein FLJ10116	1.3
10	115239	BE251328	He 283732	hypothetical protein FLJ10881 ESTs, Moderately similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE	1.4
				hypothetical protein FLJ11301	1.5
			Hs.293736		2.4
				hypothetical protein FLJ10461	6.2
15	115400	Al215069	Hs.89113	ESTs	6.6
		AA314349		tumor antigen SLP-8p	7.4 1.4
			Hs.59346	hypothetical protein FLJ10514	4.0
				ESTs, Moderately similar to 154374 gene NF2 protein [H.saplens] eukaryotic translation initiation factor 4E binding protein 1	16.3
20		Y14443	Hs.71819 Hs.88219		5.0
20			Hs.71414		2.5
			Hs.61082		6.1
				HSPC039 protein	2.9
٥.			Hs.67896	7-60 protein	5.3 4.7
25		N36110		solute carrier family 2 (facilitated glucose transporter), member 10	10.6
	110002	PE033293	Hs.38178	hypothetical protein FLJ23468 Homo sapiens, clone MGC:16063, mRNA, complete cds	12.7
		AL046269 Al138785		ESTs	2.0
		AA953006		ESTs	3.0
30		AA625132		hypothetical protein FLJ21615	1.7
	115693	AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type receptor 3, flamingo (Drosophila) homolog	6.8
		BE395161		proteasome (prosome, macropain) subunit, beta type, 2	1.7
		Al950339		ESTs	2.6 2.1
35		NM_01543		DKFZP434B168 protein	2.1
33		A1732742 A1675217	Hs.87440 Hs 42761	ESTS	1.3
				hypothetical protein MGC5370	4.4
				KIAA0867 protein	7.2
	115875	N55669	Hs.333823	mitochondrial ribosomal protein L13	1.2
40				hypothetical protein FLJ20739	5.5
				KIAA1332 protein	9.8 1.4
	116003	BE275469	HS.66493	Down syndrome critical region gene 5 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 2005735	2.4
				H2A histone family, member L	1.8
45				CGI-04 protein	1.4
		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypothetical protein KIAA0684 [H.sapiens]	1.2
		AW821113	Hs.72402	ESTs	2.1
		AV660717		DKFZP586N0819 protein	1.7
50				baculoviral IAP repeat-containing 6	1.7 1.7
50			Hs.59838 Hs.94109	hypothetical protein FLJ10808 Homo sapiens cDNA FLJ13634 fis, clone PLACE1011133	1.9
	116238	AI955411 AF097645		deleted in cancer 1; RNA helicase HDB/DICE1	4.9
			Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HEMBA1004631	1.4
	116336	AL133033		KIAA1025 protein	1.9
55	116339	AK000290	Hs.44033	dipeptidyl peptidase 8	1.5
	116350	AA497129			1.9 1.9
	116358	A1149586	Hs.38125	interferon-induced protein 75, 52kD	6.1
	116365	N50174	Hs.46765 Hs.71109	ESTs KIAA1229 protein	1.6
60	116308	N90466 AW499664		Human clone 23826 mRNA sequence	7.4
00	116436	AA161411	Hs.58668	chromosome 21 open reading frame 57	2.1
	116462	AF218313	Hs.236828	putative helicase RUVBL	1.5
	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1
	116470	Al272141	Hs.83484	SRY (sex determining region Y)-box 4	1.2 1.5
65	116575	AA312572	MS.0241	phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) integrin-linked kinase-associated serine/threonine phosphatase 2C	2.7
	11663/	AK001043	He 211563	Bacell CLI Avenhanse 74	2.3

	116700	A1800202	Hs.317589	hypothetical protein MGC10765	1.4	
				hypothetical protein FLJ14566	3.4	
	116732	AW152225	Hs.165909		2.9	
_	116921	AW068115	Hs.821		8.3	
5	116926	H73608	Hs.290830	ESTs	1.7	
	117034	U72209	Hs. 180324	YY1-associated factor 2	3.4	
	117132	Al393666	Hs.42315	p10-binding protein	5.2	
	117247	N21032		gb:yx46f06.s1 Soares melanocyte 2NbHM Homo sapiens cDNA clone IMAGE:264803 3', mRNA se	equence.	5.5
	117276	N71183	Hs.121806	Homo sapiens cDNA FLJ11971 fis, clone HEMBB1001208	1.5	
10	117284	AK001701	Hs.183779	Homo sapiens cDNA FLJ10590 fis, clone NT2RP2004392, weakly similar to MNN4 PROTEIN	2.0	
		A1041793			2.0	
	117368	A1878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacuolar proton pump), member J	2.1	
		AF150275			2.7	
		N32536		solute carrier family 16 (monocarboxylic acid transporters), member 6	1.4	
15		AF123050		diubiquitin	3.4	
		N34895	Hs.44648		3.4	
				CGI-12 protein	3.0	
				zinc finger protein 281	1.9	
				chromosome 11 open reading frame 24	1.8	
20				hutvrate-induced transcript 1	5.7	
				hypothetical protein MGC5370	5.9	
				hypothetical protein FLJ13912	1.7	
		Y10518		hypothetical protein FLJ20048	1.7	
				KIAA1785 protein	5.4	
25		N54321	Hs.47790	•	5.2	
25		AA453902			2.6	
				cytochrome c oxidase subunit VIc	2.5	
		AL157545			4.1	•
				rapa-2 (rapa gene)	1.2	
30		N22617	He 43228	Homo sapiens cDNA FLJ11835 fis, clone HEMBA1006595	1.5	
50		Al949952			7.4	
		A1458020			2.5	
	110030	A A 222845	Ho 152618	ESTs, Moderately similar to ZN91_HUMAN ZINC FINGER PROTEIN 91 [H.sapiens]	1.2	
	110070	AD022112	Ho 50197	KIAA1287 protein	2.1	
35			DS.30101	gb:zq75g09.r1 Stratagene hNT neuron (937233) Homo saplens cDNA clone IMAGE:647488 5	5.2	
22		AA199686	Nº 306033	ESTS, Moderately similar to ALU8_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION		
	110923	N92293	HS.200032	ESTs, Moderately similar to ALUS_HUMAN ALU SUBFAMILY SX SEQUENCE CONTAMINATION	13.6	
	110904	A1000/09	IIS.240/22	ESTS, Wooderatery Stitulat to ALUO_HUMAN ALU SUBFAMILLE SA SEQUENCE SUBTAMINATION	4.8	
				bladder cancer overexpressed protein	1.7	
40		W24781		KIAA1710 protein	2.2	
40		AW453069		activity-dependent neuroprotective protein	1.6	
		AW453069		activity-dependent neuroprotective prote	1.4	
		BE539706			25.1	
		N57568	Hs.48028		1.6	
15	119298	NM_00124	1Hs.1554/8	Cyclin 12	1.3	
45				ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	8.4	
		T65004	Hs.163561		6.7	
				nucleolar protein NOP5/NOP58		
		A1624342			2.4	
~ 0		A1796730	Hs.55513		2.1	
50	119513	W37933		Empirically selected from AFFX single probeset	1.9	
	119601	AK000155	Hs.91684	Homo sapiens mRNA; cDNA DKFZp667I103 (from clone DKFZp667I103)	3.7	
				hypothetical protein FLJ11350	3.0	
		AA243837			1.4	
		W61019			1.2	
55		AB032977		KIAA1151 protein	1.8	
				hypothetical protein	3.1	
	119789	BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum comeum tryptic enzyme)	9.2	
	119805	AJ223810	Hs.43213	ESTS, Weakly similar to IEFS_HUMAN TRANSFORMATION-SENSITIVE PROTEIN IEF SSP	3.6	
				hypothetical protein FLJ11101	2.5	
60	119863	AA081218	Hs.58608	Homo sapiens cDNA FLJ14206 fis. clone NT2RP3003157	2.7	
	119905	AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Danios syndrome type IV, autosomal dominant)	2.6	
		AA703129			2.7	
		W57554		lymphoid nuclear protein (LAF-4) mRNA	1.2	
		H26735		Homo sapiens clone PP1498 unknown mRNA	45.7	
65				uncharacterized bone marrow protein BM033	1.2	
				fibroblast growth factor 12B	38.9	
		AW131940			9.6	

	120274	AA177051			4.6
	120280	AA190577		gb:zp52g02.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 3', mRNA sequence	2.0
	120296	AW995911	Hs.299883	hypothetical protein FLJ23399	1.8
_				Edito, redaily division to E roo_reductive interest violation for the principle	15.2
5	120324	AA195517	Hs.191643	E010	5.5
		AA195651		2010	6.4
				.,, posicione, process, 2000-00	16.1
				canaly out a amount of ongazon restor . a prize .	2.9
10				hypothetical protein DKFZp434I143	5.7
10		AA210722			4.5
				hypothetical protein	16.8
		R06859		ESTs, Weakly similar to I38022 hypothetical protein [H.sapiens]	5.0
				parato paratogo compres	28.1 12.4
15		AA219305			4.0
15		AA228026			9.7
				FSH primary response (LRPR1, rat) homolog 1 hypothetical protein DKFZp434D0127	32.6
		AA232874			3.1
	120300	AM232014 AM067085	He 225572	ESTS, Moderately similar to ALU7_HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION	
20	120309	4413410R	He 70306	eukaryotic translation initiation factor 4E	12.5
20				KIAA1013 protein	7.2
		AW966893	Hs 26613		11.4
		AA236453			1.9
		A1950087	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone 3', mRNA sequence	19.4
25		AA251973	Hs.269988		5.4
		AA253170		EST	10.4
	120504	AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAGE:682387 3*, mRNA sequen	ce. 3.9
	120509	BE047718	Hs.96545		9.4
		AA258601			2.4
30		BE350244			2.5
	120551	AA279160	Hs.111407	Homo sapiens, clone IMAGE:3613029, mRNA, partial cds	5.2
	120570	AA280679	Hs.271445	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	14.4
				ZNF135-like protein	10.2 2.1
35				leucine-nch repeat-containing 2	7.5
33		AW965339		N-acetylglucosamine-phosphate mutase	2.5
				M-phase phosphoprotein homolog	52.0
		AA286942	113.170010	gb:zs56f05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:701505 3' similar to contains	
			Hs 140309	Homo sapiens, clone IMAGE:3677194, mRNA, partial cds	5.0
40		AW063659			2.2
. •				6.2 kd protein	2.2
		BE536739		ESTs	1.9
		AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone 3' similar to contains PTR7.t1 PTR7	46.8
	120696	AI821539	Hs.97249	ESTs	2.5
45	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT2RP2000027	5.9
	120718	AA292747	Hs.97296	ESTs	2.9
		Al191410		ESTs, Moderately similar to 2109260A B cell growth factor [H.sapiens]	7.0
			Hs.193985		7.8 6.8
50			Hs.30002	SH3-containing protein SH3GLB2; KIAA1848 protein	
50		AA346495	11- 404000	gb:EST52657 Fetal heart II Homo sapiens cDNA 3' end similar to EST containing O family repeat,	4.4
	120938	AA386260	HS.104032	E51	4.4
	120977	AA398155	MS.97000	E018	5.6
	120984	BE262951 Al219896	HS.99002	EG15 EGTe	1.2
55	120900	AA398360	Hc 07608	FOT	3.1
<i>J J</i>	121011	Al439713	He 165295	ESTs	3.5
•	121020	AA398721	Hs 186749	ESTs, Highly similar to 137550 mismatch repair protein MSH2 [H.sapiens]	5.4
		AA363307			3.7
	121176	AL121523	Hs.97774	ESTs	1.7
60	121223	Al002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.sapiens]	2.9
- -	121320	AA403008	Hs.301927	c6.1A	1.9
	121340	AW956981	Hs.97910	Homo sapiens cDNA FLJ13383 fis, clone PLACE1001024	3.5
	121408	AA406137	Hs.98019	EST	6.0
	121439	AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell growth factor precursor [H.sapiens]	7.4
65	121450	AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, complete cds	6.9
		AW971063	Hs.292882	ESTS	1.8
	121455	H58306	Hs.15165	retinoic acid induced 14	10.5

	121457	W07404	Hs.144502	hypothetical protein FLJ22055	3.4
	121496	AA442224	Hs.97900	ESTs	14.4
	121505	AA494172	Hs.194417	ESTs	13.1
_	121508	AA402515	Hs.97887	ESTs	28.0
5	121513	AA416653	Hs.181510	ESTs	6.2
	121514	AA412112		gb:zt69b02.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:727563 3', mRNA sequence	æ. 2.6
	121549	AA412477	Hs.98142	EST	7.4
	121558	AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:730150 3' similar to contain	ns2.8
			Hs.98096		3.5
10		AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	6.1
			Hs 89718	spermine synthase	3.9
			Hs.98247		2.2
			Hs.126065		4.2
				Homo sapiens mRNA; cDNA DKFZp434B1023 (from done DKFZp434B1023)	7.8
15			Hs.86043		2.0
13			Hs.110286		4.7
		U55184		hypothetical protein FLJ11585	12.7
					8.1
				Homo sapiens cDNA FLJ11953 fis, clone HEMBB1000883	1.8
20			Hs.98325		4.0
20			Hs.180744		7.1
			Hs.97514		19.5
				hypothetical protein NUF2R	7.9
				KIAA1196 protein	
^-			Hs.161008		1.7
25				hypothetical protein FLJ22501	6.6
			Hs.98376		10.5
			Hs.98434		5.8
			Hs.218289		3.8
• •				ESTs, Highly similar to KIAA1048 protein [H.sapiens]	5.0
30				serine/threonine kinase 23	2.7
	121847	AA446628	Hs.2799	cartilage linking protein 1	2.3
	121871	AW972668	Hs.293044	ESTs	2.9
	121882	AA426376	Hs.98459	ESTs	5.0
	121911	AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:773499 3'	7.2
35	121915	AA428179	Hs.223405	ESTs, Moderately similar to A46010 X-linked retinopathy protein [H.saplens]	2.5
			Hs.98611		2.3
	121983	AA298760	Hs.180191	hypothetical protein FLJ14904	3.4
	121985	Al862570	Hs.299214	Homo sapiens, clone IMAGE:2822295, mRNA, partial cds	11.4
		AA210863		nemo-like kinase	3.8
40	121999	AA430211	Hs.98668	EST	6.4
	122009	AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone ADKA01804	2.2
	122013	AA431085	Hs.98706	ESTs	6.5
		W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU SUBFAMILY SC SEQUENCE CONTAMINATION	13.1
		AI453076		ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2	9.1
45			Hs.98750		13.1
			Hs.104921		1.5
		AA398838		gb:zt80d01.r1 Soares_testis_NHT Homo sapiens cDNA clone 5', mRNA sequence	3.3
		AA435936	Hs.98842	EST	5.6
				HCF-binding transcription factor Zhangfei	5.1
50			Hs.98899		5.6
			Hs.104947		5.8
		AW601969		hypothetical protein FLJ22263 similar to nuclear receptor-binding SET-domain protein 1	2.0
		AA443794		ESTs	7.3
	122369	ΔΔ443985	Hs.303222	ESTs	12.2
55	122371	AA868555	Hs.178222	FSTs	5.0
<i>JJ</i>	122372	AA446008	Hs.336677	EST	7.6
	122378	AR032948	Hs 21356	hypothetical protein DKFZp762K2015	2.5
	122405	ΔΔ446572	Hs.303223	EST	2,8
	122400	ΔΔ446869	Hs.119316	ESTS	7.3
60			Hs.99088		1.9
50	122410	AAAAAAAA	Hs ganan	ESTs, Moderately similar to similar to KIAA0766 [H.saplens]	6.8
	122410	AW505139	Hs QARN	Homo sapiens mRNA; cDNA DKFZp547C244 (from clone DKFZp547C244)	2.6
	122440	V V V V V V V V V V V V V V V V V V V	Hs.99123	EST	1.8
			Hs.99127	EST	3.5
65	122440	A1266460	Hs.104980		1.5
UJ	122400	AW418788	He QQ1/P	ESTs, Weakly similar to S43569 R01H10.6 protein - Caenorhabditis elegans [C.elegans]	9.7
	122400	VANA 10100		EST	4.8
	122404	AA448158	175,55102	LUI	1.0

	122490	AA448349	Hs.238151	EST ESTs Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492 ESTs adaptor-related protein complex 1, sigma 2 subunit ESTs ESTs ESTs ESTs ESTs	6.1	
		AA448417		ESTs	5.4	
	122502	V V 30 40 CO	He 224962	Homo sapiens cDNA FLJ12082 fis, clone HEMBB1002492	1.3	
				Tiotho Sapiralis CDNA FEU 12002 IIS, Clotte Ti Evilob 1002402	11.2	
_		AA449232		ESIS		
5				adaptor-related protein complex 1, sigma 2 subunit	10.1	
		AA779725		ESTs	2.5	
	122555	AA194055	Hs.293858	ESTs	1.9	
				ESTs	9.5	
	122572	AA452601	He 00287	ECT	11.0	
10	122312	AM402001	113.33201	ESTS EST Homo sapiens cDNA FLJ11048 fis, clone PLACE1004516 KIAA1460 protein ESTs hypothetical protein FLJ23588 ESTs ESTs	3.4	
10	122586	AK001910	HS.99303	Homo sapiens CDNA FLUT1048 is, cione PLACE 10045 to		
	122587	AB040893	Hs.6968	KIAA1460 protein	2.0	
	122598	AI028173	Hs.99329	ESTs	1.7	
	122599	AL355841	Hs.99330	hypothetical protein FLJ23588	4.4	
	122602	AA411025	He 301060	ESTe	4.6	
15	122002	AAAE2E40	Ha 00023	ECT ₂	61.5	
13	122007	AA453516	115.90023	E015	10.7	
	122614	AA453630	Hs.99339	ESI		
	122616	AA453638	Hs.161873	ESTs	107.3	
	122617	AI681535	Hs.148135	sertne/threonine kinase 33	121.4	
	122618	AA453641		qb:zx48e06.s1 Soares testis NHT Homo sapiens cDNA clone 3', mRNA sequence	31.1	
20	122622	ΔΔ453987	Hs 144802	FSTs	5.6	
~~	122717	A A A E G B E Q	Hc 178358	EQT:	8.5	
	122/1/	AA430035	11- 405440	EO13	10.4	
	122/62	A13/68/5	MS.105119	ESIS		
	122829	AW204530	Hs.99500	ESIS	81.8	
	122834	AA461492	Hs.99545	ESTs serine/threonine kinase 33 gb:zx48e06.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence ESTs ESTs ESTs ESTs Homo sapiens cDNA FLJ10658 fis, clone NT2RP2006052 ESTs ESTs, Weakly similar to putative p150 [H.sapiens] ESTs NIMA (never in mitosis gene a)-related kinase 6 Src-like-adapter ESTs ESTs	3.6	
25	122836	AA460581	Hs.290996	ESTs	4.5	
	122837	AA461509	Hs 293565	ESTs. Weakly similar to outative p 150 [H.sapiens]	2.7	
	122007	AAA6050A	He 22/1386	ECTo	75.3	
	122000	AA400304	115.334300	ANNA facus is mitasis man a) misted timese 6	7.7	
	122854	AA600235	HS.9625	NIMA (never in mitosis gene a)-related kinase o		
••	122856	A1929374	Hs.75367	Src-like-adapter	5.8	
30	122861	AA335721	Hs.119394	ESTs ESTs Janus kinase 2 (a protein tyrosine kinase) Homo sapiens cDNA: FLJ21766 fis, clone COLF7179 ESTs ESTs ESTs ESTs ESTs ESTs Homo sapiens cDNA FLJ11946 fis, clone HEMBB1000709 ninein (GSK3B interacting protein) ESTs, Weakly similar to KIAA1395 protein [H.sapiens] ESTs EST ESTS EST	1.3	
	122866	BE539656	Hs.283705	ESTs	4.1	
	122868	AF005216	Hs 115541	Janus kinase 2 (a protein tyrosine kinase)	5.3	
	122970	AM576312	He 318722	Home saries CDNA: EL 121766 fis. clone COLE7179	9.9	
	122070	AV4004304	Ha 07402	ECT	5.3	
25	1228/2	AVV081394	HS.97 103	E018	13.9	
35	122879	AA/69410	HS.128654	ES18		
	122907	AA470074	Hs.169896	ESTs	11.5	
	122916	AA470140	Hs.229170	EST	1.7	
	122981	AA478951	Hs.105629	ESTs	5.0	
	123013	AW068324	Hs 17384	FSTs	15.4	
40	122016	A1A/220067	He 323231	Home seriors CDNA EL 111046 fe. clone HEMBR1000709	2.8	
70	123010	AVV336067	115.323231	(1000 Septem CENTA 1 & 1 1340 IS, NOTE TIENES 1000 00	8.7	
	123034	AL3595/1	HS.44054	ninen (GSASB interacting protein)		
	123072	AI382600	Hs.104308	ESTs, Weakly similar to KIAA1395 protein [H.sapiens]	8.8	
	123082	AA485360	Hs.105661	ESTs	3.9	
	123088	Al343652	Hs.105667	ESTs	3.8	
45	123110	AA486256	He 193510	EST	7.4	
	120110	BE30/043	He 265949	myomogafin	2.8	
	100404	TE2027	115.200040	TOTA Madely similar to 120022 hypothetical protein [4 capicae]	2.4	
	123131	152021	HS.271795	ESTs, Weakly similar to 138022 hypothetical protein [H.sapiens]	15.6	
	123132	ARU0 1302	ms.324 179	Homo sapiens CDIVA FEB 1237 Fils, Giorie ividivina 1002404		
	123136	AW451999	Hs.194024	ESTs .	5.1	
50	123149	Al734179	Hs.105676	ESTs	23.8	
		AW601773			5.2	
	422258	V V V V V V V	He 105274	ESTS, Weakly similar to RMS1_HUMAN REGULATOR OF MITOTIC SPINDLE ASSEMBLY 1 [H.s	aniens)	9.3
	120230	A A 400000	115.1002/4	gb:zv37d10.s1 Soares ovary tumor NbHOT Homo saplens cDNA clone IMAGE:755827 3' similar to	M 1	• • •
		AA496369			6.0	
		AA504757			6.9	
55	123394	AA731404	Hs.105510	ESTs	3.6	
	123433	AW450922	Hs.112478	ESTs	3.7	
		AA599042			7.4	
	422470	VIVI3U338E	He 303633	Human DNA sequence from clone RP11-110H4 on chromosome 5 Contains a pseudogene similar		
					5 2	
CO				zinc finger protein 14 (KOX 6)	5.2	
60				Homo saplens, clone IMAGE:4098694, mRNA, partial cds	1.7	
	123482	N95059	Hs.55098	ESTs	1.6	
	123486	BE019072	Hs.334802	Homo sapiens cDNA FLJ14680 fis. clone NT2RP2004242, weakly similar to	2.4	
	123508	AW380388	Hs.155546	KIAA1080 protein; Golgi-associated, gamma-adaptin ear containing, ARF-binding protein 2	2.2	
	422645	AA609170	. 10. 1000 10	gb:af12a12.s1 Soares_testis_NHT Homo sapiens cDNA clone 3', mRNA sequence	7.8	
65	123013	77009110		ghine 07-00 -4 NOL COAD DOUBLE THE FOUND SAPERS SOLVER GOING OF MINISTER SEQUENCES	2.8	
65		AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens cDNA clone, mRNA sequence	Z.U	47
		AA609364		gb:zu71d09.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:743441 3' similar to contain	IS AIU.	1.7
	400674	V13606V0	He 105197	kinesin amtein 9 aana	5.7	

	123/35	NM_01324	1 ms.95231	FH1/FH2 domain-containing protein	10.0	
		AA609891			5.2	
				Huntingtin Interacting protein E	30.6	
_			HS.261915	EST, Weakly similar to S65657 alpha-1C-adrenergic receptor splice form 2 [H.sapiens]	2.1	
5	123811	AA620586		gb:ae60g05.s1 Stratagene lung carcinoma 937218 Homo sapiens cDNA clone IMAGE:951320 3'	2.7	
	123951	AB012922	Hs.173043	metastasis-associated 1-like 1	6.2	
				choline dehydrogenase .	4.4	
			115.140170	Chaire denythogenase		
				ralA binding protein 1	7.0	
	124006	Al147155	Hs.270016	ESTs	8.1	
10	124070	A1950314	Hs.154762	HIV-1 rev binding protein 2	3.7	
				topolsomerase-related function protein 4-2	1.2	
				putative G protein-coupled receptor	3.1	
	124203	AA372796	Hs.269339	ESTs, Weakly similar to AF161356 1 HSPC093 [H.sapiens]	5.7	
	124352	AA640891	Hs.102406	ESTs	3.1	
15				KIAA0265 protein	3.5	
13				the 40 40 40 to the French ND and 0 Here against a DNA stand similar to contains		
		AI267847		gb:aq49a10.x1 Stanley Frontal NB pool 2 Homo sapiens cDNA clone similar to contains	57.1	
		AA317338		COBW-like protein	2.8	
	124391	AF155099	Hs.279780	NY-REN-18 antigen	7.1	
		N34059		gb:yv28h09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3' similar to contains A	hı 33	
20			11- 00000	guyyzottota j come restrict 147		
20	124428	H13540	HS.02202	ribosomal protein L17	2.9	
	124440	AA532519	Hs.129043	Human DNA sequence from clone 989H11 on chromosome 22q13.1-13.2. Contains part of a	7.8	
	124466	R10084	Hs.113319	kinesin heavy chain member 2	2.6	
		N53935		gb:yv59d09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 3, mRNA sequence	7.9	
			LI= 200007		7.8	
25		H79433	Hs.268997		-	
25	124515	AA669097	Hs.109370	ESTs	3.3	
	124608	N71076	Hs.102800	ESTs, Weakly similar to neuronal thread protein AD7c-NTP [H.sapiens]	4.5	
				FLVCR protein	3.2	
					5.8	
				Homo sapiens cDNA FLJ13533 fis, clone PLACE1006371		
• •				hypothetical protein	9.3	
30	124642	AW968856	Hs.278569	sorting nexin 17	3.5	
		N92593	Hs.313054		6.1	
		AW297702			8.3	
	124661	R48170	Hs.78436	EphB1	5.6	
	124683	AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE	7.9	
35		R09166			5.7	
		R22952	Hs.268685		11.3	
				Homo saplens mRNA for KIAA1771 protein, partial cds	9.0	
		AW368528	Hs.100855	ESTs	8.1	
	124775	R41772	Hs.100878	ESTs	4.9	
40		R41933	He 140237	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE Homo sapiens cDNA: FLJ22726 fis, clone HSI15005	2.8	
	124770	D42542	He 100042	Homo sapiens cDNA: FLJ22726 fis, clone HSI15005	5.1	
		K43343	HS. 100912	Homo sapiens don's. PLUZZZZZ in , come no 15005		
	124809	AL355722	Hs.106875	Homo sapiens EST from clone 35214, full insert	4.2	
	124811	R46068	Hs.288912	hypothetical protein FLJ22604	14.2	
		R47948	Hs.188732		7.9	
45	124922	A A A 4 Q 4 G D	Ha 96043	Homo sapiens cDNA FLJ13558 fis, clone PLACE1007743	6.6	
73						
		AA501669			2.3	
	124833	AW975868	Hs.294100	ESTs	2.7	
			Hs.137190		2.3	
			Hs.101477		23.9	
50						
50				bromodomain-containing 1	2.0	
	124876	AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	4.4	
	124878	BF397530	Hs 288057	hypothetical protein FLJ22242	2.7	
		H37941	Hs.101883		5.7	
		AW296713			32.4	
55	124930	A1076343		ESTs, Weakly similar to ALUB_HUMAN !!!! ALU CLASS B WARNING ENTRY !!! [H.saplens]	22.8	
	124942	R99978	Hs.268892	ESTs, Moderately similar to B34087 hypothetical protein [H.saplens]	6.1	
		Al078645	Hs.431	murine leukemia viral (bmi-1) oncogene homolog	1.9	
		T40841	Hs.98681	ESTs	4.5	
	125002	T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU SUBFAMILY J SEQUENCE CONTAMINATION	4.9	
60		T79815	Hs.279793	ESTs	5.0	
		T79956	Hs.100588		135.3	
		T81310	Hs.100592		5.4	
	125101	A1472068	Hs.286236	KIAA1856 protein	5.6	
	125113	T96595	Hs.302270	ESTs, Weakly similar to ALUF_HUMAN !!!! ALU CLASS F WARNING ENTRY !!! [H.sapiens]	1.8	
65		T97341		gb:ye57e05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:121856 3' simi		9.6
J J		A1222202	He 240767	Human DNA sequence from clone RP1-12G14 on chromosome 6q24.1-25.2. Contains the 5' end		1.5
		Al222382	1 13.240/0/	Empirically selected from AFFY single nonheset	A DIE GELIE	1.3
	1751/7	พระหากแ		Empirically Selected from AFEX Single homoeset	1/	

	125161	W44657	Hs.144232	EST	10.7
	125249	AA630863	Hs.131375	ESTs, Moderately similar to ALUB_HUMAN III! ALU CLASS B WARNING ENTRY !!! [H.sapiens]	1.3
				timeless (Drosophila) homolog .	9.4
_		AW401809		KIAA1150 protein	1.5
5			Hs.106932		8.0
				Homo sapiens cDNA: FLJ21814 fis, clone HEP01068	1.5
		AW292171		scaffold attachment factor B	5.9
				YY1 transcription factor	1.2
10		U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.4
10		AW409701		baculoviral IAP repeat-containing 5 (survivin)	14.3
	120202	AA15/632	HS.272630	vacuolar proton pump delta polypeptide	2.4
				a disintegrin and metalloproteinase domain 10	9.1 17.0
				CGI-89 protein	12.8
15				Homo sapiens cDNA FLJ12789 fis, done NT2RP2001947	7.3
13		D87466	Hs.161623	KIAA0276 protein	3.1
		D87466		KIAA0276 protein	1.3
				putative nucleolar RNA helicase	9.4
	128527	ΔΔ5ΩΔ583	Hs 101047	transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)	1.5
20		R39234		ESTs, Weakly similar to IDN4-GGTR14 [H.sapiens]	2.8
		U31875		short-chain alcohol dehydrogenase family member	12.1
				Rho GTPase activating protein 8	2.3
	128604	AI879099	Hs.102397	GIOT-3 for gonadotropin inducible transcription repressor-3	1.3
	128608	BE267994	Hs.102419	zinc finger protein	7.1
25				hypothetical protein ASH1	1.3
				DKFZP434A043 protein	3.2
	128639	AW582962	Hs.102897	CGI-47 protein	2.0
	128656	AA458542	Hs.10326	coatomer protein complex, subunit epsilon	1.4
				coatomer protein complex, subunit epsilo	1.3
30	128658	BE397354	Hs.324830	diptheria toxin resistance protein required for diphthamide biosynthesis (Saccharomyces)-like 2	2.4
			Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700010L19 gene, clone MGC:16214, mRNA, complete of	
		W27939		hypothetical protein MGC5576	7.7
				nuclear receptor coactivator 3	3.8
35		Y15221		small inducible cytokine subfamily B (Cys-X-Cys), member 11	1.6 7.6
35		T85231		tubulin, beta 5	5.5
	120717	ANUU1004	HS.104222	hypothetical protein FLJ10702 ESTs, Moderately similar to I38022 hypothetical protein [H.sapiens]	2.7
				RP42 homolog	2.8
				proteasome (prosome, macropain) subunit, alpha type, 4	4.4
40				actin related protein 2/3 complex, subunit 4 (20 kD)	2.2
-10	128747	AR027249	Hs 104741	PDZ-binding kinase; T-cell originated protein kinase	2.8
				thymidine kinase 1, soluble	5.3
		N71826		small nuclear ribonucleoprotein polypeptide F	53.9
				stem cell growth factor; lymphocyte secreted C-type lectin	13.3
45				RD RNA-binding protein	2.6
				nuclear prelamin A recognition factor	2.2
				valosin-containing protein	5.9
				Homo sapiens mRNA; cDNA DKFZp586H0924 (from clone DKFZp586H0924)	1.6
				hypothetical protein FLJ13855	2.2
50				hypothetical protein FLJ13855	1.9
				chromosome 22 open reading frame 3	3.0
				chromosome 22 open reading frame 3	2.2
	128871	AF189723		ATPase, Ca++ transporting, type 2C, member 1	1.5
		F34856		Homo sapiens, clone MGC:16362, mRNA, complete cds	13.3
55		R57988		epithelial protein lost in neoplasm beta	4.7
				programmed cell death 5	1.4
		R67419		Homo sapiens cDNA FLJ12900 fis, done NT2RP2004321 kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	1.9 7.2
		Y13153		a disintegrin and metalloproteinase domain 12 (meltrin alpha) (ADAM-12)	2.4
60		AA009647		hypothetical protein DKFZp434N035	1.3
50				hypothetical protein FLJ11200	10.9
			Hs.107418		1.4
			Hs.165028		1.3
				NICE-5 protein	14.0
65				Homo saplens cDNA FLJ14028 fis, clone HEMBA1003838	1.6
				DKFZP566C243 protein	1.9
		Al950087		ab:wg05c02.x1 NCI_CGAP_Kid12 Homo sapiens cDNA done 3', mRNA sequence	2.9

	129021	AL044675	Hs.173081	KIAA0530 protein	3.8
				KIAA0530 protein	2.5
	129032	R80088	Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4
	129076	AW296806	Hs.326234	ESTs, Highly similar to T46422 hypothetical protein DKFZp434M2023.1 [H.sapiens]	5.0
5		Al351010			2.1
	129088	AA744610	Hs.194431	palladin	17.1
		L12350		thrombospondin 2	2.7
				WW Domain-Containing Gene	20.9
				zinc finger protein 22 (KOX 15)	3.0
10	129099	AF146074	Hs.108660	ATP-binding cassette, sub-family C (CFTR/MRP), member 5	5.8
- •		W93048		hypothetical protein MGC2747	5.9
				KIAA0050 gene product	6.3
				hypothetical protein PRO2577	1.8
		AA286914			2.1
15				latexin protein	3.2
		N57532		KIAA1415 protein	5.8
				osteoglycin (osteoinductive factor, mimecan)	8.0
		U40714		tyrosyl-tRNA synthetase	2.9
				polyadenylate binding protein-interacting protein 1	3.2
20		AA252468		DKFZp434J1813 protein	2.6
20				H1 histone family, member X	7.3
		W26392	Hs 110080	ESTs, Weakly similar to S13495 pregnancy zone protein [H.sapiens]	9.6
		AI051967			1.2
		AA287239		Homo sapiens cDNA FLJ11311 fis, clone PLACE1010102	5.1
25		H75334		F-box only protein 9	4.6
23	1203/7	RE61/1102		melanoma-associated antigen recognised by cytotoxic T lymphocytes	7.6
		U30246	He 110736	solute carrier family 12 (sodium/potassium/chloride transporters), member 2	6.7
	120366	DE220806	He 18/607	Homo sapiens done 23785 mRNA sequence	8.6
				SAR1 protein	1.4
30				CGI-99 protein	2.0
50				pituitary tumor-transforming 1 interacting protein	7.4
		AI267700			5.0
					2.5
		A1267700		hypothetical protein FLJ20647	10.2
35				ADP-ribosylation factor-like 7	8.0
33	120453	A1090900	He 111632	Lsm3 protein	3.2
		AA188185			6.7
		AA188185			3.6
				hypothetical protein AL110115	7.1
40	120010	VE3EE3U3	Hs.300103	membrane-associated nucleic acid binding protein	2.5
40	129010	A A 760221	He 270947	delta-tubulin	3.2
					7.5
		W01296 AA317841	Hs.11360		6.8
				hypothetical protein MGC2752	2.0
45		A1923097			1.6
43		F08282		progestin induced protein	6.8
		H14718		Human clone 23589 mRNA sequence	1.4
				postmeiotic segregation increased 2-like 9	7.3
		N57423		HSPC055 protein	9.0
50	129594	AW403724	115.30909	coagulation factor VII (serum prothrombin conversion accelerator)	1.6
50				REV3 (yeast homolog)-like, catalytic subunit of DNA polymerase zeta	2.2
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (melanoma, p16, Inhibits CDK4)	1.4
		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.8
		AK000398		hypothetical protein FLJ20391	3.3
	129649	AD000092	HS.16488	calreticulin	13.4
55			6HS.1/2180	KIAA0440 protein	14.1
		U03749		gb:Human chromogranin A (CHGA) gene, promoter an	2.6
		AW748482		B7 homolog 3	7.4
		Al304966			
	129720	AA156214	Hs.12152	APMCF1 protein	2.0 1.7
60.				eukaryotic translation initiation factor 2, subunit 3 (gamma, 52kD)	
		H15474		fatty acid desaturase 1	8.3 1.8
	129778	AK001676	Hs.12457	hypothetical protein FLJ10814	
	129779	AA394090	Hs.12460	Homo sapiens clone 23870 mRNA sequence	5.4
	129800	AF052112	Hs.12540	lysosomal	1.7
65	129806	AB023148	Hs.173373	KIAA0931 protein	1.2
	129815	BE565817	Hs.26498	hypothetical protein FLJ21657	3.1
	129840	NM_00659	3UHs.12820	SnRNP assembly defective 1 homolog	1.8

	129861	AL049999	Hs.85963	DKFZP564M182 protein	2.2
	129864	Al393237	Hs.129914	runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene)	1.7
	129869	AI222069	Hs.13015	hypothetical protein similar to mouse Dnajl1	2.7
_	129922	AF042379	Hs.13386	gamma-tubulin complex protein 2	4.5
5	129945	BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8
	129953	AA412195	Hs.13740	ESTs	2.5
	129972	AW753185	Hs.180628	dynamin 1-like	1.8
		U09848		zinc finger protein 36 (KOX 18)	1.3
	129989	AB015856		activating transcription factor 6	4.0
10				nucleolar phosphoprotein Nopp34	1.6
		AA287325		ESTs	4.0
		S73265	Hs.1473	gastrin-releasing peptide	1.8
		AL046962		forkhead box O3A	2.8
		AL135561			2.3
15		X53002		Integrin, beta 5	2.3
				splicing factor proline/glutamine rich (polypyrimidine tract-binding protein-associated)	3.0
				splicing factor proline/glutamine rich (2.1
		L76937		Wemer syndrome	1.8
				tubulin, gamma 1	6.1
20	130211	NM 00335	RHs 23703	ESTs, Moderately similar to CEGT_HUMAN CERAMIDE GLUCOSYLTRANSFERASE [H.saplens]	1.6
		D80001		KIAA0179 protein	1.3
		R85367		splicing factor, arginine/serine-rich 2, interacting protein	2.0
				MyoD family inhibitor	3.2
		X79201		synovial sarcoma, translocated to X chromosome	5.4
25		D81983		GAS2-related on chromosome 22	4.8
23				NIMA (never in mitosis gene a)-related kinase 2	1.4
				tumor suppressing subtransferable candidate 3	2.6
				amyotrophic lateral scierosis 2 (juvenile) chromosome region, candidate 3	6.3
					6.2
30		Z19084		mer re	2.4
50				nuclear receptor interacting protein 1 putative methyltransferase	3.4
				bromodomain adjacent to zinc finger domain, 2A	8.5
		_			1.4
		AL135301		hypothetical protein FLJ10849	3.3
35		A1077464		RNA binding motif protein 9	1.8
33	130393	N89487	U- 455250	KIAA0005 gene product	3.4
	130399	AVV3/4100	Us 224707	hypothetical protein MGC2840 similar to a putative glucosyltransferase	2.3
				hypothetical protein MGC3017	2.7
				BCL2-Interacting killer (apoptosis-inducing)	1.8
40				NS1-associated protein 1	2.3
40		U63630		protein kinase, DNA-activated, catalytic polypeptide	3.9
				PPAR binding protein	33.6
		D90041		N-acetyltransferase 1 (arylamine N-acetyltransferase)	4.6
		D90041		N-acetyltransferase 1 (arylamine N-acety	2.7
15				adducin 1 (alpha)	5.0
45			HS.180779	H2B histone family, member B	4.3
		U49844		ataxia telangiectasia and Rad3 related	1.6
		L38951		karyopherin (importin) beta 1	
				KIAA0618 gene product	16.1
50		L32137	Hs.1584	cartilage oligomeric matrix protein (pseudoachondroplasia, epiphyseal dysplasia 1, multiple)	6.1
50		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	5.3
		AW876523			2.1
	130542	U64675	Hs.179825	RAN binding protein 2-like 1	7.8
	130544	AA321238	Hs.4310	eukaryotic translation initiation factor 1A	1.5
	130553	AF062649	Hs.252587	pituitary tumor-transforming 1	14.4
55	130556	Al907018	Hs.15977	Empirically selected from AFFX single probeset	4.7
		AA383092		replication protein A3 (14kD)	7.9
		AA232119		putative G-protein coupled receptor	3.3
	130574	AF083208	Hs.16178	apoptosis antagonizing transcription factor	1.2
		AB007891		KIAA0431 protein	5.6
60		AL042210		hypothetical protein DKFZp762N2316; KIAA1803 protein	1.4
		AA609738		ESTs	1.5
		Al354355	Hs.16697	down-regulator of transcription 1, TBP-binding (negative cofactor 2)	1.3
		M90516	Hs.1674	glutamine-fructose-6-phosphate transaminase 1	12.1
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	2.4
65	130618	AA383439		Spir-1 protein	15.9
	130667	BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (UBE3B) mRNA, partial cds	13.9
	130674	AL048842	Hs.194019		1.5

	4200	* * * * * * * * * * * * * * * * * * * *	11. 42204	have the Best annie Et 140000	5.4
			Hs.17731	hypothetical protein FLJ12892	
	130692	AA652501	Hs.13561	hypothetical protein MGC4692	5.0
	130693	R68537	Hs.17962	ESTs	2.0
				bromodomain-containing 7	1.8
_					2.0
5				DNA segment on chromosome X (unique) 9879 expressed sequence	
	130730	AB007920	Hs.18586	KIAA0451 gene product	3.7
	130744	H59696	Hs.18747	POP7 (processing of precursor, S. cerevisiae) homolog	3.1
		AF052105		chromosome 12 open reading frame	1.4
					5.7
10		AL036067		protein x 0001	
10				ATP-binding cassette, sub-family A (ABC1), member 1	5.1
	130789	AK000355	Hs.8899	strtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 5	5.2
	130815	AB018298	Hs.19822	SEC24 (S. cerevisiae) related gene family, member D	1.5
		J05068	Hs.2012	transcobalamin I (vitamin B12 binding protein, R binder family)	15.7
					2.8
. -				Homo sapiens cDNA FLJ20848 fis, clone ADKA01732	
15	130843	AA447492	Hs.20183	ESTs, Weakly similar to AF164793 1 protein x 013 [H.sapiens]	1.5
_	130844	U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.4
•				putative DNA/chromatin binding motif	1.7
				HBV pX associated protein-8	1.9
	100001	NIVE COOM	01 15.20303		1.4
••		NM_003410		zinc finger protein 7 (KOX 4, clone HF.16)	
20	130880	BE514434	Hs.20830	kinesin-like 2	2.1
	130892	AL120837	Hs.20993	high-glucose-regulated protein 8	2.4
				sphingosine-1-phosphate lyase 1	1.7
				DnaJ (Hsp40) homolog, subfamily A, member 2	1.8
					2.3
~ -		N79110	Hs.21276		
25	130944	BE382657	Hs.21486	signal transducer and activator of transcription 1, 91kD	5.4
	130971	N39842	Hs.301444	KIAA1673	2.2
			Hs.74316	desmoplakin (DPI, DPII)	1.8
		T97401	Hs.21929	ESTs	1.6
					1.6
• •		AV658308		thyroid hormone receptor interactor 3	
30	131028	AI879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP), gamma	1.2
	131042	A1826288	Hs.171637	hypothetical protein MGC2628	1.6
		AA321649		small inducible cytokine subfamily B (Cys-X-Cys), member 10	7.4
		AA321649		small inducible cytokine subfamily B (Cy	3.0
				Stricts the device of the first and 40040 V links destined with protein [Li conions]	1.7
2.5		H23230	Hs.22481		
35	131060	AA194422	Hs.22564	myosin Vi	5.1
	131060	AA194422	Hs.22564	myosin VI	2.5
		N53344	Hs.22607	ESTs	7.1
		AA749230		dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (2.0
					1.9
40	131076	AA/49230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	
40	131099	AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxidase assembly protein	7.0
	131174	NM_00654	0Hs.29131	nuclear receptor coactivator 2	1.9
		BE280074		cyclin B1	5.8
			Hs.24210		2.0
					7.0
				CGI-26 protein	
45	131225	H62087	Hs.31659	thyroid hormone receptor-associated protein, 95-kD subunit	7.5
	131231	N47468	Hs.59757	zinc finger protein 281	2.9
		D89053	Hs.268012	fatty-acid-Coenzyme A ligase, long-chain 3	3.5
				spectrin SH3 domain binding protein 1	2.8
					2.8
-0				thloredoxin domain-containing	
50				fatty acid amide hydrolase	5.6
	131281	AA251716	Hs.25227	ESTs	5.7
		X80038		Homo sapiens clone F19374 APO E-C2 gene cluster	1.3
				CGI-76 protein	5.0
					1.8
				splicing factor (CC1.3)	
55	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nlbrin)	2.6
	131339	AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6
	131375	AW293165	Hs.143134	ESTS	5.4
	121200	DE360388	He 182608	mitochondrial ribosomal protein L20	5.3
	101000	DE050440	He 070000	LICEOTOTO IN THE PROTOTO IN LANCE OF THE PROTOTO IN LA	2.2
~ 0	131410	BE209110	лs.2/9836	HSPC166 protein	
60	131412	NM_01224	7Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human selenium donor protein	2.0
	131429	AL046302	Hs.26750	hypothetical protein FLJ21908	1.4
		BE297567		hypothetical protein FLJ20392	1.7
	404 A7E	AA992841	Hs 27262	KIAA1458 protein	2.0
	1314/3	AVEC4050	110.21200 Un 0007		2.6
	131501	AV661958	IIS.020/	GK001 protein	
65	131501	AV661958	Hs.8207	GK001 protein	1.6
	131511	AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 ffs, clone COL02535	2.0
	121528	A11076408	Hs 28309	UDP-alumse dehydrogenase	1.6

	131532	BE268278	Hs.28393	hypothetical protein MGC2592	7.4
		AW966881		programmed cell death 2	2.2
		AL355715		programmed cell death 9 (PDCD9)	2.1
					1.7
5		NM_003512		H2A histone family, member L	5.1
3		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PLACE1004405	
		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	1.8
				nucleoponin 50kD	5.0
		BE393822	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (from clone DKFZp761C029); partial cds	1.8
	131622	R78195	Hs.29692	Homo sapiens cDNA FLJ11436 fis, clone HEMBA1001213	1.3
10	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	2.2
	131623	AB037791	Hs.29716	hypothetical protein FLJ10980	1.9
		AW410601		HSPC182 protein	2.9
		AW960597		ESTs	1.3
		Al218918	Hs.30209	KIAA0854 protein	2.8
15		X52486			2.8
1,5			Hs.3041	uracil-DNA glycosylase 2	5.6
		BE559681		KIAA0124 protein	
		AA642831		putative DNA binding protein	2.9
		D13757	Hs.311	phosphoribosyl pyrophosphate amidotransferase	3.4
	131737	AK001641	Hs.31323	inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase complex-associated protein	3.8
20	131760	X76732	Hs.3164	nucleobindin 2	2.9
	131760	X76732	Hs.3164	nucleobindin 2	2.8
		AI878932	Hs.317	topoisomerase (DNA) I	3.4
				KIAA0948 protein	25.5
				DKFZP586J0119 protein	5.5
25		D87077		KIAA0240 protein	2.4
23					7.9
		AW966127		Homo sapiens cDNA FLJ14656 fis, clone NT2RP2002439	
		BE501849		high-mobility group 20B	1.4
		X86098		adenovirus 5 E1A binding protein	4.1
		U20536	Hs.3280	caspase 6, apoptosis-related cysteine protease	4.2
30	131824	U28838	Hs.32935	TATA box binding protein (TBP)-associated factor, RNA polymerase III, GTF3B subunit 2	3.5
	131850	Al251317	Hs.33184	ESTs	5.1
	131878	AA083764	Hs.6101	hypothetical protein MGC3178	5.8
		BE502341		ESTs	13.7
		BE502341		ESTs	2.4
35		W17064	He 332848	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily e, member	
			He 221020	Homo sapiens, done MGC:15961, mRNA, complete cds	8.7
					2.0
				Homo sapiens, clone MGC:15961, mRNA, com	5.5
				Homo sapiens cDNA: FLJ22993 fls, clone KAT11914	
40		AA179298		stomatin-like 2	11.3
40	131913	AW207440	Hs.185973	degenerative spermatocyte (homolog Drosophila; lipid desaturase)	1.7
	131916	AA025976	Hs.34569	ESTs	5.2
	131925	AF151048	Hs.183180	anaphase promoting complex subunit 11 (yeast APC11 homolog)	2.7
	131929	BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fls, clone HEMBA1001711	5.3
		BE252983		ubiquitin specific protease 1	2.3
45		AA355113		x 001 protein	1.5
10				hypothetical protein FLJ20039	2.3
			Hs.35962		1.4
		W79283		ESTS	3.5
				hypothetical protein MDS025	
50		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II	6.5
50		AA503020		hypothetical protein FLJ22418	2.4
	131991	AF053306	Hs.36708	budding uninhibited by benzimidazoles 1 (yeast homolog), beta	2.1
	132019	H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, partial cds	3.2
	132031	AF193844	Hs.3758	COP9 complex subunit 7a	5.8
		BE266155		clathrin-associated protein AP47	1.5
55		NM_00226		karyopherin alpha 3 (importin alpha 4)	3.7
33		BE171921		ESTs .	1.4
		AV646076		ESTs	5.8
		AW960474		ESTs	1.7
		AA857025		kinesin-like 1	3.3
60		NM_00446		fibroblast activation protein, alpha	14.7
		AA206153		mitochondrial ribosomal protein L37	5.5
	132194	R42432	Hs.4212	ESTs	4.4
			2Hs.194714	synaptosomal-associated protein, 29kD	2.2
		BE206939		E2F transcription factor 6	2.2
65		AV658411		KIAA1681 protein	7.8
55		AB018324		KIAA0781 protein	1.5
				Homo sapiens cDNA: FL.121550 fis. clone COL06258	1.3
	13//3/	~~~~~~~~	113, 14 17:03	FIGURE ACDICAS CLUMA. FELIX IDAU HA GIOTIO OCEUUZUU	

	132266	AA301228	He 42200	hypothetical protein FLJ12890	5.7
		AA227710			4,2
				hypothetical protein FLJ13089	2.1
		N36110		solute carrier family 2 (facilitated glucose transporter), member 10	1.5
5		AB023191		KIAA0974 protein	10.0
-		NM_015986		cytokine receptor-like molecule 9	1.9
		AW405882			9.2
		N37065	Hs.44856	hypothetical protein FLJ12116	2.0
				heterogeneous nuclear ribonucleoprotein D-like	6.5
10		AW572805		ESTs	3.8
		AF155582		core1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase	1.5
	132376	Al279892	Hs.46801	sorting nexin 14	12.5
	132384	AA312135	Hs.46967	HSPCO34 protein	28.3
	132393	AL135094	Hs.47334	hypothetical protein FLJ14495	1.9
15		AA100012		hypothetical protein FLJ12085	1.9
	132452	AW973521	Hs.247324	mitochondrial ribosomal protein S14	6.1
	132456	AB011084	Hs.48924	KIAA0512 gene product; ALEX2	1.7
	132465	AW169847	Hs.49169		8.6
	132470	A1224456		H.sapiens polyA site DNA	5.2
20		X16660		RAB4, member RAS oncogene family	1.4
		AW885606		ESTs	6.1
		T78736	Hs.50758	SMC4 (structural maintenance of chromosomes 4, yeast)-like 1	3.3
		AA306105		SEC22, vesicle trafficking protein (S. cerevisiae)-like 1	2.0
0.5		AA454132		mitochondrial ribosomal protein L16	2.9
25		BE388673		hypothetical protein MGC10433	2.2
		BE568452		protein regulator of cytokinesis 1	7.3
		AW674699		suppressor of G2 allele of SKP1, S. cerevisiae, homolog of	1.7
		AW631437		TH1 drosophila homolog	7.1 2.2
20		AK001484		CGI-45 protein	2.2
30		AA345547			6.8
		H12751	Hs.5327	PRO1914 protein	14.0
				hypothetical protein PRO1855	11.4
		A1796870		DNA segment on chromosome X (unique) 9928 expressed sequence	1.9
35		U51127			2.6
33		AB018319		KIAA0776 protein	2.0
		F11875	Hs.5534	collagen, type VIII, alpha 2 Homo sapiens cDNA FLJ12961 fis, clone NT2RP2005645	1.5
		NM_00460		Sjogren syndrome antigen A2 (60kD, ribonucleoprotein autoantigen SS-A/Ro)	3.0
		Al142265			2.4
40				hypothetical protein MGC4840	12.4
70				glutamyl-prolyt-tRNA synthetase	14.6
		AA125985			2.7
		Y10275	Hs.56407		3.0
				KIAA0493 protein	2.3
45				GDP dissociation inhibitor 2	1.8
		AI026701	Hs.5716	KIAA0310 gene product	3.7
		U07418	Hs.57301	mutL (E. coli) homolog 1 (colon cancer, nonpolyposis type 2)	1.8
	132810	AB007944	Hs.5737	KIAA0475 gene product	5.9
	132813	BE313625	Hs.57435	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	8.7
50	132815	AI815189	Hs.57475	sex comb on midleg homolog 1	6.4
	132817	N27852	Hs.57553	tousled-like kinase 2	3.6
	132821	AJ251595	Hs.169610	CD44 antigen (homing function and Indian blood group system)	2.8
	132833	U78525	Hs.57783	eukaryotic translation initiation factor 3, subunit 9 (eta, 116kD)	14.6
	132842	NM_01615	4Hs.279771	Homo sapiens clone PP1596 unknown mRNA	1.6
55	132844	F12200	Hs.5811	chromosome 21 open reading frame 59	2.5
	132851	U09716	Hs.287912	lectin, mannose-binding, 1	1.4
	132863	BE268048	Hs.236494	RAB10, member RAS oncogene family	4.2
				ESTs, Moderately similar to AF116721 89 PRO2168 [H.sapiens]	2.8
		AW007683		KIAA1266 protein	2.0
60		NM_00485		Rho-associated, coiled-coil containing protein kinase 2	1.6
		BE267143		U2(RNU2) small nuclear RNA auxiliary factor 1 (non-standard symbol)	1.4
		AW503667		ring finger protein 15	5.4
	132902	Al936442	Hs.59838	hypothetical protein FLJ 10808	6.1
<i>C</i> 5				Homo sapiens cDNA FLJ11095 fis, clone PLACE1005374	7.1
65		W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PLACE1009921	2.8 6.1
		T79136		Homo sapiens mRNA for KIAA1724 protein, partial cds	10.3
	132941	AI817165	Hs.6120	hypothetical protein FLJ13222	10.3

	132942	AA554458	Hs.197751	KIAA0666 protein	1.8
				Homo sapiens mesenchymal stem cell protein DSC96 mRNA, partial cds	2.2
		AA576635		CGI-48 protein	4.9
				Homo sapiens cDNA FLJ11392 fis, done HEMBA1000575	2.7
5			Hs.323277		5.3
	132977	AA093322	Hs.301404	RNA binding motif protein 3	3.2
	132980	AA040696	Hs.62016	ESTs	1.3
	132994	AA112748	Hs.279905	clone HQ0310 PRO0310p1	3.0
				Homo sapiens, clone IMAGE:3351295, mRNA	10.3
10				UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc-T	
		AI439688		hypothetical protein FLJ20886	1.3
		Al065016		Homo sapiens clone FLB3344 PRO0845 mRNA, complete cds	6.0
			Hs.64056		5.3
		BE247441		protein with polyglutamine repeat; calcium (ca2+) homeostasis endoplasmic reticulum protein	4.9
15			Hs.64691		3.5
10			Hs.65228		13.1
			Hs.65648		1.3
		H94227	Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA, partial cds	2.2
		Z11695		mitogen-activated protein kinase 1	1.3
20				hypothetical protein MGC2745	17.1
20					1.8
				ESTs, Weakly similar to S19560 proline-rich protein MP4 - mouse [M.musculus]	4,9
		X97795	HS.007 10	RAD54 (S.cerevisiae)-like	3.1
				hypothetical protein FLJ20671	4.4
25		A1801777		ESTS	
23				Homo saplens, Similar to bromodomain-containing 4, clone IMAGE:3542455, mRNA, partial cds	1.7 6.0
		AI492924		golgi phosphoprotein 1	1.5
				ADP-ribosylation factor-liké 1	1.4
				Homo sapiens, clone IMAGE:3544662, mRNA, partial cds	
20	133200	A1160873	MS.09233	zinc finger protein	5.6
30				ESTs, Weakly similar to FXD2_HUMAN FORKHEAD BOX PROTEIN D2 [H.sapiens]	1.9
				GM2 ganglioside activator protein	4.7
				NRAS-related gene	5.0
			Hs.70725		2.7
2.5		T79526		integral type I protein	9.3
35		AL390127		Kruppel-like factor 13	4.4
			Hs.71475		1.8
			Hs.71816	v-akt murine thymoma viral oncogene homolog 1	5.5
		AA292811		non-metastatic cells 5, protein expressed in (nucleoside-diphosphate kinase)	2.7
40		AF231919		KIAA0539 gene product	1,7
40		AF245505		DKFZP564I1922 protein	1.8
		BE313555		KIAA1224 protein	1.7
		AI950382		phosphatidylserine receptor	1.3
	133391	AW103364	Hs.727	inhibin, beta A (activin A, activin AB alpha polypeptide)	16.1
	133394	AA305127	Hs.237225	hypothetical protein HT023	12.2
45	133437	AL031591	Hs.7370	phosphotidylinositol transfer protein, beta	10.4
	133452	NM_002759	9Hs.274382	protein kinase, interferon-inducible double stranded RNA dependent	1.2
	133453	Al659306	Hs.73826	protein tyrosine phosphatase, non-receptor type 4 (megakaryocyte)	1.7
	133500	AW964804	Hs.74280	hypothetical protein FLJ22237	11.1
	133529	W45623	Hs.74571	ADP-ribosylation factor 1	2.8
50	133540	AL037159	Hs.74619	proteasome (prosome, macropain) 26S subunit, non-ATPase, 2	2.9
	133543	AU077073	Hs.108327	damage-specific DNA binding protein 1 (127kD)	2.5
	133578	AU077050	Hs.75066	translin	1.5
		X75346	Hs.75074	mitogen-activated protein kinase-activated protein kinase 2	2.1
			Hs.75087	Fas-activated serine/threonine kinase	1.3
55	133594	AW160781	Hs.172589	nuclear phosphoprotein similar to S. cerevislae PWP1	2.2
		AA393273		transcription factor 6-like 1 (mitochondrial transcription factor 1-like)	1.5
		NM_00288		RAP1, GTPase activating protein 1	5.7
		NM_004893		H2A histone family, member Y	25.5
		NM_002047		glycyl-tRNA synthetase	15.8
60		NM_000401		exostoses (multiple) 2	3.3
-		U25849	Hs.75393	acid phosphatase 1, soluble	1.6
		AV661185		mitochondrial ribosomal protein L19	4.1
		L27841	Hs.75737	pericentriolar material 1	1.5
				matrix Gla protein	6.3
65	122751	VANNOUNIN	He 33/797	Homo saplens, Similar to likely ortholog of yeast ARV1, clone IMAGE:3506392, mRNA	3.9
J.		T52946		RAE1 (RNA export 1, S.pombe) homolog	1.7
				laminin receptor 1 (67kD, ribosomal protein SA)	1.8
	133/00	DEX1 1100	113, 10 130/	iaminim receptor i (07kD, muosomai protein ori)	1.0

	133765	M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteoblast)	1.5
	133780	AA557660		decorin	3.5
		BE622743		arfaptin 1	6.8
	133791	M34338	Hs.76244	spermidine synthase	2.6
5		AL133921		retinoblastoma-binding protein 2	1.4
		D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin B)	8.0
				putative human HLA class II associated protein I	13.5
		AA147026			2.2
		W29092	Hs.7678	cellular retinoic acid-binding protein 1	1.8
10		U86782		26S proteasome-associated pad1 homolog	2.0
- •				discs, large (Drosophila) homolog 5	2.8
				KIAA0097 gene product	6.7
		AB012193			2.5
		U30872	Hs.77204		3.0
15		U30825	Hs.77608		1.4
1.5		D86326		vesicle docking protein p115	5.4
				SMC1 (structural maintenance of chromosomes 1, yeast)-like 1	4.9
		L17128		gamma-glutamyl carboxylase	3.7
		BE244332			12.1
20		X81789	Hs.77897		9.7
20				GATA-binding protein 3 (T-cell receptor gene activator)	3.1
	133370	VI UVU338	He 78202	SWI/SNF related, matrix associated, actin dependent regulator of chromatin	1.3
		Al824113		regulator of G-protein signalling 12	9.7
				RNA binding protein; AT-rich element binding factor	2.4
25		D31764		sorting nexin 17	2.5
23					1.3
		NM_003590		LIV-1 protein, estrogen regulated	4.2
		U41060	Hs.79136		2.2
		NM_014742	(US./9303	KIAA0255 gene product protein phosphatase 2, regulatory subunit B (B56), epsilon isoform	5.0
30		H86504			3.2
30				KIAA0160 protein	2.5
		AF107463		splicing factor 30, survival of motor neuron-related	2.1
		NM_000288		peroxisomal biogenesis factor 7	9.1
		NM_000402		glucose-6-phosphate dehydrogenase	2.8
25		BE300078		Homo sapiens, clone IMAGE:3535294, mRNA, partial cds	1.8
35		Al878910		cisplatin resistance-associated overexpressed protein	
		Al906291		immunoglobulin superfamily, member 3	2.0 2.5
		AW502505		Homo sapiens cDNA: FLJ21927 fis, done HEP04178, highly similar to HSU90909	
		U61397	Hs.81424	ubiquitin-like 1 (sentrin)	2.8
40				KIAA1100 protein	10.4 1.9
40		AW903838			2.6
		N92036	Hs.81848	RAD21 (S. pombe) homolog	2.0
		NM_00492		SEC24 (S. cerevisiae) related gene family, member C	
		AW291946		interleukin 6 signal transducer (gp130, oncostatin M receptor)	13.0
4.5		AA339449		phosphonbosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase,	8.8
45		X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46 kD)	1.5
				hypothetical protein MGC3222	8.1
		Al589941		Homo sapiens, Similar to tumor differentially expressed 1, clone IMAGE:3639252, mRNA,	paniai cos 2.6
		AA417383		integrin, beta-like 1 (with EGF-like repeat domains)	4.1
		AA456539		lysosomal	1.7
50		AA334551		sperm specific antigen 2	2.6
		AW067903		collagen, type XI, alpha 1	1.3
				reticulocalbin 1, EF-hand calcium binding domain	3.2
	134415	Al750762	Hs.82911	protein tyrosine phosphatase type IVA, member 2	1.9
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	10.3
55	134424	Z44190	Hs.83023	peroxisomal blogenesis factor 11B	2.4
	134446	AA112036	Hs.83419	KIAA0252 protein	1.2
	134447	M58603	Hs.83428	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)	1.6
	134470	X54942	Hs.83758	CDC28 protein kinase 2	2.1
	134480	NM_005000	0Hs.83916	Empirically selected from AFFX single probeset	5.3
60		X82153	Hs.83942	cathepsin K (pycnodysostosis)	2.5
-		AW246273		threonyl-tRNA synthetase	2.1
	134513	AA425473	Hs.84429	KIAA0971 protein	3.8
	134516	AK001571	Hs.273357	hypothetical protein FLJ10709	2.4
	134520	BE091005	Hs.74861	activated RNA polymerase II transcription cofactor 4	6.7
65	134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.3
05	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor for fRNAs)	5.5
		AA927177		CGG triplet repeat binding protein 1	5.8

	134612	AW068223	Hs 171581	ubiquitin C-terminal hydrolase UCH37	2.2
		AF035119		deleted in liver cancer 1	2.0
				chloride channel 3	2.3
		AK001741		hypothetical protein FLJ10879	1.4
5		AA256106		ESTs ·	72.9
-		BE391929		transmembrane protein 4	8.5
			Hs.88251	arylsulfatase A	6.0
	134692	NM_003474	He 8850	a disintegrin and metalloproteinase domain 12 (meltrin alpha)	4.3
		BE161887		anaphase-promoting complex subunit 10	2.3
10		Y14768	Hs.890	lysosomal	6.7
10		AA852985		chromobox homolog 5 (Drosophila HP1 alpha)	2.3
				F-box only protein 6	2.9
				ring finger protein 22	6.6
		X07871	Hs.89476	CD2 antigen (p50), sheep red blood cell receptor	2.3
15		AW630803		lamin B1	6.2
				integral membrane protein 1	1.9
		AD001528		spermine synthase	1.8
		AW451370		adaptor-related protein complex 1, gamma 2 subunit	1.4
		Al701162		hypothetical protein MGC11138	1.4
20		BE268326		5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	5.6
20		D26488	Hs.90315	KIAA0007 protein	2.8
		Al879195		15 kDa selenoprotein	1.7
		AA532963		Homo sapiens cDNA FLJ13100 fls, clone NT2RP3002255	1.7
		AW885909		PRO1073 protein	2.1
25		AW401361		protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform	1.3
				phosphoserine aminotransferase	2.1
		R50333	Hs.92186	Leman coiled-coil protein	2.3
		AB037835		KIAA1414 protein	1.6
		NM_000408		glycerol-3-phosphate dehydrogenase 2 (mitochondrial)	3.9
30				hypothetical protein FLJ12619	6.2
-		AW503733		KIAA1488 protein	2.0
		AB036063		p53-Inducible ribonucleotide reductase small subunit 2 homolog	1.3
•		AF027219		zinc finger protein 202	7.1
				zinc finger protein 36 (KOX 18)	3.2
35		Al093155		JM27 protein	2.5
				px19-like protein	1.4
				translin-associated factor X	5.0
		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATIVE C10 PROTEIN [H.sapiens]	6.1
		T78802	Hs.96560	hypothetical protein FLJ11656	4.6
40		BE463721		putative G protein-coupled receptor	5.6
		AI028767			3.5
				ESTs, Weakly similar to A46010 X-linked retinopathy protein [H.sapiens]	1.2
		Al088775		geranylgeranyl diphosphate synthase 1	2.6
	135274	AA448460	Hs.112017	GE36 gene	5.3
45	135294	AA150320	Hs.9800	protein kinase Njmu-R1	9.1
	135295	AI090838	Hs.98006	ESTs	2.4
	135307	Al743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein [H.sapiens]	13.3
				ribosome binding protein 1 (dog 180kD homolog)	2.6
				cell division cycle 2-like 1 (PITSLRE proteins)	8.3
50	135361	AA373452	Hs.167700	Homo sapiens cDNA FLJ10174 fis, done HEMBA 1003959	1.5
		U05237		fetal Alzheimer antigen	4.9
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone receptor, testicular feminization; spinal and bulbar	2.0
		R50333	Hs.92186	Leman coiled-coil protein	2.6
	135011	AB037835	Hs.92991	KIAA1414 protein	1.4
55	135022	NM_000408	3Hs.93201	glycerot-3-phosphate dehydrogenase 2 (mi	1.6
	135032	AW301984	Hs.173685	hypothetical protein FLJ12619	1.4
	135077	AW503733	Hs.9414	KiAA1488 protein	1.8
	135083	AB036063	Hs.94262	p53-inducible ribonucleotide reductase s	2.5
	135095	AF027219	Hs.9443	zinc finger protein 202	1.5
60				zinc finger protein 36 (KOX 18)	2.1
		AI093155		JM27 protein	4.4
				px19-like protein	14.9
		AA477514		translin-associated factor X	1.3
	135207	N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7
65	135214	T78802	Hs.96560	hypothetical protein FLJ11656	6.1
		BE463721	Hs.97101	putative G protein-coupled receptor	2.7
	135245	AI028767	Hs 262603		12.2

					- ^
	135257	AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	7.6
	135263	AI088775	Hs.55498	geranylgeranyl diphosphate synthase 1	1.8
		AA448460			4.1
		AA150320		protein kinase Nimu-R1	1.2
5		A1090838		ESTs .	4.8
5				2010	5.8
				ESTs, Weakly similar to KIAA0822 protein	12.3
				ribosome binding protein 1 (dog 180kD ho	
	135354	AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.7
				Homo sapiens cDNA FLJ10174 fis, clone HE	7.9
10		U05237		fetal Alzheimer antigen	1.9
10		X78592		androgen receptor (dihydrotestosterone r	13.9
					5.3
				HIV TAT specific factor 1	2.2
				HER2 receptor tyrosine klnase (c-erb-b2,	
	303135	AW592789	Hs.279474	HSPC070 protein	1.4
15	303686	AK000714	Hs.109441	MSTP033 protein	5.2
	310085	R43191	Hs.101248	Homo saplens done IMAGE:32553, mRNA seq	2.3
		AA808229			2.8
				ZW10 Interactor	2.0
				rab3 GTPase-activating protein, non-cata	5.5
20					1.4
20				Golgi apparatus protein 1	1.3
		N24236		nucleosome assembly protein 1-like 1	
	322474	AF118083	Hs.29494	PRO1912 protein	2.9
	322556	BE041451	Hs.177507	hypothetical protein	1.6
				RP42 homolog	1.8
25				BUB3 (budding uninhibited by benzimidazo	1.6
23	400406	ALOSAEAD	No.42627	SRY (sex determining region Y)-box 22	6.1
					5.6
				RNA helicase family	2.6
		R73727		ESTs, Weakly similar to T32527 hypotheti	2.4
				hypothetical protein, expressed in osteo	
30				SFRS protein kinase 1	1.5
	414846	AW304454	Hs.77495	UBX domain-containing 1	4.2
	416980	AA381133	Hs 80684	high-mobility group (nonhistone chromoso	23.6
		R57256	Hs 82037	TATA box binding protein (TBP)-associate	5.8
		S79895	He 92042	cathepsin K (pycnodysostosis)	1.3
25			115.0J342	realizable stame binding protein 6	1.6
35				retinoblastoma-binding protein 6	2.3
		U72937	Hs.96264		1.6
	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	
	421225	AA463798	Hs.102696	MCT-1 protein	3.5
	421642	AF172066	Hs.106346	retinoic acid repressible protein	4.9
40				histone deacetylase 3	3.1
-10				peptidylprolyl isomerase C (cyclophilin	1.9
					2.4
	422002	AA302744	75, 1040 10	EU15	4.1
	422055	NM_01432	UHS. 1 11029	putative heme-binding protein	7.0
	423750	AF165883	Hs.298229	prefoldin 2	4.9
45	424001	W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	
	425182	AF041259	Hs.155040	zinc finger protein 217	3.4
	425284	AF155568	Hs.155489	NS1-associated protein 1	2.1
	426372	RE304680	He 169531	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	7.5
	420012	AM/192766	He 182238	GW128 protein	1.7
50	400477	VIV 100100	115.102250	splicing factor, arginine/serine-rich 11	2.4
50				DEADA! (Ass. Ch. Als. Ass. Mis.) box notices	3,8
		AB001636		DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	5.6
		AK001333	Hs.6216	Homo sapiens hepatocellular carcinoma-as	
	441560	F13386	Hs.7888	Homo sapiens clone 23736 mRNA sequence	2.0
	445580	AF167572	Hs.12912	skb1 (S. pombe) homolog	7,5
55	446999	AA151520	Hs.334822	hypothetical protein MGC4485	2.2
	447111	AI017574	Hs 17409	cysteine-rich protein 1 (intestinal)	2.8
	447779	BE620592	He 71100	ESTs, Weakly similar to S16506 hypotheti	1.7
				and the state of t	5.9
		NM_00367	/ MS.ZZ393	density-regulated protein	5.6
		W68520	Hs.331328	Intermediate filament protein syncoilin	
60	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	1.4
	450703	AA011202	Hs.184771	nuclear factor I/C (CCAAT-binding transc	4.7
	452461	N78223	Hs.108106	transcription factor	2.9
	452511	RF408178	Hs.285165	Homo sapiens cDNA FLJ20845 fis, clone AD	12.1
		AF077036		DKFZP586G1722 protein	4.7
65	40010/	MEU//030	13.01303	Homo sapiens, clone MGC:2492, mRNA, comp	1.3
65	453556	BE541906	MS.0/019		3.2
			HS.108802	N-ethylmaleimide-sensitive factor	6.2
	102481	U50360		gb:Human calcium, calmodulin-dependent p	0.2

	102827	BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	7	7.9
		BE270465		protein kinase C, zeta	2	2.0
				cdk inhibitor p21 binding protein	5	5.3
				hypothetical protein FLJ 10697	2	2.0
5		AK001827	Hs.87889	helicase-moi	5	5,7
_	119075	M10905	Hs.287820	fibronectin 1	1	1.3
	119615	AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant	2	2.9
	125006	BE065136		splicing factor (CC1.3)	1	1.7
	127609	X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture		2.4
10	129209	R62676	Hs.17820	Rho-associated, coiled-coil containing p	5	5.2
	129917	M30773		protein phosphatase 3 (formerly 2B), reg	4	1.5
	130182	BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo	1	11.0
	130365	W56119	Hs.155103	eukaryotic translation initiation factor	3	3.3
	131135	NM 016569	9Hs.267182	TBX3-iso protein	1	1.3
15	131853	AI681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		3.2
	131881	AW361018	Hs.3383	upstream regulatory element binding prot	1	14.
	132726	N52298	Hs.55608	hypothetical protein MGC955	3	3.0
	135193	X95525	Hs.96103	TATA box binding protein (TBP)-associate		2.7
	409487	H19886		gb:yn57a05.r1 Soares adult brain N2b5H	2	2,3
20	416040	AW819158	Hs 289044	Homo sapiens cDNA FLJ12048 fis. clone HE	7	7.4

TABLE 4A

5

10

Table 4A shows the accession numbers for those pkeys lacking unigeneID's for Table 4. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey: CAT number: Accession:		Unique Eos prob Gene cluster nu Genbank access	mber	number								
15	Pkey	CAT num	ber Accession	ns								`	
20	123619 101445 124385 124417	306861 371681_1 16505 656394_1 1642364_ 1657509	AA602964 M21259 AI267847 1 N34059 N	N27351 46979									
25	102481 103349	312812 110522 19346_14	8 U50360 X89059 AA992380) N33063 N21	AA080912	AA075318	AA083403	AA076594 A 75419 AA06	.A078992 AA 33293 AA071	084926 AA 252 AA078	081881 AA 900 AA062	113913 AA11 836 AW97430	3892 05
30	113248	160212_1 328626_1 44573_2	AA190577 T63857 A' AI950087 AA908598	7 AA181657 W971220 AA4 N70208 R970 3 AA251875 A AA884444 NS	193469 T63 140 N36809 1820501 Al8	699 Al308119 320532 W8	AW967677 I 7891 T8590	N35320 Al25 4 U71456 Ti	51473 H5939 82391 BE328	7 AW97157 1571 T7510	73 R97278 2 R34725 /	W01059 AW9 \A884922 BE	967671 328517
35			AA283144 AI762688 BE612881 AI819225 AA969759	AAOOHH4 NS AA988777 AA AA988777 AA AW205862 A AW205862 A AW5628 N22	950344 AI74 1488892 AI3 14W513601 / 1683338 AI8 1388 H8472	41346 A168 356394 AW AW512843 358509 AW 9 H60052 T	39062 AA282 7103813 AI5 AA044209 A 276905 AI63 192487 AI02	2915 AW102 39642 AA64 AW856538 A 33006 AA97 2058 AA780	2898 A187219 2789 AA856 AA180009 AA 2584 AA908 419 AA5510	3 Al763273 975 AW505 .337499 AV 741 AW072 05 W80701	3 AW17358 512 AI9615 V961101 AV 629 AW513 AW613456	6 AW150329 530 AW62997 A251669 AA2 1996 AA2932	A1653832 '0 51874 73
40	129019	44573_2	AI950087 AA908598 AI219788 AA283144	N70208 R97(3 3 AA251875 A AA884444 N! 1 A1890387 AI AA988777 AA	040 N36809 1820501 Al8 92578 F134 950344 Al7	Al308119 820532 W8 93 AA9277 41346 Al68	AW967677 I 7891 T8590 94 Al56025 39062 AA28	N35320 Al25 4 U71456 T 1 AW874068 2915 AW102	51473 H5939 82391 BE328 3 AL134043 / 2898 A187219	7 AW97157 3571 T7510 AW235363 33 Al763273	73 R97278 2 R34725 / AA663345 / 3 AW17358	NA884922 BE AW008282 A 6 AW150329	328517 A488964 Al653832
45			BE612881 AI819225 AA969759	AW276997 AW205862 A O N75628 N22 0 N3488 W3718	AW513601 / 1683338 AI8 1388 H847 2 9	AW512843 358509 AW 9 H60052 T	AA044209 A 276905 A163 192487 A102	AW856538 A 33006 AA97 2058 AA780	\A180009 AA 2584 AA908 419 AA5510	.337499 AV 741 AW072 05 W80701	V961101 AV 629 AW513 AW613456	4251669 AA2 8996 AA29327	51874 73
50	122188 121581	9683_3 275673_1 283769_1 305217_1	AA976503 AA970201 AA398838 AA416568	3 A1917802 A/ 1 A1633384 A/ 3 AA435847 8 AA442889 A 1 AA454061	4953664 AA 4425910 AK	4404613 AA 017004 AI2	428771 BE:	280542 AW1	194691 Al927			00 Al935603	AW052210
55	109026 123658 123811 125115	150431_1 genbank_ genbank_ genbank_	1 AA15781 [,] _AA609364 _AA620586	1 AA836869 AA609364 AA620586 T97341	W38150								
60	118737 120274 113196 120504	382979_1 genbank_ genbank_ genbank_	1 AA199686 _AA177051										

	120809	genbank_AA34	46495	AA346495
	113702	genbank_T973	307	T97307
	129680	23162_1	U03749 NI	M_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122
		-	A1858999 (D55958 Al684005 D53170 AA854091 Al025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441
5			AW043898	8 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432
			AI038109	AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054
			AI273831 \	W32275 Al584185 C05724 AA789023 Al686818 D54392 Al022485 AA431410 AA854232 W39212 W15214 AA894441
				Al167381 AW245389 AA319430 AA335156 Al042646 AA327030 AA725170 T27943 AA889304 AA976699 Al687001
			AI621107	AI865540 AA772107 C06286 AA319661 AA405992
10	101045	entrez_J05614	J05614	
		genbank	N21032	
	110501	genbank	H55748	·
	103392	entrez_X94563	3X94563	
	105032	genbank	AA127818	
15	119513	NOT_FOUND_	entrez	W37933
	105445	genbank	AA252395	
	121514	genbank	AA412112	!
	121558	genbank	AA412497	•
	121911	genbank	AA427950	
20	123315	714071_1	AA496369	AA496646
	114911	genbank	AA236672	
		1134778_1	H19886 AV	W402806 T10231

PCT/US02/02242 WO 02/059377

TABLE 5: Figure 5 from BRCA 001 US

Table 5 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

10

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal breast tissue

Pkey: ExAccn: UnigeneID: Unigene Title:

	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
15	· noy	DOTOGII	Unigencia	omgonornac	•••
	100114	X02308	Hs.82962	thymidylate synthetase	2.9
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
		H60720	Hs.81892	KIAA0101 gene product	9.2
		AW247529		platelet-activating factor acetylhydrola	2.7
20		L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7
_ •	100667	L05424	Hs.169610	CD44 antigen (homing function and Indian	9
	100668		Hs.169610	CD44 antigen (homing function and Indian	7.6
	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	100988	AK000405	Hs.76480	ubiquitin-like 4	11.4
25	101031	J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.2
	101045	J05614		gb:Human proliferating cell nuclear anti	5
	101332	J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	3.4
	101352	AI494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	6.3
	101580	NM_012151	IHs.83363	coagulation factor VIII-associated (intr	5.7
30	101592	AF064853	Hs.91299	guanine nucleotide binding protein (5.6
	101767	M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4
	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias	8.9
		NM_000318	3Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	3.2
		AI904232	Hs.75323	prohibitin	8.4
35		BE258602		heat shock protein 75	1.4
		BE313280		death associated protein 3	4.6
		AW950852		polymerase (DNA directed), delta 2, regu	4.3
		AA829978		JTV1 gene	6.7
40		U24389	Hs.65436	lysosomal	4.3
40		AA306342		protein kinase C-like 2	2.7
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2
		U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2
		U48705	Hs.75562	discoidin domain receptor family, member	6.9
15		W81489	Hs.223025	RAB31, member RAS oncogene family	5.3
45		AL037672		extracellular matrix protein 1	5.8 4.3
		NM_007019		ubiquitin carrier protein E2-C	
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6 1.9
		AU077058		BRCA1 associated RING domain 1	2.3
50		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	6.4
30		BE252241		pyridoxal (pyridoxine, vitamin B6) kinas	5.6
		BE244588		chaperonin containing TCP1, subunit 2 (b matrix metalloproteinase 11 (MMP11; stro	4.5
		NM_005940			3.1
		AU077231 AA205475		cyclin D1 (PRAD1: parathyroid adenomatos ribosomal protein S18	9.9
55		X72755	Hs.77367	monokine induced by gamma interferon	8.8
55		A1369285	Hs.75189	death-associated protein	5.6
	103547		Hs.180062	proteasome (prosome, macropain) subunit,	9.7
		BE270465		protein kinase C, zeta	7.9
		AK001278		hypothetical protein FLJ10416 similar to	6.5
60		BE379766		polymerase (RNA) II (DNA directed) polyp	6.3
50		AW052006		PRP4/STK/WD splicing factor	10.9
		AI250789	Hs.32478	ESTs	5.6
	104854		Hs.154729	3-phospholnositide dependent protein kin	12.3
		AA278898		hypothetical protein similar to small G	2
	.0.1001			/·	

	404000	4111045040	11- 00405	507-	47 7 [°]
		AW400464		ESTs	17.7 5
		AW408164 AW958157		transcription factor 19 (SC1) NS1-associated protein 1	1.7
		AA026880		prolactin receptor	1.4
5		Y12059	Hs.278675	bromodomain-containing 4	1.4
•		Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	
		AF098158	Hs.9329	chromosome 20 open reading frame 1	3.3
	105039	AA907305	Hs.36475	ESTs	2.5
10		AA151342		CGI-147 protein	9.5
10	-	H58589	Hs.35156	Homo saplens cDNA FLJ11027 fis, clone PL	2.2
		AF167570		interleukin enhancer binding factor 3, 9	5.4
		AA262640		unknown	9.3 1.4
		BE616694		hypothetical protein FLJ14299	9.4
15		AA985190 AW151952		hypothetical protein FLJ20059 hypothetical protein FLJ20739	1.5
13		AF151066		hypothetical protein	2.9
		AF016371		peptidyl prolyl isomerase H (cyclophilin	5.2
		AA533491		hypothetical protein FLJ14681	6.8
		AK001404		cyclin B2	5.7
20	106359	AW390282	Hs.31130	transmembrane 7 superfamily member 2	6.3
		AA458882		fibulin 1	7.9
		NM_00359		tyrosylprotein sulfotransferase 2	7.7
		BE614802		hypothetical protein FLJ12549	4.5 16.2
25		AW959893		hypothetical protein FLJ23293 similar to KIAA1323 protein	2.2
23		AB037744 N49809	Hs.11197	Homo sapiens, done IMAGE:3343149, mRNA	
		BE156256		hypothetical protein	6.6
		AF264750		myeloid/lymphoid or mixed-lineage leukem	1.8
		W15477	Hs.64639	glioma pathogenesis-related protein	6.1
30		AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.4
	107901	L42612	Hs.335952	keratin 6B	2.5
		BE153855		lg superfamily receptor LNIR	2.2
		AW956103		pyruvate dehydrogenase kinase, isoenzyme	6.7
25		AF129535		F-box only protein 5	7.1 9.8
35		BE546947		homeo box C10 KIAA1077 protein	7.2
		AB029000 AK001431		hypothetical protein FLJ10569	4
		AA156542		ESTs	1.4
		AA164293		ESTs	2.9
40		AA375752		Homo sapiens mRNA; cDNA DKFZp586F182	2 (f 2.9
	109468	NM_015310	DHs.6763	KIAA0942 protein	3.2
		AI668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTO	
		Al288666	Hs.16621	DKFZP434I116 protein	6.2
45		H55748	N 20000	gb:yq94a01.s1 Soares fetal liver spleen	6.1 7.6
43		AW190338		hypothetical protein MGC11256 hypothetical protein MGC2963	9.3
		BE044245 AA992380	HS.30011	gb:ot37g06.s1 Soares_testis_NHT Homo sap	
		NM_00586	4Hs.24587	signal transduction protein (SH3 contain	6.7
		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	
50		AK000136	Hs.10760	asporin (LRR class 1)	7.1
		N90956	Hs.17230	hypothetical protein FLJ22087	7.9
		AA778711		eukaryotic translation initiation factor	6.9
	111392		Hs.325081	Homo sapiens, clone IMAGE:3659680, mRN/	A, 8.4
E E	111937	BE298665		Homo sapiens mRNA; cDNA DKFZp564D016	14.6
55		AB029000 AA737033	Hs.70823 Hs.7155	KIAA1077 protein ESTs, Moderately similar to 2115357A TYK	5.6
	112990	BE266947	Hs.10590	zinc finger protein 313	13.4
	113771	Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3
	113811	BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1
60	113834	T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3
	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7
	113870	AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1
	113923	AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.9
CF.	114275	AW515443	HS.306117	KIAA0306 protein	15.8 7.1
65	114895	AA236177 AI733881	Hs.70091 Hs.72472	KIAA0887 protein BMP-R1B	2.3
	114900	AI753661 AI751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8
	110001	711 0 1400	· W.T (4/1	Trainio auptorio mittata fun longui moort obit	

	115070	AMODOLEO	Un 201724	hypothetical protein El 111201	1.5
		AK002163		hypothetical protein FLJ11301	6.2
		BE545072	Hs.122579	hypothetical protein FLJ10461	
		BE093589	Hs.38178	hypothetical protein FLJ23468	10.6
_		AF231023	Hs.55173	cadherin, EGF LAG seven-pass G-type rece	6.8
5		Al867451	Hs.46679	hypothetical protein FLJ20739	5.5
		AB037753	Hs.62767	KIAA1332 protein	9.8
	116011	AL359053	Hs.57664	Homo sapiens mRNA full length insert cDN	2.4
	116417	AW499664	Hs.12484	Human done 23826 mRNA sequence	7.4
	116470	AI272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1
10	116637	AK001043	Hs.92033	integrin-linked kinase-associated serine	2.7
	117132	AI393666	Hs.42315	p10-binding protein	5.2
		AF161470		butyrate-induced transcript 1	5.7
		AI949952	Hs.49397	ESTs	7.4
		M10905	Hs.287820	fibronectin 1	5.7
15		BE539706		ESTs	1.4
13		T65004	Hs.163561	ESTs	8.4
		AL117554	Hs.119908	nudeolar_protein NOP5/NOP58	6.7
		BE393948		kallikrein 5 (KLK5; KLK-L2; stratum com	9.2
		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	
20					38.9
20		AA131376		fibroblast growth factor 12B	
		AA191384		ESTs, Weakly similar to Z195_HUMAN ZINC	
		AA195651		ESTs	6.4
		AK000292		hypothetical protein FLJ20285	16.1
0.5		AW969481		hypothetical protein	16.8
25		AF000545	Hs.296433	putative purinergic receptor	28.1
		AA219305		EST	12.4
	120383	AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolo	9.7
	120386	AW969665	Hs.154848	hypothetical protein DKFZp434D0127	32.6
	120389	AW967985	Hs.325572	ESTs, Moderately similar to ALU7_HUMAN A	
30	120396	AA134006	Hs.79306	eukaryotic translation initiation factor	12.5
	120418	AW966893	Hs.26613	Homo sapiens mRNA; cDNA DKFZp586F132	3 (f 11.4
	120472	AI950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapi	
	120484	AA253170	Hs.96473	EST	10.4
	120570	AA280679	Hs.271445	ESTs, Weakly similar to ALU1_HUMAN ALU !	3 14.4
35		BE244830		ZNF135-like protein	10.2
		AA282074		N-acetylglucosamine-phosphate mutase	7.5
		AW407987		M-phase phosphoprotein homolog	52
		AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapie	ns 46.8
		AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 ffs, clone NT	5.9
40		Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7
		Al608909	Hs.193985	ESTs	7.8
		AA346385		SH3-containing protein SH3GLB2; KIAA1848	
		AA346495	110.00002	gb:EST52657 Fetal heart II Homo sapiens	4.4
		BE262951	Hs.99052	ESTs	5.6
45		AA398721	Hs.186749	ESTs, Highly similar to I37550 mismatch	5.4
73		AA406137		EST	6
		AA494172		ESTs	13.1
					28
		AA416653		ESTS	6.2
50		AA416653	Hs.181510	ESTs	7.4
50		AA412477	Hs.98142	EST	
		AA412497	11 470070	gb:zt95g12.s1 Soares_testis_NHT Homo sap	2.0
	121655	AA421537		Homo sapiens mRNA; cDNA DKFZp434B102	
	121744	AA398784	Hs.97514	ESTs	7.1
~~		BE536911		hypothetical protein NUF2R	19.5
55	121773	AB033022	Hs.158654	KIAA1196 protein	7.9
	121832	AW340797	Hs.98434	ESTs	5.8
		AA425691		ESTs, Highly similar to KIAA 1048 protein	5
	121882	AA426376	Hs.98459	ESTs	5
	121911	AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.2
60	121999	AA430211	Hs.98668	EST	6.4
	122013	AA431085	Hs.98706	ESTs	6.5
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU	S 13.1
	122356	AA443794	Hs.98390	ESTs	7.3
	122371	AA868555		ESTs	5
65	122372	AA446008	Hs.336677	EST	7.6
		AW418788		ESTs, Weakly similar to S43569 R01H10.6	9.7
		AA448349		EST	6.1
	126700				

	122492	AA448417	Hs.104990	ESTs	5.4
	122510	AA449232	Hs.99195	ESTs	11.2
	122530	AW959741	Hs.40368	adaptor-related protein complex 1, sigma	10.1
	122572	AA452601	Hs.99287	EST	11
5	122607	AA453518	Hs.98023	ESTs	61.5
	122614	AA453630	Hs.99339	EST	10.7
		AA453638	Hs.161873	ESTs	107.3
		AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	
10		AA453987		ESTs	5.6
10		AA456859		ESTs	8.5
		AW204530		ESTs	81.8
		AA460584		ESTS	75.3
			Hs.75367	Src-like-adapter	5.8
15		AF005216		Janus kinase 2 (a protein tyrosine kinas ESTs	5.3 11.5
13		AA470074		Homo sapiens cDNA FLJ11946 fis, done HE	
		AW338067 AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7
		AW451999		ESTs	5.1
		AW601773		ESTs	5.2
20		AA731404		ESTs	3.6
		AA599042		EST	7.4
			Hs.334802	Homo saplens cDNA FLJ14680 fis, clone NT	2.4
		AA609170		gb:af12a12.s1 Soares_testis_NHT Homo sap	
	123735	NM_013241	Hs.95231	FH1/FH2 domain-containing protein	10
25	123753	AA609955		Huntingtin interacting protein E	30.6
		,	Hs.270016	ESTs	8.1
		AI267847		gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
		AA532519		Human DNA sequence from clone 989H11 on	
20		AW297702		ESTS	8.3
30			Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITO	11.3
		R22952 AA374756	Hs.268685	ESTs Homo sapiens mRNA for KIAA1771 protein,	9
		AW368528		ESTs	8.1
			Hs.100012	Homo sapiens cDNA: FLJ22726 ffs, clone H	5.1
35			Hs.288912	hypothetical protein FLJ22604	14.2
			Hs.188732	ESTs	7.9
			Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	6.6
	124860	R65763	Hs.101477	EST	23.9
	124903	AW296713	Hs.221441	ESTs	32.4
40			Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8
			Hs.268892	ESTs, Moderately similar to B34087 hypot	6.1
			Hs.100588	EST	135.3
			Hs.100592	ESTs	5.4
45			Hs.286236	KIAA1856 protein	5.6 9.6
45		T97341	Hs.106932	gb:ye57e05.s1 Soares fetal liver spleen ESTs	8
		Al123705 AW966158		Homo sapiens cDNA FLJ12789 fis, clone NT	12.8
			Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8
			Hs.103441	Homo saplens, Similar to RIKEN cDNA 1700	
50			Hs.103834	hypothetical protein MGC5576	7.7
		BE302796		thymidine kinase 1, soluble	5.3
	128781	N71826	Hs.105465	small nuclear ribonucleoprotein polypept	-53.9
	128797			stem cell growth factor, lymphocyte secr	13.3
			Hs.106730	chromosome 22 open reading frame 3	3
55			Hs.292457	Homo sapiens, done MGC:16362, mRNA, co	
			Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	
			Hs.284233	NICE-5 protein	14
			Hs.107747	DKFZP566C243 protein	1.9
60		A1950087	14- 200224	gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapi ESTs, Highly similar to T46422 hypotheti	5
60		AW296806		palladin	17,1
		AA744610 AA463189		WW Domain-Containing Gene	20.9
			Hs.109315	KIAA1415 protein	5.8
	120347	BE614192	Hs.279869	melanoma-associated antigen recognised b	7.6
65			Hs.110736	solute carrier family 12 (sodium/potassi	6.7
00		NM_016039		CGI-99 protein	2
		Al267700	Hs.317584	ESTs	5

	120/82	AA188185	Pr 380043	cnindin	6.7
		W01296	Hs,11360	spindlin hypothetical protein FLJ14784	7.5
		H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8
		AK000398		hypothetical protein FLJ20391	3.8
5		AD000092		calreticulin	3.3
•		U03749	15.10400	gb:Human chromogranin A (CHGA) gene, pro	
		AW748482	Hs.77873	B7 homolog 3	2.6
		Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	7.4
		AA156214		APMCF1 protein	2
10		AA301116		nucleolar phosphoprotein Nopp34	1.6
- •		AL046962		forkhead box O3A	2.8
		AA311426		tubulin, gamma 1	6.1
		NM_003358		ESTs, Moderately similar to CEGT_HUMAN C	1.6
		X79201	Hs.153221	synovial sarcoma, translocated to X chro	5.4
15	130359	NM_013449	Hs.277401	bromodomain adjacent to zinc finger doma	8.5
	130365	W56119	Hs.155103	eukaryotic translation initiation factor	11
	130448	BE513202	Hs.15589	PPAR binding protein	3.9
	130455	D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6
••		AL121438	Hs.183706	adducin 1 (alpha)	2.7
20		BE208491	Hs.295112	KIAA0618 gene product	16.1
		L32137	Hs.1584	cartilage oligomeric matrix protein (pse	6.1
		U64675	Hs.179825	RAN binding protein 2-like 1	7.8
			Hs.252587	phuitary tumor-transforming 1	14.4
0.5		AI907018	Hs.15977	Empirically selected from AFFX single pr	4.7
25		AA383092		replication protein A3 (14kD)	7.9
			Hs.16178	apoptosis antagonizing transcription fac	1.2
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1
	. •	BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9
30		R68537	Hs.17962	ESTS	2 3.1
30		H59696	Hs.18747	POP7 (processing of precursor, S. cerevi	5.7
		AL036067 BE514434		protein x 0001 kinesin-like 2	2.1
		BE382657		signal transducer and activator of trans	5.4
		AA321649		small inducible cytokine subfamily B (Cy	7.4
35		AA194422		myosin VI	5.1
55		AL133353		COX15 (yeast) homolog, cytochrome c oxid	7
		NM_016569	_	TBX3-iso protein	3.3
		BE280074		cyclin B1	5.8
		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.5
40		AL080080	Hs.24766	thioredoxin domain-containing	2.8
		X80038	Hs.339713	Homo sapiens clone F19374 APO E-C2 gene	1.3
	131569	AL389951	Hs.271623	nucleoporin 50kD	5
	131643	AW410601	Hs.30026	HSPC182 protein	2.9
	131714	AA642831	Hs.31016	putative DNA binding protein	2.9
45	131722	D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4
	131760	X76732	Hs.3164	nucleobindin 2	2.9
		AW966127		Homo sapiens cDNA FLJ14656 fls, clone NT	
		BE502341		ESTs	13.7
5 0		AA099014		Homo sapiens, clone MGC:15961, mRNA, ∞	
50		AA179298		stomatin-tike 2	11.3
		BE252983		ubiquitin specific protease 1	2.3
		BE567100		hypothetical protein MDS025	3.5
		NM_004460		fibroblast activation protein, alpha	14.7
55		NM_004782		synaptosomal-associated protein, 29kD DKFZP586L151 protein	7.8
55		AA227710 N36110	Hs.305971	solute camer family 2 (facilitated glu	10 9.2
		AB023191		KIAA0974 protein	2
		AW067708		heterogeneous nuclear ribonucleoprotein	12.5
		AW572805		ESTs	28.3
60		AA312135		HSPCO34 protein	6.1
UU		AA100012		hypothetical protein FLJ12085	8.6
		AW169847		KIAA1634 protein	6.1
		AA454132		mitochondrial ribosomal protein L16	7.1
		AW631437		TH1 drosophla homolog	14
65		AI796870	Hs.54277	DNA segment on chromosome X (unique) 993	
		NM_004600	0Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	3.7
	132726	N52298	Hs.55608	hypothetical protein MGC955	14.3

	122724	A140007E	Un 201072	bunetheliasi assisia MCC4840	5,9
		Al189075	Hs.301872	hypothetical protein MGC4840	
		AA010233		glutamyl-prolyl-tRNA synthetase	6.4
		AA459713		KIAA0493 protein	14.6
5		Al026701	Hs.5716	KIAA0310 gene product	2.5
3		AB007944		KIAA0475 gene product	4.2
		U78525	Hs.57783	eukaryotic translation initiation factor	6.1
		NM_016154		Homo sapiens clone PP1596 unknown mRNA	
		U09716	Hs.287912	lectin, mannose-binding, 1	6.1
10		BE267143		U2(RNU2) small nuclear RNA auxillary fac	2.7
10		AI817165	Hs.6120	hypothetical protein FLJ13222	2.1
		AA034365		Homo sapiens cDNA FLJ11392 fis, clone HE	
		AA040696		ESTs	1.3 17.1
		AA112748		clone HQ0310 PRO0310p1	4.4
15.			Hs.6289	hypothetical protein FLJ20886	4.4
15		X97795	Hs.66718	RAD54 (S.cerevisiae)-like	5.5
		AI801777	Hs.6774	ESTs Homo sapiens, done IMAGE:3544662, mRNA	
		AI567421	Hs.273330		16.1
			Hs.69233	zinc finger protein ESTs, Weakly similar to FXD2_HUMAN FORM	
20		AW956781 M76477	Hs.289082	GM2 ganglioside activator protein	10.4
20		A1950382	Hs.72660	phosphatidylserine receptor	5.7
		AW103364		inhibin, beta A (activin A, activin AB a	25.5
		AL037159		proteasome (prosome, macropain) 26S subu	1.7
		AW160781		nuclear phosphoprotein similar to S. cer	2.6
25		NM_004893		H2A histone family, member Y	13.5
20	133720		Hs.75737	pericentriolar material 1	6.7
		BE271766		laminin receptor 1 (67kD, ribosomal prot	5.4
		BE622743		arfaptin 1	12.1
		M34338	Hs.76244	spermidine synthase	9.7
30		AL133921	Hs.76272	retinoblastoma-binding protein 2	1.3
	133822	D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7
	133850	W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2
	133865	AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5
	133881	U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1
35	133924	D86326	Hs.325948	vesicle docking protein p115	1.8
	133959	X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	10.4
	133989	AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6
		Al824113	Hs.78281	regulator of G-protein signalling 12	13
40		BE300078		Homo sapiens, clone IMAGE:3535294, mRNA	
40		AW291946		interleukin 6 signal transducer (gp130,	6.7
		X06560	Hs.82396	2',5'-oligoadenylate synthetase 1 (40-46	5.5
		AW362124		hypothetical protein MGC3222	5.8
		AW067903		collagen, type XI, alpha 1	72.9
45		AU077196		collagen, type V, alpha 2	6.7
43		NM_005000		Empirically selected from AFFX single pr	6,2 1.4
		AK001571		hypothetical protein FLJ10709	2.8
		AW411479 AW630803		FK506-binding protein 4 (59kD) lamin B1	6.1
		BE002798		integral membrane protein 1	1.2
50		AD001528		spermine synthase	2.6
50		AI701162	Hs.90207	hypothetical protein MGC11138	9.1
		D26488	Hs.90315	KIAA0007 protein	13.3
		AI097346	Hs.286049	phosphoserine aminotransferase	2
		BE250865	Hs.279529	px19-like protein	14.9
55		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	
		AI028767	Hs.262603	ESTs	12.2
	135257	AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	7.6
		A1743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein	5.8
	135321	AI652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3
60	135354	AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.7
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	13.9
	302276	AW057736	Hs.323910	HER2 receptor tyrosine kinase (c	5.3
	317781	NM_007057	7Hs.42650	ZW10 Interactor	2.8
	321114	AA902256	Hs.78979	Golgi apparatus protein 1	5.5
65		BE041451		hypothetical protein	2.9
	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.3
	424001	W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7

	425182	AF041259	. Hs.155040	zinc finger protein 217	2.3
	446999	AA151520	Hs.334822	hypothetical protein MGC4485	7.5
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.6
	452461	N78223	Hs.108106	transcription factor	4.7
5	453157	AF077036	He 31989	DKF7P586G1722 protein	12.

TABLE 5A

Table 5A shows the accession numbers for those pkeys lacking unigeneID's for Table 5. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10	Pkey:	Unique Eos probeset identifier number
	CAT number:	Gene cluster number
	Accession:	Genhank accession numbers

15	Pkey	CAT number	Accessions
20	123615 124385 110856 120472	3068615 656394_1 19346_14 44573_2	AA609170 Al267847 N27351 AA992380 N33063 N21418 H79958 R21911 H79957 Al950087 N70208 R97040 N36809 Al308119 AW967677 N35320 Al251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 Al890387 Al950344 Al741346 Al689062 AA282915 AW102898 Al872193 Al763273 AW173586
25			AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 AI819225 AW205862 AI683338 AI858509 AW276905 AI633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 AI022058 AA780419 AA551005 W80701 AW613456 AI373032 AI564269 F00531 H83488 W37181 W78802 R66056 AI002839 R67840 AA300207 AW959581 T63226 F04005
30	129019	44573_2	AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 AA908598 AA251875 AI820501 AI820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 AI219788 AA884444 N92578 F13493 AA927794 AI560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586
35			AW150329 Al653832 Al762688 AA988777 AA488892 Al356394 AW103813 Al539642 AA642789 AA856975 AW505512 Al961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226
40	122618	305217_1	F04005 120695 9683_3 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603 AW052210 AA970201 AI633384 AA425910 AI017004 AI241295 AA402816 AA291468 AA453641 AA454061
45	125115 120809	genbank_T973 genbank_AA3	46495 AA346495
43	129680	23162_1	U03749 NM_001275 J03483 J03915 AI214509 AW245744 AL046455 AA318960 AI741505 AA843875 AI829382 AI560122 AI858999 D55958 AI684005 D53170 AA854091 AI025609 D53119 D54729 D55504 D55377 D55313 AW512244 AA846441 AW043898 AI969102 AA405741 AI091983 AA788784 AA706586 AA854361 AW470949 AA843095 AA772028 AI148432 AI038109 AA782478 AA910064 AI220384 AA781296 AA843881 AA854064 AA843125 AA843419 AA319036 AA319054 AI273831 W32275 AI584185 C05724 AA789023 AI686818 D54392 AI022485 AA431410 AA854232 W39212 W15214
50	•		AA894441 AI803081 AI167381 AW245389 AA319430 AA335156 AI042646 AA327030 AA725170 T27943 AA889304 AA976699 AI687001 AI621107 AI865540 AA772107 C06286 AA319661 AA405992
55	101045 110501 121558 121911	entrez_J05614 genbank_H55 genbank_AA4 genbank_AA4	1 J05614 748 H55748 12497 AA412497

PCT/US02/02242 WO 02/059377

TABLE 6: Figure 6 from BRCA 001 US

Table 6 shows genes upregulated in tumor tissue compared to normal breast tissue.

5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title Ratio of tumor to normal breast tissue

Pkey: ExAcon: UnigeneID: Unigene Title: R1: 10

15	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.5
	100678	AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2
	101806	AA586894	Hs.112408	S100 calcium-binding protein A7 (psorias	8.9
	102455	U48705	Hs.75562	discoidin domain receptor family, member	6.9
20	103206	X72755	Hs.77367	monokine induced by gamma interferon	8.8
	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	2.6
	105746	AW151952	Hs.46679	hypothetical protein FLJ20739	1.5
	106373	AW503807		histone acetyltransferase	1.8
	110240	AI668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.2
25	119260	AK001724	Hs.102950	coat protein gamma-cop	3.2
	120206	H26735	Hs.91668	Homo saplens clone PP1498 unknown mRNA	45.7
	120253	AA131376	Hs.326401	fibroblast growth factor 12B	38.9
	120297	AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2
	120624	AW407987	Hs.173518	M-phase phosphoprotein homolog	52
30	120695	AA976503		gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	6.8
	121508	AA402515	Hs.97887	ESTs	28
	122607	AA453518	Hs.98023	ESTs	61.5
	122616	AA453638	Hs.161873	ESTs	107.3
35	122618	AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1
	122829	AW204530	Hs.99500	ESTs	81.8
	122838	AA460584	Hs.334386	ESTs	75.3
	123753	AA609955	Hs.234961	Huntingtin interacting protein E	30.6
	124385	Al267847		gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1
40	124860	R65763	Hs.101477		23.9
	124930	AI076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!!	22.8
	125051	T79956	Hs.100588		135.3
		N71826		small nuclear ribonucleoprotein polypept	53.9
4.5				WW Domain-Containing Gene	20.9
45				melanoma-associated antigen recognised b	7.6
		AW748482		B7 homolog 3	2.6
				KIAA0618 gene product	16.1
	130511		Hs.1584	cartilage oligomeric matrix protein (pse	6.1
~ ^		AA321649		small inducible cytokine subfamily B (Cy	7.4
50		AW410601		HSPC182 protein	2.9
			Hs.183180		2.7
Ĺ		NM_004460		fibroblast activation protein, alpha	14.7
		AW572805		ESTs	28.3
			Hs.279905		17.1
55		AJ439688	Hs.6289	hypothetical protein FLJ20886	4.4
		AI160873	Hs.69233	zinc finger protein	16.1
		AW103364		inhibin, beta A (activin A, activin AB a	25.5
		Al690916	Hs.178137	transducer of ERBB2, 1	1.2
60	134219	•		glucose-6-phosphate dehydrogenase	1.9
60		AW067903		collagen, type XI, alpha 1	72.9
		AW411479		FK506-binding protein 4 (59kD)	2.8
		R50333	Hs.92186	Leman coiled-coil protein	2.6
	135181		Hs.279529	px19-like protein	14.9
	322556	BE041451	Hs.177507	hypothetical protein	2.9

TABLE 6A

Table 6A shows the accession numbers for those pkeys lacking unigeneID's for Table 6. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

L	υ	
7	_	

5

Unique Eos probeset identifier number

Pkey: CAT number. Accession:

Gene cluster number Genbank accession numbers

15

20

Pkey	CAT	number	Accessions

656394_1 124385 120695 9683_3

Al267847 N27351 AA976503 AI917802 AA953664 AA404613 AA428771 BE280542 AW194691 AI927301 AI740458 AI796100 AI935603

AW052210 AA970201 Al633384 AA425910 Al017004 Al241295 AA402816 AA291468

122618 305217_1 AA453641 AA454061

TABLE 7: Figure 7 from BRCA 001-1 US

Table 7 shows genes upregulated in tumor tissue compared to normal breast tissue. Open reading frames in the sequences have been characterized as having a signal sequence (SS), a transmembrane domain (TM) or other.

10	ExAcon: Unigene	Exe		n number, Genbank accession number		
	Unigene		gene gene title			
	R1:	Ra	tio of tumor to no	ormal breast tissue		
15	ORF str	uct info: Str	uctural characte	rization of open reading frame for the sequence of t	he gene	
	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1	ORF struct info
••		NM_001269		chromosome condensation 1	2.3	TM
20	100114	X02308	Hs.82962	thymidylate synthetase	2.9	other
	100131	D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	1.9	other
	100146	BE185499	Hs.2471	KIAA0020 gene product	1.9	TM
	100147	D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	7.6	other
	100154	H60720	Hs.81892	KIAA0101 gene product	9.2	other
25	100163	W44671	Hs.124	gene predicted from cDNA with a complete	1.6	other
	100220	AW015534	Hs.217493	annexin A2	2	other
	100265	D38521	Hs.112396	KIAA0077 protein	1.5	other
	100271	BE160081	Hs.256290	S100 calcium-binding protein A11 (calgiz	13.5	other
	100275	BE242802	Hs.154797	KIAA0090 protein	5.1	other
30	100323	D50920	Hs.23106	KIAA0130 gene product	1.9	TM
		AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.7	other
		NM_004341		carbamoyl-phosphate synthetase 2, aspart	2	other
		NM_014791		KIAA0175 gene product	2.6	other
		D84145	Hs.39913	novel RGD-containing protein	3.2	other
35		AW954324	Hs.75790	phosphatidylinositol glycan, class C	1.5	other
		D86978	Hs.84790	KIAA0225 protein	2	other
		M65028	Hs.81361	heterogeneous nuclear ribonucleoprotein	2.9	other
		NM_004415		desmoplakin (DPI, DPII)	1.9	other
		L05424	Hs.169610	CD44 antigen (homing function and Indian	5.7	other
40		L05424	Hs.169610	CD44 antigen (homing function and Indian	9	?
		L05424	Hs.169610	CD44 antigen (homing function and Indian	7.7	other
		AW502935	Hs.740	PTK2 protein tyrosine kinase 2	53.2	other
		AF078847	Hs.191356	general transcription factor IIH, polype	6	other
		BE245294	Hs.180789	S164 protein	1.7	?
45		AF002225	Hs.180686	ubiquitin protein ligase E3A (human papi	1.5	other
		AA157634	Hs.79172	solute carrier family 25 (mitochondrial	6.3	other
		AK000405	Hs.76480	ubiquitin-like 4	11.4	?
		H38765	Hs.80706	diaphorase (NADH/NADPH) (cytochrome b-5	1.6	other
		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B	8.4	other
50		J05614	1,5,1,0,1	gb:Human proliferating cell nuclear anti	5	?
•		N99692	Hs.75227	Empirically selected from AFFX single pr	2.6	other
		L06419	Hs.75093	procoilagen-lysine, 2-oxoglutarate 5-dio	1.4	?
		AA020956	Hs.179881	core-binding factor, beta subunit	2	TM
		AA284166	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	1.8	other
55		AA333387	Hs.82916	chaperonin containing TCP1, subunit 6A (1.7	TM
33		AA132666	Hs.78802	glycogen synthase kinase 3 beta	1.9	other
		L18964	Hs.1904	protein kinase C, iota	1.5	other
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5.3	other
		AI494299	Hs.16297	COX17 (yeast) homolog, cytochrome c oxid	4.2	other
60		BE267931	Hs.78996	proliferating cell nuclear antigen	1.9	TM
00		M21259	110.7 0000	gb:Human Alu repeats in the region 5' to	1.6	TM
		NM_000546	Hs.1846	tumor protein p53 (Li-Fraumeni syndrome)	2.5	other
		NM_002890		RAS p21 protein activator (GTPase activa	5.5	other
	ט/דוטו	1414 _ 00 = 000	, , , , , , , , , , , , , , , , , , , ,	pr proton doutator (o aco douta		

Unique Eos probeset identifier number

10

	101483	M24486	Hs.76768	procollagen-proline, 2-oxoglutarate 4-di	2.1	other
	101540	J04977	Hs.84981	X-ray repair complementing defective rep	1.6	other
		AW248421	Hs.250758	proteasome (prosome, macropain) 26S subu	5.7	other
		NM_012151	Hs.83363	coagulation factor VIII-associated (Intr	1.8	other
5					5.6	?
,		AF064853	Hs.91299	guanine nucleotide binding protein (G pr		
		BE391804	Hs.62661	guanylate binding protein 1, interferon-	2.4	other
		AW504089	Hs.179574	protein phosphatase 2 (formerly 2A), reg	1.3	other
	101734	M74099	Hs.147049	cut (Drosophila)-like 1 (CCAAT displacem	2.1	?
	101759	M80244	Hs.184601	solute carrier family 7 (cationic amino	5	TM
10		M81057	Hs.180884	carboxypeptidase B1 (tissue)	14.4	SS,
		AA306495	Hs.1869	phosphoglucomutase 1	5.2	other
					8.6	other
		AW409747	Hs.75612	stress-induced-phosphoprotein 1 (Hsp70/H		
		AA586894	Hs.112408	S100 calcium-binding protein A7 (psortas	8.9	SS,TM
	101810	NM_000318	Hs.180612	peroxisomal membrane protein 3 (35kD, Ze	3.2	TM
15	101879	AA176374	Hs.243886	nuclear autoantigenic sperm protein (his	1.6	other
	101911	AA441787	Hs.119689	glycoprotein hormones, alpha polypeptide	31.3	?
		AF182645	Hs.8024	IK cytokine, down-regulator of HLA II	1.8	other
		U41514	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.4	other
		BE245149	Hs.82643	protein tyrosine kinase 9	1.3	other
20					2	?
20		BE250127	Hs.82906	CDC20 (cell division cycle 20, S. cerevi		
		T35901	Hs.75117	interleukin enhancer binding factor 2, 4	1.6	other
	102107	BE258602	Hs.182366	heat shock protein 75	1.4	other
	102123	NM_001809	Hs.1594	centromere protein A (17kD)	1.8	other
	102165	BE313280	Hs.159627	death associated protein 3	4.6	?
25		AW950852	Hs.74598	polymerase (DNA directed), delta 2, regu	4.4	?
		AA829978	Hs.301613	JTV1 gene	6.7	other
		U24389		. · · · · · · · · · · · · · · · · · · ·	4.4	TM
			Hs.65436	lysosomal		
		AW163390	Hs.278554	heterochromatin-like protein 1	1.9	TM
~ ~		AL039104	Hs.159557	karyopherin alpha 2 (RAG cohort 1, impor	4.4	other
30	102302	AA306342	Hs.69171	protein kinase C-like 2	2.7	?
	102330	BE298063	Hs.77254	chromobox homolog 1 (Drosophila HP1 beta	1.5	other
	102339	BE378432	Hs.95577	cyclin-dependent kinase 4	2.3	TM
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	2	TM
		AU077055	Hs.289107	baculoviral IAP repeat-containing 2	3.2	other
35					2	other
33		U39840	Hs.299867	hepatocyte nuclear factor 3, alpha		
		U33635	Hs.90572	PTK7 protein tyrosine kinase 7	6.2	other
	102391	AA296874	Hs.77494	deoxyguanosine kinase	1.5	TM
	102455	U48705	Hs.75562	discoidin domain receptor family, member	7	other
	102465	NM_001359	Hs.81548	2,4-dienoyl CoA reductase 1, mitochondri	1.8	SS,
40		U50939	Hs.61828	amyloid beta precursor protein-binding p	1.5	?
. •		AL080116	Hs.74420	origin recognition complex, subunit 3 (y	3.3	other
		AI188137	Hs.75193	COP9 homolog	2.1	other
						other
		AF217197	Hs.74562	siah binding protein 1; FBP interacting	3.2	
45		BE250944	Hs.183556	solute carrier family 1 (neutral amino a	2.8	?
45	102532	AF040253	Hs.70186	suppressor of Ty (S.cerevisiae) 5 homolo	5.7	?
	102564	U59423	Hs.79067	MAD (mothers against decapentaplegic, Dr	2.3	other
	102568	W81489	Hs.223025	RAB31, member RAS oncogene family	5.3 `	other
		U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	2.1	other
		AU077228	Hs.77256	enhancer of zeste (Drosophila) homolog 2	1.6	?
50		U61232	Hs.32675	tubulin-specific chaperone e	2.1	other
50						other
		AW161453	Hs.198767	COP9 (constitutive photomorphogenic, Ara	1.8	
		AL037672	Hs.81071	extracellular matrix protein 1	5.8	other
	102627	AL021918	Hs.158174	zinc finger protein 184 (Kruppel-like)	1.3	other
	102663	NM_002270	Hs.168075	karyopherin (importin) beta 2	1.8	TM
55	102676	BE262989	Hs.12045	putative protein	2.3	other
		NM_007019	Hs.93002	ublquitin carrier protein E2-C	4.4	?
		U96132	Hs.171280	hydroxyacyl-Coenzyme A dehydrogenase, ty	6	?
		BE540274	Hs.239	forkhead box M1	4.2	other
				BRCA1 associated RING domain 1		
60		AU077058	Hs.54089		1.9	other
60		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	2.3	SS,TM
		AB014460	Hs.66196	nth (E.coli endonuclease III)-like 1	1.2	. LW
	102801	BE252241	Hs.38041	pyridoxal (pyridoxine, vitamin B6) kinas	6.5	other
		U90549	Hs.236774	high-mobility group (nonhistone chromoso	1.6	other
		BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	5.6	TM
65		AV653790	Hs.324275	WW domain-containing protein 1	1.3	TM
00		X02419	Hs.77274	plasminogen activator, urokinase	4.4	other
				signal recognition particle 19kD	1.9	other
	702925	BE440142	Hs.2943	aignai recognition particle 13kD	1.3	outer

				N I Nllll.	0.4	2
		BE561850	Hs.80506	small nuclear ribonucleoprotein polypept	2.4	?
	102968	AU076611	Hs.154672	methylene tetrahydrofolate dehydrogenase	2.7	other
	102983	BE387202	Hs.118638	non-metastatic cells 1, protein (NM23A)	3.1	other
	102985	U95742	Hs.2707	G1 to S phase transition 1	5.2	?
5		AW500470	Hs.117950	multifunctional polypeptide similar to S	1.6	other
•		AA926960	Hs.334883	CDC28 protein kinase 1	2.5	TM
		NM_005940	Hs.155324	matrix metalloproteinase 11 (MMP11; stro	4.5	other
		AU077231	Hs.82932	cyclin D1 (PRAD1: parathyroid adenomatos	3.1	other
					2.4	other
10	103089		Hs.179729	collagen, type X, alpha 1 (Schmid metaph	3.5	other
10		BE244377	Hs.48876	famesyl-diphosphate famesyltransferase		?
		AA205475	Hs.275865	ribosomal protein S18	9.9	
		NM_001777	Hs.82685	CD47 antigen (Rh-related antigen, integr	1.3	other
	103181	X69636	Hs.334731	Homo sapiens, clone IMAGE:3448306, mRNA,	2	other
	103185	NM_006825	Hs.74368	transmembrane protein (63kD), endoplasmi	1.6	other
15	103191	AA401039	Hs.2903	protein phosphatase 4 (formerly X), cata	2.5	other
	103193	NM_004766	Hs.75724	coatomer protein complex, subunit beta 2	2.2	TM
		NM_004939	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	6.3	TM
	103206		Hs.77367	monokine induced by gamma interferon	8.8	TM
		BE275607	Hs.1708	chaperonin containing TCP1, subunit 3 (g	3	other
20	103233		Hs.129780	tumor necrosis factor receptor superfami	1.8	other
20			Hs.75189	death-associated protein	5.6	TM
		Al369285			1.9	?
		NM_001545	Hs.9078	immature colon carcinoma transcript 1		other
		Al803447	Hs.77496	small nuclear ribonucleoprotein polypept	2.5	other
0.5	103349			gb:H.sapiens mRNA for unknown protein ex	1.6	
25	103376	AL036166	Hs.323378	coated vesicle membrane protein	1.8	other
		X94453	Hs.114366	pyrroline-5-carboxylate synthetase (glut	2.3	other
	103392	X94563		gb:H.sapiens dbi/acbp gene exon 1 & 2.	4	TM
	103430	BE564090	Hs.20716	translocase of inner mitochondrial membr	1.3	other
	103491	AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	5.7	?
30		AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.1	other
		Al376722	Hs.180062	proteasome (prosome, macropain) subunit,	9.7	?
		NM_006218	Hs.85701	phosphoinositide-3-kinase, catalytic, al	2	other
		NM_000346	Hs,2316	SRY (sex determining region Y)-box 9 (ca	1.3	?
		BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	2	other
35		AA609685	Hs.278672	membrane component, chromosome 11, surfa	2.3	TM
55		AI878883	Hs.296381	growth factor receptor-bound protein 2	1.3	other
		AI015709	Hs.172089	Homo sapiens mRNA; cDNA DKFZp586l2022 (f	1.3	other
			Hs.169992	hypothetical 43.2 Kd protein	7.6	?
		AA094752		Homo sapiens BTB domain protein (BDPL) m	1.3	SS,TM
40		H26531	Hs.7367	gb:zn04d03.r1 Stratagene hNT neuron (937	1.6	other
40		AA080912	11- 404074		1.6	other
		Al042582	Hs.181271	CGI-120 protein	1.6	other
		W02363	Hs.302267	hypothetical protein FLJ10330		TM
		AK001278	Hs.105737	hypothetical protein FLJ10416 similar to	6.6	
4.00		NM_002407	Hs.97644	mammaglobin 2	2.9	other
45		AA251242	Hs.103238	ESTs	1.4	other
	104174	AA478984	Hs.6451	PRO0659 protein	5.6	TM
	104227	AB002343	Hs.98938	protocadherin alpha 9	1.6	other
	104275	AI751970	Hs.101067	GCN5 (general control of amino-acid synt	5.4	other
	104325	BE379766	Hs.150675	polymerase (RNA) II (DNA directed) polyp	6.4	other
50	104370	AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.6	other
	104423	R83113	Hs.1432	protein kinase C substrate 80K-H	5.2	other
		AB037762	Hs.44268	myelin gene expression factor 2	1.2	other
		Al239923	Hs.30098	ESTs	1.4	other
•		AI694413	Hs.332649	olfactory receptor, family 2, subfamily	2.4	other
55		AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	1.4	other
55		AB023175	Hs.22982	KIAA0958 protein	2.4	other
		AW052006	Hs.8551	PRP4/STK/WD splicing factor	10.9	other
					5.7	other
		A1250789	Hs.32478	ESTs 3-phosphoinositide dependent protein kin	12.3	?
C 0		AA041276	Hs.154729	5-priceprioritositude dependent protein kin		other
60		AA278898	Hs.225979	hypothetical protein similar to small G	2.1	other
		T78044	Hs.28893	Homo sapiens mRNA; cDNA DKFZp564O2364 (f	1.4	
		AW015318	Hs.23165	ESTs	17.7	other
		AW408164	Hs.249184	transcription factor 19 (SC1)	5.1	TM
		AW958157	Hs.155489	NS1-associated protein 1	1.8	other
65		AA026880	Hs.25252	prolactin receptor	1.5	other
		AF043467	Hs.32893	neurexophilin 2	2.3	other
	104973	NM_015310	Hs.6763	KIAA0942 protein	5.1	other

	404074	V40050	11 070075	h de de a a a delada a . d	4 =	other
		Y12059	Hs.278675	bromodomain-containing 4	1.5	other
		AL136877	Hs.50758	SMC4 (structural maintenance of chromoso	2.4	other
		Al199268	Hs.19322	Homo saplens, Similar to RIKEN cDNA 2010	7.3	other
-		AA937934	Hs.321062	ESTs	1.3	other
5	104994	A1499930	Hs.334885	mitochondrial GTP binding protein	3.6	?
	105009	BE379584	Hs.34789	dolichyl-diphosphooligosaccharide-protei	5.6	other
	105012	AF098158	Hs.9329	chromosome 20 open reading frame 1	3.4	other
	105028	AI050715	Hs.2331	E2F transcription factor 5, p130-binding	2.2	other
	105041	AB037716	Hs.26204	KIAA1295 protein	2.2	other
10		BE242899	Hs.129951	speckle-type POZ protein	3.9	?
	_	AA151342	Hs.12677	CGI-147 protein	9.5	TM
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	5.7	other
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, clone PL	2.2	other
		Z78407			2.2	other
15			Hs.27023	vesicle transport-related protein	1.6	other
15		BE387350	Hs.33122	KIAA1160 protein		
		AW975433	Hs.36288	ESTs	6.4	?
		AA045648	Hs.301957	nudix (nucleoside diphosphate linked moi	2.2	other
		AA164687	Hs.177576	mannosyl (alpha-1,3-)-glycoprotein beta-	2.8	other
	105158	AW976357	Hs.234545	hypothetical protein NUF2R	2	other
20	105169	BE245294	Hs.180789	S164 protein	1.7	other
	105186	AA191512	Hs.28005	Homo sapiens cDNA FLJ11309 fis, clone PL	4.9	SS,TM
	105254	AA071276	Hs. 19469	KIAA0859 protein	2	TM
		AA263143	Hs.24596	RAD51-interacting protein	2.9	?
		N99673	Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ	1.9	TM
25		AA700122	Hs.3355	sentrin-specific protease	8.2	?
		AW270037	Hs.179507	KIAA0779 protein	1.8	SS,
		NM_016015	Hs.8054	CGI-68 protein	8.4	other
			Hs.282093	hypothetical protein FLJ21918	5.1	other
		BE264645			2.6	other
20		AW887701	Hs.32356	hypothetical protein FLJ20628		TM
30		BE242803	Hs.262823	hypothetical protein FLJ10326	2.2	
		AW592146	Hs.108636	membrane protein CH1	2.3	SS,TM
		AF167570	Hs.256583	interleukin enhancer binding factor 3, 9	5.5	SS,
	105399	BE386877	Hs.334811	Npw38-binding protein NpwBP	1.6	other
	105400	AF198620	Hs.65648	RNA binding motif protein 8A	1,6	other
35	105445	AA252395		gb:zs12g10.s1 NCL_CGAP_GCB1 Homo sapiens	5.1	?
	105507	BE268348	Hs.226318	CCR4-NOT transcription complex, subunit	1.6	other
	105529	AA113449	Hs.32471	hypothetical protein FLJ20364	1.3	other
		AB023179	Hs.9059	KIAA0962 protein	3.5	other
		AA262640	Hs.27445	unknown	9.3	other
40		BE616694	Hs.288042	hypothetical protein FLJ14299	1.4	other
••		AA579535	Hs.18490	hypothetical protein FLJ20452	10.9	TM
		AF054284	Hs.334826	splicing factor 3b, subunit 1, 155kD	2.9	TM
				hypothetical protein FLJ12475	1.7	?
		AI808201	Hs.287863		1.4	other
15		AA280072	Hs.99872	fetal Alzheimer antigen		
45		AK000892	Hs.4069	glucocorticoid modulatory element bindin	1.7	TM
		AW302245	Hs.181390	casein kinase 1, gamma 2	5.6	other
		AA985190	Hs.246875	hypothetical protein FLJ20059	9.4	other
	105697	AW499988	Hs.27801	zinc finger protein 278	2_	TM
	105708	R26944	Hs.180777	Homo sapiens mRNA; cDNA DKFZp564M0264 (f	1.7	other
50	105743	BE246502	Hs.9598	sema domain, immunoglobulin domain (lg),	2.7	other
	105746	AW151952	Hs.46679	hypothetical protein FLJ20739	1.5	?
	105759	Al123118	Hs.15159	chemokine-like factor, alternatively spl	1.3	other
		AI267720	Hs.153221	synovial sarcoma, translocated to X chro	1.6	other
		AA741336	Hs.152108	transcriptional unit N143	2.2	other
55		AA478756	Hs.194477	E3 ubiquitin ligase SMURF2	1.3	other
55		Al262106	Hs.12653	ESTs	2.4	other
		AF151066	Hs.281428	hypothetical protein	2.9	other
					1.4	other
		AK001708	Hs.32271	hypothetical protein FLJ10846		
CO		AF016371	Hs.9880	peptidyl prolyl isomerase H (cyclophilin	5.3	other
60		AW194426	Hs.20726	ESTS	1.7	other
		AW081202	Hs.12284	Homo sapiens, clone IMAGE:2989556, mRNA,	2.8	other
		AA477956	Hs.26268	ESTs	1.4	other
		AL157441	Hs.17834	downstream neighbor of SON	1.4	other
	106078	AA130158	Hs.19977	ESTs, Moderately similar to ALU8_HUMAN A	1.6	?
65	106094	AA533491	Hs.23317	hypothetical protein FLJ 14681	6.9	other
		AB006624	Hs.14912	KIAA0286 protein	1.6	other
		AA251393	Hs.289052	Homo saplens, Similar to RIKEN cDNA 5430	10.8	?
				• •		

	106288	AB037742	Hs.24336	KIAA1321 protein	1.3	other
		Y10043	Hs.19114	high-mobility group (nonhistone chromoso	3.7	other
		AL043114	Hs.22410	ESTs, Weakly similar to A54849 collagen	5.5	SS,
		AK001404	Hs.194698	cyclin B2	5.8	other
5	106359	AW390282	Hs.31130	transmembrane 7 superfamily member 2	6.4	other
	106381	AB040916	Hs.24106	KIAA1483 protein	6.6	other
	106389	AW748420	Hs.6236	Homo sapiens cDNA: FLJ21487 fis, clone C	2.2	TM
	106457	AF119256	Hs.27801	zinc finger protein 278	2.7	other
1.0		D63078	Hs.186180	Homo sapiens cDNA: FLJ23038 fis, clone L	2.3	other
10		AA243837	Hs.57787	ESTs	1.6	other
		AK000933	Hs.28661	Homo sapiens cDNA FLJ10071 fis, clone HE	2.4	?
		AA458882	Hs.79732	fibulin 1	8	SS,
		NM_003595	Hs.26350	tyrosylprotein sulfotransferase 2	7.8 1.8	other other
15		AL049951	Hs.22370 Hs.184164	Homo sapiens mRNA; cDNA DKFZp564O0122 (f ESTs, Moderately similar to S65657 alpha	1.3	TM
13		AV657117 BE614802	Hs.184352	hypothetical protein FLJ12549	4.6	other
		AA600357	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	1.3	other
		BE388094	Hs.21857	ESTs	1.6	SS,
		AF174487	Hs.293753	Bd-2-related ovarian killer protein-lik	5.7	other
20		AW959893	Hs.27099	hypothetical protein FLJ23293 similar to	16.2	TM
20		BE564871	Hs.29463	centrin, EF-hand protein, 3 (CDC31 yeast	1.5	other
		AB037744	Hs.34892	KIAA1323 protein	2.2	other
		AF151031	Hs.300631	hypothetical protein	1.3	other
		N49809	Hs.11197	Homo sapiens, clone IMAGE:3343149, mRNA,	16.8	other
25	106886	W79171	Hs.9567	GL002 protein	1.5	TM
	106906	AA861271	Hs.222024	transcription factor BMAL2	2.2	other
	106920	AK001838	Hs.296323	serum/glucocorticoid regulated kinase	3.4	other
	106945	AK000511	Hs.6294	hypothetical protein DKFZp434L1435 simil	6.8	?
20		BE156256	Hs.11923	hypothetical protein	6.7	other
30		AW631480	Hs.8688	ESTs	6.1	SS,
		AA146872	Hs.300700	hypothetical protein FLJ20727	1.3	other
		AF264750	Hs.288971	myeloid/lymphoid or mixed-lineage leukem	1.8 1.7	other other
		AW385224	Hs.35198	ectonucleotide pyrophosphatase/phosphodi GTPase activating protein	2.5	other
35		AK000733 AK000512	Hs.23900 ` Hs.69388	hypothetical protein FLJ20505	1.7	other
33		AV661958	Hs.8207	GK001 protein	4.7	other
		AK001455	Hs.5198	Down syndrome critical region gene 2	2	other
		AW378065	Hs.8687	ESTs	6.4	TM
		AW391927	Hs.7946	KIAA1288 protein	33.5	other
40		BE122762	Hs.25338	ESTs	5.2	?
		W15477	Hs.64639	glioma pathogenesis-related protein	6.1	other
		AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (17.4	other
	107243	BE219716	Hs.34727	ESTs, Moderately similar to 138759 zinc	7.4	?
	107248	AW263124	Hs.315111	nuclear receptor co-repressor/HDAC3 comp	1.8	other
45	107263	D60341	Hs.21198	translocase of outer mitochondrial membr	6.7	other
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.5	other
		BE277457	Hs.30661	hypothetical protein MGC4606	3.2	TM
		T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586I0324 (f	2	TM ?
50		NM_006299	Hs.96448	zinc finger protein 193	5	other
50		AW299900	Hs.267632	TATA element modulatory factor 1	1.2 1.6	other
		AA307703	Hs.279766	kinesin family member 4A nucleolar protein (KKE/D repeat)	3	TM
		BE515065	Hs.296585 Hs.59844	ESTs	1.4	other
		AA001386 BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	2.3	SS,TM
55		AA018587	Hs.303055	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.2	?
55		AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.4	TM
		L42612	Hs.335952	keratin 6B	2.5	other
		BE153855	Hs.61460	lg superfamily receptor LNIR	2.3	other
		AW956103	Hs.61712	pyruvate dehydrogenase kinase, isoenzyme	6.8	other
60	108040	AL121031	Hs.159971	SWI/SNF related, matrix associated, acti	1.6	other
	108230	AA054224	Hs.59847	ESTs	1.3	other
		AF129535	Hs.272027	F-box only protein 5	7.2	?
		N31256	Hs.161623	ESTs	2.6	other
~~		AA083069	Hs.339659	ESTS	3.6	other
65		BE300380	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	3.5	other
		AA101809	Hs.182685	ESTS	1.7 1.8	other SS,TM
	108634	AW022410	Hs.69507	ESTs	1.0	JJ, 11VI

	100047	DEC46047	11- 44070	hamaa hay 040	9.8	othor
		BE546947	Hs.44276	homeo box C10		other
		AB029000	Hs.70823	KIAA1077 protein	7.3	other
		AI089575	Hs.9071	progesterone membrane binding protein	2.8	?
_		AK001693	Hs.273344	DKFZP564O0463 protein	1.9	other
5	108859	AL121500	Hs.178904	ESTs	1.6	TM
	108872	H06720	Hs.111680	endosulfine alpha	2.2	other
	108891	AI801235	Hs.48480	ESTs	5.4	other
	108894	AK001431	Hs.5105	hypothetical protein FLJ10569	4.1	TM
	108955	AA149754	Hs.195155	Homo sapiens amino acid transport system	5.7	?
10	108982	AA151708	Hs.171980	homeo box (expressed in ES cells) 1	1.7	other
		AA152178	Hs.23467	hypothetical protein FLJ10633	6.3	other
		AB028987	Hs.72134	KIAA1064 protein	1.7	other
		AA156542	Hs.72127	ESTs	1.5	other
		AA157811	113.12121	gb:zo35d07.s1 Stratagene colon (937204)	5.4	other
15			Un 70545		3	other
13		AA164293	Hs.72545	ESTS	1,6	SS,
		AW608930	Hs.52184	hypothetical protein FLJ20618		
		AW419196	Hs.257924	hypothetical protein FLJ13782	3.3	TM
		AK000684	Hs.183887	hypothetical protein FLJ22104	1.7	other
20		AJ132592	Hs.59757	zinc finger protein 281	2.7	other
20	109166	AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	3	
	109198	BE566742	Hs.58169	highly expressed in cancer, rich in leuc	2.1	other
	109213	NM_016603	Hs.82035	potential nuclear protein C5ORF5; GAP-li	5.4	other
	109220	AW958181	Hs.189998	ESTs	5.8	other
	109233	AU077281	Hs.170285	nucleoporin 214kD (CAIN)	5.3	other
25		N99673	Hs.3585	ESTs. Weakly similar to AF126743 1 DNAJ	1,4	other
		AA375752	Hs.82719	Homo sapiens mRNA; cDNA DKFZp586F1822 (f	3	other
		AF153201	Hs.86276	C2H2 (Kruppel-type) zinc finger protein	1.3	other
		AA213506	Hs.115099	EST	3	7
		AL096858	Hs.184245	KIAA0929 protein Msx2 interacting nuclea	1.5	other
30		H83603	Hs.40408	homeo box C9	2.2	SS,
50			Hs.42215	protein phosphatase 1, regulatory subuni	3.1	TM
		N30531			2	?
		AI160029	Hs.61438	ESTS	1.8	other
		AA232103	Hs.189915	ESTs		other
25		AB032969	Hs.173042	KIAA1143 protein	3.8	
35		NM_015310	Hs.6763	KIAA0942 protein	3.3	other
		AW074143	Hs.87134	ESTs	2	TM
		L40027	Hs.118890	glycogen synthase kinase 3 alpha	2.1	other
		F02614	Hs.27319	ESTs	1.4	other
	109825	R71264	Hs.16798	ESTs	1.3	other
40	110039	H11938	Hs.21907	histone acetyltransferase	2	other
	110056	AA503041	Hs.279009	matrix Gla protein	2.5	other
	110085	AA603840	Hs.29956	KIAA0460 protein	1.7	other
	110110	T07353	Hs.7948	ESTs	2.9	other
	110129	R51853	Hs.226429	ESTs, Weakly similar to ALU1_HUMAN ALU S	1.7	SS,
45		NM_014521	Hs.17667	SH3-domain binding protein 4	4.3	other
•-		Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	4.3	?
		N41744	Hs.19978	CGI-30 protein	1.3	other
		H28428	Hs.32406	ESTs, Weakly similar to 138022 hypotheti	2.2	other
		BE256986	Hs.11896	hypothetical protein FLJ12089	2.1	other
50		H55748	113.11000	gb:yg94a01.s1 Soares fetal liver spleen	6.1	?
50		H55915	Hs.210859	hypothetical protein FLJ11016	6.1	ΤM
				EST	6.4	other
		H57330	Hs.37430		1.3	?
		AK001160	Hs.5999	hypothetical protein FLJ10298		
c		T97586	Hs.18090	ESTs	1.8	other
55		AB007902	Hs.32168	KIAA0442 protein	1.6	TM
		AW190338	Hs.28029	hypothetical protein MGC11256	7.8	other
		AL138077	Hs.16157	hypothetical protein FLJ12707	2.5	other
		BE044245	Hs.30011	hypothetical protein MGC2963	9.3	?
	110765	AK000322	Hs.18457	hypothetical protein FLJ20315	5.5	SS,
60	110769	BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 fis, clone HE	2.1	TM
	110799	AI089660	Hs.323401	dpy-30-like protein	1.5	TM
		T25829	Hs.24048	FK506 binding protein precursor	6.7	TM
		AA767373	Hs.35669	ESTs, Moderately similar to ALU1_HUMAN A	5.7	other
		R33261	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	3.4	other
65		N31598	Hs.12727	hypothetical protein FLJ21610	1.7	TM
		AI740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	1.7	other
		BE612992	Hs.27931	hypothetical protein FLJ10607 similar to	4.7	other
	110001	,				

	110856	AA992380		gb:ot37g06.s1 Soares_testis_NHT Homo sap	2.3	other
		BE384447	Hs.16034	hypothetical protein MGC13186	3.5	?
		AL117430	Hs.6880	DKFZP434D156 protein	2.2	?
		BE092285	Hs.29724	hypothetical protein FLJ13187	2.6	SS,
5		H04360	Hs.24283	ESTs, Moderately similar to reduced expr	1.9	TM
	110958	NM_005864	Hs.24587	signal transduction protein (SH3 contain	6.7	other
	110963	AK002180	Hs.11449	DKFZP564O123 protein	2	other
	110981	AK001980	Hs.24284	ADP-ribosyltransferase (NAD+; poly(ADP-r	1.3	other
	110984	AW613287	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	1.8	?
10		N63823	Hs.269115	ESTs, Moderately similar to Z195_HUMAN Z	3.7	other
		AB037807	Hs.83293	hypothetical protein	2.1	TM
		N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	2.3	other
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7	other
1.5		AL050166	Hs.26295	Homo sapiens mRNA; cDNA DKFZp586D1122 (f	7.5	other
15		AK000136	Hs.10760	asporin (LRR class 1)	7.1	other
		Al815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, clone HE	6.8 3.6	other SS,
		N67603	Hs.272130	ESTs, Weakly similar to S65824 reverse t ESTs	1.5	other
		AW139408 AB037782	Hs.152940 Hs.15119	KIAA1361 protein	2.6	other
20		AA852773	Hs.334838	KIAA1866 protein	4.7	other
20		N90956	Hs.17230	hypothetical protein FLJ22087	7.9	?
		AA778711	Hs.4310	eukaryotic translation initiation factor	7	other
		AB033091	Hs.74313	KIAA1265 protein	5	other
		AI523913	Hs.34504	ESTs	3.8	other
25	111318	T99755	Hs.334728	ESTs	1.2	TM
	111337	AA837396	Hs.263925	LIS1-interacting protein NUDE1, rat homo	5.1	other
	111352	H58589	Hs.35156	Homo sapiens cDNA FLJ11027 ffs, clone PL	2.2	other
	111370	A1478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	2.8	?
20		N94606	Hs.288969	HSCARG protein	2.2	other
30		AK000987	Hs.169111	oxidation resistance 1	2.1	other
		R02354	Hs.15999	ESTs	2.7	TM
		Al051194	Hs.227978	EST Madamatah similarta ZDE4 MUMAN Z	6.6 . 1.4	other other
		W90638	Hs.20321	ESTs, Moderately similar to ZRF1_HUMAN Z EST	1.6	?
35		R10720 R52656	Hs.20670 Hs.21691	ESTs	1.6	other
55		AB037834	Hs.18685	Homo sapiens mRNA for KIAA1413 protein,	2,4	other
		BE298665	Hs.14846	Homo sapiens mRNA; cDNA DKFZp564D016 (fr	10.6	other
		AW083791	Hs.21263	suppressor of potassium transport defect	6.6	TM
		NM_015310	Hs.6763	KIAA0942 protein	5.1	other
40		R41823	Hs.7413	ESTs; calsyntenin-2	2.8	other
	112244	AB029000	Hs.70823	KIAA1077 protein	14.6	other
	112388	R46071	Hs.301693	Homo sapiens, clone IMAGE:3638994, mRNA,	9	other
		NM_016248	Hs.232076	A kinase (PRKA) anchor protein 11	1.4	other
4.5		AW007287	Hs.28538	Homo sapiens cDNA: FLJ21086 fis, clone C	1.4	TM
45		A1742756	Hs.26079	ESTS	3.2	other
		R68425	Hs.13809	hypothetical protein FLJ10648	2 1.8	TM other
		AK001635 AK000004	Hs.14838 Hs.5013	hypothetical protein FLJ10773 Homo sapiens mRNA for FLJ00004 protein,	6.6	other
		T10258	Hs.5037	EST	1.5	?
50		AW970826	Hs.6185	KIAA1557 protein	3.2	other
50		R61388	Hs.6724	ESTs	6.1	other
		Z44718	Hs.102548	glucocorticoid receptor DNA binding fact	6.5	other
		AK000272	Hs.7099	hypothetical protein FLJ20265	1,2	other
		AA737033	Hs.7155	ESTs, Moderately similar to 2115357A TYK	5.6	other
55	112996	BE276112	Hs.7165	zinc finger protein 259	2	other
	113047	A)571940	Hs.7549	ESTs	1.9	other
		AW965190	Hs.7560	Homo sapiens mRNA for KIAA1729 protein,	2.4	TM
		T40707	Hs.270862	ESTs (2)	1.3	SS,
CO		T57317		gb:yb51a03.s1 Stratagene fetal spleen (9	1.7	other
60		T63857	Un 44440	gb:yc16e01.s1 Stratagene lung (937210) H	2.8	other other
		AK002180	Hs.11449	DKFZP564O123 protein	1.3 3.2	other
•		AW971049	Hs.11774	protein (peptidyl-prolyl cis/trans isome ESTs	1.2	other
		AA688021 AI467908	Hs.179808 Hs.8882	ESTs .	6	other
65		H59588	Hs.15233	ESTs	2	SS,
05		AA813887	Hs.188173	Homo sapiens cDNA FLJ12187 fis, clone MA	1.3	SS,
		T97307		gb:ye53h05.s1 Soares fetal liver spleen	4.4	other
				• •		

	440750			ALL CONTROL OF THE CO	4.0	-41	
		AW499665	Hs.9456	SWI/SNF related, matrix associated, acti	1.2	other	•
		BE266947	Hs.10590	zinc finger protein 313	13.4	other	
		AL359588	Hs.7041	hypothetical protein DKFZp762B226	1.7	other	
_		Al269096	Hs.135578	chitobiase, di-N-acetyl-	1.3	other	
5		W44735	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C	3.3	other	
		BE207480	Hs.6994	Homo sapiens cDNA: FLJ22044 fis, clone H	3.1	other	
		H13325	Hs.332795	hypothetical protein DKFZp761O17121	3.2	other	
		AW378212	Hs.24809	hypothetical protein FLJ10826	2.3	?	
10		T26483	Hs.6059	EGF-containing fibulin-like extracellula	11.3	TM	
10	113868	W57902	Hs.90744	proteasome (prosome, macropain) 26S subu	2.7	other	
		AL079314	Hs.16537	hypothetical protein, similar to (U06944	6.1	other	
	113885	AW959486	Hs.21732	ESTs	6.6	other	
	113923	AW953484	Hs.3849	hypothetical protein FLJ22041 similar to	1.9	?	
	113989	W87544	Hs.268828	ESTs	1.2	other	
15	114022	A1539519	Hs.120969	Homo sapiens cDNA FLJ11562 fis, done HE	5.4	other	
	114030	A1825386	Hs.164478	hypothetical protein FLJ21939 similar to	9.4	other	
	114060	AB029551	Hs.7910	RING1 and YY1 binding protein	1.8	other	
	114196	AF017445	Hs.150926	fucose-1-phosphate guanylyltransferase	1.5	other	
	114226	AB028968	Hs.7989	KIAA1045 protein	1.8	other	
20	114253	BE149866	Hs.14831	Homo sapiens, Similar to zinc finger pro	2.3	other	
	114262	AL117518	Hs.3686	KIAA0978 protein	1.4	TM	
	114275	AW515443.co	mp	Hs.306117	KIAA03	06 protein 15.8	other
		Al815395	Hs.184641	fatty acid desaturase 2	1.9	TM	
	114309	AA332453	Hs.20824	CGI-85 protein	2.4	other	
25		AA249590	Hs.100748	ESTs, Weakly similar to A28996 proline-r	1.9	other	
		BE539976	Hs.103305	Homo sapiens mRNA; cDNA DKFZp434B0425 (f	1.3	TM	
		H37908	Hs.271616	ESTs, Weakly similar to ALU8_HUMAN ALU S	5.6	other	
		AL120247	Hs.40109	KIAA0872 protein	5.3	TM	
		AI091713	Hs.106597	Homo sapiens, Similar to RIKEN cDNA 1110	1.3	other	
30		AA028074	Hs.104613	RP42 homolog	1.9	?	
•		BE066778	Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:polyp	13.4	other	
		AA766268	Hs.266273	hypothetical protein FLJ13346	2	other	
		AA476966	Hs.110857	polymerase (RNA) III (DNA directed) poly	3.6	other	
		Al373544	Hs.331328	intermediate filament protein syncoilin	3.9	other	
35		A1859865	Hs.154443	minichromosome maintenance deficient (S.	1.7	other	
50		AV656017	Hs.184325	CGI-76 protein	3.2	other	
		AA159181	Hs.54900	serologically defined colon cancer antig	3.6	other	
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	4.4	other	
		AA236177	Hs.76591	KIAA0887 protein	7.2	other	
40		BE539101	Hs.5324	hypothetical protein	1.3	other	
		AA236672	110.002	gb:zt29f02.s1 Soares ovary tumor NbHOT H	1.5	other	
		AA237022	Hs.188717	ESTs	2	SS,	
		AA242834	Hs.58384	ESTs	2.9	other	
		Al733881	Hs.72472	BMP-R1B	2.3	?	
45		AF102546	Hs.63931	dachshund (Drosophila) homolog	1.3	other	
		AA252360	Hs.87968	toll-like receptor 9	1.6	other	
		AI751438	Hs.41271	Homo sapiens mRNA full length insert cDN	11.8	other	
		Al670847	Hs.5324	hypothetical protein	1.5	other	
		AW183695	Hs.186572	ESTs	2.5	other	
50		AW365434	Hs.79741	hypothetical protein FLJ10116	1.5	other	
50		BE251328	Hs.73291	hypothetical protein FLJ10881	1.3	TM	
		Al368236	Hs.283732	ESTs, Moderately similar to ALU1_HUMAN A	1.4	other	
		AK002163	Hs.301724	hypothetical protein FLJ11301	1.5	other	
		AW972872	Hs.293736	ESTs	2.4	other	
55		BE545072	Hs.122579	hypothetical protein FLJ10461	6.3	SS,	
55		Al215069	Hs.89113	ESTs	6.7	?	
		AA314349	Hs.48499	tumor antigen SLP-8p	7.5	?	
		AK001376	Hs.59346	hypothetical protein FLJ10514	1.4	TM	
		AW301608	Hs.278188	ESTs, Moderately similar to 154374 gene	4.1	TM	
60		AW247593	Hs.71819	eukaryotic translation initiation factor	16.3	other	
UU			Hs.88219	zinc finger protein 200	5	other	
		Y14443 AJ275986	Hs.71414	transcription factor (SMIF gene)	2.5	other	
		AJ275980 AI540842	Hs.61082	ESTs	6.2	other	
		BE081342	Hs.283037	HSPC039 protein	2.9	other	
65		AA399477	Hs.67896	7-60 protein	5.3	TM	
U.J		N36110	Hs.305971	solute carrier family 2 (facilitated glu	4.8	?	
			Hs.38178	hypothetical protein FLJ23468	10.6	other	
	113032	BE093589	113.30110	nypometical protein i tuzo400		00.01	

	115655	AL048269	Hs.288544	Homo sapiens, clone MGC:16063, mRNA, com	12,7	TM
		Al138785	Hs.40507	ESTs	2	other
		AA953006	Hs.88143	ESTs	3.1 1.7	other TM
5		AA625132 AF231023	Hs.44159 Hs.55173	hypothetical protein FLJ21615 cadherin, EGF LAG seven-pass G-type rece	6.9	other
,		BE395161	Hs.1390	proteasome (prosome, macropain) subunit,	1.7	other
		Al950339	Hs.40782	ESTs	2.7	TM
		NM_015434	Hs.48604	DKFZP434B168 protein	2.1	other
10		A1732742	Hs.87440	ESTs	2.1 1.3	other other
10		Al675217 Al373062	Hs.42761 Hs.332938	ESTs hypothetical protein MGC5370	4.4	other
		AW062629	Hs.52081	KIAA0867 protein	7.3	other
		N55669	Hs.333823	mitochondrial ribosomal protein L13	1.2	other
1.5		Al867451	Hs.46679	hypothetical protein FLJ20739	5.5	other
15		AB037753	Hs.62767 Hs.66493	KIAA1332 protein	9.8 1.4	other other
		BE275469 AL359053	Hs.57664	Down syndrome critical region gene 5 Homo saplens mRNA full length insert cDN	2.4	other
		AA770688	Hs.28777	H2A histone family, member L	1.8	other
		BE243834	Hs.50441	CGI-04 protein	1.4	other
20		N35719	Hs.44749	ESTs, Moderately similar to T00358 hypot	1.2	other
		AW821113	Hs.72402	ESTs	2.1 1.7	other other
		AV660717 AF265555	Hs.47144 Hs.250646	DKFZP586N0819 protein baculoviral IAP repeat-containing 6	1.7	other
		A1936442	Hs.59838	hypothetical protein FLJ 10808	1.8	?
25		Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	1.9	other
		AF097645	Hs.58570	deleted in cancer 1; RNA helicase HDB/DI	5	SS,
		Al472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	1.4 1.9	SS,
		AL133033 AK000290	Hs.4084 Hs.44033	KIAA1025 protein dipeptidyl peptidase 8	1.5	? other
30		AA497129	Hs.184771	nuclear factor I/C (CCAAT-binding transc	1.9	?
- •		Al149586	Hs.38125	interferon-induced protein 75, 52kD	1.9	?
		N50174	Hs.46765	ESTs	6.1	other
		N90466	Hs.71109	KIAA1229 protein	1.6	? other
35		AW499664 AA161411	Hs.12484 Hs.58668	Human clone 23826 mRNA sequence chromosome 21 open reading frame 57	7.4 2.1	other other
33		AF218313	Hs.236828	putative helicase RUVBL	1.5	TM
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	2.1	TM
		AA312572	Hs.6241	phosphoinositide-3-kinase, regulatory su	1.5	other
40		AK001043	Hs.92033	Integrin-linked kinase-associated serine	2.7 2.3	other other
40		X89984 Al800202	Hs.211563 Hs.317589	B-cell CLL/lymphoma 7A hypothetical protein MGC10765	2.3 1.4	other
		AW074819	Hs.12313	hypothetical protein FLJ14566	3.4	other
		AW152225	Hs.165909	ESTs, Weakly similar to 138022 hypotheti	2.9	other
	116926	H73608	Hs.290830	ESTs	1.7	TM
45		U72209	Hs.180324	YY1-associated factor 2	3.4	TM
		Al393666	Hs.42315	p10-binding protein	5.2 5.5	? TM
		N21032 N71183	Hs.121806	gb:yx46f06.s1 Soares melanocyte 2NbHM Ho Homo sapiens cDNA FLJ11971 fis, clone HE	1.5	TM
		AK001701	Hs.183779	Homo sapiens cDNA FLJ10590 fis, done NT	2	other
50	_	AI041793	Hs.42502	ESTs	2	other
		A1878942	Hs.90336	ATPase, H+ transporting, lysosomal (vacu	2.1	?
		AF150275	Hs.40173	ESTs	2.7	TM
		N32536 AF123050	Hs.42645 Hs.44532	solute carrier family 16 (monocarboxylic diubiquitin	1.4 3.4	other TM
55		N34895	Hs.44648	ESTs	3.4	?
33		BE294925	Hs.46680	CGI-12 protein	3	SS,
		AA121673	Hs.59757	zinc finger protein 281	1.9	other
		N54706	Hs.303025	chromosome 11 open reading frame 24	1.8	other
60		BE540675	Hs.332938	hypothetical protein MGC5370	6 1.7	? other
60		AL137379 Y10518	Hs.47125 Hs.116470	hypothetical protein FLJ13912 hypothetical protein FLJ20048	1.7	other
		AL110246	Hs.47367	KIAA1785 protein	5.4	other
		N54321	Hs.47790	EST	5.2	other
	118301	AA453902	Hs.293264	ESTs	2.6	other
65		AA243332	Hs.74649	cytochrome c oxidase subunit VIc	2.5 4.1	TM
		AL157545 AJ277275	Hs.42179 Hs.50102	bromodomain and PHD finger containing, 3 rapa-2 (rapa gene)	1.2	other other
	1 10400	AUZI 1213	110.00102			30101

	118509	N22617	Hs.43228	Homo sapiens cDNA FLJ11835 fis, done HE	1.5	other
	118528	Al949952	Hs.49397	ESTs	7.4	?
		A1458020	Hs.293287	ESTs	2.5	other
	118670	AA332845	Hs.152618	ESTs, Moderately similar to ZN91_HUMAN Z	1.2	TM
5	118698	AB033113	Hs.50187	KIAA1287 protein	2.1	TM
•			110.00107		5.2	
		AA199686		gb:zq75g09,r1 Stratagene hNT neuron (937		other
	118925	N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	1.4	other
	118984	AI668709	Hs.240722	ESTs, Moderately similar to ALU8_HUMAN A	3.6	other
					4.9	?
1.0		AF148713	Hs.125830	bladder cancer overexpressed protein		
10	119206	W24781	Hs.293798	KIAA1710 protein	1.7	TM
	119235	AW453069	Hs.3657	activity-dependent neuroprotective prote	2.2	other
		BE539706	Hs.285363	ESTs	1,4	?
	119279	N57568	Hs.48028	EST	25.1	other
	11020R	NM_001241	Hs.155478	cyclin T2	1.6	?
1.5						
15		A1417240	Hs.320836	ESTs, Weakly similar to A47582 B-cell gr	1.3	other
	119403	AL117554	Hs.119908	nudeolar protein NOP5/NOP58	6.7	TM
	119478	AI624342	Hs.170042	ESTs	2.4	other
					2.1	other
		A1796730	Hs.55513	ESTs		
	119513	W37933		Empirically selected from AFFX single pr	1.9	other
20	119601	AK000155	Hs.91684	Homo sapiens mRNA; cDNA DKFZp667I103 (fr	3.7	TM
					3	other
		AW675298	Hs.233694	hypothetical protein FLJ11350		
	119676	AA243837	Hs.57787	ESTs	1.4	other
	119682	W61019	Hs.57811	ESTs	1.2	?
				KIAA1151 protein	1.8	TM
0.5		AB032977	Hs.6298			
25	119780	NM_016625	Hs.191381	hypothetical protein	3.1	other
	119789	BE393948	Hs.50915	kallikrein 5 (KLK5; KLK-L2; stratum com	9.2	other
		AJ223810	Hs.43213	ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	TM
	119818	AA130970	Hs.58382	hypothetical protein FLJ11101	2.5	?
	119863	AA081218	Hs.58608	Homo sapiens cDNA FLJ14206 fis, clone NT	2.7	TM
30		AW449064	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	2.6	other
50						other
	119966	AA703129	Hs.58963	ESTs	2.7	
	120132	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	1.2	other
		H26735	Hs.91668	Homo sapiens done PP1498 unknown mRNA	45.7	other
	120248	Al924294	Hs.173259	uncharacterized bone marrow protein BM03	1.2	other
35	120269	AW131940	Hs.104030	ESTs	9.6	other
		AA177051		qb:nc02a02.s1 NCI_CGAP_Pr3 Homo saplens	4.7	other
					2.1	other
		AA190577		gb:zp52g02.s1 Stratagene HeLa cell s3 93		
	120296	AW995911	Hs.299883	hypothetical protein FLJ23399	1.9	TM
	120297	AA191384	Hs.104072	ESTs, Weakly similar to Z195_HUMAN ZINC	15.2	other
40					5.6	?
40		AA195517	Hs.191643	ESTs		
	120325	AA195651	Hs.104106	ESTs	6.5	other
	120327	AK000292	Hs.278732	hypothetical protein FLJ20285	16.1	other
		N85785	Hs.181165	eukaryotic translation elongation factor	3	other
	120342	AW450669	Hs.45068	hypothetical protein DKFZp434I143	5.8	other
45	120345	AA210722	Hs.104158	ESTs	4.6	SS,TM
	120349	AW969481	Hs.55189	hypothetical protein	16.8	other
					5.1	other
		R06859	Hs.193172	ESTs, Weakly similar to I38022 hypotheti		
	120356	AF000545	Hs.296433	putative purinergic receptor	28.1	TM
	120371	AA219305	Hs.104196	EST	12.4	?
50				ESTs	4.1	TM
50		AA228026	Hs.38774			
	120383	AL109963	Hs.123122	FSH primary response (LRPR1, rat) homolo	9.7	TM
	120386	AW969665	Hs.154848	hypothetical protein DKFZp434D0127	32.6	other
			Hs.104245	ESTs	3.2	other
		AA232874				
	120389	AW967985	Hs.325572	ESTs, Moderately similar to ALU7_HUMAN A	21.7	other
55	120396	AA134006	Hs.79306	eukaryotic translation initiation factor	12.5	other
• •		AB023230	Hs.96427	KIAA1013 protein	7.3	other
				· · · · · · · · · · · · · · · · · · ·		other
		AW966893	Hs.26613	Homo sapiens mRNA; cDNA DKFZp586F1323 (f	11.4	
	120423	AA236453	Hs.18978	Homo sapiens cDNA: FLJ22822 fis, clone K	1.9	other
		AI950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien	19.4	other
<i>4</i> 0			Un aconos			?
60		AA251973	Hs.269988	ESTs	5.5	
	120484	AA253170	Hs.96473	EST	10.4	?
		AA256837		gb:zr84d10.s1 Soares_NhHMPu_S1 Homo sapi	4	?
			He OSEAS	ESTs	9.4	other
	120009	BE047718	Hs.96545			
		AA258601	Hs.161731	EST	2.4	other
65		BE350244	Hs.96547	ESTs	2.5	?
55		AA279160	Hs.111407	Homo sapiens, done IMAGE:3613029, mRNA,	5.3	other
	120570	AA280679	Hs.271445	ESTs, Weakly similar to ALU1_HUMAN ALU S	14.4	?

	120582	BE244830	Hs.284228	ZNF135-like protein	10.2	?
		AW372799	Hs.125790	leucine-rich repeat-containing 2	2.2	?
		AA282074	Hs.237323	N-acetylglucosamine-phosphate mutase	7.6	other
		AW965339	Hs.111471	ESTs	2.5	other
5		AW407987	Hs.173518	M-phase phosphoprotein homolog	52	other
		AA286942		gb:zs56f05.s1 NCL_CGAP_GCB1 Homo sapiens	2.4	other
		AA287095	Hs.140309	Homo sapiens, clone IMAGE:3677194, mRNA,	5	other
		AW063659	Hs.191649	ESTs	2.2	other
		AW969638	Hs.112318	6.2 kd protein	2.2	TM
10		BE536739	Hs.109909	ESTs	1.9	TM
		AA976503	•	gb:oq30a04.s1 NCI_CGAP_GC4 Homo sapiens	46.8	TM
	120696	Al821539	Hs.97249	ESTs	2.5	other
	120713	AW449855	Hs.96557	Homo sapiens cDNA FLJ12727 fis, clone NT	6	other
	120718	AA292747	Hs.97296	ESTs	2.9	other
15	120750	Al191410	Hs.96693	ESTs, Moderately similar to 2109260A B c	7.1	SS,
	120774	A1608909	Hs.193985	ESTs	7.9	other
	120807	AA346385	Hs.30002	SH3-containing protein SH3GLB2; KIAA1848	7	TM
	120809	AA346495		gb:EST52657 Fetal heart II Homo sapiens	4.5	other
	120938	AA386260	Hs.104632	EST	4.5	?
20	120977	AA398155	Hs.97600	ESTs	4.5	other
	120984	BE262951	Hs.99052	ESTs	5.6	other
		Al219896	Hs.97592	ESTs	1.3	other
		AA398360	Hs.97608	EST	3.2	other
0.5		Al439713	Hs.165295	ESTs	3.6	other
25		AA398721	Hs.186749	ESTs, Highly similar to 137550 mismatch	5.5	other
		AA363307	Hs.97032	ESTs	3.8	other
		AL121523	Hs.97774	ESTs	1.7	TM
		Al002110	Hs.97169	ESTs, Weakly similar to dJ667H12.2.1 [H.	2.9	other other
20		AA403008	Hs.301927	C6.1A	1.9	
30		AW956981	Hs.97910	Homo sapiens cDNA FLJ13383 fis, clone PL	3.5 6.1	other ?
		AA406137	Hs.98019	EST	7.5	other
		AA410190	Hs.98076	ESTs, Weakly similar to A47582 B-cell gr	7.1	other
		AA406430	Hs.105362	Homo sapiens, clone MGC:18257, mRNA, com ESTs	1.8	other
35		AW971063	Hs.292882	retinoic acid induced 14	10.5	other
33		H58306 W07404	Hs.15165 Hs.144502	hypothetical protein FLJ22055	3.5	TM
		AA442224	Hs.97900	ESTs	14.4	other
		AA494172	Hs.194417	ESTs	13.1	other
		AA402515	Hs.97887	ESTs	28	other
40		AA416653	Hs.181510	ESTs	6.3	other
-10		AA412112	1101101010	gb:zt69b02.s1 Soares_testis_NHT Homo sap	2.7	SS,
		AA412477	Hs.98142	EST	7.5	?
		AA412497		gb:zt95g12.s1 Soares_testis_NHT Homo sap	2.8	other
		AA411970	Hs.98096	EST	3.5	?
45		AA416568		gb:zu05c10.s1 Soares_testis_NHT Homo sap	6.2	TM
		AD001528	Hs.89718	spermine synthase	4	other
		AA626010	Hs.98247	ESTs	2.2	other
	121622	AA416931	Hs.126065	ESTs	4.3	TM
	121655	AA421537	Hs.178072	Homo sapiens mRNA; cDNA DKFZp434B1023 (f	7.9	other
50	121682	AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	2	other
	121690	AV660305	Hs.110286	ESTs .	4.7	?
	121706	U55184	Hs.154145	hypothetical protein FLJ11585	12.7	other
		AA419225	Hs.98269	Homo sapiens cDNA FLJ11953 fis, clone HE	8.3	?.
	121729	A1949597	Hs.98325	ESTs	1.8	TM
55	121731	AA421041	Hs.180744	ESTs	4.1	TM
		AA398784	Hs.97514	ESTs	7.1	SS,
	121748	BE536911	Hs.234545	hypothetical protein NUF2R	19.5	other
		AB033022	Hs.158654	KIAA1196 protein	8	other
C 0		AA421773	Hs.161008	ESTs	1.7	other
60	121776	AA292579	Hs.125133	hypothetical protein FLJ22501	6.7· 10.5	other other
	121786	AI810774	Hs.98376	ESTS	5.9	other
	121832	AW340797	Hs.98434	ESTs	3.9	other
		AA328348	Hs.218289	ESTs ESTs, Highly similar to KIAA1048 protein	5.9 5	other
65	121839	AA425691	Hs.191606	serine/threonine kinase 23	2.7	?
65	121642	AF027406 AA446628	Hs.104865	cartilage linking protein 1	2.3	other
	12104/	AM446628 AW972668	Hs.2799 Hs.293044	ESTs	2.9	TM
	1210/1	AVV31 2000	110,233044	LOIG		. ,,,

	40				_	
		AA426376	Hs.98459	ESTs	5	other
	121911	AA427950		gb:zw50f02.s1 Soares_total_fetus_Nb2HF8_	7.3	TM
	121915	AA428179	Hs.223405	ESTs, Moderately similar to A46010 X-lin	2.5	other
		AA428647	Hs.98611	EST	2.3	other -
5		AA298760	Hs.180191	hypothetical protein FLJ14904	3.4	other
9		Al862570	Hs.299214	Homo sapiens, clone IMAGE:2822295, mRNA,	11.4	other
		AA210863	Hs.3532	nemo-like kinase	3.8	?
		AA430211	Hs.98668	EST	6.5	other
	122009	AW292763	Hs.160822	Homo sapiens cDNA: FLJ20863 fis, clone A	2.2	other
10	122013	AA431085	Hs.98706	ESTs	6.6	other
	122036	W92142	Hs.271963	ESTs, Weakly similar to ALU5_HUMAN ALU S	13.1	other
		AI453076	Hs.166109	ELAV (embryonic lethal, abnormal vision,	9.1	other
					13.1	?
		AA431738	Hs.98750	EST		
1		AW161023	Hs.104921	ESTs	1.5	other
15	122188	AA398838		gb:zt80d01.r1 Soares_testis_NHT Homo sap	3.4	other
	122204	AA435936	Hs.98842	EST	5.6	other
	122246	AA329550	Hs.29417	HCF-binding transcription factor Zhangfe	5.2	other
		AA436819	Hs.98899	ESTs	5.6	other
		AA441801	Hs.104947	ESTs	5.8	other
20					2	other
20		AW601969	Hs.99010	hypothetical protein FLJ22263 similar to		
		AA443794	Hs.98390	ESTs	7.4	SS,TM
	122369	AA443985	Hs.303222	ESTs	12.2	?
	122371	AA868555	Hs.178222	ESTs	5	?
	122372	AA446008	Hs.336677	EST	7.8	?
25		AB032948	Hs.21356	hypothetical protein DKFZp762K2015	2.5	?
23		AA446572	Hs.303223	EST EST	2.8	тM
					7.4	other
		AA446869	Hs.119316	ESTs		
		AA446918	Hs.99088	EST	1.9	other
	122418	AA446966	Hs.99090	ESTs, Moderately similar to similar to K	6.9	?
30	122440	AW505139	Hs.9460	Homo sapiens mRNA; cDNA DKFZp547C244 (fr	2.6	other
	122446	AA447603	Hs.99123	EST	1.8	TM
		AA447626	Hs.99127	EST	3.5	other
		Al266159	Hs.104980	ESTs	1.5	other
				ESTs, Weakly similar to S43569 R01H10.6	9.7	other
25		AW418788	Hs.99148			
35		AA448158	Hs.99152	EST	4.9	other
	122490	AA448349	Hs.238151	EST	6.2	?
	122492	AA448417	Hs.104990	ESTs	5.5	other
	122502	AA204969	Hs.234863	Homo sapiens cDNA FLJ12082 fis, clone HE	1.3	other
		AA449232	Hs.99195	ESTs	11.2	?
40		AW959741	Hs.40368	adaptor-related protein complex 1, sigma	10.1	other
70			Hs.164589	ESTs	2.5	SS,
		AA779725			1.9	
		AA194055	Hs.293858	ESTs		other
		AA452578	Hs.262907	ESTs	9.5	other
	122572	AA452601	Hs.99287	EST	11	?
45	122586	AK001910	Hs.99303	Homo sapiens cDNA FLJ11048 fis, clone PL	3.4	other
	122587	AB040893	Hs.6968	KIAA1460 protein	2	other
		AI028173	Hs.99329	ESTs	1.7	?
		AL355841	Hs.99330	hypothetical protein FLJ23588	4.4	?
		AA411925	Hs.301960		4.7	other
50				ESTs		
50		AA453518	Hs.98023	ESTs	61.5	other
		AA453630	Hs.99339	EST	10.7	?
	122616	AA453638	Hs.161873	ESTs	107.3	?
	122617	AI681535	Hs.148135	serine/threonine kinase 33	121.4	other
	122618	AA453641		gb:zx48e06.s1 Soares_testis_NHT Homo sap	31.1	SS,
55		AA453987	Hs.144802	ESTs	5.6	other
55		AA456859	Hs.178358	ESTs	8.5	SS,
	122717	A1070075			10.4	other
	122/62	Al376875	Hs.105119	ESTs		
	122829	AW204530	Hs.99500	ESTs	81.8	?
		AA461492	Hs.99545	Homo sapiens cDNA FLJ10658 fis, clone NT	3.7	?
60	122836	AA460581	Hs.290996	ESTs	4.6	other
-	122837	AA461509	Hs.293565	ESTs, Weakly similar to putative p150 [H	2.7	TM
		AA460584	Hs.334386	ESTs	75.3	other
		AA600235	Hs.9625	NIMA (never in mitosis gene a)-related k	7.8	other
	122007	AI929374	Hs.75367	Src-like-adapter	5.8	other
CF					1.3	
65		AA335721	Hs.119394	ESTs		other
	122866	BE539656	Hs.283705	ESTs	4.2	other
	122868	AF005216	Hs.115541	Janus kinase 2 (a protein tyrosine kinas	5.3	other

	122870	AW576312	Hs.318722	Homo sapiens cDNA: FLJ21766 fis, clone C	9.9	?
		AW081394	Hs.97103	ESTs	5.3	other
		AA769410	Hs.128654	ESTs	13.9	other
		AA470074	Hs.169896	ESTs	11.5	other
5		AA470140	Hs.229170	EST	1.7	TM
9		AA478951	Hs.105629	ESTs	5	other
		AW968324	Hs.17384	ESTs	15.4	other
		AW338067	Hs.323231	Homo sapiens cDNA FLJ11946 fis, clone HE	2.8	other
		AL359571	Hs.44054	ninein (GSK3B interacting protein)	8.7	other
10		Al382600	Hs.104308	ESTs, Weakly similar to KIAA1395 protein	8.8	other
10		AA485360	Hs.105661	ESTs	4	?
		Al343652	Hs.105667	ESTs	3.8	other
		AA486256	Hs.193510	EST	7.4	other
		BE304942	Hs.265848	myomegalin	2.8	?
15	123131		Hs.271795	ESTs, Weakly similar to I38022 hypotheti	2.4	other
13		Al061582	Hs.324179	Homo sapiens cDNA FLJ12371 fis, clone MA	15.6	TM
		AW451999	Hs.194024	ESTs	5.2	other
		Al734179	Hs.105676	ESTs	23.8	TM .
		AW601773	Hs.270259	ESTs	5.2	other
20		AA490929	Hs.105274	ESTs, Weakly similar to RMS1_HUMAN REGUL	9.3	?
20		AA496369	H3.103274	gb:zv37d10.s1 Soares ovary tumor NbHOT H	4.2	TM
		AA504757	Hs.105738	ESTs	7	other
		AA731404	Hs.105750	ESTs	3.7	other
			Hs.112478	ESTs	3.8	other
25		AW450922 AA599042	Hs.112503	EST	7.4	other
23		AW303285	Hs.303632	Human DNA sequence from clone RP11-110H4	3.5	other
		AB021644	Hs.197219	zinc finger protein 14 (KOX 6)	5.2	?
		BE439553	Hs.250528	Homo sapiens, clone IMAGE:4098694, mRNA,	1.7	other
		N95059	Hs.55098	ESTs	1.6	other
30			Hs.334802	Homo sapiens cDNA FLJ14680 fis, clone NT	2.4	other
30		BE019072	Hs.155546	KIAA1080 protein; Golgi-associated, gamm	2.2	TM
		AW380388	HS. 100040	gb:af12a12.s1 Soares_testis_NHT Homo sap	7.9	other
		AA609170		gb;no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	2.8	other
		AA602964		gb:ru71d09.s1 Soares_test/s_NHT Homo sap	1.7	?
25		AA609364	Un 405407	-	5.7	ż
35		AI269609	Hs.105187	kinesin protein 9 gene	10	other
		NM_013241	Hs.95231	FH1/FH2 domain-containing protein EST	5.2	other
		AA609891	Hs.112777	Huntingtin interacting protein E	30.6	TM
		AA609955	Hs.234961 Hs.261915	EST, Weakly similar to S65657 alpha-1C-a	2.1	other
40		AA620464	115.201313	gb:ae60g05.s1 Stratagene lung carcinoma	2.7	other
40		AA620586 AB012922	Hs.173043	metastasis-associated 1-like 1	6.3	7
			Hs.146178	choline dehydrogenase	4.4	other
		AJ272267 L42542	Hs.75447	ralA binding protein 1	7.1	?
		AI147155	Hs.270016	ESTs	8.3	SS,
45		A1950314	Hs.154762	HIV-1 rev binding protein 2	3.8	other
40		H05635	Hs.294030	topoisomerase-related function protein 4	1.2	SS,
			Hs.97101	putative G protein-coupled receptor	3.2	?
		BE463721 AA372796	Hs.269339	ESTs, Weakly similar to AF161356 1 HSPC0	5.7	other
		AA640891	Hs.102406	ESTs	3.1	TM
50		D87454	Hs.192966	KIAA0265 protein	3.5	other
50		Al267847	113.132300	gb:aq49a10.x1 Stanley Frontal NB pool 2	57.1	?
		AA317338	Hs.7535	COBW-like protein	2.8	other
		AF155099	Hs.279780	NY-REN-18 antigen	7.1	other
		N34059	113.273700	qb:yv28h09.s1 Soares fetal liver spleen	3.3	other
55		H13540	Hs.82202	ribosomal protein L17	2.9	other
55			Hs.129043	Human DNA sequence from clone 989H11 on	7.9	other
		AA532519 R10084	Hs.113319	kinesin heavy chain member 2	2.6	TM
	124400	N53935	118.113313	gb:yv59d09.s1 Soares fetal liver spleen	7.9	TM
			Ha 269007		7.8	other
60	124490	H79433	Hs.268997 Hs.109370	ESTS ESTS	3.3	other
60	124515	AA669097		ESTs, Weakly similar to neuronal thread	4.6	?
		N71076	Hs.102800	FLVCR protein	3.2	other
	124031	NM_014053 AJ765123	Hs.270594	Homo sapiens cDNA FLJ13533 fis, clone PL	5.8	other
	124034	M100123	Hs.143671		9.3	other
6	12403/	AA160474	Hs.75798 Hs.278569	hypothetical protein	3.5	other
65	124642	AW968856		sorting nexin 17 ESTs	6.1	TM
	124649	N92593	Hs.313054	EphB1	5.6	other
	124001	R48170	Hs.78436	српо і	0.0	20101

	124683	AA381661	Hs.119878	ESTs, Weakly similar to M3K9_HUMAN MITOG	7.9	TM
	124712	R09166	Hs.191148	ESTs	5.7	other
	124735	R22952	Hs.268685	ESTs	11.3	?
_		AA374756	Hs.93560	Homo sapiens mRNA for KIAA1771 protein,	9	other
5		AW368528	Hs.100855	ESTs	8.3	other
		R41772	Hs.100878	ESTS	4.9	other
		R41933	Hs.140237	ESTs, Weakly similar to ALU1_HUMAN ALU S	2.8 5.1	other
		R43543 AL355722	Hs.100912	Homo sapiens cDNA: FLJ22726 fis, clone H	4.2	other other
10		R46068	Hs.106875 Hs.288912	Homo sapiens EST from clone 35214, full hypothetical protein FLJ22604	14.2	other
10		R47948	Hs.188732	ESTs	7.9	other
		AA418160	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	6.6	other
		AA501669	Hs.336693	ESTs	2.3	SS,TM
		AW975868	Hs.294100	ESTs	2.7	SS,TM
15		R63652	Hs.137190	ESTs	2.3	other
	124860	R65763	Hs.101477	EST	23.9	?
	124863	Al382555	Hs.127950	bromodomain-containing 1	2	other
		AF135422	Hs.27059	GDP-mannose pyrophosphorylase A	4.4	SS,
00		BE397530	Hs.288057	hypothetical protein FLJ22242	2.7	other
20		H37941	Hs.101883	ESTs	5.7	other
		AW296713	Hs.221441	ESTS	32.4 22.8	other other
		A1076343	Hs.173939	ESTs, Weakly similar to ALUB_HUMAN !!!! ESTs, Moderately similar to B34087 hypot	6.1	other
		R99978 Al078645	Hs.268892 Hs.431	murine leukemia viral (bmi-1) oncogene h	1.9	other
25		T40841	Hs.98681	ESTs	4.5	?
23		T59338	Hs.269463	ESTs, Weakly similar to ALU1_HUMAN ALU S	4.9	other
		T79815	Hs.279793	ESTs	5	?
		T79956	Hs.100588	EST	135.3	7
		T81310	Hs.100592	ESTs	5.4	other
30		AI472068	Hs.286236	KIAA1856 protein	5.6	other
		T96595	Hs.302270	ESTs, Weakly similar to ALUF_HUMAN !!!!	1.8	other
		T97341		gb:ye57e05.s1 Soares fetal liver spleen	9.6	?
		Al222382	Hs.240767	Human DNA sequence from clone RP1-12G14	1.5	TM ?
25		W38150	Un 444020	Empirically selected from AFFX single pr EST	1.7 10.7	?
35		W44657 AA630863	Hs.144232 Hs.131375	ESTs, Moderately similar to ALUB_HUMAN!	1.3	other
		AF098162	Hs.118631	timeless (Drosophila) homolog	9.4	other
		AW401809	Hs.4779	KIAA1150 protein	1.5	?
		Al123705	Hs.106932	ESTs	8.1	7
40		AW972542	Hs.289008	Homo sapiens cDNA: FLJ21814 fis, clone H	1.5	other
		AW292171	Hs.23978	scaffold attachment factor B	5.9	other
	125827	NM_003403	Hs.97496	YY1 transcription factor	1.2	?
	125891	U29589	Hs.7138	cholinergic receptor, muscarinic 3	6.5	?
4.5		AW409701	Hs.1578	baculoviral IAP repeat-containing 5 (sur	14.3	?
45		AA157632	Hs.272630	vacuolar proton pump delta polypeptide	2.5	SS,
		AA643322	Hs.172028	a disintegrin and metalloproteinase doma	9.1 17	SS,TM other
		AW411066	Hs.274351	CGI-89 protein Homo sapiens cDNA FLJ12789 fis, clone NT	12.8	other
		AW966158 AW293012	Hs.58582 Hs.161623	ESTs	7.4	SS,
50		D87466	Hs.240112	KIAA0276 protein	3.1	TM
50		BE173977	Hs.10098	putative nucleolar RNA helicase	9.4	other
		AA504583	Hs.101047	transcription factor 3 (E2A immunoglobul	1.5	other
		R39234	Hs.251699	ESTs, Weakly similar to IDN4-GGTR14 [H.s	2.8	other
	128595	U31875	Hs.272499	short-chain alcohol dehydrogenase family	12.1	TM
55		NM_015366	Hs.102336	Rho GTPase activating protein 8	2.4	?
		AI879099	Hs.102397	GIOT-3 for gonadotropin inducible transc	1.3	other
	128608	BE267994	Hs.102419	zinc finger protein	7.2	other
		AB037841	Hs.102652	hypothetical protein ASH1	1.3	other
60	128629	AL096748	Hs.102708	DKFZP434A043 protein	3.2 2	other TM
60	128639	AW582962 AA458542	Hs.102897 Hs.10326	CGI-47 protein complex, subunit epsilo	1.4	other
	120000 128658	BE397354	Hs.324830	diptheria toxin resistance protein requi	2.5	other
	128670	AA975486	Hs.103441	Homo sapiens, Similar to RIKEN cDNA 1700	7.1	?
	128691	W27939	Hs.103834	hypothetical protein MGC5576	7.8	?
65	128696	BE081143	Hs.225977	nuclear receptor coactivator 3	3.8	other
	128700	Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	1.6	other
	128714	T85231	Hs.179661	tubulin, beta 5	7.8	other

	128717	AK001564	Hs.104222	hypothetical protein FLJ10702	5.5	other
		BE147740	Hs.104558	ESTs, Moderately similar to I38022 hypot	2.7	TM
	128737	AF292100	Hs.104613	RP42 homolog	2.8	TM
_		AA307211	Hs.251531	proteasome (prosome, macropain) subunit,	4.5	?
5	128746	Al470163	Hs.323342	actin related protein 2/3 complex, subun	2.2	other
	128747	AB027249	Hs.104741	PDZ-binding kinase; T-cell originated pr	2.8	other
		BE302796	Hs.105097	thymidine kinase 1, soluble	5.4	other
		N71826	Hs.105465	small nuclear ribonucleoprotein polypept	53.9	TM
10		NM_002975	Hs.105927	stem cell growth factor, lymphocyte secr	13.3	other
10		AW630942	Hs.106061	RD RNA-binding protein	2.6	other
		AW248431	Hs.256526	nuclear prelamin A recognition factor	2.2	other
		BE281170	Hs.106357	valosin-containing protein	6 1.6	other SS,
		AK001731 BE159181	Hs.106390 Hs.168232	Homo sapiens mRNA; cDNA DKFZp586H0924 (f hypothetical protein FLJ13855	2.3	other
15		AF189723	Hs.106778	ATPase, Ca++ transporting, type 2C, memb	1.5	?
13		R57988	Hs.10706	epithelial protein lost in neoplasm beta	4.8	other
		AA622037	Hs.166468	programmed cell death 5	1.4	other
		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	1.9	other
		Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3	7.3	?
20		AA009647	Hs.8850	a disintegrin and metalloproteinase doma	2.5	other
		AI580127	Hs.107381	hypothetical protein FLJ11200	1.3	other
		AW150697	Hs.107418	ESTs	1.4	?
	128970	A1375672	Hs.165028	ESTs	1.3	other
	128975	BE560779	Hs.284233	NICE-5 protein	14	other
25		AW271217	Hs.281434	Homo sapiens cDNA FLJ14028 fis, clone HE	1.6	TM
		AI816224	Hs.107747	DKFZP566C243 protein	1.9	other
		AI950087		gb:wq05c02.x1 NCI_CGAP_Kid12 Homo sapien	2.9	other
		AL044675	Hs.173081	KIAA0530 protein	3.8	other other
30		R80088	Hs.108104	ubiquitin-conjugating enzyme E2L 3	3.4 5	other
30		AW296806	Hs.326234	ESTs, Highly similar to T46422 hypotheti hysosomal	2.1	other
		Al351010 AA744610	Hs.102267 Hs.194431	palladin	17.1	other
		L12350	Hs.108623	thrombospondin 2	2.7	other
		AA463189	Hs.288906	WW Domain-Containing Gene	20.9	TM
35		BE243933	Hs.108642	zinc finger protein 22 (KOX 15)	3	other
		AF146074	Hs.108660	ATP-binding cassette, sub-family C (CFTR	5.8	TM
		W93048	Hs.250723	hypothetical protein MGC2747	6	other
	129149	AA356620	Hs.108947	KIAA0050 gene product	6.4	TM
	129172	AW162916	Hs.241576	hypothetical protein PRO2577	1.8	TM
40	129192	AA286914	Hs.183299	ESTs	2.1	?
		AA150797	Hs.109276	latexin protein	3.3	SS,TM
		N57532	Hs.109315	KIAA1415 protein	5.9	other
		Al934365	Hs.109439	osteoglycin (osteoinductive factor, mime	8.1	other
15		U40714	Hs.239307	tyrosyl-tRNA synthetase	2.9	other ?
45		AF013758	Hs.109643	polyadenylate binding protein-interactin	3.3	
		AA252468	Hs.1098	DKFZp434J1813 protein	2.6 7.4	SS,TM other
		Al961727 W26392	Hs.109804 Hs.110080	H1 histone family, member X ESTs, Weakly similar to S13495 pregnancy	9.6	other
		AI051967	Hs.110122	ESTs	1.2	other
50		AA287239	Hs.5518	Homo sapiens cDNA FLJ11311 fis, clone PL	5.2	other
50		H75334	Hs.11050	F-box only protein 9	4.7	SS,
		BE614192	Hs.279869	melanoma-associated antigen recognised b	7.7	TM
		U30246	Hs.110736	solute carrier family 12 (sodium/potass)	6.7	TM
		BE220806	Hs.184697	Homo sapiens clone 23785 mRNA sequence	8.6	SS,
55		AI686379	Hs.110796	SAR1 protein	1.4	TM
		NM_016039	Hs.110803	. CGI-99 protein	2	other
	129403	AF149785	Hs.111126	pituitary tumor-transforming 1 interacti	7.5	other
		A1267700	Hs.317584	ESTs	5.1	other
		AA204686	Hs.234149	hypothetical protein FLJ20647	10.2	other
60		AA188185	Hs.289043	spindlin	6.8	other
		AW843633	Hs.306163	hypothetical protein AL110115	7.1	SS,
		AF255303	Hs.112227	membrane-associated nucleic acid binding	2.5	other other
		AA769221	Hs.270847	delta-tubulin	3.2 7.5	other
65		W01296	Hs.11360	hypothetical protein FLJ14784 hypothetical protein MGC2752	7.5 6.8	other
05		AA317841 Al923097	Hs.7845 Hs.11441	chromosome 1 open reading frame 8	2.1	other
		F08282	Hs.278428	progestin induced protein	1.6	other
	123010	. 00202	. 10121 0720	hindanni unnan hinam		

	129587	H14718	Hs.11506	Human clone 23589 mRNA sequence	6.8	other
		BE408300	Hs.301862	postmelotic segregation increased 2-like	1.4	TM
		N57423	Hs.179898	HSPC055 protein	7.4	other
		AW403724	Hs.36989	coagulation factor VII (serum prothrombi	9	?
5		AF035537	Hs.115521	REV3 (yeast homolog)-like, catalytic sub	1.6	other
•		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	2.2	other
		AD000092	Hs.16488	calreticulin	3.3	other
		NM_015556	Hs.172180	KIAA0440 protein	13.4	other
		U03749		gb:Human chromogranin A (CHGA) gene, pro	14.1	?
10	129689	AW748482	Hs.77873	B7 homolog 3	2.6	other
	129702	Al304966	Hs.12035	ESTs, Weakly similar to I38022 hypotheti	7.5	TM
		AA156214	Hs.12152	APMCF1 protein	2	other
		NM_001415	Hs.211539	eukaryotic translation initiation factor	1.7	TM
10		AK001676	Hs.12457	hypothetical protein FLJ10814	1.8	other
15			Hs.12460	Homo sapiens clone 23870 mRNA sequence	5.5	TM
		AF052112	Hs.12540	lysosomal	1.7	?
		AB023148	Hs.173373	KIAA0931 protein	1.2 3.1	other
		BE565817	Hs.26498	hypothetical protein FLJ21657	1.8	other other
20		NM_006590 AL049999	Hs.12820	SnRNP assembly defective 1 homolog DKFZP564M182 protein	2.3	other
20		Al393237	Hs.85963 Hs.129914	runt-related transcription factor 1 (acu	1.7	SS,
		A1222069	Hs.13015	hypothetical protein similar to mouse Dn	2.8	TM
		BE514376	Hs.165998	PAI-1 mRNA-binding protein	1.8	other
		AA412195	Hs.13740	ESTs	2.5	other
25		AW753185	Hs.180628	dynamin 1-like	1.8	?
	129983	U09848	Hs.132390	zinc finger protein 36 (KOX 18)	1.3	other
	130010	AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	1.6	other
		AA287325	Hs.14713	ESTs	4.1	other
••		S73265	Hs.1473	gastrin-releasing peptide	1.9	other
30		AL046962	Hs.14845	forkhead box O3A	2.8	other
		AL135561	Hs.14891	hypothetical protein FLJ21047	2.3	other
		X53002	Hs.149846	integrin, beta 5	2.3	other
		AA916785	Hs.180610	splicing factor proline/glutamine rich (3 1.8	other other
35		L76937 AA311426	Hs.150477 Hs.21635	Werner syndrome tubulin, gamma 1	6.1	other
55		NM_003358	Hs,23703	ESTs, Moderately similar to CEGT_HUMAN C	1.6	other
		D80001	Hs.152629	KIAA0179 protein	1.3	other
		R85367	Hs.51957	splicing factor, arginine/serlne-rich 2,	2	other
		AL035588	Hs.153203	MyoD family inhibitor	3.2	other
40		X79201	Hs.153221	synovial sarcoma, translocated to X chro	5.4	?
	130249	D81983	Hs.322852	GAS2-related on chromosome 22	4.9	other
		NM_002497	Hs.153704	NIMA (never in mitosis gene a)-related k	1.4	other
		AA479005	Hs.154036	tumor suppressing subtransferable candid	2.6	other
4.5		AB011121	Hs.154248	amyotrophic lateral sclerosis 2 (juvenil	6.3	other
45		Z19084	Hs.172210	MUF1 protein	6.2	other
		AF127577	Hs.155017	nuclear receptor interacting protein 1	2.4 3.5	other TM
		AJ224442	Hs.155020	putative methyltransferase bromodomain adjacent to zinc finger doma	3.5 8.5	other
		NM_013449 AL135301	Hs.277401 Hs.8768	hypothetical protein FLJ10849	1.4	other
50		A1077464	Hs.5011	RNA binding motif protein 9	3.3	?
50		N89487	Hs.155291	KIAA0005 gene product	1.8	other
		AW374106	Hs.155356	hypothetical protein MGC2840 similar to	3.4	other
	130407	BE385099	Hs.334727	hypothetical protein MGC3017	2,3	other
	130409	NM_001197	Hs.155419	BCL2-interacting killer (apoptosis-induc	2.7	TM
55.		AF037448	Hs.155489	NS1-associated protein 1	1.8	other
-		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	2.3	other
		BE513202	Hs.15589	PPAR binding protein	4	TM
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	33.6	?
CO		BE245851	Hs.180779	H2B histone family, member B	5	other
60		U49844	Hs.77613	ataxia telanglectasia and Rad3 related	4.4	other
		L38951 BE208491	Hs.180446	karyopherin (importin) beta 1 KIAA0618 gene product	1.6 16.1	SS,TM other
		L32137	Hs.295112 Hs.1584	cartilage oligomeric matrix protein (pse	6.1	other
		AW876523	Hs.15929	hypothetical protein FLJ12910	2.1	other
65	130544	AA321238	Hs.4310	eukaryotic translation initiation factor	1.5	other
00		AF062649	Hs.252587	pituitary tumor-transforming 1	14.4	?
	130556	AI907018	Hs.15977	Empirically selected from AFFX single pr	4.8	other

	130567	AA383092	Hs.1608	repfication protein A3 (14kD)	8	other
	130568	AA232119	Hs.16085	putative G-protein coupled receptor	3.4	other
	130574	AF083208	Hs.16178	apoptosis antagonizing transcription fac	1.2	other
_	130598	AL042210	Hs.16493	hypothetical protein DKFZp762N2316; KIAA	1.4	other
5		AA609738	Hs.16525	ESTs	1.5	TM
		A1354355	Hs.16697	down-regulator of transcription 1, TBP-b	1.3	other
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	12.1	TM
		AA383439	Hs.16758	Spir-1 protein	15.9	other
10		BE246961	Hs.17639	Homo sapiens ubiquitin protein ligase (U	13.9	other
10		AL048842	Hs.194019	attractin	1.5	other
		AA442233	Hs.17731	hypothetical protein FLJ12892	5.4	other
		AA652501	Hs.13561	hypothetical protein MGC4692	5 2	other
		R68537	Hs.17962	ESTs	1.8	other TM
1.5		AJ271881	Hs.279762	bromodomain-containing 7 DNA segment on chromosome X (unique) 987	2	TM
15		AI348274	Hs.18212		3.8	7
		AB007920	Hs.18586	KIAA0451 gene product POP7 (processing of precursor, S. cerevi	3.2	?
		H59696	Hs.18747	chromosome 12 open reading frame	1,4	other
		AF052105 AL036067	Hs.18879 Hs.18925	protein x 0001	5.7	other
20		AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	?
20		AK000355	Hs.8899	sirtuin (silent mating type information	1.6	other
		J05068	Hs.2012	transcobalamin I (vitamin B12 binding pr	15.7	SS,
		AL157468	Hs.325825	Homo sapiens cDNA FLJ20848 fis, clone AD	2.8	other
		AA447492	Hs.20183	ESTs, Weakly similar to AF164793 1 prote	1.5	other
25		U76248	Hs.20191	seven in absentia (Drosophila) homolog 2	3.5	other
		AJ243706	Hs.143323	putative DNA/chromatin binding motif	1.7	other
		NM_016578	Hs.20509	HBV pX associated protein-8	1.9	other
		NM_003416	Hs.2076	zinc finger protein 7 (KOX 4, clone HF.1	1.4	other
		BE514434	Hs.20830	kinesin-like 2	2.1	TM
30	130892	AL120837	Hs.20993	high-glucose-regulated protein 8	2.5	other
	130898	AB033078	Hs.186613	sphingosine-1-phosphate lyase 1	1.7	other
	130911	BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe	1.8	other
	130919	N79110	Hs.21276	collagen, type IV, alpha 3 (Goodpasture	2.3	TM
~ ~		BE382657	Hs.21486	signal transducer and activator of trans	5.4	other
35		N39842	Hs.301444	KIAA1673	2.2	SS,
		T97401	Hs.21929	ESTs	1.6	other
		AV658308	Hs.2210	thyroid hormone receptor interactor 3	1.6 1.2	? other
		Al879165	Hs.2227	CCAAT/enhancer binding protein (C/EBP),	1.6	other
40		AI826288	Hs.171637	hypothetical protein MGC2628	7.4	?
40		AA321649	Hs.2248 Hs.22564	small inducible cytokine subfamily B (Cy	5.1	other
		AA194422 N53344	Hs.22607	myosin VI ESTs	7.1	other
		AA749230	Hs.26433	dolichyl-phosphate (UDP-N-acetylglucosam	2.1	TM
		AL133353	Hs.226581	COX15 (yeast) homolog, cytochrome c oxid	7.1	other
45		NM_006540	Hs.29131	nuclear receptor coactivator 2	1.9	?
		BE280074	Hs.23960	cyclin B1	5.8	?
		AW138839	Hs.24210	ESTs	2	other
		AA885699	Hs.24332	CGI-26 protein	7.1	TM
		H62087	Hs.31659	thyroid hormone receptor-associated prot	7.6	?
50	131231	N47468	Hs.59757	zinc finger protein 281	2.9	other
	131233	D89053	Hs.268012	fatty-acid-Coenzyme A ligase, long-chain	3.5	other
	131243	AW383256	Hs.24752	spectrin SH3 domain binding protein 1	2.8	?
		AL080080	Hs.24766	thioredoxin domain-containing	2.8	SS,TM
		AL043100	Hs.326190	fatty acid amide hydrolase	5.6	other
55	131281	AA251716	Hs.25227	ESTs	5.8	other
		X80038	Hs.339713	Homo sapiens clone F19374 APO E-C2 gene	1.3	other
		AV656017	Hs.184325	CGI-76 protein	5	?
		AA505691	Hs.145696	splicing factor (CC1.3)	1.8	TM other
60		AF058696	Hs.25812	Nijmegen breakage syndrome 1 (nibrin)	2.6 5.4	other
60		AW293165	Hs.143134	ESTs mitochondrial ribosomal protein L20	5.4 5.3	other
		BE269388	Hs.182698 Hs.279836	HSPC166 protein	2.2	other
	131410	BE259110 NM_012247	Hs.279030 Hs.124027	SELENOPHOSPHATE SYNTHETASE; Human		2
		AL046302	Hs.26750	hypothetical protein FLJ21908	1.4	other
65		BE297567	Hs.27047	hypothetical protein FLJ20392	1.7	other
UJ		AA992841	Hs.27263	KIAA1458 protein	2	other
		AV661958	Hs.8207	GK001 protein	2.6	other
	,5.001			•		

	131511	AA732153	Hs.27865	Homo sapiens cDNA: FLJ21333 fis, clone C	2	other
	131528	AU076408	Hs.28309	UDP-glucose dehydrogenase	1.6	TM
		BE268278	Hs.28393	hypothetical protein MGC2592	7.4	other
_		AW966881	Hs.41639	programmed cell death 2	2.2	other
5		AL355715	Hs.28555	programmed cell death 9 (PDCD9)	2.1	other
		NM_003512	Hs.28777	H2A histone family, member L	1.7	other
		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	5.2	other
		AL389951	Hs.271623	nucleoporin 50kD	5 1.8	other other
10		BE393822 R78195	Hs.29645	Homo sapiens mRNA; cDNA DKFZp761C029 (fr	1.3	other
10		AB037791	Hs.29692 Hs.29716	Homo sapiens cDNA FLJ11436 fis, clone HE hypothetical protein FLJ10980	2.2	TM
		AW410601	Hs.30026	HSPC182 protein	3	other
		AW960597	Hs.30164	ESTs	1.3	other
		Al218918	Hs.30209	KIAA0854 protein	2.8	other
15		X52486	Hs.3041	uracil-DNA glycosylase 2	2.8	other
	131692	BE559681	Hs.30736	KIAA0124 protein	5.6	?
	131714	AA642831	Hs.31016	putative DNA binding protein	2.9	?
	131722	D13757	Hs.311	phosphoribosyl pyrophosphate amidotransf	3.4	other
	131737	AK001641	Hs.31323	inhibitor of kappa light polypeptide gen	3.9	?
20		AI878932	Hs.317	topoisomerase (DNA) I	3.4	other
		AA382590	Hs.170980	KIAA0948 protein	25.5	other
		D87077	Hs.196275	KIAA0240 protein	2.4	SS,
		AW966127	Hs.32246	Homo sapiens cDNA FLJ14656 fis, clone NT	8	TM
25		BE501849	Hs.32317	high-mobility group 208	1.5	other
25		X86098	Hs.301449	adenovirus 5 E1A binding protein	4.2	other
		U20536	Hs.3280	caspase 6, apoptosis-related cysteine pr	4.3 3.5	other other
		U28838 Al251317	Hs.32935 Hs.33184	TATA box binding protein (TBP)-associate ESTs	5.2	TM
		AA083764	Hs.6101	hypothetical protein MGC3178	5.9	other
30		BE502341	Hs.3402	ESTs	13.7	other
50		AA099014	Hs.231029	Homo sapiens, clone MGC:15961, mRNA, com	8.7	other
		AF078866	Hs.284296	Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	other
		AA179298	Hs.3439	stomatin-like 2	11.3	other
	131913	AW207440	Hs.185973	degenerative spermatocyte (homolog Droso	1.7	SS,
35		AA025976	Hs.34569	ESTs	5.2	TM
	131925	AF151048	Hs.183180	anaphase promoting complex subunit 11 (y	2.8	other
	131929	BE541211	Hs.34804	Homo sapiens cDNA FLJ11472 fis, clone HE	5.4	TM
		BE252983	Hs.35086	ubiquitin specific protease 1	2.4	other
40		AA355113	Hs.35380	x 001 protein	1.5	?
40		AK000046	Hs.267448	hypothetical protein FLJ20039	2.3	other
		W79283	Hs.35962	ESTs	1.4	other
		BE567100	Hs.154938	hypothetical protein MDS025	3.5	other
		U90441 AA503020	Hs.3622 Hs.36563	procollagen-proline, 2-oxoglutarate 4-di hypothetical protein FLJ22418	6.6 2.4	TM ?
45		AF053306	Hs.36708	budding uninhibited by benzimidazoles 1	2.2	SS,TM
7,7		H56995	Hs.37372	Homo sapiens DNA binding peptide mRNA, p	3.3	TM
		BE266155	Hs.3832	clathrin-associated protein AP47	1.5	other
		NM_002267	Hs.3886	karyopherin alpha 3 (importin alpha 4)	3.7	other
		BE171921	Hs.3991	ESTs	1.5	other
50		AV646076	Hs.39959	ESTs	5.8	TM
	132116	AW960474	Hs.40289	ESTs	1,7	other
	132176	AA857025	Hs.8878	kinesin-like 1	3.4	other
		NM_004460	Hs.418	fibroblast activation protein, alpha	14.7	SS,
		R42432	Hs.4212	ESTs	2.2	other
55		BE206939	Hs.42287	E2F transcription factor 6	1.5	other
		AV658411	Hs.42656	KIAA1681 protein	5.7	other
		A1566004	Hs.141269	Homo sapiens cDNA: FLJ21550 fis, clone C	2.1	other
	132266	AA301228	Hs.43299	hypothetical protein FLJ12890	1.5	other
60		AA227710	Hs.43658	DKFZP586L151 protein	10	other
60		AA653507 N36110	Hs.285711	hypothetical protein FLJ13089 solute camer family 2 (facilitated glu	2 9.2	other other
		AB023191	Hs.305971 Hs.44131	KIAA0974 protein	9.2 2	other
		NM_015986	Hs.7120	cytokine receptor-like molecule 9	6.6	SS,
		AW405882	Hs.44205	cortistatin	3.8	other
65		N37065	Hs.44856	hypothetical protein FLJ12116	1.5	other
55		AW572805	Hs.46645	ESTs	28.3	?
		AF155582	Hs.46744	core1 UDP-galactose:N-acetylgalactosamin	1.9	other

	132376	A1270902	Un 46004	corting novin 14	2	?
		A1279892 AA312135	Hs.46801 Hs.46967	sorting nexin 14 HSPCO34 protein	6.1	?
		AL135094	Hs.47334	hypothetical protein FLJ14495	1.7	other
		AA100012	Hs.48827	hypothetical protein FLJ12085	8.6	other
5		AW973521	Hs.247324	mitochondrial ribosomal protein S14	5.3	other
3		AB011084	Hs.48924	KIAA0512 gene product; ALEX2	1.5	other
		A1224456	Hs,4934	H.sapiens polyA site DNA	2	other
		X16660	Hs.119007	RAB4, member RAS oncogene family	2.9	SS,
		AW885606	Hs.5064	ESTs	2.2	other
10		AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. c	1.7	other
		AA454132	Hs.5080	mitochondrial ribosomal protein L16	7.2	TM
		BE388673	Hs.5086	hypothetical protein MGC10433	2.2	SS,
	132543	BE568452	Hs.5101	protein regulator of cytokinesis 1	2.2	other
	132574	AW631437	Hs.5184	TH1 drosophila homolog	14	?
15	132596	AK001484	Hs.5298	CGI-45 protein	1.9	other
	132611	AA345547	Hs.53263	hypothetical protein FLJ13287	2.6	TM
	132612	H12751	Hs.5327	PRO1914 protein	2	other
		BE262677	Hs.283558	hypothetical protein PRO1855	3.1	other
		AI796870	Hs.54277	DNA segment on chromosome X (unique) 992	12.4	TM
20		AB018319	Hs.5460	KIAA0776 protein	2.8	SS,
		AW191962	Hs.249239	collagen, type VIII, alpha 2	3	other
		F11875	Hs.5534	Homo sapiens cDNA FLJ12961 fis, clone NT	1.8 3.7	other other
		NM_004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	3.7 1.8	TM
25		A1142265	Hs.55498	geranylgeranyl diphosphate synthase 1	5.9	other
23		AI189075 AA010233	Hs.301872 Hs.55921	hypothetical protein MGC4840 glutamyl-protyl-tRNA synthetase	8.7	other
		AA125985	Hs.56145	thymosin, beta, identified in neuroblast	3.6	other
		Y10275	Hs.56407	phosphoserine phosphatase	2.8	TM
		AA459713	Hs.295901	KIAA0493 protein	14.6	other
30	_	Al142133	Hs.56845	GDP dissociation inhibitor 2	1.7	other
50		Al026701	Hs.5716	KIAA0310 gene product	2.5	other
		U07418	Hs.57301	mutL (E. coli) homolog 1 (colon cancer,	1.4	other
		AB007944	Hs.5737	KIAA0475 gene product	4.3	SS,
		BE313625	Hs.57435	solute carrier family 11 (proton-coupled	2.8	other
35		AI815189	Hs.57475	sex comb on midleg homolog 1	1.6	other
		N27852	Hs.57553	tousled-like kinase 2	1.4	other
	132821	AJ251595	Hs.169610	CD44 antigen (homing function and Indian	5.4	other
	132833	U78525	Hs.57783	eukaryotic translation initiation factor	6.1	?
4.0		NM_016154	Hs.279771	Homo sapiens clone PP1596 unknown mRNA	7.2	other
40		F12200	Hs.5811	chromosome 21 open reading frame 59	2.9	other
		U09716	Hs.287912	lectin, mannose-binding, 1	6.1	other
		AW963217	Hs.203961	ESTs, Moderately similar to AF116721 89	1.8	other
		AW007683	Hs.58598	KIAA1266 protein	2.2 5	other TM
45		NM_004850	Hs.58617	Rho-associated, coiled-coil containing p	2.7	?
43		BE267143 AW503667	Hs.59271	U2(RNU2) small nuclear RNA auxillary fac ring finger protein 15	5.4	7
		A1936442	Hs.59545 Hs.59838	hypothetical protein FLJ10808	3.2	other
		AW732760	Hs.167578	Homo sapiens cDNA FLJ11095 fis, clone PL	1.4	other
		W78714	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PL	3	other
50		T79136	Hs.127243	Homo sapiens mRNA for KIAA1724 protein,	10.3	other
		AA554458	Hs.197751	KIAA0666 protein	2.1	SS,
		AI658580	Hs.61426	Homo sapiens mesenchymal stem cell prote	1.3	other
		AA576635	Hs.6153	CGI-48 protein	4.9	other
	132972	AA034365	Hs.288924	Homo sapiens cDNA FLJ11392 fis, clone HE	3.6	TM
55	132973	AA035446	Hs.323277	ESTs	13.1	other
	132977	AA093322	Hs.301404	RNA binding motif protein 3	1.3	other
		AA040696	Hs.62016	ESTs	2.3	?
		AA112748	Hs.279905	clone HQ0310 PRO0310p1	17,1	other
		AA847843	Hs.62711	Homo sapiens, clone IMAGE:3351295, mRNA	1.9	other
60		AJ002744	Hs.246315	UDP-N-acetyl-alpha-D-galactosamine:polyp	5	TM
		AW500374	Hs.64056	PRO0149 protein	6.1	other TM
		BE247441	Hs.6430	protein with polyglutamine repeat; calci	1.5 1.4	other
		AK001628	Hs.64691	KIAA0483 protein ESTs	5.6	other
65		AA808177	Hs.65228	RNA binding motif protein 8A	1.9	other
U.S		AF198620 H94227	Hs.65648 Hs.6592	Homo sapiens, clone IMAGE:2961368, mRNA,	4.8	?
. '		Z11695	Hs.324473	mitogen-activated protein kinase 1	5	other
	100102	£11030	16.027713	integeri dourawe present fallace 1	-	

	133174	AA431620	Hs,324178	hypothetical protein MGC2745	2.7	other		
		AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	9.3	other		
		X97795	Hs.66718	RAD54 (S.cerevisiae)-like	4.5	TM		
		A1801777	Hs.6774	ESTs	5.5	TM		
5		AW954569	Hs.296287	Homo sapiens, Similar to bromodomain-con	2.7	other		
		A1492924	Hs.6831	golgi phosphoprotein 1	1.7	?		
	133254	A1567421	Hs.273330	Homo sapiens, clone IMAGE:3544662, mRNA,	1.3	other		
	133268	AW956781	Hs.293937	ESTs, Weakly similar to FXD2_HUMAN FORKH	12.2	other		
	133291	BE297855	Hs.69855	NRAS-related gene	1.2	other		
10	133314	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	1.7	TM		
	133321	T79526	Hs.179516	integral type I protein	11.1	?		
	133327	AL390127	Hs.7104	Kruppel-like factor 13	2.9	other		
		BE257758	Hs.71475	acid cluster protein 33	2.5	?		
		Al016521	Hs.71816	v-akt murine thymoma viral oncogene homo	1.5	other		
15		AA292811	Hs.72050	non-metastatic cells 5, protein expresse	2.1	other		
		AF231919	Hs.18759	KiAA0539 gene product	1.3	other		
		AF245505	Hs.72157	DKFZP56411922 protein	2.2 5.7	other TM		
		A1950382	Hs.72660 Hs.727	phosphatidylserine receptor inhibin, beta A (activin A, activin AB a	25.5	other		
20		AW103364 AA305127	Hs.237225	hypothetical protein HT023	3.3	other		
20		AL031591	Hs.7370	phosphotidylinositol transfer protein, b	1.6	other		
		NM_002759	Hs.274382	protein kinase, interferon-inducible dou	4.1	other		
		A1659306	Hs.73826	protein tyrosine phosphatase, non-recept	1.5	other		
		AW964804	Hs.74280	hypothetical protein FLJ22237	6.3	TM		
25		W45623	Hs.74571	ADP-ribosylation factor 1	4	?		
		AU077073	Hs, 108327	damage-specific DNA binding protein 1 (1	1.8	?		
		AU077050	Hs.75066	translin	1.5	other		
	133579	X75346	Hs.75074	mitogen-activated proteln kinase-activat	3.5	TM		
••		BE391579	Hs.75087	Fas-activated serine/threonine kinase	6.8	TM		
30		AW160781	Hs.172589	nuclear phosphoprotein similar to S. cer	2.6	TM		
		AA393273	Hs.75133	transcription factor 6-like 1 (mitochond	1.4	other		
		NM_002885	Hs.75151	RAP1, GTPase activating protein 1	8.1	other		
		NM_004893	Hs.75258	H2A histone family, member Y	13.5 2.2	other other		
25		NM_002047	Hs.75280	glycyl-tRNA synthetase	1.8	other		
35		NM_000401 U25849	Hs.75334 Hs.75393	exostoses (multiple) 2 acid phosphatase 1, soluble	2	other	,	
		AV661185	Hs.75574	mitochondrial ribosomal protein L19	2.8	other		
		L27841	Hs.75737	pericentriolar material 1	6.8	other		
		AW969976	Hs.279009	matrix Gla protein	2.5	other		
40		AW402048.∞		Hs.334787	Homo sa	apiens, Similar to likely ortholog	3.1	TM
		T52946	Hs.196209	RAE1 (RNA export 1, S.pombe) homolog	1.4	?		
		BE271766	Hs.181357	laminin receptor 1 (67kD, ribosomal prot	5.4	other		
	133765	M62194	Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	5	other		
	133780	AA557660	Hs.76152	decorin	3.8	other		
45	133797	AL133921	Hs.76272	retinoblastoma-binding protein 2	3.1	?		
		D50525	Hs.699	peptidylprolyl isomerase B (cyclophilin	9.7	?		
		AW797468	Hs.285013	putative human HLA class II associated p	2.4	other		
		AA147026	Hs.76704	ESTS	2.5	other		
50		AB011155	Hs.170290	discs, large (Drosophila) homolog 5	5 2.5	other ?		
50		AW340125	Hs.76989 Hs.183874	KIAA0097 gene product	2.5	other		
		AB012193		cullin 4A splicing factor, arginine/serine-rich 9	2.8	TM		
		U30825 D86326	Hs.77608 Hs.325948	vesicle docking protein p115	1.8	SS,		
		NM_006306	Hs.211602	SMC1 (structural maintenance of chromoso	2	7		
55		L17128	Hs.77719	gamma-glutamyl carboxylase	2.6	other		
55		BE244332	Hs.77770	adaptor-related protein complex 3, mu 2	2.9	other		
		X81789	Hs.77897	splicing factor 3a, subunit 3, 60kD	10.4	other		
		Al908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	1.9	other		
		AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	2.6	SS,		
60		AI824113	Hs.78281	regulator of G-protein signalling 12	13	other		
	134010	AB016092	Hs.197114	RNA binding protein; AT-rich element bin	8.8	other		
	134015	D31764	Hs.278569	sorting nexin 17	1.5	SS,		
	134070	NM_003590	Hs.78946	cuilin 3	8.3	other		
,-		U41060	Hs.79136	LIV-1 protein, estrogen regulated	2.7	other		
65		NM_014742	Hs.79305	KIAA0255 gene product	4.2	other other		
		H86504	Hs.173328	protein phosphatase 2, regulatory subuni KIAA0160 protein	1.7 2.6	other		
	134200	BE559598	Hs.197803	Kiroso too pioteiti	2.0	Guioi		

	13/1206	AF107463	Hs.79968	splicing factor 30, survival of motor ne	1.3	other
		NM_000402	Hs.80206	glucose-6-phosphate dehydrogenase	1.9	other
					10.3	SS,
		BE300078	Hs.80449	Homo sapiens, clone IMAGE:3535294, mRNA,		•
_		Al878910	Hs.3688	cisplatin resistance-associated overexpr	2.5	other
5		Al906291	Hs.81234	immunoglobulin superfamily, member 3	1.3	TM
		AW502505	Hs.81360	Homo saplens cDNA: FLJ21927 fis, done H	1.6	TM
		U61397	Hs.81424	ubiquitin-like 1 (sentrin)	2.1	TM
	134324	AB029023	Hs.179946	KIAA1100 protein	5.3	?
	134326	AW903838	Hs.81800	chondroitin sulfate proteoglycan 2 (vers	2.5	TM
10	134329	N92036	Hs.81848	RAD21 (S. pombe) homolog	3.9	?
		NM_004922	Hs.81964	SEC24 (S. cerevisiae) related gene famil	2.4	TM
		AW291946	Hs.82065	interleukin 6 signal transducer (gp130,	6.8	TM
		AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	2.3	TM
				2',5'-oligoadenylate synthetase 1 (40-46	5.5	other
15		X06560	Hs.82396	hypothetical protein MGC3222	5.9	TM
13		AW362124	Hs.323193			
		Al589941	Hs.8254	Homo sapiens, Similar to tumor different	2.2	other
		AA417383	Hs.82582	integrin, beta-like 1 (with EGF-like rep	2.1	other
		AA456539	Hs.8262	lysosomal	2.3	other
	134405	AW067903	Hs.82772	collagen, type XI, alpha 1	72.9	other
20	134411	BE272095	Hs.167791	reticulocalbin 1, EF-hand calcium bindin	4.4	other
	134415	AI750762	Hs.82911	protein tyrosine phosphatase type IVA, m	2.3	other
	134421	AU077196	Hs.82985	collagen, type V, alpha 2	6.8	?
		Z44190	Hs.83023	peroxisomal blogenesis factor 11B	2.4	other
		AA112036	Hs.83419	KIAA0252 protein	2.9	other
25		M58603	Hs.83428	nuclear factor of kappa light polypeptid	6.7	other
45		X54942	Hs.83758	CDC28 protein kinase 2	2.4	other
			Hs.83916	Empirically selected from AFFX single pr	6.3	?
		NM_005000			1.9	other
		X82153	Hs.83942	cathepsin K (pycnodysostosis)		
20		AW246273	Hs.84131	threonyl-tRNA synthetase	1.8	other
30		AA425473	Hs.84429	KIAA0971 protein	1.4	other
		AK001571	Hs.273357	hypothetical protein FLJ10709	1.4	other
	134520	BE091005	Hs.74861	activated RNA polymerase II transcriptio	5.6	other
	134529	AW411479	Hs.848	FK506-binding protein 4 (59kD)	2.8	?
	134577	BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	1.7	other
35		AA927177	Hs.86041	CGG triplet repeat binding protein 1	1.7	TM
		AW068223	Hs.171581	ubiquitin C-terminal hydrolase UCH37	2.1	other
		AF035119	Hs.8700	deleted in liver cancer 1	1.3	other
		X78520	Hs.174139	chloride channel 3	2.1	?
		AK001741	Hs.8739	hypothetical protein FLJ10879	2.3	other
40		BE391929	Hs.8752	transmembrane protein 4	4	other
40					6.2	other
		U62317	Hs.88251	arylsulfatase A	2	other
		NM_003474	Hs.8850	a disintegrin and metalloproteinase doma	1.3	SS,
		BE161887	Hs.88799	anaphase-promoting complex subunit 10		
4.5		Y14768	Hs.890	lysosomal	7.2	?
45	134719	AA852985	Hs.89232	chromobox homolog 5 (Drosophila HP1 alph	3.2	other
	134722	AF129536	Hs.284226	F-box only protein 6	2.5	other
	134746	X07871	Hs.89476	CD2 antigen (p50), sheep red blood cell	5	other
	134751	AW630803	Hs.89497	lamin B1	6.1	other
		BE002798	Hs.287850	integral membrane protein 1	5.6	TM
50		AW451370	Hs.8991	adaptor-related protein complex 1, gamma	5.3	other
50		Al701162	Hs.90207	hypothetical protein MGC11138	9.1	other
		BE268326	Hs.90280	5-aminoimidazole-4-carboxamide ribonude	2.4	other
		AI879195	Hs.90606	15 kDa selenoprotein	2.7	other
				PRO1073 protein	1.5	other
E E		AW885909	Hs.6975	PRO 1073 protein	4.9	other
55		AW401361	Hs.91773	protein phosphatase 2 (formerly 2A), cat		other
		AI097346	Hs.286049	phosphoserine aminotransferase	2	
	134975	R50333	Hs,92186	Leman colled-coil protein	2,6	TM
	135011	AB037835	Hs.92991	KIAA1414 protein	1.4	?
	135022	NM_000408	Hs.93201	glycerol-3-phosphate dehydrogenase 2 (mi	1.6	?
60	135032	AW301984	Hs.173685	hypothetical protein FLJ12619	1.4	other
		AW503733	Hs.9414	KIAA1488 protein	1.8	other
		AB036063	Hs.94262	p53-inducible ribonucleotide reductase s	2.5	other
		AF027219	Hs.9443	zinc finger protein 202	1.5	TM
		AA081258	Hs.132390	zinc finger protein 36 (KOX 18)	2.1	other
65		AI093155	Hs.95420	JM27 protein	4,4	?
03			Hs.279529	px 19-like protein	14.9	?
		BE250865		translin-associated factor X	1.3	other
	135199	AA477514	Hs.96247	u anamirassociateu iadul A	1.0	38101

		N26427	Hs.9634	ESTs, Highly similar to C10_HUMAN PUTATI	1.7	other
	135214	T78802	Hs.96560	hypothetical protein FLJ11656	6.2	other
	135243	BE463721	Hs.97101	putative G protein-coupled receptor	2.8	TM
	135245	AI028767	Hs.262603	ESTs	12,2	TM
5		AW291023	Hs.97255	ESTs, Weakly similar to A46010 X-linked	7.7	TM
•		AI088775	Hs,55498	geranylgeranyl diphosphate synthase 1	1.8	other
		AA448460	Hs.112017	GE36 gene	4.2	SS,
		AA150320	Hs.9800	protein kinase Njmu-R1	1.2	other
		AI090838	Hs.98006	ESTs	4.9	other
10					5.9	?
10		A1743770	Hs.98368	ESTs, Weakly similar to KIAA0822 protein		
		A1652069	Hs.98614	ribosome binding protein 1 (dog 180kD ho	12.3	TM
		AA456454	Hs.183418	cell division cycle 2-like 1 (PITSLRE pr	5.8	?
		AA373452	Hs.167700	Homo sapiens cDNA FLJ10174 fis, clone HE	8.1	other
		U05237	Hs.99872	fetal Alzheimer antigen	1.9	other
15	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	13.9	TM
	302256	AA857131	Hs.171595	HIV TAT specific factor 1 *	1.6	other
	302276	AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.3	other
		AW592789	Hs.279474	HSPC070 protein	2.2	TM
		AK000714	Hs.109441	MSTP033 protein	1.4	SS,
20		R43191	Hs.101248	Homo sapiens clone IMAGE:32553, mRNA seq	5.2	other
20		AA808229	Hs.167771	ESTs	2.3	?
					2.9	ż
		NM_007057	Hs.42650	ZW10 interactor	2.3	other
		A1268997	Hs.197289	rab3 GTPase-activating protein, non-cata		
0.5		AA902256	Hs.78979	Golgi apparatus protein 1	5.6	SS,
25		N24236	Hs.179662	nucleosome assembly protein 1-like 1	1.4	?
		AF118083	Hs.29494	PRO1912 protein	1.3	other
	322556	BE041451	Hs.177507	hypothetical protein	2.9	SS,
	323541	AF292100	Hs.104613	RP42 homolog	1.6	other
	407827	BE278431	Hs.40323	BUB3 (budding uninhibited by benzimidazo	1.8	other
30	408196	AL034548	Hs.43627	SRY (sex determining region Y)-box 22	1.6	other
		A1580090	Hs.48295	RNA helicase family	6.2	other
		R73727	Hs.101617	ESTs, Weakly similar to T32527 hypotheti	5.7	other
		H19886		gb:yn57a05.r1 Soares aduit brain N2b5HB5	2.7	other
		AB000115	Hs.75470	hypothetical protein, expressed in osteo	2.6	?
35		Al267592	Hs.75761	SFRS protein kinase 1	2.4	TM
55		AW304454	Hs.77495	UBX domain-containing 1	2.4	other
					2.3	other
		AW819158	Hs.289044	Homo sapiens cDNA FLJ12048 fis, clone	4.2	TM
		AA381133	Hs.80684	high-mobility group (nonhistone chromoso		
40		R57256	Hs.82037	TATA box binding protein (TBP)-associate	23.6	other
40		S79895	Hs.83942	cathepsin K (pycnodysostosis)	5.8	other
		NM_006910	Hs.85273	retinoblastoma-binding protein 6	1.3	other
		U72937	Hs.96264	alpha thalassemia/mental retardation syn	1.6	?
	420802	U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.3	?
	421225	AA463798	Hs.102696	MCT-1 protein	1.6	?
45	421642	AF172066	Hs.106346	retinoic acid repressible protein	3.5	other
	421828	AW891965	Hs.279789	histone deacetylase 3	5	other
		A1252640	Hs.110364	peptidylprolyl isomerase C (cyclophilin	3.1	TM
		AA302744	Hs.104518	ESTs	1.9	TM
		NM 014320	Hs.111029	putative heme-binding protein	2.4	other
50		AF165883	Hs.298229	prefoldin 2	4.2	?
50		W67883	Hs.137476	paternally expressed 10 (PEG10; KIAA105	7.1	?
		AF041259	Hs.155040	zinc finger protein 217	2.3	other
			Hs.155489	NS1-associated protein 1	3.5	other
		AF155568			1.9	?
		BE304680	Hs.169531	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	7.6	7
55		AW183765	Hs.182238	GW128 protein		-
		AW500533	Hs.11482	splicing factor, arginine/serine-rich 11	1.7	other
	437562	AB001636	Hs.5683	DEAD/H (Asp-Glu-Ala-Asp/His) box polypep	2.4	other
	438449	AK001333	Hs.6216	Homo sapiens hepatocellular carcinoma-as	3.8	other
	441560	F13386	Hs.7888	Homo sapiens clone 23736 mRNA sequence	5.6	other
60	445580	AF167572	Hs.12912	skb1 (S. pombe) homolog	2	TM
		AA151520	Hs.334822	hypothetical protein MGC4485	7.6	other
		AI017574	Hs.17409	cysteine-rich protein 1 (intestinal)	2.2	other
		BE620592	Hs.71190	ESTs, Weakly similar to S16506 hypotheti	2.9	other
	441110	NM_003677	Hs.22393	density-regulated protein	1.8	other
65			Hs.331328	intermediate filament protein syncollin	5.9	other
UJ	44900/	W68520		Homo sapiens cDNA FLJ12280 fis, done MA	5.7	other
	450/01	H39960	Hs.288467		1.4	other
	450703	AA011202	Hs.184771	nuclear factor I/C (CCAAT-binding transc	1.4	Outer

	450404			A	4.0	?
	452461		Hs.108106	transcription factor	4.8	
		BE408178	Hs.285165	Homo sapiens cDNA FLJ20845 fis, clone AD	2.9	other
	453157	AF077036	Hs.31989	DKFZP586G1722 protein	12.1	SS,TM
_	453658	BE541906	Hs.87819	Homo sapiens, clone MGC:2492, mRNA, comp	4.8	other
5	100685	AA328229	Hs.184582	ribosomal protein L24	1.8	TM
	100690	AA383256	Hs.1657	estrogen receptor 1	1.6	other
	100833	AF135168	Hs.108802	N-ethylmaleimide-sensitive factor	1.3	other
	100850	AA836472	Hs.297939	cathepsin B	1.7	?
		NM_006262	Hs.37044	peripherin	16.9	other
10		U50360		gb:Human calcium, calmodulin-dependent p	3.2	other
10		AA262170	Hs.80917	adaptor-related protein complex 3, sigma	2	?
		BE270465	Hs.78793	protein kinase C, zeta	8	other
•		AL135301	Hs.8768	hypothetical protein FLJ10849	1.8	other
					2	?
15		AB040450	Hs.279862	cdk inhibitor p21 binding protein	2.1	other
15		A1498763	Hs.203013	hypothetical protein FLJ12748	1.2	other
		AL117403	Hs.306189	DKFZP434F1735 protein		
		AA127818		gb:zl12a02.s1 Soares_pregnant_uterus_NbH	7	?
		AA907305	Hs.36475	ESTs	2.6	?
••		AA454036	Hs.8832	ESTs	1.6	other
20	106977	AL043152	Hs.50421	KIAA0203 gene product	4.9	other
	107298	N95657	Hs.6820	ESTs, Moderately similar to YOJ1_CAEEL H	2.5	TM
	108717	AA122393	Hs.70811	hypothetical protein FLJ20516	1.3	other
	110018	AW579842	Hs.104557	hypothetical protein FLJ10697	5.3	TM
	110330	A1288666	Hs.16621	DKFZP434I116 protein	6.3	other
25		NM_003896	Hs.225939	sialyltransferase 9 (CMP-NeuAc:lactosylc	5.1	SS,
		W46342	Hs.325081	Homo sapiens, clone IMAGE:3659680, mRNA,	8.4	other
		AW503990	Hs.142442	HP1-BP74	3.7	TM
		AV653556	Hs.184411	albumin	1.3	other
		AK001827	Hs.87889	helicase-moi	2	other
30		AA253314	Hs.154103	LIM protein (similar to rat protein kina	1.5	other
50			Hs.88155	ESTs	2.8	other
		A1634549	Hs.260622	butyrate-induced transcript 1	5.8	TM
		AF161470			5.7	other
		M10905	Hs.287820	fibronectin 1	1.3	other
25		AL034423	Hs.75875	ubiquitin-conjugating enzyme E2 variant	38.9	other
35		AA131376	Hs.326401	fibroblast growth factor 12B	2.9	?
		BE065136	Hs.145696	splicing factor (CC1.3)	1.8	other
		X80031	Hs.530	collagen, type IV, alpha 3 (Goodpasture		other
		AA419008	Hs.106730	chromosome 22 open reading frame 3	3	
40		F34856	Hs.292457	Homo sapiens, clone MGC:16362, mRNA, com	13.3	other
40	128959	AI580127	Hs.107381	hypothetical protein FLJ11200	10.9	other
	129209	R62676	Hs.17820	Rho-associated, coiled-coil containing p	2.4	other
	129449	A1096988	Hs.111554	ADP-ribosylation factor-like 7	8.2	TM
	129453	AW974265	Hs.111632	Lsm3 protein	3.3	?
	129629	AK000398	Hs.11747	hypothetical protein FLJ20391	3.9	other
45	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	5.3	TM
	129922	AF042379	Hs.13386	gamma-tubulin complex protein 2	4.6	other
		AB015856	Hs.247433	activating transcription factor 6	4	SS,
	130182	BE267033	Hs.192853	ubiquitin-conjugating enzyme E2G 2 (homo	4.6	other
		W56119	Hs.155103	eukaryotic translation initiation factor	11	other
50		AL121438	Hs.183706	adducin 1 (alpha)	2.7	other
50		U64675	Hs.179825	RAN binding protein 2-like 1	7.9	other
		AB007891	Hs.16349	KIAA0431 protein	5.6	TM
		AF258627	Hs.211562	ATP-binding cassette, sub-family A (ABC1	5.2	other
		BE398091	Hs.74316	desmoplakin (DPI, DPII)	1.8	TM
55				ESTs. Moderately similar to A46010 X-lin	1.7	?
22		H23230	Hs.22481	TBX3-iso protein	3.3	TM
		NM_016569	Hs.267182	Nijmegen breakage syndrome 1 (nibrin)	2.6	other
		AF058696	Hs.25812		2.9	TM
		X76732	Hs.3164	nucleobindin 2		other
		BE267158	Hs.169474	DKFZP586J0119 protein	5.6	
60		AI681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	1.3	other
	131881	AW361018	Hs.3383	upstream regulatory element binding prot	3.2	TM
	131887	W17064	Hs.332848	SWI/SNF related, matrix associated, acti	3.2	other
	132031	AF193844	Hs.3758	COP9 complex subunit 7a	5.9	?
		AA206153	Hs.4209	mitochondrial ribosomal protein L37	2.2	TM
65	132203	NM_004782	Hs.194714	synaptosomal-associated protein, 29kD	7.9	?
		AB018324	Hs.42676	KIAA0781 protein	4.3	other
•		AW067708	Hs.170311	heterogeneous nuclear ribonucleoprotein	12.5	other

		T78736	Hs.50758	SMC4 (structural maintenance of chromoso	7.4	?	
		AW674699	Hs,5169	suppressor of G2 allele of SKP1, S. cere	6.9	other	
		N52298	Hs.55608	hypothetical protein MGC955	14.3	?	
_		BE268048	Hs.236494	RAB10, member RAS oncogene family	10.3	other	
5		A1439688	Hs.6289	hypothetical protein FLJ20886	4.4	other	
		A1065016	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	1.8	SS,TM	
		AI275243	Hs.180201	hypothetical protein FLJ20671 ADP-ribosylation factor-like 1	1.8 1.8	other other	
		AK001489 Al160873	Hs.242894 Hs.69233	zinc finger protein	16.1	other	
10		M76477	Hs.289082	GM2 ganglioside activator protein	10.4	SS,	
10		BE313555	Hs.7252	KIAA1224 protein	1.5	?	
		AL037159	Hs.74619	proteasome (prosome, macropain) 26S subu	1.7	other	
		BE622743	Hs.301064	arfaptin 1	12.1	other	
		M34338	Hs.76244	spermidine synthase	9.7	other	
15	133850	W29092	Hs.7678	cellular retinoic acid-binding protein 1	4.2	SS,	
	133859	U86782	Hs.178761	26S proteasome-associated pad1 homolog	2.2	other	
	133881	U30872	Hs.77204	centromere protein F (350/400kD, mitosin	9.1	other	
	134208	NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.2	other	
• •	134403	AA334551	Hs.82767	sperm specific antigen 2	1.4	other	
20		AF045239	Hs.321576	ring finger protein 22	1.4	other	
		AD001528	Hs.89718	spermine synthase	2.6	other	
		D26488	Hs.90315	KIAA0007 protein	13.3	other	
	135193	X95525	Hs.96103	TATA box binding protein (TBP)-associate	3.1	other	
25		AA243007		ESTs	1.6 2.5	?	
25		T70541		ESTs	4.5	SS, other	
		X57766		Human stromelysin-3 mRNA Homo sapiens clone 23592 mRNA sequence	3.1	other	
		S66431 AA453483		ESTs	4.6	TM	
		R63925		ESTs	1.4	other	
30		AA173417		ESTs	1.9	other	
50		AA280588		ESTs	2.2	other	
		AA504223		ESTs Highly similar to CHROMOSOME	2.4	other	
		AA609996		ESTs Highly similar to Surf-4 protein [M.musculus]	5.5	?	
		F02907	•	ESTs	2.3	TM	
35		AA480103		ESTs Weakly similar to !!!! ALU SUBFAMILY J	2.8	TM	
		AA024664		Human NADH:ublquinone oxidoreductase subunit	6.2	other	
		AA251776		ESTs	2.3	other	
		AA399047		ESTs	2.4	other	
40		N34059		EST - RC_N34059	3.3	other	
40		U95367		Human GABA-A receptor pi subunit mRNA complete		1.7	TM
		AA490899	•	ESTs	3.3 2.9	other ?	
		T54762		ESTs Homo sapiens HP protein (HP) mRNA complete cds		?	
		Z41963 AA521186	•	ESTs	1.6	тM	
45		AA400195		ESTs	1.3	other	
73		AA045083		VITAMIN K-DEPENDENT GAMMA-CARBOXYLASI		2.5	other
		AA099589		Homo saplens mRNA for GDP dissociation inhibitor		1.6	TM
		W85712		ESTs Weakly similar to PROCOLLAGEN ALPHA 2(2.6	TM
		W45728		ESTs Highly similar to HETEROGENEOUS	3.7	other	
50		U61232		Human tubulin-folding cofactor E mRNA complete of	ds	2.1	other
		AA425154		ESTs	5.3	other	
_ ,		T39176		ESTs Weakly similar to ZK1058.4 [C.elegans]	2.6	SS,TM	
		AA496000		ESTs	1.9	SS,	
		W38150		EST - RC_W38150	1.7	?	
55		T96595		EST - RC_T96595	1.8	TM	^
		AA227463		ESTs Weakly similar to No definition line found [C.e		1.9	?
		R46025		ESTs	2.8	SS,	
		AA233177		ESTs	2	other	
60		AA338760		ESTs ESTs	1.3	? other	
60		AA412106 L47276		EST - L47276	6.2 3.4	other	
		D82307		ESTs Weakly similar to TH1 protein [D.melanogaste		11.4	other
		AA293568		ESTS Weakly Similar to This protein [D.melanogaste	1.5	other	03101
		R37778		ESTs	2.4	other	
65		AA250843		Interferon regulatory factor 5	14.6	?	
00		W49521	•	Human prolyl 4-hydroxylase alpha (II) subunit	6.5	?	
		D80000		Human mRNA for KIAA0178 gene partial cds	2	other	
				• •			

	R99978	ESTs Weakly similar to line-1 protein ORF2 [H.sapier	າຣ]	6.1	?
	AA195036	Human Ro/SSA ribonucleoprotein homolog (RoRet	5.3	?	
	Z38501	ESTs Weakly similar to PROBABLE E5	1.4	other	
	U37547	Human IAP homolog B (MIHB) mRNA complete cds :	3.2	other	
5	AA479961	ESTs	1.7	other	
	X57579	Inhibin beta A (activin A activin AB alpha polypeptide)	15.8	?
	AA449071	ESTs	1.3	TM	
	N51855	ESTs Moderately similar to NAD(+) ADP-	1.3	other	
	AA421213	ESTs Weakly similar to F28F8.3 [C.elegans]	3.2	other	
10	AA355201	ESTs	1.2	SS,TM	
	N78717	H.sapiens mRNA for translin	1.5 -	?	
	N73808	ESTS	5	?	
	U86782	Human 26S proteasome-associated pad1	2,2	other	
	AA234817		1.3	other	
15	D13666	Homo sapiens mRNA for osteoblast specific	7.5	SS,	
	AA236177	ESTs	7.1	?	
	U50648		4.1	?	
	M28211		2.9	other	
	AA446949	ESTs	2.2	other	
20	W03007		1.2	other	
	W61011		1.2	other	
	W87544	ESTs	1.2	other	
	X02751	Neuroblastoma RAS viral (v-ras) oncogene homolog		?	
	Z14077		1.2	other	
25	Z38839		1.2	?	
	AA410894		1.7	other	
	AA504499	ESTs Highly similar to probable chloride channel 3 [h	l.sap	1.3	other

TABLE 7A

Table 7 A shows the accession numbers for those pkeys lacking unigeneID's for Table 7. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (Double Twist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number:

Unique Eos probeset identifier number

Accession:

Gene cluster number Genbank accession numbers

15

Pkey CAT number

Accession

102481 31281_-28

U50360 AA127818

105032 genbank_AA127818 409487 1134778_1 20

H19886 AW402806 T10231

TABLE 8: Figure 8 from BRCA 001-1 US

5 Table 8 shows genes upregulated in tumor tissue compared to normal breast tissue.

Specifically, one column shows the ratio of expression of the indicated gene in breast tumor tissue compared to other body tissues, and another column shows the ratio of expression of the indicated gene in breast tumor tissue compared to normal breast tissue.

10						
	Pkey:	Un	ique Eos probe	set identifier number		
	ExAcon:	Ex	emplar Access	ion number, Genbank accession number		
	Unigene	ID: Un	igene number			
1.	Unigene		igene gene title			
15	R1:	Ra		normal body tissue		
	R2:		Ratio of tun	nor to normal breast tissue		
	Pkey	ExAccn	UnigeneiD	Unigene Title	R1	R2
20	100075	AF152333	Hs.284160	protocadherin gamma subfamily B, 4	1	3.8
	100229	AV652249	Hs.180107	polymerase (DNA directed), beta	1.7	5.3
		D38500		postmelotic segregation increased 2-like	0.8	4.8
		BE160081		S100 calcium-binding protein A11 (calgiz	3.2	2.3
25		Al907114	Hs.71465	squalene epoxidase	3.3	1.4
25		X51501	Hs.99949	prolactin-induced protein	11.9	0.4
		AA019521	Hs.301946		3.8	1.2
		X77343		transcription factor AP-2 alpha (activat	9.4	9.4
		X02761		fibronectin 1	3	7.8
20		AA383256	Hs.1657	estrogen receptor 1	4.4	4.4 3.9
30		U01351	Hs.75772	nuclear receptor subfamily 3, group C, m	1	3.9 4
		K01160 AA382524	Hs.250959	NM_002122:Homo sapiens major histocom	0.8	4.1
		NM 002923			1,2	12
		NM_006262		regulator of G-protein signalling 2, 24k peripherin	3.1	1.1
35		L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	4.4	0.6
55		Al186220	Hs.83164	collagen, type XV, alpha 1	3.1	3.4
		AW468397		S100 calcium-binding protein A8 (calgran	0.9	4.2
		M21305	113.100000	gb:Human alpha satellite and satellite 3	29.9	0.3
	-	AA310162	Hs.169248	cytochrome c	0.8	4.9
40		M33552	Hs.56729	lysosomal	1	5.9
	101600	BE561617	Hs.119192	H2A histone family, member Z	2.8	4
	101624	M55998		gb:Human alpha-1 collagen type I gene, 3	3.1	1.7
	101674	NM_002291	I Hs.82124	laminin, beta 1	1.5	4.1
	101861	AA350659	Hs.83347	angio-associated, migratory cell protein	3,1	1.4
45	101977	AF112213	Hs.184062	putative Rab5-interacting protein	1.3	6.9
	102193	AL036335	Hs.313	secreted phosphoprotein 1 (osteopontin,	1.9	4.9
	102199	AA334592	Hs.79914	lumican	2.2	3.8
		AF015224	Hs.46452	mammaglobin 1	4.2	0.7
		NM_003480		Microfibni-associated glycoprotein-2	1.1	4.2
50		NM_001394		dual specificity phosphatase 4	4.5	0.5
		U96759		von Hippel-Lindau binding protein 1	1.4	4.2
		Al379954	Hs.79025	KIAA0096 protein	0.9	3.9
		BE244588	Hs.6456	chaperonin containing TCP1, subunit 2 (b	1.5	10.9
55		R50032		collagen, type VI, alpha 2	2.2	6.2
55		AW293542	Hs.75309	eukaryotic translation elongation factor	5.6	5.7
		X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	3.7 1.3	0.5 4
		X69089	Hs.79227	myomesin (M-protein) 2 (165kD)	1.3	3.8
		D38616	Hs.54941 Hs.82359	phosphorylase kinase, alpha 2 (liver)	0.8	3.6 4.6
60		X83492 BE536700	Hs.4888	tumor necrosis factor receptor superfami	0.8	8
OU		BE536700 T34708		seryi-tRNA synthetase Sec23 (S. cerevisiae) homolog A	1.1	5.1
•		Y00815	Hs.75216	protein tyrosine phosphatase, receptor t	3.7	1.2
		Z14244	Hs.75752	cytochrome c oxidase subunit VIIb	0.9	4.4
	100040	- 176 77	113.13132	Systemosine o Oxidade addustri 4 lib	4.5	-11-4

	103658	NM_000088	Hs.172928	collagen, type I, alpha 1	3.2	3	
		AA084874		gb:zn13e04.r1 Stratagene hNT neuron (937	0.9	10	
	103774	H24185	Hs.92918	hypothetical protein	1.9	15. 9	
_	103821	AA095971	Hs.198793	Homo sapiens cDNA: FLJ22463 fls, clone H	1.2	3.9	
5		BE439604	Hs.24322		1.4	3.9	
		AW130242		hypothetical protein FKSG44	1.6	4.1	
		AK001913	Hs.7100	hypothetical protein	1.5 7	4.3 7	
		AF183810 AB040927	Hs.26102	opposite strand to trichorhinophalangeal KIAA1494 protein	2	4.6	
10		AB002347	Hs.15303		0.7	4.5	
10		AW583693		N-terminal acetyltransferase complex ard	3.3	3.3	
		AW365522		hypothetical protein PRO2219	2.3	4.2	
		AW804296	Hs.9950	Sec61 gamma	3.1	7	
	104425	AF283775	Hs.35380	x 001 protein	4	1.3	
15	104432	X51501	Hs.99949	prolactin-induced protein	3.8	0.6	
		AW966728	Hs.54642	methlonine adenosyltransferase II, beta	0.8	6.7	4.0
		AK001731		Homo sapiens mRNA; cDNA DKFZp586H092		1.7	4.8
		W94824	Hs.11565	_	2 1.9	7.5 7.4	
20		AW630488 AF123303	Hs.24713	protease, serine, 23 hypothetical protein	1.1	6.3	
20		R82252		protein kinase (cAMP-dependent, catalyti	1.2	4	
		AW270555		hypothetical protein	1.4	3.9	
		AA960961		zinc finger protein 83 (HPF1)	1.5	4.2	
		AA305351		uncharacterized hypothalamus protein HAR	1.1	4,1	
25	104849	Al279065	Hs.241507	ribosomal protein S6	1.3	4.6	
		AL133035	Hs.8728	hypothetical protein DKFZp434G171	1.2	3.6	
		W70164	Hs.20107	ESTS	0.8	4.2	F 4
		AA058630	Hs.29759	RNA POLYMERASE I AND TRANSCRIPT RE		1.7	5.1
30		W03831	Hs.20597 Hs.30627	host cell factor homolog	0.8 0.7	5.4 6.8	
30		W44626 AW955089		ESTs Novel human gene mapping to chomosome 2:		1 3.9	
		BE298808	Hs.33363	DKFZP434N093 protein	3.3	3.3	
		AW076098	Hs.74316	desmoplakin (DPI, DPII)	1.2	3.7	
		AB029020		KIAA1097 protein	1.1	5.5	
35		AI392640	Hs.18272	amino acid transporter system A1	3.2	1.4	
	105030	BE613061	Hs.337772	Homo sapiens, Similar to RIKEN cDNA 0610		11.4	
		N39760	Hs.8859	Homo sapiens, Similar to RIKEN cDNA 5830		7.2	
		BE410438	Hs.9006	VAMP (vesicle-associated membrane protei	1.1	3.5	
40		AF146277		CD2-associated protein	1.2	10 8.3	
40		AA313825 BE407961	Hs.21941 Hs.18271	AD036 protein golgi phosphoprotein 3	3.6 1.7	6.8	
		AI554929		ATPase, H+ transporting, lysosomal (vacu	1.1	3.7	
		BE243327		chromosome 22 open reading frame 5	1.5	4	
		AI015709		Homo sapiens mRNA; cDNA DKFZp586I2022		1.5	14
45		W20027	Hs.23439	ESTs	4.3	2.9	
	105432	W03516	Hs.76698	stress-associated endoplasmic reticulum	1.5	5	
		AA252372	Hs.12144	KIAA1033 protein	1.2	3.6	
		AL137257	Hs.23458	Homo sapiens cDNA: FLJ23015 fls, clone L	1.7	15.8	
50		AI805717	Hs.28785	CGI-43 protein microfibrillar-associated protein 3	2 1.3	4.8 3.9	
50		AL037715 AB040884		KIAA1451 protein	2.7	11.4	
		AB024334	Hs.25001	tyrosine 3-monooxygenase/tryptophan 5-mo	1.3	6.1	
		BE504200	Hs.30127	hypothetical protein	1.7	4.5	
		AA788946	Hs.16869	ESTs, Moderately similar to CA1C RAT COL	3.9	24.6	
55	105812	BE614149	Hs.20814	CGI-27 protein	1.8	3.6	
		AI559444	Hs.293960		1.9	6.6	
		AA329449	_	twisted gastrulation	1.5	4.3	
		A1827976	Hs.24391	hypothetical protein FLJ13612	3.8	1.9 4	
60		BE392914	Hs.30503 Hs.26136	Homo sapiens cDNA FLJ11344 fis, clone PL hypothetical protein MGC14156	1.7 1.7	7.4	
UU		AW028485 AL137728	Hs.12258	Homo sapiens mRNA; cDNA DKFZp434B092		1.2	3.8
		AB033075	Hs.10669	development and differentiation enhancin	1.3	4.6	0
		AB030656	Hs.17377	coronin, actin-binding protein, 1C	1.1	5.9	
		A1690586	Hs.29403	hypothetical protein FLJ22060	2	4.6	
65	106012	A1240665	Hs.8895	ESTs	4.1	1.2	
		NM_001329		C-terminal binding protein 2	2.6	7	
	106070	T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	1.4	10.7	

	106083	H62087	Hs.31659	thyroid hormone receptor-associated prot	1.5	3.6	
		AA425414	Hs.33287	nuclear factor I/B	5.4	1.2	
	106255	BE613206	Hs.279607	calpastatin	1.8	4	
-		BE568205	Hs.28827	mitogen-activated protein kinase kinase	5.1	6.1	
5		AK000274		HDCMA18P protein	1.2	5.9	
		AW051564		patched related protein translocated in	1.8	5.4	
		BE044325		U6 snRNA-associated Sm-like protein	2.3	11.2	
		N88604	Hs.30212	thyroid receptor interacting protein 15	1.2	3.6	
10		H09548	Hs.5367	ESTs, Weakly similar to I38022 hypotheti	0.9	4.4	
10		AA459480	Hs.23956	hypothetical protein FLJ20502	1.3 1.6	3.6 7.3	
		BE387614 AA741038	Hs.25797 Hs.6670	splicing factor 3b, subunit 4, 49kD ESTs	1.7	6.1	
		AA206079	Hs.6693	hypothetical protein FLJ20420	1	5.4	
		AA487416		Homo sapiens cDNA: FLJ23111 fis, clone L	1.6	5.4	
15		BE185536		molecule possessing ankyrin repeats indu	3.3	1.2	
10		BE503373		hypothetical protein FLJ13576	1.4	6.3	
	106940			hypothetical protein FLJ10120	3.3	1.8	
		AF216751	Hs.26813	CDA14	3	3	
		BE391904	Hs.12482	glyceronephosphate O-acyltransferase	1.7	7.6	
20		BE147611	Hs.6354	stromal cell derived factor receptor 1	1.2	4.3	
		Al289507		hypothetical protein FLJ23399	1.8	6.5	
	107222	BE172058	Hs.82689	tumor rejection antigen (gp96) 1	1.2	6.9	
	107233	BE267795	Hs.22595	hypothetical protein FLJ10637	1.4	3.5	
	107295	AA186629	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6	4.3	
25	107679	AA011510	Hs.60512	ESTs	1.8	4	
		AA027229	Hs.61329	ESTs, Weakly similar to T16370 hypotheti	1.3	3.5	
		AF109219		phosphatidylinositol glycan, class N	1.6	3.5	
		AW368993		Homo sapiens clone CDABP0086 mRNA sequ		1.8	8.1
20		AA291440	Hs.73149	paired box gene 8	1.1	3.5	
30		AA093668	Hs.28578	muscleblind (Drosophila)-like	0.7	5.6 1.2	5.6
		AI283611 AW068579		ESTs, Weakly similar to HMG1_HUMAN HIGH Homo sapiens mRNA; cDNA DKFZp564A072		3.1	6.9
		AW000379 AI879238	Hs.7780	collapsin response mediator protein-5; C	1.5	4.6	0.5
		AA333660	Hs.71331	hypothetical protein MGC5350	1.5	4	
35		AW151340	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU S		6.3	4.7
55		AA074374	Hs.67639	ESTs	1.3	3.8	•••
		AF086070	Hs.237519		1	3.6	
		AA079487		gb:zm97f08.s1 Stratagene colon HT29 (937	1.5	3.6	
		AA079500		gb:zm96h10.s1 Stratagene colon HT29 (937	1.1	4.3	
40		M23114	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	2	4.9	
	108641	AA112059	Hs.429	ATP synthase, H+ transporting, mitochond	1.1	3.5	
	108668	AA058522	Hs.185751	ESTs	1.2	3.6	
		AA036725	Hs.61847	ESTs	1.4	3.6	
4.5		AK001332	Hs.44672	hypothetical protein FLJ10470	1.4	3.5	
45		AA133456		glucocorticold receptor DNA binding fact	1.2	4	
		BE276891		retinolc acid induced 3	1.3	3.6	
		AA152312	Hs.72047	ESTs	1.1	4.1 3.5	
		A1732585	Hs.22394	hypothetical protein FLJ10893	1.2 1.3	5	
50		AA167512 BE220601	He 201007	gb:zp10f12.s1 Stratagene fetal retina 93 hypothetical protein FLJ13033	4	6.1	
50		BE179030	Hs.64239	Human DNA sequence from clone RP5-1174h		1.7	7.4
		AA878923		hypothetical protein FLJ21016	3.8	7.7	• • •
		AA366263	Hs.72531	hypothetical protein FLJ11838	1.9	4	
		AA173942		Homo sapiens mRNA; cDNA DKFZp564H191		3.7	1.3
55		BE075297	Hs.6614	ESTs, Weakly similar to A43932 mucin 2 p	4.6	7.4	
	110107	AW151660	Hs.31444	ESTs	1.2	3.5	
	110411	AW001579	Hs.9645	Homo sapiens mRNA for KIAA1741 protein,	3.7	3.3	
	110731	NM_014899	Hs.188006	KIAA0878 protein	2.8	3.7	
60		N21207	Hs.182999		1.6	3.5	
60		BE242691	Hs.14947	ESTs	3.1	1.2	
		AI753230		hypothetical protein DKFZp564K142	1.9	7.5	
		AI681293	Hs.12186	hypothetical protein FLJ22558 hypothetical protein FLJ10704	2	4 3.8	
		AK001566 BE301871	Hs.23618	mannosyl (alpha-1,3-)-glycoprotein beta-	1.1 1	8.2	
65		BE314949	Hs.4867 Hs.87128	hypothetical protein FLJ23309	3.3	6.1	
UJ		R27975	Hs.269401		1.2	5.4	
		AF131784	Hs.25318	Homo saplens clone 25194 mRNA sequence		0.8	
		101701					

		NM_014906			1	5.4
		NM_014927		KIAA0902 protein	1	3.8
		AW137198		Phosphatidylglycerophosphate Synthase	1.4	3.5
5		R49499	Hs.138238		1.5 4.6	3.6 2
5		NM_003655 AW500106	Hs.5637 Hs.23643		3.3	10.5
		Z42387	Hs.83883		3.2	3
		T16971		ESTs, Weakly similar to A43932 mucin 2 p	3.7	10.8
		AF019226	Hs.8036		4.5	3.7
10		AW160683		hypothetical protein	1.2	4.4
		AF143321	Hs.15572		0.9	3.6
		AL042936	Hs.211571		1.1	3.5
	113531	AK001898	Hs.16740	hypothetical protein FLJ11036	1.2	3.9
	113604	Al075407	Hs.296083	ESTs, Moderately similar to I54374 gene	1.7	5.3
15	113674	NM_014214	Hs.5753	inositol(myo)-1(or 4)-monophosphatase 2	0.8	6.1
		W30681		Homo sapiens cDNA: FLJ22130 fls, clone H	1.7	6.2
		AW243158	Hs.5297	DKFZP564A2416 proteIn	1.2	4.6
		BE255499	Hs.3496	hypothetical protein MGC15749	1.5	4
20		W17056	Hs.83623	nuclear receptor subfamily 1, group I, m	3.8	1
20		AA345519	Hs.9641	complement component 1, q subcomponent,	1.2	4.7 4.3
		Al342493	Hs.24192	Homo sapiens cDNA FLJ20767 fls, clone CO	1.1	4.3
		BE179882 N58309	Hs.19575	glutathione peroxidase 3 (plasma) CGI-11 protein	1.6	9.2
		AA075488	ns. 1937 3	gb:zm88d01.s1 Stratagene ovarian cancer	1.6	3.7
25		AI929382	He 252692	hypothetical protein FLJ20343	1.4	4
23		T10446	Hs.95388	ESTs	1	4.3
		AB037858		hypothetical protein FLJ10337	1.6	9.2
		AV660012		hypothetical protein FLJ10788	1.4	5.2
	115096	A1683069	Hs.175319		3.7	1
30	115518	BE541042	Hs.23240	Homo saplens cDNA: FLJ21848 fis, clone H	3.2	4.2
	115646	N36110		solute camer family 2 (facilitated glu	1.5	3.9
		AW582256	Hs.91011	anterior gradient 2 (Xenepus laevis) hom	1.3	5.9
		AW410233		YME1 (S.cerevislae)-like 1	1.7	6.6
25		AB037836		KIAA1415 protein	1.5	9.1
35		BE383668	Hs.42484	hypothetical protein FLJ10618	0.9 1.6	4.3 5.5
		BE395293	Hs.94491	hypothetical protein FLJ20297	3.2	2.4
		Al129767 Z24854	Hs.42299	guanine nucleotide binding protein (G pr ESTs	0.8	4.7
		Al371223			2.4	3.9
40		AF191018	Hs.279923	.,	5.5	5.5
. •		AA313607	Hs.58633	Homo sapiens cDNA: FLJ22145 fis, clone H	5	1.3
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	8.7	4.5
		D21262	Hs.75337	nucleolar and coiled-body phosphprotein	3.2	6.9
	116579	AW888411	Hs.81915	leukemia-associated phosphoprotein p18 (3.2	3
45	116589	Al557212	Hs.17132	ESTs, Moderately similar to I54374 gene	3.1	8.3
		H25836		ESTs, Moderately similar to unknown [H.s	3.2	4.5
		N25929	Hs.42500	ADP-ribosylation factor-like 5	7	5.5
		N20066		PTPRF interacting protein, binding prote	1.2	6.2
50		M18217		Homo sapiens cDNA: FLJ21409 fls, clone C	4.5	2.4
50		Al383467	Hs.44597	ESTS	1.4 4.3	4.2 0.5
		U59305	Hs.44708	Ser-Thr protein kinase related to the my butyrate-induced transcript 1	2.1	5.7
		AF161470	Hs.47166	HT021	3.6	7.7
		BE327311 N66845	110.41 100	gb:za46c11.s1 Soares fetal liver spleen	4.2	0.5
55		AL353944	Hs.50115	Homo sapiens mRNA; cDNA DKFZp761J1112		3.5
00		N67343		gb:yz50b07.s1 Morton Fetal Cochlea Homo	2.1	3.8
•		AF142419	Hs.15020	homolog of mouse quaking QKI (KH domain	3.7	1.5
		BE048061	Hs.37054	ephrin-A3	3	1.1
		BE218319	Hs.5807	GTPase Rab14	1.1	5.6
60		BE041667		Homo sapiens cervical cancer suppressor-	1.4	4.3
		AI905687	Hs.2533	EST	3.2	1
	119940	AL050097		DKFZP586B0319 proteIn-	4.3	0.7
	119943	BE565849	Hs.14158	copine III	3.5	1.9
<i>C</i>	120407	AA235207	HS.250456	hypothetical protein DKFZp762F2011	1.5 4	3.7 1.4
65	120493	AW968080 AF150208	∏S. 102939	Homo sapiens clone 24630 mRNA sequence damage-specific DNA binding protein 1 (1	1.6	6.8
	1200//	AA350781	Hs.96967	ESTs	1.1	3.6
	12000/	, 0.10001.01	. 10.00007			

3.3

	121368	BE262956	Hs.178292	KIAA0180 protein	1.5	4.1	
	121603	AA416785			2.2	5.5	
	121723	AA243499		•	3.4	3.2	
_	122223	AF169797		• •	3.9	3.9	
5		AB032948			1.4	7.1	
		AI718702			1.4	3.7	
		AF121856		- •	1.2	4.9	
		AF161426		*, .	2.4	3.6	
10		AA421581	Hs.178443		0.9	5.2	
10		W28673			1.3	5.1	
		AA608657			2.1	5.2	
		AA608751		3	2.1	9.3	
		AI932318		ESTs, Moderately similar to H2BL_HUMAN H		3.6	
1.5		AL050184			1.1	3.5	
15		AF084555			1.4	3.8	
		BE563957			1.9	11.2 4.4	
		AB037860			1.5 14.8	11.5	
		BE387335			1.2	6.2	
20		AW195237	Hs.7734		2.5	12.7	
20		BE300094		erythrocyte membrane protein band 7.2 (s	2.5 1	4.1	
		AU077333			1.5	8.4	
		BE613340 AK001552		GTP-binding protein	1.8	10.2	
		D87454		KIAA0265 protein	1.1	4.8	
25		N39016		ESTs, Weakly similar to ALUC_HUMAN !!!!	1.3	4.1	
23		N48000	113.200000		2.7	4.3	
		D54120	He 146409	cell division cycle 42 (GTP-binding prot	2.1	5.7	
		Al393320	Hs.104573		1	4.1	
		H66409	Hs.108275		1.4	4	
30		AL036596			0.7	4	
50		AA749315	Hs.77171	minichromosome maintenance deficient (S.	1.1	3.5	
		H60193		DKFZP586C1324 protein	1.4	3.6	
		Al680737		Homo sapiens cDNA FLJ11918 fis, clone HE		9.9	
		BE270465			0.7	4	
35		AW408586	Hs.91052	ESTs, Moderately similar to ALU5_HUMAN A	0.9	3.6	
		BE410405		calpain 2, (m/ll) large subunit	1.3	3.9	
		R44357		hypothetical protein FLJ20736	1.8	4.2	
	124842	R56485		gb:yg93h09.s1 Soares Infant brain 1NIB H	1	3.6	
	124940	AF068846	Hs.103804	heterogeneous nuclear ribonucleoprotein	3.2	3.4	
40	124949	AI903210	Hs.336780	tubulin, beta polypeptide	1	4.4	
	124960	AL023513	Hs.194766	seizure related gene 6 (mouse)-like	0.9	5.2	
	124995	T52700	Hs.110044	ESTs	0.9	3.5	
	125030	AA610577	Hs.187775	ESTs	1.2	5	
	125034	BE548446	Hs.5167	Homo sapiens mRNA; cDNA DKFZp434F152		1.5	3.7
45	125058	T83731	Hs.3343	phosphoglycerate dehydrogenase	0.9	6	
	125076	AA973971		gb:oq02h08.s1 NCI_CGAP_Lu5 Homo sapien		1 3.7	
	125090	T91518		gb:ye20f05.s1 Stratagene lung (937210) H	3.2	2.5	
•		AA570056	Hs.122730	ESTs, Moderately similar to KIAA1215 pro	5.3	6.6	
50		W38419		gb:zc78a07.s1 Pancreatic Islet Homo sapi	0.9	6.1	
50		AA837043	Hs.143669		1.1	4.3	
		AK000669		TRF2-interacting telomeric RAP1 protein	1.1	4.1	
		AL020996	Hs.8518	selenoprotein N	1.1	3.8 3.6	
		R40815		ESTs, Weakly similar to 2004399A chromos	1	7.8	
E E		W67577	Hs.84298	CD74 antigen (invariant polypeptide of m	1.2	4.9	
55		H05635		topoisomerase-related function protein 4	1	4.8	
		AW884980		triple functional domain (PTPRF interact	1.3	16.1	
		BE612888		myosin regulatory light chain a disintegrin and metalloproteinase doma	1.1 1.4	5.3	
		W27235	Hs.64311	short coiled-coil protein	2.4	8.7	
60		Z45258	Hs.76550			1.8	4.6
UU		AW630088		high density lipoprotein binding protein	1.9	3.8	****
		AW504721 AW160399	Hs.30376	hypothetical protein	1.4	4.1	
		BE384361		ESTs, Weakly similar to JC5024 UDP-galac	2	3.7	
		AA057593		hypothetical protein FLJ14735	1.3	4.1	
65		AA340277	Hs.10248			5	
~~		AI243596	Hs.94830	ESTs, Moderately similar to T03094 A-kin	4.3	0.9	
		J04182		lysosomal	1.5	4.7	
		· · · -	, ,				

	128453	X02761	Hs.287820	fibronectin 1	1.2	4.3	
	128460	T16206	Hs.237164	ESTs, Highly similar to LDHH_HUMAN L-LAC	3.1	44.4	
	128491	H08379	Hs.165563	hypothetical protein DKFZp434N1429	0.6	13.1	
_	128495	NM_005904	Hs.100602	MAD (mothers against decapentaplegic, Dr	1.3	4	
5	128546	NM_003478	Hs.101299		1	5.1	
	128574	AI185977	Hs.38260	ubiquitin specific protease 18	0.8	4	
	128611	NM_014721	Hs.102471	KlAA0680 gene product	1.3	3.7	
	128652	AA432202	Hs.103147	hypothetical protein FLJ21347	1.4	3.9	
	128653	D87432		solute carrier family 7 (cationic amino	1.2	3.6	
10	128655	Al246669	Hs.324275	WW domain-containing protein 1	0.8	4.1	
	128684	BE246444		hypothetical protein FLJ20396	3	1.6	
	128717	AK001564	Hs.104222	hypothetical protein FLJ10702	2.8	4.8	
	128774	AA476220		CD81 antigen (target of antiproliferativ	1.1	10.6	
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	1	3.8	
15		AA194554		ATPase, H+ transporting, lysosomal (vacu	5.3	5.3	
	128827	A1638184	Hs.106334	Homo sapiens clone 23836 mRNA sequence		5.3	
	128840	Al917602	Hs.106440	ESTs	1	4.5	
	128869	AA768242	Hs.80618		8.0	3.6	
••		D60985		DKFZP566D193 protein	4.6	3.7	
20	128890	Al222020		CocoaCrisp	3	1.5	
		AK000140		hypothetical protein	0.2	3.9	
		AA622037		programmed cell death 5	2.5	15.2	
		AF155096		hypothetical protein FLJ20585	4	4	
0.5		AA298958		MDS023 protein	1.2	4.5	
25		AW247536	Hs.10729		1.4	5	
		AW953622	Hs.223025	RAB31, member RAS oncogene family	2.3	5.6	
		AB020716	Hs.107362	KIAA0909 protein	0.9	3.9	
		AW271217		Homo sapiens cDNA FLJ 14028 fis, done HE		3.6	• •
20		AA258924		NM_002495*:Homo sapiens NADH dehydroge		0.8	3.8
30		A1770025		hypothetical protein FLJ22059	1.2	5.7	
	129009	•		Homo sapiens cDNA FLJ14368 fis, done HE		9.9	
		AA371156		DKFZP564M112 protein	2.4	3.8	
		A1634522		KIAA1268 protein	1.2	3.8	
25		AW504486		sterol regulatory element binding transc	1.2	5.5	
35		BE543205		DKFZP586A0522 protein	0.5	3.7	
		AB002450		CGI-109 protein	1	5.2	-
		AW881089		Homo sapiens mRNA; cDNA DKFZp566M094		1.5	7
	129151			C-terminal binding protein 2	2.1	9.7	
40		AA335362		Empirically selected from AFFX single pr	0.9	8.6	
40		M18916		glucosidase, beta; acid (includes glucos	1.1	3.5	
		BE542214	Hs.109697		1.1	12.8	
		W57656		ubiquitin-like 5	3.2	5.1	
		A1878857		hematological and neurological expressed	1.9	5.7	
45	_	BE169531		TAK1-binding protein 2; KIAA0733 protein	1.2	6.6	
45	129247			CGI-131 protein	1.5	3.5	
		AA344367		Empirically selected from multiple AFFX	1	5.4	
		AA250970		poly(A)-binding protein, cytoplasmic 1-l	1.3	4.1	
		AF077200		hypothetical protein ras homolog gene family, member H	1.6	3.9	
50		AA357185		putative L-type neutral amino acid trans	1.8	4.2 6.1	
50		AB007896	Hs.110		1.1 2.5	4.8	
		AA318224	Hs.296141	ribosomal protein L26 homolog	1.6	5.1	
		W94197					
		AF189062	Ha 170177	tumor metastasis-suppressor Meis1 (mouse) homolog	1.8 0.9	6.5 4	
55		AW511656	Un 110776	solute carrier family 12 (sodium/potass)	1.4	9.2	
55	129362	BE278964		CGI-111 protein	1.3	4.8	
		AA318271		hypothetical protein	i	4.1	
		AA016188		hypothetical protein	1.8	10.7	
		AI498631	He 111334	femtin, light polypeptide	1.1	4.8	
60		W92931	He 250800	heat shock factor binding protein 1	1.8	9.3	
JU		AL050260		DKFZP547E1010 protein	1.0	5.5	
	-		He 202772	FSHD region gene 1	1.1	4.2	
		NM_004477 AA449789		connective tissue growth factor	1.9	6.8	
		AI631811		STRIN protein	1.1	9.7	
65		AA769221		delta-tubulin	1.1	4.3	
00	129545			cisplatin resistance related protein CRR	1	4.2	
		AW517695		junctional adhesion molecule 1	2.3	3.5	
	120010	A1011000		James in addance diagona			

	129606	AW968941	Hs.166254	hypothetical protein DKFZp5661133	2.4	4.4
	129619	AA209534	Hs.284243	tetraspan NET-6 protein	3.2	13
		D79338	Hs.239720	CCR4-NOT transcription complex, subunit	1.6	4.6
_		AL110212	Hs.301005	purine-rich element binding protein B	1.1	5.7
5		AB020335		sel-1 (suppressor of lin-12, C.elegans)-	0.9	4.3
		A1207406	Hs.11866		1,9	4.8
-		AW889132	Hs.11916	ribokinase	0.9	4.1
		U53209	Hs.24937	transformer-2 alpha (htra-2 alpha)	1.3	4.7
10		M26939		collagen, type III, alpha 1 (Ehlers-Dani	4.7	3.7
10		U46386	Hs.12102	sorting nexin 3	1.2 1	3.6
		AL050272 BE397454	Hs.12305	DKFZP566B183 protein		8.9 3.6
		BE218319	Hs.5807	Homo sapiens clone 24707 mRNA sequence GTPase Rab14	2.9	5.1
		M62839	Hs.1252	apolipoprotein H (beta-2-glycoprotein I)	0.3	5.1
15		AF052112	Hs.12540	lysosomal	1.6	8.8
10		AL080084		CGI-100 protein	0.9	5.3
		AW410233		YME1 (S.cerevisiae)-like 1	1.8	9.9
		NM_014840		KIAA0537 gene product	0.9	3.6
		AA626937		hypothetical protein MGC2594	1.4	9.5
20		Z43161		30 kDa protein	1.1	6.3
	129904	AL119499	Hs.13285	neuronal potassium channel alpha subunit	1	3.5
	129917	M30773	Hs.278540	protein phosphatase 3 (formerly 2B), reg	2	5.1
	129976	X14008	Hs.234734	lysosomal	0.9	4.9
		Z14221		gb:H.sapiens germline transcript of lg h	1.2	3.6
25		R15917		Homo sapiens clone 24629 mRNA sequence		1.3
		BE277024	Hs.146381	RNA binding motif protein, X chromosome	1.6	3.8
		X57815.comp		Empirically selected from AFFX single pr	1.2	8.2
		M93143		plasminogen-like	1.4	7.9
20		H97878		zinc finger protein 36 (KOX 18)	1.4	12.3
30		AK001635	Hs.14838 Hs.14896	hypothetical protein FLJ10773 DHHC1 protein	0.2 1 ·	4.6 4.1
		W61005 AA916785		splicing factor proline/glutamine rich (1.2	5.3
		T47294		X-box binding protein 1	3.8	0.8
		NM_005095		zinc finger protein 262	1	4.2
35		BE094848	Hs.15113		0.5	4
		R42678		KIAA0564 protein	1	3.7
		M23115	Hs.1526	ATPase, Ca++ transporting, cardiac muscl	0.4	4.4
		BE278370	Hs.15265	heterogeneous nuclear ribonucleoprotein	1.7	7.5
	130215	BE301883	Hs.152707	glioblastoma amplified sequence	1	5.6
40	130232	U29463		gb:Human cytochrome b561 gen	1.2	4.2
	130252	U92014	Hs.153527	Homo sapiens pTM5 mariner-like transposo	1.3	3.6
		W78907	Hs.15395	similar to arginyl-tRNA synthetase (argi	1.5	4.4
		AB040914		KlAA1481 protein	2.9	7.5
45		AW067800		stanniocalcin 2	3.2	0.2
45		AW842182		small inducible cytokine A5 (RANTES)	1.4	10.6
		AW163518		huntingtin interacting protein 2	1.7	11.7
		AA852868		KIAA0171 gene product	1.1	5
		NM_006245		protein phosphatase 2, regulatory subuni	1.4	4.3 7.6
50		AW362955	Hs.15641 Hs.12457	Homo sapiens cDNA FLJ14415 fis, clone HE	0.9	4.1
50		R44163 AB007915		hypothetical protein FLJ10814 KIAA0446 gene product	1	3.8
		AI598022		TAR DNA binding protein	1.3	4.7
		AA232119	Hs.16085	putative G-protein coupled receptor	1.2	9.4
		AI652143		hypothetical protein FLJ13111	1	4.1
55		BE242873	Hs.16677	WD repeat domain 15	1.1	3.6
		AL049963		up-regulated by BCG-CWS	0.6	3.8
		AL045128	Hs.1691	glucan (1,4-alpha-), branching enzyme 1	0.9	6.6
		AL042896	Hs.1697	ATPase, H+ transporting, lysosomal (vacu	0.9	3.9
		AW073971		ESTs, Weakly similar to KIAA1204 protein	0.9	6.9
60		Al557212	Hs.17132	ESTs, Moderately similar to 154374 gene	2.6	3.9
	130641	AF158555		glutaminase	1.2	13.8
		Al861791	Hs.278479	TSPY-like	1.3	4
		Al831962	Hs.17409	cysteine-rich protein 1 (intestinal)	2.5	4
65		AL117508		KIAA0737 gene product	1.3	6.2
65		Al928985	Hs.17680	hypothetical protein MGC1314 similar to	1.4	3.9
		R68537	Hs.17962	ESTS	3.2	0.8 4.8
	130094	NM_014827	Hs.17969	KIAA0663 gene product	1.1	4.8

		AA325308	Hs.18016	Homo saplens mRNA; cDNA DKFZp586H032		1.8
		Z98883	Hs.18079	phosphatidylinositol glycan, class Q	1.1	6.7
	130707	AW190925	Hs.203559	hypothetical protein FLJ12701	1.2	4.1
_	130731	Al932971	Hs.18593	Homo sapiens cDNA: FLJ21449 fis, clone C	1.4	6.9
5	130787	AF072813	Hs.252831	reticulon 3	1.2	11.2
	130796	AA088809	Hs.19525	hypothetical protein FLJ22794	1.8	6.8
	130808	NM_001761	Hs.1973	cyclin F	1.3	4.1
	130863	Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.2	5.9
	130902	AB037750	Hs.21061	KIAA1329 protein	1 .	3.8
10	130908	AW195747	Hs.21122	hypothetical protein FLJ11830 similar to	1.3	7.9
	130911	BE409769	Hs.21189	DnaJ (Hsp40) homolog, subfamily A, membe	2.7	3.7
	130913	BE390905	Hs.21198	translocase of outer mitochondrial membr	1.9	4
	130923	H96115	Hs.21293	UDP-N-acteylglucosamine pyrophosphorylas	1.9	10.3
	130959	AB023182	Hs.184523	KIAA0965 protein	1.5	6.8
15	130967	AA393071	Hs.182579	leucine aminopeptidase	1.4	5.5
	130975	AA099923	Hs.283728	PEST-containing nuclear protein	1.3	3.8
	131037	BE243101	Hs.22391	chromosome 20open reading frame 3	1.9	4.1
	131039	D87436	Hs.166318	lipin 2	1.6	3.5
	131060	AA194422	Hs.22564	myosin VI	4.5	5
20	131097	AL137682	Hs.22937	I-kappa-B-interacting Ras-like protein 2	2	3.7
	131101	BE387561	Hs.22981	DKFZP586M1523 protein	1.6 ·	4.5
	131104	W27770	Hs.301756	ESTs, Weakly similar to T31475 hypotheti	0.9	3.5
	131107	BE620886	Hs.75354	GCN1 (general control of amino-acid synt	2.1	4.5
	131109	BE564123	Hs.23060	DKFZP564F0522 protein	1.1	4.6
25	131136	AB033099	Hs.23413	KIAA1273 protein	1.2	4.2
		AW953575		p53-induced protein PIGPC1	4.5	13.5
	131150	X77753	Hs.23582		3.4	0.4
		Al472209	Hs.323117		0.8	4.9
20		AW013807	Hs.182265		3.3	2.4
30		H25094		ESTs, Moderately similar to 138022 hypot	0.6	4
		AW864222		KIAA0997 protein	1.4	3.8
		AW979155		amino acid transporter 2	1.2	8.5
		AL050107	Hs.24341		0.7	4.7
2É		AI815486		Homo sapiens cDNA FLJ20738 fis, clone HE		8.2
35		D89053		fatty-acid-Coenzyme A ligase, long-chain	1.7	3.5
		AW956868		DKFZP564D177 protein	1.3	5.4
		AU077158	Hs.24930		1.6	4.8
		AU077002	Hs.24950		1.4 3.3	4.4 2.2
40		AI750575 AW293399		nuclear factor I/A nuclear receptor co-repressor 1	1.6	3.9
40		NM_006052		Down syndrome critical region gene 3	1.0	11.1
		NM_014810	He 02200	KIAA0480 gene product	5	2
		Al452601		nuclear receptor subfamily 2, group F, m	0.9	3.5
		AW960146		hypothetical protein FLJ12888	1	3.5
45		BE270734	Hs.2795	lactate dehydrogenase A	2	6.5
		AB040927		KIAA1494 protein	1.5	10.7
		AU076408		UDP-glucose dehydrogenase	1.3	4.7
		AF157326		TBP-interacting protein	1.3	4.9
	131555			interferon, alpha-inducible protein 27	1.5	8
50		AA936296		DKFZP586G011 protein	1.8	3.5
		C18825	Hs.29191	epithelial membrane protein 2	1.3	8.2
		D83032	Hs.169984	nuclear protein	2.8	3.9
	131626	BE514605	Hs.289092	Homo sapiens cDNA: FLJ22380 fis, clone H	1.3	11.2
		H03514	Hs.10130		1.3	4.8
55	131697	C19034	Hs.288613	Homo sapiens cDNA FLJ14175 fls, clone NT	3.2	9.7
	131701	AF103798	Hs.30819	hypothetical protein	1.3	5.2
	131703	AW160865	Hs.30888	cytochrome c oxidase subunit VIIa polype	1.3	7.8
	131739	AF017986	Hs.31386	secreted frizzled-related protein 2	10.6	14.7
	131764	A1805664	Hs.31731	peroxiredoxin 5	1.1	3.6
60		AF077036	Hs.31989	DKFZP586G1722 protein	1.6	3.7
	131791			gb:H.sapiens VII-5 gene for immunoglobul	1.1	3.5
		Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU		1.2
		NM_014874	Hs.3363	KIAA0214 gene product	0.6	4.2
		NM_004642	Hs.3436	deleted in oral cancer (mouse, homolog)	2.4	4.9
65		AW207440		degenerative spermatocyte (homolog Droso	2.4	6
		AA772603	Hs.69476	Homo sapiens cDNA FLJ12758 fis, clone NT	1.7	9.2
	131941	BE252983	Hs.35086	ubiquitin specific protease 1	0.5	5.2

	121047	A1402020	11- 400007	TCT-	0.7	
		Al123939	Hs.182997		0.7	4.1
		AA129782	Hs.3576	Homo sapiens mRNA full length insert cDN	0.9	4.8
		AW381148		2,3-bisphosphoglycerate mutase	1.1	6.1
5		AF208856		hypothetical protein	1.3	3.9
3		AF119665		pyrophosphatase (Inorganic)	3.3	6.9
		AF229181		CS box-containing WD protein	0.9	5.2
		AW162336	Hs.3709	low molecular mass ubiquinone-binding pr	1.2	3.6
		BE277910	Hs.3833	3'-phosphoadenosine 5'-phosphosulfate sy	3.2	1.8
10		BE379335	Hs.211594			3.6
10		AF217798	Hs.3850	LIS1-Interacting protein NUDEL; endoolig	0.7	5.2
		A1701457	Hs.38694	ESTs	2	5.3
		NM_016045	Hs.3945	CGI-107 protein	1.2	4.3
		AW960474	Hs.40289	ESTs	3.1	3.1
15		A1752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	1.8	3,7
15		AW961231	Hs.16773	Homo sapiens done TCCCIA00427 mRNA se		1.2
		AL031709		hypothetical protein CAB56184	1.4	4.2
		AA306325	Hs.4311	SUMO-1 activating enzyme subunit 2	2	10.3
		BE177330		Homo sapiens cDNA: FLJ21210 fis, clone C	1.2	4.1
20		U28831	Hs.44566	KIAA1641 protein	5.9	1.6
20		NM_003542	Hs.46423	H4 histone family, member G	5.8	1.5
		AA312135	Hs.46967	HSPCO34 protein	2.1	9.3
	132397	AA021160	Hs.4750	hypothetical protein DKFZp564K0822	1.3	4.6
		AW361383	Hs.260116	metalloprotease 1 (pitrilysin family)	2	4.9
		AW970859	Hs.313503	ESTs	1.2	5
25	132534	BE388673	Hs.5086	hypothetical protein MGC10433	2	3.9
	132540	BE396290	Hs.5097	synaptogyrin 2	1.4	5.1
	132554	AF065391	Hs.194718	zinc finger protein 265	1.2	4
	132575	AV660538	Hs.284162	60S ribosomal protein L30 isolog	3	1.7
	132585	AF029750	Hs.179600	TAP binding protein (tapasin)	1.8	4.7
30		AW606927	Hs.5306	hypothetical protein DKFZp586F1122 simil	1.6	4.9
	132608	AA353044	Hs.5321	ARP3 (actin-related protein 3, yeast) ho	1.8	8.1
		NM 004600	Hs.554	Sjogren syndrome antigen A2 (60kD, ribon	4.2	2
		AI264357	Hs.55405	hypothetical protein MGC16212	1.1	5.3
		AK000868	Hs.5570	hypothetical protein FLJ10006	1.4	5.2
35		BE222975	Hs.56205	insulin induced gene 1	1.1	5.8
	132782			zinc finger protein 222	1.3	3.7
		AB020713	Hs.56966	KIAA0906 protein	2.3	6.3
		AW975748	Hs.5724	sderostin	0.7	7.7
		BE268048		RAB10, member RAS oncogene family	1.8	6.2
40		D63209	Hs.5944	solute carrier family 11 (proton-coupled	1.5	20.8
. •		AA579258	Hs.6083	Homo sapiens cDNA: FLJ21028 fis, clone C	1	3.8
		AW118826	Hs.6093	Homo sapiens cDNA: FLJ22783 fis, clone K	0.7	5.4
		BE263252	Hs.6101	hypothetical protein MGC3178	1.6	4.1
		AI248173		hypothetical protein MGC12936	1	4.2
45		BE539199	Hs.62112	zinc finger protein 207	1.5	4.4
	132990			transcription factor AP-2 alpha (activat	13.9	0.8
	132998			protein tyrosine phosphatase, receptor t	0.6	4.6
		AW499985	Hs.42915	ARP2 (actin-related protein 2, yeast) ho	1.5	11.1
		NM_006379		sema domain, immunoglobulin domain (Ig),	3.5	1
50		AA847843	Hs.62711	Homo sapiens, done IMAGE:3351295, mRNA		4.5
50		AW502761	Hs.30909	KIAA0430 gene product	0.9	5.5
	133056		Hs.6396		1.7	5.3
		Al654133	Hs.30212	jumping translocation breakpoint thyroid receptor interacting protein 15	0.6	4.9
		AK000708		hypothetical protein FLJ20701		
55		AF089816		obromosomo 10 ener readina franco 2	1.2	3.5
55			Hs.6454	chromosome 19 open reading frame 3	1.2	17.5
		AA808177 AV655783	Hs.65228	ESTS	0.9	5.1
			Hs.661	Empirically selected from AFFX single pr	1.1	4.5
		AW955632	Hs.66666	ESTs, Weakly similar to S19560 proline-r	1.5	4.8
۲0		AF231981		homolog of yeast long chain polyunsatura	5.5	5.9
60		AA464362	Hs.6748	hypothetical protein PP1665	1.2	3.7
		AB037773	Hs.6762	hypothetical protein	1.6	8.6
		W32474		RAP2A, member of RAS oncogene family	2.4	4.8
		AL137480	Hs.6834	KIAA1014 protein	1	4.2
65		AW796524	Hs.68644	Homo saplens microsomal signal peptidase	1.3	3.9
65		BE617892	Hs.6895	actin related protein 2/3 complex, subun	1.4	5.4
	133271			H.sapiens mRNA for retrotransposon	3.1	0.7
	133273	142/0/2	Hs.69469	dendritic cell protein	2.5	6.5

	133287	AW797437	Hs.69771	B-factor, properdin	1.3	4	
		BE297855	Hs.69855	NRAS-related gene	1.4	5	
	133292	AA304961	Hs.699	peptidylprolyl isomerase B (cyclophilin	2.2	6.8	
_	133294	AJ001388	Hs.69997	zinc finger protein 238	1.5	4.3	
5		AF116666	Hs.70333	hypothetical protein MGC10753	1.4	6.3	
		X04898		apolipoprotein A-II	0.2	3.6	
		U56979		H factor 1 (complement)	0.6	5	
		BE257758		acid cluster protein 33	1.2 3.7	4.2 5.8	
10		AF245505 AB007916	Hs.72157	DKFZP564I1922 protein KIAA0447 gene product	1.4	5.1	
10		Al738719		hexokinase 2	0.9	6.3	
		AB033061	Hs.73287	KIAA1235 protein	1.2	3.7	
		AL137663	Hs.7378	Homo sapiens mRNA; cDNA DKFZp434G227		0.7	4.8
		M27749		immunoglobulin lambda-like polypeptide 1	1.1	4.3	
15		AF038962	Hs.7381	voltage-dependent anion channel 3	0.7	4.2	
	133501	Al962602	Hs.74284	hypothetical protein MGC2714	3.1	5.9	
	133504	NM_004415	Hs.74316	desmoplakin (DPI, DPII)	4.3	11.5	
		BE562958	Hs.74346	hypothetical protein MGC14353	1.8	19.7	
••		D87452	Hs.74579	KIAA0263 gene product	1.2	5.4	
20		H97991		Empirically selected from AFFX single pr	1.4	3.9	
		Al929645	Hs.225936		8.0	4.9	
	133589			RNA-binding protein S1, serine-rich doma	2	10.8	
		AI423369	Hs.75111	protease, serine, 11 (IGF binding)	2.1	4.5	
25		U10564		wee1+ (S. pombe) homolog	3.3 2.3	1.1 5.6	
43		BE244334 Al301740	Hs.75249	ADP-ribosylation factor-like 6 interacti dihydropyrimidinase-like 2	0.8	13.5	
		H14843		popeye protein 3	1	9.1	
		AJ006239	Hs.75438		0.5	5.8	
	133668			mitogen-activated protein kinase 6	1.1	6.9	
30		AW503116		zinc finger protein 146	1.8	3.8	
		Al352558	Hs.75544	tyrosine 3-monooxygenase/tryptophan 5-mo	1.5	11.1	
	133694	W17187.comp	Hs.232400	heterogeneous nuclear ribonucleoprotein	2	3.9	
	133708	Al018666 ,	Hs.75667	synaptophysin	0.6	3.5	
	133737	AW001130	Hs.75824	KIAA0174 gene product	1.2	7.2	
35		Al929587	Hs.75847	CREBBP/EP300 inhibitory protein 1	1.5	5	
			Hs.75873	zyxin	1.2	4.8	
			Hs.75929	cadherin 11, type 2, OB-cadherin (osteob	3.2	4.1	
				ADP-ribosyltransferase (NAD+; poly (ADP-	2.1	3.8	
40			Hs.76285	DKFZP564B167 protein	1.9 2.6	12.6 6.6	
40			Hs.76293 Hs.76297	thymosin, beta 10 G protein-coupled receptor kinase 6	1	4.9	
	133806		Hs.76325		0.5	3.8	
			Hs.7644	H1 histone family, member 2	1.5	4.5	
		AW630088	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564B1264		3.7	5.6
45		AA345824	Hs.76688		0.3	4.4	
		AA147026	Hs.76704	ESTs	5.5	2.9	
	133863	AI815523	Hs.76930	synuclein, alpha (non A4 component of am	0.6	4.8	
	133887	X07767	Hs.77271	protein kinase, cAMP-dependent, catalyti	1	10.2	
					0.9	4.8	
50			Hs.7753		2.8	10.5	
			Hs.77542	ESTs	1.8	5.6	
			Hs.7756	proteasome (prosome, macropain) 26S subu		6.6	
	133947		Hs.77810	nuclear factor of activated T-cells, cyt	1.5 0.9	3.8 4.3	
55	133987	M54968		v-Ki-ras2 Kirsten rat sarcoma 2 viral on von HippelLindau syndrome	2.3	4.3 4.3	
55		AL040328	Hs.78202	SWI/SNF related, matrix associated, acti	3.3	3.4	
		R48316	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564C121		1.3	5.7
			Hs 143601	hypothetical protein hCLA-iso	1	6.5	0.,
		NM_003470	Hs.78683	ubiquitin specific protease 7 (herpes vi	1.7	3.6	
		AI027881	Hs.7869	lysosomal	1	7.5	
			Hs.78825	matrin 3	1.2	4	
	134095	NM_004354	Hs.79069	cyclin G2	2.7	4.8	
	134098	BE513171	Hs.79086		3.3	2.1	
	134207	Z43039		KIAA0009 gene product	1.3	3.5	
			Hs.80019	programmed cell death 6	1.7	6.9	
	134218		Hs.80205		0.8	5.3	
	134270	X68194	Hs.80919	synaptophysin-like protein	1.4	11.4	

	134277	NM_004369	Hs.80988	collagen, type VI, alpha 3	2.6	3.5
	134280	NM_000712	Hs.81029		1.8	5.8
		AI022650	Hs.8117	erbb2-Interacting protein ERBIN	1.1	3.6
_	134296	R00603	Hs.8128	phosphatidylserine decarboxylase	1.1	5.9
5	134300	NM_001430	Hs.8136	endothelial PAS domain protein 1	0.5	4.8
		AL037800	Hs.8148	selenoprotein T	1.7	7.9
		D50683	Hs.82028		0.8	7.6
		X76534	Hs.82226	5.51	2.2	3.6
10		N22687	Hs.8236	ESTs	1.9	3,6
10		AL035786	Hs.82425	actin related protein 2/3 complex, subun	1.5 1.1	8.3 3.6
		BE512856 Al750762	Hs.109051	SH3 domain binding glutamic acid-rich pr	1.9	4.6
		NM_006416	Hs.82911 Hs.82921	protein tyrosine phosphatase type IVA, m solute carrier family 35 (CMP-sialic aci	1.2	7.5
		AU077196	Hs.82985		6.6	8.7
15		Z23024		Rho GTPase activating protein 1	2	3.9
13		NM_013230		CD24 antigen (small cell lung carcinoma	3.5	1.1
		D86981	Hs.84084	amyloid beta precursor protein (cytoplas	1.5	4.4
		W84869		eukaryotic translation initiation factor	1.2	5.7
		AW960673		ATP synthase, H+transporting, mitochond	1.3	3.9
20	134520	BE091005	Hs.74861	activated RNA polymerase II transcriptio	1.8	4.3
	134528	M23161	Hs.84775	Human transposon-like element mRNA	0.8	5.6
		AI902899	Hs.85155	butyrate response factor 1 (EGF-response	1.4	5
		Al203545		S-phase response (cyclin-related)	0.8	3.9
05		NM_016142		steroid dehydrogenase homolog	1.3	5.7
25		AB033017	Hs.8594	KIAA1191 protein	0.9	3.7
		BE244323	Hs.85951	exportin, tRNA (nuclear export receptor	4 2.2	6.8 4.3
		AW936928	Hs.85963	DKFZP564M182 protein	1.6	3.6
		AA927177 AF078859	Hs.86041 Hs.86347	CGG triplet repeat binding protein 1 hypothetical protein	2.1	3.5
30		AF265208		SWI/SNF related, matrix associated, acti	1.7	4,2
50		AK000606	Hs.8868	golgi SNAP receptor complex member 1	4.4	0.9
		D17530	Hs.89434	drebrin 1	3.1	1.6
		T51986		hemoglobin, gamma G	0.5	4.6
		AA428520	Hs.90061	progesterone binding protein	1.3	3.7
35		J03464		collagen, type I, alpha 2	8.7	17.3
	134865	AA587775	Hs.66295	multi-PDZ-domain-containing protein	1.7	4
	134868	AB020689	Hs.90419	KIAA0882 protein	3.4	0.9
	134874	Al803761	Hs.90458	serine palmitoyltransferase, long chain	1.3	6.9
40		AJ002030	Hs.9071	progesterone membrane binding protein	1.4	9.6
40		R51083	Hs.90787	ESTs	1	10.1
		BE089782	Hs.9877	hypothetical protein	1.9	3.9
		AF005043	Hs.91390	poly (ADP-ribose) glycohydrolase	1 1.4	4.3
		BE560779	Hs.92308	NICE-5 protein Homo sapiens cDNA FLJ11223 fls, clone PL	1.4	10.4 4.1
45		AK002085 AB037835	Hs.92991	KIAA1414 protein	1.2	5.6
43		AW301984		hypothetical protein FLJ12619	1.7	7.6
		AL034344		forkhead box C1	3.2	0.6
		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	4.2	4.1
		AK001887		protein kinase, AMP-activated, gamma 2 n	1.3	4.8
50		AK000967	Hs.93872	*	2	3.7
	135077	AW503733	Hs.9414	KIAA1488 protein	2.8	3.7
	135082	AB017363	Hs.94234	frizzled (Drosophila) homolog 1	2.4	4.8
		T97257	Hs.337531	ESTs, Moderately similar to (38022 hypot	1.4	5.8
		AA132813	Hs.69559	KIAA1096 protein	1.8	8.5
55 i		BE563088	Hs.9552	binder of Arl Two	1.2	6.8
		AB028956	Hs.12144	KIAA1033 protein	3.1	1.4
	135181	BE250865	Hs.279529	•	1.3	7.5
		AA534009	Hs.183487	Interferon stimulated gene (20kD)	1.3	3.8
60		AL038812	Hs.96800	ESTs, Moderately similar to ALU7_HUMAN A	0.9	3.9 8.4
60	135289	AW372569 AA331901	Hs.9788	hypothetical protein MGC10924 similar to hypothetical protein FLJ10097	1	3.8
		T83882	Hs.97927	ESTs	1.2	3.5
	1353/0	AA114212	Hs.9930	serine (or cysteine) proteinase inhibito	2.6	8.9
		Al565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	2.5	5.4
65	135398	M16029	Hs.287270		0.4	7.9
	135399	W79431	Hs.326249	ribosomal protein L22	1.5	4.5
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	1.8

	302665	R99693	Hs.224410	Homo sapiens cDNA FLJ12843 ffs, clone NT	3.6	3.6			
	302892	AW176909	Hs.42346	calcineurin-binding protein calsarcin-1	3.3	1.6			
		AW673106		mitochondrial ribosomal protein L43	0.9	4.2			
_	303131	AW081061	Hs.103180	DC2 protein	3	17.3			
5		AA887146	Hs.8217	stromal antigen 2	6.2	4			
		AA147979		mitochondrial import receptor Tom22	1.2	6.6			
				protein kinase, cAMP-dependent, regulato	1_	3.5			
		BE616412		junctional adhesion molecule 1	1.5	4.7			
10		AA054761	Hs.169149			5.6			
10				CGI-39 protein; cell death-regulatory pr	1.3	3.5			
		AW239226	Hs.65450	reticulon 4	1.2	13.9			
		AF279145	Hs.8966		2	5.1			
					1.3	3.9			
15		NM_015925	Hs.95697	liver-specific bHLH-Zip transcription fa	1.5	6.2			
13				•	2	11.3			
		R94023 AF119043			1.7 3.3	3.6 2.8			
				calmodulin 1 (phosphorylase kinase, delt	1.3	4.7			
		AA523543	Hs.7678	cellular retinoic acid-binding protein 1	1.1	3.7			
20					3.2	2.5			
20		Al355260			2.8	22			
		AW601325		Homo sapiens mRNA; cDNA DKFZp566M063		1.1	5.2		
					1.8	8.8	V. _		
		R23553		hypothetical protein	1.1	5.6			
25		BE395875		mitochondrial carrier homolog 2	1.5	6.1			
			Hs.8997	heat shock 70kD protein 1A	1.3	7.6			
		AB001636	Hs.5683		1.6	6.5			
	437667	BE616412	Hs.286218		1.3	3.5			
	437754	R60366	Hs.5822	Homo sapiens cDNA: FLJ22120 fis, clone H	2	5.7			
30	440252	BE513940	Hs.6101	hypothetical protein MGC3178	1.1	6.2	•		
	441471	AL042986	Hs.7857	erythrocyte membrane protein band	0.5	3.7			
	448292	BE281316	Hs.47334		2.5	4.9			
	449404	H51066	Hs.23581		1.1	3.6			
25					1.4	3.5			
35					4	11.2			
	452685	Al634651	Hs.30250		0.8	5.6			
		RC_H15847_s			1.8	4.8			
		RC_W84712	•		3.5	4.6			
40		X14008_ma1_i	ĺ		0.9	4.5			
40		RC_H86543_f			1.8	6.6			
		H07011			1.8 ESTs	3.9 6.2	0.8		
		RC_AA164586 RC_AA070485			3.4	2.6	0.0		
		RC_H98714_s			1.6	3.5			
45		RC_AA406145	f		ESTs	4.6	3		
		AA458584	_'		3.4	0.4	•		
		AA031548		cell division cycle 42 (GTP-binding protein; 25)		3.1	3.9		
		X02761			3.6	15.2			
		RC_AA487193			4.7	4			
50		R25326			0.9	5			
		RC_AA393805			1.1	8.4			
		RC_AA449333		ESTs	2.9	4.6			
		RC_AA287681			ESTs	1.3	4 .		
		RC_AA490864		ESTs; Highly similar to heat shock factor	1.4	5			
55		RC_C14243_f			1.7	5			
		R21443			1.6	3.7			
		RC_AA251902			2.2	3.8			
•		M21121_s			0.9	9.9			
C O		C00038_s			2.8	4.8			
60		Y00503			3.1	1.1			
		RC_R27006_f			1.6	3.7			
		RC_AA416886			3.1 1.5	3.1 3.7			
		RC_AA460450 RC_AA488433		fibroblast growth factor receptor 2 (bacteria- ESTs; Weakly similar to deduced amino acid	1.5	3. <i>1</i> 4			
65		RC_AA278400					5 mRNA; partial cds	1.5	3.6
05		U28831	-'	Human protein immuno-reactive with anti-PTH		0.6	o marry partial cos		5.5
		RC_AA199588		Homo sapiens actin-related protein Arp3 (ARP		1.8	4.7		
				and and a contraction bearing the first	- •				

	AF006082	Homo sapiens actin-related protein Arp2 (A	RP2)	1.6	10.9
	RC_H90899	desmoplakin (DPI; DPII)	5.4	5.5	
	RC_W95070	desmoplakin (DPI; DPII)	5	2.6	
_	RC_T90946_f	Human mRNA for KIAA263 gene; complete	e cds	1.1	3.9
5	D87258	protease; serine; 11 (IGF binding)	2.4	3.5	
	AA313414_s	ESTs; Weakly similar to cDNA EST EMBL:	T1157	1.5	5.3
	RC_H73484_s	ESTs; Weakly similar to similar to Yeast	1.3	6.3	
	AFFX-HUMISGF3A/M	97935_3		2.3	13.5
	AFFX-HUMRGE/M100	098_5	1.1	7.9	
10	AFFX-M27830_5			0.5	7.4
	AFFX-M27830_5			0.6	5.4
	RC_AA063431_f		ESTs	0.8	4.1
	RC_T63769_f	ferritin; light polypeptide	1.1	3.7	

TABLE 8A

Table 8A shows the accession numbers for those pkeys lacking unigeneID's for Table 8. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset Identifier number CAT number: Gene cluster number Accession: Genbank accession numbers

15

35

40

45

50

60

Pkey CAT number Accessions

	, ney	OAT HUMBE	7000331011	3									
20		116761_1 190299 1	AA079487 AA973971			AA079587	AA079600						
		109698_1	AA075488 AA074510	AA129081 / AA113824 /	AA074851 AA102437	AA070833	AA070143	AA084693	AA084389	AA076373	AA075492	AA062834	AA079519 AA084335
			AA078829	AA079344 /	\A069916	AA079275	AA070914	AA654069	AA081976	AA080957	AA083115	AAU70942	2 AA085296
	123526	genbank_AA6	08657	AA608657							•		
25	123533	genbank_AA6	08751	AA608751									
		genbank_T915		T91518									
		genbank_W38		W38419		•							
		genbank_N66		N66845									
		genbank_N67		N67343									
30	101046	entrez K0116	0K01160									•	
	129982	221 267	Z14221 AW	/381862 M9	7920 AW	101444 Z66	542 M2947	O AW4065	02 X61011	M34024 A	4327072 Z	14166 Z14°	167 Z14165
		-	AW403806	Z14200 AA	383972 Z	14205 Z142	01 M18513	3 Z14202 A	W403684 >	(14584 AF(062221 U43	3760 X6589	92 X65883 X62
			780847 X6										

2107 AF062134 AF062139 X81723 Z80840 X81733 X81743 X81744 X81732 Z80843 AW402942 AW403516 X65919 AF062190 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 U77373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174083 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321 AF103335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115 AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 Al857980 AW368899 Al905833 AW406586 AA482084 Al872299 AA715266 AW404328 Al831674 Al709348 AA603112

AWS14864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113
55 108470 genbank_AA079500 AA079500
101447 entrez_M21305 M21305
124447 genbank_N48000 N48000
101624 entrez_M55998 M55998

131791 221_260

X62111 S67984 AJ131056 Z47243 Z47235 AF062268 Z47237 AJ131058 AF062130 AF062282 X62108 AA385989 AA464794 X69861 AW402964 M90808 Z98735 Z98734 Z98736 AF035018 X79161 U00545 AF174046 AF174071 U00552 U96288 AF021989 AF062255 AF174061 S73953 AF062135 AF062155 X64147 U00555 AF174070 AF129754 U86789 Z98714 Z98738 S75886 AJ008175 AJ008186 AJ008188 Y08403 H15753 H22208 AA327241 AW405737 H42300 H39677 H26239 H26903

H45128 R86072 AA327565 AI660584 AW361537 AW383759 S71043 H15014 H45570 H42819 H45523 H45134 R72043

H24543 H27636 H27610 T28147 H25496 AW364071 AW364072 H45561 H45556 H42605 Al735017 T47421 R48719 H27570 H44599 Al459598 H42347 H41938 H24993 AA345888 H22339 Al538691 AJ012264 AA664201 Al880450 AA327310 Al991250 Al833028 AW001210 Al956075 H30467 AA326915 H41943 Al749266 Al744441 AA327377 AW512326 Al735170 H01634 5 Al587047 Al571623 AA327486 AA327103 AA327195 AA326973 T28143 124842 217726_1 R56485 R37248 R59992 103758 AA084874_f_at AA084874 f X57815 L29157 AA367448 AW328098 AW404536 L29156 L29163 H27683 R83195 AA295096 AW327822 H25458 AW404692 X57819 X57823 AW405604 AW404447 Z34914 AW406542 AA427726 AA604389 AW405606 AW405918 AW405117 130064 221_264 10 AW407182 L03632 AW405058 L03627 AW407470 R72738 L21959 AW375738 X87888 AF124166 AF054638 AJ241406 U09902 AW405284 M12025 AA360219 L03631 L03629 AW327727 AF194810 AF058076 AF194686 AF063774 AF063737 AF063755 AF063740 AF063739 AF063738 S73129 L43088 AF063775 L33026 AF060138 AF194813 AF194812 AF194811 AF194809 AF194814 AF194808 AF064505 AF064503 AF063765 AF063757 AF063752 AF063716 AF063736 AF194806 AF058077 AF063747 AF063772 AF063781 AF060137 AF194805 AF060134 AF060132 AF058074 AF063754 AF063704 15 U38589 Z18332 AF060122 AF194807 AF060135 AF064506 AF064504 AF063773 L26540 AF058072 AF060131 AF064500 AF060136 AF064513 AF194683 AF194711 AF058075 AF063717 Z19546 AF194581 X72746 U96393 U09890 X98897 AF194592 M80916 AJ241405 AF194632 AJ388659 AF194625 Z73694 AF194588 AF194661 U09901 U09911 U09992 AJ010336 AJ006162 AJ249377 AJ241414 AA327392 U97248 X72747 Z46850 X95739 AW406701 AJ243109 AF194609 S80758 AF194595 AF194596 L22483 Z70262 D84141 AW405758 AF001788 AF194580 D84143 U76684 AF194593 L03630 20 X87892 X91134 U21249 Z46346 AJ132426 AF103659 AJ233718 AF021038 AJ233727 H24657 U09882 S75627 AA573599 AF047231 AF047232 AF103616 AW404484 Z46848 S76132 AF103663 AF103713 Y17940 AF047216 AF103595 Y17956 AF052799 AF052797 AF052802 AF052798 AF052801 AF052794 AF052796 AF047218 AF052800 AF047217 AF052795 AF032351 AF103701 AF103708 AF103710 AF103706 S62232 AF103645 AF103632 AF103647 AF103644 AF103640 AF103692 AF103701 AF103706 AF103710 AF103706 362232 AF103032 AF103032 AF103037 AF103032 AF103037 AF103032 AF103 25 AA864302 H25133 D87023 J03011 M61771 D87017 AA526865 AA253450 U29463 U06715 W24970 AA584303 T39581 AA155603 AA305043 AA429426 W05664 AA102382 AA482044 W24487 AA319060 130232 18831 2 T88946 F10106 AA232161 AA243117 AA158937 AA100864 109097 genbank_AA167512 AA167512

TABLE 9: Figure 9 from BRCA 001-2 US

5 **Table 9** depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10	Pkey: ExAccn: Unigene!D: Unigene Title:		Inique Eos probeset identifier number Exemplar Accession number, Genbank accession number Inigene number Inigene gene title						
15	Pkey	ExAccn	UnigenelD	UnigeneTitle					
	102211	AA383256 BE314524		estrogen receptor 1 putative transmembrane protein 5T4 oncofetal trophobiast glycoprotein					
20	104115 105038	AF183810 AW50373	Hs.26102	opposite strand to trichorhinophalangeal syndrome I KIAA1488 protein CEGP1 protein					
25	106155 106373		Hs.33287 7 Hs.21907	hypothetical protein FLJ22060 nuclear factor I/B histone acetyltransferase					
	110009 111900	BE075297 AF131784 AI904232	Hs.25318	mitogen-activated protein kinase kinase kinase 2 ESTs, Weakly similar to A43932 mucin 2 precursor, Intestinal Homo sapiens done 25194 mRNA sequence prohibitin					
30	116470 117280 119771	Al272141 M18217 Al905687	Hs.83484 Hs.172129 Hs.2533	SRY (sex determining region Y)-box 4 Homo sapiens cDNA: FLJ21409 fis, clone COL03924 EST					
35	124059 131148	AW953575	Hs.104800 Hs.283713 Hs.303125 Hs.46677	hypothetical protein FLJ10134 ESTs, Weakly similar to S64054 hypothetical protein YGL050w p53-induced protein PIGPC1 PRO2000 protein					
	302235	AL049987	Hs.178137 Hs.166361 Hs.29383	transducer of ERBB2, 1 Homo sapiens mRNA; cDNA DKFZp564F112 Homo sapiens mRNA; cDNA DKFZp434					

TABLE 10: Figure 10 from BRCA 001-3 PCT

5 **Table 10** depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

	Pkey:	Unique Eos probeset Identifier number
10	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigeneiD:	Unigene number
	Unigene Title:	Unigene gene title
	R1:	Ratio of tumor to normal body tissue
	R2:	Ratio of 90th percentile tumor to body
15	R3:	Ratio of 75th percentile body to tumor
	R4:	Ratio of tumor to normal breast tissue

	114.		THE OF ED	ino to normal broadt adda.				
20	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20	100082	AA130080	He 4205	proteasome (prosome, macropain) 26S subu	4.2	152	36	12.2
		AA380887		dolichyl-phosphate mannosyltransferase p	9.8	123	13	5
		D12485	Hs.11951	ectonucleotide pyrophosphatase/phosphodi	13.2	244	19	9.9
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin	15.7	1030	66	5
25		H60720	Hs.81892	KIAA0101 gene product	4.1	320	· 78	10.6
45		D14661	Hs.119	Wilms' tumour 1-associating protein	4.7	119	26	3
		AL037228		D123 gene product	5.1	106	21	9.2
		BE242284		adenylate cyclase 7	4.7	47	1	4.3
		D26361	Hs.3104	KIAA0042 gene product	4.7	47	4	0.7
30		AW972300		bone marrow stromal cell antigen 2	3.8	350	93	1.9
50		D29677	Hs.3085	KIAA0054 gene product; Helicase	4.1	64	16	3
		NM_01515		KIAA0071 protein	3.4	77	23	5.9
		NM_00620		platelet-derived growth factor receptor-	4.5	45	4	4
		D38491	Hs.322478	KIAA0117 protein	5.9	59	1	2.6
35		D42084	Hs.82007	KIAA0094 protein	3.5	96	28	1.3
-		BE247550		growth factor receptor-bound protein 7	3.1	306	98	1.5
		AA331881		peroxiredoxin 3	12.8	128	1	11.7
		AW247529		platelet-activating factor acetylhydrola	4.2	187	44	5.4
		AI878927	Hs.79284	mesoderm specific transcript (mouse) hom	4.5	129	29	3.1
40		D80004	Hs.75909	KIAA0182 protein	3.5	78	23	4.8
		D86957	Hs.80712	KIAA0202 protein	10.2	102	1	4.8
		D86961	Hs.79299	lipoma HMGIC fusion partner-like 2	4	40	1	3.8
		NM_01473		KIAA0215 gene product	3.2	32	2	2.9
		D86978	Hs.84790	KIAA0225 protein	3.6	36	7	3.2
45		AA013051		topoisomerase (DNA) II binding protein	5.6	76	14	2
		AA347720		KIAA0264 protein	3.5	35	9	3.1
		AF234887		cadherin, EGF LAG seven-pass G-type rece	5.5	145	27	2.2
		D87470	Hs.75400	KIAA0280 protein	3.4	34	1	1.2
		X51501	Hs.99949	prolactin-induced protein	22.7	760	34	1.4
50	100552	AA019521	Hs.301946	lysosomal	14.4	144	9	4.7
	100643	NM_00503	2Hs.4114	plastin 3 (T isoform)	4.1	259	63	1.9
		BE623001		Homo sapiens ribosomal protein L39 mRNA,	3.3	116	36	2.2
	100666	L05424	Hs.169610	CD44 antigen (homing function and Indian	8.5	85	1	3.2
		L05424	Hs.169610	CD44 antigen (homing function and Indian	3	594	201	2.3
55		BE207168		nuclear receptor subfamily 2, group F, m	5	82	17	0.9
		J05581	Hs.89603	mucin 1, transmembrane	3.5	37	11	2.8
		AF078847	Hs.191356	general transcription factor IIH, polype	9.7	97	10	7.2
		M26460		gb:Homo sapiens (clone 104) retinoblasto	3.3	33	1	0.8
	100864	BE563957	Hs.74861	activated RNA polymerase II transcriptio	3.7	477	130	3.1
60		X80821	Hs.27973	KIAA0874 protein	6.3	63	4	5.7
	100892	BE245294	Hs.180789	S164 protein	4.7	47	1	4.2
		BE297139		replication protein A2 (32kD)	3.8	115	30	7.1
		K01160		NM_002122:Homo saplens major histocompat	3.9	390 -	100	11,1
	101079	BE264901	Hs.250502	carbonic anhydrase VIII	3.9	39	8	3.6

	101084	AW409934	Hs.75528	nucleolar GTPase	4.1	53	13	4
		AW862258		neuropeptide Y receptor Y1	15.3	153	1	14.1
	101185	NM_00162	1Hs.170087	aryl hydrocarbon receptor	11.3	113	8	3.9
		L20320	Hs.184298	cyclin-dependent kinase 7 (homolog of Xe	3.1	118	38	2
5	101201	L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	8.2	396	48	0.9
	101232	AU077288	Hs.242894	ADP-ribosylation factor-like 1	4	110	28	10.7
	101275	BE545277	Hs.3273	Ts translation elongation factor, mitoch	4.2	50	12	4.4
	101300	BE535511	Hs.74137	transmembrane trafficking protein	6.6	135	21	13.1
	101396	BE267931	Hs.78996	proliferating cell nuclear antigen	6.4	249	39	22.4
10	101447	M21305		gb:Human alpha satellite and satellite 3	6.5	878	135	0.8
	101448	NM_00042	4Hs.195850	keratin 5 (epidermolysis bullosa simplex	· 4.8	622	130	0.7
	101470	NM_00054	6Hs.1846	tumor protein p53 (Li-Fraumeni syndrome)	5.1	97	19	9.3
	101478	NM_00289	0Hs.758	RAS p21 protein activator (GTPase activa	9.6	96	1	8.5
		AA053486	Hs.20315	interferon-induced protein with tetratri	11.2	112	8	5.9
15		X16896	Hs.82112	interleukin 1 receptor, type I	3.9	39	2	3.5
		BE391804	Hs.62661	guanylate binding protein 1, interferon-	3.6	36	1	2.6
	101624	M55998		gb:Human alpha-1 collagen type I gene, 3	3.1	2898	923	2.2
		AA436989		H2A histone family, member A	6.9	103	15	8.4
20		M63256	Hs.75124	cerebellar degeneration-related protein	6.4	64	2	4.9
20		L11690	Hs.620	bullous pemphigold antigen 1 (230/240kD)	9.4	94	1	0.3
		S70114	Hs.239489	TIA1 cytotoxic granule-associated RNA-bi	8.9	89	5	8
		M81057	Hs.180884	carboxypeptidase B1 (tissue)	3.6	824	227	1.4
		M83822	Hs.62354	cell division cycle 4-like	9	144	16	13
25		M84605	Hs.957	putative opioid receptor, neuromedin K (3.3	36	11	2.4
25		AW024390		pre-B-cell leukemia transcription factor	5.4	180	34	15.9
		M86849	Hs.323733	gap junction protein, beta 2, 26kD (conn	12	120	8	9
		AA446644		GA733-2 antigen; epithelial glycoprotein	3.1	353	116	2.8
		AL049610		transcription elongation factor A (SII)-	7.3	73	1	5.3
20			Hs.194662	calponin 3, acidic	3.8	399	105	3.3
30		BE245149		protein tyrosine kinase 9	4.6	148	32	11.3
		U11313	Hs.75760	sterol carrier protein 2	9.5	95	4	8.8
		NM_00180		centromere protein A (17kD)	4.2	42	7	3.4
		NM_00645		sialyltransferase	9.3	93 137	4 26	3 2.5
35		NM_00441		dual specificity phosphatase 5	5.4 4.6	151	33	2.5
55		AA450274 BE313280		CDC16 (cell division cycle 16, S. cerevi death associated protein 3	9.3	93	5	8
		AL036335		secreted phosphoprotein 1 (osteopontin,	45.7	457	1	39.7
		BE314524		putative transmembrane protein	3.9	442	114	1.3
		NM_00676		LIM domain only 4	4.9	49	1	3.6
40		U27185	Hs.82547	retinoic acid receptor responder (tazaro	3.1	31	i	1.3
10		NM_00154		Inhibitor of DNA binding 4, dominant neg	3.8	163	43	0.5
		AA306342		protein kinase C-like 2	4.5	45	1	3.6
		AF015224		mammaglobin 1	8.5	2058	243	1.4
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	6.4	428	67	2.3
45		U39840	Hs.299867	hepatocyte nuclear factor 3, alpha	6.7	67	9	6.3
		AW602154		E74-like factor 2 (ets domain transcript	5.3	53	1	4.8
		BE300330		selenophosphate synthetase 2	3.3	111	34	7.5
		NM_001394		dual specificity phosphatase 4	20.2	202	5	1.3
		NM_00393		kynureninase (L-kynurenine hydrolase)	3.8	38	1	1.5
50	102567	U63830	Hs.146847	TRAF family member-associated NFKB activ	8.2	82	1	6.8
	102580	U60808	Hs.152981	CDP-diacylglycerol synthase (phosphatida	4.1	41	1	3.3
	102618	AL037672	Hs.81071	extracellular matrix protein 1	10.2	628	62	17.2
	102638	U67319	Hs.9216	caspase 7, apoptosis-related cysteine pr	5	66	13	5.3
	102663	NM_00227	0Hs.168075	karyopherin (importin) beta 2	6.1	126	21	2.4
55	102669	U71207	Hs.29279	eyes absent (Drosophila) homolog 2	4.5	45	1	2.8
	102742	U79293	Hs.159264	Human clone 23948 mRNA sequence	4.1	41	1	2.4
		U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.4	255	58	1.6
	102805	U90304	Hs.25351	iroquois homeobox protein 5	3.6	142	39	1.6
	102813	BE242035	Hs.151461	embryonic ectoderm development	3.5	35	1	2.7
60		D85390	Hs.5057	carboxypeptidase D	5.6	56	1	5.3
		BE262386		clones 23667 and 23775 zinc finger prote	4.2	42	7	3.7
		AI815559	Hs.75730	signal recognition particle receptor (d	3.2	58	18	5
		NM_00227		keratin 15 .	5.8	753	131	0.4
<i>(</i>		BE512730		keratin 18	3.1	815	266	1.7
65			Hs.198166	activating transcription factor 2	3.2	32	4	2.6
			Hs.154672	methylene tetrahydrofolate dehydrogenase	5.7 5.6	251 1346	44 239	6.6 5.4
	103003	AI910275	Hs.1406	trefoil factor 1 (pS2)	J.U	1340	203	J.7

	103023	AW500470	Hs.117950	multifunctional polypeptide similar to S	5.8	218	38	13
		NM_002343		lactotransferrin	3.7	1421	388	1.9
		M13509	Hs.83169		3.1	94	30	5.8
_		AA926960			3.5	332	94	3.1
5	103119		Hs.2877		4.8	312	65	30.9
	103134		Hs.2839		5.2 4.9	331 49	64 5	1.5 3.8
	103134		Hs.2839		4.9 3.3	1497	458	2.1
	103171	AW583058	Hs.77367		3.5	796	228	3.2
10		AW411340			5.6	191	34	3.5
10	103226		Hs.44313		4.1	53	13	4.9
		AA206186			3.4	34	8	2.3
	103346		Hs.5464		3.9	43	11	1
	103352		Hs.78853		9.3	93	8	8.2
15	103375	NM_005982	2Hs.54416	sine oculis homeobox (Drosophila) homolo	9.7	97	1	9.3
	103376	AL036166	Hs.323378		6.3	98	16	9.1
	103391		Hs.114366	p)	4.3	77	18	7.2
		AW175781		bring - bring-bringht-	4.9	153	31	2.4
20		AI878922		SMT3 (suppressor of mif two 3, yeast) ho	4.9	261	53	3.7
20		Y00815	Hs.75216	protein tyrosine phosphatase, receptor t	3.5	564 49	162 13	1.7 2.5
		AW408009		alkylglycerone phosphate synthase	3.9 7. 5	136	18	3.4
		AL133415		vimentin 5T4 oncofetal trophoblast glycoprotein	7.9 7.9	79	2	6.9
		BE270266 BE409838			3.3	745	229	1.8
25		AW403814		BCL2-associated athanogene	3.2	41	13	2.8
23		NM_000346			7,3	73	1	5.2
		NM_000088		collagen, type I, alpha 1	3.8	1612	429	3.1
		NM_003528		H2B histone family, member Q	3.2	32	5	2.8
		AA314389		ADP-ribosylation factor-like 5	3.2	32	9	2.7
30	103990	AB033112	Hs.42179	bromodomain and PHD finger containing, 3	4.9	49	1	4.2
	104052	NM_002407	7Hs.97644	mammaglobin 2	7.2	498	69	9.3
		AF183810		opposite strand to trichorhlnophalangeal	29	290	1	26.8
		H63349	Hs.98806	hypothetical protein	3.7	37	7	2.1
25		AW880614		RNA binding motif protein, X chromosome	5.2	52	1	4.3
35		BE081342		HSPC039 protein	8	84 50	.11	6.3 3.2
		AB012113		small inducible cytokine subfamily A (Cy	5.8 6.4	58 64	1 8	3.2 3
		AB002367 AW583693		doublecortin and CaM kinase-like 1 N-terminal acetyltransferase complex ard	4.7	229	49	7.9
		A1337300	Hs.284123	hypothetical protein MGC4604	3.2	32	7	2.4
40		AA129551		Homo sapiens cDNA: FLJ21409 fis, clone C	5.3	144	27	13.1
70		X51501	Hs.99949	prolactin-induced protein	6.9	1494	218	1.3
		R56678	Hs.88959	hypothetical protein MGC4816	7.7	77	8	6.9
		AA040620		hypothetical protein AF140225	3.7	37	5	2.5
		AW373062		nuclear receptor subfamily 1, group I, m	6.1	493	81	0.7
45	104602	H47610		gb:yp75f03.s1 Soares fetal liver spleen	3.8	38	4	1.2
		AF123303	Hs.24713	hypothetical protein	4.8	231	49	7.3
		H00820	Hs.30977	ESTs, Weakly similar to B34087 hypotheti	3.4	154	46	3
		R82252	Hs.106106	protein kinase (cAMP-dependent, catalyti	5	468	94	4.7 3.1
50		BE298665		Homo sapiens mRNA; cDNA DKFZp564D016 (fr	3.8 14.9	82 149	22 1	6.4
50		Al239923	Hs.30098	ESTs macrophage erythroblast attacher	6.3	165	26	3.2
		BE244072 AA027317	N3.20013	gb:ze97d11.s1 Soares_fetal_heart_NbHH19W	3.8	40	11	3.8
		AI858702	Hs.31803	ESTs, Weakly similar to N-WASP [H.sapien	7,7	77	1	5.1
		Al139058	Hs.125790	leucine-rich repeat-containing 2	7	70	1	6.5
55		AI250789	Hs.32478	ESTs	4.7	201	43	4.5
,		AW015318		ESTs	7.4	74	1	6
		AA026880		prolactin receptor	3.9	280	72	3.3
		BE298808		DKFZP434N093 protein	4.2	135	32	4
			Hs.114218	frizzled (Drosophila) homolog 6	16.2	162	1	4.2
60		AI249502	Hs.29669	ESTs	3.8	38	1	2.4
		Al392640	Hs.18272	amino acid transporter system A1	3.2	522	165	1.9
		AA121686		ESTs	3.2	32	4	2.9
		Al122691	Hs.13268	ESTs	3.7	157	43	3.6
65		AW503733		KIAA1488 protein	5.5	55 103	1	5.2 3.9
65		AB037716		KIAA1295 protein	10.3	103	1	5.4
		AA148710		lumican Homo sapiens cDNA FLJ11027 fis, clone PL	6.6 3.1	66 31	1	2.5
	103000	H58589	Hs.35156	Tromo sapions obtan FLJ (1027 lis, cione PL	J. I	٠,	•	

	105004	A A 4 400E0	Un 470000	hundhatiaal acatain EL 199005	2.2	20	4	,
		AA148859		hypothetical protein FLJ22995	3.2	32	1	3
		Al368836	Hs.24808	ESTs, Weakly similar to 138022 hypotheti	7.3	73	1	3.8
		AA307279		methyl-CpG binding domain protein 4	4.2	90	22	2.8
_		AL133033		KIAA1025 protein	6	60	6	4.6
5	105167	AW612147	Hs.32058	Homo sapiens C1orf19 mRNA, partial ods	3.8	38	2	3.2
	105178	AA313825	Hs.21941	AD036 protein	9.3	436	47	5.8
	105195	AA975096	Hs.19522	hypothetical protein PRO2849	5.7	57	8	5.3
	105200	AA328102	Hs.24641	cytoskeleton associated protein 2	4.5	45	1	3.6
	105248	AW952479	Hs.22826	tropomodulin 3 (ubiquitous)	4.3	43	1	3.9
10		AB039670		ALEX1 protein	8	80	6	7.3
-0		AW997484		KIAA0456 protein	3.9	39	6	3.2
		AA894638		ESTs	3.5	35	7	2.7
		N99673			4.5		10	0.5
			Hs.3585	ESTs, Weakly similar to AF126743 1 DNAJ		45		
15		AK000796		hypothetical protein	3.8	93	25	7.5
15		AA234561		ESTs	2.8	131	47	3.9
		AF151073		hypothetical protein	3.9	79	20	6.5
		AW994032		hypothetical protein FLJ10849	5.1	181	36	15.8
	105386	AW500718	Hs.8115	Homo sapiens, clone MGC:16169, mRNA, com	4.1	41	2	3.3
	105400	AF198620	Hs.65648	RNA binding motif protein 8A	6.2	62	6	5.6
20	105426	W20027	Hs.23439	ESTs	3.3	206	63	2.2
	105483	AL137257	Hs.23458	Homo saplens cDNA: FLJ23015 fis, clone L	3.2	466	146	8.4
	105496	AL117441	Hs.301997	hypothetical protein FLJ13033	16.6	166	8	12.7
		AW602166		CEGP1 protein	25.4	508	20	3
		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (f		117	13	10.6
25		AB037829		regulator of nonsense transcripts 2; DKF	3.2	32	6	1.5
		AK001269		hypothetical protein FLJ10407	8.3	83	3	1.8
		AB040884		KIAA1451 protein	3.5	73	21	1.6
					5.8	336	58	2
		BE616694		hypothetical protein FLJ14299				1
20		AA280072		fetal Alzhelmer antigen	3.2	32	1	
30		R35343	Hs.24968	Human DNA sequence from clone RP1-233G16		79	17	5.2
		AA281279		hypothetical protein FLJ14681	4	75	19	1.7
		AA001021		thyroid hormone receptor Interactor 8	4.5	45	1	3.7
	105645	AW294631	Hs.11325	ESTs	3.6	36	1	0.1
	105674	AI609530	Hs.279789	histone deacetylase 3	6.4	64	8	6
35	105687	NM_014517	7Hs.28423	upstream binding protein 1 (LBP-1a)	4.7	152	33	5.3
	105691	A1680737	Hs.289068	Homo sapiens cDNA FLJ11918 fis, clone HE	5.7	57	8	4.1
•	105730	AW377314	Hs.5364	DKFZP564I052 protein	6.9	69	1	4.4
		AA834664		nuclear receptor coactivator 2	3.4	34	1	3.1
		BE246502		sema domain, immunoglobulin domain (lg),	3	30	10	0.9
40			Hs.15159	chemokine-like factor, alternatively spl	5.4	54	1	4.4
10	105772		Hs.221132	ESTs	5.3	67	13	5.3
					4.9	49	1	4.5
		AW369278		hypothetical protein FLJ20160				
		W84446	Hs.226434	hypothetical protein MGC4643	3.3	98	30	4.7
15		AA878183		Homo saplens cDNA FLJ13618 fis, clone PL	3.2	143	46	3.6
45		AF206019		REV1 (yeast homolog)- like	4	40	3	3.2
		AA788946		ESTs, Moderately similar to CA1C RAT COL	4.7	747	158	5.7
		Al559444	Hs.293960	ESTs	3.9	371	94	4.6
	105832	AW802282	Hs.22265	pyruvate dehydrogenase phosphatase	3.6	68	19	6
	105840	AA601518	Hs.22209	secreted modular calcium-binding protein	4.8	134	28	3.2
50	105851	Al827976	Hs.24391	hypothetical protein FLJ13612	4.3	772	179	1.7
•	105864		Hs.28332	Homo sapiens cDNA: FLJ21560 fis, clone C	4.3	43	1	3.7
		AW021691		GCN5 (general control of amino-acid synt	3.6	36	7	3.1
		AK001708		hypothetical protein FLJ10846	3.4	34	8	2.9
		AK001735		UDP-glucose:glycoprotein glucosyltransfe	3.6	45	13	1.3
55	105906		Hs.22380	ESTs	3.4	34	1	1.5
55				ESTS		212	6	17.4
			Hs.8895	EO I S	21.2			
		AA043039		hypothetical protein	3.9	47	12	4.4
		AL122072		heterogeneous nuclear ribonucleoprotein	4,4	174	40	1.6
	106034	AW952005	Hs.14928	hypothetical protein FLJ12903	4.7	47	1_	4
60		AA382267	Hs.10653	ESTs	3.4	49	15	4.4
	106055	AA417034		gb:zu04f10.s1 Soares_testis_NHT Homo sap	3.5	53	15	1.2
	106057	BE614474	Hs.289074	F-box only protein 22	3.4	116	35	2.2
	106060	NM_001329	Hs.171391	C-terminal binding protein 2	3.6	444	125	4.6
	106070		Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.6	365	103	6.9
65		AF115402		E74-like factor 5 (ets domain transcript	26.3	356	14	1
		AW379378		protein tyrosine phosphatase, receptor t	3.2	267	83	2.3
		AA576953		hypothetical protein FLJ13352	3.8	38	ī	3.3
	,			When the branch of 1000F			•	•

	106155	AA425414	He 33287	nuclear factor I/B	9.9	483	49	1.8
		W37943	Hs.34892		6.7	94	14	8
			Hs.325531	Homo sapiens clone 015h12 My015 protein	3.3	95	29	4.4
		AB040896		KIAA1463 protein	3.8	83	22	7.5
5		AI765107			3.3	97	30	6.4
•		AW961393		7F	4.5	116	26	4.5
	106310		Hs.17240		7	70	3	1.3
		AB007866		KIAA0406 gene product	3.2	37	12	2.6
		AW977397		ESTs	3.8	38	1	1.9
10		AA447453		Homo sapiens mRNA; cDNA DKFZp586M0723 (i	16	255	16	6.6
		AW748420		Homo sapiens cDNA: FLJ21487 fis, clone C	4.9	337	70	2.7
	106394		Hs.25320	Homo saplens clone 25142 mRNA sequence	3.1	72	23	5
		AK000310		hypothetical protein FLJ20303	3.1	165	54	1.6
		AA789081		glioma-amplified sequence-41	3.1	31	1	2.6
15		AB033042		cofactor required for Sp1 transcriptiona	5.5	147	27	4.4
	106508	Al205785	Hs.30348	ESTs	4,4	222	51	1.8
	106565	NM_014892	2Hs,227602	KIAA1116 protein	7.4	74	3	1.7
		AA243837		ESTs	15.2	152	1	12.6
	106589	AK000933	Hs.28661	Homo sapiens cDNA FLJ10071 fis, clone HE	3.8	263	69	3.9
20	106596	AA452379	Hs.293552	ESTs, Moderately similar to ALU7_HUMAN A	4.9	49	1	4.1
	106611	R49131	Hs.26267	ATP-dependant interferon response protei	5.8	58	5	3.1
	106628	AW188205	Hs.12311	Homo sapiens clone 23570 mRNA sequence	5.3	166	32	14.9
	106650	AL049951	Hs.22370	Homo sapiens mRNA; cDNA DKFZp564O0122 (f	5.4	75	14	0.8
	106683	BE296396	Hs.14512	DIPB protein	3.6	210	58	4.7
25	106698	N28524	Hs.29403	hypothetical protein FLJ22060	5.7	57	10	4.8
	106710	N38902	Hs.334437	hypothetical protein MGC4248	4.4	371	84	3.2
		AA600357		TIA1 cytotoxic granule-associated RNA-bi	4.3	101	24	1.6
		NM_007118		triple functional domain (PTPRF interact	4.6	46	1_	4.
	106834	AL044182	Hs.28070	KIAA0753 gene product	3.5	58	17	1.6
30		AB037744		KIAA1323 protein	5.4	192	36	4.4
		BE185536		molecule possessing ankyrin repeats indu	3.3	696	214	1.8
		AA149537		hypothetical protein FLJ20477	3.8	38	1	1.6
		AA835868		mannosidase, alpha, class 1A, member 1	4.3	43	10	2.2
25		AK001826		hypothetical protein FLJ11269	3.6	36	1	1.2
35		AF039023		RAN binding protein 6	4.5	45	1	3.8
		AA134329		Homo sapiens, clone IMAGE:3685398, mRNA,	5.7	94	17	7.3 2.3
		A1868648	Hs.22315	ESTS	3.5	180	52 24	12,5
		AF216751		CDA14	5.5 3.2	130 266	83	1.8
40		AA280722		ESTs, Weakly similar to I38022 hypotheti	5.1	298	59	4.4
40		AL157479	NS.23740	KIAA1598 protein	3.3	228	69	2.8
		AA598820 AV650537	Un 247200	gb:ae36h12.s1 Gessler Wilms tumor Homo s succinate-CoA ligase, GDP-forming, beta	3.1	55	18	3.8
		AW401864		programmed cell death 8 (apoptosis-induc	3.1	75	24	2.2
		AW385224		ectonucleofide pyrophosphatase/phosphodi	3.1	367	119	2.3
45		AL122043		hypothetical protein DKFZp566G1424	3.9	98	25	8.6
7.5		AB037765		KIAA1344 protein	6.3	63	1	5.4
		AA249096		ESTs	4.6	71	16	3.6
		AV661958		GK001 protein	2.5	392	155	4.3
		AW378065		ESTs	15.6	156	7	10.8
50		AL080235		DKFZP586E1621 protein	4.8	48	8	3.1
• •		BE172058		tumor rejection antigen (gp96) 1	3.4	251	74	23.7
		Al290284	Hs.159872	ESTs	3.6	36	6	0.5
		AW263124		nuclear receptor co-repressor/HDAC3 comp	5.4	483	90	4
	107295	AA186629	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	199	44	19.2
55		BE277457		hypothetical protein MGC4606	12.5	156	13	2.9
	107316	T63174	Hs.193700	Homo sapiens mRNA; cDNA DKFZp586I0324 (f	3,2	110	35	9.6
		T74445	Hs.5957	Homo sapiens clone 24416 mRNA sequence	3.5	35	1	2.6
	107485	AL042613	Hs.262476	S-adenosylmethionine decarboxylase 1	5.8	151	26	11.4
	107612	A1498986	Hs.60090	Homo saplens cDNA FLJ13595 fis, clone PL	3.2	32	5	2.1
60	107638	A1580492	Hs.42743	hypothetical protein	4.4	73	17	6.2
	107727	AA149707	Hs.173091	ubiquitin-like 3	3.5	282	80	3.7
		AW732573		potassium voltage-gated channel, delayed	5.7	85	15	7.8
		AW372451		CGI-79 protein	3.5	35	1	1
~ =		AA054949		ESTs	4.3	43	10	2.7
65		AA025782		ESTs	3.1	31	9	2.2
		AF087999		ESTs	4.7	47	4	4.3
	107922	BE153855	Hs.61460	lg superfamily receptor LNIR	9	90	1	5.5

	107004	A A D 2 C 0 4 4	Un 40460	Little domaine explaining 4	A E	AE	4	20
		AA036811		LIM domains containing 1	4.5	45	1	3.8
		AL121031		SWI/SNF related, matrix associated, acti	6.5	65	2	6
	108055	AJ404672	Hs.334483	hypothetical protein FLJ23571	7.4	74	8	6
	108063	BE548479	Hs.14838	hypothetical protein FLJ10773	3.4	34	1	2.3
5	108339	AW151340	Hs.51615	ESTs, Weakly similar to ALU7_HUMAN ALU S	18.7	187	1	17
•		Al478658	Hs.94631	brefeldin A-inhibited guanine nucleotide	3.8	38	1	3.2
					5.7	57	i	4.9
		AA084677		hypothetical protein FLJ22222				
		AW022410		ESTs	3.2	32	5 .	1.7
	108647	BE546947	Hs.44276	homeo box C10	8.7	247	29	5.7
10	108695	AB029000	Hs.70823	KIAA1077 protein	3.7	625	168	3.8
	108778	AF133123	Hs.90847	general transcription factor IIIC, polyp	3.7	37	1	3.2
		AF070578		Homo sapiens done 24674 mRNA sequence	3.4	34	1	2.8
		Al652236	Hs.49376	hypothetical protein FLJ20644	3.5	35	i	3.2
1.0		AW295647		hypothetical protein MGC5350	5.3	53	1	2.8
15		AL117452		DKFZP586G1517 protein	4.8	96	20	6.5
	108857	AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act	5.4	54	1	4
	108893	BE276891	Hs.194691	retinoic acid induced 3	3.1	529	170	4.1
		Al380268	Hs.173648	ESTs, Weakly similar to Zinc-finger prot	3.3	33	5	1.7
		NM_007240		dual specificity phosphatase 12	3.4	34	1	2.6
20					3.1	31	8	2
20		BE062109		chloride channel, calcium activated, fam				
		AW608930		hypothetical protein FLJ20618	3.4	71	21	2.4
	109112	AW419196	Hs.257924	hypothetical protein FLJ13782	4.1	334	82	3.4
	109124	AK000684	Hs.183887	hypothetical protein FLJ22104	3.3	33	1	2.9
	109128	H89083	Hs.181915	ESTs	4	40	7	1.1
25		BE220601		hypothetical protein FLJ13033	3.8	233	62	3.8
		AA219691		RAB6 interacting, kinesin-like (rabkines	8.8	199	23	16.1
							1	2.2
		AA179962		EST	3.2	32		
		AW976516		Homo sapiens cDNA: FLJ21354 fis, clone C	3.2	32	10	2.9
	109235	AI381800	Hs.300684	calcitonin gene-related peptide-receptor	4.9	121	25	10.4
30	109273	AA375752	Hs.82719	Homo sapiens mRNA; cDNA DKFZp586F1822 (f	2.9	114	39	9.9
	109292	AW975746	Hs.188662	KIAA1702 protein	7.1	71	1	6.5
		AL096858		KIAA0929 protein Msx2 interacting nuclea	6.9	69	5	6.2
	109411		Hs.109655	sex comb on midleg (Drosophila)-like 1	3.3	39	12	1.5
					4.2	56	14	2.2
25		BE543313		hypothetical protein FLJ10520				
35		U80736	Hs.110826	trinucleotide repeat containing 9	12.3	123	1	11.3
	109481	AA878923	Hs.289069	hypothetical protein FLJ21016	3.2	286	91	5.7
	109517	Al631874	Hs.155140	casein kinase 2, alpha 1 polypeptide	8.3	83	8	1.9
	109597	AA989362	Hs.293780	ESTs	5.9	59	10	4.2
	109729		Hs.268740	ESTs	3.2	41	13	3.3
40		AA173942		Homo sapiens mRNA; cDNA DKFZp564H1916 (f		208	36	1.8
- U								
		AW965076		hypothetical protein 669	5	50	5	4.1
		R68827	Hs.95011	syntrophin, beta 1 (dystrophin-associate	3.7	37	4	2
	109912	AW390822	Hs.301528	L-kynurenine/alpha-aminoadipate aminotra	14.2	142	1	9.5
	109937	Al084066	Hs.20072	myosin regulatory light chain interactin	4.1	41	7	1.7
45		AA001266		ESTs	4.2	58	14	8.0
		Al796320	Hs.10299	Homo saplens cDNA FLJ13545 fis, clone PL	3.2	136	43	3.6
		BE075297		ESTs, Weakly similar to A43932 much 2 p	6.3	693	110	7,2
			Hs.176588	ESTs, Wealdy similar to CP4Y_HUMAN CYTOC		913	199	2.9
		AK000768		hypothetical protein FLJ20761	3.8	38	7	2.8
50	110426	A1610702	Hs.28212	ESTs, Weakly similar to TRHY_HUMAN TRICH	6.7	78	12	3
	110478	H11236	Hs.31034	peroxisomal biogenesis factor 11A	3.7	37	1	2.1
	110481	AF075089	Hs.36823	ESTs	3,6	36	10	2.5
	110581			gb:yr22g03.s1 Soares fetal liver spleen	3.3	33	1	1.8
		AA071276	He 10460		3.5	35	8	1.9
55				KIAA0859 protein				
33		AB007902		KIAA0442 protein	3.6	282	79	1.7
	110721		Hs.31319	ESTs	4.4	103	24	3.8
	110731	NM_014899	Hs.188006	KIAA0878 protein	3.3	138	42	3.6
	110769	BE000831	Hs.23837	Homo sapiens cDNA FLJ11812 fis, clone HE	13.5	135	1	5.1
	110775	N22414		qb:yw39a07.s1 Weizmann Olfactory Epithel	5.4	54	1	3.7
60		AA831267	Hs 12244	hypothetical protein FLJ20097	4.7	47	4	4.2
UU		AI089660			5	50	i	4.3
			Hs.323401	dpy-30-like protein				
		AL157503		Homo sapiens mRNA; cDNA DKFZp586N2424 (f		31	1	2.7
		AF153330		solute camer family 19 (thiamine trans	8,4	84	1	5.3
	110844	AI740792	Hs.167531	methylcrotonoyl-Coenzyme A carboxylase 2	10.5	105	4	7.1
65	110854	BE612992	Hs.27931	hypothetical protein FLJ10607 similar to	7.9	79	1	6.2
		AW963705		molecule possessing ankyrin repeats indu	3.9	353	90	1.2
			Hs.9856	ESTs	3.1	31	1	1.3
	, ,0000			20.0		٠.	•	

		BE092285		hypothetical protein FLJ13187	20.9	209	1	19.5
		BE242691		ESTs	3.4	115	34	2.4
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.5 4.3	35 43	9 1	3.2 2
5		H44186 N63823	Hs.15456 Hs.269115	PDZ domain containing 1 ESTs, Moderately similar to Z195_HUMAN Z	4.3 5.4	43 54	1	4.3
,		AB037807		hypothetical protein	7.2	72	10	6.1
		N46180	Hs.122489	Homo sapiens cDNA FLJ13289 fis, clone OV	7.7	77	1	5
		AK000136		asporin (LRR class 1)	25.1	288	12	6.7
		AI815486		Homo sapiens cDNA FLJ20738 fis, clone HE	3.9	146	37	9.8
10	111190	AK002055	Hs.151046	hypothetical protein FLJ11193	6.3	63	1	5.8
		AB037782		KIAA1361 protein	3.7	119	33	6.7
		AA852773		KIAA1866 protein	3.6	402	112	4.9
		AW389845		ESTs	4.3	43	1	1
15		AA902656		NIF3 (Ngg1 interacting factor 3, S.pombe	3.3	33 61	1 13	1.1 5.6
13		AA345644 AW263155		PAN2 protein hypothetical protein FLJ10540	4.8 4.3	43	5	2.2
		W20090	Hs.6616	ESTs	4.1	41	ĭ	2.6
		BE314949		hypothetical protein FLJ23309	3.8	425	111	4
		AW160993		hypothetical gene DKFZp434A1114	4.3	65	15	5.7
20		AK000987		oxidation resistance 1	3.4	314	91	2.4
		U82670	Hs.9786	zinc finger protein 275	3.5	35	1	2.1
	111806	BE071382	Hs.279008	hypothetical protein FLJ20170	3.5	105	30	9.6
		AW502285		hypothetical protein FLJ12879	3.2	37	12	3.5
25		BE383234		Homo sapiens, clone MGC:15393, mRNA, com		62	2	5.9
25		AF027208		prominin (mouse)-like 1	8.1 4.2	328 125	41 30	1.7 7.4
		R40576	Hs.21590	hypothetical protein DKFZp564O0523 KIAA0942 protein	6.5	65	10	1.5
•		NM_015310 R44538	0113.0703	gb:yg29c02.s1 Soares Infant brain 1NIB H	3.3	33	10	2.3
		R41823	Hs.7413	ESTs; calsyntenin-2	6.1	185	31	6.6
30		NM_00365		ESTs	3.5	507	145	3.3
		AI432672	Hs.288539	hypothetical protein FLJ22191	3.5	40	12	2.5
	112244	AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
		R51818		gb:yg77h12.s1 Soares infant brain 1NIB H	4	70	18	6.8
25		R53734	Hs.25978	ESTs, Weakly similar to 2109260A B cell	3.7	37	1	3
35		AW972635		hypothetical protein FLJ12671	4.3	45 751	11	4.4
		AA863360		ESTs, Weakly similar to fatty acid omega	2.8 3.5	751 41	270 12	1.3 3.7
		AK000914 AW969785		hypothetical protein FLJ10052 Homo sapiens cDNA FLJ11321 fis, clone PL	4.2	42	6	3.6
		R68425	Hs.13809	hypothetical protein FLJ10648	4.7	54	12	4.5
40		AA412205		ESTs	4:8	48	2	3.4
		Z42387	Hs.83883	transmembrane, prostate androgen induced	4.5	390	87	5.3
	113023	AL134324	Hs.7312	ESTs	3.2	99	31	3.1
		A1571940	Hs.7549	ESTs	9.6	124	13	9
4.5		N39342	Hs.103042	microtubule-associated protein 1B	9.1	91	6	8.3
45		AA283057		hypothetical protein FLJ14281	6.5 3.5	65 35	6 1	4.8 1.4
		T66847 AW449560	Hs. 194040	ESTs, Weakly similar to I38022 hypotheti inner mitochondrlai membrane peptidase 2	3.5	35	4	3.3
		AI791905	Hs.95549	hypothetical protein	7.6	76	1	4.2
		A1075407	Hs.296083	ESTs, Moderately similar to I54374 gene	3.1	453	148	7
50		AI869372	Hs.17207	Homo sapiens cDNA FLJ11922 fis, clone HE	3.6	36	4	2.6
		T97307		gb:ye53h05.s1 Soares fetal liver spleen	12.3	129	11	11.7
		AL359588	Hs.7041	hypothetical protein DKFZp762B226	4.6	46	4	4.3
	113791	AI269096	Hs.135578	chitobiase, di-N-acetyl-	3.6	36	1	1.2
E E		T62849	Hs.11090	membrane-spanning 4-domains, subfamily A	3.3	744	227	2.5
55		BE247683		dual specificity phosphatase 11 (RNA/RNP	3.3 5.1	180 51	54 5	2.1 4.5
		W44735 NM_00503	Hs.9286	Homo sapiens cDNA: FLJ21278 fis, clone C plastin 3 (T isoform)	3.2	238	75	2.1
		AA457211		bromodomain adjacent to zinc finger doma	4.3	43	8	3.6
	113867	AW002834	Hs.24095	ESTs	6.1	110	18	10.2
60		W76027	Hs.23920	hypothetical protein FLJ11105	4	48	12	4
		AW953484		hypothetical protein FLJ22041 similar to	3.7	239	65	3.6
		W17056	Hs.83623	nuclear receptor subfamily 1, group I, m	4.3	819	191	1.2
		Al267652	Hs.30504	Homo saplens mRNA; cDNA DKFZp434E082 (fi		123	12	7
<i>C</i> =		AI825386	Hs.164478	hypothetical protein FLJ21939 similar to	4.4	44	6	2.3
65			Hs.177534	dual specificity phosphatase 10	4.5 3.5	45 35	4 6	2.6
	114057	AF116653 AK001612	∏3,34 [3Z He 26062	Homo sapiens PRO0823 mRNA, complete cds Homo sapiens cDNA FLJ10750 fis, clone NT	3.1	35 31	5	3.2 1.5
	114002	ANWIOIZ	110,40304	Lionio adhicila chiliA LETI IA (an ile) cione in i	V.1	٥.	•	1,5

	114124	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
		AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr		67	1	6.3
		AF155661		pyruvate dehydrogenase phosphatase	3.8	73	19	1.8
		AF017445		fucose-1-phosphate guanylyltransferase	4.4	104	24	5.1
5		AL049466		ESTs	5.7	57	1	4.9
		AL137667		Homo saplens mRNA; cDNA DKFZp434B231 (fr	3.3	33	1	2.4
	114251		Hs.21948	ESTs	4.2	46	11	1.4
		AF100143		fibroblast growth factor 13	4.5	45	2	3
		AF183810		trichorhinophalangeal syndrome I	4.4	44	1	3
10	114542	AW970128	Hs.91011	anterior gradient 2 (Xenepus laevis) hom	4.7	770	166	5.8
			Hs.107149	novel protein similar to archaeal, yeast	5.2	52	3	2.3
			Hs.154443	minichromosome maintenance deficient (S.	4.6	196	43	10
		AF212848	Hs.182339	ets homologous factor	13.7	137	1	8.9
		AV656017		CGI-76 protein	3.3	168	51	7.3
15		AA159181		serologically defined colon cancer antig	7.4	137	19	1.8
	114821	AI648602	Hs.55468	ESTs	4.7	57	12	4.7
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	9.1	91	1	7.6
		BE165762		hypothetical protein from BCRA2 region	10.1	111	11	10.2
		BE092696		ESTs	6.4	67	11	5
20	114965	A1733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
		AW162998		KIAA1376 protein	9.4	94	8	7.3
		AA251089		gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens	11.5	115	1	6.9
		AA329340	Hs.4867	mannosyl (alpha-1,3-)-glycoprotein beta-	4.2	42	9	1.1
	115054	AW265668	Hs.87729	hypothetical protein FLJ12428	5.1	51	1	4.2
25	115061	Al751438	Hs.41271	Homo sapiens mRNA full length insert cDN	4.5	290	65	3.7
		NM_014158	3Hs.279938	HSPC067 protein	4.8	48	1	4.4
	115142	AI623693	Hs.191533	ESTs	3.2	49	16	4.2
	115188	AK000219	Hs.88367	hypothetical protein FLJ20212	3.3	33	1	3
		AW183695		ESTs	5.8	58	1	5
30	115221	AW365434	Hs.79741	hypothetical protein FLJ10116	5.5	343	62	2.5
			Hs.88594	ESTs	11.2	112	1	10.3
		BE545072	Hs.122579	hypothetical protein FLJ10461	4.5	96	21	7.8
	115536	AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act	5.9	59	1	4.2
		NM 012317		leucine zipper, down-regulated in cancer	9.8	98	1	8.8
35		AA081395		Homo sapiens cDNA FLJ10366 fis, clone NT	4.6	46	2	1.8
			Hs.208414	Homo sapiens mRNA; cDNA DKFZp564D0472 (f	4.4	44	7	1.1
	115646		Hs.305971	solute carrier family 2 (facilitated glu	3.2	372	115	2.1
		AW992356	Hs.8364	Homo sapiens pyruvate dehydrogenase kina	10.2	506	50	2.8
	115675	W87707	Hs.82065	interleukin 6 signal transducer (gp130,	5.2	405	78	10.1
40	115719	AW992405	Hs.59622	Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
	115725	AW899053	Hs.76917	F-box only protein 8	3.1	58	19	2.5
	115764	AW582256	Hs.91011	anterior gradlent 2 (Xenepus laevis) hom	5.7	368	65	28.5
	115821	AW338063	Hs.130965	zinc-finger protein ZBRK1	3.9	39	8	2.2
	115825	R50956	Hs.159993	gycosyltransferase	4.2	79	19	1.9
45	115839	BE300266	Hs.28935	transducin-like enhancer of split 1, hom	5.8	58	1	4.4
	115844	Al373062	Hs.332938	hypothetical protein MGC5370	6.2	62	1	5.4
	115892	AA291377	Hs.50831	ESTs	3.2	40	13	0.7
	115967	AI745379	Hs.42911	ESTs	8.4	101	12	8.7
	116093	AW673312	Hs.50848	hypothetical protein FLJ20331	3.6	36	1	2
50	116097	Al198719	Hs.176376	ESTs	5.1	51	1	2
	116107	AL133916	Hs.172572	hypothetical protein FLJ20093	3.4	34	8	1
	116127	AF126743	Hs.279884	DNAJ domain-containing	3.5	35	8	3.3
				putative ribonuclease III	4.5	45	9	3.4
	116204	AW861622	Hs.108646	Homo sapiens cDNA FLJ14934 fis, clone PL	5.2	52	4	3.9
55	116226	AW976438	Hs.17428	RBP1-like protein	3.8	38	7	2.1
	116238	AV660717	Hs.47144	DKFZP586N0819 protein	5.1	198	39	17.9
	116250	N76712	Hs.44829	ESTs, Weakly similar to I38022 hypotheti	13.3	133	8	3.2
	116256	AA328153	Hs.88201	ESTs, Weakly similar to A Chain A, Cryst	3.3	106	33	9.8
	116298	Al955411	Hs.94109	Homo sapiens cDNA FLJ13634 fis, clone PL	4.8	179	38	2.8
60	116336	AL133033	Hs.4084	KIAA1025 protein	3.2	173	55	3
	116351	AL133623	Hs.82501	similar to mouse Xm1 / Dhm2 protein	3.7	37	1	1.8
		N50174	Hs.46765	ESTs	3.9	39	10	0.6
		AA448588	Hs.71252	hypothetical protein DKFZp761C169	5.6	106	19	9
		AF191018	Hs.279923	putative nucleotide binding protein, est	3.6	256	72	3.7
65		A1654450	Hs.47274	Homo saplens mRNA; cDNA DKFZp564B176 (fr		119	39	2
			Hs.58633	Homo sapiens cDNA: FLJ22145 fis, clone H	5.5	315	58	3.1
	116470	AI272141	Hs.83484	SRY (sex determining region Y)-box 4	3.4	496	144	1.6

	116507	AI418366	Hs.68501	ESTs	3.1	31	4	1.9
		AW888411		leukemia-associated phosphoprotein p18 (3.3	931	279	5.6
		F01601	Hs.241567	RNA binding motif, single stranded inter	3.6	36	1	1.9
5		AI768015	Hs.92127	ESTs	4.5	96	22	6.9
5		AW902848 F10577	Hs.273829 Hs.306088	ESTs v-crk avian sarcoma virus CT10 oncogene	4.2 7.1	42 71	1 9	2.7 6.9
		AA741307		hypothetical protein FLJ20073	4.3	190	44	5.4
		H25836	Hs.301527	ESTs, Moderately similar to unknown [H.s	22.8	228	9	12.4
		AW362955		Homo saplens cDNA FLJ14415 fis, clone HE	4.9	108	22	9
10	116790	AW161357	Hs.101174	microtubule-associated protein tau	4.6	163	35	7.3
		H64938	Hs.337434	ESTs, Weakly similar to A46010 X-linked	6.9	69	10	2.4
		AW085208		ESTs	4.8	48	1	2.5
		H91164	Hs.335797	ESTS	3.3 3.1	33 38	1 13	2.3 1.7
15		H95785 AW901347	Hs.167652	ESTs, Highly similar to 1819485A CENP-E hypothetical protein FLJ23342	4.8	48	1	0.9
13		N25929	Hs.42500	ADP-ribosylation factor-like 5	3.1	295	96	27.9
		W03011	Hs.306881	MSTP043 protein	3.6	41	12	2.8
		M18217	Hs.172129	Homo sapiens cDNA: FLJ21409 fis, done C	3.9	322	83	4.4
• •		Al041793	Hs.42502	ESTs	3.5	72	21	1.3
20		N32536	Hs.42645	solute camer family 16 (monocarboxylic	17.4	174	9	6.9
		N30205	Hs.93740	ESTs, Weakly similar to I38022 hypotheti	3.2	35	11	0.7 4.7
		AW341639 U59305	Hs.13323 Hs.44708	hypothetical protein FLJ22059	5 4.5	50 211 ₁	1 47	5
		AW877787		Ser-Thr protein kinase related to the my KIAA0853 protein	4.6	46	1	3.8
25		N49967	Hs.46624	HSPC043 protein	3.1	31	<u>i</u>	2,7
		AI521436	Hs.38891	ESTs	4.9	49	1	4.4
	118138	AA374756	Hs.93560	Homo sapiens mRNA for KIAA1771 protein,	5	50	2	3.1
		Al813865	Hs.164478	hypothetical protein FLJ21939 similar to	3.6	89	25	0.9
20		AF091434		platelet derived growth factor C	3.2	378	117	2.8
30		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	14.5 3.1	145 199	1 64	2.4 1
		N66845 N22617	Hs.43228	gb:za46c11.s1 Soares fetal liver spleen Homo saplens cDNA FLJ11835 fis, done HE	3. i	60	5	3.7
		Al949952	Hs.49397	ESTs	3.3	81	25	1.5
		N79496	Hs.50824	EST, Moderately similar to I54374 gene N	3.4	740	217	2.8
35		AW134482		hypothetical protein FLJ13964	4.3	162	38	12.1
	118854	T58283	Hs.10450	Homo sapiens cDNA: FLJ22063 fis, clone H	3.4	118	35	2.3
			Hs.44577	ESTs	3.5	35	1	2.9
		Al191811	Hs.54629	ESTs	8.4	84 73	10	0.8 5.4
40		AW292577 N29309	Hs.39288	ESTs ESTs	7.3 5	73 50	3 5	4.7
70		NM_01665		KDEL (Lys-Asp-Glu-Leu) endoplasmic retic	3.7	37	6	0.5
		N98488	7 1 13.200050	gb:zb82h01.s1 Soares_senescent_fibroblas	3.3	36	11	0.6
		R39261	Hs.90790	Homo sapiens cDNA: FLJ22930 fis, clone K	3.3	167	51	2.6
	119126	R45175	Hs.117183	ESTs	5.3	53	6	2.3
45		H09334	Hs.92482	ESTs	3.7	37	4	3
		AI061118	Hs.65328	Fanconi anemia, complementation group F	8.2 4	82	1	6.4 1.2
		NM_00124 BE048061		cyclin T2 ephdn-A3	3.3	40 571	4 171	2
		T78324	Hs.250895	ribosomal protein L34	3.4	34	3	2.4
50		AW474547		Homo sapiens PIG-M mRNA for mannosyltran	4.6	60	13	4.8
		AL079310		high-mobility group protein 2-like 1	8.1	94	12	6.5
	119586	AF088033	Hs.159225	ESTs	3.3	33	8	0.9
	119638	NM_01612	2Hs.56148	NY-REN-58 antigen	3.3	33	10	0.5
<i></i>		AA243837		ESTs	5.4	54	1	4.1
55		AA918317		B-cell CLL/lymphoma 11B (zinc finger pro	4.6	46 2072	7 595	0.8
		Al905687	Hs.2533	EST hypothetical protein	3.5 4.4	2073 44	1	2.1 3.1
		NM_01662 AL133396		prion protein 2 (dublet)	3.4	34	i	2.5
		AJ223810		ESTs, Weakly similar to IEFS_HUMAN TRANS	3.6	36	i	2.9
60		AW245741		ESTs, Weakly similar to A35659 krueppel-	5.2	52	6	1.8
		Al057404	Hs.58698	ESTs	3.7	37	4	1.9
	119940	AL050097	Hs.272531	DKFZP586B0319 protein	6.9	162	24	2.6
		BE565849		copine III	3.7	590	159	3.8
65	120132	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	6.9	319	47	2.1
65			Hs.153746	hypothetical protein FLJ22490	5.3 3.2	53 106	5 34	0.9 3.3
			Hs.108787 Hs.101590	phosphatidylinositol glycan, class N hypothetical protein	3.4	34	34 1	1.7
	120200	, 11 10 00 00 1	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				•	

	120206	AW995911	He 200883	hypothetical protein FLJ23399	4.2	124	30	1.8
		R06859	Hs.193172	ESTs, Weakly similar to I38022 hypotheti	7.5	112	15	2.5
			Hs.285728	abl-interactor 12 (SH3-containing protei	3.3	33	10	2.8
		AW966893		Homo sapiens mRNA; cDNA DKFZp586F1323 (f		48	1	0.5
5	120473	AA251973	Hs.269988	ESTs	3.4	34	4	0.1
		AW968080		Homo sapiens done 24630 mRNA sequence	3.9	161	42	2
		AA261852		ESTs	6.8	68	1	0.2
		AA284447		ESTs	3.2	32	5	0.6
10		BE244580		hypothetical protein FLJ10330	8.5	127	15	1.6
10		AB037744		KIAA1323 protein	3.7 3.6	37 36	1 8	0.5 0.2
		H39599 AA703226	Hs.294008	ESTs Homo sapiens mRNA; cDNA DKFZp586B211 (fr		101	18	1.6
		AA687322		leucine zipper protein FKSG14	5.4	54	10	2.5
		Al952639	Hs.98267	ESTs	3.2	32	8	3
15		AW449855		Homo sapiens cDNA FLJ12727 fis, clone NT	5.3	58	11	3.3
		Y19062	Hs.96870	staufen (Drosophila, RNA-binding protein	3.3	33	3	0.2
		AA347422		EST, Weakly similar to B34087 hypothetic	3.8	38	7	0.2
	120915	AL135556	Hs.97104	ESTs	3.5	37	11	0.1
20		AA481003		ESTs	3.1	31	1	0.4
20		AA398155		ESTs	7.9	79	1	2.7
		AI972375	Hs.29626	hypothetical brain protein my038	5.1	51	1	2.4
		AL042981		KIAA1201 protein	3.7 7	37 70	10 1	1 0.9
		AL121523 AA970946		ESTs ESTs	3.9	39	i	0.2
25		AA406293		ESTs	3.4	34	i	8.0
		AF044197		B-cell attracting chemokine 1 (CXCL13;	3.5	35	1	2.6
		AK000282		hypothetical protein FLJ20275	10.3	103	1	9.3
	121517	AI002968	Hs.235402	ESTs, Weakly similar to T26525 hypotheti	3.5	143	41	2.6
	121553	AA412488	Hs.48820	TATA box binding protein (TBP)-associate	4.6	46	3	8.0
30		AA412494	Hs.98152	EST	4.2	77	19	1,4
		AA416568	11 00044	gb:zu05c10.s1 Soares_testis_NHT Homo sap	3.2	32	1	0.8
		Al338247	Hs.98314	Homo sapiens mRNA; cDNA DKFZp586L0120 (f		34 214	10 74	0.7 3.7
		AA243499 AA449644		hypothetical protein FLJ10134	2.9 3.9	39	1	0.2
35		AA425887		Homo sapiens cDNA FLJ14201 fls, clone NT hypothetical protein FLJ14303	4.4	48	i 1	0.9
55		AV650929		splicing factor (CC1.3)	3.6	150	42	3.2
		AI249368	Hs.98558	ESTs; protease inhibitor 15 (PI15)	2.7	864	321	0.6
		AW117207		ESTs	3.5	35	3	2.3
	122004	AI810721	Hs.95424	ESTs	4.9	49	7	3.7
40		AW794215		KIAA1085 protein	3.2	88	28	1.2
		AF169797		adaptor protein containing pH domain, PT	12.6	126	7	7.5
		AA436475		membrane-associated nucleic acid binding	4.1	43 31	11 1	1.6 1
		AI298368 AA446189	Hs.150926	fucose-1-phosphate guanylyltransferase ESTs	3.1 3.3	53	16	4
45		BE567620		ESTs	3.2	291	91	4
75		AA449453		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.1	31	6	8.0
		AW651706		hypothetical protein FLJ14007	3.5	35	1	3
	122637	AA454149	Hs.99357	EST	3.2	32	10	3.1
		AW366286		splicing factor (CC1.3)	3.2	36	11	2.5
50	-	AA335721		ESTs	5.6	108	20	1.8
		AA749382		ubiquitin-conjugating enzyme E2D 3 (homo	3.6	36	1	3.4
		A1718702	Hs.308026	major histocompatibility complex, class	3.7 7.2	162 72	44 1	12.4 5.7
		AA478446 AA447871		KIAA1096 protein ESTs, Weakly similar to I38022 hypotheti	4.7	59	13	4.7
55		AW338067		Homo sapiens cDNA FLJ11946 fis, clone HE	3.3	207	63	3.5
		AL135185		niban protein	3.8	207	55	5.5
		AI073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
	123255	AA830335	Hs.105273	ESTs	4.1	72	18	1.5
		AA488988		ESTs	3.7	41	11	1.6
60		AA299652		Homo saplens cDNA FLJ11643 fis, clone HE	6.7	67	2	2.1
			Hs.112493	Homo sapiens mRNA; cDNA DKFZp564D036 (fr		34	1	2.6
			Hs.250528 Hs.112110	Homo sapiens, clone IMAGE:4098694, mRNA,	9.7 4.2	102 42	11 7	6 2.9
			Hs.293156	mitochondrial ribosomal protein L42 ESTs, Weakly similar to I78885 serine/th	3.9	39	1	3.2
65			Hs.173933	nuclear factor I/A	4.3	43	i	3.5
55	123518	AL035414	Hs.21068	hypothetical protein	5.8	58	1	4.9
	123523	AA608588		gb:ae54e06.s1 Stratagene lung carcinoma	3.1	927	295	2.1

	123527	AF150208	Hs.108327	damage-specific DNA binding protein 1 (1	5	121	25	5.9
	123570	AA608955	Hs.109653	ESTs	6.8	68	10	6.1
	123619	AA602964		gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	8.5	85	1	4.3
	123673	BE550112	Hs.158549	ESTs, Weakly similar to T2D3_HUMAN TRANS	3.9	39	5	3.7
5	123709	AA706910	Hs.112742		3.9	60	16	4.8
	123926	AA425769	Hs.227933	Alg5, S. cerevisiae, homolog of	3.4	80	24	3.8
	123960	AW082862	Hs.287733		4.5	45	2	3.6
			Hs.270016	ESTs	5.8	321	55	17
	124059	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypotheti	10.4	880	85	5.3
10	124287		Hs.5123	inorganic pyrophosphatase	3.1	41	14	2.7
	124292		Hs.13366	Homo saplens cDNA: FLJ23567 fis, clone L	3.2	32	1	1.5
		AA249027		ribosomal protein S6	10.5	105	1	9.9
		NM_005402		v-ral simian leukemia viral oncogene hom	12.8	141	11	12.2
		AF283776		Homo sapiens mRNA; cDNA DKFZp586C1723 (f		31	1	1.8
15			Hs.179864	ESTs	3.3	33	1	1.7
10	124677		113.11.300	qb:ye84c03.s1 Soares fetal liver spleen	4.2	42	7	3
	124777		Hs,140237	ESTs, Weakly similar to ALU1_HUMAN ALUS	3.4	210	63	3.3
		AF068846		heterogeneous nudear ribonudeoprotein	6.5	162	25	14.7
	125079		Hs.271396	ESTs	3.1	31	6	2.4
20	125079		NS.21 1330		3.4	985	286	2.8
20			Un 400720	gb:ye20f05.s1 Stratagene lung (937210) H	3.6	224	63	4
		AA570056		ESTs, Moderately similar to KIAA1215 pro	6.3	63	6	5
		AB037742	TIS.24336	KIAA1321 protein		38	11	2.6
		W38240) (= 050700	Empirically selected from AFFX single pr	3.6	31	1	
25		W93048	Hs.250723	hypothetical protein MGC2747	3.1		12	2.8
25		AA782536		N-myristoyltransferase 2	3.2	37	1	3.6
		AW401809		KIAA1150 protein	13.1	131		5.1
	125299		Hs.102720	ESTs	7.7	81	11	7.6
		AA173319		hypothetical protein MGC12217	14.3	143	9	13.1
20		W72949	Hs.77495	UBX domain-containing 1	3.3	34	11	3.2
30	-	AL038165		translocase of outer mitochondrial membr	8.2	124	15	11.5
	-	AA421691		UDP-glucose ceramide glucosyltransferase	3.7	224	61	21
		AA287921		ESTs	6.7	67	1	6
	125621		Hs.278544	acetyl-Coenzyme A acetyltransferase 2 (a	5.5	55	10	4.2
25 .			Hs.241493	natural killer-tumor recognition sequenc	5.5	63	12	1
35 ·		AW292171		scaffold attachment factor B	4.3	68	16	2.8
			Hs.191356	general transcription factor IIH, polype	4.8	48	5	4.1
			Hs.75722	ribophorin II	6.8	223	33	2.8
		AA143045		v-kit Hardy-Zuckerman 4 feline sarcoma v	8.3	87	11	0.4
40		NM_003403		YY1 transcription factor	11.3	124	11	9.7
40		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (f	30.6	306	4	26.5
	126349		Hs.13531	hypothetical protein FLJ10971	4.9	68	14	1.4
		AW090198	Hs.4779	KIAA1150 protein	6.4	74	12	6.6
	126590	W78968	Hs.181307	H3 histone, family 3A	5	264	53	3.4
		AA316181		six transmembrane epithelial antigen of	3.8	38	1	2.7
45			Hs.181297	ESTs	3.6	36	6	2.9
	126695	AA643322	Hs.172028	a disintegrin and metalloproteinase doma	3.1	31	1	2.5
	126764	AA036755	Hs.102178	syntaxin 16	4.4	76	18	1
	126801	AW663887	Hs.7337	hypothetical protein FLJ10936	3.8	38	1	3
	126813	AW163483	Hs.48320	double ring-finger protein, Dorfin	6.7	155	23	1.4
50	126838	AL043489	Hs.279609	mitochondrial carrier homolog 2	8.8	110	13	10.5
	126855	AA129640	Hs.128065	ESTs	3.6	36	10	1.9
	126971	T26989	Hs.283664	aspartate beta-hydroxylase	5.5	79	15	4.4
	127167	AA625690	Hs.190272	ESTs	3.1	33	11	2.3
	127251	AA936428	Hs.128638	ESTs	3.5	35	1	3.1
55	127349	AA412108	Hs.269350	ESTs	4.8	106	22	1
	127439	D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr	7.5	75	1	6.5
	127537	AI926047	Hs.162859	ESTs	3.8	38	7	3.4
	127542	AA703684	Hs.245474	ESTs, Moderately similar to ALU5_HUMAN A	3.3	33	9	0.9
	127677	AF175265	Hs.264190	vacuolar protein sorting 35 (yeast homol	4.3	152	35	12.5
60	127774	AA313639	Hs.119488	cysteln-rich hydrophobic domain 2	5.4	73	14	6.8
	127999	AW978827	Hs.69851	nucleolar protein family A, member 1 (H/	5.2	81	16	1.1
			Hs.292154	stromal cell protein	3.9	220	57	2.5
		AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3
_			Hs.100261	Homo sapiens mRNA; cDNA DKFZp564B222 (fr	4.6	46	8	3.9
65	128482	Al694143	Hs.296251	programmed cell death 4	7.2	72	1	5.8
	128501	AL133572	Hs.199009	protein containing CXXC domain 2	3.8	38	1	0.9
	128517	AW994403	Hs.100861	hypothetical protein FLJ14600	5.6	73	13	6.1

	128530	AI932995	Hs.183475	Homo sapiens done 25061 mRNA sequence	4.2	104	25	7.8
		N25956	Hs.101810	Homo sapiens cDNA FLJ14232 fls, clone NT	3.1	172	55	3.1
		U31875	Hs.272499	short-chain alcohol dehydrogenase family	3.3	105	32	3
_	128610	N48373	Hs.10247	activated leucocyte cell adhesion molecu	7.3	106	15	5
5		D87432	Hs.10315	solute camer family 7 (cationic amino	3.1	31	1	2.2
		AA307211		proteasome (prosome, macropain) subunit,	3.6	130	36	3.5
		NM_004131		granzyme B (granzyme 2, cytotoxic T-lymp	3.9	43	11	1.8
		AF026692		secreted frizzled-related protein 4	17.4	409	24	7.8
10		AB011125		KIAA0553 protein	3.1	34	11	2.7
10		NM_014720		Ste20-related serine/threonine kinase	3.6	36 288	5 87	1.5 7.9
		AK001731 R57988		Homo sapiens mRNA; cDNA DKFZp586H0924 (f	11.3	113	8	2.5
		R67419	Hs.10706 Hs.21851	epithelial protein lost in neoplasm beta Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
		AA009647		a disintegrin and metalloproteinase doma	4.6	132	29	9.7
15		AA115333		ESTs	8.2	82	1	7.4
10		BE250162		dihydrofolate reductase	5	50	1	3.3
		L12350	Hs.108623	thrombospondin 2	3.2	814	257	2.4
		N23018	Hs.171391	C-terminal binding protein 2	4.4	44	1	3.8
	129168	AI132988	Hs.109052	chromosome 14 open reading frame 2	14.2	142	6	9.4
20	129229	AF013758	Hs.109643	polyadenylate binding protein-interactin	7.1	71	1	6.2
	129243	BE169531	Hs.109727	TAK1-binding protein 2; KIAA0733 protein	5	64	13	6.3
		AF220050		uncharacterized hematopoietic stem/proge	5.2	75	15	6.4
		NM_015344		leptin receptor overlapping transcript-l	3.7	39	11	3.2
25		NM_014918		KIAA0990 protein	9.5	95	1	8.5
25		AL049538		ras association (RalGDS/AF-6) domain con	7.6	92	12	1.4 14.5
		BE220806		Homo sapiens clone 23785 mRNA sequence	7.1 3.9	150 54	21 14	5.1
		BE219987 X61959		phosphatidylinositol glycan, class F aspartylglucosaminidase	3.6	36	1	2.7
		NM_005754	Hs.207776	Ras-GTPase-activating protein SH3-domain	4	40	4	3.2
30		AW964541		hypothetical protein FLJ21127	4.6	199	44	2.3
50		N30436	Hs.11556	Homo sapiens cDNA FLJ12566 fis, clone NT	4.2	42	1	3.8
		M26939	Hs.119571	collagen, type III, alpha 1 (Ehlers-Dani	6.4	1111	175	5
		BE242144		ATP-binding cassette, sub-family E (OABP	4.8	48	8	3.8
		NM_001415		eukaryotic translation initiation factor	5.8	171	30	2.9
35		BE165866		nuclear receptor subfamily 1, group I, m	4.5	45	1	2.4
	129755	R42216	Hs.12342	Homo sapiens clone 24538 mRNA sequence	5.3	53	9	3.6
		R39246	Hs.239666	Homo saplens cDNA FLJ13495 fis, clone PL	3.1	31	2	2.5
		AB028945		cortactin SH3 domain-binding protein	11.4	114	1	10
40		AI222069	Hs.13015	hypothetical protein similar to mouse Dn	4.7	556	119	4.5
40		T71333	Hs.13854	ESTs	3.1	31	3	3
		NM_000399		early growth response 2 (Krox-20 (Drosop	3.2	32	1	0.2 5.7
		BE061916		chromosome 8 open reading frame 2	6.7 1	67 1	1	1
	_	AF027153 AK001635		solute carrier family 5 (inositol transp hypothetical protein FLJ10773	14.6	219	15	7.6
45		T47294	Hs.149923	X-box binding protein 1	3.1	1336	434	1.4
7,7		AW977534		calcium/calmodulin-dependent serine prot	5.3	53	9	3.2
		U38847	Hs.151518	TAR (HIV) RNA-binding protein 1	4.2	46	11	1.1
		AB040914		KIAA1481 protein	13.2	331	25	12.4
		AF127577		nuclear receptor interacting protein 1	3.3	354	108	4
50	130367	AL135301	Hs.8768	hypothetical protein FLJ10849	8.1	81	9	5.5
	130385	AW067800	Hs.155223	stanniocalcin 2	72.2	722	1	1.9
		BE385099		hypothetical protein MGC3017	6.5	65	4	5.3
		AW163518		huntingtin interacting protein 2	3.5	79	23	2.5
<i></i>		U63630	Hs.155637	protein kinase, DNA-activated, catalytic	6.1	61	1 .	5.7
55		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
		W19744	Hs.180059	Homo sapiens cDNA FLJ20653 fis, clone KA	3.9	39	1	1.9
		AW876523		hypothetical protein FLJ12910	3.9 4.4	39 44	1	2.6 4.1
		AA383092 AA383256		replication protein A3 (14kD) estrogen receptor 1	32.2	322	1	4.7
60		AI354355	Hs.16697	down-regulator of transcription 1, TBP-b	5.2	251	48	21
UU		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	10	100	1	7.6
		Al963376	Hs.12532	chromosome 1 open reading frame 21	3.9	39	1	3.4
		AF176012	Hs.260720	J domain containing protein 1	10.5	105	i	9
		AL161961	Hs.17767	KIAA1554 protein	6.8	129	19	12.1
65	130681	R62676	Hs.17820	Rho-associated, colled-coll containing p	4.1	41	1	3.6
	130693	R68537	Hs.17962	ESTs	9.2	234	26	16.8
	130712	AJ271881	Hs.279762	bromodomain-containing 7	17.5	175	2	12.8

	130723	BE247676	Hs.18442	E-1 enzyme	8.1	81	3	2.8
	130751	AF052105	Hs.18879	chromosome 12 open reading frame	4.9	49	1	4.3
	130780	AA197226	Hs.19347	hypothetical protein MGC11321	3.6	100	28	6.6
_	130863	Y10805	Hs.20521	HMT1 (hnRNP methyltransferase, S. cerevi	3.4	525	154	5.3
5		AF080158		inhibitor of kappa light polypeptide gen	10.5	121	12	1.6
	130888	AL044315	Hs.173094	Homo sapiens mRNA for KIAA1750 protein,	6	202	34	3.7
		NM_003528		H2B histone family, member Q	7.1	100	14	7.5
		NM_01244		single-stranded-DNA-binding protein	3.2	87	27	1.7
10	_	BE613269		hypothetical protein DKFZp761N0624	3.5	124	35	6.5
10		T97401	Hs.21929	ESTs	4.5	45	1	2.5
•		AA749230		dolichyl-phosphate (UDP-N-acetytglucosam	3.2	210	66	3.8
		BE207357		KIAA1821 protein	3.8	42	11	0.6
		NM_01615		KIAA1073 protein	6.7	67	6	1.9
1.5		BE541042		Homo sapiens cDNA: FLJ21848 fis, clone H	5.8	115	20 153	2.5
15		AW953575		p53-induced protein PIGPC1	3.8 5.2	585 1320	256	3.7 3.2
		AW013807 AA465113		keratin 19	3.8	38	1	3.3
		BE540516		ESTs, Weakly similar to A34615 profilage hypothetical protein MGC3195	4.8	48	i	4.1
		AI815486	Hs.243901	Homo sapiens cDNA FLJ20738 fis, done HE	6.1	343	56	16.4
20		AL080080		thioredoxin domain-containing	8	100	13	2.9
20		A1038989	Hs.332633	Bardet-Biedl syndrome 2	4	95	24	1.1
		AW206008		Homo sapiens cDNA: FLJ21778 fis, clone H	4.6	239	53	3.5
		NM_00315		stanniocalcin 1	3.5	402	114	2.1
			Hs.173933	nuclear factor I/A	3.3	775	233	2.4
25		AW293165		ESTs	3.8	38	1	3
	131379	AK001123	Hs.26176	hypothetical protein FLJ10261	3.9	116	30	0.5
	131388	NM_01481	0Hs.92200	KIAA0480 gene product	7.6	76	1	5
	131475	AA992841	Hs.27263	KIAA1458 protein	5.1	113	22	6.1
	131492	AI452601	Hs.288869	nuclear receptor subfamily 2, group F, m	8.4	169	20	4.6
30		AV661958		GK001 protein	3.1	197	63	18.7
		N22120	Hs.75277	hypothetical protein FLJ13910	5.9	59	1	4.4
		AL355715		programmed cell death 9 (PDCD9)	5.1	51	1	3.9
		AA093668		muscleblind (Drosophila)-like	3.8	79 250	21	6.9
25		NM_00351		H2A histone family, member L	4	350	88	3
35		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 fis, clone PL	4.7	381 46	81 7	6.4 3.8
		AA306477		hypothetical protein FLJ10687	4.6 3.2	82	26	6.6
		NM_002104 BE297635		granzyme K (serine protease, granzyme 3; heat shock 70kD protein 98 (mortalin-2)	6.7	93	14	8.4
		AB012124		transcription factor-like 5 (basic helix	3.8	51	14	1.7
40		AW963776		SAR1 protein	7.2	72	4	5.7
70		AF017986		secreted frizzled-related protein 2	2.1	1561	757	1.7
		AA961420		ESTs	11.7	117	1	10.1
		AB014548		KIAA0648 protein	4.8	48	1	4.6
		D87077	Hs.196275	KIAA0240 protein	3.2	207	64	5.5
45	131798	X86098	Hs.301449	adenovirus 5 E1A binding protein	3.4	115	34	9.1
	131836	W00712	Hs.32990	DKFZP566F084 protein	5.8	91	16	1.4
	131853	Al681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	4.9	632	129	1.7
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	6.8	68	1	5.6
5 0		AW361018		upstream regulatory element binding prot	4	140	35	1.8
50		BE502341		ESTs	5.7	57	1	4.5
		AF078866		Homo sapiens cDNA: FLJ22993 fis, clone K	5.5	90	17	2.9
		T15803	Hs.272458	protein phosphatase 3 (formerly 2B), cat	5.6	95	17 14	9.1 6.5
		BE252983		ubiquitin specific protease 1	7.4 3.7	103	1	3.4
55		NM_00291	Hs.258798	replication factor C (activator 1) 4 (37 hypothetical protein FLJ20003	3.5	37 35	i	2.5
33		W79283	Hs.35962	ESTs	5.5	168	31	4.4
		U90441	Hs.3622	procollagen-proline, 2-oxoglutarate 4-di	3.7	37	9	2.8
		AA503020		hypothetical protein FLJ22418	40.2	402	1	4
		AI878910	Hs.3688	cisplatin resistance-associated overexpr	7.3	73	1	1.2
60		AA121098		serum-inducible kinase	22.6	226	10	0.9
		NM_01604		CGI-107 protein	3.1	227	73	16.8
	132109	AW190902	Hs.40098	cysteine knot superfamily 1, BMP antagon	3.5	73	21	6.3
	132116	AW960474	Hs.40289	ESTs	3.6	141	39	12.6
	132143	D52059	Hs.7972	KIAA0871 protein	4.9	49	1	4.1
65	132160	W26406	Hs.295923	seven in absentia (Drosophila) homolog 1	4.4	53	12	2.1
	132164	AI752235	Hs.41270	procollagen-lysine, 2-oxoglutarate 5-dio	5	225	45	9.1
	132180	NM_00446	UHs.418	fibroblast activation protein, alpha	10.7	433	41	7.2

	132197	AI699482	Hs.42151	ESTs	3.4	58	17	4
		AI078645		murine leukemia viral (bmi-1) oncogene h	4.2	42	1	2.2
	132298	NM_01598	6Hs.7120	cytokine receptor-like molecule 9	3.4	34	2	3
-		U28831	Hs.44566	KIAA1641 protein	18.6	186	10	1.5
5		N37065	Hs.44856	hypothetical protein FLJ12116	5.5	323	59	10.5
		NM_00354		H4 histone family, member G	3.3	979	298	2.2
		AA312135		HSPCO34 protein	3.6	36 196	1	3.1
		W32624 AL135094	Hs.278626	Arg/Abl-interacting protein ArgBP2	5.9 4.2	186 159	32 38	3.7 7.1
10		BE613126		hypothetical protein FLJ14495 B aggressive lymphoma gene	4.6	46	1	4.3
10		N87549	Hs.125287	zinc finger protein ZNF140-like protein	3.6	146	41	1.1
		AB020699		KIAA0892 protein	3.3	33	4	2.9
		AW169847		KIAA1634 protein	8.3	145	18	3.7
		AB023164		KIAA0947 protein	4.6	46	1	4.4
15	132528	T78736	Hs.50758	SMC4 (structural maintenance of chromoso	9.3	93	1	8.4
	132530	AA306105	Hs.50785	SEC22, vesicle trafficking protein (S. c	4.9	49	1	4.4
		BE568452		protein regulator of cytokinesis 1	11.8	201	17	19.1
		Al929659		signal recognition particle 72kD	3.8	38	1	3
20		AW803564		Homo sapiens cDNA: FLJ22528 fis, clone H	4.8	93	20	3.1
20		AW606927		hypothetical protein DKFZp586F1122 simil	6.1 3.4	61 193	2 58	5.9 12.3
		BE262677 AF037335		hypothetical protein PRO1855 carbonic anhydrase XII	14.2	390	28	22.5
		AL050025	_	hypothetical protein FLJ20151	3.3	909	274	3.2
		AU076916		guanine monphosphate synthetase	5	50	1	4.1
25		AB018319		KIAA0776 protein	4.2	171	41	12.6
		AA025480		ESTs, Weakly similar to T33468 hypotheti	6.5	65	1	5.6
	132790	AW242243	Hs.168670	peroxisomal famesylated protein	3.7	37	1	2.2
	132811	U25435	Hs.57419	CCCTC-binding factor (zinc finger protei	7	115	17	5.4
••		AL120050		Homo sapiens cDNA: FLJ23005 fis, clone L	3.3	61	19	5.1
30		NM_00144		glypican 4	4.8	48	1	3.6
		BE077155		hypothetical protein DKFZp761B1514	12.6	126	8	9.9
		AI936442	Hs.59838	hypothetical protein FLJ10808	11 3.3	187 106	17 33	10.4 2.6
		BE613337 AL047045		geminin Homo sapiens clone 122482 unknown mRNA	3.5	110	32	2.1
35		AF234532		myosin X	4.1	62	15	4.9
55		AA093322		RNA binding motif protein 3	22.1	221	9	17.8
		X77343	Hs.334334	transcription factor AP-2 alpha (activat	12.7	311	25	2.4
	132994	AA112748	Hs.279905	done HQ0310 PRO0310p1	3	380	127	5.5
	133011	NM_00637	9Hs.171921	sema domain, immunoglobulin domain (ig),	7.3	271	37	2.3
40		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4
		U92649	Hs.64311	a disintegrin and metalloproteinase doma	3.6	36	1	3.1
		AK001628		KIAA0483 protein	5.2	117	23	5
		AA218564		vacuolar protein sorting 26 (yeast homol	3,1 5,1	359 58	118 12	2.5 5.7
45		Al275243 AF231981	Hs.180201	hypothetical protein FLJ20671 homolog of yeast long chain polyunsatura	3	816	275	3.9
77		W32474	Hs,301746	RAP2A, member of RAS oncogene family	3.1	234	76	8.6
		AK001489		ADP-ribosylation factor-like 1	8.1	81	1	4.6
		Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
	133291	BE297855	Hs.69855	NRAS-related gene	3.3	33	1	2.9
50	133294	AJ001388	Hs.69997	zinc finger protein 238	7.9	234	30	18.9
		AI499220	Hs.71573	hypothetical protein FLJ10074	4.6	46	5	3.5
		AK001519		CGI-74 protein	5	110	22	9.7
		AF245505		DKFZP564I1922 protein	3.2	725	227	3.2
55		AF017987		secreted frizzled-related protein 1	4.1 4.3	374 43	91 1	1.1 3.9
55		AB033061 Al929357	Hs.323966	KIAA1235 protein Homo sapiens clone H63 unknown mRNA	5.5	186	34	16.5
		W01556	Hs.238797	ESTs. Moderately similar to I38022 hypot	3.5	35	7	2.1
		AW998046		arginine-glutamic acid dipeptide (RE) re	3.6	39	11	0.4
	133504	NM_00441	5Hs.74316	desmoplakin (DPI, DPII)	4.1	640	158	3
60		NM_00016		gap junction protein, alpha 1, 43kD (con	3.2	351	111	5.2
	133536	W25797	Hs.177486	amyloid beta (A4) precursor protein (pro	3.2	226	71	2.8
	133578	AU077050		translin	3.4	178	53	8.8
	133633	D21262	Hs.75337	nucleolar and coiled-body phosphprotein	4.7	47	1	4
<i>(</i> =		AW246428		ubiquitin-conjugating enzyme E2N (homolo	8.5	85 36	1	7.2
65		NM_00692		splicing factor, arginine/serine-rich 5	3.6	36 234	1 68	-0.4 10.7
		Al352558 AW410035		tyrosine 3-monooxygenase/tryptophan 5-mo MAD (mothers against decapentaplegic, Dr	3.4 9.3	234 93	1	7.8
	155740	. 1117 10000	110.1 0002	in the fellowing addition accompanion big of the	0.0		•	

		M62194 AA557660	Hs.75929 Hs 76152	cadherin 11, type 2, OB-cadherin (osteob decorin	3.2 5.4	560 144	174 27	2.6 13.3
		BE622743		arfaptin 1	4.7	47	1	4.1
_		NM_002462		myxovirus (influenza) resistance 1, homo	3.3	380	114	4.9
5		AW630088		Homo sapiens mRNA; cDNA DKFZp564B1264 (f		304	46	7.8
		AA147026		ESTs	6.2	600	97	4.1
		AU076964 AA355986		calumenin	3.3 3.7	889 91	267 25	5 2.6
	133990		Hs.7822	transcription factor 8 (represses interl Homo sapiens mRNA; cDNA DKFZp564C1216 (f		91	25 27	8.5
10		AA535244		RAB2, member RAS oncogene family	7.8	78	1	5.6
		NM_005025		serine (or cysteine) proteinase inhibito	5.9	59	1	3.3
		AF091622		KIAA0244 protein	5.8	58	1	4.9
		U51166	Hs.173824	.,	6.4	100	16	4.4
15	134089		Hs.79029		5.1	51	9	3.8
15		NM_004354		cyclin G2	5 4.8	50 246	1 51	3.2 3.9
		BE513171 U41060	Hs.79006 Hs.79136	mitochondrial ribosomal protein L3 LIV-1 protein, estrogen regulated	4.0 4.5	1472	330	2.1
		NM_014781		KIAA0203 gene product	4.6	69	15	5.8
		D28459	Hs.80612	ubiquitin-conjugating enzyme E2A (RAD6 h	7	97	14	7.5
20		C05768	Hs.8078	Homo sapiens clone FBD3 Cri-du-chat crit	3.4	34	5	2.6
	134272	X76040	Hs.278614	protease, serine, 15	3.6	36	1	2.8
	134282		Hs.81057	hypothetical protein MGC2718	6.7	67	9	5.7
			Hs.8117	erbb2-interacting protein ERBIN	4.5	137	31	12
25		BE538082 AW903838		ESTs, Moderately similar to A46010 X-lin chondroitin sulfate proteoglycan 2 (vers	5.2 8.6	52 568	1 66	4.9 22.4
23		AW959281		ESTs	4.8	53	11	3.7
		AW291946		interleukin 6 signal transducer (gp130,	7.1	71	4	6.4
		NM_001982		v-erb-b2 avian erythroblastic leukemia v	3	68	23	2.8
		AA339449		phosphoribosylglycinamide formyltransfer	4.4	44	1	4.1
30		N22687	Hs.8236	ESTs	13.3	445	34	6
		AU077143		minichromosome maintenance deficient (S.	4.5	45	2	3.4
		AA456539		lysosomal	6 4.1	60 301	5 73	5.9 6.1
		Al916662 AW067903	Hs.211577	kinectin 1 (kinesin receptor) collagen, type XI, alpha 1	4.6	1216	267	4.4
35			Hs.82911	protein tyrosine phosphatase type IVA, m	4.9	163	34	15.1
-		NM_006416		solute carrier family 35 (CMP-slalic aci	4.9	49	3	3.8
		W95642	Hs.82961	trefoil factor 3 (intestinal)	3.2	1872	592	3.3
		AU077196		collagen, type V, alpha 2	6.3	1075	171	3.8
40		U29344	Hs.83190	fatty acid synthase	3.3	710	217 12	2
40	134485		Hs.83942	cathepsin K (pycnodysostosis)	34.3 4.8	411 153	12 32	5.1 4.3
		AF061739 D63477	Hs.84087	protein associated with PRK1 KIAA0143 protein	3.1	147	48	12.7
		BE091005		activated RNA polymerase II transcriptio	3.3	33	1	2
		M14156	Hs.85112	insulin-like growth factor 1 (somatomedi	4.2	42	5	2.6
45	134570	U66615	Hs.172280	SWI/SNF related, matrix associated, acti	3.9	39	1	2.5
		AW903849		HUEL (C4orf1)-Interacting protein	3.7	41	11	0.6
		NM_002884		RAP1A, member of RAS oncogene family	5.2	52	1	3
		AW068223 AW299723		ubiquitin C-terminal hydrolase UCH37 bone morphogenetic protein receptor, typ	4.9 5.2	49 52	1 5	3.7 3.5
50		AK001741		hypothetical protein FLJ10879	6.4	64	1	5.1
50		Al750878	Hs.87409	thrombospondin 1	12.6	126	1	10.8
		AF271212		disrupter of silencing 10	5.4	81	15	2.6
	134700	AK000606	Hs.8868	golgi SNAP receptor complex member 1	3.4	179	52	1.5
	134711		Hs.88974	cytochrome b-245, beta polypeptide (chro	3.2	143	45	13.9
55			Hs.284226	F-box only protein 6	7	70	6	6
			Hs.9030	TONDU 15 kDa selenoprotein	3.1	31 57	1	2.3 5
	134917	AI879195	Hs.90606 Hs.166994	FAT tumor suppressor (Drosophila) homolo	5.7 3.2	57 153	48	4.7
			Hs.125511	Homo sapiens mRNA; cDNA DKFZp434P1530 (f		452	114	2
60			Hs.92308	Homo sapiens cDNA FLJ11223 fis, clone PL	5.1	150	30	7.2
		AW968058	Hs.92381	nudix (nucleoside diphosphate linked mol	8.2	114	14	9.9
	135029	H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
		AL034344	Hs.284186	forkhead box C1	5.4	259	48	1.4
65		Al272141	Hs.83484	SRY (sex determining region Y)-box 4	3.3	1296	394	2.2 3.2
65		AK000967 W55956	Hs.93872 Hs.94030	KIAA1682 protein Homo sapiens mRNA; cDNA DKFZp586E1624 (f	3.8	240 101	64 13	3.2 7.9
		AW274526		ovarian carcinoma antigen CA125	3.3	33	1	2.6
	.55000				J			-

	135117	W52493	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	5.3	53	1	4.1	
٠.	`135144	NM_01625	5Hs.95260	Autosomal Highly Conserved Protein	7.4	74	5	2,4	
	135154	AK001835	Hs.267812	sorting nexin 4	6.6	69	11	6.3	
_	135155	A1207958	Hs.166556	Homo sapiens, Similar to TEA domain fami	6.1	61	1	5.1	
5	135172	AB028956	Hs.12144	KIAA1033 protein	3.4	88	26	1.4	
	135242	AI583187	Hs.9700	cyclin E1	3.1	31	1	2.3	
	135243	BE463721	Hs.97101	putative G protein-coupled receptor	3.4	169	50	9.1	
	135269	NM_00340	3Hs.97496	YY1 transcription factor	3.4	475	142	2.5	
	135356	BE312948	Hs.18104	hypothetical protein FLJ11274	3.1	31	10	1.7	
10	135357	AI565004	Hs.79572	cathepsin D (lysosomal aspartyl protease	4.7	710	151	2.5	
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1	
	135397	L14922	Hs.166563	replication factor C (activator 1) 1 (14	3.2	32	1	2.4	
	-135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	3.2	117	37	9.4	
		AI471525	Hs.247486	ESTs	3.8	58	16	5.5	
15		X70683	Hs.93668	ESTs	1.8	1047	596	1.6	
		L14922	Hs.82128	5T4 oncofetal trophoblast glycoprotein	5	285	58	1.2	
		M23263	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotransfer	as	3.1	31	1	2.6
		Al267886	Hs.148027	polymerase (RNA) II (DNA directed) polypeptide	в	7.8	137	18	11.9
		AA044840	Hs.241676	stromal cell-derived factor 1	4.7	114	25	0.9	
20		N90960	Hs.227459	ESTs; Moderately similar to !!!! ALU SUBFAMIL	Υ	4.7	151	32	9.3
		AA873285	Hs.137947	ESTs	4.7	47	3	4.4	
		T56679	Hs.865	RAP1A; member of RAS oncogene family	4	40	1	3.4	
, -		AA305536		"EST176522 Colon carcinoma (Caco-2) cell line		3.6	121	34	11.8
0.5		Al369384		arylsulfatase D	3.5	113	33	1.7	
25		AA219081	Hs 242396	FSTs: Moderately similar to IIII ALU SUBFAMIL	Y1	3.4	107	32	9.9

TABLE 10A

Table 10 A shows the accession numbers for those pkeys lacking unigeneID's for Table 10. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: Unique Eos probeset identifier number

CAT number: Gene cluster number

Accession:

Genbank accession numbers

15

	Pkey	CAT number	Accession	
	123619	371681_1	AA602964 AA609200	
20	104602	524482_2	H47610 R86920	
	121581	283769_1	AA416568 AA442889 AA4	17233 AA442223
	123523	genbank_AA608588	AA608588	
	100821	tigr_HT4306	M26460 U09116	
	125091	genbank_T91518	T91518	
.25	125150	NOT_FOUND_entre:	_W38240 W38240	
	118475	genbank_N66845	N66845	
	104787	genbank_AA027317	AA027317	
	106055	genbank_AA417034	AA417034	
	113702	genbank_T97307	T97307	
30	101046	entrez_K01160	K01160	•
	101447	entrez_M21305	M21305	
	101624	entrez_M55998	M55998	
	124677	genbank_R01073	R01073	
	110581	genbank_H61560	H61560	
35	119023	genbank_N98488	N98488	
	110775	genbank_N22414	N22414	
	112092	genbank_R44538	R44538	
	112253	genbank_R51818	R51818	
_	107014	genbank_AA598820	AA598820	
40	114988	genbank_AA251089	AA251089	

TABLE 11: Figure 11 from BRCA 001-3 PCT

5 Table 11 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

10 15	Pkey: ExAcon: Unigene Unigene R1: R2: R3:	ExemelD: Unige Title: Unige Ratio Ratio	nplar Accessione number ene gene title of tumor to of 90th perce	eset identifier number ion number, Genbank accession number e normal body tissue entile tumor to normal body entile normal body to tumor				
15	R4:			normal breast tissue				
20	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
	100147 100522	D12485 D13666 X51501	Hs.11951 Hs.136348 Hs.99949	prolactin-induced protein	13.2 15.7 22.7 8.5	244 1030 760 85	19 66 34 1	9.9 5 1.4 3.2
25	101104 101478	L05424 AW862258 NM_00289 L11690	Hs.169266	CD44 antigen (homing function and Indian neuropeptide Y receptor Y1 RAS p21 protein activator (GTPase activa bullous pemphigoid antigen 1 (230/240kD)	9.6 9.4	153 96 94	1 1 1	14.1 8.5 0.3
30	101754 101888	S70114 AL049610	Hs.239489 Hs.95243	TIA1 cytotoxic granule-associated RNA-bi transcription elongation factor A (SII)- death associated protein 3	8.9 7.3 9.3	89 73 93	5 1 5	8 5.3 8
-	102304 102348 102457	AF015224 U37519 NM_00139- U63830	Hs.46452 Hs.87539 4Hs.2359	mammaglobin 1 aldehyde dehydrogenase 3 famlly, member dual specificity phosphatase 4 TRAF family member-associated NFKB activ	8.5 6.4 20.2 8.2	2058 428 202 82	243 67 5 1	1.4 2.3 1.3 6.8
35	102823 103557 103613	D85390	Hs.5057 Hs.297753 6Hs.2316	carboxypeptidase D	5.6 7.5 7.3 29	56 136 73 290	1 18 1	5.3 3.4 5.2 26.8
40	104804 104807 104896	Al239923 Al858702 Al139058 AW015318	Hs.23165	ESTs ESTs, Weakly similar to N-WASP [H.sapien leucine-rich repeat-containing 2 ESTs	14.9 7.7 7 7.4 16.2	149 77 70 74 162	1 1 1 1	6.4 5.1 6.5 6 4.2
45	105038 105329 105500 105516	AW503733 AA234561 AW602166 AK001269	Hs.9414 Hs.22862 Hs.222399 Hs.30738	frizzled (Drosophila) homolog 6 KIAA1488 protein ESTs CEGP1 protein hypothetical protein FLJ10407	5.5 2.8 25.4 8.3	55 131 508 83	1 47 20 3	5.2 3.9 3 1.8
50	106012 106095 106155	AW377314 AI240665 AF115402 AA425414 AB037765	Hs.8895 Hs.11713 Hs.33287	DKFZP564l052 protein ESTs E74-like factor 5 (ets domain transcript nuclear factor I/B KIAA1344 protein	6.9 21.2 26.3 9.9 6.3	69 212 356 483 63	1 6 14 49 1	4.4 17.4 1 1.8 5.4
55	107136 107151 107922	AV661958 AW378065 BE153855 AW151340	Hs.8207 Hs.8687 Hs.61460	GK001 protein ESTs Ig superfamily receptor LNIR ESTs, Weakly similar to ALU7_HUMAN ALU S	2.5 15.6 9 18.7	392 156 90 187	155 7 1 1	4.3 10.8 5.5 17
60	109292 109415	AW975746 U80736	Hs.188662 Hs.110826	hypothetical protein FLJ13782 KIAA1702 protein trinucleotide repeat containing 9 L-kynurenine/alpha-am/noadipate aminotra	4.1 7.1 12.3 14.2	334 71 123 142	82 1 1	3.4 6.5 11.3 9.5
00	110009 110915	BE075297 BE092285 N46180	Hs.6614 Hs.29724	ESTs, Weakly similar to A43932 mucin 2 p hypothetical protein FLJ13187 Homo sapiens cDNA FLJ13289 fis, clone OV	6.3 20.9 7.7	693 209 77	110 1 1	7.2 19.5 5

	111179	AK000136	He 10760	asporin (LRR class 1)	25.1	288	12	6.7
				hypothetical protein FLJ11193	6.3		1	5.8
		AA852773		KIAA1866 protein	3.6		112	4.9
				hypothetical protein FLJ23309	3.8		111	4
5		AB029000	Hs.70823	KIAA1077 protein	5.7	567	100	6.7
		Al571940	Hs.7549	ESTs	9.6		13	9
	113702			gb:ye53h05,s1 Soares fetal liver spleen	12.3	129	11	11.7
	114124	W57554	Hs.125019	lymphoid nuclear protein (LAF-4) mRNA	24.2	242	10	5.6
	114138	AW384793		Homo sapiens mRNA; cDNA DKFZp434E033 (fr	6.7	67	1	6.3
10	114768	AF212848	Hs.182339	ets homologous factor	13.7	137	1	8.9
	114860	AL157545	Hs.42179	bromodomain and PHD finger containing, 3	9.1	91	1	7.6
	114965	Al733881	Hs.72472	BMP-R1B	35.9	359	10	29.7
	114988	AA251089		gb:zs04f05.s1 NCI_CGAP_GCB1 Homo sapiens	11.5	115	1	6.9
			Hs.186572		5.8	58	1	5
15		AW992405		Homo sapiens, clone IMAGE:3507281, mRNA,	7.6	144	19	13.9
		Al373062		hypothetical protein MGC5370	6.2 ·	62	1	5.4
		AI272141	Hs.83484	SRY (sex determining region Y)-box 4	1.8	1047		1.6
		H25836		ESTs, Moderately similar to unknown [H.s	22.8		9	12.4
20		M18217		Homo sapiens cDNA: FLJ21409 fis, clone C	3.9		83	4.4
20		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	17.4		9	6.9
		AL157545	Hs.42179	bromodomain and PHD finger containing, 3	14.5	145	1	2.4
		AI061118	Hs.65328	Fanconi anemia, complementation group F	8.2	82	1	6.4 2.1
•		Al905687	Hs.2533	EST	3.5	2073 127	15	1.6
25		BE244580 AK000282		hypothetical protein FLJ10330	8.5 10.3	103	1	9.3
23		AA243499		hypothetical protein FLJ20275 hypothetical protein FLJ10134	2.9		74	3.7
				KIAA1096 protein	7.2	72	1	5.7
		AI073913		ESTs, Weakly similar to JE0350 Anterior	9.9	351	36	13.9
		AA602964	113.100000	gb:no97c02.s1 NCI_CGAP_Pr2 Homo sapiens	8.5	85	1	4.3
30			Hs.112742		3.9	60	16	4.8
20		Al147155	Hs.270016		5.8		55	17
				ESTs, Weakly similar to S64054 hypotheti	10.4		85	5.3
		AA249027		ribosomal protein S6	10.5	105	1	9.9
	125279	AW401809		KIAA1150 protein	13.1	131	1	5.1
35	125617	AA287921	Hs.164950		6.7	67	1	6
		D60237	Hs.14368	SH3 domain binding glutamic acid-rich pr	30.6	306	4	26.5
	128305	Al954968	Hs.279009	matrix Gla protein	7.5	75	1	6.5
	128482	Al694143	Hs.296251	programmed cell death 4	7.2	72	1	5.8
	128790	AF026692	Hs.105700	secreted frizzled-related protein 4	17.4	409	24	7.8
40		R67419	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	7.1	392	56	3.6
	-		Hs.107968		8.2	82	1	7.4
		AF013758		polyadenylate binding protein-interactin	7.1	71	1	6.2
				KIAA0990 protein	9.5	95	1	8.5
45		BE220806		Homo sapiens clone 23785 mRNA sequence	7.1 11.4	150 114	21 1	14.5 10
40		AB028945		cortactin SH3 domain-binding protein chromosome 8 open reading frame 2	6.7	67	i	5.7
		AF027153		solute carrier family 5 (Inositol transp	1	1	i	1
		AK001635		hypothetical protein FLJ10773	14.6	219	15	7.6
		AB040914		KIAA1481 protein	13.2	331	25	12.4
50				stanniocalcin 2	72.2	722	1 .	1.9
		BE385099		hypothetical protein MGC3017	6.5	65	4	5.3
	130441	U63630		protein kinase, DNA-activated, catalytic	6.1	61	1	5.7
		D90041	Hs.155956	N-acetyltransferase 1 (arylamine N-acety	10.8	706	66	9.2
	130604	AA383256	Hs.1657	estrogen receptor 1	32.2	322	1	4.7
55		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	10	100	1	7.6
		AJ271881		bromodomain-containing 7	17.5	175	2	12.8
				p53-induced protein PIGPC1	3.8	585	153	3.7
		NM_014810		KIAA0480 gene product	7.6	76	1	5
C 0		T93500	Hs.28792	Homo sapiens cDNA FLJ11041 ffs, clone PL	4.7	381	81	6.4
60		AA961420		ESTs (470LD)	11.7	117	1	10.1
	131877			topoisomerase (DNA) II alpha (170kD)	6.8	68	1	5.6
		AA503020	Hs.36563 Hs.44566	hypothetical protein FLJ22418	40.2 18.6	402 186	1 10	4
		U28831 T78736	Hs.50758	KIAA1641 protein SMC4 (structural maintenance of chromoso	9.3	93	1	1.5 8.4
65				ESTs, Weakly similar to T33468 hypotheti	6.5	65	i	5.6
05		X77343		transcription factor AP-2 alpha (activat	12.7	311	25	2.4
		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	4.6	427	93	10.4

	133199	AF231981	Hs.250175	homolog of yeast long chain polyunsatura	3	816	275	3.9
				ADP-ribosylation factor-like 1	8.1	81	1	4.6
	133271	Z48633	Hs.283742	H.sapiens mRNA for retrotransposon	12.4	124	6	10.8
_	133640	AW246428	Hs.75355	ubiquitin-conjugating enzyme E2N (homolo	8.5	85	1	7.2
5	133746	AW410035	Hs.75862	MAD (mothers against decapentaplegic, Dr	9.3	93	1	7.8
	133999	AA535244	Hs.78305	RAB2, member RAS oncogene family	7.8	78	1	5.6
	134110	U41060	Hs.79136	LIV-1 protein, estrogen regulated	4.5	1472	330	2.1
	134485	X82153	Hs.83942	cathepsin K (pycnodysostosis)	34.3	411	12	5.1
	134654	AK001741	Hs.8739	hypothetical protein FLJ10879	6.4	64	1	5.1
10	134880	Al879195	Hs.90606	15 kDa selenoprotein	5.7	57	1	5
	135029	H58818	Hs.187579	hydroxysteroid (17-beta) dehydrogenase 7	11.5	115	1	10
	135389	U05237	Hs.99872	fetal Alzheimer antigen	20.6	206	4	19.1
	128305	AI954968	Hs.279009	matrix Gla protein	9.4	94	3	5.3

TABLE 11A

Table 11A shows the accession numbers for those pkeys lacking unigeneID's for Table 11. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15

Pkey CAT number Accession

20 123619 371681_1 AA602964 AA609200 113702 genbank_T97307 T97307 114988 genbank_AA251089 AA251089

TABLE 12: Figure 12 from BRCA 001-3 PCT

5 Table 12 depicts a preferred group of genes upregulated in tumor tissue compared to normal breast tissue.

4.0	Pkey:	U	Inique Eos pr	obeset identifier number				
10	ExAccn:	E	xemplar Acce	ession number, Genbank accession number				
	Unigene	ID: U	Inigene numb	er				
	Unigene	Title: L	Inigene gene	title .				
	R1:	R	latio of tumor	to normal body tissue				
	R2:		Ratio of	90th percentile tumor to body				
15	R3:		Ratio of	75th percentile body to tumor				
	R4:		Ratio of	tumor to normal breast tissue				
	Pkey	ExAccn	UnigenelD	Unigene Title	R1	R2	R3	R4
20	100131	D12485	Hs.11951	phosphodiesterase I (PC-1)	13.2	244	19	9.9
20		AW602166			25.4	508	20	3.5
		AB029000		KIAA1077 protein	5.7	567	100	6.7
		W57554	Hs.125019	•	24.2	242	10	5.6
		AI905687	Hs.2533	ESTs	3.5	2073	595	2.1
25		AA243499			2.9	214	74	3.7
23				secreted frizzled-related protein 4	17.4	409	24	7.8
		AF026692		•		585	153	3.7
			Hs.303125		3.8		103	
		AA503020		ESTs Homo sapiens clone 23904 mRNA sequence	40.2	402 816	275	4 3.9
	1.5.5199	AF231981	HS.Z5U1/5	nomo sabiens cione 2.1904 MKNA sequence	J	010	213	ა.ყ

TABLE 13: Table 1 from BRCA 001-5 US

Table 13 depicts a preferred group of genes upregulated in breast cancer cells.

10	Pkey: ExAccn: UnigenelD: Unigene Title:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title ·
	R1:	Ratio of tumor to normal body tissue

	RI:	K	ago of turnor to	normal body tissue	
15					
	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100038	M97935		control	16.7
	100039	M97935		control	6.3
20	100040	M97935		control	8.3
	100041	M97935		control	14.8
	100082	AB003103	Hs.4295	proteasome (prosome; macropain) 26S sub	7.5
	100091	AF000177	Hs.111783	Lsm1 protein	4.9
	100100	AF006084	Hs,11538	actin related protein 2/3 complex; subunit	4.7
25		AF007875		dolichyl-phosphate mannosyltransferase p	13.4
	100114	D00596	Hs.82962	thymidylate synthetase	15.9
		D10495	Hs.155342	protein kinase C; delta	4.6
		D10523	Hs.168669	oxoglutarate dehydrogenase (lipoamide)	7.5
20		D11094	Hs.61153	proteasome (prosome; macropain) 26S sub	4.4
30		D12485	Hs.11951	phosphodiesterase l/nucleotide pyrophosp	8.7
		D13627	Hs.15071	chaperonin containing TCP1; subunit 8 (t	9.5
		D13643	Hs.75616	Human mRNA for KIAA0018 gene; comp	6
		D13666	Hs.136348	osteoblast specific factor 2 (fasciclin I-like	8.5
25		D14657	Hs.81892	KIAA0101 gene product	10.5
35		D14812	Hs.173714	MORF-related gene X	4.6
		D14878	Hs.82043	D123 gene product	7.9 5.6
		D21090	Hs.178658	RAD23 (S. cerevislae) hornolog B	9,9
		D25538	Hs.172199	adenylate cyclase 7	4,9
40		D26308	Hs.76289	biliverdin reductase B (flavin reductase (N proteasome (prosome; macropain) subunit	14.2
40		D26598	Hs.82793	proteasome (prosome; macropain) subunit	11.3
		D26599 D28137	Hs.1390 Hs.118110	bone marrow stromal cell antigen 2	5.7
		D28915	Hs.82316	interferon-induced; hepatitis C-associated	5.7
		D20313 D31888	Hs.78398	KIAA0071 protein	7.4
45		D43950	Hs.1600	chaperonin containing TCP1; subunit 5 (e	5.6
73		D49396	Hs.75454	antioxidant protein 1	12.9
		D50525	Hs.699	hypothetical protein	8.4
		D63391	Hs.6793	platelet-activating factor acetylhydrolase;	6.8
		D63487	Hs.82563	KIAA0153 protein	4.4
50		D78129	Hs.71465	Homo sapiens mRNA for squalene epoxid	12.6
	-	D78514	Hs.78563	ubiquitin-conjugating enzyme E2G 1 (hom	4.6
		D79987	Hs.153479	extra spindle poles; S. cerevisiae; homolo	6.5
		D79997	Hs.184339	KIAA0175 gene product	8.4
		D80004	Hs.75909	KIAA0182 protein	4.5
55	100379	D82060	Hs.278721	Ke4 gene; mouse; human homolog of	8.1
		D83777	Hs.75137	KIAA0193 gene product	10.7
	100393	D84145	Hs.39913	novel RGD-containing protein	7.2
	100398	D84557	Hs.155462	minichromosome maintenance deficient (m	7.2
	100405	D86425	Hs.82733	nidogen 2	5.4
60	100406	D86479	Hs.118397	AE-binding protein 1	4.3
	100409	D86957	Hs.80712	KIAA0202 protein	11.9
	100421	D86985	Hs.79276	Human mRNA for KIAA0232 gene; comp	9.7
		D87464	Hs.10037	KIAA0274 gene product	6.4
	100447	D87465	Hs.74583	KIAA0275 gene product	10
65	100448	D87469	Hs.57652	EGF-like-domain; multiple 2	6.2

	100467	D89052	Hs.7476	ATPase; H+ transporting; lysosomal (vacu	7.5
		D89289	Hs.118722	fucosyftransferase 8 (alpha (1;6) fucosyftr	5
		HT1112	Hs.10842	Ras-Like Protein Tc4	16.9
		HT1400	Hs.79137	Carboxyl Methyltransferase, Aspartate, A	5.6
5		HT2710	Hs.114599	Collagen, Type Viii, Alpha 1	7.5
	100661	HT3018	Hs.132748	Ribosomal Protein L39 Homolog	4.4
		HT3127	Hs.169610	Epican, Alt. Splice 11	4.6
		HT3938	Hs.169610	Epican, Alt. Splice 12	4.4
10		HT3742	Hs.287820	Fibronectin, Alt. Splice 1	9
10		HT26388	Hs.89603	Mucin 1, Epithelial, Alt. Splice 9	4.7
		HT4018	Hs.191356	Basic Transcription Factor, 44 Kda Subun	13.7
		HT4343 HT4344	Hs.278544	Cytosolic Acetoacetyl-Coenzyme A Thio	10.6 5.5
		HT4392	Hs.4756 Hs.183418	Rad2 Protein Kinase Pitslre, Alpha, Alt. Splice	4.1
15	100850		Hs.297939	Cathepsin B	4
13		HT4582	Hs.75113	Transcription Factor Ilia	4.9
		HT5158	Hs.5398	Guanosine 5'-Monophosphate Synthase	8.7
	100914		Hs.324178	Ras Inhibitor Inf	7.2
	100916		Hs.73946	Endothelial Cell Growth Factor 1	5.9
20	100945		Hs.180686	Oncogene E6-Ap, Papillomavirus	4.6
		J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin	30.1
	100988	J03589	Hs.76480	ubiquitin-like 4	8.3
	100996	J03909	Hs.14623	interferon; gamma-inducible protein 30	6.9
		J03934	Hs.80706	diaphorase (NADH/NADPH) (cytochrom	4.3
25		J04430	Hs.1211	acid phosphatase 5; tartrate resistant	5.9
		J04599	Hs.821	biglycan	5.1
		J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B;	37.2
		J05249	Hs.79411	replication protein A2 (32kD)	6.1
30		K02405	Hs.73931	Human MHC class II HLA-DQ-beta mRN	4.3 4.3
50		K03515 L06132	Hs.180532 Hs.149155	glucose phosphate isomerase voltage-dependent anion channel 1	7.4
		L06797	Hs.89414	chemokine (C-X-C motif); receptor 4 (fus	4.6
		L07615	Hs.169266	Human neuropeptide Y receptor Y1 (NPY	18.3
		L12723	Hs.90093	heat shock 70kD protein 4	17.4
35		L13800	Hs.9884	Homo sapiens liver expressed protein gen	7.6
		L19779	Hs.795	H2A histone family; member O	10.9
	101216	L25876	Hs.84113	cyclin-dependent kinase inhibitor 3 (CDK	7.4
		L29008	Hs.878	sorbitol dehydrogenase	14.6
40		L33801	Hs.78802	glycogen synthase kinase 3 beta	7.5
40		L38810	Hs.79387	proteasome (prosome; macropain) 26S sub	4.4
		L42572	Hs.78504	inner membrane protein; mitochondrial (m	5.8
		L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topo	18.9 7.5
		L77213	Hs.30954	phosphomevalonate kinase	9.3
45		L77701 M13755	Hs.16297 Hs.833	COX17 (yeast) homolog; cytochrome c ox interferon-stimulated protein; 15 kDa	18.1
73		M15796	Hs.78996	proliferating cell nuclear antigen	8.6
		M16342	Hs.182447	heterogeneous nuclear ribonucleoprotein C	4.5
		M20902	Hs.268571	apolipoprotein C-I	6.1
		M22538	Hs.51299	NADH dehydrogenase (ubiquinone) flavo	8.7
50		M22877	Hs.169248	Human somatic cytochrome c (HCS) gene	4.2
	101472	M22960	Hs.118126 '	protective protein for beta-galactosidase (6.5
	101478	M23379	Hs.758	RAS p21 protein activator (GTPase activa	14
		M24594	Hs.20315	interferon-induced protein 56	9.2
		M30818	Hs.926	myxovirus (influenza) resistance 2; homol	5.1
55		M30938	Hs.84981	X-ray repair complementing defective rep	4.7
		M31169		Human propionyl-CoA carboxylase beta-s	5.5
		M31642	Hs.82314	hypoxanthine phosphoribosyltransferase 1	8.5
		M34677	Hs.83363	DNA segment on chromosome X (unique)	4.5 5.7
60		M37583 M60750	Hs.119192 Hs.2178	H2A histone family; member Z H2B histone family; member A	5.8
00				H2A histone family; member A	13.5
		M60752 M60858	Hs.121017 Hs.79110	nudeolin	4
		M63256	Hs.75124	cerebellar degeneration-related protein (62	7.6
		M64929	Hs.179574	protein phosphatase 2 (formerly 2A); regu	4.2
65		M77142	Hs.239489	TIA1 cytotoxic granule-associated RNA-b	4.5
		M77836	Hs.79217	руггоline-5-carboxylate reductase 1	5.7
		M81057	Hs.180884	carboxypeptidase B1 (tissue)	21.7
				•	

	404770 1404004	11- 70000	t A (CII): 1	4.6
	101770 M81601		transcription elongation factor A (SII); 1	4.6 9.7
	101791 M83822		cell division cycle 4-like	
	101803 M86546 101809 M86849		pre-B-cell leukemia transcription factor 1	5.5 22.5
5			Homo sapiens connexin 26 (GJB2) mRNA	4
,	101839 M93036 101851 M94250		membrane component; chromosomal 4; su	7.6
			midkine (neurite growth-promoting factor	7.0 11.4
	101888 M99701		transcription elongation factor A (SII)-like	4.6
	101973 S82597		UDP-N-acetyl-alpha-D-galactosamine:po	
10	101991 U00968		Human SREBP-1 mRNA; complete cds	4.1 4.4
10	102009 U02680		protein tyrosine kinase 9	4.4
	102025 U03911		mutS (E. coli) homolog 2 (colon cancer; n	6.1
	102047 U07158		syntaxin 4A (placental)	4.4
	102051 U07550		heat shock 10kD protein 1 (chaperonin 10	10.4
15	102083 U10323		Interleukin enhancer binding factor 2; 45k	9.5
13	102095 U11313		sterol carrier protein 2	6.6
	102130 U15009		small nuclear ribonucleoprotein D3 polyp	4.3
	102133 U15173		BCL2/adenovirus E1B 19kD-interacting p	4.3 6.9
	102148 U16954		ALL1-fused gene from chromosome 1q	4.8
20	102179 U19713		allograft inflammatory factor 1	4.6 7.2
20	102180 U19718		microfibrillar-associated protein 2	7.2 7.2
	102193 U20758		secreted phosphoprotein 1 (osteopontin; b	4.3
	102198 U21090		polymerase (DNA directed); delta 2; regu	4.5 4.5
	102202 U21931		fructose-bisphosphatase 1	
25	102209 U22970		interferon; alpha-inducible protein (clone	9.9
25	102211 U23070		putative transmembrane protein	4.9
	102220 U24389		lysyl oxidase-like 1	8.5
	102224 U24704		proteasome (prosome; macropain) 26S sub	5.4
	102234 U26312		chromobox homolog 3 (Drosophila HP1 g	7.7
20	102250 U28014		caspase 4; apoptosis-related cysteine prot	5.4
30	102260 U28386		karyopherin alpha 2 (RAG cohort 1; impo	6.3
	102261 U28488		complement component 3a receptor 1	5.7
	102273 U30888		ubiquitin specific protease 14 (tRNA-guan	6.1
	102298 U32849		N-myc (and STAT) interactor	4.1
25	102302 U33052		protein kinase C-like 2	4.3
35	102305 U33286		chromosome segregation 1 (yeast homolo	5.4
	102320 U34683		glutathione synthetase	4.1
	102330 U35451		chromobox homolog 1 (Drosophila HP1 b	4
	102348 U37519		aldehyde dehydrogenase 8	9.4
40	102361 U39400		chromosome 11 open reading frame 4	5.2
40	102362 U39412		N-ethylmaleimide-sensitive factor attachm	9.3
	102369 U39840		hepatocyte nuclear factor 3; alpha	7.7
	102395 U41767		a disintegrin and metalloproteinase domai	10.4
	102409 U43286		selenophosphate synthetase 2	6.2
4 -	102418 U43923		suppressor of Ty (S.cerevisiae) 4 homolog	4.1
45	102425 U44772		palmitoyi-protein thioesterase (ceroid-lipo	4.8
	102457 U48807		dual specificity phosphatase 4	6.3
	102465 U49352		2;4-dienoyl CoA reductase 1; mitochondri	9.4
	102495 U51240		Lysosomal-associated multispanning mem	6.5
	102534 U56833	Hs.198307	von Hippel-Lindau binding protein 1	8.6
50	102546 U57877	Hs.3577	succinate dehydrogenase complex; subuni	4.3
	102549 U58046	Hs.198899	eukaryotic translation initiation factor 3; s	6.3
	102557 U58766		tissue specific transplantation antigen P35	5
	102562 U59309	Hs.75653	fumarate hydratase	6
	102568 U59877	Hs.223025	RAB31; member RAS oncogene family	9.1
55	102580 U60808		CDP-diacylglycerol synthase (phosphatid	7.9
	102581 U61145	Hs.77256	enhancer of zeste (Drosophila) homolog 2	7.6
	102590 U62136		Homo sapiens enterocyte differentiation a	7
	102591 U62325	Hs.324125	amyloid beta (A4) precursor protein-bindi	4
	102592 U62389	Hs.11223	Human putative cytosolic NADP-depende	5
60	102617 U65928	Hs.198767	Jun activation domain binding protein	6.1
	102618 U65932		extracellular matrix protein 1	23.2
	102638 U67319		caspase 7; apoptosis-related cysteine prot	8.9
	102663 U70322	Hs.168075	karyopherin (importin) beta 2	7.1
	102666 U70660		ATX1 (antioxidant protein 1; yeast) homo	4.7
65	102679 U72661	Hs.11342	ninjurin 1; nerve injury-induced protein-1	4.7
	102687 U73379		ubiquitin carrier protein E2-C	7.7
	102704 U76638		BRCA1 associated RING domain 1	5.6

	100705	U77 180	Hs.50002	amall indusible adeline subfamily A (Cv	11.8
				small inducible cytokine subfamily A (Cy	
		U79241	Hs.118666	Human clone 23759 mRNA; partial cds	15
		U79254	Hs.181311	asparaginyl-tRNA synthetase	5
_		U79282	Hs.155572	Human clone 23801 mRNA sequence	6
5		U79293	Hs.159264	Human clone 23948 mRNA sequence	13.1
		U82130	Hs.118910	tumor susceptibility gene 101	7
	102788	U86602	Hs.74407	nucleolar protein p40	4.1
	102790	U87269	Hs.154196	E4F transcription factor 1	7.1
	102801	U89606	Hs.38041	pyridoxal (pyridoxine; vitamin B6) kinase	4.7
10	102808	U90426	Hs.179606	nuclear RNA helicase; DECD variant of D	7.5
		U90904	Hs.83724	Human done 23773 mRNA sequence	15.2
		U90914	Hs.5057	carboxypeptidase D	6.6
		U91327	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
		U94592	Hs.80658	Human uncoupling protein homolog (UCP	6.1
15		U95006	Hs.37616	Human D9 splice variant B mRNA; comp	4.2
13		U96113	Hs.324275	Homo sapiens Nedd-4-like ubiquitin-prot	6.8
		X02419	Hs.77274	plasminogen activator; urokinase	4
					22.7
		X06985	Hs.202833	heme oxygenase (decycling) 1	
20		X12447	11 74040	aldolase A; fructose-bisphosphate	9.9
20		X13238	Hs.74649	cytochrome c oxidase subunit VIc	5.4
		X16663	Hs.14601	hematopoietic cell-specific Lyn substrate	4.8
		X17620	Hs.118638	non-metastatic cells 1; protein (NM23A)	4.6
		X17644	Hs.2707	G1 to S phase transition 1	20.6
	103003	X52003	Hs.1406	trefoil factor 1 (breast cancer; estrogen-ind	10.7
25	103018	X53296	Hs.81134	interleukin 1 receptor antagonist	5.8
	103023	X53793	Hs.117950	multifunctional polypeptide similar to SA	4
	103036	X54925	Hs.83169	matrix metalloproteinase 1 (interstitial col	7.3
	103060	X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin	17.8
	103073	X59417	Hs.74077	proteasome (prosome; macropain) subunit	5.6
30		X59543	Hs.2934	ribonucleotide reductase M1 polypeptide	4.2
		X59798	Hs.82932	cyclin D1 (PRAD1; parathyroid adenomat	6.7
		X60787	Hs.296281	interleukln enhancer binding factor 1	5.7
		X61970	Hs.76913	proteasome (prosome; macropain) subunit	5.8
		X63679	Hs.4147	translocating chain-associating membrane	4.2
35		X66363	Hs.171834	PCTAIRE protein kinase 1	12
55		X69433	Hs.5337	Isocitrate dehydrogenase 2 (NADP+); mit	18.9
		X69819		Intercellular adhesion molecule 3	10.7
			Hs.99995		4.1
		X70040	Hs.2942	macrophage stimulating 1 receptor (c-met	10.7
40		X70218	Hs.2903	protein phosphatase 4 (formerly X); cataly	
40		X70476	Hs.75724	coatomer protein complex; subunit beta 2	8.2
		X70649	Hs.78580	DEAD/H (Asp-Glu-Ala-Asp/His) box pol	13.7
		X70940	Hs.2642	eukaryotic translation elongation factor 1	13.4
		X72755	Hs.77367	monokine induced by gamma interferon	15.1
45		X72790		Human endogenous retrovirus mRNA for	5.3
45		X72841	Hs.31314	retinoblastoma-binding protein 7	12.3
		X74262	Hs.16003	retinoblastoma-binding protein 4	4.1
		X75042	Hs.44313	v-rel avian reticuloendotheliosis viral onco	6.9
	103230	X75861	Hs.74637	testis enhanced gene transcript	7.9
		X78565	Hs.289114	hexabrachion (tenascin C; cytotactin)	5
5.0	103278	X79882	Hs.80680	lung resistance-related protein	5.7
	103297	X81788	Hs.9078	immature colon carcinoma transcript 1	4.6
	103302	X82103	Hs.3059	coatomer protein complex; subunit beta	4.5
	103316	X83301	Hs.324728	SMA5	7.1
	103330	X85373	Hs.77496	small nuclear ribonucleoprotein polypepti	4
55		X89059		serine/threonine kinase 9	4.7
		X89398	Hs.78853	uracil-DNA glycosylase	5.3
		X90872	Hs.279929	SULT1C sulfotransferase	4
		X91788	Hs.84974	chloride channel; nudeotide-sensitive; 1A	4.2
		X92396	Hs.24167	synaptobrevin-like 1	13.6
60		X94754	Hs.279946	methionine-tRNA synthetase	14.2
50		X95404	Hs.180370	cofilin 1 (non-muscle)	4.6
		X96506	Hs.295362	DR1-associated protein 1 (negative cofact	8.3
					o.3 4.9
		X97065	Hs.173497	Sec23 (S. cerevisiae) homolog B	
65		X97074	Hs.119591	adaptor-related protein complex 2; sigma	5
65		X97303	Hs.250655	H.sapiens mRNA for Ptg-12 protein	7 1 E
		X97544	Hs.20716	translocase of inner mitochondrial membr	4.5
	103438	X98263	Hs.152720	M-phase phosphoprotein 6	4.5

	400404	V0000C	11- 70470	installing tiller assembly foreton O annuality	4.2
	_	Y00285	Hs.76473	insulin-like growth factor 2 receptor	
		Y00796	Hs.174103	integrin; alpha L (antigen CD11A (p180);	4.5
		Y08991	Hs.83050	phosphatidylinositol 3-kinase-associated p	4.1
_		Y09912	Hs.33102	transcription factor AP-2 beta (activating	4.5
5		Z14982	Hs.180062	proteasome (prosome; macropaln) subunit	4.3
	103551	Z15115	Hs.75248	topoisomerase (DNA) II beta (180kD)	4
	103565	Z22548	Hs.146354	thioredoxin-dependent peroxide reductase	7.6
	103587	Z29083	Hs.82128	5T4 oncofetal trophoblast glycoprotein	14.6
	103621	Z47727	Hs.150675	polymerase (RNA) II (DNA directed) pol	6.3
10	103622	Z48042	Hs.278672	membrane component; chromosome 11; s	4.4
		Z74615	Hs.172928	collagen; type I; alpha 1	5.9
		Z93784		Homo sapiens DNA sequence from PAC	4.4
			Hs.278554	chromobox homolog 3 (Drosophila HP1 g	4.9
		AA092898		ESTs; Weakly similar to R07G3.8 [C.eleg	6.1
15			Hs.198793	KIAA0750 gene product	23,3
15		AA172215		ESTs; Moderately similar to TRANSCRIP	4
			Hs.105737		4.9
				ESTs; Weakly similar to gene 9306 protei	7.8
		AA236843		ESTs; Weakly similar to unknown [S.cere	4.8
20			Hs.239189	ESTs	
20		AA393432		hypothetical protein	5.3
		AA428090		ESTs	28.7
		AA442669		zv68f6.r1 Soares_total_fetus_Nb2HF8_9w	5.7
			Hs.283037	ESTs; Highly similar to HSPC039 protein	6.9
		AA476564		ESTs; Weakly similar to finger protein HZ	5.2
25	104181	AA479521	Hs.283740	ESTs	7.8
	104183	AA480838	Hs.114309	ESTs	5.1
	104192	AA486946	Hs.21321	Homo sapiens mRNA; cDNA DKFZp564	4.3
	104209	AB000221	Hs.16530	small inducible cytokine subfamily A (Cy	12.3
	104234	AB002357	Hs.168212	kinesin family member 3B	6.2
30	104271	C01687	Hs.7381	ATP synthase; H+ transporting; mitochon	4.2
20	104278	C02582	Hs.109253	ESTs; Highly similar to N-terminal acetyl	4.5
		D52818	Hs.111680	endosulfine alpha	4.7
		D55869	Hs.284123	Homo saplens mRNA full length insert cD	4.2
		H19378	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4
35		L44497	Hs.7351	ESTs	4.9
		M19169	Hs.123114	cystatin SN	11.6
		N33807	Hs.324275	protease; serine; 15	5.6
		R56678	Hs.88959	Human DNA sequence from done 967N2	6.3
		R81003	Hs.325820	serine protease; umbilical endothelium	13.6
40		AA004274		ESTs	6.3
- U			Hs.106106	ESTs	10.1
				Homo sapiens mRNA; cDNA DKFZp564	4.3
		AA007145			16.6
		AA007234		ESTs	4.6
45			Hs.301553	ESTs; Moderately similar to IIII ALU SU	
43		AA025534		ESTS	4.8
		AA027163		ESTs	8.1
			Hs.301871	ESTs; Moderately similar to cAMP induc	10.9
		AA031357		ESTs; Weakly similar to N-WASP [H.sap	5.5
50		AA032147		ESTs	10.4
50		AA039469		ESTs; Weakly similar to KIAA0299 [H.s	4.6
			Hs.241507	Homo sapiens mRNA; cDNA DKFZp564	4.3
			Hs.225979	Human gene from PACs 37M17 and 305B	4.5
		AA053021		SCO (cytochrome oxidase deficient; yeast	4.7
	104906	AA055809	Hs.26802	ESTs; Weakly similar to phosphoprotein [8.8
55	104919	AA057193	Hs.25252	ESTs	5.5
	104921	AA057839	Hs.1508	ESTs	4.2
•	104926	AA058846	Hs.33363	DKFZP434N093 protein	7
	104938	AA064627	Hs.318725	ESTs; Highly similar to CGI-72 protein [H	7.1
	104943	AA065217	Hs.114218	ESTs	5.7
60	104957	AA074919	Hs.10026	ESTs; Weakly similar to ORF YJL063c [S	4.7
		AA076672		ESTs	5.5
		AA084602		ESTs	4.3
		AA086071		chromosome-associated polypeptide C	8.3
		AA088228		ESTs	6.2
65		AA088458		ESTs	6.7
		AA101723		ESTs	9.2
			Hs.182704	ESTs; Moderately similar to alternatively	6.9
					-

	105010	A A 14C02C	Ha 0220	abramasama 20 agan saading frama 4	10.7
		AA116036		chromosome 20 open reading frame 1	10.7
		AA121879		proteasome (prosome; macropain) subunit	5.7
		AA126855		ESTs	4.4
_			Hs.274329	TP53 target gene 1	6.3
5	105035	AA128486	Hs.8859	ESTs	6.5
	105039	AA130349	Hs.36475	ESTs	4
	105062	AA134968	Hs.36529	ESTs	4.3
	105076	AA142858	Hs.37810	ESTs	6.4
	105087	AA147884	Hs.9812	ESTs ·	9.2
10			Hs.179909	ESTs; Weakly similar to !!!! ALU SUBFA	5.7
		AA149051		ESTs	6.3
		AA152302		DKFZP566G223 protein	6.2
			Hs.301957	ESTs; Weakly similar to contains similar	5.7
					4.2
15			Hs.247280	HBV associated factor	
13		AA165333		ESTs	4.7
		AA171736		methyl-CpG binding domain protein 4	9
		AA176690		KIAA1025 protein	9.1
	105186	AA191512	Hs.28005	Homo sapiens mRNA; cDNA DKFZp564	19.3
	105209	AA205072	Hs.227743	KIAA0980 protein	7.4
20	105223	AA211388	Hs.7750	ESTs	5.1
	105252	AA227428	Hs.9728	ESTs; Weakly similar to KIAA0512 prote	11.1
		AA227448		KIAA0456 protein	6.4
		AA227871		MEK partner 1	9.1
		AA227926		ESTS	6.7
25			Hs.281866	ATPase; H+ transporting; lysosomal (vacu	5.3
23			Hs.183858	transcriptional intermediary factor 1	8.7
		AA233790			7.4
				ESTs; Weakly similar to cDNA EST yk38	
		AA233854		S-phase kinase-associated protein 2 (p45)	5.8
20			Hs.157078	ESTs	4.5
30		AA236559		ESTs; Weakly similar to !!!! ALU SUBFA	5.8
		AA236950		ESTs	5.5
		AA242868		ESTs; Weakly similar to house-keeping p	7.7
		AA243007		ESTs; Highly similar to SH3 domain-bind	5.6
	105400	AA243052	Hs.65648	RNA binding motif protein 8	5.8
35	105404	AA243303	Hs.21187	ESTs	9.1
	105409	AA243562	Hs.301855	ESTs ·	4.4
			Hs.237856	ESTs; Moderately similar to cAMP induc	5.1
		AA255874		ESTs	4.9
		AA256268		ESTs	6
40		AA256317		Homo sapiens mRNA; cDNA DKFZp586	5.2
-10			Hs.301997	DKFZP434N126 protein	8.7
			Hs.222399	CGI-96 protein	9.5
			Hs.226318	ESTs; Moderately similar to CCR4-associ	4.1
					4.1
15		AA258860		ring finger protein (C3H2C3 type) 6	
45		AA261954		ESTs	8
			Hs.268281	ESTs; Weakly similar to 62D9.a [D.melan	8.1
		AA262417		ESTs	4.6
		AA262477		ribonuclease HI; large subunit	9.1
	105560	AA262783	Hs.306915	ESTs	4.5
50	105565	AA278302	Hs.18349	ESTs; Weakly similar to partial CDS [C.e	4.2
	105566	AA278323	Hs.17481	Homo sapiens clone 24606 mRNA sequen	11.9
	105575	AA278717	Hs.12772	ESTs	5.9
		AA279012		ESTs; Weakly similar to KIAA0665 prote	4.4
		AA279418		ESTs	4
55		AA279787		ESTs; Moderately similar to putative pho	5.6
-		AA279991		ESTs; Weakly similar to trithorax homolo	5.3
		AA280865		Homo sapiens mRNA; cDNA DKFZp564	4.8
		AA281245		ESTS	7.5
60			Hs.247817	Homo sapiens mRNA for for histone H2B	5.9
60		AA282138		ESTs	6.4
		AA282347		ESTs; Highly similar to HSPC003 [H.sap	11.3
		AA283930		ESTs	4.7
			Hs.279789	CDW52 antigen (CAMPATH-1 antigen)	8
		AA286809		ESTs	7.1
65	105700	AA287643	Hs.35254	ESTs; Weakly similar to hypothetical pro	4.9
			Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8
	105709	AA291268	Hs.26761	DKFZP586L0724 protein	6.8
				•	

	105724	4 4 000744	11- 00404	FOT-	
		AA292711		ESTs	6.4
			Hs.110857	ESTs	7
		AA348014		ESTs	7.1
5		AA350771		ESTs	13.4
3		AA358038		SH3-binding domain glutamic acid-rich p	4.3
		AA393803		ESTs; Moderately similar to COLLAGEN	5.3
	100008	AAJ93808	Hs.286131	KIAA0438 gene product	4.1
			Hs.20814	ESTs; Highly similar to CGI-27 protein [H	14.6
10		AA394140		ESTs	4.9
10		AA397920		Homo sapiens mRNA; cDNA DKFZp564	4.9
			Hs.101067	ESTs	4.8
			Hs.171118	ESTs	4
		AA400999		Human ring zinc-finger protein (ZNF127-	4.8
1.0		AA404248		ESTs	5.2
15			Hs.263727	ESTs; Weakly similar to bisphosphate 3'-	4
		AA406105		adaptor-related protein complex 1; gamma	8.3
		AA406321		KIAA0895 protein	4.6
		AA410336		ESTs; Weakly similar to PROBABLE AT	4.5
20		AA410510		ESTs	4.9
20		AA410972		ESTs	5.8
		AA411462		ESTs; Weakly similar to veli 1 [H.sapiens	6.9
	106016	AA411819	Hs.8164	KIAA0898 protein	5
		AA412473		ESTs	6.6
	106042	AA412700	Hs.169895	ubiquitin-conjugating enzyme E2L 6	4.6
25	106057	AA417067	Hs.289074	ESTs	4.5
	106065	AA417558	Hs.25206	ESTs	12.3
	106070	AA417761	Hs.5957	Homo sapiens clone 24416 mRNA sequen	5
	106103	AA421104	Hs.12094	ESTs	15.4
	106126	AA424006	Hs.22972	ESTs; Moderately similar to H5AR [M.m	6.4
30	106154	AA425304	Hs.6994	ESTs	5.1
		AA425367		ESTs	11.1
		AA425872		NADH dehydrogenase (ubiquinone) 1 alp	19.3
		AA428024		ESTs	4.7
		AA428239		ESTs	5.7
35		AA428582		ESTs; Moderately similar to metargidin p	7.7
		AA429951		ESTs	8
		AA430074		ESTs; Weakly similar to YIr218cp [S.cere	4.4
		AA431462		ESTs	4.9
		AA435536		ESTs	8.8
40			Hs.301444	signal sequence receptor; gamma (transloc	8.7
		AA436244		ESTs	4.5
			Hs.108124	ESTs	4
		AA436705		KIAA0766 gene product	4.4
		AA441798		ESTs; Moderately similar to pIL2 hypoth	23.7
45		AA442253		ESTs	4.7
			Hs. 194698	cydin B2	6.1
			Hs.170310	ESTs	6.8
		AA446949		ESTs	4.7
		AA447223		Homo sapiens clone 25142 mRNA sequen	4.4
50		AA448282		ESTs; Weakly similar to F55C12.5 [C.ele	4.5
50		AA449741		glioma-amplified sequence-41	4.8
		AA449912		ESTs; Highly similar to CGI-77 protein [H	5.2
		AA450047		ESTs	6.8
		AA450351		ESTs	12.4
55		AA452108			
55		AA452411		transcription factor AP-2 alpha (activating	4.5
			Hs.267819	ESTs; Highly similar to mediator [H.saple	5.1
				protein phosphatase 1; regulatory (inhibito	4.9
			Hs.145998	ESTs	8.3
60		AA455970		patched related protein translocated in ren	7.6
UU .		AA456598		ESTS	8.2
		AA456646		ESTs Market Ball	4.8
	100000	MA450004	Hs.283437	Homo sapiens clone 23851 mRNA sequen	4.4
		AA458904		ESTs; Weakly similar to torsinA [H.saple	7
65			Hs.256150	ESTs	4.5
O)		AA459657		Homo sapiens clone 23570 mRNA sequen	6.5
			Hs.250824	ESTs	5.5
	100044	AA460239	ns.12660	ESTs	4.4

	106664	AA460969	Hs 7510	mitogen-activated protein kinase kinase ki	8.4
		AA463745			5.3
				ESTs; Weakly similar to PROBABLE AT	5.6
			Hs.236844	ESTS	10.1
5		AA465339		ESTs	
5			Hs.171957	triple functional domain (PTPRF interacti	10.4
		AA477263		ESTs	4.2
			Hs.306117	interleukin 13 receptor; alpha 1	6.9
			Hs.227913	API5-like 1	5.1
		AA482014		centrin; EF-hand protein; 3 (CDC31 yeast	5.1
10	106836	AA482112	Hs.238707	ESTs	4.8
	106840	AA482548	Hs.5534	ESTs	10.3
	106856	AA486183	Hs.285123	ESTs; Weakly similar to similar to oxyste	6.2
•	106865	AA487228	Hs.19479	ESTs	4.5
	106878	AA488872	Hs.12314	Homo sapiens mRNA; cDNA DKFZp586	7.9
15	106888	AA489101	Hs.24734	oxysterol binding protein	6.4
		AA489665		ESTs	4.6
	106909	AA490323	Hs.250747	SUMO-1 activating enzyme subunit 1	4.2
		AA490885		ESTs	12.3
			Hs.296323	ESTs	6.2
20		AA496204		ESTs	4
20		AA496347		retinoblastoma-binding protein 7	4.8
		AA496788		KIAA0532 protein	4
		AA504631		ESTs; Weakly similar to hypothetical 43.2	4.4
		AA505141			5.4
25				Human DNA sequence from done 167A1	4.1
23		AA521121		bromodomain adjacent to zinc finger dom	
		AA521157		ESTs	5.7
			Hs.195464	insulin-like growth factor binding protein	18.7
		AA598710		ESTs	6.2
20		AA599214		ESTs	4.1
30			Hs.247309	succinate-CoA ligase; GDP-forming; beta	5.3
		AA600134		glyceronephosphate O-acyltransferase	4.8
		AA600147		ESTs; Weakly similar to NADH-cytochro	5.8
		AA600310		programmed cell death 8 (apoptosis-induc	4.9
		AA609210		ESTs	8.4
35	107102	AA609723	Hs.30652	ESTs	8
	107109	AA609943	Hs.32793	ESTs	9.5
	107129	AA620553	Hs.4756	flap structure-specific endonuclease 1	4.9
	107132	AA620598	Hs.9052	ESTs	5.3
	107136	AA620795	Hs.8207	ESTs	4
40	107140	AA620889	Hs.170088	ESTs	6.7
	107151	AA621169	Hs.8687	ESTs	19
		AA621340		ESTs; Weakly similar to ORF YKR081c [8.1
		AA621714		ESTs	8.5
		D51095	Hs.35861	DKFZP586E1621 protein	7.2
45		D59971	Hs.25925	ESTs	7.9
	_	T34527	Hs.80120	UDP-N-acetyl-alpha-D-galactosamine:po	5.6
		T40327	Hs.30661	lung resistance-related protein	8.4
		T81665	Hs.278422	DKFZP586G1122 protein	7.5
		U85625	Hs.8297	ribonuclease 6 precursor	4.7
50		U85773	Hs.154695	phosphomannomutase 2	4.8
20		W58247	Hs.279766	Homo sapiens kinesin superfamily motor	6.3
		Y13936			8.3
			Hs.17883	protein phosphatase 1G (formerly 2C); ma	7.3
		AA024835		potassium voltage-gated channel; delayed	
55		AA026030		ESTs; Weakly similar to CALPAIN 2; LA	7.3
22		AA026894		ESTs	4.9
		AA041341		ESTs	5.4
			Hs.159971	ESTs	8.4
		AA046424		ESTs; Weakly similar to HYPOTHETICA	6.6
C O		AA058686		ESTs	7.7
60			Hs.172608	ESTs	4
		AA071514		ESTs	4
		AA100694		Human DNA sequence from BAC 15E1 o	5.5
		AA112396		ESTs; Moderately similar to HOMEOBO	14.3
	108676	AA115562	Hs.274417	Homo sapiens mRNA; cDNA DKFZp564	5.2
65	108687	AA120785	Hs.54347	ESTs	5.6
	108695	AA121315	Hs.70823	KIAA1077 protein	10.5
		AA126422		zn84f1.s1 Stratagene lung carcinoma 9372	4.4
	-			▼ =	

	108774	AA128125	He 710/0	ESTs; Moderately similar to CELL GROW	4.6
		AA131584		DKFZP564O0463 protein	5.5
		AA134063		ESTs	7.2
		AA134958		ESTs	11.3
5		AA135894		retinoic acid induced 3	8.9
_		AA156360		ESTs	14.7
		AA156460		dual specificity phosphatase 12	4.9
		AA156542		ESTs	4.6
		AA159525		Homo sapiens DNA from chromosome 19	7.2
10	109086	AA166695	Hs.270737	tumor necrosis factor (ligand) superfamily	4
	109090	AA167006	Hs.70499	ESTs	5.9
	109101	AA167708	Hs.52184	ESTs	4.2
	109112	AA169379	Hs.257924	ESTs	4
	109160	AA179387	Hs.301997	DKFZP434N126 protein	4
15	109166	AA179845	Hs.73625	RAB6 interacting; kinesin-like (rabkinesin	13.6
	109178	AA181600	Hs.283707	ESTs	11.8
		AA181902		ESTs; Weakly similar to !!!! ALU SUBFA	5.4
		AA195255		ESTs	6.7
00		AA195515		ESTs; Weakly similar to alternatively spli	4.9
20		AA196332		ESTs	5.4
		AA206800		ESTs; Moderately similar to zinc finger p	5.5
		AA227219		trinucleotide repeat containing 9	20.1
		AA232255		ESTs	4.7
25		AA232904		ESTs	6.8
25		AA233342		ESTs; Weakly similar to WD40 protein C	10.6 8
		AA233892		ESTs; Weakly similar to !!!! ALU SUBFA	8.2
		AA234087		ESTs; Weakly similar to ORF2: function	4.8
		F02027 F04165	Hs.171937 Hs.235873	ESTs ESTs; Weakly similar to K11C4.2 [C.eleg	5.2
30		F04477	Hs.291531	ESTs; Moderately similar to GLYCERAL	6.6
50		F09684	Hs.24792	ESTs; Weakly similar to ORF YOR283w	7.1
		F10009	Hs.9196	ESTs	5
		F10161	Hs.22969	ESTs	4.7
		F10770	Hs.180378	Homo sapiens clone 669 unknown mRNA	4.5
35		F10979	Hs.153106	Homo sapiens clone 23728 mRNA sequen	8.7
		H20543	Hs.6278	DKFZP586B1621 protein	16.6
		H25577	Hs.176588	ESTs; Weakly similar to CYTOCHROME	6.2
		H29285	Hs.32468	ESTs	4.5
		H56965	Hs.4082	yr09f06.s1 Soares fetal liver spleen 1NFL	5.7
40	110561	H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CO	19.5
	110707	H95079	Hs.15617	ESTs; Weakly similar to !!!! ALU SUBFA	6.2
	110734	H98714	Hs.24131	ESTs	30.2
		N22262	Hs.131705	ESTs	5.8
4.5		N23174	Hs.22891	solute carrier family 7 (cationic amino aci	8.2
45		N24716	Hs.12244	ESTs; Weakly similar to C44B9.1 [C.eleg	6.7
		N25262	Hs.27931	ESTs	5.9
		N26101	Hs.323401	Human ring zinc-finger protein (ZNF127-	4 4.3
		N29454	Hs.27552	ESTs; Weakly similar to putative p150 [H	12.8
50		N30856	Hs.30246	solute carrier family 19 (thiamine transpo	10.1
30		N31952	Hs.167531	Homo sapiens mRNA full length insert cD	4.7
		N32919 N33063	Hs.27931	ESTs; Weakly similar to S164 [H.sapiens	4.2
		N33438	Hs.170065	ESTs Veakly similar to 3 to 4 (1.5apiers	12,5
		N39148	Hs.6880	DKFZP434D156 protein	4
55		N46252	Hs.29724	ESTs	23.2
55		N48787	Hs.305979	protease inhibitor 1 (anti-elastase); alpha-	4.8
		N51374	Hs.96870	Homo saplens mRNA full length insert cD	5.4
		N53375	Hs.166146	Homer; neuronal immediate early gene; 3	4.7
		N53388	Hs.7222	ESTs	13,3
60		N54067	Hs.3628	mitogen-activated protein kinase kinase ki	5.7
		N59543	Hs.15456	PDZ domain containing 1	8.3
		N62522	Hs.20450	ESTs	14.3
	111125	N63823	Hs.269115	ESTs	7.9
		N64378	Hs.83293	ESTs; Highly similar to unknown function	4.4
65	111139	N64683	Hs.290943	ESTs	6
		N66857	Hs.14808	ESTs; Weakly similar to IIII ALU CLASS	4.1
	111172	N67102	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	5.5

	111178	N67227	Hs.24633	ESTs	5.7
		N67239	Hs.10760	ESTs	37
		N67278	Hs.171802	ESTs; Weakly similar to hypothetical pro	5.6
_		N67437	Hs.243901	Homo sapiens mRNA; cDNA DKFZp564	8.7
5	111221	N68869	Hs.15119	ESTs	7.3
	111223	N68921	Hs.297939	ESTs; Weakly similar to neogenin [H.sap	9
		N69113	Hs.110855	ESTs	8.9
		N69514			6.9
			Hs.288880	ESTs; Weakly similar to CGI-82 protein [
10		N70481	Hs.26118	Homo sapiens done 24766 mRNA sequen	4.5
10	111295	N73275	Hs.21275	ESTs; Weakly similar to ubiquitin-conjug	5.6
	111299	N73808	Hs.24936	ESTs	8.5
		N79565	Hs.29894	ESTs	6.7
					15
		N91023	Hs.87128	ESTs	
		N92915	Hs.94631	brefeldin A-inhibited guanine nucleotide-e	5.2
15	111806	R33468	Hs.279008	ESTs	10
•	111825	R35885	Hs.286148	stromal antigen 1	4.5
		R36228	Hs.25119	ESTs	7.2
		R38678	Hs.12365	ESTs	17.3
00		R39995	Hs.25925	Homo sapiens done 23860 mRNA sequen	7.3
20	111942	R40576	Hs.21590	ESTs	9.2
	111987	R42036	Hs.6763	KIAA0942 protein	10.6
		R44793	Hs.296341	adenylyl cyclase-associated protein 2	5.3
•		R46025	Hs.7413	ESTs	17.4
~~		R49482	Hs.5637	ESTs	4.4
25	112244	R51309	Hs.70823	KlAA1077 protein	11
	112253	R51818		Homo sapiens mRNA; cDNA DKFZp566	9.3
		R54822	Hs.26244	ESTs	4.4
		R63802	Hs.124186	ring finger protein 2	6.3
20		R66534	Hs.285885	ESTs	4.9
30	112519	R68631	Hs.11861	ESTs	14.3
	112610	R79392	Hs.23643	ESTs	5.2
	112693	R88741	Hs.91065	ESTs; Moderately similar to proliferation	4.6
		R93507	Hs.8207	ESTs	5.6
25		R97486	Hs.157160	protein kinase; DNA-activated; catalytic p	8.7
35	112869	T03313	Hs.4747	dyskeratosis congenita 1; dyskerin	5.9
	112871	T03352	Hs.12285	ESTs	5.8
		T10065	Hs.3530	TLS-associated serine-arginine protein	4.1
		T17119	Hs.102548	glucocorticold receptor DNA binding fact	5.7
40		T17185	Hs.83883	ESTs	6.4
40		T23528	Hs.7155	ESTs; Weakly similar to TYKi protein [M	9.1
	113047	T25867	Hs.7549	ESTs	5.4
	113075	T34660	Hs.6986	ESTs; Weakly similar to !!!! ALU SUBFA	5.7
		T47819	Hs.159153	ESTs	5.8
			Hs.241471		6.4
15		T58044	NS.24 147 1	ESTs; Moderately similar to III! ALU SU	
45	113248	T63857		yc16e1.s1 Stratagene lung (#93721) Homo	4.6
	113260	T64896	Hs.287420	ESTs	6.9
	113277	T65797	Hs.11774	protein (peptidyl-prolyl cis/trans isomeras	5.6
	113278	T65802	Hs.11135	yc11h10.s1 Stratagene lung (#937210) Ho	4.5
		T86121	Hs.191445	ESTs	6.4
50					
30		T90037	Hs.95549	ESTs	6.4
	113604	T92735	Hs.296083	ESTs	8.7
	113702	T97307		ESTs; Moderately similar to !!!! ALU SU	9.5
		W19222	Hs.7041	ESTs; Weakly similar to !!!! ALU SUBFA	5.2
		W37382	Hs.11090	ESTs	11.9
55					16.7
22		W44735	Hs.9286	ESTs	
	113811	W44928	Hs.6994	ESTs	4
	113822	W47350	Hs.17466	retinoic acid receptor responder (tazaroten	4.8
	113823	W47388	Hs.55099	rab6 GTPase activating protein (GAP and	4
		W56792	Hs.12040	ESTs; Weakly similar to KIAA0881 prote	4.1
60					4.3
UU		W65477	Hs.5297	Homo sapiens mRNA; cDNA DKFZp564	
		W72471	Hs.23920	ESTs	4.6
	113895	W73738	Hs.12921	ESTs	7.1
		W80763	Hs.3849	ESTs; Weakly similar to FK506-binding p	6.8
		W81205	Hs.3496	ESTs	6.1
65		W85765	Hs.30504	Homo sapiens mRNA; cDNA DKFZp434	14
UJ					
	1139/0	W86748	Hs.8109	ESTs .	15
	114051	W94942	Hs.177534	dual specificity phosphatase 10	5.4

	114057	W96222	Hs.34192	ESTs	4.8
	114086	Z38266	Hs.288649	Homo sapiens PAC clone DJ0777O23 fro	5.1
	114098	Z38347	Hs.118338	ESTs; Weakly similar to similar to S. cere	6.2
_		Z38435	Hs.184108	ribosomal protein L21	4.6
5		Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 prote	22
		Z38763	Hs.15740	amyloid beta (A4) precursor protein-bindi	8.8
		Z38814	Hs.27196	ESTs	4
		Z38909	Hs.22265	ESTs	7.2
10		Z39062	Hs.23740	ESTs	5.3
10		Z39211	Hs.150926	fucose-1-phosphate guanylyltransferase	4.4
		Z39301	Hs.7859	ESTs	5.1 7.2
		Z39897 Z39898	Hs.13297	ESTs	14.7
			Hs.21948	ESTs	19.4
15		Z40715 Z40758	Hs.184641 Hs.173091	detta-6 fatty acid desaturase DKFZP434K151 protein	8.9
15		Z41342	Hs.22941	ESTs	13.7
		AA024604		ESTs .	10.1
			Hs. 104613	ESTs	5.7
			Hs.151678	UDP-N-acetyl-alpha-D-galactosamine:po	7.3
20			Hs.106469	suppressor of var1 (S.cerevisiae) 3-like 1	4.3
			Hs.293380	ESTs	11.7
	114549	AA056484	Hs.292833	ESTs	7.3
	114652	AA101416	Hs.107149	ESTs; Weakly similar to PTB-ASSOCIAT	6.1
	114673	AA113303	Hs.95583	transmembrane 4 superfamily member (te	4.3
25			Hs.110857	ESTs; Highly similar to putative DNA-dir	7.1
			Hs.154443	minichromosome maintenance deficient (S	5.3
			Hs. 109929	ESTs	4.2
			Hs.269956	ESTs	4.8
20		AA161161		multiple inositol polyphosphate phosphata	7.1 4.4
30		AA165313 AA235035		ESTs Medaratak similar ta ubiguitin ana	5
			Hs,196437	ESTs; Moderately similar to ubiquitin spe ESTs; Weakly similar to R26660_1; parti	16.9
		AA236359		ESTs	5.1
		AA243012		ESTs	8.5
35		AA250737		ESTs	35.1
		AA252627		homeo box B5	5.7
	115054	AA252863	Hs.87729	ESTs	6.2
	115061	AA253217	Hs.41271	ESTs	13
4.0			Hs.198269	NADH dehydrogenase (ubiquinone) 1 alp	28.2
40		AA256486		ESTS	8.8
			Hs.279938	ESTs; Weakly similar to supported by GE	4.1
	115205	AA262470	Hs.284216	ESTs	8.3
			Hs.186572	ESTs	5.1 4.6
45		AA278650	Hs.283732	ESTs; Weakly similar to similar to the bet ESTs	8.3
7.7		AA278961		ESTs	10.1
		AA279071		splicing factor 3b; subunit 1; 155kD	9.5
			Hs.293736	ESTs	5.8
			Hs.122579	ESTs	5.1
50		AA281793		ESTs	5
	115377	AA282247	Hs.193063	ESTs	6.1
	115400	AA283198	Hs.89113	ESTs	4.9
	115439	AA284561	Hs.193090	ESTs	5.8
		AA287138		ESTs; Weakly similar to ASPARTYL-TR	11.7
55		AA292537		Human DNA sequence from clone 620E1	6.8
		AA331393		ESTs	5.8
		AA398392		ESTs; Weakly similar to F33G12.3 gene p	9.7 8.7
		AA399264 AA400247	Hs.283037	ESTs; Highly similar to HSPC039 protein ESTs	4
60		AA400247 AA400948		ESTS; Weakly similar to zinc finger prote	8.4
00			Hs.305971	ESTs	5.3
		AA405098		ESTs .	16.1
		AA405620		ESTs; Weakly similar to weak similarity t	4.7
			Hs.183056	Human DNA sequence from done 34B21	5.1
65	115675	AA406546	Hs.82065	Homo sapiens mRNA; cDNA DKFZp564	20.5
	115721	AA417102	Hs.90960	ESTs	4.8
		AA421560		ESTs	7

	115764	AA421562	Hs.91011	anterior gradient 2 (Xenepus laevis) homo	41.6
	115835	AA428576	Hs.41371	ESTs	4.2
		AA430124		ESTs	11.9
_		AA433943		ESTs; Weakly similar to Weak similarity	33.5
5		AA435839		KIAA0887 protein	7.2
		AA441911		ESTs; Weakly similar to KIAA0926 prote	5.1
		AA443602 AA443793		ESTs	4.8
		AA443798		ESTs	8.3 13.5
10			Hs.301048	poly(A)-specific ribonuclease (deadenylat cofilin 1 (non-muscle)	7.5
		AA446887		ESTs	8.8
		AA447687		ESTs	13.1
		AA449448		ESTs	5.5
		AA451748		Human DNA sequence from clone 718J7	7.5
15	116028	AA452112	Hs.42644	thioredoxin-like	12.7
		AA453656		ESTs	7.2
			Hs.176376	ESTs	11.8
		AA457566		ESTs	4.5
20		AA459254		ESTs	4.5
20			Hs.279884	v-myc avian myelocytomatosis viral onco	4.3
		AA459956 AA460649		ESTs; Highly similar to putative ribonucle ESTs	7.6 4.8
			Hs.108646	ESTs	6.8
		AA478397		ESTs	4.9
25		AA478415		ESTs	4
_		AA479362		DKFZP586N0819 protein	4.6
			Hs.250646	ESTs; Highly similar to ubiquitin-conjuga	4
	116249	AA480886	Hs.86693	ESTs	18.5
••		AA480975		ESTs .	10.8
30		AA481146		ESTs; Weakly similar to OXYSTEROL-B	9.1
		AA481256		ESTs; Weakly similar to lysophospholipa	8.4
			Hs.272239	Homo sapiens mRNA; cDNA DKFZp586	7.2
		AA482595 AA486550		ESTs; Weakly similar to F25B5.3 [C.eleg	11.1 6.2
35		AA489046		ESTs; Weakly similar to Wiskott-Aldrich ESTs	4.9
JJ		AA489194		ESTs; Weakly similar to snRNP protein B	4.6
		AA490959		Homo sapiens mRNA; cDNA DKFZp564	5.8
		AA491457		ESTs	4.3
	116337	AA496127	Hs.44070	ESTs	8.4
40		AA504116		Homo sapiens mRNA; cDNA DKFZp434	5.3
		AA504806		Homo sapiens clone 23620 mRNA sequen	5.2
		AA609204		KIAA0874 protein	6.6
		AA620313		ESTs; Weakly similar to KERATIN; TYP	4.5
45		C13992 C14088	Hs.83484	ESTs	4.5 5.6
40		D51272	Hs.75337	glyceraldehyde-3-phosphate dehydrogena nucleolar phosphoprotein p130	4.1
		D51276	Hs.81915	leukemia-associated phosphoprotein p18	5.8
		F02028	Hs.81907	ESTs	4.9
		F03069	Hs.15395	ESTs; Weakly similar to ARGINYL-TRN	6.1
50	116674	F04816	Hs.92127	ESTs	10.6
	116680	F08813	Hs.273829	LINE retrotransposable element 1	4.2
		F09983	Hs.317589	ESTs	13
	116724		Hs.65641	ESTs	8.5
55		F13681	Hs.53913	ESTs	5.6
55		F13779 F13789	Hs.165909 Hs.93796	ESTs DKFZP586D2223 protein	11.6
		H11054	Hs.155342	protein kinase C; delta	5.4 4.3
		H22566	Hs.30098	ESTs	5.7
		H25836	Hs.301527	tumor necrosis factor (ligand) superfamily	8.8
60		H28581	Hs.15641	ESTs	8.6
		H29532	Hs.101174	microtubule-associated protein tau	22.2
		H47357	Hs.109701	ESTs; Moderately similar to weak similar	6.7
		H68116	Hs.168732	ESTs	6.5
65		H72948	Hs.821	biglycan	20.7
65		N20083	Hs.42792	ESTs	4.4
		N20579 N22162	Hs.61153 Hs.183779	ESTs; Weakly similar to cDNA EST yk33	7.4 4.1
	111204		110,100770	COTO, Treatly similar to obtain COT years	7.1

	117344	NOVOR	Hs.210706	ESTs	7.4
	117367		Hs.42502	ESTs	10.5
	117392		Hs.93405	ESTs	5.8
	117394		Hs.39871	KIAA0727 protein	8.4
5	117412		Hs.42645	ESTs	18.1
•	117498		Hs.44268	ESTs; Highly similar to myelin gene expr	5.8
	117557		Hs.44532	diubiquitin	12.3
	117634		Hs.13323	ESTs; Weakly similar to SODIUM- AND	4.4
	117639		Hs.44833	ESTs	6
10	117754	N47469	Hs.59757	ESTs	7.6
	117852	N49408	Hs.136102	KIAA0853 protein	5.9
	117879	N50050	Hs.303025	ESTs; Weakly similar to keratin; 67K typ	7.9
	117924		Hs.38891	ESTs	7.9
1.7	117950		Hs.75478	KIAA0956 protein	5
15	117992		Hs.172089	Homo sapiens mRNA; cDNA DKFZp586	7
	118138		Hs.93560	ESTs; Weakly similar to trg [R.norvegicu	4.8
	118215		Hs.77910	3-hydroxy-3-methylglutaryl-Coenzyme A	13.4
	118229		Hs.166254	heat shock 90kD protein 1; alpha	5.4 4.2
20	118265		Hs.48645	EST	7.2
20	118336		Hs.47166 Hs.48938	ESTs ESTs	6
	118363 118429		Hs.74649	ESTs	4.1
	118470		Hs.291033	ESTs	5.4
		N66818	Hs.42179	ESTs	10.8
25		N66845	113.42110	ESTs; Weakly similar to IIII ALU CLASS	4.5
		N67149	Hs.50115	ESTs	5.3
		N67889	Hs.49397	ESTs	10.4
		N68010	Hs.49427	ESTs	7.9
		N69222		ESTs	9.2
30	118695	N71781	Hs.50081	Homo sapiens mRNA full length insert cD	9.8
	118698	N72113	Hs.50187	ESTs	4.3
		N90719	Hs.94445	ESTs	8.1
		N92966		ESTs; Highly similar to CGI-90 protein [H	12.5
25		N93629	Hs.93391	ESTs	5
35		N94362	Hs.125830	ESTs	7.3
		N94439	Hs.45105	ESTS	8.2 5
		N99256	Hs.114611	ESTs	4
		R05316 R36451	Hs.5472 Hs.287820	ESTs fibronectin 1	6
40		T15916	Hs. 102950	ESTs; Highly similar to coat protein gamm	4.1
40		T16387	Hs.65328	ESTs	12,1
		T23820	Hs.155478	cyclin T2	5.6
	119302			ESTs	14.3
	119341		Hs.146388	microtubule-associated protein 7	4
45		W35390	Hs.55533	ESTs	5.3
	119580	W42451	Hs.92260	high-mobility group protein 2-like 1	5.6
	119602	W46286	Hs.233694	ESTs; Weakly similar to ZK1058.5 [C.ele	6.5
		W47620	Hs.56009	2'-5'oligoadenylate synthetase 3	8.1
~ 0		W60473	Hs.57787	ESTs	5.5
50		W69134	Hs.57987	ESTs	4.6
		W69747	Hs.94806	KIAA 1062 protein	4 4
		W73788	Hs.43213	ESTs	4.8
		W80702 W80852	Hs.58461 Hs.250696	ESTs KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4.2
55		W81129	Hs.44865	Homo sapiens mRNA; cDNA DKFZp586	4.8
55		W84767	Hs.58698	ESTs	5.9
		W86779	Hs.272531	DKFZP586B0319 protein	9
		W86835	Hs.14158	copine III	4.8
		W87812	Hs.93581	Homo sapiens mRNA; cDNA DKFZp586	4
60		Z38656	Hs.75887	coatomer protein complex; subunit alpha	4.2
	120150	Z39549	Hs.153746	ESTs	11
	120206	Z40805	Hs.91668	ESTs	8.2
		Z41815	Hs.65946	ESTs	15.6
6 5		AA169752		ESTs; Weakly similar to Similarity to Yea	4.2
65			Hs.221040	KIAA1038 protein	6.8
	120325	AA195651	Hs.104106	ESTs .	15.2
	120352	AAZ11400	Hs.193172	ESTs	6.8

			Hs.173694	KIAA1097 protein	5.6
			Hs.192905	ESTs	5.6
	120528	AA262107	Hs.104413	ESTs	4.5
_		AA280738		ESTs	4.9
5	120649	AA287115	Hs.192843	ESTs	4.5
			Hs.238205	ESTs	6.7
	120668	AA287833	Hs.292913	ESTs	8.3
	120712	AA292654	Hs,102506	eukaryotic translation initiation factor 2 al	4.6
	120713	AA292655	Hs.96557	ESTs	10.6
10	120724	AA293470	Hs.100747	ESTs	5.4
	120873	AA358015		EST	7.1
	120885	AA365515	Hs.301872	ESTs; Moderately similar to IIII ALU SU	4.6
	120919	AA381125	Hs.301444	ESTs	8.2
			Hs. 104650	ESTs; Highly similar to similar to mago n	8.6
15			Hs.129206	casein kinase 1; gamma 3	10.5
		AA398155		ESTs	10.9
		AA398936		EST	7.4
		AA401753		lung cancer candidate	5.3
			Hs.301927	T-cell receptor, alpha (V;D;J;C)	13.5
20			Hs.239681	ESTs; Weakly similar to KIAA0554 prote	8.9
20			Hs.174104	ESTs	22.6
			Hs.104800		8
			Hs.234545	ESTs; Weakly similar to Mouse 19.5 mRN	5.6
				ESTS	5.3
25		AA434411		ESTs	3.3 4
43		AA449444		ESTS	
		AA454756		ESTs	4
		AA456326		ESTs	6.2
		AA459894		ESTs	5.3
20		AA463740		Src-like-adapter	13.1
30			Hs.108812	ESTs; Weakly similar to B0041.5 [C.eleg	5.5
			Hs.101840	ESTs	6.3
			Hs.194215	ESTs	6
			Hs.106290	Kelch motif containing protein	12.5
	123016	AA480103	Hs.323231	ESTs; Weakly similar to alternatively spli	4.4
35	123107	AA486071	Hs.104207	ESTs	8.3
	123111	AA486273	Hs.191721	ESTs	4.2
	123114	AA486407	Hs.129928	ESTs; Moderately similar to KIAA0454 p	5.2
	123136	AA487449	Hs.194024	ESTs	4.2
	123137	AA487468	Hs.100686	ESTs; Weakly similar to secreted cement	14.6
40	123169	AA488892		ESTs; Weakly similar to Gag-Pol polypro	4.5
	123176	AA489020	Hs.69233	ESTs	5.2
	123338	AA504249	Hs.187585	ESTs	4
	123436	AA598714	Hs.223014	protease; serine; 15	7.3
			Hs.111496	ESTs	5.9
45			Hs.112493	Homo sapiens mRNA; cDNA DKFZp564	4.1
_			Hs.112110	ESTs	4
			Hs.293156	ESTs	12.8
		AA608751		ESTs; Weakly similar to !!!! ALU SUBFA	7.9
		AA609200		ESTs	23.1
50			Hs.158549	ESTs	6.6
• •			Hs.278672	membrane component; chromosome 11; s	4.7
			Hs.112264	ESTs	4
			Hs.287733	methylmalonate-semialdehyde dehydroge	7.6
		D57317	Hs.74861	activated RNA polymerase II transcription	4.4
55		D60302	Hs.270016	ESTs	20,6
55		D80240	Hs.241471	HUM5G11A Human fetal brain (TFujiwa	6.7
		F02859	Hs.13974	ESTs ·	4.7
		F10523	Hs.74519	primase; polypeptide 2A (58kD)	4.7
				ESTs	7.7
60		F13673	Hs.283713 Hs.133525	ESTs	5.5
JU		H66710	Hs.241507		11.4
		H93575		Homo sapiens mRNA; cDNA DKFZp564 GTP-binding protein	13,7
		H94877	Hs.215766	v-ral simian leukemia viral oncogene hom	14
		H94892	Hs.288757		
65		N21359	Hs.101282	Homo sapiens mRNA; cDNA DKFZp434	8.6
65		N21626	Hs.102406	ESTS	7.2
		N22401	Do 7525	yw37g07.s1 Morton Fetal Cochlea Homo	5.2
	124390	N29325	Hs.7535	ESTs; Highly similar to COBW-like place	7.9

	124438	N40188	Hs.11090	ESTs	9.5
		N48000	110.11000	Homo sapiens mRNA; cDNA DKFZp586	4.8
		N50114	Hs.266175	ESTs	6.1
		N63172	Hs.146409	cell division cycle 42 (GTP-binding prote	5.6
5		N74604	Hs.11090	ESTs	12.8
-		N79515	Hs.306117	interleukin 13 receptor; alpha 1	6.4
		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.3
		R01037	Hs.181013	phosphoglycerate mutase 1 (brain)	12.3
		R01073		ESTs; Weakly similar to !!!! ALU CLASS	5.4
10	124724	R12405	Hs.112423	Homo sapiens mRNA; cDNA DKFZp586	6.6
	124773	R40923	Hs.106604	ESTs	4.9
	124777	R41933		ESTs	7.2
	124792	R44357	Hs.48712	ESTs; Weakly similar to cDNA EST EMB	8.6
	124857	R63652	Hs.137190	ESTs	4.9
15		R88992	Hs.180612	ESTs	4.7
		T10598	Hs.324841	ESTs; Weakly similar to !!!! ALU SUBFA	4.4
		T11134	Hs.431	murine leukemia viral (bmi-1) oncogene h	12.6
		T78089	Hs.270134	ESTs	4.1
20		T92544	Hs.137548	CD84 antigen (leukocyte antigen)	14.8
20		W15495	Hs.129781	chromosome 21 open reading frame 5	6.7
		W37999	Hs.24336	ESTs	4.8
		W38419	11 400440	ESTs	5.3 6.6
		W86423	Hs.105413	ESTs	5.8
25		W93640	Hs.4779	ESTs; Moderately similar to similar to AD	12.2
23		Z39436	Hs.102720	ESTs ESTs	10.2
		Z39821 Z39833	Hs.288193	GTP-binding protein	6.8
		AA151216	Hs.124940	tyrosine 3-monooxygenase/tryptophan 5-m	8
			Hs.288967	ESTs	5.4
30			Hs.267812	sorting nexin 4	4.1
50		AA507383		cytochrome c oxidase subunit VIc	11.5
		A1432621		CD47 antigen (Rh-related antigen; integri	4
			Hs.191356	general transcription factor IIH; polypepti	9.4
		Al283493		ribophorin II	6.2
35		H09290	Hs.76550	Homo sapiens mRNA; cDNA DKFZp564	25.9
		AA434562	Hs.35406	ESTs	4.1
		N90960	Hs.265398	ESTs; Weakly similar to transformation-r	16.4
	126257	N99638	Hs.124084	tumor necrosis factor receptor superfamily	9.5
	126337	A1066486	Hs.40500	similar to S. cerevisiae RER1	5.6
40		U46278	Hs.122489	ESTs	7.5
		W40262	Hs.146310	ESTs, Weakly similar to putative p150 [H	4.1
		W78968	Hs.181307	H3 histone; family 3A	4.5 5.2
		AA205862		ESTs	4.4
45		T72569	Hs.125359	Thy-1 cell surface antigen	4.6
43		AI334393	Hs.102178	ESTs ESTs	11.7
•		AI203334	Hs.160628 Hs.279607	ESTS ·	4
		A1052047	Hs.26102	ESTs	7
		R31652	Hs.821	biglycan	5.6
50			Hs.179729	collagen; type X; alpha 1 (Schmid metaph	14.3
			Hs.204214	ESTs	4.5
		W07286	Hs.10340	ESTs; Weakly similar to weak similarity t	5.1
			Hs.264190	ESTs; Highly similar to MEM3 [M.muscu	17.3
			· Hs.136713	ESTs; Weakly similar to V4-1 [H.sapiens	4.1
55		Al281549	Hs.311054	ESTs	5.5
	128092	AA904617	Hs.166229	ESTs	5.8
	128218	H02682	Hs.292154	ESTs; Moderately similar to recombinatio	5.8
	128466	D59653	Hs.241471	EST	7.4
		U83908	Hs.296251	programmed cell death 4	5.8
60			Hs.100861	ESTs; Weakly similar to p60 katanin [H.s	8.3
			Hs.183475	Homo sapiens clone 25061 mRNA sequen	6.6
			Hs.101448	metastasis associated 1	5.2
		AA412048		keratin 8	5.1
65		U31875	Hs.152677	short-chain alcohol dehydrogenase family activated leucocyte cell adhesion molecule	27.1 13.2
65		L38608	Hs.10247		6.7
			Hs.102708	DKFZP434A043 protein Homo sapiens mRNA for G7b protein (G	4.5
	120049	AA 142003	Hs.103106	Compagnition of Orbifoldin (a	٦.5

	128651	AA446990	Hs.103135	ESTs	6.1
		R48943	Hs.10315	solute carrier family 7 (cationic amino aci	4.4
		AA458542		coatomer protein complex; subunit epsilon	14.3
		T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566	24.5
5		M64174	Hs.50651	Janus kinase 1 (a protein tyrosine kinase)	7.3
-		N49308	Hs.104938	ESTs; Weakly similar to alpha 1(XVIII) c	9.2
		X85372	Hs.105465	small nuclear ribonucleoprotein polypepti	5.4
	128793	W93562	Hs.105749	KIAA0553 protein	4.6
_	128835	W15528	Hs.106390	Homo sapiens mRNA; cDNA DKFZp586	4
10	128845	AA455658	Hs.10649	basement membrane-induced gene	6.9
	128871	AA400271	Hs.106778	Homo sapiens mRNA for putative Ca2+t	4.5
	128922	AA252023	Hs.9589	ESTs; Weakly similar to HRIHFB2157 [H	6.4
	128925	D61676	Hs.21851	Homo sapiens mRNA; cDNA DKFZp586	6.4
	128938	AA410325	Hs.107260	ESTs	7
15	128946	N29353	Hs.107318	kynurenine 3-monooxygenase (kynurenin	5.2
			Hs.223025	proteasome (prosome; macropain) subunit	13.1
		F10290	Hs.185807	Horno sapiens clone 24758 mRNA sequen	5,8
		AA460049		ESTs; Weakly similar to SODIUM-AND	12.6
00		AA131421		ESTs	9.8
20		H13108	Hs.107968	ESTs	13.9
		X62466	Hs.276770	CDW52 antigen (CAMPATH-1 antigen)	10.7
		AA129465		ESTs	4.7
		L12350	Hs.108623	thrombospondin 2	4.4
25		AA234530		N-ethylmaleimide-sensitive factor	20.7
25		AA131252		ESTs	5.9
		AA282183		ESTs	5.8
		R40556	Hs.318401	ESTs; Highly similar to HSPC039 protein	7.6
		X89109	Hs.109606	coronin; actin-binding protein; 1A	12
30		AA211941		polyadenylate binding protein-interacting	7.9 5.3
50		W24360 AA435665	Hs.237868	interleukin 7 receptor ESTs; Moderately similar to HN1 [M.mus	8.4
				•	7.8
		H88033 AA151574	Hs.109727	KIAA0733 protein	6.4
		AA090695		pilin-like transcription factor ESTs	6.2
35		Z35227	Hs. 109918	ras homolog gene family; member H	5.4
33		AA026318		glucose regulated protein; 58kD	4.4
		C20976	Hs.110165	ESTs; Highly similar to ribosomal protein	5.7
		N93155	Hs.285976	calmodulin 1 (phosphorylase kinase; delta	7.7
		AA037467		ESTs	6
40		AA167268		Human ras inhibitor mRNA; 3' end	9.3
		H18027	Hs.184697	plexin C1	18.2
	129383	W92984	Hs.288224	ESTs	5.9
	129388	AA151621	Hs.110964	ESTs	4.1
	129391	T80814	Hs.11101	discs; large (Drosophila) homolog 3 (neur	10.9
45	129404	AA172056	Hs.317584	ESTs	5.3
		N23707	Hs.111138	KIAA0712 gene product	4
	129426	AA412087	Hs. 111323	EST; Highly similar to protein inhibitor o	8
		AA421213		Lsm3 protein	5.5
CO		C00225	Hs.306163	ESTs; Weakly similar to fos39554_1 [H.s	5.5
50		AA298786		ESTs	6.8
		R21443	Hs.166254	heat shock 90kD protein 1; alpha	5
		AA278243		ESTs	6.8
		AA447410		ESTs; Weakly similar to !!!! ALU SUBFA	5.1
55		AA258308		Homo sapiens mRNA; cDNA DKFZp564	5.3
55		U26727	Hs.1174	cyclin-dependent kinase inhibitor 2A (mel	8.2
		R50008	Hs.11806	7-dehydrocholesterol reductase translocase of inner mitochondrial membr	4.3
		AA442768		KDEL (Lys-Asp-Glu-Leu) endoplasmic re	4.4
		M88458	Hs.118778	collagen; type III; alpha 1 (Ehlers-Danios	4 6
60		X06700 AA454618	Hs.119571	associated molecule with the SH3 domain	6.4
JU		AA454618 AA252436		associated molecule with the SH3 domain lysophospholipase I	6.4 7.7
		AA452161		YME1 (S.cerevisiae)-like 1	7.7 5
		N20593	Hs.288932	GDP dissociation inhibitor 2	6.9
		AA102520		ESTs: Weakly similar to heat shock prote	5
65		AA043021		UDP-Gal:betaGloNAc beta 1;4- galactosy	6.6
J.J		M87789		immunoglobulin gamma 3 (Gm marker)	4
		AA450045	Hs.140452	cargo selection protein (mannose 6 phosp	5.8
	,_,,,,,,				

	400000		11 000540	TOT: 14 1 1 1 1 7 1 DETOT D4	
		AA236412		ESTs; Moderately similar to PFT27 [M.m	5.6
		M90696	Hs.181301	cathepsin S	5,4
	130036	AA195260	Hs.125849	ESTs; Moderately similar to IIII ALU SU	7.4
	130069	AA055896	Hs.146428	collagen; type V; alpha 1	· 7.6
5	130077	T24055	Hs.91379	ribosomal protein L26	4
	130080	X14850	Hs.147097	H2A histone family; member X	12.1
			Hs.197955	KIAA0704 protein	5
		AA234717		ESTs	7.8
10		M36803	Hs.1504	hemopexin	7.2
10		M61764	Hs.21635	tubulin; gamma 1	5.6
	130170	AA610070	Hs.151469	calcium/calmodulin-dependent serine pro	7.5
	130189	D43947	Hs.151761	KIAA0100 gene product	6.4
	130208	AA620556	Hs.15250	peroxisomal D3;D2-enoyl-CoA isomerase	6.4
		D50840	Hs.23703	UDP-glucose ceramide glucosyltransferas	4.5
15		X14046	Hs.153053	CD37 antigen	9.1
10		S75295	Hs.169149	karyopherin alpha 1 (importin alpha 5)	8.6
		L13738	Hs.153937	activated p21cdc42Hs kinase	5
		AA620323		ubiquitin-activating enzyme E1C (homolo	6.1
••	130314	D86967	Hs.154332	KIAA0212 gene product	10
20	130328	AA135673	Hs.154668	KIAA0391 gene product	6.1
	130356	X84373	Hs.155017	nuclear receptor interacting protein 1	10.6
		Z38501	Hs.8768	ESTs; Weakly similar to !!!! ALU SUBFA	8.3
		T47333	Hs.155188	TATA box binding protein (TBP)-associa	7.1
		X66364	Hs.166071	cyclin-dependent kinase 5	5.6
25					
23		D13630	Hs.155291	KIAA0005 gene product	4.1
		AA449417		Homo sapiens mRNA for putative glucosy	4.6
		N29888	Hs.155410	ESTs	7
	130414	M21121	Hs.241392	small inducible cytokine A5 (RANTES)	4.1
	130417	U58522	Hs.155485	huntingtin-interacting protein 2	7.9
30	130421	D21260	Hs.178710	clathrin; heavy polypeptide-like 2	4
		U35835	Hs.155637	protein kinase; DNA-activated; catalytic p	6.8
		X17059	Hs.155956	N-acetyltransferase 1 (arylamine N-acetyl	26.4
		L38951	Hs.180446	karyopherin (importin) beta 1	4.8
					6.1
25			Hs.158286	Homo saplens mRNA for KIAA0446 prot	
35		L32137	Hs.1584	cartilage oligomeric matrix protein (pseud	8.3
			Hs.252587	pituitary tumor-transforming 1	7.5
	130558	H96654	Hs.15984	ESTs; Weakly similar to gene pp21 protei	5.6
	130568	AA232535	Hs.16085	ESTs; Highly similar to CGI-13 protein [H	4
	130583	W24957	Hs.293907	ESTs; Moderately similar to similar to C.e	13.3
40		H66211	Hs.16331	ESTs	10.1
		X03635	Hs.1657	estrogen receptor 1	39.9
		AA132007		ESTs	5.1
					5.9
		AA477739		ESTs	
15		AA235247		ESTs; Weakly similar to cytochrome P45	4.1
45		F03969	Hs.260720	matrix metalloproteinase 2 (gelatinase A;	8.3
	130627	L23808	Hs.1695	matrix metalloproteinase 12 (macrophage	10.3
	130629	M60346	Hs.1697	ATPase; H+ transporting; lysosomal (vacu	7
	130635	M87503	Hs.1706	interferon-stimulated transcription factor	5.5
		D59711	Hs,17132	ESTs	7.2
50		H17861	Hs.17767	ESTs	13.5
50		D82808	Hs.17820	Rho-associated; coiled-coil containing pro	6
					6.1
		AA487202		ESTs	
		N63295	Hs.18103	ESTs	4.3
			Hs.201673	comichon-like	4
55			Hs.279762	adenylate cyclase 7	5.1
	130714	X92896	Hs.18212	DNA segment on chromosome X (unique)	8.4
	130715	T98227	Hs.171952	occludin	5.7
		AA203527	Hs.18747	POP7 (processing of precursor, S. cerevis	6.2
		AA471293		ESTs	8.2
60		AA435633		Homo sapiens clone 23965 mRNA sequen	8.3
00			Hs.19525	ESTs	4.5
		R39390			
		AA223386		ESTs; Weakly similar to katanin p80 subu	7.7
			Hs.143323	putative DNA/chromatin binding motif	4.3
		AA287327		ceroid-lipofuscinosis; neuronal 2; late infa	9.8
65	130866	M58028	Hs.2055	ubiquitin-activating enzyme E1 (A1S9T a	4.3
	130880	D14678	Hs.20830	kinesin-like 2	4.5
		D31891	Hs.20991	SET domain; bifurcated; 1	4
		•			

	130905	AA056489	Hs.129998	ESTs	8.7
		W03592	Hs.21198	translocase of outer mitochondrial membr	20.9
•		AA291710		collagen; type IV; alpha 3 (Goodpasture a	9
			Hs.194688	bromodomain adjacent to zinc finger dom	5.3
5		M97935	Hs.21486	signal transducer and activator of transcrip	18.8
		X57985	Hs.2178	H2B histone family; member Q	13.4
		R45698	Hs.21893	ESTs; Weakly similar to cAMP inducible	8.5
		N48963	Hs.21992	KIAA0689 protein	7.2
	131010	AA435748	Hs.169341	ESTs; Weakly similar to phosphatidic acid	5.2
10		X02530	Hs.2248	small inducible cytokine subfamily B (Cy	10,1
	131091	T35341	Hs.22880	ESTs; Highly similar to dipeptidyl peptid	6.3
	131153	H11760	Hs.23606	ESTs	7.3
	131185	M25753	Hs.23960	cyclin B1	6.2
	131200	AA609427	Hs.293732	ESTs; Moderately similar to !!!! ALU SU	4.3
15	131206	AA044078	Hs.24210	ESTs	5.5
	131210	AA430047	Hs.95549	ESTs	7.1
	131227	AA429472	Hs.236522	DKFZP434P106 protein	5.6
		D38076	Hs.24763	RAN binding protein 1	5.5
		AA620599		DKFZP564E1962 protein	6.7
20		AA256042		ESTs	5.8
		U25997	Hs.25590	stanniocalcin	8.9
		AA463450		Nijmegen breakage syndrome 1 (nibrin)	6.5
		R34531	Hs.92200	KIAA0480 gene product	9.2
25		H84658	Hs.279836	ESTs	12.1
25		AA608962		calcyclin binding protein	18.1
		Z39053	Hs.27263	ESTs	7.5
		AA121127		H3 histone; family 3A	5.5
		X02152	Hs.2795	lactate dehydrogenase A	5.1
30		N39152	Hs.301804	ESTs	4.3
30		D60856	Hs.28309	UDP-glucose dehydrogenase	8.4
		N33236	Hs.28555	ESTs; Weakly similar to B0511.8 [C.eleg	5.6
		D30946	Hs.28707	signal sequence receptor; gamma (transloc	8.7
		U90551	Hs.28777	H2A histone family; member L ESTs	18.8 11.8
35		AA491465 AA235385		ESTs; Moderately similar to alternatively	4.7
55		M15182	Hs.183868	glucuronidase; beta	5.2
		U52100	Hs.29191	epithelial membrane protein 2	4.4
		D14533	Hs,192803	xeroderma pigmentosum; complementatio	4.6
		AA136126		mitogen-activated protein kinase-activated	4.3
40		AA136660		ESTs	9,4
. •		U26174	Hs.3066	granzyme K (serine protease; granzyme 3	9.7
		L11066	Hs.3069	heat shock 70kD protein 9B (mortalin-2)	6.2
		AA599653		transcription factor-like 5 (basic hellx-loo	8.3
		W60913	Hs.110796	ESTs; Weakly similar to cDNA EST yk45	9
45		AA233225		MRS1 protein	5.2
		D49738	Hs.31053	cytoskeleton-associated protein 1	6.6
	131742	D31352	Hs.31433	ESTs	11
		H46831	Hs.107767	ESTs; Moderately similar to CaM-KII inh	4.9
	131781	AA460450	Hs.31989	DKFZP586G1722 protein	9,2
50	131795	N32724	Hs.32317	Sox-like transcriptional factor	4.5
		L76517	Hs.3260	presenilin 1 (Alzheimer disease 3)	5.4
		AA437226		interleukin 10 receptor; alpha	4
		AA091932		dynamin-like protein	6.7
		J04088	Hs.156346	topoisomerase (DNA) II alpha (170kD)	5
55		AA044095		ESTs	11.1
		AA158258		heterogeneous nuclear protein similar to r	5.6
			Hs.183180	ESTs; Weakly similar to RING finger pro	4.5
		AA205460		ESTs	14.3
60		D62657	Hs.35086	ubiquitin-specific protease 1	6.2
60		W90146	Hs.35962	ESTs .	6.3
		D86960	Hs.3610	KIAA0205 gene product	4.2
		R70167	Hs.154938	ESTs Homo sapiens mRNA; cDNA DKFZp586	4.3
		AA410424 F09788	Hs.268122 Hs.3622	procollagen-proline; 2-oxoglutarate 4-diox	4.6 6.4
65		AA479515		Human DNA sequence from clone 703H1	12
05		D82399	Hs.136644	Homo sapiens clone 23714 mRNA sequen	10
		W67251	Hs.267659	Homo sapiens vav 3 oncogene (VAV3) m	4.7
	102017			Come achieria ana a amadama (a) III	

	132024	TEODAE	De 20€070	chaperonin containing TCP1; subunit 5 (e	5.2
		T68246	Hs.306079		8.5
		D82226	Hs.211594	proteasome (prosome; macropain) 26S sub	13.5
		D44466	Hs.3887	proteasome (prosome; macropain) 26S sub	
5		AA131971		ESTs	4.8
3		AA599801		ESTs	6.2
		AA257056		KIAA0871 protein	14.6
		T10822	Hs.324743	ESTs	5.3
	132153	N90141	Hs.41066	ESTs; Moderately similar to ELONGATI	9.2
	132160	AA281770	Hs.295923	seven in absentia (Drosophila) homolog 1	5.5
10	132164	U84573	Hs.41270	procollagen-lysine; 2-oxoglutarate 5-dioxy	8.1
	132180	AA405569	Hs.418	fibroblast activation protein; alpha; sepras	15.4
	132183	L19183	Hs.199695	hypothetical protein	12.2
	132225	AA128980		ESTs	5.6
	132227	AA412620	Hs.4248	ESTs	6.7
15	132235	F09058	Hs.42656	ESTs	6.2
	132256	AA608856	Hs.431	murine leukemia viral (bmi-1) oncogene h	6
		N41849	Hs.7120	Homo sapiens cytokine receptor related p	5.6
		AA285290		small EDRK-rich factor 2	6.8
		N37065	Hs.44856	ESTs	4.7
20		AA479933		Human DNA sequence from clone 167A1	4.2
		R70914	Hs.281434	heat shock 70kD protein 1	9.1
		W85888	Hs.47334	ESTs; Moderately similar to IIII ALU SU	4
		F09979	Hs.4774	ESTs	15
				ESTs	8
25		AA431459			4
23			Hs.260116	KIAA1104 protein	5.3
		AA426218		ESTs	15.4
		AA047896		ESTs	
			Hs.238126	ESTs; Highly similar to CGI-49 protein [H	9
20		T03749	Hs.4990	KIAA1089 protein	8.5
30		AA283006		chromosome-associated polypeptide C	4.3
		AA488987		synaptogyrin 2	9.8
		AA417152		protein regulator of cytokinesis 1	10.1
	132580	L37042	Hs.283738	casein kinase 1; alpha 1	5.9
	132586	AA412452	Hs.52515	DKFZP434N024 protein	4.2
35	132608	AA199588	Hs.5321	ARP3 (actin-related protein 3; yeast) hom	4.2
	132616	AA386264	Hs.283558	isocitrate dehydrogenase 2 (NADP+); mit	5.2
	132617	AA171913	Hs.5338	carbonic anhydrase XII	10.1
	132618	AA253330	Hs.279916	adaptor-related protein complex 1; gamma	4.8
	132640	U33821	Hs.5437	Tax1 (human T-cell leukemia virus type I	5.7
40	132668	AA453614	Hs.5460	KIAA0776 protein	4.4
		M60830	Hs.5509	ecotropic viral integration site 2B	15.6
		N47109	Hs.5521	ESTs	7
		AA417962		geranylgeranyl diphosphate synthase 1	5.6
		W42674	Hs.264636	ESTs; Moderately similar to neuronal thre	4.9
45			Hs.292812	ESTs; Weakly similar to C43H8.1 [C.eleg	7.9
		X54326	Hs.55921	glutamyl-prolyl-tRNA synthetase	4.1
		H99152	Hs.57079	ESTs	8
		AA331777		mutL (E. coli) homolog 1 (colon cancer; n	8
		U25435	Hs.57419	transcriptional repressor	4
50		AB004884		tousled-like kinase 2	6.5
50		N23817	Hs.5807	Homo sapiens clone 23675 mRNA sequen	5.6
					12.4
		D62588	Hs.5813	ESTS	7
		T48195	Hs.58189	eukaryotic translation initiation factor 3; s	6.2
55		W79865	Hs.58367	glypican 4	
23		N26855	Hs.203961	ESTs	6.5
		AA425776		ESTs	5.6
			Hs.177537	ESTs	7.2
		D82422	Hs.5944	ESTs	7.5
		N56451	Hs.5978	LIM domain only 7	4.4
60		AA235404		Homo sapiens clone 25186 mRNA sequen	9.1
		X83618	Hs.59889	3-hydroxy-3-methylglutaryl-Coenzyme A	10.7
			Hs.234896	ESTs; Highly similar to geminin [H.sapie	10.2
	132914	AA496037	Hs.60293	ESTs	4.7
	132918	AA252605	Hs.6051	KIAA0616 protein	7.1
65	132936	AB002305	Hs.6111	KIAA0307 gene product	8.3
	132951	U04209	Hs.61418	microfibrillar-associated protein 1	4.3
		AA234791		Human gene from PAC 753P9; chromoso	13.2

	132959	AA028103	Hs.61472	ESTs; Weakly similar to unknown [S.cere	18.9
		N77151	Hs.61638	myosin X	5.8
		H80409	Hs.62112	zinc finger protein 207	4.3
_		AA458761		transcription factor AP-2 alpha (activating	4.2
5			Hs.279905	solute carrier family 2 (facilitated glucose	26.4
		Y00062	Hs.170121	protein tyrosine phosphatase; receptor typ	4.4
		AF006082		ARP2 (actin-related protein 2; yeast) hom	4.7
		C21400	Hs.278605	KIAA0970 protein	6.6
10		W81298	Hs.246315	ESTs	7.9 5.2
10		X62055	Hs.6289 Hs.63489	growth factor receptor-bound protein 2 protein tyrosine phosphatase; non-recepto	4
		S67325	Hs.63788	propionyl Coenzyme A carboxylase; beta	5.2
		AA071387		jumping translocation breakpoint	5
		R33663	Hs.64056	ESTs	5.4
15		N70633	Hs.6456	chaperonin containing TCP1; subunit 2 (b	6
		AA122147		KIAA0483 protein	5
			Hs.285996	ESTs	5.6
	133124	AA156049	Hs.267923	ESTs	4.1
	133126	D16469	Hs.6551	ATPase; H+ transporting; lysosomal (vacu	6.2
20		R37367	Hs.6727	Ras-GTPase activating protein SH3 doma	5.1
		Y10659	Hs.285115	interleukin 13 receptor, alpha 1	6.2
		Z41415	Hs.6823	ESTs; Weakly similar to Intrinsic factor-B	8.3
		N90029	Hs.6831	Homo sapiens clone 1400 unknown prote	4.7
25			Hs.179882	Homo sapiens clone 24655 mRNA sequen	5.5
25		D31161	Hs.242894	ESTs	9
		AF006086		actin related protein 2/3 complex; subunit ESTs; Weakly similar to cDNA EST yk37	7.7 6.7
		W72187 AA488886	Hs.69192	ESTs	4.2
		AA421079		ESTs; Weakly similar to Sox-like transcri	4.9
30		AA410507		ESTs	4.3
		L15702	Hs.69771	B-factor; properdin	9.3
		R79723	Hs.69997	zinc finger protein 238	30.4
	133297	AA600057		KIAA0905 protein	10.4
	133318	AA256168	Hs.152316	ESTs	8.5
35		H06195	Hs.7194	ESTs; Highly similar to CGI-59 protein [H	14
		AA156897		DKFZP564l1922 protein	5
		X57579	Hs.727	Inhibin; beta A (activin A; activin AB alp	13.9
		AA491296		ESTs	4.3
40		N79516	Hs.73287	ESTs; Weakly similar to eyelid [D.melano	4.5
40		AA255438		Homo sapiens mRNA; cDNA DKFZp566	8
		T23983	Hs.323966	ESTs	5
		AA094989 X03068	Hs.73931	voltage-dependent anion channel 3 major histocompatibility complex; class II	8.7 5
		X78710	Hs.211581	metal-regulatory transcription factor 1	5.3
45		AA316868		ESTs; Weakly similar to 140G11.h [D.me	6.8
		X52947	Hs.74471	gap junction protein; alpha 1; 43kD (conn	5.7
		D63480	Hs.278634	KIAA0146 protein	4.8
			Hs.172772	transcription elongation factor B (SIII); po	9.5
	133572	W94333	Hs.279915	translocase of inner mitochondrial membr	5
50	133577	F03717	Hs.75063	human immunodeficiency virus type I enh	7.4
		L37368	Hs.75104	RNA-binding protein S1; serine-rich dom	5
		D13315	Hs.75207	glyoxalase I	4.2
		AA148318		KIAA0069 protein	4.5
55		U09587	Hs.75280	glycyl-tRNA synthetase	10
55		D21262	Hs.75337	nucleolar phosphoprotein p130	4.5
		U24166	Hs.234279	microtubule-associated protein; RP/EB fa	15.2
		D83004	Hs.75355	ubiquitin-conjugating enzyme E2N (homo	9.1
		D89077 AA479139	Hs.75367 Hs.75393	Src-like-adapter acid phosphatase 1; soluble	6.4 4.8
60		AA287383	Hs.7540	ESTs	4.0
50		AA458946		ESTs	4.3
		K01396	Hs.297681	protease inhibitor 1 (anti-elastase); alpha-	8.3
		N21648	Hs.75659	MpV17 transgene; murine homolog; glom	4.6
		Y00282	Hs.75722	ribophorin	7.5
65		L27841	Hs.75737	pericentriolar material 1	9.4
	133752	U49278	Hs.75875	ubiquitin-conjugating enzyme E2 variant	4.5
	133765	D21255	Hs.75929	cadherin 11 (OB-cadherin; osteoblast)	6.4

	133772	W73693	Hs.76038	isopentenyl-diphosphate delta isomerase	7.9
	133774		Hs.76067	heat shock 27kD protein 1	4.1
	133776	J03473	Hs.177766	ADP-ribosyltransferase (NAD+; poly (AD	13
_		AA214305		ESTs	5.2
5		M33882	Hs.76391	myxovirus (influenza) resistance 1; homol	11.7
		AA453783		Homo sapiens mRNA; cDNA DKFZp564	9.4
		AA147510		serine protease; umbilical endothelium	4.8 6.7
		M59815	Hs.170250	complement component 4A	7.1
10	133845	U73477	Hs.285013 Hs.76704	putative human HLA class If associated p ESTs	6.3
10 .		U86782	Hs.178761	26S proteasome-associated pad1 homolog	13.7
		D43948	Hs.76989	KIAA0097 gene product	4.1
		U58090	Hs.183874	cullin 4A	4
			Hs.182793	ESTs	4.7
15	133893	X01060	Hs.77356	transferrin receptor (p90; CD71)	8.3
	133914	N32811	Hs.77542	ESTs	5
	133918	W72783	Hs.58382	ESTs; Weakly similar to C13F10.5 [C.ele	4.5
	133944	AA045870	Hs.7780	Homo sapiens mRNA; cDNA DKFZp564	6.3
			Hs.173878	4-nitrophenylphosphatase domain and non	6.4
20	133963		Hs.184693	transcription elongation factor B (SIII); po	6.3
		D00760	Hs.250811	proteasome (prosome; macropain) subunit	11.9
		C02374	Hs.7822	Homo sapiens mRNA; cDNA DKFZp564	8.2 5.2
		M28213	Hs.78305 Hs.78575	RAB2; member RAS oncogene family	4.6
25		J03077 Z81326	Hs.78589	prosaposin (variant Gaucher disease and v protease inhibitor 12 (neuroserpin)	6.5
23		S82470	Hs.78768	BB1	11.9
		D28473	Hs.172801	isoleucine-tRNA synthetase	5.2
		D87685	Hs.78893	KIAA0244 protein	7.3
		H98621	Hs.78946	cullin 3	4.7
30	134087	U51166	Hs.173824	thymine-DNA glycosylase	7
	134090	M22382	Hs.79037	heat shock 60kD protein 1 (chaperonin)	4.5
	134098	X06323	Hs.79086	ribosomal protein; mitochondrial; L3	9.4
		U41060	Hs.79136	LIV-1 protein; estrogen regulated	4.4
25		U32519	Hs.220689	Ras-GTPase-activating protein SH3-doma	6.6
35		AA398908		Human Chromosome 16 BAC clone CIT9	8.6 9.3
		M63138	Hs.79572	cathepsin D (lysosomal aspartyl protease)	6.3
		U88871 L28010	Hs.79993 Hs.808	peroxisomal biogenesis factor 7 heterogeneous nuclear ribonucleoprotein F	4.3
		AA430008		ESTs	6.9
40		AA313414		Homo saplens clone 24856 mRNA sequen	7.4
		U16306	Hs.81800	chondroitin sulfate proteoglycan 2 (versic	6.1
		D38551	Hs.81848	RAD21 (S. pombe) homolog	8.6
	134331	AA452020	Hs.111222	ESTs; Weakly similar to CGI-128 protein	6.1
	134351	R82074	Hs.82109	syndecan 1	4.4
45		L43575	Hs.82171	Human clone 191B7 placenta expressed m	6.6
		M37033	Hs.82212	CD53 antigen	5.3
		X54199	Hs.82285	phosphoribosylglycinamide formyltransfe	4.8 15.2
		D62633	Hs.8236	ESTS ESTS: Highly similar to CGI 118 protein	7.2
50		AA412720		ESTs; Highly similar to CGI-118 protein 2';5'-oligoadenylate synthetase 1	6.4
50		X02874 U56637	Hs.82396 Hs.184270	capping protein (actin filament) muscle Z-	4
		·M15841	Hs.82575	small nuclear ribonucleoprotein polypepti	5.7
		L09717	Hs.8262	lysosomal-associated membrane protein 2	6.9
		H99801	Hs.82689	tumor rejection antigen (gp96) 1	4.5
55		AA243746		kinectin 1 (kinesin receptor)	11.2
	134405	J04177	Hs.82772	collagen; type XI; alpha 1	15.3
	134415	AA329274	Hs.82911	protein tyrosine phosphatase type IVA; m	4.1
		D87969	Hs.82921	solute carrier family 35 (CMP-sialic acid t	4.2
~		L08044	Hs.82961	trefoil factor 3 (intestinal)	5.9
60		AA122386		collagen; type V; alpha 2	5.8
		W96151	Hs.83006	ESTs; Highly similar to CGI-139 protein	4.4
		AA449984		ESTs; Highly similar to proteine kinase JN KIAA0252 protein	7 4.6
		T25732 X70683	Hs.83419 Hs.83484	SRY (sex determining region Y)-box 4	4.6 5.1
65		X70003 X54942	Hs.83758	CDC28 protein kinase 2	20.3
0,5		R38185	Hs.83954	Homo sapiens unknown mRNA	5
		D63477	Hs.84087	KIAA0143 protein	16.1

	424400	1400400	11- 04404	IS - LAMBIA - II A	
		M63180	Hs.84131	threonyl-tRNA synthetase	6.1
		U45328	Hs.84285	ubiquitin-conjugating enzyme E2I (homol	4.6
		H24460	Hs.848	FK506-binding protein 4 (59kD)	6.2
5		U66615	Hs.172280	SWI/SNF related; matrix associated; actin	4.8
5		AA234966		CGG triplet repeat binding protein 1	4.7
		R68884	Hs.86347	ESTs; Weakly similar to predicted using G	5.8
		X74496	Hs.86978	prolyl endopeptidase	4.5
		W23625	Hs.8739	ESTs; Weakly similar to ORF YGR200c [13.7
10			Hs.123090	ESTs .	5.8
10		AA250745		protein kinase; cAMP-dependent; catalyti	8.9
		X04011	Hs.88974	cytochrome b-245; beta polypeptide (chro	6.8
		U89922	Hs.890	lymphotoxin beta (TNF superfamily; mem	35.7
		W47183	Hs.284226	ESTs; Weakly similar to neural F box pro	8.1
15		J05582	Hs.89603	mucin 1; transmembrane	6.2
15		Z49099	Hs.89718	spermine synthase	4.2
		M27394	Hs.89751	membrane-spanning 4-domains; subfamily	7
		U51477	Hs.89981	diacylglycerol kinase; zeta (104kD)	4.1
		H60595	Hs.90061	progesterone binding protein	4.7
20		D82348	Hs.90280	5-aminolmidazole-4-carboxamide ribonuc	10.2
20		U84011 Z39762	Hs.904	amylo-1;6-glucosidase; 4-alpha-glucanotr	12.1
		N27670	Hs.90419 Hs.9071	KIAA0882 protein	6 5
		N46086	Hs.92308	progesterone membrane binding protein ESTs	3 4.1
		AA236324		Homo sapiens mRNA; chromosome 1 spe	16.8
25		H05625	Hs.5831	ESTs	4
20		AA282343		purine-rich element binding protein B	4.4
		D59675	Hs.92927	ESTs	7
		U54999	Hs.278338	LGN protein	4.8
		AA224180		ESTs; Moderately similar to 17-beta-hydr	13.6
30		AA243497	Hs.173685	Human DNA sequence from clone 30M3	4
		U77948	Hs.278589	general transcription factor II; I	8
		AA598449		Homo sapiens done 24483 unknown mRN	5.4
	135071	L08069	Hs.94	heat shock protein; DNAJ-like 2	9.3
	135083	AA495950	Hs.94262	ESTs	6.7
35	135117	W52493	Hs.94694	Homo sapiens clone 24837 mRNA sequen	10.2
	135144	AA044842	Hs.95260	Homo sapiens mRNA; cDNA DKFZp586	6.6
	135154	AA126433	Hs.267812	sorting nexin 4	7.4
	135218	D31157	Hs.324277	ESTs; Weakly similar to growth factor-res	6.2
40		AA454930		ESTs	19.5
40		AA215333		putative G protein-coupled receptor	8.8
		H20989	Hs.198281	pyruvate kinase; muscle	12.4
	135349	D83174	Hs.9930	collagen-binding protein 2 (colligen 2)	5.5
		AA480109		TYRO protein tyrosine kinase binding pro	5.4
15		U05237	Hs.99872	fetal Alzheimer antigen	7.8
45		M23263	Hs.99915	androgen receptor (dihydrotestosterone re	9.1
	135411		Hs.99947	reticulon 1	5.3
		M97935		AFFX control: STAT1	8.3
		M97935		AFFX control: STAT1	7
50		M97935 Al199738	Un 200275	AFFX control: STAT1	14
50				ESTs; Weakly similar to IIII ALU CLASS	9.1
		AW079607	Hs.270464	ESTs; Weakly similar to !!!! ALU CLASS ESTs; Weakly similar to ZnT-3 [H.sapien	7.4 30.1
		AW015860		ESTs	11.9
		AA699328		ESTs	5.5
55		Al492179	Hs.166244	ESTs; Weakly similar to cDNA EST yk40	11
		AW293224		ESTs	11
	301124		Hs.298262	ESTs; Weakly similar to dJ88J8.1 [H.sapi	8.8
	301165		Hs.150186	ESTs; Weakly similar to PTERIN-4-ALP	6
			Hs.270431	ESTs; Weakly similar to !!!! ALU SUBFA	4.7
60		AA373124		ESTs; Weakly similar to C17G10.1 [C.ele	8
-		AA526313		ESTs	4.2
	301782		Hs. 143046	EST cluster (not in UniGene) with exon h	18
		AA312082		GDNF family receptor alpha 1	20.7
	301936	NM_004694	Hs.114924	EST cluster (not in UniGene) with exon h	11.6
65		AF013956		chromobox homolog 4 (Drosophila Pc cla	9.2
		NM_001992		EST cluster (not in UniGene) with exon h	4.3
	302067	H05698	Hs.222399	ESTs; Weakly similar to protein-tyrosine	7.8

	302145	NM_003613	3Hs.151407	EST cluster (not in UniGene) with exon h	15.1
			Hs.6557	zinc finger protein 161	25.8
	302276	NM_004448	3Hs.323910	EST cluster (not in UniGene) with exon h	21.6
_		AL117607		Homo sapiens mRNA; cDNA DKFZp564	41,4
5		NM_00427		EST cluster (not in UniGene) with exon h	8.9
	302342	AB023141	Hs.190386	KIAA0924 protein	5.4
		AL117406		Homo sapiens mRNA; cDNA DKFZp434	8.9
		AB021227		matrix metalloproteinase 24 (membrane-in	5.2
10		AF129530		EST cluster (not in UniGene) with exon h	5.3
10		AF022726		EST cluster (not in UniGene) with exon h	9.9
		AL049650		multiple UniGene matches	4.3
		L36149	Hs.248116	chemokine (C motif) XC receptor 1	4.9
		AA463798		ESTs; Weakly similar to C11D2.4 [C.eleg	5.3
15		AW293005		ESTs	8.4
13		AA343696		ESTs; Weakly similar to putative (H.sapie	4.5
		X04588	Hs.85844	EST cluster (not in UniGene) with exon h	6.8 8.4
		U66049	Hs.82171	EST cluster (not in UniGene) with exon h	22.8
		N58545	Hs.42346	histone deacetylase 3	6.8
20		AW263124 N46406	Hs.84700	EST cluster (not in UniGene) with exon h EST cluster (not in UniGene) with exon h	8.9
20		AA478876		pallid (mouse) homolog; pallidin	10.1
		AF140242		EST cluster (not in UniGene) with exon h	24.4
		AW081061		actin-like 6	6.3
		AI929819	Hs.4055	ESTs	17.7
25		U09759	Hs.246857	mitogen-activated protein kinase 9	11.4
		AA908797		ESTs	15.8
		Al815990	Hs.293515	ESTs	7.2
		AA488528		EST duster (not in UniGene) with exon h	5.3
		T07216	Hs.301226	EST cluster (not in UniGene) with exon h	16.2
30		AA397546		ESTs	8.9
		Al953377	Hs.28444	ESTs; Weakly similar to predicted using G	12
	303642	AW299459	Hs.111977	EST cluster (not in UniGene) with exon h	4.2
	303654	AA436942	Hs.288529	ESTs	8.4
	303733	AW502498	Hs.15220	ESTs; Weakly similar to zinc finger prote	5.2
35	303780	Al424014	Hs.18995	ESTs; Moderately similar to KIAA0456 p	28.4
		C75094	Hs.199839	ESTs; Highly similar to NG22 [H.sapiens	4.4
		Al337304	Hs.126268	ESTs; Weakly similar to similar to PDZ d	8.1
		AW475081	Hs.172928	collagen; type I; alpha 1	7.5
40		AA421948		EST singleton (not in UniGene) with exon	6.5
40		AA456426		EST	5.4
		AA505702		EST singleton (not in UniGene) with exon	9.8
		AA507875		EST singleton (not in UniGene) with exon	7.5 7
		AA533185 AA630582	Un 160476	EST singleton (not in UniGene) with exon	12.4
45		AA653159		glyceraldehyde-3-phosphate dehydrogena EST singleton (not in UniGene) with exon	8.7
45		AA725116		EST singleton (not in UniGene) with exon	5.3
,		AA738110	1 10.7 0 100	EST singleton (not in UniGene) with exon	4.1
		AA872838		keratin 8	7.7
		AA876109		EST singleton (not in UniGene) with exon	6.3
50		AA884479		EST singleton (not in UniGene) with exon	5.6
- •		AA889992	Hs.2186	EST singleton (not in UniGene) with exon	13.2
		AA894560		EST singleton (not in UniGene) with exon	4.4
		AA906161		EST singleton (not in UniGene) with exon	4.6
	306398	AA970548	Hs.297681	EST singleton (not in UniGene) with exon	7.6
55	306505	AA987722	Hs.172928	EST singleton (not in UniGene) with exon	19.7
		AA995761	Hs.276092	EST singleton (not in UniGene) with exon	5.5
		Al184111	Hs.76067	heat shock 27kD protein 1	7.7
		Al185516	Hs.172928	collagen; type I; alpha 1	8.8
C O		Al190870	Hs.276417	EST singleton (not in UniGene) with exon	4.1
60		Al280859	Hs.62954	EST singleton (not in UniGene) with exon	6
		AI281603	Hs.172928	EST singleton (not in UniGene) with exon	10.8
		AI351739	Hs.276726	EST singleton (not in UniGene) with exon	4.7
		AI472733	Hs.270208	ESTs	4.2
65		A1581398	Hs.172928	collagen; type I; alpha 1 EST singleton (act in UniCone) with even	5.4
U.S		Al687580 Al738593	Hs.169476	EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	10.1
		A1761173	Hs.101774	EST singleton (not in UniGene) with exon	15.1 4.6
	300011	VII 0 1112		CO. Sui Ricion (Hot III OTROCHE) MILL 6X0II	4.0

	308852	A(829848	Hs.182937	peptidylprolyl isomerase A (cyclophilin A	5.9
	308974	A1872290	Hs.300697	immunoglobulin gamma 3 (Gm marker)	4.5
		A1873242		EST singleton (not In UniGene) with exon	7.6
5		A1880172		EST singleton (not in UniGene) with exon	6.6
)		Al951118 Al952723	Hs.90207	EST singleton (not in UniGene) with exon EST singleton (not in UniGene) with exon	24.3 6.1
		A1955915	110.30207	major histocompatibility complex; class I;	5.6
		Al969897		EST singleton (not in UniGene) with exon	6.2
		Al990102		EST singleton (not in UniGene) with exon	7.9
10	309583	AW170035		EST	64.5
	309624	AW191929	Hs.252989	EST	5.3
		AW192764		collagen; type I; alpha 1	6.9
		AW194230		EST	11.4
15		AW238461		ribosomal protein; large; P0	4.3 11.9
13		AW241170 Al335004		Homo sapiens done 24703 beta-tubulin m ESTs	4.2
		AW450967		ESTs	5.7
		AW080778		ESTs	4.8
		AW022192		ESTs	39.1
20	310470	Al281848	Hs.194691	ESTs	4.9
		AW205632		ESTs	7
		T47784	Hs.188955	ESTs	4.1
		Al587332	Hs.209115	ESTs	11.2
25		A1821294 T57896	Hs.118599	ESTs	24.1 5.7
23		A1758660	Hs.191095	EST cluster (not in UniGene) ESTs	15.7
		A1828254		ESTs	6.4
		AA700870		ESTs	6.2
		A1056769	Hs.133512	ESTs	5
30	311923	T60843	Hs.189679	ESTs	5.9
	311935	AA216387		EST cluster (not in UniGene)	5.5
		N51511	Hs.188449	ESTs	5.2
		A1435650	Hs.128778	ESTs	4.3
35		AA588275		ESTs EST charter (not in UniGene)	14.7 9.8
55		T89855 AA759250	Hs.195648 Hs.153028	EST cluster (not in UniGene) cytochrome b-561	27,1
		T92251	Hs.198882	ESTs	4.2
		A1222168	Hs.191168	ESTs	6.1
		A1796815	Hs.199993	ESTs; Weakly similar to ubiquitous TPR	5.5
40	312292	AW451893	Hs.151124	ESTs	18.4
		Al080505	Hs.134529	ESTs	11.9
		AA582039		Homo sapiens mRNA; chromosome 1 spe	4
		R46180	Hs.153485	ESTs	13.6 4,1
45		AW139117 AW451347		ESTs ESTs	4.6
-15		Al417526	Hs.7753	ESTs	15.3
		AA033609		ESTs	12.5
		Al498371	Hs.183526	ESTs	14.6
		AW439195		ESTs	5.3
50		R99834	Hs.250383	ESTs	8.4
		H63791	11- 200000	EST cluster (not in UniGene)	4.3
		AA699325 AW292286		ESTs ESTs	8.3 7.1
		AA846353		ESTS	5.9
55		AA828713		EST cluster (not in UniGene)	4.1
		AA088446		ESTs	7.3
	313096	AI422367	Hs.163533	ESTs	6.1
		AA732534		ESTs	4.2
60		AA720887		EST cluster (not in UniGene)	18.1
60		N59284	Hs.288010	ESTs	17
		A1738851	Hs.222487 Hs.182099	ESTs ESTs	12.9 7.1
		N74924 AW068358		ESTs	13.7
	_	AW449211		ESTs	27.9
65		AW292127		ESTs	9.8
		AA741151		ESTs	8.2
	313455	AW081702	Hs.98571	ESTs	6.9

	313590 AA804410 Hs.291677	EST cluster (not in UniGene)	5.3
	313663 AI953261 Hs.169813	ESTs	7.6
	313667 U69201 Hs.13684	ESTs; Weakly similar to choline kinase is	12.5
	313749 AW450376 Hs.119004	ESTs	5.5
5	313832 AW271022 Hs.133294	ESTs	4.3
	313881 AA535580 Hs.16331	ESTs	7.7
	313915 A)969390 Hs.163443	ESTs	27.1
	313955 AI858884 Hs.270647	ESTs	5.7
	313974 Al310151 Hs.173524	ESTs	4.3
10	314097 AA648744 Hs.269493	ESTs	14.5
	314129 AA228366 Hs.115122	ESTs	9.5
	314359 AA205569 Hs.194193	ESTs	5.4
	314384 AA535840 Hs.162203	ESTs; Weakly similar to alternatively spll	5.3
	314394 Al380563 Hs.130816	ESTs	13.2
15	314462 AA347951 Hs.326413	ESTs	6.2
15	314465 AA602917 Hs.156974	ESTs	18.1
	314470 Al934422 Hs.30661	ESTs :	4.2
	314488 AA358265 Hs.182890	ESTs	6.1
	314506 AA833655 Hs.206868	ESTs	27.8
20	314510 Al204418 Hs.190080	ESTs	9.5
20	314558 AI873274 Hs.190721	ESTs	22.5
	314661 AA436432 Hs.324239	EST cluster (not in UniGene)	13.3
	314691 AW207206 Hs.136319	ESTs	21.4
	314754 AW026761 Hs.134374	ESTS	4.4
25		ESTS	4.4
23	314775 Al149880 Hs.188809	cell division cycle 2; G1 to S and G2 to M	18.4
	314943 Al476797 Hs.184572	ESTs	10.2
	314961 AW008061 Hs.231994		5.3
	314963 Al689617 Hs.200934	ESTs	20.7
20	315006 Al538613 Hs.298241	ESTs	5
30	315010 AA531082 Hs.240049	ESTs	6.1
	315019 AA532807 Hs.105822	ESTs	12
	315033 Al493046 Hs.146133	ESTs	8.3
	315036 AA534953 Hs.163297	ESTs	6.1
25	315037 AW205863 Hs.133988	ESTs; Weakly similar to gene MAC25 pr	12.7
35	315051 AW292425 Hs.163484	EST	
	315054 Al968598 Hs.78768	ESTs	7.6 13.9
	315073 AW452948 Hs.257631	ESTs	
	315080 AA744550 Hs.136345	ESTs	4.4
40	315083 Al221325 Hs.205442	ESTs	5.1 4.7
40	315088 AA557351 Hs.152448	ESTs; Moderately similar to MULTIFUN	11.9
	315175 Al025842 Hs.152530	ESTs	
	315196 AA972756 Hs.44898	ESTs	28.8
	315296 AA876905 Hs.125286	ESTs	16.1
45	315303 AW194364 Hs.128022	ESTs; Weakly similar to FIG-1 PROTEIN	25.7
45	315352 AA604799 Hs.136528	ESTs; Moderately similar to !!!! ALU SU	12.3
	315364 AA643602 Hs.155485	ESTs; Highly similar to serine protease [H	4.6
	315368 AW291563 Hs.104696	ESTs	4.8
	315390 Al801565 Hs.200113	ESTs; Weakly similar to alternatively spli	4.4
~^	315408 AW273261 Hs.216292	ESTs	5
50	315458 AA872000 Hs.116104	ESTs	7.6
	315472 AA828850 Hs.165469	ESTs	4.9
	315478 AA665612 Hs.120874	ESTs	5.2
	315498 AA628539 Hs.116252	ESTs; Moderately similar to !!!! ALU SU	4.8
e e	315527 AI791138 Hs.116768	ESTs	4.4
55	315530 Al200852 Hs.127780	ESTs .	22.4
	315562 AA737415 Hs.152826	ESTs	5.9
	315634 AA837085 Hs.220585	ESTs	8.8
	315647 AA648983 Hs.212911	ESTs	15
C C	315652 Al521489 Hs.3053	ESTs	6.3
60	315676 AW002565 Hs.124660	ESTs	9.2
	315680 AA814309 Hs.123583	ESTs	8.1
	315735 Al831760 Hs.155111	ESTs	13.4
	315741 AA812168 Hs.122559	ESTs	5.4
	315769 AA744875 Hs.189413	ESTs	4.4
65	315978 AA830893 Hs.119769	ESTs	10.4
	315984 Al015862 Hs.131793	ESTs	5
	316042 AW297979 Hs.170698	ESTs	. 14.7

	316136	AA830808	Hs.124366	ESTs	4
		AI908272		EST duster (not in UniGene)	32.6
		AA741300		ESTs	4.8
		AA757900		ESTs	4.8
5	316480	Al749921	Hs.205377	ESTs	12.9
	316564	AI743571	Hs.168799	ESTs; Weakly similar to !!!! ALU SUBFA	8.1
	316714	AA809792	Hs.123307	ESTs	5
		AI440266		ESTs	4.2
10		AA828116		ESTs	5.2
10		AI954880		ESTs	13.3
		AW138241		ESTs	6.2
	316943	AW014875	Hs.137007	ESTs	5.3
		AA856749		ESTs	7.2
15		AW051597		ESTS	4.1
13	_	AA962623		ESTs; Weakly similar to RENAL SODIU	4.2
		Al805392 Al732892		ESTs ESTs	4.5 6.4
		AA490718	113.130403	EST duster (not in UniGene)	4.4
		AI922374	Hs 158549	ESTs	5.9
20		AW139077		ESTs	4.6
-0		AW294909		ESTs	5.2
			Hs.149997	ESTs	4.3
		AA983913		ESTs	12.4
		Al827248		ESTs	12.1
25	317902	AI828602	Hs.211265	ESTs	8.8
		Al565071	Hs.159983	ESTs	12.6
		AW294522	Hs.149991	ESTs	5.6
		A1074465	Hs.133469	ESTs	4
20		AW296888		ESTs	5.2
30		AJ024594		ESTs	4.7
		AW167087		ESTS	15.7
			Hs.150521	ESTs	5.9
		AW016773 Al291584		ESTs ESTs; Weakly similar to HYPOTHETICA	5.3 7.6
35		Al335361	Hs.145921 Hs.226376	ESTS, Weakly Silling to HTFOTHETICA	5.8
55		AW247252		nucleoside phosphorylase	11.1
			Hs.294014	ESTs	16.3
		AW192139		H3 histone; family 3A	4
		NM_002543		EST cluster (not in UniGene)	21.3
40			Hs.144479	ESTs	35
	318948	AA317274	Hs.13996	ESTs	11.7
	319163	F15257	Hs.27	glycine dehydrogenase (decarboxylating;	7
	319478		Hs.270307	EST cluster (not in UniGene)	8.9
4 ~		R83716	Hs.14355	ESTs	8.2
45		NM_002731		EST cluster (not in UniGene)	25.4
		AA460775		ESTs	7
		AA179304		ESTs; Moderately similar to !!!! ALU SU	8.7
		W22152 AA307665	Hs.282929	EST cluster (not in UniGene)	5.6 4.9
50		H06350	Hs.135056	ESTs ESTs	9.2
50		AA632632	113. 133030	EST cluster (not in UniGene)	4.6
		AA321166	Hs 278233	EST cluster (not in UniGene)	16.7
		AF022799		calpain 9 (nCL-4)	5.4
		AA836461		EST cluster (not in UniGene)	5.3
55		D63271		EST cluster (not in UniGene)	5.5
	320167	AA984373	Hs.90790	EST cluster (not in UniGene)	15
	320187		Hs.303428	EST cluster (not in UniGene)	6.7
		AL039402		DEME-6 protein	24.3
CO		U90449	Hs.152717	nucleoside diphosphate kinase type 6 (inh	10
60		AI884396	Hs.24131	ESTs	5.4
	320488		Hs.191791	EST cluster (not in UniGene)	4.9
	320521		Hs.24743	ESTs	9.5
		AA864846		EST duster (not in UniGene)	6.6
65	320699	R61576	Hs.313951	hypothetical protein EST cluster (not in UniGene)	5.9 4
03	320727		Hs.118249 Hs.181125	EST cluster (not in UniGene)	4 15.3
		AL050145		Homo sapiens mRNA; cDNA DKFZp586	7.2
	52000	2000 170		come experie many designates a phone	

	321012	AA737314	He 10/32/	EST cluster (not in UniCone)	6.1
		AW393497	ns. 194324	EST cluster (not in UniGene)	5
			Ha 240205	EST cluster (not in UniGene)	11.4
		AF134149 AI769410		EST cluster (not in UniGene)	7.7
5		AA295304	Hs.221461	ESTs	5.5
,			NS.231 303	ESTs; Weakly similar to neogenin [H.sap	16.9
		AA078493 H68014	Lin 444770	EST cluster (not in UniGene)	4.2
		AW366305	Hs.141278	ESTs; Weakly similar to !!!! ALU SUBFA	6.3
				EST cluster (not in UniGene)	9
10		AW392474		ESTs; Moderately similar to !!!! ALU SU	
10		N98619	Hs.42915	ARP2 (actin-related protein 2; yeast) hom	11.3 10.4
		H84762	Hs.253197 Hs.272897	ESTs charter (not in UniCone)	19.9
		D28390		EST cluster (not in UniGene)	5.6
		AW157424		ESTS	5.4
15		H67065	Hs.271530	ESTs; Weakly similar to !!!! ALU SUBFA ESTs; Weakly similar to !!!! ALU CLASS	6.5
13		AW068268 N77342			10.2
			Hs.21851	EST cluster (not in UniGene)	9.8
		AA310039		ESTs	27.8
		AA233527		low density lipoprotein receptor (familial	40.2
20		AL137517		EST cluster (not in UniGene)	
20		AF085968	HS.484/4	EST cluster (not in UniGene)	5.7
		AF085975		EST cluster (not in UniGene)	7.7
	_	AL134970		follistatin-like 1	14.4
		W07459	Hs.157601	EST cluster (not in UniGene)	13.4
25		AA086123		EST cluster (not in UniGene)	7.6
23		AA679082		ESTs	4.4
		AW043782		ESTs	21
		AW248508	HS.2/9/2/	DiGeorge syndrome critical region gene 2	15.3
		C16391	11- 450470	EST cluster (not in UniGene)	21.3
20		C18965	Hs.159473	ESTs	11.7
30		AA580288	11- 040704	EST cluster (not in UniGene)	8.9 10.8
		AW014094		ESTs	
		Al301107	Hs.150790	ESTs	6.5
		AL120351		EST cluster (not in UniGene)	5.5
25		AL120862		ESTs	17.9
35		AI064982	Hs.117950	multifunctional polypeptide similar to SA	5.8 11.6
		AL049370		Homo sapiens mRNA; cDNA DKFZp586	
		AA203135		ESTs	6.4 7.3
		W44372 T70731	Hs.110771	EST cluster (not in UniGene)	15.8
40			Hs.193620	EST cluster (not in UniGene)	4.8
40		AA228078 Al829520		EST cluster (not in UniGene) ESTs	20.2
		AA228883	Hs.227513		8.8
		AL038623		EST cluster (not in UniGene) ESTs; Weakly similar to !!!! ALU SUBFA	5
		AI751438	Hs.41271	ESTs; Weakly similar to !!!! ALU SUBFA	6.5
45		AA344205		EST duster (not in UniGene)	7.1
73		AA327102		EST cluster (not in UniGene)	6.1
		AA410943	113.70200	EST cluster (not in UniGene)	16.8
		AI684674	Hs.41127	ESTs; Weakly similar to waclaw [D.melan	10.1
		AA570698		ESTs	6.4
50		AA844907		EST cluster (not in UniGene)	8
50		AA378201		EST cluster (not in UniGene)	6.3
		AL044891		EST cluster (not in UniGene)	50.1
		AA543008		ESTs; Weakly similar to !!!! ALU SUBFA	5.7
		AL138357		ESTs	9.5
55		AW502000		EST cluster (not in UniGene)	4.4
55		AA464510		EST duster (not in UniGene)	16.7
		AW501411		ESTs; Weakly similar to IIII ALU CLASS	5.5
		AW152624			5.4
		AA502659		ESTs ESTs	8.8
60		AW016378			23.1
		AA448021		ESTs EST cluster (not in UniGene)	21.2
		AI610425	Hs.19597	ESTs	5
		A1031771	Hs.132586	ESTs	5
		AA640770		EST cluster (not in UniGene)	4.1
65		AI826999	Hs.224624	ESTs (not in onlicency)	6.3
03		AA704806		ESTs	11.7
		D31323	Hs.271492	ESTs	4.8
	J273UZ	551525	113.21 1432	LUIS	7.0

	324961 AA613	792	EST cluster (not in UniGene)	13.3
	324987 T0688		ESTs	19.6
	324988 T0699	7 Hs.121028	EST cluster (not in UniGene)	24.5
	325146 AI064	690 Hs.171176	ESTs	-, 4.6
5	325622		CH.14_hs gi 5867000	5.2
	326213		CH.17_hs gi 5867224	8.1
	326474		CH.19_hs gì 5867405	12.7
	326816		CH.20_hs gi 6552458	9.4
	326817		CH.20_hs gi 6552458	11.7
10	327110		CH.21_hs gi 6117842	14.7
	327196		CH.01_hs gi 5867446	5.1
	327283		CH.01_hs gij5867478	4.3
	327313		CH.01_hs gi 5867501	4.8
	327450		CH.02_hs gi 5867766	4.1
15	328059		CH.06_hs gi 6117819	6.2
	328304		CH.07_hs gi 6004478	5.4
	328492		CH.07_hs gi 5868455	7
	328857		CH.07_hs gi 6381927	5.2
•	329367		CH.X_hs gi 5868842	7.6
20	329373		CH.X_hs gi 6682537	12
	329655		CH.14_p2 gi 6448516	4
	329899		CH.15_p2 gi 6563505	4
	329960		CH.16_p2 gi 5091594	7.6
0.5	330084		CH.19_p2 gi 6015302	4
25	330384 M2320		androgen receptor (dihydrotestosterone re	5.8
	330385 AA449		ESTs; Highly similar to secreted apoptosi	10.2
	330387 H1462		ESTs; Highly similar to secreted apoptosi	4.4
	330388 X0336		HER2 receptor tyrosine kinase (c-erbB-2;	17.7
20	330409 D5069		c-myc binding protein	10.1
30	330460 TIGR:		Hs.73946	Endothelial Cell Growth Factor 1 5.5
	330486 M137		interferon-stimulated protein; 15 kDa	67
	330494 M2969		interleukin 7 receptor	6
	330500 M344		galactosidase; beta 1	13.1
25	330510 M7509		FK506-binding protein 2 (13kD)	29
35	330513 M810		carboxypeptidase B1 (tissue)	38.5
	330541 U2297		multiple UniGene matches	7.4
	330542 U2394		cytochrome P450; 51 (lanosterol 14-alpha	15
	330547 U3298		tryptophan 2;3-dioxygenase	11
40	330551 U3984		hepatocyte nuclear factor 3; alpha	6.5
40	330562 U4908		transporter protein	7.7
	330573 U6280		cystatin E/M	4
	330673 D5782		Sec23 (S. cerevisiae) homolog A	10.5
		687 Hs.177576	mannosyl (alpha-1;3-)-glycoprotein beta-1	24.3
15		730 Hs.265398	ESTs; Weakly similar to transformation-r	44.1
45		298 Hs.322710	ESTs	4.4
		474 Hs.191157	ESTs; Weakly similar to !!!! ALU SUBFA	8.1 5.2
		457 Hs.102548	ESTs	5
		936 Hs.82719	general transcription factor IIA; 1 (37kD a	9.1
50		136 Hs.159737 2 Hs.9302	Homo sapiens mRNA; cDNA DKFZp434	7.6
50	330997 H5576 331014 H9859		ESTs ESTs	13.5
	331024 N3291		ESTs	9.1
	331024 NS25		ESTS	10.5
			ESTs	7.4
55	331135 R6139 331145 R7242		ESTs; Weakly similar to CYTOCHROME	41.9
55	331148 R7381		ESTs	4.7
	331222 T9853		ESTs	4.1
	331230 W698	7 Hs.16537	hypothetical protein; similar to (U06944)	4.9
		079 Hs.63931	dachshund (Drosophila) homolog	15.1
60		076 Hs.109221	ESTs	4.8
00		662 Hs.50495	ESTs	7.6
		1125 Hs.23240	ESTs; Weakly similar to !!!! ALU SUBFA	7.0 13
		927 Hs.126550	ESTs	12.4
		956 Hs.40782	ESTs	6.5
65		562 Hs.91011	anterior gradient 2 (Xenepus laevis) homo	28.2
0.5		802 Hs.41007	ESTs; Weakly similar to cDNA EST yk47	15.1
	331384 AA456	001 Hs.93847	ESTs	7.9
	201001 101701			• • •

	331478	N26608	Hs.40639	ESTs	7
		N49967	Hs.46624	ESTs	19.8
		N51517	Hs.47282		6.5
5		W85712	Hs.119571	collagen; type III; alpha 1 (Ehlers-Danios	13.8
3		W88502	Hs.182258		9.9 5.6
		AA284372 AA284840		ESTs ESTs	5.8
		AA292721			7.4
		AA312861			7.8
10	331825	AA411144	Hs.292882	ESTs	15.2
		AA432166			24.3
		AA454756		ESTS	5
		AA487910 AA490831		ESTs; Weakly similar to !!!! ALU CLASS ESTs	10.5 11.4
15		AA504779		EST's	13.6
10		AA598594		ESTs	9.1
	332093	AA608794	Hs.112592	ESTs	8.8
		AA620669		EST	9
20		N22508	Hs.139315	ESTs	7.1
20		N33213 N57927	Hs.100425 Hs.120777	ESTs ESTs; Weakly similar to RNA POLYME	12.2 15.6
		N58172	Hs.109370	ESTS CONTROL TO THE CONTROL TH	16.9
		N70088	Hs.138467	ESTs	4
		N91279	Hs.109654	ESTs; Moderately similar to outer membr	8.2
25		T96130	Hs.137551	ESTs	7.7
		W15495	Hs.129781	chromosome 21 open reading frame 5	14.1
		W60326 W93640	Hs.288684 Hs.4779	ESTs ESTs; Moderately similar to similar to AD	4.4 16.9
		AA489630		KIAA0665 gene product	4.8
30		M12036	Hs.323910	Human tyrosine kinase-type receptor (HE	10.4
	332513	AA018182		delodinase; lodothyronine; type II	5.8
		AA281753		inositol 1;4;5-triphosphate receptor; type	19
		N63192	Hs.1892	EST; Highly similar to PHENYLETHAN	15.3
35		AA234896		E1A binding protein p300 LIM domain kinase 1	12.3 11.1
55		R41791 AA417152	Hs.36566 Hs.5101	protein regulator of cytokinesis 1	18.2
		AA262768		KIAA1067 protein	15.2
		H93968	Hs.75725	transgelin 2	4.7
40		T59161	Hs.76293	thymosin; beta 10	5.5
40		AA479968	Hs.88251	arylsulfatase A	9.8
	332927 332929			CH22_FGENES.38_1 CH22_FGENES.38_3	17.7 4.7
	332930			CH22_FGENES.38_4	7.4
	332955			CH22_FGENES.48_12	5.4
45	332958			CH22_FGENES.48_15	17.8
	332961			CH22_FGENES.48_18	10.6
	332983			CH22_FGENES.54_5	4.3
	333009 333010			CH22_FGENES.61_1 CH22_FGENES.61_2	5.2 8.1
50	333013			CH22_FGENES.61_5	8.5
	333108			CH22_FGENES.79_14	5.6
	333139			CH22_FGENES.83_16	6.3
	333254			CH22_FGENES.118_2	6.8
55	333305			CH22_FGENES.137_2	11.4 5.1
55	333343 333388			CH22_FGENES.139_12 CH22_FGENES.144_3	12.7
	333456			CH22_FGENES.157_5	4.2
	333459			CH22_FGENES.157_8	7.6
CO	333517			CH22_FGENES.173_2	8.2
60	333585			CH22_FGENES.203_4	5
	333679			CH22_FGENES.247_6 CH22_FGENES.264_1	4.3 13.4
	333743 333758			CH22_FGENES.268_1	4
	333767			CH22_FGENES.271_6	5.6
65	333768			CH22_FGENES.271_7	12.2
	333769			CH22_FGENES.271_8	48.3
	333795			CH22_FGENES.275_1	6.1

	333796	CH22_FGENES.275_3	6.8
	333892	CH22_FGENES.292_14	4.4
	333904	CH22_FGENES.294_2	6.5
-	333905	CH22_FGENES.294_3	9.3
5	333921	CH22_FGENES.296_12	9.6
	333968	CH22_FGENES.307_4	15.9
	334102	CH22_FGENES.327_60	7.1
	334222	CH22_FGENES.360_3	6.7
10	334223	CH22_FGENES.360_4	33.5
10	334264	CH22_FGENES.367_15	18.5
	334343	CH22_FGENES.375_25	6.1 6.1
	334360	CH22_FGENES.378_5	4.8
	334784 334789	CH22_FGENES.432_9 CH22_FGENES.432_14	5.1
15	334794	CH22_FGENES.434_2	7
13	334889	CH22_FGENES.452_3	12.4
	335004	CH22_FGENES.472_8	7.9
	335115	CH22_FGENES.496_2	18.8
	335287	CH22_FGENES.526_11	4.5
20	335342	CH22_FGENES.536_1	5.3
	335491	CH22_FGENES.570_23	24
	335495	CH22_FGENES.570_28	7
	335498	CH22_FGENES.571_7	12.2
	335544	CH22_FGENES.576_5	8.4
25	335610	CH22_FGENES.583_4	12.9
	335653	CH22_FGENES.590_4	6.7
	335682	CH22_FGENES.595_2	12.1
	335687	CH22_FGENES.596_2	13.9
••	335755	CH22_FGENES.604_4	11.5
30	335782	CH22_FGENES.609_4	17.9
	335791	CH22_FGENES.611_7	27.3
	335809	CH22_FGENES.617_6	19.2
	335822	CH22_FGENES.619_7	19.1
25	335823	CH22_FGENES.619_8	4.5
35	335824	CH22_FGENES.619_11	40.2
	335825	CH22_FGENES.619_12	34.3 10.2
	335895	CH22_FGENES.635_3	6
	335917 335920	CH22_FGENES.636_13 CH22_FGENES.636_16	8.8
40	336035	CH22_FGENES.678_6	5.9
70	336042	CH22_FGENES.679_4	5.8
•	336093	CH22_FGENES.691_2	11.6
	336096	CH22_FGENES.691_5	7.6
	336150	CH22_FGENES.706_6	6.3
45	336152	CH22_FGENES.706_9	10.5
•	336416	CH22_FGENES.823_38	5
	336444	CH22_FGENES.827_10	4.8
	336449	CH22_FGENES.829_6	13.6
	336471	· CH22_FGENES.829_30	6.9
50	336512	CH22_FGENES.834_7	21.4
	336558	CH22_FGENES.842_3	8.2
	336560	CH22_FGENES.842_5	9
	336676	CH22_FGENES.43-4	9.4
E E	336959	CH22_FGENES.367-13	19
55	337968	CH22_EM:AC005500.GENSCAN.103-2	13.4
	338008	CH22_EM:AC005500.GENSCAN.127-9	15.2
	338057	CH22_EM:AC005500.GENSCAN.160-1 CH22_EM:AC005500.GENSCAN.341-6	13.9 8
	338410	CH22_EM:AC005500.GENSCAN:351-0	11.6
60	338451 338588	CH22_EM:AC005500.GENSCAN.535-5 CH22_EM:AC005500.GENSCAN.432-1	10.3
JU	338665	CH22_EM:AC005500.GENSCAN.464-2	4.8
	338689	CH22_EM:AC005500.GENSCAN:475-3	6.7
	338832	CH22 DJ246D7.GENSCAN.6-9	4.8
	338980	CH22_DA59H18.GENSCAN.2-4	5.1
65	339352	CH22_BA354I12.GENSCAN.29-7	6.9
55	339373	CH22_BA232E17.GENSCAN.1-29	4.3
		- ·	

TABLE 13A

Table 13 A shows the accession numbers for those pkeys lacking unigeneID's for Table 13. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Unique Eos probeset identifier number CAT number. Gene cluster number

Accession: Genbank accession numbers 15 **CAT number Accession** Pkey 123619 371681 1 AA602964 AA609200 20 103207 30635_-4 X72790 103349 11052 -2 X89059 AA992380 N33063 N21418 H79958 R21911 H79957 110856 19346_14 113248 328626_1 T63857 AW971220 AA493469 T63699 AI950087 N70208 R97040 N36809 AI308119 AW967677 N35320 AI251473 H59397 AW971573 R97278 W01059 AW967671 123169 44573_2 25 AA908598 AA251875 Al820501 Al820532 W87891 T85904 U71456 T82391 BE328571 T75102 R34725 AA884922 BE328517 Al219788 AA884444 N92578 F13493 AA927794 Al560251 AW874068 AL134043 AW235363 AA663345 AW008282 AA488964 AA283144 AI890387 AI950344 AI741346 AI689062 AA282915 AW102898 AI872193 AI763273 AW173586 AW150329 AI653832 AI762688 AA988777 AA488892 AI356394 AW103813 AI539642 AA642789 AA856975 AW505512 AI961530 AW629970 BE612881 AW276997 AW513601 AW512843 AA044209 AW856538 AA180009 AA337499 AW961101 AA251669 AA251874 30 Al819225 AW205862 Al683338 Al858509 AW276905 Al633006 AA972584 AA908741 AW072629 AW513996 AA293273 AA969759 N75628 N22388 H84729 H60052 T92487 Al022058 AA780419 AA551005 W80701 AW613456 Al373032 Al564269 F00531 H83488 W37181 W78802 R66056 Al002839 R67840 AA300207 AW959581 T63226 F04005 123533 genbank_AA608751 AA608751 C14088 116480 genbank_C14088 35 132225 genbank_AA128980 AA128980 125154 genbank_W38419 W38419 118475 genbank_N66845 102919 25180 2 M21191 AL035748 AA021266 AA323126 AA180515 Al613029 D28356 NM_000034 M11560 AW401425 AW248248 AA012956 AA323294 W04965 H38759 AA206622 AA580747 AI541172 AA381075 AA354229 AW402353 AW405575 AW404021 AW406207 AA075752 AW176066 AA287222 AA195818 T20243 R87945 AA295539 AA402533 AA232419 AA224515 AW401583 AA331367 40 AW402140 AW249079 R31488 AA075757 X05236 AW239490 AA338036 AW239495 AA357262 AA431005 AA306726 R33804 AA216544 AW275288 AA227044 AL038124 AA243300 C03242 AA315615 AL035840 R64336 AA313917 AA018963 AA001385 AA054395 H30840 AW498825 AA086141 AI557324 AA121576 H39128 R77161 AA019688 AA380987 AA348140 AA348257 AW176086 AA362432 AA171389 AA362416 AA299938 AA319093 AA337972 C04921 AA345696 R89640 AA085425 AA481708 45 AA313637 AL039229 H84490 H86153 F00656 AA326668 AA347304 R65890 H41949 AA339309 AW402002 AW404854 AA192582 AA112802 H09248 N83165 H38367 AA356339 AA455763 R66853 AA294935 H85911 AA310414 H93436 N87014 AA001186 H83640 AA411328 AA317929 C04192 AW406288 U46335 AA323179 AA427649 Al366131 H14328 AA197161 AA379497 AA311816 AA017206 AA001137 AA017420 AA012990 AW163775 AA021397 AA295513 AA355248 AA374921 AW380419 AA345864 AA318058 AA371711 AA363255 AA057094 R88057 AA394045 AW362741 AA479579 AW362789 50 AW362775 AA223624 AW362809 AW362746 AW362753 AW380412 AA057104 AA295271 X06352 AW362771 X12447 R59553 R87925 AA292864 R83920 F01120 AA496740 AA852551 AL039209 AA093339 AA333961 N86416 C03325 C03831 AA194750 AA359270 AA359460 AW245492 AA339400 AA330784 AI908970 N89223 AW361938 AI940063 AA134323 AA371741 F01267 AW372970 AA341973 AA346098 AW372969 AA337549 AA327342 H93855 Al074079 F29118 AA852940 F35696 AA345963 AA079578 AA113785 C02989 AA095945 C03145 C05199 AA346024 AA190506 AW361659 Al909845 AW374374 AW374382 55 AW374401 AW374373 AW374370 AI909831 AW374367 AA353658 F01041 C02843 AA375948 AW374414 AA213946 AI525039 H13744 R31007 AA112044 AA134404 H47935 AW177018 AA429768 AA336873 AA112875 H46393 AA191267 D59131 AW406037 AA055244 AA341880 AA179024 AA308537 AW406985 AW327311 H30301 AA300705 H43788 AW364149 AA806213 AA481936 C04941 AW375299 M21190 AA410818 AA250940 Al354547 AA317422 AA250903 Al865497 AA890603 AA366197 AW498538 M78072 AW406461 C03092 F00308 H56488 AA336320 AW406501 AA354102 AA382942 AA096393 AW376830 AA383446 F01259 AW081388 T94036 AA379643 H43842 AI524063 AA621727 AA379099 AA371417 R66811 60

H44129 N84794 F01135 AA477852 AA293062 AW361595 H27194 Al831650 H43253 H24797 Al564680 AA380090 W20057 AI921586 AI192549 AW090808 H25967 AA918121 AI626060 H20221 AA812572 H42178 AA887222 H96000 C03180 F00946

C03986 Al318091 Al860172 AA582179 Al633388 AA557193 R68075 F24105 AW518239 W56622 Al625219 Al925243 AW468046 AI921828 AA339164 AI144391 AA643334 AA459631 AA873247 AW373432 AA604384 H27600 AI680458 AA159956 AA610836 AA364298 AW373435 AA604225 W73754 AW087924 AA599776 N89227 Al630871 Al633128 AW514329 AA010455 AA563928 AI571596 AI128394 W73707 AI423575 AA583809 AA657988 AI950837 AA169782 AA600009 AI885540 AA771884 A3033920 AI571390 A1723394 W15707 AI423373 AA3030305 AC057305 AI533037 AC 105702 AA000003 AI003340 AA77 AI978829 AA505408 AA533937 AA481469 AA610869 AA775241 AW273870 AW070909 AI905695 AA480115 AA574051 AI889185 AA773167 AA331375 AA001437 AA194324 AA194300 AA558632 AI038538 AA411329 AA781570 AI833176 5 AA935520 AW074197 AA583063 AW073099 AW001198 AA948025 AA587857 AA191540 AI460085 AA193244 AI538037 AA515572 AA758587 AI149311 AA508610 AA206409 AA534004 AA994600 AA827543 AI916349 AW245129 AW517804 D25663 AA781985 AA284536 AI819422 H16040 H27531 AA456564 AA845555 AI423596 AA012908 AA889439 AA716311 AA968868 10 AA320508 AA725731 AA834202 AA935997 AA724815 AA769353 AA594803 F00827 Al342442 Al003519 Al002503 Al347597 Al040946 AA197162 AA987883 AA292865 AW001944 Al640711 AW244044 AA456784 F30588 AA290829 H24754 Al978683 AA483686 AA583939 AA121382 AA833831 AA477102 AA977322 AA666379 F35456 AA993537 AI749610 AA226934 AA716204 AW513025 AA628543 AA583705 F25702 Al368748 Al124097 Al880086 AA477513 Al758834 Al690753 AA477746 F37761 AA642243 AA159957 AA250844 AA459406 AA427566 F25054 Al569314 AA961665 Al922050 Al759000 AA5555236 AA514432 AA293474 AA001129 AA826789 AA641390 AA134405 F35585 AA477416 AW193359 Al361315 AA284988 F36340 Al361322 F26969 AA991922 AA021267 F26973 Al361314 F35891 Al918509 AA250964 AA190992 AA577139 AA865535 AA134324 15 AW192842 Al224046 F18975 AA779626 AA856894 AW269997 AW014614 H95554 F31378 AA374868 F26343 AA654007 AI830942 AA113195 F26432 W56652 AA464690 AA055263 AA340654 AA031448 AA976399 AA972526 AA063476 R83921 T16240 AA533290 N91545 H44053 AA883451 AA513761 AA086477 H09249 F20482 F26737 AA054148 AA857063 AA017259 AA179789 AA088908 H43704 AA194320 F35950 A1880127 F20441 F32878 AA962483 H39094 H56489 H44621 F19390 A1302232 F25162 AA826965 AA086052 AA917410 AA454513 R59554 AA196755 AA086369 AA079530 H28106 AA243301 20 AI025737 AA101239 AA088887 AI214910 AA974886 F16089 F26054 AA515092 F33436 F32829 M78061 AA235645 F19715 F37529 Al811549 AA665180 AA708200 F01124 F32382 AA346220 AA627361 F30741 F30010 F28543 AA211715 F20245 AA331222 F25634 F21996 W28215 F21911 R65793 AI192566 H20130 H84491 AA719223 AA557435 F16967 F26989 F30353 AA857159 AA291918 F28234 F20840 F25176 F22437 T27904 AA480355 F19528 R87926 H14286 F27532 AW337864 F28411 H13692 F25651 AA975454 F24229 F29657 F18024 AA464779 F17588 F34954 AA947328 F18063 AA657777 AA459644 N91455 F27850 F29608 F27206 F18418 F31459 F18564 F33496 F16376 F29740 F29843 F29904 F29866 F19135 AW276602 T40337 25 F24835 F34672 F26474 Al926215 AA464185 F18217 N26193 AL043256 T41197 F33055 F00386 F29500 F34191 F33297 Al937207 F22724 F15909 F26232 F18889 AA318627 F29085 AA872104 F17509 F23373 F15660 F17552 F17412 F16863 30 F34033 F21515 F17364 F18383 F16546 F17561 F17260 AA292000 F15723 T47438 F16798 F18046 F18319 F17978 F17566 F34230 F33258 F20860 F17998 Al695701 118600 genbank_N69222 N69222 118952 genbank_N92966 N92966 120873 genbank_AA358015 AA358015 35 113702 genbank T97307 T97307 129982 221_267 Z14221 AW381862 M97920 AW401444 Z66542 M29470 AW406502 X61011 M34024 AA327072 Z14166 Z14167 Z14165 Z14221 AW30182 N8792 AW401444 260542 NW341644 200542 NW341684 X14003 X04003 X0500 X0 40 AF062177 AF062222 AF062115 Z47240 AF062263 AF062261 AF062223 AF062211 Z47238 AW401714 AW404008 AW404991 AF062280 M99595 Z47214 Z47232 Z47218 M26995 AF062184 X65895 L38433 X81731 Z11946 Z47226 AF062205 AF174012 L01276 AF062168 AF062136 X81755 X81748 AF174019 AF062285 L06924 L11699 AW402665 L09070 L28049 L08090 AW407843 Z14171 AW402944 L08083 AW405627 L33035 L26907 M17750 L28052 M17751 AJ239360 U19885 L14821 X56526 AB014341 L12087 L12098 U68231 L12184 AF062242 AF022000 U64499 U00570 Al268604 Y15773 X64239 X62969 U00506 45 X73605 X99360 U00577 D83677 AB021539 AF035796 Z33899 U00588 AJ239353 AF174062 Z33901 X98899 AF174058 X63080 D83676 AB021529 Z18318 U00488 L01412 X81746 U21262 U21272 U00560 AF174060 U00547 U00561 Z18321 S73957 M26435 AF115130 AF115117 Z92896 U21254 Z92895 AF115112 AF062290 T28938 Y09386 AF174067 U27189 Y09384 107373 AF174057 M17749 X69692 AF174038 U64478 U64486 AF174098 X99365 AF174077 AF174089 AF015133 AF127792 AJ006171 U00510 U58144 AF004323 AF115109 AF004324 AF015130 AF090414 AF090418 AB021536 AB021519 Z96957 AF021986 Z92898 Z96956 L34164 AF062251 AF052524 U00549 U00541 D83687 AF052522 AF087420 AF052520 50 AF022011 L43085 U00536 L19915 L43083 AF090420 AB021530 AB021534 Z96955 Z96954 Z33903 X62964 AF103282 U00509 AF062298 AF062289 AF062307 AW408326 L33037 L04337 L04328 X81742 L04336 L03385 AF032360 S56184 AF062191 AF191092 AI906954 AF103184 L04343 AW364860 AF001424 AF103163 Z98717 AF103143 AJ008250 L04323 AF103321
AF193335 L04342 L03818 L03817 AW404978 AW403690 U86801 AF103150 AJ010334 AF035027 AJ007327 AF103115
AF017458 AJ008207 AJ008183 AJ008196 AJ008241 AJ008208 AF103210 AF068668 AF068670 AF068671 AF068664 55 AF068669 AF068666 AF068665 AF068672 AW371244 AW403670 AW408074 AW404575 AW362153 AW403803 AW406702 AW351514 D78345 T29140 J00231 NM_002179 AW405146 AA301091 X04646 H64660 AW402990 AW406534 T93007 AI857980 AW368899 AI905833 AW406586 AA482084 AI872299 AA715266 AW404328 AI831674 AI709348 AA603112 AW514864 AA485775 H64492 AW404789 AA487630 AA715498 AA295885 T27613 T98113 60 AA421560 115763 genbank_AA421560 124357 genbank_N22401 N22401 108733 504187_1 AA121022 AA126422 101544 entrez_M31169 M31169 124447 genbank_N48000 124677 genbank_R01073 N48000 65 R01073 124777 genbank_R41933 R41933 119302 genbank_T25725 T25725

```
103680 entrez_Z93784Z93784
          135029 H58818_at H58818
         112253 genbank_R51818
                                            R51818
         Pkey CAT number Accession
322175 46877_1 AF085975
  5
                                 AF085975 H53458 H53459
          323011 139750_1
                                 AA580288 AA315655 AA133031 AA377748
         322975 1510563 1
                                 C16391 C16413
         317210 211994_1
                                 AW881145 AA490718 M85637 AA304575 T06067 AA331991
         323817 233566_1
                                 AA410943 AW948953 AA334202 AA332882
10
          309583 1046029_-2
                                 AW170035
         324961 376239_1
                                 AA613792 AW182329 T05304 AW858385
          303502 325188_1
                                 BE174240 AA488528 AL042253
         320133 447553_1
                                 BE151746 BE336853 D63271 T94955 AA774994
                                 AA216387 T63548 AA228676
         311935 174129_1
15
         321050 502195_1
                                 C05928 AW393497
         319977 345248_1
                                 AA534222 AA632632 T81234
         312772 4380_7
                                 AW962299 AA310349 AW962294 H63791 H63751
         321354 116028 -2
                                AA078493
         336512 CH22_3941FG_834_7_LINK_DJ
20
         336558 CH22_3992FG_842_3_LINK_DJ
          336560 CH22_3994FG_842_5_LINK_DJ
         329367 c_x_hs
         329373 c_x_hs
329373 c_x_hs
336676 CH22_4154FG_43_4_
338008 CH22_6490FG__LINK_EM:AC00
25
         338057 CH22_6558FG__LINK_EM:AC00
         329655 c14_p2
336959 CH22_4764FG_367_13_
         329899 c15_p2
30
         329960 c16_p2
         338410 CH22_7067FG__LINK_EM:AC00
338451 CH22_7124FG__LINK_EM:AC00
         338588 CH22_7331FG_LINK_EM:ACO0
338665 CH22_7438FG_LINK_EM:ACO0
338689 CH22_7464FG_LINK_EM:ACO0
35
         308677 Al761173
         338832 CH22_7678FG__LINK_DJ246D7
         338980 CH22_7859FG__LINK_DA59H18
         333009 CH22_233FG_61_1_LINK_EM:A
333010 CH22_234FG_61_2_LINK_EM:A
40
         333013 CH22_237FG_61_5_LINK_EM:A
         308981 Al873242
         308995 AI880172
         333108 CH22_336FG_79_14_LINK_EM:
45
         333139 CH22_368FG_83_16_LINK_EM:
         333254 CH22_495FG_118_2_LINK_EM:
333305 CH22_550FG_137_2_LINK_EM:
333343 CH22_589FG_139_12_LINK_EM
         333388 CH22_634FG_144_3_LINK_EM:
50
         326213 c17_hs
         333456 CH22_706FG_157_5_LINK_EM:
         333459 CH22_709FG_157_8_LINK_EM:
         333517 CH22_773FG_173_2_LINK_EM:
         333585 CH22_846FG_203_4_LINK_EM:
55
          333679 CH22_941FG_247_6_LINK_EM:
         326474 c19 hs
         333743 CH22_1009FG_264_1_LINK_EM
333758 CH22_1024FG_268_1_LINK_EM
         333767 CH22_1034FG_271_6_LINK_EM
60
         333768 CH22_1035FG_271_7_LINK_EM
         333769 CH22_1036FG_271_8_LINK_EM
333795 CH22_1063FG_275_1_LINK_EM
333796 CH22_1065FG_275_3_LINK_EM
         335004 CH22_2326FG_472_8_LINK_EM
333892 CH22_1163FG_292_14_LINK_E
65
         335115 CH22_2447FG_496_2_LINK_EM
```

333904 CH22_1176FG_294_2_LINK_EM

```
333905 CH22_1177FG_294_3_LINK_EM
333921 CH22_1194FG_296_12_LINK_E
              333968 CH22_1245FG_307_4_LINK_EM
              328059 c_6_hs
              335287 CH22_2629FG_526_11_LINK_E
             326816 c20_hs
             326817 c20_hs
             335342 CH22_2689FG_536_1_LINK_EM
335491 CH22_2843FG_570_23_LINK_E
335495 CH22_2847FG_570_28_LINK_E
335498 CH22_2850FG_571_7_LINK_EM
10
              328304 c_7_hs
              305453 AA738110
             335544 CH22_2899FG_576_5_LINK_EM
335610 CH22_2969FG_583_4_LINK_EM
335653 CH22_3013FG_590_4_LINK_EM
15
             335682 CH22_3043FG_595_2_LINK_EM
             335687 CH22_3048FG_596_2_LINK_EM
             328492 c_7_hs
335755 CH22_3122FG_604_4_LINK_EM
335782 CH22_3151FG_609_4_LINK_EM
335791 CH22_3160FG_611_T_LINK_EM
20
             335809 CH22_3181FG_617_6_LINK_EM
             335822 CH22_3195FG_619_7_LINK_EM
335823 CH22_3195FG_619_8_LINK_EM
335824 CH22_3197FG_619_11_LINK_E
335825 CH22_3198FG_619_12_LINK_E
335895 CH22_3272FG_635_3_LINK_EM
25
             335917 CH22_3294FG_636_13_LINK_E
30
             335920 CH22_3297FG_636_16_LINK_E
             305898 AA872838
             305913 AA876109
305950 AA884479
             328857 c_7_hs
35
             330084 c19_p2
             337968 CH22_6419FG__LINK_EM:AC00
309177 AI951118
             309198 Al955915
             309226 AI969897
40
             339352 CH22_8317FG__LINK_BA354I1
             309279 Al990102
             339373 CH22_8348FG__LINK_BA232E1
             325622 c14_hs
             334102 CH22_1380FG_327_60_LINK_E
332927 CH22_148FG_38_1_LINK_C20H
45
             332929 CH22_150FG_38_3_LINK_C20H
332930 CH22_151FG_38_4_LINK_C20H
332955 CH22_179FG_48_12_LINK_EM:
332958 CH22_182FG_48_15_LINK_EM:
50
             332961 CH22_185FG_48_18_LINK_EM:
             332983 CH22_207FG_54_5_LINK_EM:A
             334222 CH22_1506FG_360_3_LINK_EM
334223 CH22_1507FG_360_4_LINK_EM
334264 CH22_1551FG_367_15_LINK_E
55
             327110 c21_hs
334343 CH22_1636FG_375_25_LINK_E
334360 CH22_1654FG_378_5_LINK_EM
             327196 c_1_hs
327283 c_1_hs
60
             327313 c_1_hs
304465 AA421948
             304507 AA456426
             327450 c_2_hs
             304591 AA505702
304601 AA507875
65
             304659 AA533185
             334784 CH22_2096FG_432_9_LINK_EM
```

334789 CH22_2101FG_432_14_LINK_E
334794 CH22_2106FG_434_2_LINK_EM
336035 CH22_3420FG_678_6_LINK_DJ
336042 CH22_3427FG_679_4_LINK_DJ
336093 CH22_3481FG_691_2_LINK_DJ
336096 CH22_3481FG_691_2_LINK_DJ
334889 CH22_2206FG_452_3_LINK_EM
336150 CH22_3540FG_706_6_LINK_DA
336152 CH22_3543FG_706_9_LINK_DA
336416 CH22_3833FG_823_38_LINK_B
336444 CH22_3864FG_827_10_LINK_D
336449 CH22_3870FG_829_6_LINK_DJ
336447 CH22_3894FG_829_30_LINK_D

TABLE 13B

Table 13B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 13B. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication			
	Strand: Nt_position:	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.			

15	Pkey	Ref	Strand	Nt_position
	332955	Dunham, I. et.al.	Plus	2508896-2508992
	332958	Dunham, f. et.al.	Plus	2516164-2516310
20	332961	Dunham, I. et.al.	Plus	2521424-2521555
	333139	Dunham, I. et.al.	Plus	3369495-3369571
	333254	Dunham, I. et al.	Plus	2521424-2521555
	333305	Dunham, I. et al.	Plus	4630388-4630645
	333388	Dunham, I. et.al.	Plus	4913749-4913805
25	333517	Dunham, I. et.al.	Plus	5570729-5570925
	333585	Dunham, I. et.al.	Plus	6234778-6234894
	333679	Dunham, I. et.al.	Plus	7068795-7068896
	333767	Dunham, I. et.al.	Plus	7694407-7694623
	333768	Dunham, I. et.al.	Plus	7695440-7695697
30	333769	Dunham, I. et.al.	Plus	7696625-7696707
	333795	Dunham, I. et.al.	Plus	7807688-7807795
	333796	Dunham, I. et.al.	Plus	7808253-7808319
	333892	Dunham, I. et.al.	Plus	8156825-8157001
	333921	Dunham, I. et.al.	Plus	8380325-8380441
35	333968	Dunham, I. et.al.	Plus	8681004-8681241
	334102	Dunham, l. et.al.	Plus	9995140-9996373
	334264	Dunham, I. et.al.	Plus	13234447-13234544
	334343	Dunham, I. et.al.	Plus	13655828-13656307
40	334794	Dunham, I. et.al.	Plus	16374312-16374458
40	334889	Dunham, I. et.al.	Plus	19286024-19286515
	335287	Dunham, I. et.al.	Plus	22299047-22299299
	335491	Dunham, I. et.al.	Plus	24128651-24128827
	335495	Dunham, I. et al.	Plus	24140688-24140872
4.5	335498	Dunham, I. et.al.	Plus	24172082-24172161
45	335653	Dunham, I. et.al.	Plus	25329710-25329802
	335687	Dunham, I. et.al.	Plus	25445952-25446064
	335809	Dunham, I. et.al.	Plus	26310772-26310909
	335822	Dunham, I. et al.	Plus	26364087-26364196
5 0	335823	Dunham, I. et.al.	Plus	26365925-26366004
50	335824	Dunham, I. et.al.	Plus	26376860-26376942
	335825	Dunham, I. et.al.	Plus	26378175-26378268
	336035	Dunham, I. et al.	Plus	29016748-29017410
	336093	Dunham, I. et.al.	Plus	29556922-29557002
55	336096	Dunham, I. et.al.	Plus	29578878-29579047
55	336444	Dunham, I. et.al.	Plus	34190585-34190718
	336959	Dunham, I. et.al.	Plus	13233040-13233126
	338008	Dunham, I. et.al.	Plus	7697068-7697236
	338057	Dunham, I. et.al.	Plus	8526397-8526522
60	338410 338588	Dunham, I. et.al.	Plus	19292807-19292916
UU		Dunham, I. et.al.	Plus	22896767-22896920
	338665 338832	Dunham, I. et.al.	Plus	24472654-24472853
	338980	Dunham, I. et.al. Dunham, I. et.al.	Plus Plus	27775128-27775290
	339352	Dunham, I, et.al.	Plus	29896789-29896874
	JJJJJZ	ouman, i, cl.di.		33544784-33545121

	332929	Dunham, I. et.al.	Minus	2020758-2020664
	332930	Dunham, I. et.al.	Minus	2022565-2022497
	332983	Dunham, I. et.al.	Minus	2631933-2631797
_	333009	Dunham, I. et.al.	Minus	2766043-2765856
5	333010	Dunham, I. et.al.	Minus	2766207-2766119
	333013	Dunham, I. et.al.	Minus	2772278-2772039
	333108	Dunham, I. et al.	Minus	3240494-3240389
	333343	Dunham, I. et.al.	Minus	4692886-4692753
10	333456	Dunham, I. et.al.	Minus	2631933-2631797
10	333459	Dunham, I. et al.	Minus Minus	5144548-5144344 7573218-7573060
	333743 333758	Dunham, I. et al. Dunham, I. et al.	Minus	7666413-7666091
	333904	Dunham, I. et.al.	Minus	8217374-8217261
	333905	Dunham, I. et.al.	Minus	8217796-8217670
15	334222	Dunham, I. et.al.	Minus	12732417-12732289
15	334223	Dunham, I. et.al.	Minus	12734365-12734269
	334360	Dunham, I. et.al.	Minus	13728850-13728751
	334784	Dunham, I. et.al.	Minus	16294548-16294360
	334789	Dunham, I. et.al.	Minus	16306095-16305996
20	335004	Dunham, I. et.al.	Minus	20581911-20581794
	335115	Dunham, I. et.al.	Minus	21388250-21388146
	335342	Dunham, I. et.al.	Minus	22597448-22597284
	335544	Dunham, I. et.al.	Minus	24650505-24650403
0.5	335610	Dunham, I. et.al.	Minus	25068943-25068841
25	335682	Dunham, I. et.al.	Minus	25421215-25421093
	335755	Dunham, I. et.al.	Minus	25763806-25763747
	335782	Dunham, I. et.al.	Minus	25908578-25908440
	335791	Dunham, I. et.al.	Minus Minus	25948563-25948411
30	335895 335917	Dunham, I. et al.	Minus	26975307-26975239 27028481-27028377
50	335920	Dunham, I. et.al. Dunham, I. et.al.	Minus	27034927-27034811
	336042	Dunham, I. et.al.	Minus	29041694-29041500
	336150	Dunham, I. et.al.	Minus	30150423-30150256
	336152	Dunham, I. et.al.	Minus	30156053-30155870
35	336416	Dunham, I. et.al.	Minus	34047408-34047311
	336449	Dunham, I. et.al.	Minus	34204707-34204577
	336471	Dunham, I. et.al.	Minus	34215091-34214978
	336512	Dunham, I. et.al.	Minus	34278373-34278275
4.0	336558	Dunham, i. et.al.	Minus	34375825-34375698
40	336560	Dunham, I. et.al.	Minus	34376814-34376596
	336676	Dunham, I. et al.	Minus	2022565-2022497
	337968	Dunham, I. et.al.	Minus	7095797-7095680
	338451	Dunham, I. et al.	Minus	20174286-20174193
45	338689	Dunham, I. et.al.	Minus	24893073-24892972 33860127-33860047
43	339373 325622	Dunham, I. et.al. 5867000	Minus Plus	69994-70075
	329655	6448516	Minus	35565-35843
	329899	6563505	Minus	111058-111783
	329960	5091594	Minus	1031-1162
50	326213	5867224	Minus	60751-60927
	326474	5867405	Plus	16995-18101
	330084	6015302	Minus	57019-59337
	326816	6552458	Plus	198354-198436
	326817	6552458	Plus	199909-200001
55	327110		Plus	94608-94785
	327196		Plus	180921-181333
	327283		Minus	567-962
	327313		Minus	89734-89838
60	327450		Minus	47928-48076
60	328059 328492		Plus	37052-37204
	328304		Minus Minus	46094-46241 3884-3952
	328857	6381927	Minus	80557-81051
	329367		Minus	87201-87587
65	329373		Minus	38950-39301

TABLE 14: Table 2 from BRCA 001-5 US

Table 14, a subset of table 13, depicts a preferred group of genes highly upregulated in breast cancer cells.

	10	UnigeneID: Unigene Title:	Unigene gene title
--	----	------------------------------	--------------------

15	Pkey	ExAccn	UniGene ID	Unigene Title		R1
	100038	M97935		AFFX control: STAT1		16.7
	100114	D00596	Hs.82962	thymidylate synthetase		15.9
	100975	J02923	Hs.76506	lymphocyte cytosolic protein 1 (L-plastin)		30.1
20	101031	J05070	Hs.151738	matrix metalloproteinase 9 (gelatinase B; 9		37.2
	101104	L07615	Hs.169266	Human neuropeptide Y receptor Y1 (NPYY		18.3
	101143	L12723	Hs.90093	heat shock 70kD protein 4		17:4
	101332	L47276	Hs.156346	Homo sapiens (cell line HL-6) alpha topois		18.9
		M13755	Hs.833	interferon-stimulated protein; 15 kDa		18.1
25		M86849	Hs.323733	Homo sapiens connexin 26 (GJB2) mRNA		22.5
		U65932	Hs.81071	extracellular matrix protein 1		23.2
		U79241	Hs.118666	Human clone 23759 mRNA; partial cds		15
		U90904	Hs.83724	Human clone 23773 mRNA sequence		15.2
20		X06985	Hs.202833	heme oxygenase (decycling) 1		22.7
30		X17644	Hs.2707	G1 to S phase transition 1		20.6
		X57766	Hs.155324	matrix metalloproteinase 11 (stromelysin 3		17.8
		X69433	Hs.5337	isocitrate dehydrogenase 2 (NADP+); mito		18.9
		X72755	Hs.77367	monokine induced by gamma Interferon		15.1
25			Hs.198793	KIAA0750 gene product		23.3
35		AA428090		ESTs		28.7
		AA007234		ESTs		16.6
		AA191512		Homo sapiens mRNA; cDNA DKFZp564G		19.3
		AA421104		ESTs		15.4
40		AA621169		ESTs		19
40		AA227219		trinucleotide repeat containing 9		20.1
		H20543	Hs.6278	DKFZP586B1621 protein		16.6
		H59617	Hs.5199	ESTs; Weakly similar to UBIQUITIN-CON		19.5
		H98714	Hs.24131	ESTs		30.2
15		N46252	Hs.29724	ESTs		23.2
45		N67239	Hs.10760	ESTs		37
		N91023	Hs.87128	ESTs		15
		R46025	Hs.7413	ESTs		17.4
		W86748	Hs.8109	ESTs		15
50		Z38595	Hs.125019	ESTs; Highly similar to KIAA0886 protein		22
30		Z40715	Hs.184641	delta-6 fatty acid desaturase		19.4
			Hs.196437	ESTs; Weakly similar to R26660_1; partial		16.9
		AA250737		ESTs		35.1
		AA405098		ESTs		16.1
55		AA433943	Hs.101174	ESTs; Weakly similar to Weak similarity t		33.5
55		H29532		microtubule-associated protein tau		22.2
		H72948	Hs.821	biglycan		20.7
		N26722	Hs.42645 Hs.65946	ESTs ESTs		18.1
		Z41815			-	15.6
60		AA195651 AA416740		ESTs ESTs		15.2
00		AA4 16740 AA609200	113.174104	ESTS		22.6
		D60302	He 270016	ESTs		23.1
		H09290	Hs.270016 Hs.76550			20.6
		N90960	Hs.265398	Homo sapiens mRNA; cDNA DKFZp564B		25.9
	120100	DDEDEKI	113.203330	ESTs; Weakly similar to transformation-rel		16.4

	4070				
		AA916752		ESTs; Highly similar to MEM3 [M.muscul	17.3
		U31875	Hs.152677	short-chain alcohol dehydrogenase family m	27.1
	128717	T30617	Hs.104222	Homo sapiens mRNA; cDNA DKFZp566L	24.5
_	129124	AA234530	Hs.108802	N-ethylmaleimide-sensitive factor	20.7
5	129366	H18027	Hs.184697	plexin C1	18.2
	130455	X17059	Hs.155956	N-acetyltransferase 1 (arylamine N-acetylt	26.4
	130604	X03635	Hs.1657	estrogen receptor 1	39.9
	130913	W03592	Hs.21198	translocase of outer mitochondrial membra	20.9
		M97935	Hs.21486	signal transducer and activator of transcript	18.8
10		AA608962		calcyclin binding protein	18.1
		U90551	Hs.28777	H2A histone family; member L	18.8
		AA405569		fibroblast activation protein; alpha; seprase	15.4
		F09979	Hs.4774	ESTs	15
		AA047896		ESTs	15.4
15				•	26.4
13		AA505133		solute carrier family 2 (facilitated glucose t	
		R79723	Hs.69997	zinc finger protein 238	30.4
		U24166	Hs.234279	microtubule-associated protein; RP/EB fam	15.2
		D62633	Hs.8236	ESTs	15.2
20		J04177	Hs.82772	collagen; type XI; alpha 1	15.3
20		X54942	Hs.83758	CDC28 protein kinase 2	20.3
		D63477	Hs.84087	KIAA0143 protein	16.1
		U89922	Hs.890	lymphotoxin beta (TNF superfamily; memb	35.7
	135237	AA454930	Hs.9691	ESTs	19.5
	301884	AA312082	Hs.105445	GDNF family receptor alpha 1	20.7
25	302276	NM_004448	8Hs.323910	EST cluster (not in UniGene) with exon hit	21.6
	302290	AL117607	Hs.175563	Homo sapiens mRNA; cDNÁ DKFZp564N	41.4
	309177	AI951118		EST singleton (not in UniGene) with exon	24.3
		AW170035		EST	64.5
		AW022192	Hs.200197	ESTs	39.1
30		AI821294		ESTs	24.1
-		AA759250		cytochrome b-561	27.1
		AI969390		ESTs	27.1
		AA833655		ESTs	27.8
		AI873274		ESTs	22.5
35	-	AW207206		ESTs	21.4
55		A1476797		cell division cycle 2; G1 to S and G2 to M	18.4
		AA972756		ESTs	28.8
		Al908272			32.6
				EST cluster (not in UniGene)	15.7
40		AW167087		ESTs	16.3
40		A1285898		ESTs	21.3
		NM_002543		EST duster (not in UniGene)	
		A1793124		ESTs	35
		NM_00273		EST cluster (not in UniGene)	25.4
45		AA321166		EST duster (not in UniGene)	16.7
45		AL039402		DEME-6 protein	24.3
		U96044	Hs.181125	EST duster (not in UniGene)	15.3
		AW043782		ESTs	21
		AW248508		DiGeorge syndrome critical region gene 2	15.3
		AL044891		EST cluster (not in UniGene)	50.1
50	324432	AA464510	Hs.152812	EST cluster (not in UniGene)	16.7
	324603	AW016378	Hs.292934	ESTs .	23.1
	324620	AA448021	Hs.94109	EST duster (not in UniGene)	21.2
	324988	T06997	Hs.121028	EST cluster (not in UniGene)	24.5
	330388	X03363		HER2 receptor tyrosine kinase (c-erbB-2; E	17.7
55		M13755	Hs.833	interferon-stimulated protein; 15 kDa	67
		AA015730		ESTs; Weakly similar to transformation-rel	44.1
		R72427	Hs.129873	ESTs; Weakly similar to CYTOCHROME	41.9
		AA252079		dachshund (Drosophila) homolog	15.1
		AA432166		succinate dehydrogenase complex; subunit	24.3
60		AA281753		Inositol 1:4:5-triphosphate receptor; type 3	19
00		N63192	Hs. 1892	EST: Highly similar to PHENYLETHANO	15.3
		AA262768		KIAA1067 protein	15.2
	332958	MYZ0Z100	110.240301	CH22_FGENES.48_15	17.8
	333769			CH22_FGENES.271_8	48.3
65	333968			CH22_FGENES.307_4	15.9
UJ					33.5
	334223			CH22_FGENES.360_4	18.5
	334264			CH22_FGENES.367_15	10.0

335791	CH22_FGENES.611_7	27.3
336512	CH22_FGENES.834_7	21.4
338008	CH22_FM:AC005500.GENSCAN.127-9	15.2

TABLE 14A

Table 14A shows the accession numbers for those pkeys lacking unigeneID's for Table 14. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number

Accession:

Genbank accession numbers

15

Pkey CAT number Accession

20 309583 1046029_-2 AW170035 336512 CH22_3941FG_834_7_LINK_DJ 338008 CH22_6490FG__LINK_EM-AC00 333769 CH22_1036FG_271_8_LINK_EM 333968 CH22_1245FG_307_4_LINK_EM 335791 CH22_3160FG_611_7_LINK_EM 309177 AI951118 332958 CH22_182FG_48_15_LINK_EM: 334223 CH22_1507FG_360_4_LINK_EM 334264 CH22_1551FG_367_15_LINK_E 123619 371681_1 AA602964 AA609200

TABLE 14B

Table 14B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 14. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10 15	Pkey: Ref: Strand: Nt_post	Sequen er Indicate	ce source ntitled "Th s DNA str	orresponding to an Eos probeset The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication EDNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication EDNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham I. et al." refers to the publication of Dunham II. et al., Nature (1999) 402:489-495.
	Pkey	Ref	Strand	Nt_position
20	332958 333769 333968 334264	Dunham, I. et.al.	Plus Plus	2516164-2516310 7696625-7696707 8681004-8681241 13234447-13234544
25	338008 334223 335791 336512	Dunham, I. et al.	Minus Minus	7697068-7697236 12734365-12734269 25948563-25948411 34278373-34278275

TABLE 15: Table 3 from BRCA 001-5 US

Table 15 shows genes downregulated in breast cancer cells.

5

10

Pkey:	Unique Eos probeset identifier number
ExAcon:	Exemplar Accession number, Genbank accession number
UnigenelD:	Unigene number
Unigene Title:	Unigene gene title
R1:	Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100115	D00632	Hs.172153	glutathione peroxidase 3 (plasma)	1.7
	100499	TIGR:HT1428	Hs.283108	Globin, Beta	1.5
	100502	TIGR:HT1496	Hs.169228	Adrenal-Specific Protein Pg2	2.3
	100815	TIGR:HT4268	Hs.9739	L-Glycerol-3-Phosphate:Nad+ Oxidoreduct	1.7
20	101125	L10373	Hs.82749	transmembrane 4 superfamily member 2	1.5
	101367	M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha po	2.9
	101397		Hs.180878	lipoprotein lipase	1.6
	101883		Hs.75613	CD36 antigen (collagen type I receptor; thr	1.6
0.5	102227		Hs.93841	potassium large conductance calcium-activ	1.6
25		X00129	Hs.76461	retinol-binding protein 4; interstitial	3
		X73079	Hs.288579	polymeric immunoglobulin receptor	1.8
		Y09267	Hs.132821	flavin containing monooxygenase 2	1.5
		Z21966	Hs.2815	POU domain; class 6; transcription factor 1	1.8
30		AA007629	Un 10701	glycerol-3-phosphate dehydrogenase 1 (sol	2.4 1.7
50		AA146619 AA164519	Hs.18791 Hs.15248	ESTs; Weakly similar to CALCIUM-BIND ESTs	1.5
		AA417915	Hs.25930	ESTS	1.5
		AA487576	Hs.26530	serum deprivation response (phosphatidyls	1.6
		AA609645	Hs.211568		2.7
35		AA004901	Hs.261164		1,6
		AA037388	Hs.82223	Human DNA sequence from clone 141H5 o	1.7
		AA099820	Hs.49696	ESTs	2.4
	111130	N64265	Hs.19515	yz44h12.s1 Morton Fetal Cochlea Homo sa	1.7
	111837	R36447	Hs.24453	ESTs	1.6
40	112538	R70255		ESTs	1.9
	112808	R97970	Hs.281022	EST	1.5
		T40652		DKFZP434C171 protein	1.9
		AA418033	Hs.283559	=	1.6
4 =		AA443800	Hs.43125	ESTs	2
45	115965		Hs.173233		2.2
		N20300	Hs.218707		1.7
		N32174	Hs.44317	SRY (sex-determining region Y)-box 10	1.7 1.7
		R15436	Hs.77889	Friedreich ataxla region gene X123	2.8
50		R71792 T71021 .		ESTs; Weakly similar to cell death activato ESTs; Highly similar to WS basic-helix-loo	1.9
50	119359	W73386	Hs.249129		3
	120889		Hs.97044	ESTs	1.6
		AA405747	Hs.97984	ESTs; Weakly similar to WASP-family pro	1.8
		AA421184	Hs.97549	ESTs	1.5
55		AA434447	Hs.106771		2.5
		AA443695	Hs.293410		2.1
		AA448300	Hs.160318	phospholemman	1.5
		AA598841	Hs.167382	natriuretic peptide receptor Alguanylate cy	1.8
	123505	AA600135		ESTs; Moderately similar to !!!! ALU SUB	1.5
60		W94688	Hs.103253		1.7
		D81972		HUM427D08B Human fetal brain (TFujiw	1.8
	126747			phospholemman	1.6
	127218		Hs.116017		1.5
	127357	AA452788	Hs.75432	zx39g11.r1 Soares_total_fetus_Nb2HF8_9	1.7

	407600	A A CO 4 4 OF	11- 400000	FOT-	4 =
		AA634405	Hs.122608		1.5
	128213	AA972780	Hs.129194	ESTs; Weakly similar to IIII ALU SUBFA	1.5
	128351	Al092391	Hs.134886	ESTs	1.5
		N44757	Hs.20340	ESTs	1.6
5		R71403	Hs.75309	eukaryotic translation elongation factor 2	1.7
9					
		AA459944		DKFZP586P1422 protein	1.5
	129285	T62068	Hs.11006	ESTs	2.1
	129331	N93465	Hs.279772	ESTs; Highly similar to CGI-38 protein [H	1.5
		M62402	Hs.274313		1.7
10		M25079			1.7
10			Hs.283108		
		AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
	131277	AA131466	Hs.23767	ESTs	1.9
	131282	M12272	Hs.4	alcohol dehydrogenase 3 (class I); gamma p	2.2
		AA295848	Hs.25475	aguaponn 7	1.7
15		D49487	Hs.194236	• •	2.5
IJ					
		AA045503	Hs.56874	ESTs; Weakly similar to Homo sapiens p2	1.6
	132931	Z41452	Hs.6090	deleted in bladder cancer chromosome regl	1.5
	133120	X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2
		U95367	Hs.70725	gamma-aminobutyric acid (GABA) A recep	1.5
20		X74295	Hs.74369	integrin; alpha 7	1.7
20					2.3
		S95936	Hs.284176		
	133702	N56898	Hs.75652	glutathione S-transferase M5	1,9
	134111	N79674	Hs.8022	TU3A protein	4.6
	134699	U56814	Hs.88646	deoxyribonuclease I-like 3	1.5
25		L10955	Hs.89485	carbonic anhydrase IV	1.6
20	135173		Hs.95910	Human G0S2 protein gene; complete cds	1.9
					1.7
		AW027556	Hs.156286		
	300732	Al369956	Hs.257891	ESTs	1.5
	300750	AA514805	Hs.293055	ESTs	1.8
30	301140	AI807692	Hs.129129	ESTs	1.6
		AA923549	Hs.224121		2,1
					1.8
		N77976		hemoglobin; alpha 1	
		V00505	Hs.36977	hemoglobin; delta	1.6
~ ~	303831	T04868	Hs.46780	EST cluster (not in UniGene) with exon hit	1.7
35	303844	U94362	Hs.58589	glycogenin 2	1.5
	304182	H91086		EST singleton (not in UniGene) with exon	1.5
		AA516384		EST singleton (not in UniGene) with exon	1.5
		AA550994		EST singleton (not in UniGene) with exon	1.7
		AA782347	He 272572	EST singleton (not in UniGene) with exon	1.5
40			113.272372		1.5
40		AA923457		EST singleton (not in UniGene) with exon	
	307206	Al192534		EST singleton (not in UniGene) with exon	1.6
	307377	Al222691		EST singleton (not in UniGene) with exon	1.5
	308023	Al452732	Hs.251577	EST singleton (not in UniGene) with exon	1.9
		AI612774	Hs.79372	retinoid X receptor; beta	1.5
45			Hs.255504		1.5
73		AW296073			
		Al720978		ESTs; Moderately similar to alternatively s	1.8
	311671	AW241947	Hs.232478		1.6
	311794	AW238092	Hs.254759	ESTs	2.1
	312082	T79860	Hs.118180	ESTs	1.9
50		H25237	Hs.306814		2.3
50		N49684	Hs.143040		1.8
		W32480	Hs.157099		2.2
	313374	AW328672	Hs.132760	ESTS	1.9
	314701	A1754634	Hs.131987	ESTs	1.7
55		AA759098	Hs.192007	ESTs	1.8
		AA680055	Hs.264885		1.5
		AA948612	Hs.130414		1.6
	310249	AA540012			
		Al205077	Hs.294085		1.7
		AA837079	Hs.24647	ESTs	1.5
60	316983	AI480204	Hs.177131	ESTs	1.5
		AI650625	Hs.300756		1.6
		AW206520	Hs.129621		1.5
	240400	M36003			1.7
		W26902	Hs.154085		
	320757	H22654	Hs.6382	EST cluster (not in UniGene)	1.5
65	321594	AA021402	Hs.11067	ESTs	1.7
	322102	H45589		EST duster (not in UniGene)	1.5
	322814	AI824495	Hs.211038	ESTs	2.2

	322929	Al365585	Hs.146246	ESTs	2.3
	323831	AA335715	Hs.200299	ESTs	1.7
	324044	AL045752	Hs.22350	ESTs	1.8
_	324675	AW014734	Hs.157969	ESTs	2.2
5	325272			CH.11_hs gi]5866902	1.5
	325558			CH.12_hs gij6056302	1.6
	325656			CH.14_hs gi 6056305	1.6
	326120			CH.17_hs gi 5867194	1.5
	326139			CH.17_hs gi 5867203	1.5
10	326855			CH.20_hs gi 6552460	1.5
	327438			CH.02_hs gi 6004454	1.6
	329733			CH.14_p2 gi 6065783	1.6
	330931	F01443	Hs.284256	ESTs	4.6
	331591	N71677	Hs.42146	ESTs	1.9
15	332159	AA621393	Hs.112984	EST	1.5
	332364	W94688	Hs.103253	perilipin	2.1
	332502	H21819	Hs.14896	Homo saplens clone 24590 mRNA sequenc	1.5
	334175			CH22_FGENES.349_10	1.5
	334347			CH22_FGENES.375_31	1.8
20	334737			CH22_FGENES.424_12	1.8
	335352			CH22_FGENES.539_5	1.5
	335639			CH22_FGENES.584_19	1.6
	336244			CH22_FGENES.746_2	1.5
	336336			CH22_FGENES.814_8	1.7
25	336865			CH22_FGENES.305-1	1.6
	337494			CH22_FGENES.799-12	1.6
	337764			CH22_EM:AC000097.GENSCAN.119-1	1.8
	337983			CH22_EM:AC005500.GENSCAN.110-1	2
	338192			CH22_EM:AC005500.GENSCAN.228-1	1.5
30	339366			CH22_BA354l12.GENSCAN.34-2	1.5

TABLE 15A

Table 15A shows the accession numbers for those pkeys lacking unigeneID's for Table 15. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

```
Pkey: Unique Eos probeset identifier number 
CAT number: Gene cluster number 
Accession: Genbank accession numbers
```

D81972 BE003132

15

40

```
Pkey CAT number Accession
```

126300 250375_2

329735 C14_p2
326120 c17_hs
326139 c17_hs
326855 c20_hs
335352 CH22_2699FG_539_5_LINK_EM
335639 CH22_2999FG_584_19_LINK_E
307206 Al192534
35 307377 Al222691
337494 CH22_5727FG_799_12
337764 CH22_6115FG_LINK_EM:AC00

337494 CH22_5727FG_799_12_ 337764 CH22_6115FG__LINK_EM:AC00 337983 CH22_6438FG__LINK_EM:AC00 339366 CH22_8336FG__LINK_BA354I1 325272 c11_hs 325558 c12_hs 325656 c14_hs

334175 CH22_1455FG_349_10_LINK_E

304182 H91086 45 334347 CH22_1640FG_375_31_LINK_E 327438 c_2_hs 304622 AA516384

334737 CH22_2049FG_424_12_LINK_E 304682 AA550994 50 336244 CH22_3642FG_746_2_LINK_DA 306193 AA923457

TABLE 15B

Table 15B shows the genomic positioning for those pkeys lacking unigene ID's and
 accession numbers in Table 15. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
10	1101,	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:	Indicates DNA strand from which exons were predicted.
	Nt_position:	Indicates nucleotide positions of predicted exons.
1		

15				
	Pkey	Ref	Strand	Nt_position
	334347	Dunham, I. et.al.	Plus	13663814-13663926
•	334737	Dunham, I. et.al.	Plus	15998517-15998685
20	335639	Dunham, I. et.al.	Plus	25173591-25173696
	337494	Dunham, I. et.al.	Plus	33339024-33339148
	334175	Dunham, I. et.al.	Minus	11668659-11668597
	335352	Dunham, I. et.al.	Minus	22681512-22681384
	336244	Dunham, I. et.al.	Minus	31402729-31402583
25	336336	Dunham, I. et.al.	Minus	33797209-33797076
	336865	Dunham, I. et.al.	Minus	8622405-8622289
	337764	Dunham, I. et.al.	Minus	4035640-4035446
	337983	Dunham, I. et.al.	Minus	7275495-7275271
••	338192	Dunham, I. et.al.	Minus	13248453-13248277
30	339366	Dunham, I. et.al.	Minus	33647431-33647293
	325272	5866902	Minus	13247-13312
	325558	6056302	Plus	70930-71030
	325656	6056305	Minus	78190-78707
	329733	6065783	Plus	163237-163450
35	326120	5867194	Plus	36116-36276
	326139	5867203	Minus	218901-218960
	326855	6552460	Minus	111390-111463
	327438	6004454	Minus	199569-199692

TABLE 16: Table 4 from BRCA 001-5 US

Table 16, a subset of table 15, depicts a preferred group of genes highly downregulated in breast cancer cells.

10	Pkey: ExAccn: UnigenelD: Unigene Title:	Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number Unigene gene title
	Unigene Title:	
	R1:	Ratio of normal breast tissue to tumor

15	Pkey	ExAccn	UniGene ID	Unigene Title	R1
	100502		Hs.169228	Adrenal-Specific Protein Pg2	2.3
		M12963	Hs.4	alcohol dehydrogenase 1 (class I); alpha	2.9
20		X00129	Hs.76461	retinol-binding protein 4; interstitial	3
20		AA007629		glycerol-3-phosphate dehydrogenase 1	2.4
		AA609645	Hs.211568	eukaryotic translation initiation factor 4 gam	2.7
		AA099820	Hs.49696	ESTs	2.4
		AA443800	Hs.43125	ESTs	2
25		AA446661	Hs.173233	ESTs	2.2
25		R71792	Hs.301002	ESTs; Weakly similar to cell death activator	2.8
		W73386	Hs.249129	ESTs	3
		AA434447	Hs.106771	ESTs	2.5
		AA443695	Hs.293410	ESTs	2.1
20		T62068	Hs.11006	ESTs	2.1
30		AA211776	Hs.2504	myomesin 1 (skelemin) (185kD)	3.8
		M12272	Hs.4	alcohol dehydrogenase 3 (class I); gamma	2.2
		D49487	Hs.194236	leptin (murine obesity homolog)	2.5
		X64559	Hs.65424	tetranectin (plasminogen-binding protein)	2
25		S95936	Hs.284176	transferrin	2.3
35	134111	N79674	Hs.8022	TU3A protein	4.6
		AA923549	Hs.224121	ESTs	2.1
		AW238092	Hs.254759	ESTs	2.1
		H25237	Hs.306814	ESTs .	2.3
40		W32480	Hs.157099	ESTs	2.2
40		A1824495	Hs.211038	ESTs	2.2
		Al365585	Hs.146246	ESTs	2.3
		AW014734	Hs.157969	ESTs	2.2
			Hs.284256	ESTs	4.6
4.0		W94688	Hs.103253	perilipin	2.1
45	337983			CH22 EM;AC005500,GENSCAN,110-1	2

TABLE 16A

Table 16A shows the accession numbers for those pkeys lacking unigeneID's for Table 16. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

5

Pkey: CAT number: Unique Eos probeset identifier number

Accession:

Gene cluster number Genbank accession numbers

15

20

Pkey CAT number Accession

104672 6735_7

AA349096 Al368018 F21390 F17759 R48772 Al421485 Al300352 H43971 Al378525 F33652 R47898 Al264177 F22289 N28263 Al276281 R48205 Al245302 Al190036 Al281050 AW242903 H42892 AA910870 AW473816 H25721 AW451438 F19647 F22375

H45809 F33447 AA774528 AA007629 H42537 C01077 F32386

TABLE 17: Table 1 from BRCA 014 P

Table 17 shows accession numbers representing 759 sequences of breast cancer genes or fragments thereof encoding breast cancer modulating proteins. For each overexpressed gene identified, a ratio of the relative amount of expression in breast tumors versus normal breast tissue.

10		
	Pkey:	Unique Eos probeset identifier number
	ExAcon:	Exemplar Accession number, Genbank accession number
	UnigenetD:	Unigene number
	Unigene Title:	Unigene gene title
15	R1·	Ratio of tumor to normal breast tissue

	Pkey	ExAccn	UnigeneiD	Unigene Title	R1
20	100227	AV654694	Hs.82316	interferon-induced, hepatitis C-associat	3
	100405	AW291587	Hs.82733	nldogen 2	3.2
	100406	AI962060	Hs.118397	AE-binding protein 1	3.6
	100420	D86983	Hs.118893	Melanoma associated gene	3.2
		X83300	Hs.289103	SMA4	5.2
25	100960	J00124	Hs.117729	keratin 14 (epidermolysis bullosa simple	4.3
	101011	BE387036	Hs.1211	acid phosphatase 5, tartrate resistant	3
		AA442324	Hs.795	H2A histone family, member O	3.2
	101194		Hs.188	phosphodiesterase 4B, cAMP-specific (dun	3
20		U66042	Hs.82171	Homo sapiens clone 191B7 placenta expres	4.1
30		BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5.3
		R07566	Hs.73817	small inducible cytokine A3 (homologous	3.9
		M25809	Hs.64173	ATPase, H+ transporting, lysosomal (vacu	4.5
		M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
35		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	3.4
33		NM_003528	Hs.2178	H2B histone family, member Q	5.6
		BE019494	Hs.79217	pyrroline-5-carboxylate reductase 1	3.6
		M81057		carboxypeptidase B1 (tissue)	12
		M89907		SW/SNF related, matrix associated, acti	3.2
40		BE260964	Hs.82045	midkine (neurite growth-promoting factor	4.1
40		M97815		cellular retinoic acid-binding protein 2	6.5
		NM_002038		Interferon, alpha-inducible protein (clo	3 3
		U23752 NM_001504	Hs.32964	SRY (sex determining region Y)-box 11 G protein-coupled receptor 9	3.7
		NM_005824		37 kDa leucine-rich repeat (LRR) protein	3.7
45		NM_005651		tryptophan 2,3-dioxygenase	5.2
73		AL043202	Hs.90073	chromosome segregation 1 (yeast homolog)	3.5
		U39840		hepatocyte nuclear factor 3, alpha	3.9
	102591			amyloid beta (A4) precursor protein-bind	3. 5
		H16646		hypothetical protein PP591	3.5
50		AA363025		Human clone 23801 mRNA sequence	3.2
50		AF080229	113,100012	qb:Human endogenous retrovirus K done 1	3
		NM_002318	Hs.83354	lysyl oxidase-like 2	3.2
		M73779		retinoic acid receptor, alpha	3.3
		X52509		tyrosine aminotransferase	12.4
55	103042			ribosomal protein S3	4.5
	-	X63578		parvalbumin	3
	103207		110.200110	qb:Human endogenous retrovirus mRNA for	5.9
		BE390551	Hs.77628	steroidogenic acute regulatory protein r	3.9
		AI751601	Hs.8375	TNF receptor-associated factor 4	3.3
60	103329		Hs.72984	retinoblastoma-binding protein 5	3.1
	103364				3
		NM_007069	Hs.37189	similar to rat HREV107	3.4
		AA496425	Hs.9629	papillary renal cell carcinoma (transloc	3.2
	.50.50			backman's response and annual functions	

	103498	Y09306	Hs.30148	homeodomain-Interacting protein kinase 3	3.4
		BE616547	Hs.2785	keratin 17	3.7
	103563			Activin A receptor, type I (ACVR1) (ALK	3.2
5		BE336654	Hs.70937	H3 histone family, member A	4.5
5		AI571835	Hs.55468	ESTs ESTs	4 3.8
		AW779318 AW021102	Hs.88417 Hs.21509	ESTs	4.3
		AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
		AA461618	Hs.31704	ESTs, Weakly similar to KIAA0227 [H.sapi	3.6
10	104173	AA084273	Hs.76561	ESTs, Weakly similar to S47072 finger pr	4
		AF173296		DC6 protein	3
		AB040927		KIAA1494 protein	3.2
		A1559444	Hs.293960	endosulfine alpha	4.3 3.1
15		Al929700 H20816	He 112423	Homo sapiens mRNA; cDNA DKFZp586I1420 (f	3.2
10		AV650851	Hs.96900	hypothetical protein; KIAA1830 protein	4.4
		AA360954	Hs.27268	Homo sapiens cDNA: FLJ21933 fis, clone H	3.2
	104748	AA015879	Hs.33536	ESTs	3.2
20	104755		Hs.9029	DKFZP434G032 protein	4.5
20		AA035613	Hs.141883		6.9 11.1
		AW294092 T79340	Hs.21594 Hs.22575	hypothetical protein MGC15754 B-cell CLL/lymphoma 6, member B (zinc fi	3.5
•		BE298684	Hs.26802	protein kinase domains containing protei	6.5
		H78517	Hs.33905	ESTs	3.6
25		AW503733	Hs.9414	KIAA1488 protein	4.5
		H58589	Hs.35156	Homo saplens cDNA FLJ11027 fis, clone PL	3.8
		AA148982	Hs.29068	ESTs	3
		AL137566	Hs.32405 Hs.190325	Homo sapiens mRNA; cDNA DKFZp586G0321 (f	4.8 8.2
30		AW134924 AA814807	Hs.7395	hypothetical protein FLJ23182	3.1
50		AW505076		DiGeorge syndrome critical region gene 8	4.2
		AA252033		hypothetical protein DKFZp434K1421	4.4
	105552	AA256750	Hs.28802	centaurin-alpha 2 protein	3.2
26		AA279439		hypothetical protein FLJ 10504	3.5
35		W16741	Hs.25635	HSPC003 protein	3.7 5.5
		Al299139 Al133161	Hs.17517	ESTs CGI-101 protein	3.5
		AW973653	Hs.20104	hypothetical protein FLJ00052	3.3
		AA195191	Hs.5111	hypothetical protein FLJ20729	3.2
40		AA131657	Hs.23830	ESTs	3.3
		AL117474	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3.2
		W28948	Hs.10762	ESTS	3.3
		N39842	Hs.301444	Homo sapiens cDNA FLJ13634 fis, clone PL	4.1 3.1
45		BE397649 BE383668	Hs.94109 Hs.42484	hypothetical protein FLJ10618	3.2
		AA351978	Hs.4943	hepatocellular carcinoma associated prot	7.8
		AL134708	Hs.145998		3
	106614	AA648459	Hs.335951		3.8
50		AW958037	Hs.286	nibosomal protein L4	3.3
50		AW499914	Hs.7579	hypothetical protein FLJ10402	3 4.2
		BE613328 AA485055	Hs.21938	hypothetical protein FLJ12492 sperm associated antigen 6	3.4
		AJ311928	115.150215	gb:qo89h04.x1 NCI_CGAP_Kid5 Homo sapiens	4.4
		AW192535	Hs.19479	ESTs	3.6
55		AW472981	Hs.321130	hypothetical protein MGC2771	4.1
		AA995351	Hs.31314	retinoblastoma-binding protein 7	3.6
		AF216751	Hs.26813	CDA14	5.3
		AW963419	Hs.155223 Hs.31844	stanniocalcin 2 hypothetical protein FLJ12586	3.4 3.1
60		N32849 AW263124	Hs.315111		5.9
50		BE379594	Hs.49136	ESTs. Moderately similar to ALU7_HUMAN A	3.9
		AW961576	Hs.60178	ESTs	4.6
		AJ955040		ESTs, Weakly similar to transformation-r	3
65		AA025386	Hs.61311	ESTs, Weakly similar to S10590 cysteine	3.1
65		T40064	Hs.71968	Homo sapiens mRNA; cDNA DKFZp564F053 (fr	4.8 3.3
		Al263307 AA058686	Hs.62588	H2B histone family, member L ESTs	3.8
	100217	, 17000000	113.02300	2010	0.0

	100405	T00 407	11: 404404	11	•
		T82427		Homo sapiens cDNA: FLJ20869 fis, clone A	3
		AB033073	Hs.43857	similar to glucosamine-6-sulfatases	3.3
		AA121022	11- 70744	gb:zn84f10.r1 Stratagene lung carcinoma	3.9
5		AF068290	Hs.79741	hypothetical protein FLJ10116	6.1
3		AA011449	Hs.271627		3.6
		AA136674	Hs.118681		3.9
		AF186114		tumor necrosis factor (ligand) superfami	3.7
		AK000684		hypothetical protein FLJ22104	3.1
10		A1970536	Hs.16603	hypothetical protein FLJ13163	3.7
10		N23235	Hs.30567	ESTs, Weakly similar to B34087 hypotheti	4.5
		AA196443 AW504732	Hs.86043	Homo sapiens cDNA FLJ13558 fis, clone PL	3.7
			Hs.21275	hypothetical protein FLJ11011	4.6
		AA232255		ESTs, Moderately similar to A46010 X-lin	6.4 4.8
15		AA234087 R45584	Hs.23025	ESTs, Weakly similar to S72482 hypotheti ESTs, Weakly similar to ALU5_HUMAN ALU S	3.3
13		AA325138		hypothetical protein FLJ22672	3.3
		AW973964	Hs.291531		3
		F09609	HS.Z51001	gb:HSC33H092 normalized infant brain cDN	3.2
		F06838	Hs.14763	ESTs	3.2
20		R43646	Hs.12422	ESTs	3.8
20		AW818436	Hs.23590	solute carrier family 16 (monocarboxylic	3.3
		AK001680	Hs.30488	DKFZP434F091 protein	3.6
		AW973152	Hs.31050	ESTs	4.2
		AA379597	Hs.5199	HSPC150 protein similar to ublquitin-con	5.1
25		H89355		adrenergic, alpha-2A-, receptor	5.3
23		Al239832	Hs.15617	ESTs, Weakly similar to ALU4_HUMAN ALU S	3.7
		BE092285	Hs.29724	hypothetical protein FLJ13187	3.7
		N64683	Hs.290943		4
		N66563	Hs.191358		3.1
30		AI767435	Hs.29822	ESTs	4.5
50		AI457338	Hs.29894	ESTs	5.4
		R07856	Hs.16355	ESTs	3.2
		R08440	110110000	gb:yf19f09.s1 Soares fetal liver spleen	3.1
		AA602004	Hs.23260	ESTs	3.2
35		R35252	Hs.24944	ESTs, Weakly similar to 2109260A B cell	3.3
		R38239		ESTs, Weakly similar to putative p150 [H	3.1
		AA421081	Hs.12388	ESTs	3.4
		AF070526	Hs.13429	Homo sapiens clone 24787 mRNA sequence	3.3
		AW379029		ESTs, Weakly similar to unnamed protein	4.4
40	112170	BE246743		hypothetical protein FLJ22635	7.3
	112287	AB033064	Hs.334806	KIAA1238 protein	3.2
	112300	H24334	Hs.26125	ESTs	4.4
	112303	R54797		gb:yg87b07.s1 Soares infant brain 1NIB H	3.4
	112478	R66067	Hs.28664	ESTs	8.2
45	112561	Al791493	Hs.129873	ESTs, Weakly similar to A36036 cytochrom	5.5
	112631	R82040		gb:yj06b06.s1 Soares placenta Nb2HP Homo	3.9
	112637	R82331	Hs.164599	ESTs	5.4
	112657	AW844878	Hs.19769	hypothetical protein MGC4174	3.2
	112678	Al418466	Hs.33665	ESTs	4.7
50	112917	AA082465	Hs.125031	choline/ethanolaminephosphotransferase	3.7
	113070	AB032977	Hs.6298	KIAA1151 protein	3.1
	113095	AA828380	Hs.126733		3.4
		AW813731	Hs.159153	ESTs, Moderately similar to S65657 alpha	3.4
	113187	BE613410	Hs.31575	SEC63, endoplasmic reticulum translocon	3.2
55	113200		Hs.10263	ESTs	3.5
		BE262470	Hs.241471		6.2
		T79925		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
		U54727	Hs.191445		3
	113494		Hs.86538	ESTs	3.4
60		AW367788		postmeiotic segregation increased 2-like	3.1
		A1702609	Hs.15713	hypothetical protein MGC2776	3.1
		NM_004585	Hs.17466	retinolc acid receptor responder (tazaro	3.9
		Al912410	Hs.27475	Homo sapiens cDNA FLJ12749 fis, clone NT	3
65		W81598		gb:zd88g02.s1 Soares_fetal_heart_NbHH19W	4.6
65		W84768	110 0400	gb:zh53d03.s1 Soares_fetal_liver_spleen_	3.1
		W27249	Hs.8109	hypothetical protein FLJ21080	6.9
	114086	AA378776	HS.288649	hypothetical protein MGC3077	4.3

	44440	4141470444	11- 000 400		4.4
		AW470411		neurotrimin	4.1
		AW780192	Hs.267596		3.4
		AW163267		suppressor of var1 (S.cerevisiae) 3-like	3.1
~		Al979168	Hs.82226	glycoprotein (transmembrane) nmb	4.8
5	114965	Al733881	Hs.72472	BMP-R1B	10.1
	114995	AA769266	Hs.193657	ESTs	3.6
	115121	Al634549	Hs.88155	ESTs	3.2
	115134	AW968073	Hs.194331	ESTs, Highly similar to A55713 inositol	4.2
	115167	AA749209	Hs.43728	hypothetical protein	3
10	115253	BE149845	Hs.289038	hypothetical protein MGC4126	3.6
	115277	AA814100	Hs.86693	ESTs	3.9
		N46436	Hs.109221	ESTs	3.4
		AA281636	Hs.334827		4.8
		AA405620	Hs.55158	ESTs, Weakly similar to T29520 hypotheti	3.5
15		AA953006	Hs.88143	ESTs	9.3
13		AW293849	Hs.58279	ESTs, Weakly similar to ALU7_HUMAN ALU S	3.4
		AA417812	Hs.38775	ESTs	4
		A)126772	Hs.40479	ESTs	3.1
		AW970529	Hs.86434	hypothetical protein FLJ21816	3.6
20					3.1
20		AA521410	Hs.41371	ESTs	3.1
		NM_014937	Hs.52463	KIAA0966 protein	3.2
		AK001500		hypothetical protein FLJ13852	
		AA354549	Hs.41181	Homo sapiens mRNA; cDNA DKFZp727C191 (fr	3
0.5		AL042465	Hs.43445	poly(A)-specific ribonuclease (deadenyla	3.1
25		AB041035	Hs.93847	NM_016931:Homo sapiens NADPH oxidase 4 (6.7
		AL042355	Hs.70202	WD repeat domain 10	3.6
	116184	AW450737		CGI-09 protein	3.1
		AA464976	Hs.62528	ESTs, Moderately similar to A46010 X-lin	3.3
	116208	A1219083	Hs.42532	ESTs, Moderately similar to ALU8_HUMAN A	3.2
30	116246	AF265555		baculoviral IAP repeat-containing 6	3.6
	116443	AW962196	Hs.321264	LBP protein 32	4.1
	116470	AI272141	Hs.83484	SRY (sex determining region Y)-box 4	4.1
	116726	AK001114	Hs.53913	hypothetical protein FLJ10252	8.6
	116845	AA649530		gb:ns44f05.s1 NCI_CGAP_Alv1 Homo sapiens	3.2
35	117026	H88256	Hs.50456	ESTs, Moderately similar to ZN75_HUMAN Z	3.5
		AI569804	Hs.42792	ESTs, Weakly similar to I78885 serine/th	3.1
		AL133427	Hs.42506	Homo sapiens mRNA full length insert cDN	3.2
		H84455	Hs.40639	ESTs	4.7
		AB040959	Hs.93836	DKFZP434N014 protein	3
40		AW968941	Hs.166254		3.3
. •		AI183838	Hs.48938	hypothetical protein FLJ21802	4.3
		N66028	Hs.49105	FKBP-associated protein	3.1
		AW970584	Hs.291033		3.4
		AL157488	Hs.50150	Homo sapiens mRNA; cDNA DKFZp564B182 (fr	5.2
45		AK000465	Hs.50081	KIAA1199 protein	3.4
73		N92293		ESTs, Moderately similar to ALU8_HUMAN A	3.3
		BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	19.7
		R95872		chemokine binding protein 2	3.7
				ESTs, Moderately similar to ALU1_HUMAN A	4.1
50		R16833	Hs.53106	fibronectin 1	3.2
50		M10905			3.3
		W47620	Hs.56009	2'-5'-oligoadenylate synthetase 3 (100 k	· 3.1
		AF041853	Hs.43670	kinesin family member 3A	
		A1970797	Hs.64859	ESTs	5
~ ~		AL037824	Hs.194695	ras homolog gene family, member I	3.8
55		AW449064		collagen, type III, alpha 1 (Ehlers-Dani	3.1
		W94472	Hs.59529	ESTs, Moderately similar to ALU1_HUMAN A	8.4
	120241	AA825686		ESTs, Weakly similar to S65824 reverse t	3.6
	120326	AA196300	Hs.21145	hypothetical protein RG083M05.2	3.2
	120742	AA225084		gb:nc21d06.r1 NCI_CGAP_Pr1 Homo sapiens	3.6
60	120870	AA357172	Hs.292581	ESTs, Moderately similar to ALU1_HUMAN A	5.8
	120885	AA365515	Hs.301872	hypothetical protein MGC4840	3
		AA398118	Hs.97579	ESTs, Weakly similar to A46010 X-linked	3.7
		AW976570	Hs.97387	ESTs	5.3
		AA320134		Homo sapiens mRNA for KIAA1657 protein,	4
65		AA398936	Hs.97697	EST	3.5
00	121121	AA399371		similar to SALL1 (sal (Drosophila)-like	6.3
		AW885727	Hs.301570		4.7
	121001				

	121351	AW206227	Hs.287727	hypothetical protein FLJ23132	5
	121611	M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	3.6
	121643	AA640987	Hs.193767	ESTs	5.6
-	121770	NM_015902	Hs.278428	progestin induced protein	3.4
5		AK000492	Hs.98806	hypothetical protein	4.1
		AA443311	Hs.98998	ESTs	3
		AA446965	Hs.112092		4.7
		A1767879	Hs.99214	ESTs	3.8
10		AW973253	Hs.292689		3 5.6
10		AA323296 AA526911	Hs.97837 Hs.82772	Homo sapiens mRNA; cDNA DKFZp547J047 (fr collagen, type XI, alpha 1	3.2
		AW205931	Hs.99598	hypothetical protein MGC5338	8.6
		AA487809		catenin (cadherin-associated protein), d	3
		AA228776	Hs.191721		6.9
15	123249	AA371307	Hs.125056		3.6
	123273	AA491253	Hs.173611	Empirically selected from AFFX single pr	7
	123385	BE149685	Hs.17767	KIAA1554 protein	3.1
		T66087		Homo sapiens unknown mRNA sequence	3.4
00		AI308876		hypothetical protein DKFZp761D112	3.1
20		AI675944		Homo sapiens cDNA FLJ12033 fis, clone HE	3.8
		AA580082	Hs.112264		4.7
		AA352723	Hs.241471		3.8 4.1
		H69125 N22401	Hs.133525	gb:yw37g07.s1 Morton Fetal Cochlea Homo	4.1
25		N22508	He 130315	Homo sapiens cDNA: FLJ21479 fis, clone C	3.6
23		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	3.1
		N34151		interferon induced transmembrane protein	3.5
		R41396		hypothetical protein FLJ23045	4.3
		BE065136		splicing factor (CC1.3)	6
30	125042	T78906	Hs.269432	ESTs, Moderately similar to ALU1_HUMAN A	8.1
		W60326		Homo sapiens cDNA FLJ11750 fis, clone HE	4.7
		AW970536	Hs.105413		3.1
		AF086534		ESTs, Moderately similar to ALU1_HUMAN A	3.3
25		AL359573		GTP-binding protein	3
35		AW880562	Hs.114574		3 3.2
		A1422996 A1924630	Hs.161378 Hs.4943	hepatocellular carcinoma associated prot	3.2
		N99638	113,4343	gb:za39g11.r1 Soares fetal liver spleen	4
		AW975814	Hs.326714	Homo sapiens clone IMAGE:713177, mRNA se	4
40		AA648886	Hs.151999		3.8
		AW450979		gb:UI-H-BI3-ala-a-12-0-UI.s1 NCI_CGAP_Su	3
	127431	AW771958	Hs.175437	ESTs, Moderately similar to PC4259 ferri	3.6
	127980	AA961459	Hs.125644	ESTs	4.1
4 ~		AW068311		Homo sapiens mRNA full length insert cDN	3.3
45		AA650274	Hs.41296	•	4.6
		NM_003616		survival of motor neuron protein interac	3.9
		Y13153		kynurenine 3-monooxygenase (kynurenine 3	3.1
		AA775076 D56365	Hs.63525	Homo sapiens, Similar to PRO0478 protein poly(rC)-binding protein 2	3.9 3.3
50		AA357185		ras homolog gene family, member H	3.1
50		AF182277		cytochrome P450, subfamily IIB (phenobar	3.9
		AA172106		Rag C protein	6.2
		AA209534		tetraspan NET-6 protein	3.4
		AK000398	Hs.11747	hypothetical protein FLJ20391	3
55		X56411	Hs.1219	alcohol dehydrogenase 4 (class il), pi p	3.2
	130069	AI754813	Hs.146428	collagen, type V, alpha 1	5.4
		X03363		v-erb-b2 avian erythroblastic leukemia v	4.4
		AI347487		class I cytokine receptor	4.6
<i>c</i> 0		NM_003450		zinc finger protein 174	5.6
60		Al582291	Hs.16846	ESTs, Weakly similar to O4HUD1 debrisoqu	3
		R77776	Hs.18103	ESTS	3.8
		AA809875 AB014544	Hs.25933 Hs.21572	ESTs KIAA0644 gene product	4.2 4.7
		Al399653	Hs.22917	ESTs .	4.7
65		H09048	Hs.23606	ESTS	3.8
		R71802	Hs.24853	ESTs	3.5
		AW293399		nuclear receptor co-repressor 1	3.6
				•	

	131507	A1826268	Hs.27769	ESTs, Weakly similar to MCAT_HUMAN MITOC	3.2
		AI695549	Hs.183868	glucuronidase, beta	3.1
	131739	AF017986	Hs.31386	secreted frizzled-related protein 2	3.2
_	131795	BE501849	Hs.32317	high-mobility group 20B	3.2
5	131970	D86960	Hs.3610	KIAA0205 gene product	3.6
		NM_002314	Hs.36566	LIM domain kinase 1	3.2
		AA400091	Hs.39421	ESTs	3.2
		AA426202	Hs.40403	Cbp/p300-interacting transactivator, wit	3
10	132159		Hs.41154	Zic family member 1 (odd-paired Drosophi	3.2
10		AA192669	Hs.45032	ESTS	3.5
		AL133731	Hs.4774	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	9.2 8.2
		AV660345		CGI-49 protein	3.4
		BE568452 AA326108	Hs.5101	protein regulator of cytokinesis 1	3.2
15		AA320100 AA319233	Hs.33829 Hs.5521	bHLH protein DEC2 ESTs	4.8
13		NM_006276		splicing factor, arginine/serine-rich 7	3.6
		W73311		SAC2 (suppressor of actin mutations 2, y	3.2
		T48195	Hs.58189	eukaryotic translation initiation factor	3.5
		Y00272		cell division cycle 2, G1 to S and G2 to	4.4
20		AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transl	4.8
	133130	Al128606	Hs.6557	zinc finger protein 161	3.3
	133142	AW952412	Hs.65874	ESTs, Weakly similar to A40348 Elav/Sex-	3.5
		AW162840	Hs.6641	kinesin family member 5C	4.5
		AW600291	Hs.6823	hypothetical protein FLJ10430	3.3
25		AA085191	Hs.6949	hypothetical protein MGC11275	3
		Z93241		CGI-96 protein	4.5
		AW797437	Hs.69771	B-factor, properdin	4.1
		BE618768	Hs.7232	acetyl-Coenzyme A carboxylase alpha	5.1 3
30		AW675064	Hs.73875	fumarylacetoacetate hydrolase (fumarylac	3.4
30		AW162919 BE274552	Hs.76578	RAB2, member RAS oncogene family-like protein inhibitor of activated STAT3	3.9
		Al908165		GATA-binding protein 3 (T-cell receptor	6.2
		BE391929	Hs.8752	transmembrane protein 4	3.1
		AI433797	Hs.8889	serine hydroxymethyltransferase 1 (solub	3
35		D89377	Hs.89404	msh (Drosophila) homeo box homolog 2	5.8
		J05582	Hs.89603	mucin 1, transmembrane	4
		AF064804	Hs.96757	suppressor of Ty (S.cerevisiae) 3 homolo	3.2
	135303	R61253	Hs.98265	KIAA1877 protein	3.3
	135400	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	4.8
40		L10333	Hs.99947	reticulon 1	3.8
		Al199738		ESTs, Weakly similar to ALUA_HUMAN !!!!	3.8
		AW614220	Hs.189402		4.2 9.9
		AW183618	Hs.55610		4.9
45		AW591433		Transmembrane protease, serine 3	3.4
43		Z45270 AA572949	Hs.207566	hypothetical protein FLJ22672	3.5
		R10799	Hs.191990		3.8
		AA887801		G protein-coupled receptor	13.9
		AI091631		two pore potassium channel KT3.3	4,4
50		AA312082		GDNF family receptor alpha 1	5.7
•		U79745		solute carrier family 16 (monocarboxylic	8.6
		T97905		gb:ye54c10.r1 Soares fetal liver spleen	3.9
	302001	AB020711		KIAA0904 protein	7.7
	302067	BE542706	Hs.222399	CEGP1 protein	7.3
55		AW749321	Hs.6786	ESTs	3.3
		AL049670		ribosomal protein L34 pseudogene 1	4.2
		NM_003613	Hs.151407	cartilage intermediate layer protein, nu	7.9
	302235	AL049987	Hs.166361	Homo sapiens mRNA; cDNA DKFZp564F112 (fr	5.6
60		AW057736	Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.4
60		AA179949	MS.1/5563	Homo sapiens mRNA; cDNA DKFZp564N0763 (f ATP-binding cassette transporter MRP8	34.1 6.7
		AL117406		Homo sapiens mRNA full length insert cDN	4
		AL109712 Al678059		synaptonemal complex protein 2	4,3
	302304	AJ224172		lipophilin B (uteroglobin family member)	13.8
65		AW192334	Hs.38218		9.6
05		AI038997	Hs.132921	ESTs	5
		AF282265	Hs.44836	inner centromere protein antigens (135kD	3.4
	552501				

	302892	AW176909	Hs.42346	calcineurin-binding protein calsarcin-1	3.4
	302970	W05608	Hs.312679	ESTs, Weakly similar to A49019 dynein he	5.1
		AA652687	Hs.96151	Human DNA sequence from clone RP5-1103G7	3.7
_		AL121460	Hs.272673	hypothetical protein FLJ20508	4.1
5		AW006352		ESTs, Weakly similar to T32554 hypotheti	4.2
		AA355607		ESTs, Weakly similar to putative WHSC1 p	4.3
		AA367699	Hs.10082	potassium intermediate/small conductance	3.3
		AW299459	II- 4000E	gb:xs50d08.x1 NCI_CGAP_Kid11 Homo sapien	4.2
10		A1424014	Hs.18995	KIAA1304 protein	3.6
10		AW629759	Un 00007	gb:hh70e05.y1 NCI_CGAP_GU1 Homo sapiens	4.9
		R53434	Hs.90207	hypothetical protein MGC11138	3.7
		AA149951	Hs.62112	zinc finger protein 207	3 4.1
		AA582081 AA876109		gb:nn32h08.s1 NCI_CGAP_Gas1 Homo sapiens	3
15		AA876469		gb:nx24h01.s1 NCI_CGAP_GC3 Homo sapiens gb:oe48b04.s1 NCI_CGAP_Pr25 Homo sapiens	3.1
13		AI140014		gb:ga68f09.x1 Soares_fetal_heart_NbHH19W	3.5
		Al144243		gb:qb85b12.x1 Soares_fetal_heart_NbHH19W	3.9
		AI476803		gb:ti77e12.x1 Soares_NSF_F8_9W_OT_PA_P_S	4.3
		AI581398	Hs.172928	collagen, type I, alpha 1	4.6
20		AK000142		hypothetical protein FLJ23045	4.4
		Al951118		Homo sapiens breast cancer antigen NY-BR	17.3
		AW024348		EST, Weakly similar to A27217 glucose tr	3.2
		AW168083	*-	gb:xg59g04.x1 NCI_CGAP_Ut4 Homo sapiens	3.1
	309583	AW170035	Hs.326736	Homo sapiens breast cancer antigen NY-BR	57.6
25	310064	Al199712		ESTs, Weakly similar to 1917210A Pro/Arg	4.6
	310098	Al685841	Hs.161354	ESTs	3.6
	310438	AW022192	Hs.200197		4.6
		Al939456	Hs.160870		3.2
20		AK000703		Homo sapiens mRNA for KIAA1551 protein,	3.6
30		Al380797	Hs.158992		10,2
•• ,		Al955121		N-acetylgalactosamine-4-O-sulfotransfera	3.4
		A1476732	Hs.263912		10.9
		Al671439		Homo sapiens mRNA for KIAA1657 protein,	3.1
35 -		AI821005	Hs.118599		10.8
33.		AA641098 AI758660	Hs.206132	ESTs, Moderately similar to ALU1_HUMAN A	4.3 4.4
		Al828254		ESTs, Weakly similar to A47582 B-cell gr	5.1
		AW023595	Hs.232048		5.8
		AA700870	Hs.14304		3.3
40		AI056769	Hs.133512		3.9
		R12375	Hs.194600		3,3
	311889	AA767342		ESTs, Weakly similar to PSF_HUMAN PTB-AS	3
	311913	Al358522	Hs.270188		3
	311923	T60843	Hs.189679	ESTs	5.6
45	311935	AA216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
		AA373630	Hs.188750		3
		AA759263	Hs.14041	ESTs	3.4
		T78968	Hs.14411	ESTs	3.5
50		T80177		similar to rat nuclear ubiquitous casein	3.8
50		AI633744		ESTs, Weakly similar to I38022 hypotheti	4.4
		BE261944		hexokinase 1	5.2
		T92251	Hs.198882		3.3
		T94344 AA700439	Hs.326263		3.3 3.4
55		AW438602	Hs.188490		3.9
33	212133	H73505	Hs.191179 Hs.117874		4
		AA315703		ESTs, Weakly similar to ALUB_HUMAN III!	4.9
		AA972712	Hs.269737		5.7
		AA516420		ESTs, Weakly similar to I38022 hypotheti	6.3
60		AW439195	Hs.256880	ESTs, Weakly similar to S65657 alpha-1C-	4.9
••		AW291545	Hs.185018		4.9
		AW292286	Hs.255058		4.4
		AA497043	Hs.115685		3.1
		Al422023	Hs.161338	ESTs	4.3
65	313079	N76497	Hs.1787	proteolipid protein 1 (Pelizaeus-Merzbac	3.3
		AF026944	Hs.293797	ESTs	5.8
	313096	AW073310	Hs.163533	Homo sapiens cDNA FLJ14142 fis, clone MA	4.5

	313126	AA746503	Hs.283313	FSTs	10
		AI801098	Hs.151500		3.5
		AW979008	Hs.222487		3.3
		AW960454	Hs.222830		4.7
5		Al420611	Hs.127832		3.4
•		AW449211		GDNF family receptor alpha 1	12.4
		AW150945	Hs.144758		4.1
		AI032087	Hs.269819		
		AI674685	Hs.200141	=	5.2
10		AA741151	Hs.137323		3.5
10		W92070	1 13. 131 323	gb:zh48g05.r1 Soares_fetal_liver_spleen_	3.7
		Al273419	He 1351/6	hypothetical protein FLJ13984	3
		AA046309	113.155140	gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	5.6
		Al540978	He 301007	hypothetical protein FLJ13033	3.2
15		C18863		Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
10		AW175896	Hs.65114		3
		AI535895	Hs.221024		4.9
		AV657317		hypothetical protein MGC3077	3.9
		AA827082	Hs.291872		3.1
20		AW129357	Hs.329700		8.3
20	-	AA648744	Hs.269493		6.6
		A1732083	Hs.187619		6.2
		AA228366	Hs.115122		4
		AA740616	ПS. 115 122		5.9
25		AA740616 AA743396	Un 400000	gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	3.1
23			Hs.189023 Hs.103238		4
		AL036450 Al280112			8
			Hs.192425	Homo sapiens cDNA FLJ13266 fis, clone OV	3.7
		A1697901			3.3
30		AA907153	Hs.190060		
30		AW961597		ESTs, Moderately similar to 138022 hypot	4.2
		A1660412	Hs.234557		3.3
		AA602917	Hs.156974		4.7
		AA833655		Homo sapiens cDNA FLJ14056 fis, done HE	8.5
35		A1204418	Hs.190080		4
33		AW007211		hypothetical protein FLJ12876	3.4
		AA399272	Hs.144341	•	6.7
		A1873274	Hs.190721		27.4
		AA425310	MS.155/66	ESTs, Weakly similar to A47582 B-cell gr	4.4
40		AW979268	11 400040	gb:EST391378 MAGE resequences, MAGP Homo	
40		AW207206	Hs.136319		20.7
		AA457367	Hs.191638		3.6
		AW026761	Hs.134374		3.6
		BE350122		ESTs, Weakly similar to I78885 serine/th	4.9
45		AW971198	Hs.294068		4.3
43		A1095087		ESTs, Moderately similar to S65657 alpha	3.7
		AA828032	Hs.189076		3.1
		AW972359	Hs.293334		3
		AI538613		Transmembrane protease, serine 3	10.9
50		AA533447	Hs.312989		5.3
50		AW292425	Hs.163484		12.9
		AA551104		ESTs, Moderately similar to ALUC_HUMAN I	5.8
		AW452948	Hs.257631		4.2
		AA744550	Hs.136345		3.7
		AI025842	Hs.152530		6
55		AW136134	Hs.220277		3.9
		AI241331		ESTs, Moderately similar to 138937 DNA/R	4.4
		Al367347	Hs.44898	Homo sapiens done TCCCTA00151 mRNA sequ	8.2
		AI741506		ESTs, Weakly similar to ALU1_HUMAN ALU S	3.6
		R38772		myelin transcription factor 1-like	3.4
60		AW510994	Hs.220740		3.4
		Al222165	Hs.144923	=	4.9
		AA876905	Hs.125286		4
		AB037745		KIAA1324 protein	4.7
		AA218940	Hs.137516	fidgetin-like 1	3.1
65		AI378817	Hs.191847		3.1
		AA628539	Hs.116252	ESTs, Moderately similar to ALU1_HUMAN A	3.2
	315526	Al193043	Hs.128685	ESTs, Weakly similar to T17226 hypotheti	4.1
				•	

	245520	AUMO4E #4E	Un 427700	CCT-	9.0
		AW015415	Hs.127780		8.9
		AA737415	Hs.152826		5.5
		AA837085	Hs. 220585	ESTs	6.3
_	315647	AA648983	Hs.212911	ESTs	3.6
5	315707	A1418055	Hs.161160	ESTs	5.1
		AW515373		Homo sapiens cDNA FLJ13580 fis, clone PL	3.1
		AW270550	Hs.116957		3.8
		AA737345	Hs.294041		5
1.0		AA683336	Hs.189046		3.1
10	315977	AW865916	Hs.151206	ESTs	4.7
	315978	AA830893	Hs.119769	ESTs	4.1
	315995	Al217477	Hs.194591	ESTs	4.1
		AA764950	Hs.119898		7
		A1469960	Hs.170698	=	4.9
15					
15		A1962796	Hs.136754		4.1
		AW517524		NOD2 protein	3.2
	316074	AW975114	Hs.293273	ESTs	3.8
	316100	AW203986	Hs.213003	ESTs	3.2
	316133	AI187742	Hs.125562	ESTs	3.7
20		Al904982	-	ESTs, Moderately similar to ALU1_HUMAN A	30.7
20		AI433540	113,233 102		3.1
			11- 004000	gb:ti69g05.x1 NCI_CGAP_Kid11 Homo sapien	
		AI640761	Hs.224988		3.5
		AA740994	Hs.209609	ESTs	3.8
	316313	AA741300	Hs.202599	ESTs, Weakly similar to I38022 hypotheti	4.4
25	316364	AA747807	Hs.149500	ESTs	3.2
		AA938198		poly(A) polymerase gamma	9.4
		AW293174	Hs.252627		4.4
		AI440266			3
				ESTs, Weakly similar to T24832 hypotheti	
20		AI660898	Hs.195602		3.2
30		A1954880	Hs.134604	— ; · -	3.2
	316886	AA836331	Hs.134981	ESTs ·	4.4
	316897	AA838114	Hs.221612	ESTs	3.7
	316943	AW014875	Hs.137007	ESTs	4.6
		Al732892	Hs.190489		5.9
35 ·		AW445167	Hs.126036		4.1
"				_	
		AI125252	Hs.126419		3.5
		A1806867	Hs.126594		5.1
	317452	AA972965	Hs.135568	ESTs	6.9
	317501	AI822034	Hs.137097	ESTs	4.6
40	317674	AW294909	Hs.132208	ESTs	4.3
		AW664964	Hs.128899		6.1
		X56348		ret proto-oncogene (multiple endocrine n	3.1
		AI681545		hypothetical protein FLJ13117	3.4
15		AI827248		Homo sapiens cDNA FLJ11469 fis, clone HE	9.6
45	317902	AW102941	Hs.211265	ESTs	4.1
	317916	AI565071	Hs.159983	ESTs	10.3
	318042	AW294522	Hs.149991	ESTs	3.1
	318223	AI077540	Hs.134090	ESTs	3.9
		AW294013	Hs.200942		3
50		AI093930			4.4
50				Homo sapiens cDNA: FLJ21000 fis, clone C	
		AF107493	ns.110490	Homo sapiens LUCA-15 protein mRNA, splic	5.4
		AW402677		RNA binding motif protein, X chromosome	4.4
		AA526235	Hs.193162	Homo sapiens cDNA FLJ11983 fis, clone HE	5.9
	318634	T49598	Hs.156832	ESTs	4
55	318740	NM_002543	Hs.77729	oxidised low density lipoprotein (lectin	7.3
		AI793124	Hs.144479		17.8
	318781		Hs.6818	ESTs	3
	-		Hs.79414	prostate epithelium-specific Ets transcr	3.6
		NM_012391			
60		AI524124	Hs.270307		4.6
60		W88532	Hs.254562	ESTS	3.3
	319551	AA761668		gb:nz24c08.s1 NCI_CGAP_GCB1 Homo sapiens	3.2
	319745		Hs.108258	actin binding protein; macrophin (microf	3.3
		AA071267		gb:zm61g01.r1 Stratagene fibroblast (937	6.2
	319840		Hs.164259		3.3
65		AA534222	. 10. 107200	gb:nj21d02.s1 NCI_CGAP_AA1 Homo sapiens	4.3
0.5	21007/	A A 2014CC	Un 070000		
	320074	AA321166	Hs.278233		. 3.4
	320167	AA984373	Hs.90790	Homo saplens cDNA; FLJ22930 fis, clone K	4.1

	320187	T99949	Hs.303428	Homo sapiens cDNA FLJ14832 fis, clone OV	5.3
		AL039402		DEME-6 protein	9.2
	320416	AI026984	Hs.293662	ESTs	3.1
_		U78082		RNA polymerase II transcriptional regula	3.1
5		N50617 .		small nuclear ribonucleoprotein polypept	6.1
		AI160015	Hs.118112		3.5 3
		AI601188 AA214584	Hs.120910 Hs.290167		3.7
		Al359144		Homo sapiens cDNA: FLJ23031 fis, clone L	3.1
10		BE144167	Hs.49994	hypothetical protein similar to RNA-bind	3.3
		AI732643	Hs.144151		12.3
		AI769410	Hs.221461		3.3
		AA610649	Hs.333239		3
15		AB033041		vang (van gogh, Drosophila)-like 2	3.9
13		Al432199 AW975944	Hs.247084 Hs.237396		3 11.7
		A1471598	Hs.197531		3.8
	_	U29112	Hs.196151		4.4
		D80630		qb:HUM091D02B Human fetal brain (TFujiwa	3.2
20	321828	R59890	Hs.83623	nuclear receptor subfamily 1, group I, m	3.1
	321910	H67065	Hs.271530	ESTs, Weakly similar to ALU7_HUMAN ALU S	4.7
		AL049351		Homo sapiens mRNA; cDNA DKFZp566C093 (fr	3.5
		N77342	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	5
25		AL137517	HS.3344/3	hypothetical protein DKFZp564O1278 gb:Homo sapiens full length insert cDNA	19 3.6
25		AF075083 BE265745	He 194359	ESTs, Weakly similar to ALUC_HUMAN !!!!	3.0
		W76326	113.104000	gb:zd60d04.r1 Soares_fetal_heart_NbHH19W	4.4
		Al357412	Hs.157601		11.5
	322476	AW963372	Hs.46677	PRO2000 protein	3
30		T55958		gb:yb35f05.r1 Stratagene fetal spleen (9	3
		AF147347		gb:Homo sapiens full length insert cDNA	4.2
		AF155108	Hs.256150 Hs.118394	Homo sapiens, Similar to RIKEN cDNA 2810	4 5.4
		W92147 AA017656	ns.110394	gb:ze39h01.r1 Soares retina N2b4HR Homo	3.1
35		AW068805	Hs 288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.2
-		AW043782	Hs.293616		7.6
		AW248508		Homo sapiens cDNA FLJ14035 fis, clone HE	5.9
	322975	C16391		gb:C16391 Clontech human aorta polyA mRN	16.5
40		Al902456		ESTs, Weakly similar to I38022 hypotheti	4
40		AK002088		Homo sapiens cDNA FLJ11226 fis, clone PL	3.3
		AL120862		programmed cell death 9 (PDCD9)	6.3 4.6
		AW675572 AL133990	Hs.193620 Hs.190642		10.5
		AI829520	113.100042	gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens	6.2
45		AV651680	Hs.208558		4.3
		Al655499	Hs.161712	ESTs	9.2
		AW445014	Hs.197746		3.1
		BE081058	Hs.243023		4
50		AA317962	Hs.249721 Hs.97600	ESTs, Moderately similar to PC4259 femi	3 3.2
50		AW961560 AA410943	HS.97000	ESTs BMP-R1B	8.4
		AL043683	Hs.8173	hypothetical protein FLJ10803	3.3
		AI825204	Hs.211408		4.5
		AL044949	Hs.116298		4.5
55		AI472078	Hs.303662		8.4
		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	49.4
		AA431159	Hs.122954		3
		AI524039	Hs.192524		3 3.3
60		AA642007 AA464510	Hs.116369 Hs.152812		3.3 16.5
00		AI823969	Hs.132678		3.3
		AW972227		Homo sapiens cDNA: FLJ22765 fis, clone K	5
		AW993522	Hs.292934		10.4
	324631	AA937116		ESTs, Weakly similar to I54374 gene NF2	3.3
65	324716	BE169746	Hs.12504		3.2
	324748	AW974941		ESTs, Weakly similar to 178885 serine/th	3
	324771	AA631739	Hs.335440	ESI	3

5	324774 AI031771 324823 AW516704 324824 AI826999 324826 AA704806 324961 AA613792		ESTs ESTs ESTs, Weakly similar to 2004399A chromos gb:no97h03.s1 NCI_CGAP_Pr2 Homo saplens	4.2 3.4 3.1 4.4 3.9	
	324987 Al375572 324994 Al805416 325146 Al064690	Hs.172634 Hs.213897 Hs.171176	ESTs ESTs	18.8 3.3 4.2	
10	325372 325544 327075		Phase 2 & 3 Exons	4.4 5.7 3.8	
15	332798 334223 334447	•	C22000007:gi 12314195 emb CAB99338.1 (A NM_005080*:Homo sapiens X-box binding pr NM_012429*:Homo sapiens SEC14 (S. cerevi	4.3 26.2 3.9	
13	335809 335824 338255 409430 R21945	He 166075	NM_014509*:Homo sapiens kraken-like (BK1 ENSP00000249072*:DJ222E13.1 (N-TERMINAL NM_014323*:Homo sapiens zinc finger prot splicing factor, arginine/serine-rich 5	10.1 20 9 4	
20	428046 AW812795 432558 R97268 436808 AA731602		ESTs, Moderately similar to I38022 hypot ESTs	4.6 3.2 3.9	
	448569 BE382657 453542 AW836724 M97935	Hs.21486		4.1 3.7 3.2	
25	M97935 M55150 M13755		AFFX control: STAT1 furnarylacetoacetate interferon stimulated protein; 15 kDa	3 3 4.5	
30	Al052047 AA252033 AA401739		ESTs ESTs; Weakly similar to IIII ALU SUBFAMILY J ESTs	6.7 3.2 3.3	
	H18459 R48744 M31682		hepatocellular carcinoma associated protein; ESTs inhibin; beta B (activin AB beta polypeptide)	3 4.2 3	
35	AA416873 D80240 R49590		ESTs HUM5G11A Human fetal brain (TFujiwara) Homo ESTs	3 4 3.2	
40			CH22_FGENES.678_5 CH22_FGENES.619_7 CH22_FGENES.619_12	16.8 12.9 11.3	
40			CH22_EM:AC005500.GENSCAN.127 9 CH22_EM:AC005500.GENSCAN.304 2 CH22_FGENES.271_8 CH22_FGENES.619_13	9.2 8.5 8.4 8	
45			CH22_FGENES.271_7 CH22_FGENES.617_7 CH.07_hs gil6004473	7.3 7.2 7.1	
	X03363		CH22_FGENES.264_1 HER2 receptor tyrosine kinase (c erbB 2; ERBB2; CH22_FGENES.617_9	6.8	
50	•		CH.07_hs gij5868264 CH.19_hs gij5867439 CH22_FGENES.6 3	5.8 5.7 5.3	
55			CH.17_hs glj5867230 CH.20_hs gij6552458 CH22_EM:AC005500.GENSCAN.148 22	5.1 5.1 4.7	
	AA034918		CH22_FGENES.669_10 KIAA1028 protein CH22_FGENES.48_12 CH22_FGENES.118_2	4.6 4.6 4.5 4.5	
60	AF049569 M13955		CH22_FGENES.110_2 ESTs multiple UniGene matches CH22 FGENES.619_8	4.4 4.3 4.3	
65	HG4126 HT43	396	CH22_FGENES.13.7 CH22_FGENES.360_3	4.3 Zinc Finger Protein Hzf4 4.3	4.3
			CH22_FGENES.706_9 CH.21_hs gi 6531965	4.3 4.2	

		CH.17_hs gi 5867215	4.1	
		CH22_FGENES.669_8	4.1 Collagen, Type Viii, Alpha 1 4.1	
	HG2614 HT2710	0.100 -0.51.1-0 40 40	00.mg-1, 1, 1 - 1 - m, 1 - m - 1 - 1	
_		CH22_FGENES.48_18	4.1	
5	X83535	matrix metalloproteinase 14 (membrane inserted)	4	
		CH22_FGENES.271_6	3.9	
		CH22_FGENES.617_3	3.9	
		CH22_FGENES.290_8	3.8	
10	HG4716 HT5158		Guanosine 5' Monophosphate Synthase	3.8
10		CH22_FGENES.13 5	3.8	
		CH22_FGENES.13 2	3.8	
		CH.14_hs gi 6682474	3.8	
		CH.02_hs gi 5867750	3.8	
1.5		CH22_FGENES.617_8	3.7	2.7
15	HG4677 HT5102		Oncogene Ret/Ptc2, Fusion Activated	3.7
		CH22_DJ32I10.GENSCAN.23 39	3.7	
		CH22_FGENES.543_20	3.7	
		CH22_EM:AC005500.GENSCAN.96 1	3.7	
		CH22_FGENES.204_2	3.5	
20		CH22_FGENES.619_4	3.5	
		CH.16_hs gi 5867087	3.5	
	AA714311	EST cluster (not in UniGene)	3.4	
		CH22_EM:AC005500.GENSCAN.1499	3.4	
		CH22_EM;AC005500.GENSCAN.421 5	3.4	
25		CH22_FGENES.13 4	3.3	
		CH.07_hs gi 6004478	3.3	
		CH22_FGENES.360_1	3.3	
	HG2465 HT4871		Dna Binding Protein Ap 2, Alt. Splice 3	3.3
		CH22_FGENES.6_2	3.3	
30		CH22_C20H12.GENSCAN.16 2	3.2	
		CH22_C65E1.GENSCAN.8 1	3.2	
	AA707750	ESTs; Weakly similar to cis Golgl matrix	3.1	
		CH22_FGENES.307_4	3.1	
		CH22_EM:AC005500.GENSCAN.248 14	3.1	
35		CH.06_hs gi 5902482	3.1	
		CH22_FGENES.669_5	3.1	
		CH22_DJ32I10,GENSCAN.19 8	3.1	
		CH22_FGENES.527_6	3.1	
		CH22_FGENES.330_10	3.1	
40		CH22_FGENES.14 2	3.1	
	AA976074	ESTs	3	
		CH22_FGENES.226 7	3	
		CH22_FGENES.13 3	3	
		CH22_EM:AC005500.GENSCAN.209 12	3	
45	•	CH22_FGENES.271_3	3	

TABLE 17A

Table 17A shows the accession numbers for those pkeys lacking unigeneID's for Table 17. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

```
Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number
```

_ Accession:

Genbank accession numbers

15

```
Pkey
               CAT number Accession
        116845 393481_1
                            AA649530 AA659316 H64973
20
        103207 30635_-4
                            X72790
                            N99638 AW973750 AA328271 H90994 AA558020 AA234435 N59599 R94815
        126257 182217_1
                            AF080229 AF080231 AF080230 AF080232 AF080233 AF080234 BE550633 Al636743 AW614951 BE467547 Al680833
        102791 37186_1
                            AI633818 N29986 U87592 U87593 U87590 U87591 S46404 U87587 AA463992 AW206802 AI970376 AI583718 AI672574
                            N25695 AW665466 Al818326 AA126128 Al480345 AW013827 AA248638 Al214968 AA204735 AA207155 AA206262 AA204833
25
                            AW003247 AW496808 Al080480 Al631703 Al651023 Al867418 AW818140 AA502500 Al206199 Al671282 Al352545 BE501030
                            AIG52535 BE465762 AA206331 AW451866 AA471088 AA206342 AA204834 AA206100 AW021661 AA332922 N66048
                            AA703396 H92278 AW139734 H92683 U87589 U87595 H69001 U87594 BE466420 AI624817 BE466611 AI206344 AA574397
                            AA348354 AI493192
        126872 142696_1
                            AW450979 AA136653 AA136656 AW419381 AA984358 AA492073 BE168945 AA809054 AW238038 BE011212 BE011359
30
                            BE011367 BE011368 BE011362 BE011215 BE011365 BE011363
        112631 1746257 1
                            R82040 R70934
        120742 176835_1
                            AA225084 AA302713
                            Al311928 AA936030 T51931 AA609816 AA487195 AA664207
        106864 324239_1
        109700 genbank_F09609
                                     F09609
35
        111532 genbank_R08440
                                     R08440
        113938 genbank_W81598
                                      W81598
        113947 genbank_W84768
                                     W84768
        124357 genbank_N22401
                                     N22401
        108733 504187_1
                           AA121022 AA126422
40
        112303 genbank_R54797
                                     R54797
                           AF075083 H52291 H52528
        322136 46802_1
        322296 47334 1
                            W76326 AF086341 W72300
                            D80630 D80896 D80895
        321811 1527481_1
                            AW979268 AA878419 AA431342 AA431628
       314648 293660_1
45
        322520 38916_1
                            T55958 T57205 AF147346
        322521 38917_1
                            AF147347 T55426 T55503
       322675 86787_1
                            AA017656 AA017374 AA019761
                            AI829520 AI791832 AA228414 AI791823 AA229211 AA229315
        323332 179142 1
                            AI433540 AA728984 AA804981
       316186 425440_1
50
        322975 1510563_1
                            C16391 C16413
        324261 273265_1
                            BE069341 AW748403 AL044891 Al908240 AA393080
                            AA410943 AW948953 AA334202 AA332882
        323817 233566_1
       301976 128835_1
                            T97905 AA101672
                            AA613792 AW182329 T05304 AW858385
       324961 376239_1
55
        303642 284260_1
                            AW299459 AA417112
        303797 386364_1
                            AW629759 AW749955 AA633408 AI651005
       319551 357371_1
                            AA761668 AA573621 R92814 R09670
       311935 174129_1
                            AA216387 T63548 AA228676
                            AA071267 T65940 T64515 AA071334
       319834 112523_1
60
                            AA534222 AA632632 T81234
       319977 345248_1
       314138 179960_1
                            AA740616 AA654854 AA229923
       313591 103087_1
                            AA046309 Al263500 AA046397
```

```
308106 Al476803
338255 CH22_6856FG__LINK_EM:AC00
335809 CH22_3181FG_617_6_LINK_EM
335824 CH22_3197FG_619_11_LINK_E

5 307010 Al140014
307041 Al144243
305913 AA876109
305917 AA876469
309574 AW168083

10 325372 c12_hs
325544 c12_hs
325784 C12_hs
32798 CH22_14FG_6_5_LINK_C4G1.G
334223 CH22_1507FG_360_4_LINK_EM
327075 c21_hs
15 334447 CH22_1746FG_387_7_LINK_EM
304782 AA582081
304782 AA582081
313434 441798_1 W92070 AW019952 W92053
```

TABLE 17B

Table 17B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 17. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
	Strand; Nt_position:	entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15	Pkey	Ref	Strand	Nt_position
	334447	Dunham, I. et.al.	Plus	14308764-14308824
	335809	Dunham, I. et.al.	Plus	26310772-26310909
20	335824	Dunham, I. et.al.	Plus	26376860-26376942
	332798	Dunham, I. et.al.	Minus	232147-231974
	334223	Dunham, I. et.al.	Minus	12734365-12734269
	338255	Dunham, I. et.al.	Minus	15242294-15242231
	325372	5866920	Minus	1117061-1117304
25	325544	6682452	Plus	171228-171286
	327075	6531965	Plus	4041318-4041431

PCT/US02/02242 WO 02/059377

TABLE 18: Table 2 from BRCA 014 P

Table 18 shows genes with atleast five times the expression in breast tumor tissue than is expressed in normal body tissues.

10

5

Unique Eos probeset identifier number Exemplar Accession number, Genbank accession number Unigene number

Pkey: ExAcon: UnigeneID: Unigene Title: R1:

Unigene gene title Ratio of tumor to normal body tissue

15	Pkey	ExAccn	UnigenelD	Unigene Title	R1
	101378	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	5,3
	101530	M29874	Hs.1360	cytochrome P450, subfamily IIB (phenobar	9
	101767	M81057	Hs.180884	carboxypeptidase B1 (tissue)	12
20	101878	M97815	Hs.183650	cellular retinoic acid-binding protein 2	6.5
	103010	X52509	Hs.161640	tyrosine aminotransferase	12.4
	104115	AF183810	Hs.26102	opposite strand to trichorhinophalangeal	7.6
	104825	AA035613	Hs.141883	ESTs	6.9
		AW963419		stannlocalcin 2	5.3
25		AA011449		ESTs	6.1
		AB033064		KIAA1238 protein	7.3
		Al791493	Hs.129873	ESTs, Weakly similar to A36036 cytochrom	8.2
		R82331	Hs.164599	ESTs	5.4
20		BE262470		RNB6	6.2
30		W27249	Hs.8109	hypothetical protein FLJ21080	6.9
		AI733881	Hs.72472	BMP-R1B	10.1
		N92293	Hs.206832	ESTs, Moderately similar to ALU8_HUMAN A	19.7
		AW449064		collagen, type III, alpha 1 (Ehlers-Dani	8.4
25		M31669	Hs.1735	inhibin, beta B (activin AB beta polypep	5.6
35		AF182277		cytochrome P450, subfamily IIB (phenobar	6.2 6.2
		AI908165	Hs.169946	GATA-binding protein 3 (T-cell receptor	5.8
		D89377	Hs.89404	msh (Drosophila) homeo box homolog 2 solute carrier family 30 (zinc transport	9.9
		AW183618 AA312082		GDNF family receptor alpha 1	5.7
40		AB020711		KIAA0904 protein	7.7
40			Hs.222399	CEGP1 protein	7.3
			Hs.323910	HER2 receptor tyrosine kinase (c-erb-b2,	5.4
			Hs.175563	Homo sapiens mRNA; cDNA DKFZp564N0763 (-
		AL117406		ATP-blnding cassette transporter MRP8	6.7
45		AJ224172		lipophilin B (uteroglobin family member)	13.8
		AI951118	Hs.326736	Homo sapiens breast cancer antigen NY-BR	17.3
			Hs.326736	Homo sapiens breast cancer antigen NY-BR	57.6
	310781		Hs.158992	ESTs	10.2
		AI821005	Hs.118599	ESTs	10.8
50		AA216387		gb:nc16b02.s1 NCI_CGAP_Pr1 Homo sapiens	5.2
		BE261944	Hs.118625	hexokinase 1	5.2
			Hs.105445	GDNF family receptor alpha 1	12.4
	313915	C18863	Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	26.3
	314097	AA648744	Hs.269493	ESTs	6.6
55	314138	AA740616		gb:ny97f11.s1 NCI_CGAP_GCB1 Homo sapiens	5.9
	314506	AA833655	Hs.206868	Homo sapiens cDNA FLJ14056 fis, clone HE	8.5
	314558	AI873274	Hs.190721	ESTs	27.4
	314691	AW207206	Hs.136319	ESTs	20.7
		AI538613	Hs.298241	Transmembrane protease, serine 3	10.9
60			Hs.312989	ESTs	5.3
			Hs.163484	ESTs	12.9
	315060	AA551104	Hs.189048	ESTs, Moderately similar to ALUC_HUMAN I	5,8

315196 Al367347 Hs.44898 315530 AW015415 Hs.127780 315634 AA837085 Hs.220585 ESTs 6.3 316012 AA764950 Hs.119898 ESTs 7 316177 Al904982 Hs.293102 ESTs, Moderately similar to ALU1_HUMAN A 30.7 316580 AA938198 Hs.146123 poly(A) polymerase gamma 9.4 317803 AW664964 Hs.128899 ESTs 6.1 317881 Al827248 Hs.224398 Homo sapiens cDNA FLJ11469 fis, clone HE 9.6 318740 NM_002543Hs.77729 Oxidaed low density lipoprotein (lectin 7.3 318744 Al793124 Hs.144479 ESTs 17.8 320211 AL039402 Hs.125783 DEME-6 protein 9.2 321107 Al732643 Hs.144151 ESTs 12.3 321644 AW975944 Hs.237396 ESTS 11.7 321978 N77342 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT 5 321978 N77342 Hs.234473 Homo sapiens cDNA FLJ12280 fis, clone MA 5.2 322818 AW043782 Hs.293616 ESTs gb:C16391 Clontech human aorta polyA mRN 16.5 322975 C16391 Hs.190642 ESTs gb:w119c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 323332 Al829520 323317 AAA10943 gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTs 16.5 324598 AW972227 Hs.163986 Homo sapiens cDNA; FLJ122765 fis, clone K 5
5 316012 AA764950 Hs.119898
5 316177 Al904982 Hs.293102 STs, Moderately similar to ALU1_HUMAN A 30.7 poly(A) polymerase gamma 9.4 s17881 Al827248 Hs.128899 Hs. 128498 Homo sapiens cDNA FLJ11469 fis, clone HE 9.6 oxidlsed low density lipoprotein (lectin 7.3 s18740 Al793124 Hs.144479 STs 125783 DEME-6 protein 9.2 s21107 Al732643 Hs.144151 SSTs 12.3 s21644 AW975944 Hs.237396 Hs. 125783 DEME-6 protein 9.2 s21978 N77342 Hs.1851 Homo sapiens cDNA FLJ12900 fis, clone NT 5 Homo sapiens cDNA FLJ12900 fis, clone NT 5 Homo sapiens cDNA FLJ1280 fis, clone MA 5.2 STS 12.3 s22035 AL137517 Hs.334473 Hs.288467 322818 AW043782 Hs.293616 322975 C16391 S22975 C16391 S23332 Al829520 323332 Al829520 323817 AA410943 SDM-R1B GESTS 10.5 gb:w1l9c06.x1 NCl_CGAP_Ut1 Homo sapiens 6.2 SBM-R1B gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 SETS 16.5
316580 AA938198 Hs.146123 poly(A) polymerase gamma 9.4 317803 AW664964 Hs.128899 ESTs 6.1 Homo sapiens cDNA FLJ11469 fis, clone HE 9.6 oxidised low density lipoprotein (lectin 7.3 18744 AI793124 Hs.144479 ESTs 17.8 20211 AL039402 Hs.125783 DEME-6 protein 9.2 321107 AI732643 Hs.144151 ESTs 12.3 321644 AW975944 Hs.237396 ESTs 12.3 321644 AW975944 Hs.237396 ESTs 11.7 Homo sapiens cDNA FLJ12900 fis, clone NT 5 17.8 322035 AL137517 Hs.334473 hypothetical protein DKFZp564O1278 19 322766 AW068805 Hs.288467 Homo sapiens cDNA FLJ12280 fis, clone MA 5.2 ESTs 7.6 322818 AW043782 Hs.293616 322975 C16391 323262 AL133990 Hs.190642 ESTs 9b:C16391 Clontech human aorta polyA mRN 16.5 ESTs 10.5 gb:W19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 BMP-R1B gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTS 16.5
316580 AA938198 Hs.146123 317803 AW664964 Hs.128899 317881 AI827248 Hs.224398 318740 NM_002543Hs.77729 318744 AI793124 Hs.144479 320211 AL039402 Hs.125783 321617 AI732643 Hs.144151 321978 N77342 Hs.244151 321978 N77342 Hs.248151 322035 AL137517 Hs.334473 322766 AW068805 Hs.288467 322818 AW043782 Hs.293616 322975 C16391 323262 AL133990 Hs.190642 20 323332 AI829520 323817 AA410943 324426 BE069341 324432 AA464510 Hs.152812 31788 Hs.12899 STs
317803 AW664964 Hs.128899 317881 Al827248 Hs.224398 318740 NM_002543Hs.77729 318744 Al793124 Hs.144479 ESTs 17.8 320211 AL039402 Hs.125783 DEME-6 protein (lectin 7.3) 321107 Al732643 Hs.144151 ESTs 12.3 321644 AW975944 Hs.237396 321978 N77342 Hs.21851 Hs.21851 322035 AL137517 Hs.334473 322766 AW068805 Hs.288467 322818 AW043782 Hs.293616 322975 C16391 323262 AL133990 Hs.190642 323332 Al829520 323817 AA410943 324261 BE069341 324432 AA464510 Hs.152812 BSTs 6.1 Homo sapiens cDNA FLJ12900 fis, clone NT 5 hypothetical protein DKFZp564O1278 19 Homo sapiens cDNA FLJ12280 fis, clone MA 5.2 ESTs 7.6 gb:C16391 Clontech human aorta polyA mRN 16.5 ESTs 10.5 gb:W19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 BMP-R1B gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812
318740 NM_002543Hs.77729 oxidised low density lipoprotein (lectin 7.3 318744 AI793124 Hs.144479 ESTs 17.8 320211 AL039402 Hs.125783 DEME-6 protein 9.2 321107 AI732643 Hs.144151 ESTs 12.3 321644 AW975944 Hs.237396 ESTs 12.3 321644 AW975944 Hs.237396 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT 5 17 hypothetical protein DKFZp564O1278 19 322035 AL137517 Hs.334473 Homo sapiens cDNA FLJ12280 fis, clone NA 5.2 22818 AW043782 Hs.293616 322975 C16391 S23262 AL133990 Hs.190642 ESTs 7.6 323332 AI829520 Sphw19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 BMP-R1B gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTS 16.5
10 318744 AI733124 Hs. 144479 320211 AL039402 Hs. 125783 DEME-6 protein 9.2 321107 AI732643 Hs. 144151 ESTs 12.3 321644 AW975944 Hs. 237396 STS 11.7 321978 N77342 Hs. 21851 Homo saplens cDNA FLJ12900 fis, clone NT 5 1202035 AL137517 Hs. 334473 hypothetical protein DKFZp564O1278 19 Homo saplens cDNA FLJ12280 fis, clone MA 5.2 ESTs 22818 AW043782 Hs. 293616 322975 C16391 S23262 AL133990 Hs. 190642 ESTs 10.5 gb:C16391 Clontech human aorta polyA mRN 16.5 ESTs 10.5 gb:W19c06.x1 NCI_CGAP_Ut1 Homo saplens 6.2 323817 AA410943 BMP-R1B gb:CV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs. 152812 ESTS 16.5
320211 AL039402 Hs.125783 DEME-6 protein 9.2 321107 AI732643 Hs.144151 ESTs 12.3 321644 AW975944 Hs.237956 321978 N77342 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT 5 322035 AL137517 Hs.334473 Homo sapiens cDNA FLJ12280 fis, clone NT 5 15 322766 AW068805 Hs.288467 322818 AW043782 Hs.293616 322975 C16391 Gb.216391 Clontech human aorta polyA mRN 323262 AL133990 Hs.190642 ESTs 10.5 323332 AI829520 323332 AI829520 323817 AA410943 BMP-R1B gb:04/3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTs 16.5
321107 Al732643 Hs.144151 SSTs 12.3 321644 AW975944 Hs.237396 Hs.21851 Hs.237396 S32935 AL137517 Hs.33473 322736 AW068805 Hs.288467 Homo sapiens cDNA FLJ12900 fis, clone NT 5 hypothetical protein DKFZp564O1278 19 Homo sapiens cDNA FLJ12280 fis, clone MA 5.2 SSTs 232818 AW043782 Hs.293616 322975 C16391 S32362 AL133990 Hs.190642 SSTs 9b:C16391 Clontech human aorta polyA mRN 16.5 ESTs 10.5 gb:w19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 BMP-R1B gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTS 16.5
321107 Al732643 Hs.144151 SSTs 12.3 321644 AW975944 Hs.237396 Hs.24851 Hs.237396 321978 N77342 Hs.21851 Homo sapiens cDNA FLJ12900 fis, clone NT 5 hypothetical protein DKFZp564O1278 19
15 321978 N77342 Hs.21851 Hs.334473 322766 AW068805 Hs.288467 322818 AW043782 Hs.293616 322975 C16391 Js.22975 C16391 Hs.190642 ESTs 7.6 gb:C16391 Clontech human aorta polyA mRN 16.5 ESTs 7.6 gb:W19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 BMP-R1B 8.4 gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTs 16.5
15 322035 AL137517 Hs.334473 hypothetical protein DKFZp564O1278 19 322766 AW068805 Hs.288467 322818 AW043782 Hs.293616 322975 C16391 gb:C16391 Clontech human aorta polyA mRN 16.5 apt:C16392 AL133990 Hs.190642 ESTs gb:C16391 Clontech human aorta polyA mRN 10.5 apt:w119c06.x1 NCl_CGAP_Ut1 Homo sapiens 6.2 BMP-R1B gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 apt:C16392 BT0381 Homo 49.4 apt:C16
15 322035 AL137517 Hs.334473 hypothetical protein DKFZp564O1278 19 322766 AW068805 Hs.288467 322818 AW043782 Hs.293616 322975 C16391 gb:C16391 Clontech human aorta polyA mRN 16.5 apt:C16391 Clontech human aorta polyA mRN 16.5 apt:C16391 Clontech human aorta polyA mRN 16.5 apt:W19c06.x1 NCl_CGAP_Ut1 Homo sapiens 6.2 apt:W19c06.x1
322818 AW043782 Hs.293616 322975 C16391 gb:C16391 Clontech human aorta polyA mRN 16.5 323262 Al.133990 Hs.190642 ESTs 10.5 323332 Al829520 gb:w19c06.x1 NCl_CGAP_Ut1 Homo sapiens 6.2 323817 AA410943 BMP-R1B gb:CV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTs 16.5
322818 AW043782 Hs.293616 322975 C16391 gb:C16391 Clontech human aorta polyA mRN 16.5 323262 Al.133990 Hs.190642 ESTs 10.5 323332 Al829520 gb:w19c06.x1 NCl_CGAP_Ut1 Homo sapiens 6.2 323817 AA410943 BMP-R1B gb:CV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTs 16.5
20 32332 AL133990 Hs.190642 ESTs gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 8.4 324261 BE069341 gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 2432 AA464510 Hs.152812 ESTs 16.5
20 323262 AL133990 Hs.190642 ESTs gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 gb:wl19c06.x1 NCI_CGAP_Ut1 Homo sapiens 6.2 8.4 324261 BE069341 gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 2432 AA464510 Hs.152812 ESTs 10.5
323817 AA410943 BMP-R1B 8.4 324261 BE069341 gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTs 16.5
324261 BE069341 gb:QV3-BT0381-270100-073-c08 BT0381 Homo 49.4 324432 AA464510 Hs.152812 ESTs 16.5
324432 AA464510 Hs.152812 ESTs 16.5
324432 AA464510 Hs.152812 ESTs 16.5
324598 AW972227 Hs.163986 Homo sapiens cDNA: FLJ22765 fis, clone K 5
25 324603 AW993522 Hs.292934 ESTs 10.4
324987 Al375572 Hs.172634 ESTs 18.8
325544 Phase 2 & 3 Exons 5.7
330388 Hs.46 HER2 receptor tyrosine kinase (c-erb-b2, 6.6
334223 NM_005080*:Homo sapiens X-box binding pr 26.2
30 335809 NM_014509*:Homo sapiens kraken-like (BK1 10.1
335824 ENSP00000249072*:DJ222E13.1 (N-TERMINAL 20
AI052047 ESTs; Weakly similar to CYTOCHROME P450 6.7
R72427 CH22_EM:AC005500.GENSCAN.127 9 5.5
CH22_FGENES.619_13 9.2
35 CH22_FGENES.617_9 8
CH22_FGENES.271_7 6.5
CH22_FGENES.619_7 7.3
CH22_FGENES.271_8 12.9
01122_FGENEG.271_0 12.9
CH22 FGENES.619 12 8.4
CH22_FGENES.619_12 8.4
CH22_FGENES.619_12 8.4 40 CH22_EM:AC005500.GENSCAN.304 2 11.3 CH.07_hs gl 6004473 8.5 CH22_FGENES.617_7 7.1
CH22_FGENES.619_12 8.4 40 CH22_EM:AC005500.GENSCAN.304 2 11.3 CH.07_hs gl 6004473 8.5

TABLE 18A

Table 18A shows the accession numbers for those pkeys lacking unigeneID's for Table 18. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number
 Accession:	Genbank accession numbers

15

	Pkey	CAT number	Accession
	323332	179142_1	Al829520 Al791832 AA228414 Al791823 AA229211 AA229315
20	322975	1510563_1	C16391 C16413
	324261	273265_1	BE069341 AW748403 AL044891 Al908240 AA393080
	323817	233566 1	AA410943 AW948953 AA334202 AA332882
	311935	174129 1	AA216387 T63548 AA228676
	314138	179960 1	AA740616 AA654854 AA229923
25	335809	CH22 3181FG	617_6_LINK_EM
			619_11 LINK E
		c12 hs	• • • • • • • • • • • • • • • • • • •
			360 4 LINK EM

TABLE 18B

Table 18B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 18. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also 5 listed.

10	Pkey: Ref: Strand: Nt_posit	Sequen er Indicate	ce source. 1 ntitled "The I s DNA stran	esponding to an Eos probeset The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495. d from which exons were predicted. positions of predicted exons.
	Pkey	Ref	Strand	Nt_position
20	335824 334223	Dunham, I. et.al. Dunham, I. et.al. Dunham, I. et.al. 6682452	Plus	26310772-26310909 26376860-26376942 12734365-12734269 171228-171286

TABLE 19: 1045 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES

5 Table 19 shows 1045 genes up-regulated in breast cancer compared to normal adult tissues. These were selected from 59680 probesets on the Affymetrix/Eos-Hu03 GeneChip array such that the ratio of "average" breast cancer to "average" normal adult tissues was greater than or equal to 2.5. The "average" breast cancer level was set to the 90th percentile value. The "average" normal adult tissue level was set to the 90th percentile value amongst 144 non-malignant tissues. In order to remove gene-specific background levels of non-specific 10

mailgnant dissues. In order to remove gene-specific background levels of non-specific
hybridization, the 15 th percentile value amongst the 144 non-malignant tissues was subtracted
from both the numerator and the denominator before the ratio was evaluated.

15	Pkey:	Unique Eos probeset identifier number
	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number
	Unigene Title:	Unigene gene title

Ratio of turnor to normal body tissue 20

	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
	408591	AF015224	Hs.46452	mammaglobín 1	137.6
25	406964	M21305		gb:Human alpha satellite and satellite 3	71.0
	400291	AA401369	Hs.190721	ESTs	68.4
	407277	AW170035		Homo sapiens breast cancer antigen NY-BR	54.2
		Al668594	Hs.176588	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	
••		BE069341		gb:QV3-BT0381-270100-073-c08 BT0381 Homo	
30		AA250737	Hs.72472	BMP-R1B	37.4
	427585		Hs.179729	collagen, type X, alpha 1 (Schmid metaph	32.9
		AW138959	Hs.245123		31.9
		AA195651	Hs.104106		30.4
25	407377			gb:C16391 Clontech human aorta polyA mRN	27.7
35	450705		Hs.25351	iroquois homeobox protein 5	24.8
		AA412108		ESTs	22.0
		NM_000230	Hs.194236	leptin (murine obesity homolog)	21.9
	404561			trichorhinophalangeal syndrome I (TRPS1)	21.8
40		AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
40		Al375572	Hs.172634		17.3
		AA009647	Hs.8850	a disintegrin and metalloproteinase doma	16.6
	422109		Hs.1473	gastrin-releasing peptide	16.5
		AW840171	Hs.265398	ESTs, Weakly similar to transformation-r	16.0
		AI263307		H2B histone family, member L	15.8
45	420813		Hs.99949	prolactin-induced protein	15.8
		AI267700	Hs.317584		15.5
		AL120862		programmed cell death 9 (PDCD9)	14.8
		AI905687	Hs.2533	aldehyde dehydrogenase 9 family, member	14.5
50	423575		Hs.163443	Homo sapiens cDNA FLJ11576 fis, clone HE	13.7
50		AJ224172	Hs.204096		13.6
		AL133990	Hs.190642		13.5
		AB014544	Hs.21572	KIAA0644 gene product	13.0
		AA399272	Hs.144341		12.8
	402578			C1001134:gi]2117372[pir][65981 fatty ac	12.6
55		AA436989		H2A histone family, member A	12.2
	424634	NM_003613	Hs.151407		12.0
	456207	AA193450		gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	11.9
		Al351010	Hs. 102267	lysyl oxidase	11.9
	459587	AA031956		gb:zk15e04.s1 Soares_pregnant_uterus_NbH	11.5

		AW291168	Hs.41295	ESTs, Weakly similar to MUC2_HUMAN MUCIN	11.5
	429170	NM_001394	Hs.2359	dual specificity phosphatase 4	11.5
		Al951118	Hs.326736	Homo sapiens breast cancer antigen NY-BR	11.4
_	434377	AW137148	Hs.306593	Homo sapiens cDNA FLJ11382 fis, clone HE	11.3
5		AL035414	Hs.21068	hypothetical protein	11.1
		NM_007115	Hs.29352	tumor necrosis factor, alpha-induced pro	11.0
		AI684808	Hs.197653	programmed cell death 9 (PDCD9)	10.9
		N78223	Hs.108106	transcription factor	10.7
	443348	AW873596	Hs.182278	calmodulin 2 (phosphorylase kinase, delt	10.6
10		H87879	Hs.102267	lysyl oxldase	10.5
	402606			NM_024626:Homo sapiens hypothetical prot	10.4
		AA576953	Hs.22972	hypothetical protein FLJ13352	10.4
		AI370413	Hs.36563	hypothetical protein FLJ22418	10.3
1.5		Al357412	Hs.157601		10.2
15		W72838	Hs.2533	aldehyde dehydrogenase 9 family, member	10.1
		NM_002497		NIMA (never in mitosis gene a)-related k	10.1
		AW292425	Hs.163484		9.9
		AI873274	Hs.190721		9.9
20		H23789	Hs.144530		9.8
20		BE218705		metallothionein-like 5, testis-specific	9.7
		D90041		N-acetytransferase 1 (arylamine N-acety	9.7
		W20027	Hs.23439	ESTS	9.6
		AL360204	Hs.170042	Homo sapiens mRNA full length insert cDN	9.6
25		A1624342 A1907673	⊓\$.17004Z	qb:IL-BT152-080399-004 BT152 Homo sapien	9.5 9.3
23		AI267652	Hs.30504	•	
		AJ224741	Hs.278461	Homo saplens mRNA; cDNA DKFZp434E082 (fr	9.1
		Al127076		hypothetical protein DKFZp564O1278	9.1
		D60730	Hs.57471	ESTs	9.1
30		AA410943	113.01411	gb:zt32h03.r1 Soares ovary turnor NbHOT H	9.1
-	406348	701710040		Target Exon	9.0
		U31875	Hs 272499	short-chain alcohol dehydrogenase family	9.0
		U23752	Hs.32964	SRY (sex determining region Y)-box 11	9.0
		AF026944	Hs.293797		8.8
35	405654			C12001521:gi 7513934 pir T31081 cca3 pr	8.8
	418601	AA279490	Hs.86368	calmegin	8.8
	451110	A1955040	Hs.265398	ESTs, Weakly similar to transformation-r	8.7
	408771	AW732573	Hs.47584	potassium voltage-gated channel, delayed	8.5
	409041	AB033025	Hs.50081	KIAA1199 protein	8.4
40	442353	BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	8.3
	451561	N52812	Hs.177403	ESTs.	8.2
	424001	W67883		paternally expressed 10	8.2
		NM_007050		protein tyrosine phosphatase, receptor t	8.1
15		AL080207	Hs.134585	DKFZP434G232 protein	8.1
45	405095			Target Exon	8.1
		AA236115	Hs.120785		8.0
		AF026941	Hs.17518	Homo sapiens cig5 mRNA, partial sequence	8.0
		BE242870 AW876523	Hs.75379	solute carrier family 1 (glial high affi	8.0
50	415385		Hs.15929	hypothetical protein FLJ12910	8.0 7.9
50		AI811202	Hs.7535	COBW-like protein Homo sapiens cDNA: FLJ23523 fis, clone L	7.9 7.9
		AF044197		small inducible cytokine B subfamily (Cy	7.9
		M31126	Hs.272620	•	7.8
	400285		113.272020	The state of the s	7.7
55	437207		Hs.15929		7.6
•••		AW880562	Hs.114574		7.5
		AW976987			7.5
	433426		Hs.133525	·	7.5
		Al222020			7.4
60		H59846	Hs.128355		7.4
		Al380797	Hs. 158992		7.3
		AA948033	Hs.130853		7.2
	439569	AW602166	Hs.222399	CEGP1 protein	7.2
	414142	AW368397			7.1
65		AW242243			7.0
		AK001468	Hs.62180		6.9
	445885	AI734009	Hs.127699	KIAA1603 protein	6.9

	429432	Al678059	He 202676	synaptonemal complex protein 2	6.9
		Al375672	Hs.165028		6.9
		Al732643	Hs.144151		6.9
		AA808229	Hs.167771		6.8
5		Al793124	Hs.144479		6.8
,	404253	A1733124	ע נדדרו יטוו	NM_021058*:Homo sapiens H2B histone fami	6.8
	_	Al015591	He 131004	ESTs, Weakly similar to T17227 hypotheti	6.7
		AW963419		stanniocalcin 2	6.6
		AA321649	Hs.2248	small inducible cytokine subfamily B (CX	6.6
10		BE545072		hypothetical protein FLJ10461	6.6
- 0		AW818127	113.122010	gb:CM1-ST0277-061299-059-b07 ST0277 Homo	
		Al418055	Hs.161160		6.6
		Al733682	Hs.130239		6.6
		Al970394	Hs.197075		6.6
15		L11690	Hs.620	bullous pemphigoid antigen 1 (230/240kD)	6.5
		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	6.5
		BE041395		ESTs, Weakly similar to unknown protein	6.5
		X03635	Hs.1657	estrogen receptor 1	6.5
		AW023482	Hs.97849	ESTs	6.5
20		U79293		Human done 23948 mRNA sequence	6.4
		W29092	Hs.7678	cellular retinoic acid-binding protein 1	6.4
		NM_003866		inositol polyphosphate-4-phosphatase, ty	6.4
		AW004854		hypothetical protein FLJ23537	6.4
		AL137517		hypothetical protein DKFZp564O1278	6.2
25		NM_014398	Hs.10887	similar to lysosome-associated membrane	6.1
-		AA586894	Hs.112408	\$100 calcium-binding protein A7 (psorias	6.1
		Al240665	Hs.8895	ESTs	6.1
		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; inters	6.0
	441233	AA972965	Hs.135568		6.0
30	418092	R45154	Hs.106604	ESTs	6.0
	430044	AA464510	Hs.152812	ESTs	5.9
	432837	AA310693	Hs.87329	HSPC072 protein	5.9
	433285	AW975944	Hs.237396	ESTs	5.9
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	5.9
35	425707	AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	5.9
	410785	AW803341		gb:(L2-UM0079-090300-050-D03 UM0079 Homo	5.9
	425398	AL049689	Hs.156369	hypothetical protein similar to tenascin	5.9
		X72755	Hs.77367	monokine induced by gamma interferon	5.8
40		R20991		gb:yg06h01.r1 Soares infant brain 1NIB H	5.8
40		N28519		ESTs, Weakly similar to unnamed protein	5.8
		AL031224	Hs.33102	transcription factor AP-2 beta (activati	5.8
		W52854	Hs.27099	hypothetical protein FLJ23293 similar to	5.7
		AW162916		hypothetical protein PRO2577	5.7
A =		Al733881	Hs.72472	BMP-R1B	5.6
45		AW016531	Hs.122147		5.6
•		AW067903	Hs.82772	collagen, type XI, alpha 1	5.5
		AA463893	Hs.220933		5.5
		R41396		hypothetical protein FLJ23045	5.5
50		AW299598	Hs.50895	homeo box C4	5.4
50		AW748078		ESTs, Weakly similar to MUC2_HUMAN MUCIN	
		AI742605	Hs.193696		5.4
		AL121278	Hs.25144	ESTS	5.4
		BE246919	Hs.10290	U5 snRNP-specific 40 kDa protein (hPrp8-	5.4
55		BE167434	Hs.98471	ESTs, Weakly similar to T18712 hypotheti	5.4
55		AI879148	Hs.26770	fatty acid binding protein 7, brain	5.4
		AW067800		stanniocalcin 2	5.3
		AA291553	Hs. 190086		5.3
		AW970060	11- 40000	gb:EST382140 MAGE resequences, MAGK Hom	
60		AA421081	Hs.12388	ESTs	5.3
00	452838		Hs.30743	preferentially expressed antigen in mela	5.3
		AB028945	Hs.12696	cortactin SH3 domain-blnding protein	5.3
	456938			tyrosine aminotransferase	5.3
	422867		Hs.1584	cartilage oligomeric matrix protein (COM	5.2
65		R28363	Hs.24286	ESTs hypothetical protein MGC14801	5.2
05		AW207084		ESTs, Moderately similar to ALU8_HUMAN A	5.2 5.2
		N92293	Hs.79136	LIV-1 protein, estrogen regulated	5.2
	410276	U41060	110.13130	Erver protein, estrogen regulateu	J.2

	400300	X03363		HER2 receptor tyrosine kinase (c-erb-b2,	5.2
		U37519	Hs.87539	aldehyde dehydrogenase 3 family, member	5.2
		AW449211		GDNF family receptor alpha 1	5.2
		AB028992		KIAA1069 protein	5.2
5		AW852530		gb:PM1-CT0243-071099-001-g06 CT0243 Homo	5.2
		AW851980	Hs.262346	ESTs, Weakly similar to S72482 hypotheti	5.2
		AI916269		ESTs, Weakly similar to ALU5_HUMAN ALU S	5.1
		AA032279	Hs.61635	six transmembrane epithelial antigen of	5.1
		Al283133	Hs.297420		5.1
10	427666	Al791495	Hs.180142	calmodulin-like skin proteln	5.1
	427718	Af798680	Hs.25933	ESTs	5.1
	434531	AA642007	Hs.116369	ESTs	5.1
	429220	AW207206	Hs.136319	ESTs	5.1
	405494	NA		C2001837*:gij12697903 dbj BAB21770.1 (A	5.1
15	452930	AW195285	Hs.194097	ESTs, Weakly similar to I38022 hypotheti	5.1
	444910	AJ201849		gb:qs76g04.x1 NCI_CGAP_Pr28 Homo sapiens	5.1
	453310	X70697	Hs.553	solute carrier family 6 (neurotransmitte	5.0
	444381	BE387335	Hs.283713	ESTs, Weakly similar to S64054 hypotheti	5.0
	450603	R43646	Hs. 12422	ESTs	5.0
20	416575	W02414	Hs.38383	ESTs	5.0
	438504	AW665281	Hs.224625	ESTs	5.0
	416209	AA236776	Hs.79078	MAD2 (mitotic arrest deficient, yeast, h	5.0
		AK000713		hypothetical protein FLJ20706	5.0
~ ~		AW512260	Hs.87767	ESTs	4.9
25		X82125	Hs.25040	zinc finger protein 239	4.9
		AJ003029	Hs.65792	syntrophin, gamma 2	4.9
		M30703		amphiregulin (schwannoma-denved growth	4.9
		AI655499	Hs.161712		4.8
20		A1820662	Hs.129598		4.8
30		AF220050	Hs.181385	uncharacterized hematopoletic stem/proge	4.8
	400286			C16000922:gi 7499103 pir T20903 hypothe	4.8
		U71600	Un 100070	gb:Human zinc finger protein zfp31 (zf31	4.8 4.8
		A!831190	Hs.166676 Hs.202656	— - · ·	4.8
35		BE218239 Al217477	Hs.194591		4.8
55		AW997556	Hs.78521	KIAA1717 protein	4.8
		BE440042	Hs.83326	matrix metalloproteinase 3 (stromelysin	4.7
		AI349764	Hs.217081		4.7
		AA191493	Hs.48778	niban protein	4.7
40	400284		110.10710	estrogen receptor 1	4.7
		AW248508	Hs.279727	Homo sapiens cDNA FLJ14035 fis, clone HE	4.7
		R42185	Hs.274803		4.7
		BE062109		chloride channel, calcium activated, fam	4.7
		AW961489	Hs.154116		4.7
45		NM_003462	Hs.33846	dynein, axonemal, light intermediate pol	4.7
		AF077345	Hs.177936		4.6
	421751	AW813731	Hs.159153	ESTs, Moderately similar to S65657 alpha	4.6
	454074	R63503	Hs.28419	ESTs	4.6
	405718			C4000799*:gi[6330365 dbj[BAA86508.1] (AB	4,6
50	444649	AW207523	Hs.197628		4.6
	429431	Z40313		Homo saplens clone IMAGE:23371, mRNA seq	4.6
		M81057	Hs.180884	carboxypeptidase B1 (tissue)	4.6
		AI199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	4.6
		AK000282	Hs.239681	hypothetical protein FLJ20275	4.6
55		AW855717		gb:RC1-CT0279-081299-013-b01 CT0279 Homo	
		AA242758	Hs.79136	LIV-1 protein, estrogen regulated	4.6
		AA808189	Hs.272151	ESTS	4.6
		AW936273		gb:QV0-DT0020-090200-107-g07 DT0020 Homo	
60		AL036877	Hs.282878		4.6
60		AA514660	Hs.128443		4.6
		H15261	Hs.21948	ESTS	4.6 4.6
		AW246333	Hs.17901	Homo sapiens, clone IMAGE:3937015, mRNA,	4.5
		AJ245671	Hs.12844	EGF-like-domain, multiple 6 (EGFL6) hypothetical protein FLJ20086	4.5
65		AW966399	Hs.46821	Homo sapiens cDNA FLJ11346 fis, done PL	4.5
UJ		W68815	113.30 1003	gb:UI-HF-BN0-akx-e-02-0-UI.rl NIH_MGC_50	4.5
		AW503329	He 217/02	annexin A2	4.5
	400/4/	AI925153	115.2 1/483	GILIGAIII AZ	7.5

	£12102	H56435		gb:yq98e09.r1 Soares fetal liver spleen	4.5
		D89053	⊔ e 268012	fatty-acid-Coenzyme A ligase, long-chain	4.5
		AW814902	113.200012	qb:MR1-ST0206-120400-022-f08 ST0206 Homo	
	401418			C14000338*:gi[7459502 pir S74665 outer	4.5
5		AK001074	Hc 223/35	Homo sapiens cDNA FLJ10212 fis, clone HE	4.5
,		AK001581		hypothetical protein FLJ10719; KIAA1794	4.4
		AA135257	Hs.47783		4.4
		AA335497		B aggressive lymphoma gene ESTs, Weakly similar to I38022 hypotheti	4.4
		AW419196		hypothetical protein FLJ13782	4.4
10		AW664964	Hs.128899		4.4
10		BE463857			4.4
				hypothetical protein FLJ21062	4.4
		R31178	⊓S.207 02U	fibronectin 1	
	-	AW905138		gb:QV0-NN1071-280400-207-g07 NN1071 Home	
15	405196		U. 220004	C2000662*:gi 7512792 pir T12482 hypothe	4.4 4.4
13		N47863	U8.33090 I	ribosomal protein S24	4.4
	401793	A B 204000		C17001545:gi 5360127 gb AAD42882.1 AF155	
		AA381209	11- 404454	gb:EST94257 Activated T-cells I Homo sap	4.4
		AB007975	MS.131454	KIAA0506 protein	4.4
20	400238		11- 007007	C19000274*:gi 12741327 ref XP_008833.2	4.4
20		AF019612	HS.29/00/	membrane-bound transcription factor prot	4.4
	400608	1) (0=7040	11 000000	C10001899:gi 7508633 pir T25392 hypothe	4.4
		AV657310	Hs.282898		4.3
		AL138272	Hs.62713	ESTs	4.3
25	405906	•		Target Exon	4.3
25	405925			Target Exon	4.3
		BE247684	Hs.103070		4.3
		H57646	Hs.42586	KIAA1560 protein	4.3
		N63855	Hs.142634	zinc finger protein	4.3
20		AA603305		gb:np12d11.s1 NCI_CGAP_Pr3 Homo sapiens	4.3
30	454359			gb:za36e03.s1 Soares fetal liver spleen	4.3
		AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto	4.2
		Al266484	Hs.31570	ESTs, Weakly similar to KIAA1324 protein	4.2
		AA291377	Hs.50831	ESTs	4.2
25		AA033714		hypothetical protein FLJ14260	4.2
35		NM_001898	Hs.123114	cystatin SN	4.2
		BE158766		gb:IL2-HT0397-071299-024-F02 HT0397 Homo	
		BE144884		gb:CM0-HT0182-041099-065-e11 HT0182 Homo	
		BE538082	Hs.8172	ESTs, Moderately similar to A46010 X-lin	4.2
40		AF123050	Hs.44532	diubiquitin	4.2
40	406992			gb:beta -pol=DNA polymerase beta (exon a	4.2
	404285			C6001909:gi[704441]dbj[BAA18909.1] (D298	4.2
		NM_005940		matrix metalloproteinase 11 (MMP11; stro	4.2
		AW812795		ESTs, Moderately similar to I38022 hypot	4.2
4.5		AA026880	Hs.25252	prolactin receptor	4.2
45		AW592167	Hs.293299		4.2
		Al908165		GATA-binding protein 3 (T-cell receptor	4.2
		AW821113	Hs.72402	ESTs	4.2
		AA024538		Human DNA sequence from clone RP1-28H20	4.2
50		AW378065	Hs.8687	ESTs	4.2
50		AI085198	Hs.164226		4.2
		AB007948		KIAA0479 protein	4.1
	424687			matrix metalloproteinase 9 (gelatinase B	4.1
		AA894564	Hs.22242	ESTs	4.1
		AA634806		gb:ab28c02.r1 Stratagene lung (937210) H	4.1
55		BE241831	Hs.172330		4.1
	450229		Hs.8929	hypothetical protein FLJ11362	4.1
		BE068115		gb:CM1-BT0368-061299-060-g07 BT0368 Homo	
		AK000850		Homo sapiens cDNA FLJ20843 fis, clone AD	4.1
	438885	Al886558	Hs.184987	=	4.1
60	401451			NM_004496*:Homo sapiens hepatocyte nucle	4.1
		A1685464		gb:tt88f04.x1 NCI_CGAP_Pr28 Homo sapiens	4.1
		A1735283	Hs.172608		4.1
		W60379	Hs.57773	ESTs	4.1
		A1220547	Hs.135223		4.1
65	427122	AW057736		HER2 receptor tyrosine kinase (c-erb-b2,	4.1
	410275	U85658	Hs.61796	transcription factor AP-2 gamma (activat	4.1
	432912	BE007371	Hs.200313	ESTs	4.1

	102505			T1 F	
	403585	A1004454	11- 07000		4.1
		AI394151	Hs.37932 Hs.102406	ESTS	4.1 4.1
		AA640891 BE264901			4.1
5		NM_004354		carbonic anhydrase VIII	4.1
,		AA296520	Hs.79069 Hs.89546	·/ · · · · ·	4.1
	400555	AA230320	115.05540		4.1
		U94362	Hs.58589		4.0
		NM_003528	Hs.2178	H2B histone family, member Q	4.0
10		AA448460			4.0
		AL359055			4.0
		AL117406			4.0
	421296	NM_002666	Hs.103253		4.0
	418819	AA228776	Hs.191721	ESTs	4.0
15	424188	AW954552	Hs.142634		4.0
		AW938484		gb:CM0-DT0057-290200-253-d06 DT0057 Homo	
	404142			•	4.0
		Al027604	Hs.159650		4.0
20		Al693927	Hs.265165		4.0
20		AA165232	Hs.222069	·	4.0
		N75582	HS.2120/5	ESTs, Weakly similar to DYH9_HUMAN CILIA gb:601283601F1 NIH_MGC_44 Homo sapiens c	4.0
	452281	BE390440	Hs.28792		4.0
		AA417383	Hs.82582		4.0
25		AI281848			4.0
~	447377				4.0
		AL119723	110,000		4.0
	446140	AA356170	Hs.26750	hypothetical protein FLJ21908	4.0
	452240	Al591147	Hs.61232		4.0
30	459574	AI741122	Hs.101810		4.0
		N99626		•	4.0
		AI199738			4.0
		AI948607	Hs.264680		4.0
25		AF153330	Hs.30246		3.9
35		AA263143	Hs.24596	RAD51-interacting protein	3.9
	406554		Un 40472	Target Exon	3.9 3.9
	445813	AA573006	Hs.19173	ESTs alanine-glyoxylate aminotransferase 2-li	3.9
		AA442176	115.100370	gb:zw63b08.r1 Soares_total_fetus_Nb2HF8_	3.9
40		M86153	Hs.75618	RAB11A, member RAS oncogene family	3.9
	401781	11100100	10.,0010		3.9
	415296	F05086	Hs.328142	0 -	3.9
		AA026777		gb:ze93c11.r1 Soares_fetal_heart_NbHH19W	3.9
	442500	AI819068	Hs.209122	ESTs	3.9
45	419759	Z21336	Hs.135411	actin related protein	3.9
	424638	AI472106	Hs.49303	Homo sapiens cDNA FLJ11663 fis, clone HE	3.9
		AF086534			3.9
		AA419529	Hs.76391		3.9
50		AB037791	Hs.29716		3.9
50		BE537217	Hs.30343		3.9
		BE568414		•	3.9
		AI073512 BE152428	Hs.133916	gb:CM0-HT0323-151299-126-b04 HT0323 Homo	3.9
	401785	DE 132420			3.9
55		M86699	He 169840		3.9
-		Al989885	Hs.231926		3.9
	436033		Hs.255748	-	3.9
		BE172186	110.200. 10	gb:MR0-HT0559-110300-005-h11 HT0559 Homo	
		AA236645	Hs.98274		3.8
60	444635	AI184268	Hs.339665		3.8
	412140	AA219691	Hs.73625	•	3.8
	403593				3.8
		AW016669	Hs.29190		3.8
65		AW664873	Hs.87836		3.8
65		W02410	Hs.205555		3.8
		AI217928 AA503020	Hs.144762 Hs.36563		3.8
	403342	AA303020	110.00000	nypositional protein r cozzer to	J.U

	443162	T49951	Hs.9029	DKFZP434G032 protein	3.8
	458194	AW383618	Hs.265459	ESTs, Moderately similar to ALU2_HUMAN A	3.8
	422475	AL359938		Meis (mouse) homolog 3	3.8
	440705	AA904244	Hs.153205	ESTs	3.8
5	447290	Al476732	Hs.263912	ESTs	3.8
	403426			Target Exon	3.8
		AA470158	Hs.98202	ESTs	3.8
		BE222648		ESTs, Highly similar to c380A1.1b [H.sap	3.8
		AW206942	Hs.253594		3,8
10		AW105231	Hs.192035		3.8
		AW794600		gb:RC6-UM0014-170300-022-C05 UM0014 Hom	
		NM_005756	Hs.184942	G protein-coupled receptor 64	3.8
		BE622641	Hs.38489		3.8
		Al742618		ESTs, Weakly similar to nitrilase homolo	3.7
15	401747	7.11 42010	1101101100	Homo sapiens keratin 17 (KRT17)	3.7
10		NM_014581	Hs 274480	odorant-binding protein 2A	3.7
		AP000692		chromosome 21 open reading frame 5	3.7
		AB029496	Hs.59729	semaphorin sem2	3.7
		BE005346	Hs.116410		3.7
20		AK001666		similar to SALL1 (sal (Drosophila)-like	3.7
20		AA018534	Hs.103334		3.7
	402696		113,100004	C3002523:gi]6686211 sp Q27533 YH2M_CAEEL	
		AV660737	Hs,135100		3.7
		AW816379	Hs.335018		3.7
25				trinucleotide repeat containing 9	3.7
23		U80736 AB020689	Hs.90419		3.7
					3.7
		AA312082		GDNF family receptor alpha 1	3.7
		N62840	Hs.48648		3.7
20	401508		11- 04054	NM_024817:Homo sapiens hypothetical prot	3.7
30		AA324597	Hs.21851	Homo sapiens cDNA FLJ12900 fis, clone NT	3.7
		U79734	Hs.97206	huntingtin interacting protein 1	3.7
		Al021992	Hs.124244		
		AA629065	Hs.116301		3.7
25		R55373	Hs.20864	ESTs	3.7
35		BE623004		gb:601441282F1 NIH_MGC_72 Homo saplens c	
		Al347502		hypothetical protein FLJ20761	3.7
		T32982	Hs.102720		3.7
	405232		11 044550	NM_015832:Homo sapiens methyl-CpG bindin	3.7
40		AL109791	HS.241559	Homo sapiens mRNA full length insert cDN	3.7
40		BE011668		gb:CM3-BN0223-100500-177-a04 BN0223 Home	
		Al239923	Hs.30098	ESTs	3.7
		Al970797	Hs.64859	ESTs	3.7
		Al248584	Hs.190745	Homo sapiens cDNA: FLJ21326 fis, clone C	3.7
45	401049			Target Exon	3.6
45		D31771	Hs.89404	msh (Drosophila) homeo box homolog 2	3,6
		N74530	Hs.21168	ESTs	3.6
		AV658444		tankyrase, TRF1-interacting ankyrin-rela	3,6
		Al377755	Hs.120695		3.6
50		M97815	Hs.183650	cellular retinoic acid-binding protein 2	3.6
50		Al698839		gb.wd31f02.x1 Soares_NFL_T_GBC_S1 Homo s	
		AL120173	Hs.301663		3,6
		AW901456		gb:RC0-NN1012-270300-031-c07 NN1012 Home	
		AA352111		gb:EST60061 Activated T-cells XX Homo sa	3.6
		Al142095	Hs.143273	ESTS	3.6
55		BE164500		gb:RC4-HT0469-230300-014-e10 HT0469 Homo	
		AA157291	Hs.21479	ubinuclein 1	3.6
		AA062954	Hs.141883		3.6
		Y12735	Hs.38018	dual-specificity tyrosine-(Y)-phosphoryl	3.6
		AK000054	Hs.12347	hypothetical protein FLJ20047	3.6
60	404091			Target Exon	3.6
		AA125985	Hs.56145	thymosin, beta, identified in neuroblast	3.6
	405153			Target Exon	3,6
		AA380177	Hs.125845	ribulose-5-phosphate-3-epimerase	3.6
	403639	NA		ENSP00000233023*:CDNA FLJ12662 fis, clon	3.6
65	404360			C7001385:gi 12082809 gb AAG48618.1 AF315	3.6
		AA766296	Hs.99200	ESTs	3.6
	423338	AR007961	Hs.127338	KIAA0492 protein	3.6

	424202	BE350295	Hs.15032	RAN binding protein 17	3.6
		AA514986	Hs.283705		3.6
		AA853978	Hs.124577		3.6
_	453596	AA441838	Hs.62905	hypothetical protein FLJ14834	3.6
5	406446	NA		Target Exon	3.6
	418454	AA315308	Hs.195870	hypothetical protein FLJ14991	3.6
		AW015415	Hs.127780	ESTs	3.6
		W87707	Hs.82065	interleukin 6 signal transducer (gp130,	3.6
• •		Al697121		ESTs, Weakly similar to S65824 reverse t	3.6
10		AW291095	Hs.21814	interleukin 20 receptor, alpha	3.6
		AW297920	Hs.130054		3.5
		AW860158		gb:RC0-CT0379-290100-032-b04 CT0379 Homo	
		AW968226	Hs.60798	ESTs	3.5
15	402820	4444740	11-044744	NM_017646*:Homo sapiens tRNA isopenteryl	3.5
13		AA191719	Hs.314714		3.5
		AW393080 AI806335		hypothetical protein FLJ23537	3.5
		AA420683	Hs.98321	ESTs, Weakly similar to T30171 ninein -	3.5
		NM_015368	Hs.30985	hypothetical protein FLJ14103 pannexin 1	3.5 3.5
20	400610	_	113,30303	Target Exon	3.5
2.0		W07361	Hs.22545	Homo saplens cDNA FLJ12935 fis, done NT	3.5
		AW960146		hypothetical protein FLJ12888	3.5
		AI805416	Hs,213897		3.5
		NM_004272		Homer, neuronal immediate early gene, 1B	3.5
25		AW392342		centrosomal P4.1-associated protein; unc	3.5
		AW448937	Hs.197030		3.5
	423841	AW753967		gb:RC2-CT0304-080100-011-h12 CT0304 Homo	3.5
	416806	NM_000288	Hs.79993	peroxisomal biogenesis factor 7	3.5
••		R20893	Hs.325823		3.5
30		AL043002		ESTs, Moderately similar to unnamed prot	3.5
		H84847	Hs.49391	hypothetical protein LOC54149	3.5
		AW316843	Hs.66309	hypothetical protein MGC11061	3.5
		N32536	Hs.42645	solute carrier family 16 (monocarboxylic	3.5
35		AI917494 AI057094	Hs.9812 Hs.96867	Home saplens cDNA FLJ14388 fis, clone HE	3.5 3.5
55		Al370876	Hs.79090	Homo saplens cDNA: FLJ23155 fis, clone L exportin 1 (CRM1, yeast, homolog)	3.5
		AW850178	113.1 3030	gb:IL3-CT0219-271099-022-H12 CT0219 Homo	
		AA314337	Hs.301547	ribosomal protein S7	3.5
		AA877124	Hs.172844		3.5
40	431291		Hs.25275		3.5
		Al935016	Hs.216639		3.5
	455838	BE145808		gb:MR0-HT0208-101299-103-f11 HT0208 Homo	3.5
	458771	AW295151	Hs.163612	ESTs	3.5
	442942	AW167087	Hs.131562		3.5
45	436550			ESTs, Weakly similar to MMHUB1 laminin b	3.5
		AW474547	Hs.53565	Homo saplens PIG-M mRNA for mannosyltran	3.5
		BE614743		prostaglandin E synthase	3.5
		AW505021	Hs.88414	BTB and CNC homology 1, basic leucine zi	3.5
50		AI908400	Hs.143789		3.5
30		AF086224	Hs.55238		3.5
	405917	NA AW993582	Hs.176220		3.5 3.5
		W47595			3.4
		AA283185	Hs.19327	ESTs	3.4
55		AW904466			3.4
		BE252383		F	3.4
		BE064962		gb:RC1-BT0313-130400-016-c02 BT0313 Homo	
	410555		Hs.64311		3,4
	447754	AW073310	Hs.163533	Homo sapiens cDNA FLJ14142 fis, clone MA	3.4
60	418636	AW749855		gb:QV4-BT0534-281299-053-c05 BT0534 Homo	3.4
	404097			C5000242*:gi 9369379 gb AAF87128.1 AC006	3,4
		AF119861		hypothetical protein PRO2015	3.4
		AI215069	Hs.89113		3.4
65	402421			13-1	3.4
65	405248		Nº 334403		3.4
	407038	AJ404672 BE247275			3.4 3.4
	403000	DEZ41213	10,131/0/	оз эпглиг-араспіс рюшін, тто ко	J. 4

		AF038564	Hs.98074	itchy (mouse homolog) E3 ublquitin prote	3.4
	432239		Hs,2936	matrix metalloproteinase 13 (collagenase	3.4
		BE618395	Hs,257391	hypothetical protein DKFZp761J1523	3.4
_	442082		Hs.7413	ESTs; calsyntenin-2	3.4
5		AA210765		gb:zr90c06.r1 NCI_CGAP_GCB1 Homo sapiens	
		AI346468	Hs.145789		3.4
		AI613276	Hs.5662	guanine nucleotide binding protein (G pr	3.4
		AI247716 AA164366	Hs.232168	hypothetical protein FLJ23511	3,4 3,4
10		AI971313		KIAA0551 protein	3.4
10		AF102546	Hs.63931	dachshund (Drosophila) homolog	3.3
	405460		. 13.0000	Target Exon	3.3
		AW503603	Hs.129915	phosphotriesterase related	3.3
		AL037925		gb:DKFZp564M037_r1 564 (synonym: hfbr2)	3.3
15	447078	AW885727	Hs.301570		3.3
	441690	R81733	Hs.33106	ESTs	3.3
	420092	AA814043	Hs.88045	ESTs	3.3
	418478		Hs.1174	cyclin-dependent kinase Inhibitor 2A (me	3.3
20		BE296227		serine/threonine kinase 15	3.3
20		AI160386	Hs.125087		3.3
		AF055575		calcium channel, voltage-dependent, L ty	3.3
		NM_000685	Hs.89472	angiotensin receptor 1 Homo sapiens mRNA for partial 3'UTR, seq	3.3 3.3
		AA160079 AW503857	Hs.4007	Sarcolemmal-associated protein	3.3
25		NM_005982	Hs.54416	sine oculis homeobox (Drosophila) homolo	3.3
		AW138872	Hs.135288		3.3
		AA280627	Hs.57846	ESTs	3,3
		AA296961		gb:EST112514 Adrenal gland tumor Homo sa	3,3
		AI936450	Hs.147482		3.3
30	402892	NA		Target Exon	3.3
	426681	AA994896	Hs.22514	ESTs	3.3
		AA741545		ESTs, Weakly similar to T24961 hypotheti	3.3
	409430			splicing factor, arginlne/serine-rich 5	3.3
25		A1954968	Hs.279009	matrix Gla protein	3.3
35		AV653771	Hs.10592	gb:AV653771 GLC Homo sapiens cDNA clone	3.3
	406151	AA121686	ns. 10092	ESTs Target Exon	3.3
		AW511956	Hs.293261		3.3
		AW820260	113.200201	gb:QV2-ST0296-150200-040-c10 ST0296 Homo	
40	432415		Hs.289014	ESTs, Weakly similar to A43932 mucin 2 p	3.3
		AF086120	Hs.102793		3.3
	401575	NA		Target Exon	3.3
	420900	AL045633	Hs.44269	ESTs	3.3
	445628	Al344166	Hs.155743	ESTs	3.3
45		AW369771	Hs.52620	integrin, beta 8	3.3
		AW204610	Hs.22270	ESTs	3.3
		AA976718	Hs.202242		3.3
		AA206186	Hs.79889	monocyte to macrophage differentiation-a	3.3 3.3
50	451474	AW043921	Hs.130526 Hs.207636		3.2
50	442559			gycosyltransferase	3.2
		AI824009	Hs.44577	ESTs	3.2
	420036		Hs.52792	Homo sapiens mRNA; cDNA DKFZp586I1823 (f	
		W88774	Hs.118370	FOT.	3.2
55		BE336654	Hs.70937	H3 histone family, member A	3.2
	446733	AA863360	Hs.26040	ESTs, Weakly similar to fatty acid omega	3.2
	410153	BE311926	Hs.15830	hypothetical protein FLJ12691	3.2
	403637	NA		C3001106*:gi 10047201 dbj BAB13394.1 (A	3.2
CO	405547			NM_018833*:Homo saplens transporter 2, A	3.2
60	427878			CGI-07 protein	3.2
		AJ821005	Hs.118599		3.2
	410313		Hs.185683	ESTS, Weakly similar to I38022 hypotheti	3.2 3.2
		N27833 AI652777	Hs.197069		3.2
65		NM_004460	Hs.418	fibroblast activation protein, alpha	3.2
55		AI253123		ESTs, Highly similar to S21424 nestin [H	3.2
		N23235	Hs.30567	ESTs, Weakly similar to B34087 hypotheti	3.2

		H26735	Hs.91668	Homo sapiens clone PP1498 unknown mRNA	3.2
		AA489732	Hs.154918		3.2
	405394 424693	BE169810	Hs.47557	Target Exon ESTs	3.2 3.2
5		H03556		ESTs, Weakly similar to thyrold hormone	3.2
		AA765917	Hs.122840	ESTs	3.2
		AK000684		hypothetical protein FLJ22104	3.2
		AL121282 AW856552	Hs.257786	gb:RC1-CT0294-080100-012-a04 CT0294 Homo	3.2
10		NM_005429	Hs.79141	vascular endothelial growth factor C	3.2
		AA758239	Hs.180330		3.2
		A1249368 H38857	Hs.98558	ESTs Homo sapiens cDNA FLJ20738 fis, clone HE	3.2 3.2
		AI904743		hypothetical protein FLJ10292	3.2
15		AI016377	Hs.131693		3.2
		AB033052	Hs.22151	KIAA1226 protein	3.2
	419519	AI198719	Hs.176376	NM_014112*:Homo sapiens trichorhinophala	3.2 3.2
		AA326187	Hs.17170	G protein-coupled receptor 4	3.2
20	457473	AW974903	Hs.291231		3.1
		AW904907	Hs.30732	hypothetical protein FLJ13409; KIAA1711	3.1
	459702	AI204995 NA		gb:an03c03.x1 Stratagene schizo brain S1 NM_007057*:Homo saplens ZW10 Interactor	3.1 3.1
		AW408557	Hs.235498	hypothetical protein FLJ14075	3.1
25		AW974175	Hs.188751	ESTs, Weakly similar to MAPB_HUMAN MICRO	
		AA312735	Hs.30512	Homo saplens mRNA for KIAA0556 protein,	3.1 3.1
		AA701327 AA906366	Hs.17949 Hs.190535	ESTs FSTs	3.1
		D38122	Hs.2007	tumor necrosis factor (ligand) superfami	3.1
30		AW891294		solute carrier family 4, sodium blcarbon	3.1
	-	R82331 AI638627	Hs.164599		3.1 3.1
		AA503653			3.1
		AA339449	Hs.82285	phosphoribosylglycinamide formyltransfer	3.1
35		AA470519	I.). 47400	J	3.1
		BE327311 AW806906	Hs.47166	HT021 gb;QV4-ST0023-160400-172-d12 ST0023 Homo	3.1
		H15302	Hs.168950	Homo sapiens mRNA; cDNA DKFZp566A1046 (f	
40	405336			Target Exon	3.1
40		AI683150			3.1
		AI583052 BE160636	Hs.270058	qb:PM1-HT0422-291299-002-c08 HT0422 Homo	3.1 3.1
		AI768801	Hs.169943	Homo sapiens cDNA FLJ13569 fls, clone PL	3.1
15	405848			Target Exon	3.1
45		BE066976 M29994		gb:PM0-BT0340-211299-003-c12 BT0340 Homo gb:Human alpha-I spectrin gene, exon 12.	3.1 3.1
		W26713	Hs.256972		3.1
	423518				3.1
50		AI065104			3.1
50		BE165753 AA706910	Hs.112742		3.1 3.1
		AL050027	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:Homo sapiens mRNA; cDNA DKFZp566C0324	
		AI541305	Hs.48778		3.1
55		AW407181	Hs.218377		3.1
55		AF026942 AW807227		gb:MR4-ST0062-180200-001-e10 ST0062 Homo	3.1 3.1
		NM_002914	Hs.139226		3.1
	416790		Hs.7043		3.1
60		BE295866 W94997	Hs.94382 Hs.189917		3.1 3.1
	426968				3,1
-	457421	AL117431	Hs.112165	Homo sapiens cDNA FLJ12198 fis, clone MA	3.1
		BE466639	Hs.61779	Homo sapiens cDNA FLJ13591 fis, clone PL	3.1
65		AW138413 AA382814	ms.139336		3.1 3.1
0.0		AI248013	Hs.106532		3.1
		AW135274	Hs.12433		3.1

	446466	H38026	Hs.308	arrestin 3, retinal (X-arrestin)	3.1
		BE219794	Hs.293471		3.1
		AK001423	Hs.94694	Homo sapiens cDNA FLJ10561 fis, clone NT	3.0
_		AB033035	Hs.51965	KIAA1209 protein	3.0
5		BE153855	Hs.61460	lg superfamily receptor LNIR	3.0
		AA232658		UDP-glucose:glycoprotein glucosyltransfe	3.0
		AI830417	Hs.44143	polybromo 1	3.0
		N93266 AL133731	Hs.40747 Hs.4774	ESTs Homo sapiens mRNA; cDNA DKFZp761C1712 (f	3.0
10		NM_005357	Hs.95351	lipase, hormone-sensitive	3.0
	405609		113.50001	ENSP00000241065*:CDNA	3.0
	404274			NM_002944*:Homo sapiens v-ros avian UR2	3.0
		Al971362	Hs.231945		3.0
	415459	H07118	Hs.6099	ESTs ·	3.0
15		N59650	Hs.27252	ESTs	3.0
	406291			Target Exon	3.0
		BE383592		gb:601297871F1 NIH_MGC_19 Homo sapiens c	
		AW972359	Hs.293334		3.0
20		Al791988 N21043	Hs.129115 Hs.42932	ESTs	3.0 3.0
20		Al969716	Hs.13034	ESTs	3.0
		BE379727	Hs.83213	fatty acid binding protein 4, adipocyte	3.0
	401326			C10000447*:gi 1168375 sp P43467 AGA1_PED	
	409920	BE169746	Hs.12504	likely ortholog of mouse Arkadia	3.0
25	432887	Al926047	Hs.162859	ESTs	3.0
		AF245505	Hs.72157	DKFZP564I1922 protein	3.0
	401045			C11001883*:gi 6753278 ref NP_033938.1 c	3.0
		AA584062		hypothetical protein FLJ20413	3.0
30		AI221894 BE077155	Hs.39311	ESTs hypothetical protein DKFZp761B1514	3.0
50		AW958879	Hs.270535		3.0
		H91882		Dvl-binding protein IDAX (inhibition of	3.0
		NM_014711	Hs.279912	KIAA0419 gene product	3.0
	415542	R13474	Hs.290263	ESTs, Weakly similar to I38022 hypotheti	3.0
35		R52782		gb:yg99d09.r1 Soares infant brain 1NiB H	3.0
		AB014528	Hs.43133	KIAA0628 gene product	3.0
		AW004683	Hs.78934	mutS (E. coli) homolog 2 (colon cancer,	3.0
		AI754212	Hs.21951	Homo sapiens Xq pseudoautosomal region; Homo sapiens cDNA: FLJ21909 fis, clone H	3.0
40		AW021173 AW901879	Hs.18612 Hs.314453		3.0
40		D31118		hypothetical protein MGC10520	3.0
		AW294795	Hs.198529		3.0
	440310	AA878939	Hs.125406	ESTs	3.0
4.5		Al375957	Hs.289074	F-box only protein 22	3.0
45		AA281279	Hs.23317	hypothetical protein FLJ14681	3.0
		NM_014400	Hs.11950	GPI-anchored metastasis-associated prote	3.0
		AA701259 Al041793	Hs.189299 Hs.42502	ESTS	3.0
		BE175605	H5.42302	gb:RC5-HT0580-100500-022-H07 HT0580 Homo	
50		AW295923	Hs.255472	KIAA1843 protein	3.0
		M31659		solute carner family 25 (mitochondrial	3.0
	450382	AA397658	Hs.60257	Homo sapiens cDNA FLJ13598 fis, clone PL	3.0
		W01938	Hs.337243	ESTs, Weakly similar to ALU7_HUMAN ALU S	2.9
<i></i>		W57554		lymphoid nuclear protein (LAF-4) mRNA	2.9
55		U22376	Hs.1334	v-myb avian myeloblastosis viral oncogen	2.9
	445625	BE246743	HS.288529	hypothetical protein FLJ22635 C4001462:gi 4887715 gb AAA79329.2 (L088	2.9 2.9
		BE067650		qb;MR4-BT0358-090300-003-e01 BT0358 Homo	
		W87434	Hs 106015	ESTs, Moderately similar to ALU1_HUMAN A	2.9
60		BE568102	Hs.180312	mitochondrial ribosomal protein S16	2.9
		AI674818		Homo saplens cDNA FLJ11375 fis, done HE	2.9
	427315	AA179949	Hs.175563	Homo sapiens mRNA; cDNA DKFZp564N0763 (
		AW365665	Hs.120388		2.9
65		AI633559	Hs.310359		2.9
-65		N34128	Hs.145268		2.9
	402109	NA BE501732	Hs.30622	Target Exon Homo sapiens cDNA FLJ13010 fis, clone NT	2.9 2.9
	423023	0E301/32	113.50022	Fromo adpiena obraz i m rao to na, dione ra i	د.5

	442295	Al827248	Hs.224398	Homo sapiens cDNA FLJ11469 fis, clone HE	2.9
		AA249573			2.9
	404721				2.9
_		Al208121	Hs.147313		2.9
5	401987				2.9
		AA481282	Hs.190149		2.9
		A1939339	Hs.146883		2.9
		AW873606 AW194426	Hs.149006 Hs.20726		2.9 2.9
10		AI868634			2.9
10	401458	, ,	113.240000		2.9
		NM 003478	Hs.101299		2,9
	459504	BE514127		gb:601315974F1 NIH_MGC_8 Homo sapiens cD	2.9
	424962	NM_012288	Hs.153954		2.9
15		BE003760	Hs.55209	Homo sapiens mRNA; cDNA DKFZp434K0514 (f	
	416931		Hs.80485		2.9
		BE161151	11- 50440	gb:PM0-HT0425-141299-001-F08 HT0425 Homo	
		NM_016122	Hs.56148	NY-REN-58 antigen gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	2.9
20		AA743991 AI193043	Ue 420605		2.9
20		Z45439	Hs.270425		2.9
	421379				2.9
		AF015592	Hs.28853		2.9
		AW452648	Hs.149342		2.9
25	449051	AW961400	Hs.333526		2.9
		AA057264	Hs.238936		2.9
	401093				2.9
		Al651474 Al681475	Hs.163944 Hs.200949		2.9 2.9
30		AW235786			2.9
50		A1472078	Hs.303662	**_	2.9
		BE265067	110.000002	gb:601193893F1 NIH_MGC_7 Homo sapiens cD	
	405953				2.8
	420854	AW296927			2.8
35		AA846811			2.8
		AA295331		· ·	2.8
		AA243837	Hs.57787		2.8
		AW206453	Hs.3782		2.8 2.8
40		AW452434 BE176480	Hs.58006	ESTs, Weakly similar to ALU5_HUMAN ALU S gb:RC3-HT0585-160300-022-c02 HT0585 Homo	
70		AL039852	Hs.49136		2.8
		Al038997	Hs.132921		2.8
	409038		Hs.50002	small inducible cytokine subfamily A (Cy	2.8
	454545	AW806899		gb:QV4-ST0023-160400-172-c12 ST0023 Homo	
45		Al910896	Hs.132413		2.8
		Y00272			2.8
		AL035588 BE070800	MS.153203	MyoD family inhibitor gb:RC3-BT0502-251199-011-c07 BT0502 Homo	2.8
	400250			Eos Control	2.8
50		NM_016206	Hs.23142		2.8
		AA485224		gb:aa41b12.s1 NCI_CGAP_GCB1 Homo sapiens	
	426044	AA502490	Hs.336695		2.8
	431854	AA383550	Hs.271699		2.8
	405873				2.8
55		AA994364			2.8
		A1075375	HS.128193	ESTs, Weakly similar to IRX2_HUMAN IROQU gb;IL2-HT0397-091299-025-D02 HT0397 Homo	2.8
		BE158791 AA398155	Hs.97600		2.8
		AI754813			2.8
60		AW294631	Hs.11325		2.8
•		AA298758			2.8
		R64719		gb:EST22d11 WATM1 Homo sapiens cDNA clon	
	402765			C1003621*:gi 12407405 gb AAG53491.1 AF22	2.8
<i>(</i>		R41339	Hs.12569		2.8
65		AW338625	Hs.22120		2.8
	401497				2.8 2.8
	402376			C18000703 .gif1303812[bill[bC428010]]	2.0

	400041	INA		C3001700 .gif1343032jspfF13303jCA30_C111C	2.0
	408758	NM_003686	Hs.47504	exonuclease 1	2.8
	431917	D16181	Hs.2868	peripheral myelin protein 2	2.8
		AA761190	Hs.244627	• • •	2.8
5		AA744862		ESTs, Weakly similar to I54374 gene NF2	2.8
,			113.134233		
		AF086325		gb:Homo sapiens full length insert cDNA	2.8
	401283			Target Exon	2.8
	410784	AW803201		gb:IL2-UM0077-070500-080-E06 UM0077 Homo	
	417601	NM_014735	Hs.82292	KIAA0215 gene product	2.8
10	418236	AW994005	Hs.337534	ESTs	2.8
		AW291488	Hs.117305	Homo sapiens, clone IMAGE:3682908, mRNA	2.8
		AW815098	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	gb:QV4-ST0212-091199-023-f10 ST0212 Homo	
		BE247550	Hs.86859	growth factor receptor-bound protein 7	2.8
					2.8
15		A1651930	Hs.135684		
15		AK000375	Hs.88820	HDCMC28P protein	2.8
		T97401	Hs.21929	ESTs	2.8
	425589	Al650633	Hs.143688	Homo sapiens cDNA: FLJ23031 fis, clone L	2.8
	429638	Al916662	Hs.211577	kinectin 1 (kinesin receptor)	2.7
	428824	W23624	Hs.173059	ESTs	2.7
20	421566	NM_000399	Hs.1395	early growth response 2 (Krox-20 (Drosop	2.7
		BE386870		gb:601275271F1 NiH_MGC_20 Homo sapiens c	2.7
		R79707	He 263330	ESTs, Moderately similar to I38022 hypot	2.7
		BE247449	Hs.31082		2.7
					2.7
25		AV646449	Hs.282872		
25		Al378562	Hs.159585		2.7
		AW371048	Hs.93758	H4 histone family, member H	2.7
	406504	NA		C5000558:gi 4504675 ref NP_002175.1 int	2.7
	423279	AW959861	Hs.290943	ESTs	2.7
	424871	NM_004525	Hs.153595	low density lipoprotein-related protein	2.7
30	453619	H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, comp	2.7
	423961	D13666		osteoblast specific factor 2 (fasciclin	2.7
		N34524	***********	gb:yy56d10.s1 Soares_multiple_sclerosis_	2.7
		BE314524	Hs.78776	putative transmembrane protein	2.7
		NM 005014	Hs.94070	osteomodulin	2.7
35			113.34070		2.7
JJ	406182		11- 70050	Target Exon	
		X69970	Hs.79350	RYK receptor-like tyrosine kinase	2.7
		AI916512	Hs.198394		2.7
	408171	AA301228	Hs.43299	hypothetical protein FLJ12890	2.7
	430153	AW968128	Hs.336679	ESTs	2.7
40	413383	AA128978	Hs.154706	hypothetical protein FLJ14917	2.7
	414831	M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	2.7
	413278	BE563085	Hs.833	interferon-stimulated protein, 15 kDa	2.7
		AB026264		hypothetical protein IMPACT	2.7
		AA742577	Hs.303781		2.7
45		AF075079	113.303701	gb:Homo sapiens full length insert cDNA	2.7
45			Un 274502	ESTs, Moderately similar to A47582 B-cel	2.7
		W74653	. Пз.27 1595	•	2.7
	406153	V40047	11- 440507	Target Exon	
		Y13647		stearoyl-CoA desaturase (delta-9-desatur	2.7
		Al188139	Hs.147050	ESIS	2.7
50	432328	Al572739		6-phosphofructo-2-kinase/fructose-2,6-bi	2.7
,	429628	H09604	Hs.13268	ESTs	2.7
	420149	AA255920	Hs.88095	ESTs	2.7
	431207	AA495925	Hs.9394	ESTs	2.7
		BE379623	Hs.27693	peptidylprolyl isomerase (cyclophilin)-l	2.7
55		AI050073	Hs.135338		2.7
-		AI741320	Hs 11/121	Homo sapiens cDNA: FLJ23228 fis, clone C	2.7
		AA054726	Hs.285574		2.7
			Ho 404440	ESTs, Weakly similar to 138022 hypotheti	2.7
		N91716 .			2.7
<i>c</i> 0	429922	Z97630		H1 histone family, member 0	
60	418203	X54942	Hs.83758	CDC28 protein kinase 2	2.7
		AF086332	Hs.58314	ESTs	2.7
	402184	NA		ENSP00000245238*:CDNA FLJ10922 fis, clon	2.7
	450496	AW449251	Hs.257131	ESTs	2.7
	451963	A1825440	Hs.224952	ESTs	2.7
65	457938	AI373638	Hs.133900	ESTs	2.7
	441541	AA938663	Hs.199828		2.7
		A1806867	Hs 126594		2.7

	423020	AA383092	Hs.1608	replication protein A3 (14kD)	2.7
	445354	AV653485	Hs.6390	Homo sapiens clone FLB3344 PRO0845 mRNA,	
		AW293165	Hs.143134		2.7
5	-	X91662	Hs.66744	twist (Drosophila) homolog (acrocephalos	2.7
5		AW137636 AA496493	Hs.146059 Hs.23136	ESTS	2.7 2.7
	406069		H\$.23 130	Target Exon	2.7
		AI470235	Hs.172698		2.7
	401256			NM_024089*:Homo sapiens hypothetical pro	2.7
10	415139	AW975942	Hs.48524	ESTs	2.7
		AW958037	Hs.286	ribosomal protein L4	2.7
		BE144762		gb:CM0-HT0180-041099-065-b04 HT0180 Homo	
		BE327427	Hs.79953	ESTs	2.6
15		AA045857 AL121053	Hs.54943 Hs.5534	fracture callus 1 (rat) homolog Homo sapiens cDNA FLJ12961 fis, clone NT	2.6 2.6
15		AF160477	Hs.61460	Ig superfamily receptor LNIR	2.6
		AK001122		hypothetical protein FLJ10260	2.6
		AW893940	Hs.59698	ESTs	2.6
	430785	Z30201		gb:HHEA22G Atrium cDNA library Human hea	2.6
20		D38299		prostaglandin E receptor 3 (subtype EP3)	2.6
		NM_006456		sialyltransferase	2.6
		AA300900	Hs.98849	ESTs, Moderately similar to AF161511 1 H	2.6
,		AA447990	Hs.190478		2.6
25		AW975920 AI346487	Hs.283361 Hs.28739	ESTs	2.6 2.6
23		AI123555	Hs.81796	ESTs	2.6
		AW451645		Homo sapiens cDNA FLJ11973 fis, clone HE	2.6
		AW754311		gb:CM1-CT0337-141299-068-f07 CT0337 Homo	2.6
	417061	Al675944	Hs.188691	Homo sapiens cDNA FLJ12033 fis, clone HE	2.6
30		M25809	Hs,64173	ATPase, H transporting, lysosomal (vacuo	2.6
		AK002016		Homo sapiens, clone MGC:16327, mRNA, com	2.6
		NM_013989		deiodinase, iodothyronine, type II	2.6
		AW292286	Hs.255058		2.6 2.6
35	405822	AA018311	Hs.114762	Target Exon	2.6
33		AW976201	Hs.53913	hypothetical protein FLJ10252	2.6
		AI080042		ribosomal protein S24	2.6
		AA643687		Homo saplens cDNA FLJ11980 fis, clone HE	2.6
		AW205878	Hs.29643	Homo sapiens cDNA FLJ13103 fis, clone NT	2.6
40	405638			Target Exon	2.6
		AW812256		gb:RC0-ST0174-191099-031-a07 ST0174 Homo	
	403943	705004	11- 424402	C5000355:gl 4503225 ref NP_000765.1 cyt	2.6
	404535 402800		IIS.121463	chloride channel 1 , skeletal muscle (Th Target Exon	2.6 2.6
45		Al989503	Hs.233405		2.6
		AW846080	Hs.314324		2.6
		H03754		wingless-type MMTV integration site fami	2.6
	428303	AW974476	Hs.183601	regulator of G-protein signalling 16	2.6
50		AA418187	Hs.330515		2.6
50		AK001826	Hs.25245	hypothetical protein FLJ11269	2.6
		BE246010	Hs.271468	Homo saptens mRNA for FLJ00038 protein,	2.6
		AW855802 AB028955	Un 175700	gb:RC1-CT0279-170200-023-d08 CT0279 Homo	2.6
		NM_015434	Hs.48604	KIAA1032 protein DKFZP434B168 protein	2.6
55	427510			small nuclear RNA activating complex, po	2.6
		NM_000163		growth hormone receptor	2.6
	406271			Target Exon	2.6
		BE566962	Hs.7063	Homo sapiens cDNA: FLJ20913 fis, clone A	2.6
C O		AW016892	Hs.100855		2.6
60		AI928513	Hs.59203	ESTs	2.6
		AA121098	Hs.3838	serum-inducible kinase gb:QV3-BT0381-170100-060-g03 BT0381 Homo	2.6
		BE069326 W24320	Hs 1020/11	gb:QV3-B10381-170100-060-g03 B10361 Homo Homo sapiens cDNA: FLJ21531 fis, clone C	2.6
		X64984	113. TVZ34	gb:H.sapiens mRNA HTPCRX10 for olfactory	2.6
65		AA830431	Hs.180811		2.6
-		AA668763	Hs.291939	ESTs	2.6
		AI681917	Hs.3321	ESTs, Highly similar to IRX1_HUMAN IROQU	2.6
				-	

	455100	BE160198		gb:QV1-HT0413-010200-059-h03 HT0413 Homo	2.6
		BE274552	Hs.76578	protein inhibitor of activated STAT3	2.6
		Al732892	Hs.190489		2.6
		AA831267	Hs. 12244	hypothetical protein FLJ20097	2.6
5	431473	AA825686	Hs.321176	ESTs, Weakly similar to S65824 reverse t	2.6
	404440			NM_021048:Homo sapiens melanoma antigen,	2.6
	403388	NA		C3001398*:gi 12248917 dbj BAB20375.1 (A	2.6
	403775	NA		Target Exon	2.6
10	405037			NM_021628*:Homo saplens arachidonate lip	2.6
10		AF290544		gb:Homo sapiens aminopeptidase mRNA, par	2.6
		AA282067	Hs.88972	ESTs, Moderately similar to A46010 X-lin	2.6
		AI872932	11- 405000	gb:wm72e03.x1 NCI_CGAP_Ut2 Homo sapiens	
		AW516211		ring finger protein 21, interferon-respo	2.6
15		AI702885 BE391727	Hs.145568	general transcription factor IIH, polype	2.6 2.6
13		N72264		KIAA1204 protein	2.6
		AW085961	Hs.130093		2.6
		Y08565		UDP-N-acetyl-alpha-D-galactosamine:polyp	2.6
	404443		,,_,,	C8001428*:gi[6572242 emb CAB62951.1] (Z9	2.6
20	452268	NM_003512	Hs.28777	H2A histone family, member L	2.6
	430832	Al073913	Hs.100686	ESTs, Weakly similar to JE0350 Anterior	2.6
	444779	Al192105	Hs.147170	ESTs	2.6
		AW963372	Hs.46677	PRO2000 protein	2.6
25		F13036	Hs.27373	Homo sapiens mRNA; cDNA DKFZp564O1763 (1	
25		R36075		gb:yh88b01.s1 Soares placenta Nb2HP Homo	2.6
		AW081681	Hs.269064		2.6
		NM_000169	Hs.69089	galactosidase, alpha	2.6 2.6
		S70284 H62943	Hs.154188	gb:stearoyl-CoA desaturase [human, adipo	2.6
30		BE065837	113,134100	gb:RC2-BT0318-110100-012-g12 BT0318 Homo	
50		NM_012247	Hs 124027	SELENOPHOSPHATE SYNTHETASE; Human	
		AI538613		Transmembrane protease, serine 3	2,5
		AF012023		integrin cytoplasmic domain-associated p	2.5
		AK001058	Hs.12680	Homo sapiens cDNA FLJ10196 fis, clone HE	2.5
35	422225	BE245652	Hs.118281	zinc finger protein 266	2.5
		L22524	Hs.2256	matrix metalloproteinase 7 (MMP7; uterin	2.5
		AB020641	Hs.57856	PFTAIRE protein kinase 1	2.5
		NM_000909		neuropeptide Y receptor Y1	2.5
40		AW973708	Hs.201925 Hs.122897	Homo sapiens cDNA FLJ13446 fis, done PL	2.5 2.5
40		AA767881 AK001741	Hs.8739	hypothetical protein FLJ10879	2.5
		AL042306	Hs.97689	VASA protein	2.5
		AW628666	Hs.98440	ESTs, Weakly similar to I38022 hypotheti	2.5
		AK002032		Homo sapiens cDNA FLJ11170 fis, clone PL	2.5
45		BE080908		gb:QV1-BT0631-280200-084-h07 BT0631 Homo	2.5
	458624	Al362790	Hs.278639	KIAA1684 protein; likely homolog of mous	2.5
		BE394723		S100 calcium-binding protein A6 (calcycl	2.5
		NM_002318	Hs.83354	lysyl oxidase-like 2	2.5
50		AW375610		hypothetical protein FLJ13046 similar to	2.5
50		AI424899	Hs.188211	gb:PM4-BT0724-130400-006-c07 BT0724 Homo	2.5
		BE091089	Un CCE21		2.5
		U64820 AW972565	Hs.66521 Hs.32399	Machado-Joseph disease (spinocerebellar ESTs, Weakly similar to S51797 vasodilat	2.5
		AW089705		ESTs, Weakly similar to S64329 probable	2.5
55		AI471598	Hs.197531		2.5
55		AA065081	1101101001	gb:zm13a03.s1 Stratagene pancreas (93720	2.5
		BE178536	Hs,11090	membrane-spanning 4-domains, subfamily A	2.5
		AF109298		prostate cancer associated protein 1	2.5
		AW247529	Hs.6793	platelet-activating factor acetylhydrola	2.5
60		BE158687		gb:CM0-HT0395-280100-169-b09 HT0395 Home	2.5
		AW953168	Hs.12407	ESTs	2.5
		AA652687	Hs.96151	Human DNA sequence from done RP5-1103G7	
	404826	NINA 004000	Un 4504	Target Exon	2.5
65	422938	NM_001809	Hs.1594 Hs.110488	centromere protein A (17kD) KIAA0990 protein	2.5 2.5
05	421991	NM_014918 NM_007350	Hs,82101	pleckstrin homology-like domain, family	2.5
		AW898595	. 10,02 10 1	gb:RC1-NN0073-260400-011-g09 NN0073 Hom	02.5
	770010	V1100000		g	

	403356	NA		ENSP00000251525*:Hypothetical protein KI	2.5
	404983			ENSP00000252242*:Keratin, type II cytosk	2.5
		AA215535	Hs.98133	ESTs	2.5
5		AW467143		actin related protein	2.5
3		AF186114 AW071349	Hs.215937	tumor necrosis factor (ligand) superfami	2.5 2.5
		AW582962		CGI-47 protein	2.5
		AF086041	Hs.42975	ESTs	2.5
	400925		,	Target Exon	2.5
10	404552			ENSP00000220888*:ZINC FINGER TRANSCRIP	PT12.5
	-	AL133117	Hs.81376	Homo saplens mRNA; cDNA DKFZp586L1121 (f	
		NM_002332	Hs.89137	low density lipoprotein-related protein	2.5
		U32974		baculoviral IAP repeat-containing 4 peroxisomal membrane protein 3 (35kD, Ze	2.5 2.5
15		NM_000318 AA501760	Hs.15806	Homo sapiens mRNA; cDNA DKFZp434H2019 (i	
10		AI271898	Hs.164866		2.5
		AW813428	. 10. 10 1000	gb:MR3-ST0192-010200-210-c05 ST0192 Homo	-
	434657	AA641876	Hs.191840	ESTs	2.5
20	402077			Target Exon	2.5
20		X07820	Hs.2258	matrix metalloproteinase 10 (MMP10; str	2.5
		AW885757 T27308	Hs.257862 Hs.16986		2.5 2.5
		A1807894	Hs.47274	hypothetical protein FLJ11046 Homo sapiens mRNA; cDNA DKFZp564B176 (fr	
		AI024353		hypothetical protein FLJ14298	2.5
25		AA059013	Hs.22607	ESTs	2.5
	411571	AA122393	Hs.70811	hypothetical protein FLJ20516	2.5
		AW162919		RAB2, member RAS oncogene family-like	2.5
		AI126772	Hs.40479	ESTs	2.5
30		AI580090 N80077	Hs.48295 Hs.24792	RNA helicase family chromosome 12 open reading frame 5	2.5 2.5
50		AA449644		Homo sapiens cDNA FLJ14201 fis, clone NT	2.5
		AW297921	Hs.255703		2.5
		AA256769	Hs.94949	methylmalonyl-CoA epimerase	2.5
2.5		AW086180	Hs.37636	ESTs, Weakly similar to KIAA1392 protein	2.5
35		U29344	Hs.83190	fatty acid synthase	2.5
		AA356923		nuclear cap binding protein subunit 2, 2	2.5
		AL039402 N52639	Hs.32683	DEME-6 protein ESTs	2.5 2.5
		AI743977	Hs.205144		2.5
40		AA740875	Hs.44307		2.5
		AW500507		KIAA1600 protein	2.5
		AI920783	Hs.191435		2.5
		AA479033		ESTs, Weakly similar to A47582 B-cell gr	2.5
45		AI446747		olfactory receptor, family 7, subfamily	2.5 2.5
40		AA116021 NM_007069	Hs.38260 Hs.37189	ubiquitin specific protease 18 similar to rat HREV107	2.5
		H00820	Hs.30977	ESTs, Weakly similar to B34087 hypotheti	2.5
		AA236255	Hs.298419		2.5
~^	429118	H20669	Hs.35406	ESTs, Highly similar to unnamed protein	2.5
50		AL046412	Hs.202151		2.5
		AI640355	Hs.312691		2.5
		AW298631 AI937547	Hs.27721	Wolf-Hirschhorn syndrome candidate 1-lik hypothetical protein MGC2601	2.5 2.5
		AW837349	16.124313	gb:QV2-LT0038-270300-108-d12 LT0038 Homo	
55		AA843719	Hs.122341		2.5
	406414			C5000506*:gi 124941 sp P18614 ITA1_RAT	2.5
		AB033043		hypothetical protein DKFZp761L0424	2.5
		BE548446	Hs.5167	Homo saplens mRNA; cDNA DKFZp434F152 (fr	
60		AA347746 BE159984	Hs.9521 Hs.125395	ESTs, Weakly similar to ZN43_HUMAN ZINC	2.5 2.5
00		AA635062	Hs.50094	Homo saplens mRNA; cDNA DKFZp434O0515 (
		D86983		Melanoma associated gene	2.5
		AL135623		KIAA0575 gene product	2.5
<i>-</i> -	412520	AA442324	Hs.795	H2A histone family, member O	2.5
65		D13752		cytochrome P450, subfamily XIB (steroid	2.5
		AA081395	Hs.42173	Homo saplens cDNA FLJ10366 fis, clone NT	2.5
	403133			Target Exon	2.5

a 2.5
2.5
2.5

TABLE 19A

Table 19A shows the accession numbers for those pkeys lacking unigeneID's for Table 19. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10			
15	Pkey: CAT num Accession	ber: Gene cl	Eos probeset identifier number uster number k accession numbers
	Pkey	CAT number	Accessions
20	407647 407980	1007366_1 103087_1	AW860158 AW862385 AW860159 AW862386 AW862341 AW821 AA046309 Al263500 AA046397

414596

1465004_1

BE386870 Z41986 H08501

1869 AW821893 AW062660 AW062656 408254 1049346 1 AW807227 AW807576 AW807137 AW807157 AW807495 AW807494 AW807417 AW807083 AW845786 AW845801 AW807130 AW807335 AW807081 AW807349 AW807339 AW807164 AW807341 AW807224 AW845903 AW177424 AW807159 AW807123 BE141576 AW807340 AW807334 AW807520 AW807205 AW807505 BE141574 AW807390 AW807395 AW845789 AW807101 AW807089 AW807519 AW807239 AW807509 AW807356 AW807526 AW807098 25 AW807307 AW807153 AW807295 AW807313 AW807322 AW807265 AW807513 AW807516 AW807166 AW807501 AW807120 AW807168 AW807121 AW807527 AW807151 AW807203 AW807489 AW807511 AW807158 AW845800 AW807507 AW845793 AW845796 AW807296 AW845781 AW807444 AW845871 AW807512 AW807242 AW807141 AW807522 AW807487 AW807514 AW807142 AW807232 AW807379 AW807114 AW807518 AW807199 AW807211 AW807498 AW807086 AW807492 AW807218 AW807082 AW807525 AW807493 AW807523 AW807087 AW845784 30 AW807037 AW807128 AW807080 AW807118 AW845807 AW807524 AW845803 AW807249 AW845795 AW807160 AW807343 AW807515 AW807233 AW807289 AW177102 AW807352 AW807394 AW177105 AW807176 AW177103 AW845870 AW177099 AW177101 AW807528 AW807336 AW807038 AW177100 AW807411 AW807088 AW845865 AW807226 AW807517 AW807397 AW807303 AW807177 AW807154 AW807136 AW807146 AW807085 AW807521 AW807488 AW807385 AW807355 AW807223 AW807155 35 409163 110418_1 AA065081 AA075017 AA084791 AA071015 AA081560 AA071459 AA545727 AA083100 AA085366 AA115845 AA075457 AA064704 AA082878 AA075742 AA069162 409695 114876_1 AA296961 AA296889 AA076945 AA077528 AA077497 410534 1207247_1 AW905138 AW753008 R13818 Z43519 410672 1214882_1 AW794600 AW794730 40 410784 1221005_1 AW803201 BE079700 BE062940 410785 1221055_1 AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 410835 AW806906 AW806915 AW866460 AW866475 AW866462 AW866448 AW866372 AW866604 1223785 1 1230330_1 411050 AW814902 BE156656 BE156667 BE156590 BE156441 BE156447 411086 1231500_1 BE070800 AW875226 BE149115 45 411093 1231970_1 BE067650 AW817053 411111 1232669_1 AW818127 AW818161 R09719 411171 1234393 1 AW820260 AW820332 R94406 1239217_1 AW837349 AW837355 AW882717 411337 411514 1248638_1 AW850178 AW850233 AW850445 AW850446 50 411670 1253680_1 AW856552 AW861101 AW856574 AW861099 AW861100 AW856573 AW856576 AW856562 411905 1265181 1 BE265067 BE264978 AW875420 412102 1277395_1 H56435 H56572 AW892929 412209 1283610_1 AW901456 AW901450 AW901441 412248 1285000_1 BE176480 AW903298 AW903313 55 413043 1346556_1 BE158766 BE061699 BE147360 BE147362 BE061666 BE061697 BE061647 BE061678 413111 1349546_1 BE065837 BE065805 BE065799 BE065818 BE065839 BE065831 BE065894 BE065789 BE065792 1352723_1 413189 BE070231 BE070229 BE070255 1353887_1 413221 BE161151 BE162495 BE161002 BE072205 BE160989 BE162482 413499 1373910_1 BE144884 H97942 60 413708 1384140_1 BE158791 BE158806 BE158748 BE158744 BE158740 BE158739 BE158811 BE158700 BE158741 BE158683 BE158685 414210 1426051_1 BE383592 BE261671

```
414605
                  1465790_-1
                              BE390440
        415747
                  155189_1
                              AA381209 AA381245 AA167683
                              R52782 R17313 H24192 R19876
        416173
                  1574973_1
        417742
                  1696282_1
                              R64719 Z44680 R12451
  5
        417974
                  171237_1
                              AA210765 T95700 H94407
        418636
                  177402_1
                              AW749855 AA225995 AW750208 AW750206
                              AA603305 AA244095 AA244183
        419536
                  185688_1
                              AW296927 AI684514 AI263168 AA281079
        420854
                  197072_1
                              N34524 AA305071 AW954803 AA502335 Al433430 Al203597 AW026670 AW265323 AW850787 AA317554 AW993643
        422156
                  212379_1
10
                              AW835572 AW385512 Al334966 W32951 H62656 H53902 R88904 AW835732
        422996
                  223666_1
                              BE091089 BE091123 AA319959
                              AW503329 N46610 AA331571
AW753967 AA370795 AA331630 AW962550
        423833
                  232451_1
        423841
                  232507_1
        423945
                  233566_1
                              AA410943 AW948953 AA334202 AA332882
15
        425201
                              AA352111 AW962247 AA429695
                  247933 1
                  270283_1
                              AA382814 AA402411 AA412355
        426650
        426878
                              BE069341 AW748403 AL044891 AI908240 AA393080
                  273265 1
                               AA470519 BE303010 BE302954 BE384120
                  315008_1
        430264
        430785
                  323486_1
                              Z30201 AA486132 T72025
20
        431676
                  336411_1
                              AI685464 AW971336 AA513587 AA525142
        433687
                  373061 1
                              AA743991 AA604852 AW272737
                  383982_1
                              AW754311 AA630185 AW803285
        434338
        434469
                              AA634806 C18732 AA729161 AA729860
                  387447_1
                              Al872932 AA682306 BE220163 W88695 T81307 H91447
        435447
                  406400_1
25
                              AL050027 BE089051
        437152
                  43386_1
                              AL119723 AL119874 AI909018 U50537
        437854
                  44418 1
                              AF075079 H48601 H48795
                  46798 1
        439031
                              BE164500 AA832198 BE164502
        439255
                  470321_1
                              Al201849 BE069007 AW946544
        444910
                  624951_1
30
                               AV653771 BE089370
        445432
                  63943_1
        446922
                  69865_1
                              BE175605 Z43529 F06610 BE175602 AV661027
                              R36075 Al366546 R36167
        447197
                  711623 1
                              BE623004 AA380669 BE263627 BE246433
        448420
                  76273 1
                              AW898595 AW898588 AW898590 AW898663 AW898592 Al525093
        448516
                  766241_1
35
                              Al698839 Al909260 Al909259
        450522
                  837264_1
        450736
                  844652_1
                              AW970060 AI732366 AI792313 AW839644
        451024
                  85565_1
                              AA442176 AA259181
        451067
                  85759_1
                              BE172186 AA059279 AA020815 AA013437
                              AW936273 AW340350 AA017208
                  86640 1
        451340
                              AW812256 AW812257 Al906423 Al906422
40
                  921410_1
        452542
                              AA026777 N50065 R09961 N54721
        452564
                  92227_1
        453472
                  968371_1
                              AL037925 AL037931 AL037957
                              AW855717 AW362452 AW362443
        454307
                  1106070_1
                  1130674_1
        454359
                              N71277 AW390764
45
                              AW806899 AW866451 AW866393 AW866297 AW817869
        454545
                  1223779_1
                              AW813428 AW813444 AW813367 AW813368 AW813429 AW813424
        454693
                  1229132_1
                              AW815098 BE154843 BE154831
        454714
                  1230493 1
        455047
                              AW852530 AW852527 AW852526
                  1250536_1
                              BE152428 AW855572 AW855607
        455092
                  1252971_1
50
                  1253130_1
                               AW855802 AW855794 AW855797 AW855806 AW855796 AW855808 AW855793 AW855807
        455097
                              BE160198 AW935898 T11520 AW935930 AW856073 AW861034
        455100
                  1253334_1
                               AW938484 BE001245 BE001190
        455431
                  1289854_1
        455511
                  1321229_1
                              BE144762 AW979091
                              BE011668 BE011689 BE011627 BE011679 BE011699 BE011678 BE011696 BE011675 BE011622 BE011635
        455609
                  1337548_1
55
                  1348732_1
                              BE064962 BE064979 BE064853 BE064857 BE064856 BE064977 BE064960 BE064860 BE064815 BE064957 BE064804
        455651
                              BE064816 BE064850 BE064806 BE064796 BE064818 BE064975 BE064819 BE064810 BE064668 BE065059
                              BE066976 BE066928 BE066927
                  1350393_1
        455685
                              BE068115 BE068104 BE068102 BE068096 BE068103 BE068154 BE068198
        455700
                  1351264_1
        455708
                  1352232_1
                               BE069326 BE069290 BE069352
60
                  1353874_1
                              BE080908 BE072258 BE072190 BE072236
        455732
                              BE145808 BE145807 BE181883
                  1374605_1
        455838
                              BE158687 BE158688
        455935
                  1384144_1
                              BE160636 BE160606 BE160703
        455945
                  1385588_1
        456207
                  165078_-1
                              AA193450
65
                              AA485224 AA287308 AA258121
        456482
                  192289_1
                               AF086325 W72956 W73221 AA219112
        458094 .
                  47311 1
                              N99626 Al302701
        458673
                  679507 1
```

PCT/US02/02242 WO 02/059377

TABLE 19B

Table 19B shows the genomic positioning for those pkeys lacking unigene ID's and 5 accession numbers in Table 19. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

			·
10	Pkey:	Unious	e number corresponding to an Eos probeset
10	Ref:	Seguence so	ource. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication
	rtoi.	entitle	d "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand:		tes DNA strand from which exons were predicted.
	Nt_position:		tes nucleotide positions of predicted exons.
15	Ni_position.	IIIQICa	ies nucleotide positions of predicted exons.
15			
	Diese Def	Cinana	Ma maridan
	Pkey Ref	Strand	Nt_position
	400555 9801191	Minus	134694-134817
20	400608 9887666	Minus	96756-97558
20	400610 9887671	Minus	117606-117928,124040-124147
	400925 7651921	Plus	38183-38391,43900-44086
	401045 8117619	Plus	90044-90184,91111-91345
25	401049 7232177	Plus	149157-150692
25	401093 8516137	Minus	22335-23166
	401256 9796573	Minus	45482-45620
	401283 9800093	Minus	47256-47456
	401326 9212516	Minus	226246-227505
	401418 7452889	Minus	124865-125075
30	401451 6634068	Minus	119926-121272
	401458 9187886	Plus	76485-77597
	401497 7381770	Plus	92607-92813
	401508 7534110	Minus -	110779-110983
	401575 7229804	Minus	76253-76364
35	401747 9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-
_			131258,131866-131932,132451-132575,133580-134011
	401781 7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
	401785 7249190	Minus	165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942
	401793 7263888	Minus	102945-103083
40	401987 4406829	Minus	72893-73021,76938-77049
	402077 8117414	Plus	65014-65195
	402109 8131678	Minus	171722-171859,173197-173303
	402184 8576001	Minus	112844-112986,113505-113636
	402376 9625329	Minus	21753-22385
45	402421 9796341	Minus	46609-46662,46758-46811,86293-86346,89776-89829,90048-90101,102817-102924
73	402421 9790341	Plus	· · · · · · · · · · · · · · · · · · ·
			66350-66496 04747-82004
	402606 9909429	Minus	81747-82094
	402696 7328818	Minus	23600-23731
50	402765 9367757	Plus	109588-109726
30	402800 6010175	Plus	43921-44049,46181-46273
	402820 6456853	Minus	82274-82443
	402892 8086844	Minus	194384-194645
	403133 7331427	Plus	38314-38634
	403356 8569930	Plus	92839-93036
55	403388 9438331	Plus	112733-113001,114599-114735
	403426 9719529	Minus	157156-158183
	403585 8101208	Minus	131266-131769
	403593 6862650	Minus	62554-62712,69449-69602
	403637 8671936	Minus	142647-142771,145531-145762
60	403639 8671948	Plus	113234-113326,115186-115287,119649-119786
	403677 7331517		55008-55083,62860-63051
	403775 7770580	Minus	102247-102326,103095-103148
	403943 7711864	Plus	100742-100904,101322-101503
			·

```
404091 7684554
                          Minus
                                    82121-83229
        404097 7770701
                                    55512-55781
                          Plus
        404142 9856692
                          Minus
                                    80316-80459
                                    55675-56055
        404253 9367202
                          Minus
 5
        404274 9885189
                                    104127-104318
                          Plus
        404285 2326514
                          Plus
                                    32282-32416
        404360 9858450
                          Minus
                                    122873-122966,151324-151469,153093-153253
        404440 7528051
                          Plus
                                    80430-81581
        404443 7579073
                                    87198-87441
                          Minus
10
        404552 7243881
                                    19854-20010
                          Plus
        404561 9795980
                          Minus
                                    69039-70100
        404580 6539738
                                    240588-241589
                          Minus
        404721 9856648
                                    173763-174294
                          Minus
                                    47726-48046
        404826 6572184
                          Plus
15
                                    51178-51374,52000-52173
        404983 4432779
                          Minus
        405037 7543748
                          Minus
                                    127374-127578
        405041 7547195
                                    121230-121714
                          Plus
                                    138877-139066
        405095 8072599
                          Plus
        405153 9965565
                                    175317-175500
                          Minus
20
                                    135716-135851
        405196 7230083
                          Minus
        405232 7249042
                                    125904-126063
                          Plus
        405248 7259728
                          Plus
                                    637-777
        405336 6094635
                                    33267-33563
                          Plus
        405394 6624123
                                    31900-32373
                          Minus
25
                                    52223-52389
        405460 7684569
                          Minus
        405494 8050952
                          Minus
                                    70284-70518
        405547 1054740
                          Plus
                                    124361-124520,124914-125050
                                    42814-43010,43583-43783,44863-45033,46429-46554,47815-48018,49961-50153,51624-51727,51823-51959,52702-
        405609 5757553
                          Minus
                                    52918,55469-55601,57111-57307,58169-58296,60215-60332,61482-61727
30
        405638 6289229
                                    199260-199372,199826-199929
                          Plus
                                    53624-53759
        405654 4895155
                          Minus
        405718 9795467
                          Plus
                                    113080-113266
                                    154660-154974,155203-155379
        405822 6273498
                          Minus
        405848 7651809
                                    28135-28244
                          Minus
35
        405873 6758747
                                    32129-32764
                          Minus
                                    10835-11059
        405906 7705124
                          Minus
                                    106829-107213
        405917 7712162
                          Minus
        405925 6758795
                          Plus
                                    129935-130282
        405953 7960374
                          Minus
                                    65101-65574
40
                                    68880-69374
        406069 9117732
                          Plus
                                    94087-94285
        406151 7144806
                          Minus
                                    12902-13069
        406153 9929734
                          Minus
        406182 5923650
                          Minus
                                    28256-28935
        406271 7534217
                          Plus
                                    36179-36692
45
        406291 5686274
                          Plus
                                    9562-9867
        406348 9255985
                                    71754-71944
                          Minus
        406414 9256407
                          Plus
                                    49593-49850
                                    116424-116527,118721-118859,121187-121364
                          Minus
        406446 9454509
                                    107068-107277
        406504 7711360
                          Minus
50
        406554 7711566
                                    106956-107121
                          Plus
```

TABLE 20: 544 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EXTRACELLULAR OR CELL-SURFACE PROTEINS

Table 20 shows 544 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst the 73 breast cancer specimens was greater than or equal 100 units, and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains). The predicted protein domains are noted.

15

10

5

Pkey: U

Unique Eos probeset identifier number

ExAcon:

Exemplar Accession number, Genbank accession number

UnigenelD:

Unigene number

20 Pred.Prot.Domains:

Predicted Protein Domains

Unigene Title: Unigene gene title

R1:

Ratio of 93rd percentile of tumor to 85th percentile of normal body tissue

25	Pkey	ExAccn	UnigenelD	Pred.Prot.Domains	UnigeneTitle	R1
	408591	AF015224	Hs.46452	SS,Uteroglobin,SS,Uteroglobin	mammaglobin 1	168.6
	400291	AA401369	Hs.190721	TM	ESTs	73.2
	449746	Al668594	Hs.176588	,SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
30	407277	AW170035	Hs.326736	TM	Homo sapiens breast cancer antigen NY-BR	57.6
		AA250737	Hs.72472	death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B .	55.9
		U31875	Hs.272499	,SS,TM	short-chain alcohol dehydrogenase family	53.8
		BE069341		TM	gb:QV3-BT0381-270100-073-c08 BT0381 Homo	50.3
		NM_000230		SS,Leptin,SS,Leptin,	leptin (murine obesity homolog)	40.8
35		AA 195651		,SS,Dihydroorotase,	ESTs	39.3
		L11690	Hs.620	Plectin_repeat,SH3,spectrin,SS,Plectin_r	bullous pemphigoid antigen 1 (230/240kD)	37.3
		D31152	Hs.179729	SS,C1q,Collagen,SS,C1q,Collagen,	collagen, type X, alpha 1 (Schmid metaph	35.2
		AJ224172		,SS,Uteroglobin,	lipophilin B (uteroglobin family member)	30.0
40		AA009647		,SS,TM,disintegrin,Pep_M12B_propep,Repro		25.7
40		AF044197		SS,IL8,SS	small inducible cytokine B subfamily (Cy	25.2
		S73265	Hs.1473	SS,Bombesin,SS	gastrin-releasing peptide	24.8
		AI624342		,SS,TM,Cation_efflux	ESTs	24.1
		AI955040		SS	ESTs, Weakly similar to transformation-r	24.0
15				TM	hypothetical protein DKFZp564O1278	23.8
45		X51501	Hs.99949	SS,SS	prolactin-induced protein	22.8
		AI267652		,SS,TM,GNS1_SUR4,cNMP_binding,Rila	Homo sapiens mRNA; cDNA DKFZp434E082 (fr	22.6
		NM_003613		ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
		X78592	Hs.99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
50		AI905687	Hs.2533	SS	aldehyde dehydrogenase 9 family, member ESTs	20.3 19.2
30		Al375572 AA193450	Hs.172634	,pkinase,		18.3
		AL137517	Un 224472	,SS,TM,p450,p450	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.2
		AA399272		TM SS	hypothetical protein DKFZp564O1278 ESTs	18.2
		X52509	Hs.161640	,SS,TM,aminotran_1_2,Cadherin_C_term,cad		18.1
55		AW840171		SS	ESTs, Weakly similar to transformation-r	17.9
55	402578	ANOTOTO	H3.203390	- -	C1001134:gi[2117372 pir 65981 fatty ac	17.8
		A1263307	He 230884	SS,p450,SS,TM,p450 SS	H2B histone family, member L	17.8
		AL120862		SS	programmed cell death 9 (PDCD9)	17.5
		NM_014398		Lamp, SS, TM, Lamp,	similar to lysosome-associated membrane	17.5
	444347	MIN_014090	10001	Lamp,00, mi,camp,	annual to tyaosome associated mentionane	17.5

	449765	N02203	Hs.206832	SS	ESTs, Moderately similar to ALU8_HUMAN A	17.3
		AA321649		SS,IL8,	small inducible cytokine subfamily B (CX	17.0
		D90041	Hs.155956	,SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
		W67883	Hs.137476	,pkinase,	paternally expressed 10	16.5
5		AB014544		LRRCT,LRR,SS,LRRCT,serine_carbpept	KIAA0644 gene product	16.3
•		D60730	Hs.57471	SS	ESTs	16.2
		M13509	Hs.83169	SS,hemopexin,PeptIdase_M10,SS,PeptIdase_		15.7
		AA296520		SS,lectin_c,sushi,EGF,SS,EGF,lectin_c,su	selectin E (endothelial adhesion molecul	15.5
		AA441838		SS	hypothetical protein FLJ14834	15.5
10		NM_00711		,SS,CUB,Xlink,	tumor necrosis factor, alpha-induced pro	15.0
		H44186	Hs.15456	PDZ,SS	PDZ domain containing 1	14.9
	419296	AA236115	Hs.120785	SS	ESTs	14.8
	452838	U65011	Hs.30743	SS,SS	preferentially expressed antigen in mela	14.7
	422805	AA436989	Hs.121017	histone, SS, histone, histone	H2A histone family, member A	14.3
15		AL035414		SS	hypothetical protein	14.2
		Al199268	Hs.19322	,SS,lipocalin	Homo sapiens, Similar to RIKEN cDNA 2010	14.2
		W20027	Hs.23439	,SS,Peptidase_M1,	ESTs	13.9
			Hs.134662	,SS,TM,SNF	ESTs	13.7
20		AA031956		,SS,LIM,	gb:zk15e04.s1 Soares_pregnant_uterus_NbH	13.7
20			Hs.130239	SS	ESTs	13.5
		X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1		13.5
		BE336654		histone, SS, histone, histone	H3 histone family, member A	13.3 13.2
			Hs.130853	,SS,histone,histone,linker_histone	ESTs	13.1
25			Hs.112742	,SS,Ribosomal_L7Ae,	ESTs Homo sapiens breast cancer antigen NY-BR	13.1
25		AI951118		TM OO DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
			Hs.182278	,SS,DENN	programmed cell death 9 (PDCD9)	12.9
			Hs.197653	SS SS Lynul ovidana	hvsvl oxidase	12.8
		W72838	Hs.102267 Hs.2533	,SS,Lysyl_oxidase SS	aldehyde dehydrogenase 9 family, member	12.7
30		N78223	Hs.108106	,SS,G9a,PHD,	transcription factor	12.5
50		AI873274		,56,63a,71b, TM	ESTs	12.4
			Hs.293797	,SS,TPR	ESTs	12.3
		AA576953		SS,TM,UPF0016,SS,TM,UPF0016	hypothetical protein FLJ13352	12.0
			Hs.278461	SS,EGF,vwa,SS,TM,vwa,	matrilin 3	11.9
35		AW732573		TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
50			Hs.200313	,SS,TM,Folate_carrier	ESTs	11.9
			Hs.157601	SS	ESTs	11.8
		H87879	Hs.102267	SS,LysyL_oxidase,Aldose_epim,Epimerase,S		11.8
			7Hs.153704	pkinase, SS, TM, pkinase, polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
40	425398	AL049689	Hs.156369	SS	hypothetical protein similar to tenascin	11.6
	438167	R28363	Hs.24286	,SS,TM,7tm_1,p450,rm	ESTs	11.5
	459583	Al907673		,pkinase,	gb:lL-BT152-080399-004 BT152 Homo saplen	11.5
		AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
4.5		AL360204	Hs.283853	SS	Homo sapiens mRNA full length insert cDN	11.4
45	402606			SS	NM_024626:Homo sapiens hypothetical prot	11.3
		H57646	Hs.42586	,SS,Acyltransferase,	KIAA1560 protein	11.2
		N47863	Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S2	te,nbosomai protein 524	11.1 11.1
		AF026941		,TM,IBR	Homo sapiens clg5 mRNA, partial sequence membrane-spanning 4-domains, subfamily A	11.1
50		BE178536		,SS,TM	• • • • • • • • • • • • • • • • • • • •	10.9
50			Hs.134585	,SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
		R17798	Hs.7535	,SS,Fork_head,	COBW-like protein Human clone 23948 mRNA sequence	10.7
		U79293	Hs.159264 0Hs.225952	SS ,SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
			Hs.158244	,SS,laminin_B,laminin_EGF,laminin_Nterm	KIAA0479 protein	10.3
55		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase		10.3
55		NM_00068		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
		U80736	Hs.110826	SS	trinucleotide repeat containing 9	10.3
			Hs.301663	,SS,pkinase,	ESTs	10.3
			Hs.122147	,SS,ArfGap,	ESTs	10.2
60	400608	7		SS,TM,SS,TM	C10001899:qi 7508633 pir T25392 hypothe	10.1
00		BE242870	Hs.75379	SS	solute carrier family 1 (glial high affi	10.0
		W68815	Hs.301885	SS	Homo sapiens cDNA FLJ11346 fis, clone PL	9.9
	402408	NA		,SS,carb_anhydrase	NM_030920*:Homo sapiens hypothetical pro	9.8
	445537	AJ245671	Hs.12844	,SS,TM,ras	EGF-like-domain, multiple 6 (EGFL6)	9.7
65		Al879148	Hs.26770	SS,lipocalin,lipocalin,	fatty acid binding protein 7, brain	9.6
	405654	NA		BTB,SS	C12001521:gi 7513934[pir T31081 cca3 pr	9.6
			Hs.161160	SS	ESTs	9.6

		N49776	Hs.170994	,SS,TM	hypothetical protein MGC10946	9.5
		M30703	Hs.270833	SS,TM,EGF,SS	amphiregulin (schwannoma-derived growth	9.5
	414142	AW368397	Hs,150042	,SS,UDPGT	Homo sapiens cDNA FLJ14438 fis, clone HE	9.4
	400298	AA032279	Hs.61635	TM	six transmembrane epithelial antigen of	9.4
5	418601	AA279490	Hs.86368	SS,TM,calreticulin,SS,TM,calreticulin,	calmegin	9.4
		AI733881		death,ZU5,TM,Activin_recp,pklnase,	BMP-R1B	9.4
		AA291377		TM	ESTs	9.3
		Al678059		SS	synaptonemal complex protein 2	9.3
		Al820662		SS	ESTs	9.1
10						9.1
10		X73114	Hs.169849	,SS,TM,fn3,ig,	myosin-binding protein C, slow-type	
		M31126	Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase		9.1
	448693	AW004854	Hs.228320	SS	hypothetical protein FLJ23537	9.1
	419948	AB041035	Hs.93847	Femic_reduct,TM,Ferric_reduct,	NM_016931:Homo sapiens NADPH oxidase 4 (9.1
	426214	H59846	Hs.128355	SS	ESTs, Moderately similar to ALU7_HUMAN A	9.0
15	427718	A1798680	Hs.25933	,SS,TM,histone,Sec1,histone,sugar_tr	ESTs	8.9
		X72755	Hs.77367	SS,IL8,SS,IL8	monokine induced by gamma interferon	8.8
	400285		,	,TM,ABC_tran,ABC_membrane,	Eos Control	8.8
		D30783	Hs.115263	SS,TM,EGF,SS,TM	epiregulin	8.8
		NM_004354		cyclin,SS	cyclin G2	8.8
20		AW512260		SS	ESTs	8.7
20						
	452281		Hs.28792	,SS,TGF-beta,TGFb_propeptide,	Homo saplens cDNA FLJ11041 fis, clone PL	8.7
		AA642007		SS	ESTs	8.6
		AF123050		,SS,TM,ubiquitin,7tm_3,ANF_receptor,sush	diubiquitin	8.6
		A1732643		TM	ESTs	8.6
25	411078	Al222020	Hs.182364	SS,SS	CocoaCrisp	8.5
	445495	BE622641	Hs.38489	SS,SS,ENTH,I_LWEQ,ENTH,I_LWEQ,DNA_I	mis_reESTs, Weakly similar to l38022 hypotheti	8.5
	433426	H69125	Hs.133525	,SS,TM	ESTs	8.5
		NM_004525		SS,EGF,ldl_recept_a,ldl_recept_b,SS,TM,E	low density lipoprotein-related protein	8.4
		AW963419		SS	stanniocalcin 2	8.4
30		AA635062		TM	Homo sapiens mRNA; cDNA DKFZp434O0515 (f	8.4
50		Al831297		TM	ESTs	8.3
						8.3
		AA780473		SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	
		NM_003866		SS,SS	inositol polyphosphate 4-phosphatase, ty	8.3
25	431725		Hs.2839	SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
35	418092		Hs.106604	,death,ZU5,pkinase,Activin_recp,	ESTs	8.3
		AW449211	Hs.105445	SS	GDNF family receptor alpha 1	8.2
	427811	M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_N	114carboxypeptidase B1 (tissue)	8.2
	420807	AA280627	Hs.57846	SS,cpn10	ESTs	8.2
			Hs.169300	SS,TGF-beta,TGFb_propeptide,SS	transforming growth factor, beta 2	8.2
40		AW885727		,SS,kazal,	ESTs	8.1
		AW419196		SS	hypothetical protein FLJ13782	8.1
		AW248508		SS .	Homo sapiens cDNA FLJ14035 fis, clone HE	8.0
	404347	7111210000	1.5.210121	SS	Target Exon	8.0
		AA743991		TM	gb:ny57g01.s1 NCI_CGAP_Pr18 Homo sapiens	8.0
45	-		Lla 407774			
45		AA808229		,SS,IMPDH_C,IMPDH_N,CBS	ESTs	8.0
		NM_016010		SS	CGI-62 protein	7.9
	453310		Hs.553	TM,SNF,SS,TM,SNF,	solute carrier family 6 (neurotransmitte	7.9
	435957		Hs.190368	,SS,TM	ESTs	7.8
		AL138272		,TM,cpn60_TCP1,Sema,	ESTs	7.8
50	443646	Al085198	Hs.164226	,TSPN,vwc,tsp_1,EGF,thlored,	ESTs	7.8
	446142	A1754693	Hs.145968	,TM,cadherin,Cadherin_C_term,	ESTs	7.7
	444649	AW207523	Hs.197628	,SS,rrm,	ESTs	7.6
		AL133731		,TM,SDF,UPAR_LY6,	Homo sapiens mRNA; cDNA DKFZp761C1712 (f	7.6
		AI742605		TM	ESTs	7.6
55		AW207206		SS	ESTs	7.6
55		AK000713			hypothetical protein FLJ20706	7.5
				,SS,UDPGT		
		AL031224		SS,SS	transcription factor AP-2 beta (activati	7.5
	439809		Hs.101774	SS	hypothetical protein FLJ23045	7.5
CO		AA157291		SS	ubinuclein 1	7.5
60	416276		Hs.79136	SS,TM,TM	LIV-1 protein, estrogen regulated	7.5
		AW378065	Hs.8687	,SS,Pep_M12B_propep,Reprolysin,tsp_1,	ESTs	7.4
	452926	Al742170	Hs.31297	,SS,TM	duodenal cytochrome b	7.4
	453331	Al240665	Hs.8895	,SS,TM,disIntegrin,Pep_M12B_propep,Repro		7.3
	420802		Hs.1334	SS,NA,myb_DNA-binding	v-myb avian myeloblastosis viral oncogen	7.3
65	450603		Hs.12422	SS	ESTs	7.2
	422867		Hs. 1584	SS,EGF,tsp_3,SS,E2F_TDP,	cartilage oligomeric matrix protein (COM	7.2
	418004		Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2
			2.0.00			

	426451	Al908165	He 1600/6	SS,GATA,	GATA-binding protein 3 (T-cell receptor	7.1
		H39960		,SS,LRR	Homo sapiens cDNA FLJ12280 fis, clone MA	7.1
		Al198719		SS	ESTs	7.1
			Hs.64311		a disintegrin and metalloproteinase doma	7.1
5		AB029496		SS,ig,Sema,SS,Sema,efhand	semaphorin sem2	7.0
-		AA102670		SS,TM,SS,TM	gamma-aminobutyric acid (GABA) A recepto	7.0
					interieukin 6 signal transducer (gp130,	7.0
		X63578		SS,efhand,SS,efhand,ras	parvalbumin	7.0
		R31178	Hs.287820	,SS,fn3,fn1,fn2,fn2,fn1	fibronectin 1	6.9
10		AK001741			hypothetical protein FLJ10879	6.9
		AF026942		,TM,IBR	gb:Homo sapiens cig33 mRNA, partial sequ	6.8
	427427	AF077345	Hs.177936	SS,lectin_c,SS	ESTs	6.8
	410785	AW803341		SS	gb:IL2-UM0079-090300-050-D03 UM0079 Homo	6.7
	401045			ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_		
15		C11001883	*:gi 6753278 ref	NP_033938.1 c	6.7	
		Al123555		,SS,Reprolysin,tsp_1,	ESTs	6.7
		R41823	Hs.7413	,TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
		AA243837		SS	ESTs	6.6
00		A1655499		,TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
20		R20893	Hs.325823		ESTs, Moderately similar to ALU5_HUMAN A	6.6
		BE387335			ESTs, Weakly similar to S64054 hypotheti	6.6
	404091			,TM,7tm_3,ANF_receptor,	Target Exon	6.6
		AW067903			collagen, type XI, alpha 1	6.6
25		AL135623		SS,SS	KIAA0575 gene product	6.5 6.4
23		U85658	Hs.61796	· · · · · -	transcription factor AP-2 gamma (activat	6.2
		AW067800		SS ,SS,serpin,	stanniocalcin 2 serine (or cystelne) proteinase inhibito	6.2
		NM_005025 A1815601			CD83 antigen (activated B lymphocytes, i	6.2
		AA219691		SS,TM,ig,SS,TM ,SS,kinesin,	RAB6 interacting, kinesin-like (rabkines	6.2
30		AW167087		,SS,ig,Sema,pkinase,	ESTs	6.2
20		AA026880		,SS,TM,fn3,	prolactin receptor	6.1
		T49951		filament,SS,filament,filament	DKFZP434G032 protein	6.1
		W26713	Hs.256972	,SS,TM,DAGKa,DAGKc,	ESTs	6.1
		Y00272	Hs.184572		cell division cycle 2, G1 to S and G2 to	6.1
35		X03363		,SS,TM,pkinase,Recep_L_domain,SH2,PH,FL		6.1
		T32982	Hs.102720	SS	ESTs	6.1
		U94362	Hs.58589	Glyco_transf_8,SS	glycogenin 2	6.1
	401781			,SS,filament,Pribosyltran,filament,Armad	Target Exon	6.1
	447359	NM_012093	3Hs.18268	SS,adenylatekinase,	adenylate kinase 5	6.1
40	402230	NA		,SS,TM,p450,	Target Exon	6.1
	427674	NM_003528	3Hs.2178	histone, SS, histone,	H2B histone family, member Q	6.1
		A1249368		,SS,TM	ESTs	6.0
		BE550224		SS	metallothionein 1E (functional)	6.0
15				SS,IL6,IL6,	interleukin 6 (interferon, beta 2)	6.0
45		N32536	Hs.42645	,SS,TM	solute carrier family 16 (monocarboxylic	6.0
		A1793257		,SS,zf-C2H2,	ESTs	5.8
		J05070		SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe		5.8 5.8
		AI823951		SS	tolloid-like 1	5.8
50		NM_002666 AW664964		SS TA	perilipin ESTs	5.7
30	. —	AA242758		,SS,TM ,SS,TM	LIV-1 protein, estrogen regulated	5.7
		AB020689		SS	KIAA0882 protein	5.7
		AI199738		SS	ESTs, Weakly similar to ALUA_HUMAN !!!!	5.7
		X81334	Hs.2936	SS.Peptidase M10,hemopexin,SS,Peptidase	matrix metalloproteinase 13 (collagenase	5.6
55		AA904244		TM	ESTs	5.6
-	400286		710.1002.00	SS,TM,ABC_tran,ABC_membrane,SS	C16000922:gij7499103 pir T20903 hypothe	5.6
		H38026	Hs.308	arrestin,SS	arrestin 3, retinal (X-arrestin)	5.5
		NM_00016		SS,TM,fn3,SS	growth hormone receptor	5.5
		W57554	Hs. 125019	SS	lymphoid nuclear protein (LAF-4) mRNA	5.5
60		AF086332		,SS,TM,Syntaxin	ESTs	5.4
		NM_00594		SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
		NM_00189		,SS,cystatin,	cystatin SN	5.4
	425292	NM_005824	4Hs.155545	SS	37 kDa leucine-rich repeat (LRR) protein	5.4
		AJ297436		,SS,TM	prostate stem cell antigen	5.4
65		AF153330		,SS,TM	solute carrier family 19 (thiamine trans	5.3
		AL355715		SS	programmed cell death 9	5.3
	439310	AF086120	Hs.102793	,SS,TM,UDPGT,casein_kappa	ESTs	5.2
					•	

		A1806867		,SS,TM,Phosphodiest,	ESTs	5.2
	452355		Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
		M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
_	418636	AW749855		,SS,TM,HECT	gb:QV4-BT0534-281299-053-c05 BT0534 Homo	5.2
5	429353	AL117406	Hs.200102	,SS,TM,ABC_tran,ABC_membrane,	ATP-binding cassette transporter MRP8	5.1
		R81733	Hs.33106	,SS,HECT,zf-UBR1,PABP,14-3-3,	ESTs	5.1
	430447	W17064	Hs.332848	SS	SWI/SNF related, matrix associated, acti	5.1
	429698	A1685086	Hs.26339	,SS,ras,	ESTs, Weakly similar to S21348 probable	5.1
	425325	X52730	Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_1	TEMT, STAR	
10		phenylethar	nolamine N-met	hyltransferase	5.1	
	423600	AI633559	Hs.310359	ŠS	ESTs ·	5.1
	414737	AI160386	Hs.125087	SS	ESTs	5.1
	403593			,CIDE-N,pkinase	Target Exon	5.1
	407758	D50915	Hs.38365	SS.SS	KIAA0125 gene product	5.0
15	445234	AW137636		,SS,TM	ESTs	5.0
	411165	NM_000169	Hs.69089	SS, Melibiase, BTK, PH, pkinase, SH2, SH3, Ribo	galactosidase, alpha	4.9
	420633	NM_014581	Hs.274480		odorant-binding protein 2A	4.9
	414117		Hs.1787	,TM,ion_trans,K_tetra,	proteolipid protein 1 (Pelizaeus-Merzbac	4.9
		AA206186		SS,TM,TM	monocyte to macrophage differentiation-a	4.9
20	401093			TM,LRRCT,TM,LRRCT,	C12000586*:gi[6330167 dbj BAA86477.1] (A	4.9
	411096	U80034	Hs.68583	Peptidase_M3,	mitochondrial intermediate peptidase	4.9
		AW085961		SS	ESTs	4.9
		Al247716		,SS,adh_zinc,	ESTs	4.9
		NM_004460		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_		4.9
25		AA641836		,SS,trypsin	hypothetical protein FLJ23186	4.9
		AI215069		SS	ESTs	4.8
		AF012023		,SS,14-3-3	integrin cytoplasmic domain-associated p	4.8
	447752		Hs.105938	SS,transferrin,7tm_1,transferrin,	lactotransferrin	4.8
	403199				NM_025243*:Homo sapiens solute carrier f	4.8
30		AW057736	Hs.323910	,SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		4.8
		AF070526		,SS,Ca_channel_B,	Homo sapiens clone 24787 mRNA sequence	4.7
	413048		Hs.75182		mannose receptor, C type 1	4.7
		AA526235			Homo saplens cDNA FLJ11983 fis, clone HE	4.7
		BE093589			hypothetical protein FLJ23468	4.6
35		AA447453			Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
		AW016669		,SS,TM,CBS,voltage_CLC	ESTs	4.6
		AI668605			ESTs, Moderately similar to ALU6_HUMAN A	4.6
	435542	AA687376	Hs.269533	,SS,pkinase,RhoGEF,Ig,PH,SH3,	ESTs	4.6
	417576	AA339449	Hs.82285	AIRS,formyl_transf,GARS,SS,GARS,AIRS,for	phosphoribosylglycinamide formyltransfer	4.6
40	446089	A1860021	Hs.270651	,pkinase	ESTs, Moderately similar to A47582 B-cel	4.6
	445413	AA151342	Hs.12677	SS,UPF0099,SS,UPF0099,	CGI-147 protein	4.6
	424420	BE614743	Hs.146688	,SS,TM,MAPEG,	prostaglandin E synthase	4.5
	432378	A1493046	Hs.146133	,SS,TM,UDPGT	ESTs	4.5
	452190	H26735	Hs.91668	,SS,TM,PH,SH2,Furin-like,pkinase,Recep_L	Homo sapiens clone PP1498 unknown mRNA	4.5
45	434674	AA831879	Hs.136985		ESTs	4.5
	419986	A1345455	Hs.78915	pkinase,OPR,	GA-binding protein transcription factor,	4.5
	421582	Al910275	Hs.1406	SS,trefoil,SS,TM,ldLrecept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.5
	410361	BE391804	Hs.62661	SS,TM,GBP,TM,GBP	guanylate binding protein 1, interferon-	4.5
	426327	W03242	Hs.44898	SS	Homo sapiens clone TCCCTA00151 mRNA sequ	4.5 '
50	406639	M97711		SS,SS,ig,	gb:Human T-cell receptor (V beta 18.1, J	4.5
	452834	A1638627	Hs.105685	,SS,DEAD,Fork_head	KIAA1688 protein	4.5
	427315	AA179949	Hs.175563	SS	Homo sapiens mRNA; cDNA DKFZp564N0763 (f	4.4
	446733	AA863360	Hs.26040	,SS,TM,p450,	ESTs, Weakly similar to fatty acid omega	4.4
		AA976718			ESTs	4.4
55	421524	AA312082	Hs.105445	SS	GDNF family receptor alpha 1	4.4
	453060	AW294092	Hs.21594		hypothetical protein MGC15754	4.4
	453403	BE466639	Hs.61779	,SS,HMG_box,filament,	Homo sapiens cDNA FLJ13591 fis, clone PL	4.4
	444301	AK000136	Hs.10760	SS,LRR,SS	asporin (LRR class 1)	4.4
	453619	H87648	Hs.33922	SS	Homo sapiens, clone MGC:9084, mRNA, comp	4.3
60	432656	NM_000246	Hs.3076	SS,LRR,	MHC class II transactivator	4.3
	426384	A1472078	Hs.303662	,SS,ArfGap,	ESTs	4.3
	431701	AW935490	Hs.14658	,SS,BIR	Human chromosome 5q13.1 clone 5G8 mRNA	4.3
	416931		Hs.80485	SS,C1q,Collagen,SS,C1q,	adipose most abundant gene transcript 1	4.3
	420854	AW296927	•	,SS,TM,Peptidase_M1,	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3
65	418867	D31771	Hs.89404		msh (Drosophila) homeo box homolog 2	4.3
	443514	BE464288	Hs.141937	,SS,TM,MIP,	ESTS	4.3
	447499	AW262580	Hs.147674	,SS,TM,cadherin,cadherin	protocadherin beta 16	4.3

				•	
	441560	F13386 Hs.7888	,pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
	409064	AA062954 Hs.141883	,SS,CUB,	ESTs	4.3
	422667	H25642 Hs.133471	,SS,TM,FMO-like	ESTs	4.3
_	454032	W31790 Hs.194293	,SS,TM	ESTs, Weakly similar to I54374 gene NF2	4.3
5	432663	Al984317 Hs.122589	TM	ESTs	4.3
	401747		,SS,filament,filament	Homo sapiens keratin 17 (KRT17)	4.3
		NM_013257Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2
		Al571514 Hs.133022	,SS,TM	ESTs	4.2
10		AW073310 Hs.163533		Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
10		AI954968 Hs.279009	,SS,TM	matrix Gla protein	4.2 4.2
		Al821005 Hs.118599	,SS,GDNF,	ESTs	4.2 4.2
		AW972565 Hs.32399	WH1,WH1	ESTs, Weakly similar to S51797 vasodilat	4.2
			zf-C2H2,SS	early growth response 2 (Krox-20 (Drosop ESTs, Weakly similar to B34087 hypotheti	4.1
15		Al345227 Hs.105448 AA829286 Hs.332053	,SS,TM,pkinase ,SS,SAA_proteins,ABC_membrane,ABC_tran		4.1
13		Al192105 Hs.147170	\$\$	ESTs	4.1
		Al827248 Hs.224398	,COLFI,vwc,Collagen,	Homo sapiens cDNA FLJ11469 fls, clone HE	4.1
		Al683487 Hs.152213	,wnt,	wingless-type MMTV integration site fami	4.1
		Al150491 Hs.90756	,TM,Gly∞_hydro_1	ESTs	4.1
20		NM_001809Hs.1594	,SS,TM,thiolase,	centromere protein A (17kD)	4.1
	406922		SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
		AL133916 Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
		AL035588 Hs.153203	HLH,SS	MyoD family inhibitor	4.1
	429922	Z97630 Hs.226117	,SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
25	447178	AW594641 Hs.192417	,SS,TM	ESTs	4.0
	409038	T97490 Hs.50002	SS,IL8,SS,IL8	small inducible cytokine subfamily A (Cy	4.0
		BE153855 Hs.61460	,ss,hl h	lg superfamily receptor LNIR	4.0
		NM_005357Hs.95351	,SS,TM,p450,	lipase, hormone-sensitive	4.0
20		AA479033 Hs.130315	,SS,TM	ESTs, Weakly similar to A47582 B-cell gr	4.0 4.0
30	403329		SS,SS	Target Exon	4.0
		AW014875 Hs.137007	SS	ESTs Weekly similar to 150350 Anterior	4.0
		AI073913 Hs.100686	SS ,SS,Collagen,COLFI,TSPN,	ESTs, Weakly similar to JE0350 Anterior Homo sapiens cDNA FLJ11973 fis, clone HE	4.0
		AW451645 Hs.151504 AL133619 Hs.29383	,SS,TM,ras	Homo sapiens mRNA; cDNA DKFZp434E2321 (f	4.0
35		NM_001949Hs.1189	SS	E2F transcription factor 3	4.0
33		X63629 Hs.2877	SS,TM,Cadherin_C_term,cadherin,SS,TM,cad		4.0
		NM_013989Hs.154424	SS,T4_delodinase,T4_delodinase,	delodinase, iodothyronine, type II	4.0
		R36075	,TM,SDF,	gb:yh88b01.s1 Soares placenta Nb2HP Homo	4.0
		U76456 Hs.190787	.SS,TIMP.	tissue inhibitor of metalloproteinase 4	3.9
40		L22524 Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemo	pematrix metalloproteinase 7 (MMP7; uterin	3.9
	423242	AL039402 Hs.125783	SS	DEME-6 protein	3.9
•	449048	Z45051 Hs.22920	SS,SS,TM	similar to S68401 (cattle) glucose induc	3.9
		M31158 Hs.77439	,SS,cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
45		AW452631 Hs.313803	,SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8
45		NM_015434Hs.48604	SS	DKFZP434B168 protein	3.8
		BE247550 Hs.86859	SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8 3.8
		AB006190 Hs.25475	SS,TM,MIP,SS,TM,MIP,	aquaporin 7	3.8
		N72264 Hs.300670	SS . SS	KIAA1204 protein ESTs	3.8
50		Al935962 Hs.26289 NM_007069Hs.37189	TM,TM	similar to rat HREV107	3.8
50		AA371307 Hs.125056	,SS,DENN	ESTs	3.8
		BE170651 Hs.8700	,SS,START,	deleted in liver cancer 1	3.8
		AW293165 Hs.143134	SS	ESTs	3.8
		AW873606 Hs.149006	,SS,WH1,WH1	ESTs	3.8
55	403943	,	p450,SS,p450	C5000355;qi 4503225 ref NP_000765.1 cyt	3.8
•		AA057264 Hs.238936	,SS,TM,7tm_1,	ESTs, Weakly similar to (defline not ava	3.8
		AW959861 Hs.290943	SS	ESTs	· 3.8
		NM_002407Hs.97644	,SS,SRCR,Uteroglobin	mammaglobin 2 (MGB2; mammaglobin B; lip	3.8
		Al208121 Hs.147313	,SS,TM	ESTs, Weakly similar to I38022 hypotheti	3.7
60		AW974476 Hs.183601	SS,RGS,RGS,RGS	regulator of G-protein signalling 16	3.7
		BE160198	TM	gb:QV1-HT0413-010200-059-h03 HT0413 Homo	3.7
		M26380 Hs.180878	,SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7
		X54942 Hs.83758	CKS,SS,CKS,	CDC28 protein kinase 2	3.7 3.7
65		AW292053 Hs.12532	SS	chromosome 1 open reading frame 21	3. <i>1</i> 3.7
65		AI878918 Hs.10526	SS IN MHC Learning SCAN SS TM	cysteine and glycine-rich protein 2 alpha-2-glycoprotein 1, zinc	3.7 3.7
		AW373784 Hs.71	SS,lg,MHC_I,connexin,SCAN,SS,TM	kinectin 1 (kinesin receptor)	3.7
	429038	Al916662 Hs.211577	SS,TM,SS	wheelit i (wheelit terebroi)	0.1

		AI041793	Hs.42502	,TM,7tm_1,	ESTs	3.7
		H44491	Hs.252938	,SS,TM,EGF,ldl_recept_a,ldl_recept_b,EGF	ESTs, Weakly similar to ALU1_HUMAN ALU S	3.7
			Hs.191533	,SS,AAA,	ESTs	3.7
5		AW194426		,SS,Glycos_transf_2,	ESTs	3.7
3		W23624		SS	ESTs	3.7
		Y08565 BE379727	Hs.151678	Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7 3.7
		AW301344		lipocalin,SS,lipocalin,lipocalin,ferriti ,SS,Pribosyltran,Sulfatase	fatty acid binding protein 4, adipocyte DNA replication factor	3.7
		NM_01473		PHD,pkinase,SS	KIAA0215 gene product	3.7
10		AJ126271		SS SS	ESTs, Weakly similar to YZ28_HUMAN HYPOT	3.7
10		AA890023		SS,TM,fn3,SS,TM,fn3,	prolactin receptor	3.7
		AU076643		,SS,TM,efhand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	411213	AA676939	Hs.69285	SS,TM,CUB,F5_F8_type_C,MAM,SS,TM,CUI		3.6
		Y13647	Hs.119597	SS,TM,Desaturase,SS	stearoyl-CoA desaturase (delta-9-desatur	3.6
15	417511	AL049176	Hs.82223	SS	chordin-like	3.6
	428769	AW207175	Hs.106771	,SS,7tm_1,SPRY,	ESTs	3.6
		T97307		,SS,TM,GDA1_CD39	gb:ye53h05.s1 Soares fetal fiver spleen	3.6
	401866			,SS,filament,	Target Exon	3.6
20		U10492	Hs.438	SS,homeobox,Ets,SS,homeobox,	mesenchyme homeo box 1	3.6
20		AA502490		SS	ESTs	3.6
		NM_00090		SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
		AW089705		SS SS The Deeple Claustin	ESTs, Weakly similar to S64329 probable	3.6 3.6
		AA284775 Y16645	Hs.271387	,SS,TM,PMP22_Claudin, ,SS,TM,IL8	ESTs small inducible cytokine subfamily A (Cy	3.6
25		NM_014400		,SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
23		Al791493		,SS,p450,p450	ESTs, Weakly similar to A36036 cytochrom	3.6
		Al308876		,TM,hemopexin,Peptidase_M10,hemopexin,P		3.6
		AF245505			DKFZP564I1922 protein	3.6
		AI417828		,SS,TM	ESTs	3.5
30	453968	AA847843	Hs.62711	,SS,HMG_box,	Homo sapiens, clone IMAGE:3351295, mRNA	3.5
		S57296	Hs.323910	,SS,TM,SH2,PH,pkinase,Recep_L_domain,Fu		3.5
		AW961400		SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
		AA121098		pkinase,POLO_box,SS,pkinase,POLO_box,	serum-inducible kinase	3.5
35		H22570	Hs.172572	,SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
33		AA808940		,SS,TM,KRAB,SCAN,zf-C2H2,ig	EST	3.5
		NM_002543 AA116021		,SS,TM	oxidised low density lipoprotein (lectin ubiquitin specific protease 18	3.5 3.5
		AI651930		SS,UCH-1,UCH-2,SS,TM,G_glu_transpept SS	ESTs	3.5
		BE280074		cyclin,SS,TM,cyclin,	cyclin B1	3.5
40		AW452434		SS	ESTs, Weakly similar to ALU5_HUMAN ALU S	3.5
. •		NM_014918		SS	KIAA0990 protein	3.4
		AK001423			Homo sapiens cDNA FLJ10561 fis, clone NT	3.4
	425776	U25128	Hs.159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4
4.5	407846	AA426202	Hs.40403	,TM,ABC_membrane,ABC_tran,Ribosomal_S	4eCbp/p300-interacting transactivator, wit	3.4
45			Hs.9739	,SS,TM,transport_prot,SWIB,RhoGAP,DAG_F	Eglycerol-3-phosphate dehydrogenase 1 (so	3.4
		AA250970			poly(A)-binding protein, cytoplasmic 1-l	3.4
		NM_002318			tysyl oxidase-like 2	3.4
		BE390551		SS,START,SS,START,NNMT_PNMT_TEMT,	sterologenic acute regulatory protein r	3.4
50		NM_003512 NM_000346		SS,histone,Calc_CGRP_IAPP,lg,MHC_I,SPR'SS,HMG_box,	SRY (sex determining region Y)-box 9 (ca	3.4 3.4
50		AA442324			H2A histone family, member O	3.4
			Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
	401780	11120000	16.01110	filament,SS,filament,filament	NM_005557*:Homo saplens keratin 16 (foca	3.4
		NM_004585	5Hs,17466	TM	retinoic acid receptor responder (tazaro	3.4
55		AA319233		,SS,TM,RibosomaLL27e,	ESTs	3.4
	415138	C18356	Hs.295944	,Kunitz_BPTI,	tissue factor pathway inhibitor 2	3.4
	421168	AF182277	Hs.330780	SS,p450,SS	cytochrome P450, subfamily IIB (phenobar	3.4
		AA825686		SS	ESTs, Weakly similar to S65824 reverse t	3.4
60	421379		Hs.103982		small indudble cytokine subfamily B (Cy	3.4
60		NM_005419			signal transducer and activator of trans	3.4
		AW968504	Hs.123073	,pkinase,	CDC2-related protein kinase-7	3.4
	405366	DE074550	Uc 76570		NM_003371*:Homo sapiens vav 2 oncogene (3.4 3.4
		BE274552 AW797437		SAP,SS,FG-GAP,vwa SS,sushi,trypsin,vwa,rrm,fibrinogen_C,fn	protein inhibitor of activated STAT3 B-factor, properdin	3.4 3.3
65	411393		Hs.117874	,SS,Peptidase_S8,P,Peptidase_S8,P	ESTs	3.3
0.0	416406		Hs,79299		lipoma HMGIC fusion partner-like 2	3.3
		NM_006456			sialyltransferase	3.3
				• • •	•	

	445462	AA378776	Hs.288649	SS,SS	hypothetical protein MGC3077	3.3
	439452	AA918317	Hs.57987	SS,SS	B-cell CLL/lymphoma 11B (zinc finger pro	3.3
	452017	AF109302	Hs.27495	SS	prostate cancer associated protein 7	3.3
	409099	AK000725	Hs.50579	SS	hypothetical protein FLJ20718	3.3
5	452106	Al141031	Hs.21342	SS	ESTs	3.3
	447519	U46258	Hs.339665	SS	ESTs	3.3
	426928	AF037062	Hs.172914	,SS,adh_short,TGF-beta,TGFb_propeptide	retinol dehydrogenase 5 (11-ds and 9-ci	3.3
	438825	BE327427	Hs.79953	,SS,TM,histone,ANF_receptor,guanylate_cy	ESTs	3.3
	414575		Hs.22968	,SS,pkinase,ig,	Homo sapiens clone IMAGE:451939, mRNA se	3.3
10	417837	AL079905		SS,TGFb_propeptide,TGF-beta,SS	transforming growth factor, beta 1	3.3
		AW881145		SS	gb:QV0-OT0033-010400-182-a07 OT0033 Homo	3.3
		Al267371	Hs.172636	SS,SS,lipoxygenase,PLAT	ESTs	3.3
		AJ423317		,SS,T-box,UDPGT	ESTs	3.3
		Al161293		SS,SS,Peptidase_M1,EGF,lg,lectin_c,sushi	aminopeptidase	3.3
15		A1547306		SS	ESTs	3.3
		AF052152		,pkinase,	Homo sapiens clone 24628 mRNA sequence	3.3
		AW043782		SS	ESTs	3.3
		AA502764		SS	ESTs, Weakly similar to AF208855 1 BM-01	3.3
	434228		Hs.283978	,SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
20		BE314524		TM	putative transmembrane protein	3.3
		AF084545		,SS,Peptidase_M1,	Target	3.3
			Hs.57664 .	,TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
		AL137326		,SS,TM	Homo sapiens mRNA; cDNA DKFZp434B0650 (f	3.3
		AW236861		,SS,START,NNMT_PNMT_TEMT,	ESTs	3.3
25		AA852773		SS	KIAA1866 protein	3.3
		Y09763	Hs.22785	SS,TM,TM	gamma-aminobutyric acid (GABA) A recepto	3.3
		N62937	Hs.269109	,Sema,ig,	ESTs	3.3
		BE270266		SS,TM,LRRCT,LRRNT,LRR,TM,LRRCT,	5T4 oncofetal trophoblast glycoprotein	3.3
		AI694413		,SS,TM,7tm_3,ANF_receptor,sushi	olfactory receptor, family 2, subfamily	3.2
30		N48373	Hs.10247	,SS,ig,	activated leucocyte cell adhesion molecu	3.2
		AW015140		,SS,CUB,	ESTs	3.2
		AI921270		SS,TM,SS,TM,G-patch	hypothetical protein FLJ14251	3.2
		NM_003654		SS	carbohydrate (keratan sulfate Gal-6) sul	3.2
		AW970859		,Sema,ig,	ESTs	3.2
35		BE562136		,SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
		AW973708		,FGF,	Homo sapiens cDNA FLJ13446 fis, clone PL	3.2
	415447	Z97171	Hs.78454	SS,OLF,OLF,OLF,Ribosomal_L4	myodlin, trabecular meshwork inducible	3.2
	443464	BE548446	Hs.5167	SS,TM,SSF,SS,TM	Homo sapiens mRNA; cDNA DKFZp434F152 (fr	3.2
	423431	AA326062		,SS,p450,p450	gb:EST29171 Cerebellum II Homo sapiens c	3.2
40	413278	BE563085	Hs.833	,SS,TM,ubiquitin,laminin_G,laminin_EGF,k	interferon-stimulated protein, 15 kDa	3.2
			Hs.195922	,SS,Ribosomal_L14	ESTs	3.2
	440449	AA885430	Hs.201925	,FGF,	Homo sapiens cDNA FLJ13446 ffs, clone PL	3.2
	413753	U17760	Hs.75517	SS,laminin_EGF,laminin_Nterm,adh_short,S	laminin, beta 3 (niceln (125kD), kalinin	3.2
	434876	AF160477	Hs.61460	,SS,HLH	lg superfamily receptor LNIR	3.2
45	435575	AF213457	Hs.44234	SS,ig,SS,TM	triggering receptor expressed on myeloid	3.2
	415773	R21651	Hs.324725	,SS,TM,Ribosomal_S3Ae,G-gamma	ESTs, Moderately similar to A47582 B-cel	3.2
	446440	AV658411	Hs.42656	SS	KIAA1681 protein	3.2
		NM_00315		,SS,homeobox,	stanniocaldn 1	3.2
	426075	AW513691	Hs.270149	,SS,fn3,	ESTs, Weakly similar to 2109260A B cell	3.2
50	452110	T47667	Hs.28005	,SS,TM,Activin_recp,pkinase	Homo sapiens cDNA FLJ11309 fls, clone PL	3.2
	439963	AW247529	Hs.6793	,TM,p450,Ets	platelet-activating factor acetylhydrola	3.2
	402837	NA		SS	ENSP00000241312*:DJ947L8.1.8 (novel Sush	3.2
	439451	AF086270	Hs.278554	,SS,Chromo_shadow,chromo,	heterochromatin-like protein 1	3.1
		L34041	Hs.9739	,SS,TM,transport_prot,SWIB,RhoGAP,DAG_	PEglycerol-3-phosphate dehydrogenase 1 (so	3.1
55	417315	A1080042	Hs.336901	,SS,RNA_pol_A,RNA_pol_A2,Ribosomal_S2		3.1
	413011	AW068115	Hs.821	SS,LRR,LRRNT,SS,LRRNT,LRR,	biglycan	3.1
			Hs.294022	,SS,connexin,hormone_rec,zf-C4,connexin	hypothetical protein FLJ14950	3.1
•		H24471	Hs.26930	,SS,Gelsolin,	ESTs, Weakly similar to T20272 hypotheti	3.1
		N30714	Hs.325960	,SS,TM	membrane-spanning 4-domains, subfamily A	3.1
60			Hs.249239	,SS,TM,C1q,	collagen, type VIII, alpha 2	3.1
		J05581	Hs.89603	SS,TM,SEA,	mucin 1, transmembrane	3.1
			Hs.114727	,SS,PK,PK	Homo sapiens, clone MGC:16327, mRNA, com	3.1
		BE281128		SS,TM,7tm_1,rrm,SS	TONDU	3.1
	452256	AK000933		,TM,GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
65		AI538613	Hs.298241	SS,TM,trypsin,SS,TM,trefoil,trypsin,tref	Transmembrane protease, serine 3	3.1
		AJ245210		SS	gb:Homo sapiens mRNA for immunoglobulin	3.1 3.1
	400903	NA		SS	Target Exon	J. 1

	424400	11004774	11- 400000	00.01: 1.1:-0	F0#-	2.4
			Hs.132586	,SS,Gly∞_hydro_2	ESTs	3.1
		AW962597		SS,WD40,SS,WD40,	KIAA1547 protein	3.1
			Hs.132781	fn3,SS,TM,EF1BD	class I cytokine receptor	3.1
_			Hs.201189	SS	ESTs, Weakly similar to G01763 atrophin-	3.1
5		A1936442		UBACT_repeat,SS,UBACT_repeat,ThiF_fami	llyhypothetical protein FLJ10808	3.1
		T29618	Hs.89640	,TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
	433417	AA587773	Hs.8859	,SS,SRCR,	Homo sapiens, Similar to RIKEN cDNA 5830	3.1
	418624	A1734080	Hs.104211	,Sema,ig,	ESTs	3.1
	436291	BE568452	Hs.5101	,SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
10	411000	N40449	Hs.201619	SS	ESTs, Weakly similar to S38383 SEB4B pro	3.1
	412519	AA196241	Hs.73980	SS,Troponin,Hemagglutinin,SS,TM,C2,Tropo		3.1
			Hs.241493	,SS,pro_isomerase,	natural killer-tumor recognition sequenc	3.1
		AA809875		,TM,histone,Sec1,histone,sugar_tr	ESTs	3.1
			Hs.199754	,SS,TM,7tm_2,GPS	ESTs	3.1
15		AJ278120		,SS,WD40	putative ankyrin-repeat containing prote	3.1
		AW630534		,SS,TM,rm,oxidored_q6,oxidored_q6	Homo sapiens, clone MGC:9381, mRNA, comp	3.1
		R00866	113.70277	SS	gb:ye79c02.s1 Soares fetal liver spleen	3.0
			Hs.298241	,SS,TM,trefoil,trypsin,trefoil	Transmembrane protease, serine 3	3.0
			Hs.126730	,TM,PH,	ESTs, Weakly similar to KIAA1214 protein	3.0
20			Hs.325823	,1M,E11, ,SS,TM,CD36	ESTs, Moderately similar to ALU5_HUMAN A	3.0
20		R91600	HS.323023			3.0
			Hs.162209	,SS,Ran_BP1,LIM,Ran_BP1,GRIP,TPR,LIM	gb:yq10c02.r1 Soares fetal liver spleen	3.0
		H58373		SS,TM,SS,TM,PMP22_Claudin,PMP22_Claud		
	401197	Поозго	Hs.332938	,SS,TM	hypothetical protein MGC5370	3.0
25		4141004050	11- 004007	arf,arf,	ENSP00000229263*:HSPC213.	3.0
23			Hs.291887	,wnt,	ESTs	3.0
			Hs.336432	,SS,rm,zf-RanBP,pkinase,C2,pkinase_C,DA		3.0
		AA381807		SS,SS	hypoxia-inducible protein 2	3.0
		W27249	Hs.8109	SS	hypothetical protein FLJ21080	3.0
20	404826			,SS,TM	Target Exon	3.0
30		H70284	Hs.160152	,SS,RA	ESTs, Weakly similar to FPHU alpha-fetop	3.0
		AL034548		HMG_box,pkinase,zf-CCHC,SS,TM,HMG_box		3.0
		AW977653		,SS,rîbonuc_red_sm,	ribonucleotide reductase M2 polypeptide	3.0
			Hs.193465	,death,ZU5,pkinase,Activin_recp,	ESTs	3.0
			Hs.282804	SS,Cu-oxidase,SS,Cu-oxidase,Cu-oxidase	hypothetical protein FLJ22704	3.0
35	415992	C05837	Hs.145807	,SS,TM	hypothetical protein FLJ13593	3.0
	424631	AA688021	Hs.179808	SS	ESTs	3.0
	409956	AW103364	Hs.727	SS,TGF-beta,TGFb_propeptide,SS,TGF-beta,	inhibin, beta A (activin A, activin AB a	3.0
	419667	AU077005	Hs.92208	SS,disintegrin,Reprolysin,Pep_M12B_prope	a disintegrin and metalloproteinase doma	3.0
	450946	AA374569	Hs.127698	SS	ESTs, Moderately similar to 2109260A B c	3.0
40	447770	AB032417	Hs.19545	Frizzled,Fz,SS,TM,Frizzled,Fz,	frizzled (Drosophila) homolog 4	3.0
		U20325	Hs.1707	SS,SS	cocaine- and amphetamine-regulated trans	3.0
		AW385224		,SS,TM,Phosphodiest,	ectonucleotide pyrophosphatase/phosphodi	3.0
			Hs.131257	,SS,TM,G-gamma	ESTs	3.0
			Hs.105822	,SS,TM,pkinase,	ESTs	3.0
				10 01 16 moot		

TABLE 20A

Table 20A shows the accession numbers for those pkeys lacking unigeneID's for Table 20. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

ı	\sim
ı	u
	. •

5

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number

_ Accession:

Genbank accession numbers

15

	Pkey	CAT number	Accessions
20	410785 411667 418636 420854	1221055_1 1253334_1 177402_1 197072_1	AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 BE160198 AW935898 T11520 AW935930 AW856073 AW861034 AW749855 AA225995 AW750208 AW750206 AW296927 A1684514 A1263168 AA281079
25	422128	211994_1	AW881145 AA490718 M85637 AA304575 T06067 AA331991
	423431	228162_1	AA326062 AA325758 AW962182
	423945	233566_1	AA410943 AW948953 AA334202 AA332882
	426878	273265_1	BE069341 AW748403 AL044891 AI908240 AA393080
	433687	373061_1	AA743991 AA604852 AW272737
30	447197	711623_1	R36075 Al366546 R36167
	451631	878098_1	R00866 R01523 Al806815
	456207	1650781	AA193450
	456592	202684_1	R91600 T87079 AA291455

TABLE 20B

Table 20B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 20. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	O Ref:		Sequence	mber corresponding to an Eos probeset source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication ed "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_posit	tion;	Indicates D	NA strand from which exons were predicted. ucleotide positions of predicted exons.
15				
	Pkey	Ref	Strand	Nt_position
	400608	9887666	Minus	96756-97558
	400903	2911732	Plus	59112-59228
20	401045	8117619	Plus	90044-90184,91111-91345
	401093	8516137	Minus	22335-23166
	401197	9719705	Plus	176341-176452
	401747	9789672	Minus	118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-131258,131866-131932,132451-132575,133580-134011
25	401780	7249190	Minus	28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573
	401781	7249190	Minus	83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814
	401866	8018106	Plus	73126-73623
	402230	9966312	Minus	29782-29932
	402408	9796239	Minus	110326-110491
30	402578	9884928	Plus	66350-66496
		9909429	Minus	81747-82094
		9369121	Minus	2013-2186,9570-9758,11136-11309,19429-19677,21210-21455,23368-23562,24342-24527,29132-29320
	403199	9958183	Minus	58895-59036,66618-66789
		8516120		96450-96598
35		6862650		62554-62712,69449-69602
		7711864		100742-100904,101322-101503
		7684554		82121-83229
		9838195		74493-74829
40		6572184		47726-48046
40		2182280		22478-22632
	405654	4895155	Minus	53624-53759

TABLE 21: 210 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT TISSUES THAT ARE LIKELY TO ENCODE EITHER ENZYMES OR PROTEINS AMENABLE TO MODULATION BY SMALL MOLECULES

Table 21 shows 210 genes up-regulated in breast cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small
 molecules. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the "average" normal adult tissue level was set to the 85th percentile value amongst 144 non-malignant tissues, and the 96th percentile value amongst 73 breast cancers was greater than or equal 80 units, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulatable by small molecules (e.g. pkinase, peptidase, phosphatase, ATPase, or ion_transporter domains). The predicted protein domains are noted.

	Pkey:	Unique Eos probeset identifier number
20	ExAccn:	Exemplar Accession number, Genbank accession number
	UnigenelD:	Unigene number

Unigene Title: Unigene gene title

5

R1: Ratio of 93rd percentile tumor to 85th percentile of normal body tissue

25						
	Pkey	ExAcen	UnigenelD	Predicted Protein Domains	UnigeneTitle	R1
	449746	AI668594	Hs.176588	SS,p450	ESTs, Weakly similar to CP4Y_HUMAN CYTOC	65.7
	400292	AA250737	Hs.72472	death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	55.9
30	424735	U31875	Hs.272499	SS,TM	short-chain alcohol dehydrogenase family	53.8
		AA195651		SS,Dihydroorotase,	ESTs	39.3
		AW138959		Phosphodiest,Somatomedin_B,	ESTs	34.9
		AA009647				25.7
	429170	NM_001394	4Hs.2359	DSPc,Rhodanese,	dual specificity phosphatase 4	24.9
35	445730	A1624342	Hs.170042	SS,TM,Cation_efflux	ESTs	24.1
	424634	NM_003613	3Hs.151407	ig,tsp_1,SS,AAA	cartilage intermediate layer protein, nu	21.7
		X78592	Hs,99915	hormone_rec,Androgen_recep,zf-C4,	androgen receptor (dihydrotestosterone r	21.7
	424399	A1905687	Hs.2533	SS	aldehyde dehydrogenase 9 family, member	20.3
40	447350	Al375572	Hs.172634	pkinase,	ESTs	19.2
40	456207	AA193450		SS,TM,p450,p450	gb;zr40e07.r1 Soares_NhHMPu_S1 Homo sapi	18.3
	456938	X52509	Hs.161640	SS,TM,aminotran_1_2,Cadherin_C_term,cad		18.1
	402578			SS,p450,SS,TM,p450	C1001134:gi[2117372[pir]][65981 fatty ac	17.8
	425692	D90041	Hs.155956	SS,Acetyltransf2,	N-acetyltransferase 1 (arylamine N-acety	16.7
		W67883	Hs.137476	pkinase,	paternally expressed 10	16.5
45			Hs.83169	SS,hemopexin,Peptidase_M10,SS,Peptidase		15.7
	421727	Y13153	Hs.107318		kynurenine 3-monooxygenase (kynurenine 3	15.3
	411869	W20027	Hs.23439	SS,Peptidase_M1,	ESTs	13.9
	400289	X07820	Hs.2258	hemopexin,Peptidase_M10,SS,Peptidase_M1	0matrix metalloproteinase 10 (MMP10; str	13.5
	443348	AW873596	Hs.182278	SS,DENN	calmodulin 2 (phosphorylase kinase, delt	13.0
50	424086	AJ351010	Hs.102267	SS,Lysyl_oxidase	lysyl oxidase	12.8
	400295	W72838	Hs,2533	SS	aldehyde dehydrogenase 9 family, member	12.7
	408771	AW732573	Hs.47584	TM,K_tetra,ion_trans,SS,TM,K_tetra,ion_t	potassium voltage-gated channel, delayed	11.9
	421155	H87879	Hs.102267	SS,Lysyl_oxidase,Aldose_epim,Epimerase,S	lysyl oxidase	11.8
	424905	NM_00249	7Hs,153704	pkinase,SS,TM,pkinase,polyprenyl_synt,	NIMA (never in mitosis gene a)-related k	11.7
55	438167	R28363	Hs.24286	SS,TM,7tm_1,p450,rrm	ESTs	11.5
	459583	AI907673		pkinase,	gb:IL-BT152-080399-004 BT152 Homo sapien	11.5
	423945	AA410943		death,ZU5,TM,Activin_recp,pkinase,	gb:zt32h03.r1 Soares ovary tumor NbHOT H	11.4
	445263	H57646	Hs.42586	SS,Acyltransferase,	KIAA1560 protein	11.2

	492007	A1 000007	U- 424505	CO THAT DOOT and ADO from ADO from	DVEZD424C022 aretain	400
		AL080207		SS,TM,BRCT,ank,ABC_tran,ABC_tran	DKFZP434G232 protein	10.9
		NM_00705		SS,TM,Y_phosphatase,MAM,fn3,	protein tyrosine phosphatase, receptor t	10.4
		BE440042		SS,Peptidase_M10,hemopexin,SS,Peptidase		10.3
_		NM_00068		SS,TM,7tm_1,SS,TM,7tm_1,	angiotensin receptor 1	10.3
5		AL120173	Hs.301663	SS,pkinase,	ESTs	10.3
	402408			SS,carb_anhydrase	NM_030920*:Homo saplens hypothetical pro	9.8
		AJ733881		death,ZU5,TM,Activin_recp,pkinase,	BMP-R1B	9.4
		M31126	Hs.272620	SS,Peptidase_M10,hemopexin,SS,Peptidase	_matrix metalloproteinase 11 (MMP11; stro	9.1
	419948	AB041035	Hs.93847	Ferric_reduct, TM, Ferric_reduct,	NM_016931:Homo sapiens NADPH oxidase 4 (9.1
10	400285	NA		TM,ABC_tran,ABC_membrane,	Eos Control	8.8
	408380	AF123050	Hs.44532	SS,TM,ubiquitin,7tm_3,ANF_receptor,sushi	diubiquitin	8.6
	409203	AA780473	Hs.687	SS,p450,SS,p450	cytochrome P450, subfamily IVB, polypept	8.3
		NM_00386		SS,SS	inositol polyphosphate-4-phosphatase, ty	8.3
		X65724	Hs.2839	SS,Cys_knot,SS	Norrie disease (pseudoglioma)	8.3
15		R45154	Hs.106604	death,ZU5,pkinase,Activin_recp,	ESTs	8.3
		M81057	Hs.180884	SS,Zn_carbOpept,Propep_M14,SS,Propep_M		8.2
		M90516	Hs.1674	GATase_2,SIS,	glutamine-fructose-6-phosphate transamin	8.1
		AW242243		SS,TM,WD40,ubiquitin,E1-E2_ATPase,Cation		7.8
		NM_001034		SS SS	ribonuckeotide reductase M2 polypeptide	7.6
20						
20		NM_004482		SS,TM,Glycos_transf_2,Ricin_B_lectin,DPP	UDP-N-acetyl-alpha-D-galactosamine:polyp	7.6
		D38299	Hs.170917	SS,TM,7tm_1,	prostaglandin E receptor 3 (subtype EP3)	7.5
			Hs.8895	SS,TM,disintegrin,Pep_M12B_propep,Reprol		7.3
		Y12735	Hs.38018	pkinase,	dual-specificity tyrosine-(Y)-phosphoryl	7.2
0.5		U37519	Hs.87539	SS,aldedh,SS,aldedh,	aldehyde dehydrogenase 3 family, member	7.2
25		U92649	Hs.64311	TM,disintegrin,Reprolysin,	a disintegrin and metalloproteinase doma	7.1
		AW204099			ESTs, Weakly similar to AF126780 1 retin	6.9
	423545	AP000692	Hs.129781	GAF,PDEase	chromosome 21 open reading frame 5	6.8
	401045			ICE_p20,SS,ICE_p10,ICE_p20,ICE_p10,ICE_	p	
		C11001883	*:gi 6753278 re	f NP_033938.1 c	6.7	
30	442082	R41823	Hs.7413	TM,EPH_lbd,pkinase,SAM,fn3,	ESTs; calsyntenin-2	6.7
		A1655499	Hs.161712	TM,Activin_recp,pkinase,death,ZU5,	ESTs	6.6
	404091			TM,7tm_3,ANF_receptor,	Target Exon	6.6
		Al248013	Hs.106532	zf-C2H2	ESTs, Weakly similar to I38588 reverse t	6.5
		NM_002914		SS,AAA,Viral_helicase1,rrm,	replication factor C (activator 1) 2 (40	6.5
35		AF055575		TM,ion_trans,SS,TM,ion_trans,	calcium channel, voltage-dependent, L ty	6.4
		AA932186		TM,7tm_1,	ESTs	6.2
		NM_005025		SS,serpin,	serine (or cysteine) proteinase inhibito	6.2
		AW167087		SS,ig,Sema,pkinase,	ESTs	6.2
		R45503			ESTs, Highly similar to A39769 N-acetyll	6.1
40			Hs.97469	SS,TM		6.1
70	428479		Hs.184572	SS,pkinase,pkinase	cell division cycle 2, G1 to S and G2 to	
	400300	-	40000	SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu		6.1
		NM_012093	3Hs.18268	SS,adenylatekinase,	adenylate kinase 5	6.1
	402230				Target Exon	6.1
15	424687		Hs.151738	SS,Peptidase_M10,fn2,hemopexin,SS,TM,Pe		5.8
45		A1572739	Hs.195471	6PF2K,PGAM,	6-phosphofructo-2-kinase/fructose-2,6-bi	5.8
	432239		Hs.2936	SS,Peptidase_M10,hemopexin,SS,Peptidase_		5.6
	400286			SS,TM,ABC_tran,ABC_membrane,SS	C16000922;gi 7499103 pir T20903 hypothe	5.6
	425247	NM_005940)Hs.155324	SS,Peptidase_M10,hemopexin,SS	matrix metalloproteinase 11 (MMP11; stro	5.4
	434737	AA828246	Hs.291884	UCH-1,pkinase,OPR,Rhodanese,AMP-binding	g,ESTs	5.4
50	439310	AF086120	Hs.102793	SS,TM,UDPGT,casein_kappa	ESTs	5.2
	441111	AI806867	Hs.126594	SS,TM,Phosphodiest,	ESTs	5.2
	452355		Hs.29202	TM,7tm_1,TM	G protein-coupled receptor 34	5.2
		M31659	Hs.180408	SS	solute carrier family 25 (mitochondrial	5.2
		AL117406			ATP-binding cassette transporter MRP8	5.1
55	425325		Hs.1892	SS,NNMT_PNMT_TEMT,SS,NNMT_PNMT_T		•••
-	.20020		olamine N-met		5.1	
	44870G	AW291095		SS,TM,pkinase,	interleukin 20 receptor, alpha	5.1
	403593		113.21014	CIDE-N,pkinase	Target Exon	5.1
			Un 200477	alpha-amylase.		5.0
60		AA564991			ESTs	
60			Hs.194691	SS,TM,7tm_3,Ribosomal_L13	retinolc acid induced 3	4.9
		NM_000169		SS,Melibiase,BTK,PH,pkinase,SH2,SH3,Ribo		4.9
		W88559	Hs.1787	TM,ion_trans,K_tetra,	proteolipid protein 1 (Pellzaeus-Merzbac	4.9
	411096		Hs.68583		mitochondrial intermediate peptidase	4.9
<i></i>		NM_004460		SS,DPPIV_N_term,Peptidase_S9,SS,DPPIV_	· ·	4.9
65		AA641836			hypothetical protein FLJ23186	4.9
	447752	M73700	Hs.105938		lactotransferrin	4.8
	427122	AW057736	Hs.323910	SS,TM,pkinase,Recep_L_domain,SH2,PH,Fu	riHER2 receptor tyrosine kinase (c-erb-b2,	4.8

	400181	NA	•	SS,TM,3Beta_HSD,	ENSP00000171555:CDNA FLJ10727 fis, clone	4.6
_	452093	AA447453	Hs.27860	SS,TM,7tm_1,	Homo sapiens mRNA; cDNA DKFZp586M0723 (f	4.6
•	435542	AA687376	Hs.269533	SS,pkinase,RhoGEF,ig,PH,SH3,	ESTs	4.6
		AA339449	Hs.82285	AJRS,formyl_transf,GARS,SS,GARS,AJRS,for	phosphoribosylglycinamide formyltransfer	4.6
5			Hs.270651		ESTs, Moderately similar to A47582 B-cel	4.6
•			Hs.146688		prostaglandin E synthase	4.5
	452190				Homo sapiens clone PP1498 unknown mRNA	4.5
		Al345455			GA-binding protein transcription factor,	4.5
						4.5
10		AI910275		SS,trefoil,SS,TM,ldl_recept_a,SRCR,tryps	trefoil factor 1 (pS2)	4.4
10		AA863360			ESTs, Weakly similar to fatty acid omega	
		AW294092	Hs.21594		hypothetical protein MGC15754	4.4
	400205				NM_006265*:Homo sapiens RAD21 (S. pombe)	4.4
	420854	AW296927		SS,TM,Peptidase_M1,	gb:UI-H-BW0-ajc-c-07-0-UI.s1 NCI_CGAP_Su	4.3
	432690	AF181490	Hs.278627	SS,pyr_redox,SS,Rlbosomal_L39	prenylcysteine lyase	4.3
15	441560	F13386	Hs.7888	pkinase,	Homo sapiens clone 23736 mRNA sequence	4.3
	416445	AL043004	Hs.79337	SS,pkinase,	KIAA0135 protein	4.3
	439024	R96696	Hs.35598		ESTs	4.3
			7Hs.279696	pkinase,pkinase_C,	serum/glucocorticoid regulated kinase-li	4.2
			Hs.163533	pkinase,	Homo sapiens cDNA FLJ14142 fis, clone MA	4.2
20			6Hs.35120	SS,AAA,PI3_PI4_kinase,PI3Ka,PI3K_rbd,PI3		4.2
20			Hs.105448		ESTs, Weakly similar to B34087 hypotheti	4.1
				SS,SAA_proteins,ABC_membrane,ABC_tran,		4.1
			Hs.332053			4.1
		NM_00180		SS,TM,thiolase,	centromere protein A (17kD)	
25	418478		Hs.1174	,	cyclin-dependent kinase inhibitor 2A (me	4.1
25	406922			SS,TM,Desaturase,SS	gb:stearoyl-CoA desaturase [human, adipo	4.1
			Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	4.1
	429922		Hs.226117	SS,TM,linker_histone,7tm_1	H1 histone family, member 0	4.1
	420139	NM_00535	7Hs.95351	SS,TM,p450,	lipase, hormone-sensitive	4.0
	425071	NM_01398	9Hs.154424	SS,T4_deiodinase,T4_deiodinase,	delodinase, iodothyronine, type II	4.0
30	424511	BE300512	Hs.193557	SS,Y_phosphatase,Band_41	ESTs, Moderately similar to ALU7_HUMAN A	4.0
	428722	U76456	Hs.190787	SS,TIMP,	tissue inhibitor of metalloproteinase 4	3.9
	428330	L22524	Hs.2256	SS,Peptidase_M10,SS,Peptidase_M10,hemo	pematrix metalloproteinase 7 (MMP7; uterin	3.9
	414831	M31158	Hs.77439	SS,cNMP_binding,Rlla,HMG_box	protein kinase, cAMP-dependent, regulato	3.9
	413589	AW452631	Hs.313803	SS,abhydrolase	ESTs, Highly similar to AF157833 1 noncl	3.8
35			Hs.86859	SS,SH2,PH,SS,TM,PH,SH2,Furin-like,pkinas		3.8
-			Hs.128065	SS,Peptidase_C1,gpdh	ESTs	3.8
	403943	701120010	110.120000	p450,SS,p450	C5000355:gi 4503225 ref NP_000765.1 cyt	3.8
		A1/652795	Hs.173334	p+50100,p+00	ELL-RELATED RNA POLYMERASE II, ELONGATIO	3.8
			Hs.238936	CC TM 7tm 1	ESTs, Weakly similar to (defline not ava	3.8
40				SS,TM,7tm_1,		3.7
40		M26380	Hs.180878	SS,lipase,PLAT,Sec7,PH,	lipoprotein lipase	3.7
	418203		Hs.83758	CKS,SS,CKS,	CDC28 protein kinase 2	
			Hs.42502	TM,7tm_1,	ESTs	3.7
	424676		Hs.151678	Glycos_transf_2,Ricin_B_lectin,SS,Glycos	UDP-N-acetyl-alpha-D-galactosamine:polyp	3.7
4.5			Hs.122908	SS,Pribosyltran,Sulfatase	DNA replication factor	3.7
45	417601	NM_01473	5Hs.82292	PHD,pkinase,SS	KIAA0215 gene product	3.7
	446619	AU076643	Hs.313	SS,TM,efhand,ion_trans	secreted phosphoprotein 1 (osteopontin,	3.7
	406625	Y13647	Hs.119597	SS,TM,Desaturase,SS	stearoyl-CoA desaturase (delta-9-desatur	3.6
	428769	AW207175	Hs.106771	SS,7tm_1,SPRY,	ESTs	3.6
	426310	NM 000909	9Hs.169266	SS,TM,7tm_1,	neuropeptide Y receptor Y1	3.6
50		NM 00315		SS,pkinase,vwa,vwa,Glyco_transf_8	senne/threonine kinase 2	3.6
		NM_014400		SS,PH,lactamase_B	GPI-anchored metastasis-associated prote	3.6
			Hs.129873	SS,p450,p450	ESTs, Weakly similar to A36036 cytochrom	3.6
			Hs.194687	colb toolb too	cholesterol 25-hydroxylase	3.6
			Hs.103849	TM,hemopexin,Peptidase_M10,hemopexin,Pe	enhyrothetical protein DKEZn761D112	3.6
55				TM,ion_trans,K_tetra,	gb:QV4-NN0039-290300-154-f06 NN0039 Homo	3.6
55		AW895719		TW, sor_uans, r_tena,	a disintegrin and metalloproteinase doma	3.6
		NM_00381		And transforth sine testanged aunt on hi		
	425320		Hs.83190	Acyl_transf,adh_zinc,ketoacyl-synt,pp-bi	fatty acid synthase	3.5
			Hs.271699	IMS,SS	polymerase (DNA directed) iota	3.5
60	407104	\$57296	Hs.323910	SS,TM,SH2,PH,pkinase,Recep_L_domain,Fu		3.5
60			Hs.333526	SS	HER2 receptor tyrosine kinase (c-erb-b2,	3.5
		AA121098		pkinase,POLO_box,SS,pkinase,POLO_box,	serum-inducible kinase	3.5
	454042	H22570	Hs.172572	SS,ig,pkinase,LRRNT,LRRCT,	hypothetical protein FLJ20093	3.5
	407756	AA116021	Hs.38260	SS,UCH-1,UCH-2,SS,TM,G_glu_transpept	ubiquitin specific protease 18	3.5
		AF039241		Peptidase_M24,	histone deacetylase 5	3.5
65			Hs.177534	DSPc,Myosin_tail,	dual specificity phosphatase 10	3.5
	412049		Hs.18268	SS,adenylatekinase,	adenylate kinase 5	3.5
	425776		Hs.159499	SS,TM,7tm_2,SS,TM,7tm_2	parathyroid hormone receptor 2	3.4

		AA426202 Hs.40403	TM,ABC_membrane,ABC_tran,Ribosomal_9		3.4
		L34041 Hs.9739		PE-glycerol-3-phosphate dehydrogenase 1 (so	3.4
	445873	AA250970 Hs.251946	SS,rrm,PABP,pkinase,14-3-3,rrm	poly(A)-binding protein, cytoplasmic 1-l	3.4
_	418054	NM_002318Hs.83354	SS,TM,mito_carr,Lysyl_oxidase	lysyl oxidase-like 2	. 3.4
5	406815	AA833930 Hs.288036	S SS,IPPT.	tRNA isopentenylpyrophosphate transferas	3.4
	410530	M25809 Hs.64173	ATP-synt_ab,SS,7tm_1,ATP-synt_ab	ATPase, H transporting, lysosomal (vacuo	3.4
	407021	U52077		gb:Human mariner1 transposase gene, comp	3.4
		AF182277 Hs.330780	SS,p450,SS	cytochrome P450, subfamily IIB (phenobar	3.4
		AA825686 Hs.321176		ESTs, Weakly similar to S65824 reverse t	3.4
10		AW968504 Hs.123073		CDC2-related protein kinase 7	3.4
10		NM_001141Hs.111256		arachidonate 15-lipoxygenase, second typ	3.3
					3.3
		AW797437 Hs.69771	SS,sushi,trypsin,vwa,rrm,fibrinogen_C,fn	B-factor, properdin	
		H73505 Hs.117874		ESTs	3.3
1.0		NM_006456Hs.288215		sialyltransferase	3.3
15		AF037062 Hs.172914		retinol dehydrogenase 5 (11-cis and 9-ci	3.3
		H11257 Hs.22968	SS,pkinase,ig,	Homo sapiens clone IMAGE:451939, mRNA se	3.3
		Al267371 Hs.172636		ESTs	3.3
	444542	Al161293 Hs.280380	SS,SS,Peptidase_M1,EGF,ig,lectin_c,sushi	aminopeptidase	3.3
	425741	AF052152 Hs.159412	pkinase,	Homo sapiens clone 24628 mRNA sequence	3.3
20	434228	Z42047 Hs.283978	SS,TM,7tm_1	Homo sapiens PRO2751 mRNA, complete cds	3.3
	433264	D85782 Hs.3229		cysteine dioxygenase, type I	3.3
		AF084545	SS,Peptidase_M1,	Target	3.3
		AL359053 Hs.57664	TM,integrin_B,Ricin_B_lectin,rrm	Homo sapiens mRNA full length insert cDN	3.3
		R19897 Hs.106604		ESTs	3.3
25		Al694413 Hs.332649		olfactory receptor, family 2, subfamily	3.2
23		NM_003654Hs.104576		carbohydrate (keratan sulfate Gal-6) sul	3.2
		BE562136 Hs.9736	SS,PCI,RasGEF,hormone_rec,zf-C4,	proteasome (prosome, macropain) 26S subu	3.2
				Melanoma associated gene	3.2
					3.2
20		AA326062	SS,p450,p450	gb:EST29171 Cerebellum II Homo sapiens c	
30		Al768235	SS,Trehalase	gb.wg82g08.x1 Soares_NSF_F8_9W_OT_PA_P_S	3.2
		T47667 Hs.28005	SS,TM,Activin_recp,pkinase	Homo sapiens cDNA FLJ11309 fis, clone PL	3.2
		AW247529 Hs.6793	TM,p450,Ets	platelet-activating factor acetylhydrola	3.2
		U39817 Hs.36820	SS,DEAD,HRDC,helicase_C,	Bloom syndrome	3.1
		L34041 Hs.9739	SS,TM,transport_prot,SWIB,RhoGAP,DAG_I	PE-	glycerol-3-
35	phospha	te dehydrogenase 1 (so	3.1		
	453487	R31770 Hs.23540	TM,7tm_1,	ESTs	3.1
	420911	U77413 Hs.100293		O-linked N-acetylglucosamine (GlcNAc) tr	3.1
	443171	BE281128 Hs.9030	SS,TM,7tm_1,rm,SS	TONDU	3.1
	452256	AK000933 Hs.28661	TM,GDI,7tm_1,	Homo sapiens cDNA FLJ10071 fis, clone HE	3.1
40		Al538613 Hs.298241		Transmembrane protease, serine 3	3.1
		T29618 Hs.89640	TM,pkinase,fn3,	TEK tyrosine kinase, endothelial (venous	3.1
		Al149286 Hs.55099	SS	rab6 GTPase activating protein (GAP and	3.1
		NM_003937Hs.169139		kynureninase (L-kynurenine hydrolase)	3.1
		BE568452 Hs.5101	SS,abhydrolase,	protein regulator of cytokinesis 1	3.1
45		AA418204 Hs.241493		natural killer-tumor recognition sequenc	3.1
70					3.1
		AW137691 Hs.199754		ESTs	3.0
		AW591433 Hs.298241		Transmembrane protease, serine 3	3.0
	402000	BE077084 Hs.336432	SS,rm,zf-RanBP,pkinase,C2,pkinase_C,DA	3 2018	3.0

TABLE 21A

Table 21 A shows the accession numbers for those pkeys lacking unigeneID's for Table 21. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

l	U	

Pkey:	Unique Eos probeset identifier number
CAT number:	Gene cluster number

15

20

Accession:

Pkey	CAT number	Accessions
420854	197072_1	AW296927 AI684514 AI263168 AA281079
423431	228162_1	AA326062 AA325758 AW962182
423945	233566_1	AA410943 AW948953 AA334202 AA332882
451264	863988_1	AI768235 R31400 H29082 H23107
455325	1279475_1	AW895719 N31451 N41451
456207	1650781	AA193450

Genbank accession numbers

TABLE 21B

Table 21B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 21. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

401045 8117619 Plus 90044-90184,91111-91345	
401403 6117619 Plus 90044-90164,51111-91545 402230 9966312 Minus 29782-29932 402408 9796239 Minus 110326-110491 402578 9884928 Plus 66350-66496 403593 6862650 Minus 62554-62712,69449-69602 403943 7711864 Plus 100742-100904,101322-1015 404091 7684554 Minus 82121-83229	503

PCT/US02/02242 WO 02/059377

TABLE 22: 739 GENES UP-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 22 shows 739 genes up-regulated in breast cancer compared to normal adult breast. These were selected as for Table 19, except that the ratio was greater than or equal to 3.0, the denominator was the 85th percentile value for 12 non-malignant breast specimens, and the 96th percentile value amongst the 73 breast cancers was greater than or equal 100 units.

10

5

Pkey: ExAccn: Unique Eos probeset Identifier number

Exemplar Accession number, Genbank accession number

UnigenelD: Unigene number 15 Unigene gene title Unigene Title:

Ratio of 90th percentile tumor to 85th percentile normal breast tissue

20	Pkey	ExAccn	UnigenelD	UnigeneTitle	R1
_	400292	AA250737	Hs.72472	BMP-R1B	51.5
	424735	U31875	Hs.272499	short-chain alcohol dehydrogenase family	38.3
	400297	AI127076	Hs.334473	hypothetical protein DKFZp564O1278	29.9
	431448	AL137517	Hs.334473	hypothetical protein DKFZp564O1278	26.9
25	451110	AI955040	Hs.265398	ESTs, Weakly similar to transformation-r	25.8
	431211	M86849	Hs.323733	gap junction protein, beta 2, 26kD (conn	23.2
	418203	X54942	Hs.83758	CDC28 protein kinase 2	22.6
	407980	AA046309		gb:zf12f01.s1 Soares_fetal_heart_NbHH19W	19.8
		AA353776	Hs.901	CD48 antigen (B-cell membrane protein)	18.9
30	446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	18.0
	409041		Hs.50081	KIAA1199 protein	17.6
		AA219691	Hs.73625	RAB6 interacting, kinesin-like (rabkines	17.6
		AA147884	Hs.9812	Homo sapiens cDNA FLJ14388 fis, clone HE	17.1
25		Al263307	Hs.239884		17.0
35	407137			gb:ye53h05.s1 Soares fetal liver spleen	16.1
		D90041		N-acetyltransferase 1 (arylamine N-acety	16.1
		AI440266	Hs.170673		16.0
		AA321649		small inducible cytokine subfamily B (CX	15.5
40		NM_01439		similar to lysosome-associated membrane	15.1
40		AL120862	Hs.124165	programmed cell death 9 (PDCD9)	14.9
		AA746503	Hs.283313	=	14.7
		H60720	Hs.81892	KIAA0101 gene product	14.4
	452744		Hs.30504	Homo sapiens mRNA; cDNA DKFZp434E082	(1114.4
15		Al768015	Hs.92127	ESTS	14.2
45		AI733881	Hs.72472	BMP-R1B	14.1
		AW840171			13.8
	438209	AL120659	Hs.6111	aryl-hydrocarbon receptor nuclear transi	13.8
		AA489732	Hs.154918	NM_006265*:Homo saplens RAD21 (S. pomb ESTs	13.4
50		AA948033	Hs.130853		13.3
50		AL120173	Hs.301663		13.2
		BE280074	Hs.23960	cyclin B1	13.2
		M18728	113.23300	gb:Human nonspecific crossreacting antig	13.0
	406690		Hs.220529	carcinoembryonic antigen-related cell ad	12.8
55	429925		6Hs.226213		12.8
55		U33632	Hs.79351	potassium channel, subfamily K, member 1	12.7
		AI493046	Hs.146133		12.5
	441377		Hs.202656		12.5
		AA193450	, 15.E52000	gb:zr40e07.r1 Soares_NhHMPu_S1 Homo sa	
60		AA436989	Hs.121017	H2A histone family, member A	12.2
-	407811			cysteine knot superfamily 1, BMP antagon	12.2
		AA195651	Hs.104106		12.2
					

	420931	AF044197	Hs.100431	small inducible cytokine B subfamily (Cy	12.1
	421727	Y13153	Hs. 107318	kynurenine 3-monooxygenase (kynurenine 3	12.0
		AI031771	Hs.132586		12.0
_		H44186	Hs.15456	PDZ domain containing 1	11.9
5		BE178536		membrane-spanning 4-domains, subfamily A	
				calmodulin 2 (phosphorylase kinase, delt	11.7
		NM_00615	9HS.79389 Hs.293797	nel (chicken)-like 2	11.7 11.6
		AA156781		metallothionein 1E (functional)	11.5
10			Hs.293836		11.4
~ 0		H15261	Hs.21948	ESTs	11.3
		AW600291		hypothetical protein FLJ10430	11.3
	420757	X78592	Hs.99915	androgen receptor (dihydrotestosterone r	11.3
	411598	BE336654	Hs.70937	H3 histone family, member A	11.2
15		A1633559	Hs.310359		11.2
			Hs.123296		11.0
		AI684808		programmed cell death 9 (PDCD9)	10.9
		N78223		transcription factor	10.7
20		AA576953	Hs.111471	hypothetical protein FLJ13352	10.6 10.6
20		Al370413		hypothetical protein FLJ22418	10.4
		W67883	Hs.137476		10.4
		Al199268	Hs.19322	Homo sapiens, Similar to RIKEN cDNA 2010	
				NIMA (never in mitosis gene a)-related k	10.1
25		H87648	Hs.33922	Homo sapiens, clone MGC:9084, mRNA, com	p10.1
			Hs.131562		10.1
				Homo sapiens cDNA FLJ11382 fis, clone HE	
			Hs.144341		10.1
30		Al624342	Hs.170042 Hs.162859		10.0 10.0
50		Al926047 AL355715		programmed cell death 9	9.9
		AW966399		hypothetical protein FLJ20086	9.9
		Y00971	Hs.2910	phosphoribosyl pyrophosphate synthetase	9.9
		H23789	Hs.144530		9.9
35		Al655499			9.8
				CGI-49 protein	9.8
		BE613126	Hs.47783	B aggressive lymphoma gene	9.7
		C16391	11: 40077	gb:C16391 Clontech human aorta polyA mRN	
40		AA151342		CGI-147 protein	9.7 9.7
70		Al064690 Al022650	Hs.171176 Hs.8117	erbb2-interacting protein ERBIN	9.7
				uncharacterized bone marrow protein BM04	9.7
				Homo sapiens mRNA full length insert cDN	9.6
				cholesterol 25-hydroxylase	9.6
45		D60730	Hs.57471	ESTs	9.6
		Al375499	Hs.27379	ESTs	9.5
		R31178		fibronectin 1	9.3
				leucine-rich repeat-containing 2	9.3
50		R17798	Hs.7535	COBW-like protein	9.3
50		U80736 AJ224741		trinucleotide repeat containing 9 matrilin 3	9.2 9.2
				heterochromatin-like protein 1	9.2
		AA410943	713.270001	gb:zt32h03.r1 Soares ovary tumor NbHOT H	
		BE093589	Hs.38178	hypothetical protein FLJ23468	9.1
55		AI337735	Hs.173919		9.0
	408771	AW732573	Hs.47584	potassium voltage-gated channel, delayed	9.0
	437021		Hs.292239		9.0
		Y00272		cell division cycle 2, G1 to S and G2 to	8.9
60	-	A1767756	Hs.82302	Homo sapiens cDNA FLJ14814 fis, clone NT	
60	402408	NA AA279490	He SESES	NM_030920*:Homo sapiens hypothetical pro calmegin	8.9 8.8
	426327		Hs.44898	Homo sapiens clone TCCCTA00151 mRNA s	
		Al198719	Hs.176376		8.8
65	440621		Hs.150434		8.8
	446142	A1754693	Hs.145968		8.8
		A1745649	Hs.26549	KIAA1708 protein	8.7
	447178	AW594641	Hs.192417	ESTS	8.7

	427585	D31152	Hs.179729	collagen, type X, alpha 1 (Schmid metaph	8.6
				Homo sapiens cDNA FLJ11381 fis, clone HE	
	435061	Al651474	Hs.163944	ESTs	8.6
_	431374	BE258532	Hs.251871	CTP synthase	8.4
5	417866	AW067903	Hs.82772	collagen, type XI, alpha 1	8.4
		AA382207		ecotropic viral integration site 2B	8.3
		AA767373		ESTs, Moderately similar to ALU1_HUMAN A	
				DKFZP434G232 protein	8.2
10		BE268362		COBW-like protein	8.2
10				protein tyrosine phosphatase, receptor t	8.2
			Hs.59757 Hs.2839	zinc finger protein 281 Norrie disease (pseudoglioma)	8.2 8.1
			Hs.263478		8.1
		AW876523		hypothetical protein FLJ12910	8.1
15				Homo sapiens cDNA: FLJ23523 ffs, clone L	8.1
		AA781795			8.0
				ESTs, Weakly similar to 2109260A B cell	8.0
				DNA replication factor	8.0
		AW293165			8.0
20	436481	AA379597	Hs.5199	HSPC150 protein similar to ubiquitin-con	8.0
				AF15q14 protein	8.0
			Hs.83918	adenosine monophosphate deaminase (isofo	
	400285		11. 0000	Eos Control	7.9
25			Hs.9028	histone deacetylase 5	7.9
23		M18728	Un 442274	gb:Human nonspecific crossreacting antig	7.8 7.8
				transcription factor EC hypothetical protein FLJ23403	7.8 7.8
				aminopeptidase	7.8
				wingless-type MMTV Integration site fami	7.7
30			Hs.12285		7.6
			Hs.48269	vaccinia related kinase 1	7.6
	437207	T27503	Hs.15929	hypothetical protein FLJ12910	7.6
	442818	AK001741	Hs.8739	hypothetical protein FLJ10879	7.6
26				kynureninase (L-kynurenine hydrolase)	7.5
35				matrix metalloproteinase 9 (gelatinase B	7.5
		NM_016293		bridging integrator 2	7.5
			Hs.133525		7.5
		M97711 AW512260	Uc 97767	gb:Human T-cell receptor (V beta 18.1, J ESTs	7.5 7.4
40				kinesin protein 9 gene	7.4
-10		NM_001809		centromere protein A (17kD)	7.4
				Homo sapiens, clone MGC:12318, mRNA, coi	
				ELL-RELATED RNA POLYMERASE II, ELON	
	410361	BE391804	Hs.62661	guanylate binding protein 1, interferon-	7.3
45	400268			NM_003292:Homo sapiens translocated prom	
			Hs.58314	ESTs	7.3
			Hs.62713	ESTs	7.3
			Hs.109370		7.3
50				carboxylesterase 2 (Intestine, liver)	7.2 7.1
50				F-box only protein 5 ESTs, Weakly similar to JE0350 Anterior	7.1 7.1
				ESTs, Weakly similar to LEU5_HUMAN LEUK	
			Hs.97600	ESTs	7.0
		A1475858	110.07 000	gb:tc87d07.x1 NCI_CGAP_CLL1 Homo sapie	
55			Hs.326736	Homo sapiens breast cancer antigen NY-BR	
			Hs.28338	KIAA1546 protein	7.0
	444783	AK001468	Hs.62180	anillin (Drosophila Scraps homolog), act	7.0
		AA808229			6.9
C O		AW241821			6.9
60				cytochrome P450, subfamily IIJ (arachido	6.8
		AW500106		senne/threonine protein klnase MASK	6.8
		AW449211		GDNF family receptor alpha 1 B aggressive lymphoma gene	6.8 6.8
	414080	AA135257 Al767056	Hs.47783 Hs.193002	D aggressive lymphoma gene	6.8 6.7
65			Hs.44532	diubiquitin	6.7
55	422956	BE545072		hypothetical protein FLJ10461	6.7
	446651		Hs.97179	ESTs	6.7
	TOUGI				

		U24577	Hs.93304	phospholipase A2, group VII (platelet-ac	6.7
		AA810265 AI910275	Hs.122915 Hs.1406	trefoil factor 1 (pS2)	6.7 6.7
		AW023482		ESTs	6.6
5	429597	NM_003816	6Hs.2442	a disintegrin and metalloproteinase doma	6.6
	422634	NM_01601	DHs.118821	CGI-62 protein	6.6
		Al215069	Hs.89113	ESTs	6.5
		Al798680	Hs.25933	ESTS	6.5
10		N40449 Al151418	Hs.272458	ESTs, Weakly similar to S38383 SEB4B pro protein phosphatase 3 (formerly 2B), cat	6.5 6.4
10			3Hs.123114		6.4
		AF026941		Homo saplens cig5 mRNA, partial sequence	6.4
	456938			tyrosine aminotransferase	6.4
1.5		AI820961	Hs.193465		6.4
15			3Hs.153687		6.4
		U65011 AA918317	Hs.30743	preferentially expressed antigen in mela	6.4 6.4
		AJ235664	US:01.801	B-cell CLL/lymphoma 11B (zinc finger pro gb:Homo sapiens mRNA for immunoglobulin	6.3
		Al222020	Hs.182364	CocoaCrisp	6.3
20				done HQ0310 PRO0310p1	6.3
		Al193043		ESTs, Weakly similar to T17226 hypotheti ,	6.2
		AA394183	Hs.26873	ESTs	6.2
	402578	A1A14.C42.O4	1 lo 700	C1001134:gi 2117372 pir l65981 fatty ac	6.2
25		AW161391 W17064	Hs.332848	deoxycytidine kinase SWI/SNF related, matrix associated, acti	6.1 6.1
23	432415		Hs.289014	The state of the s	6.1
		AI082692	Hs.134662		6.1
	420929	AI694143	Hs.296251	programmed cell death 4	6.1
20		BE440042		matrix metalloproteinase 3 (stromelysin	6.1
30		AI126772	Hs.40479	ESTs	6.0
		BE463721 U23752	Hs.97101 Hs.32964	putative G protein-coupled receptor SRY (sex determining region Y)-box 11	6.0 6.0
	425397			topoisomerase (DNA) II alpha (170kD)	6.0
		M13509	Hs.83169	matrix metalloproteinase 1 (MMP1; inters	6.0
35			Hs.185140	KIAA0403 protein	6.0
		AA761605		ESTs, Weakly similar to ALU1_HUMAN ALU	
		AA583206		RAR-related orphan receptor A	6.0
	418092	M31126	Hs.272620 Hs.106604	•	6.0 6.0
40				ESTs, Weakly similar to Con1 [H.sapiens]	6.0
			Hs.135568		6.0
	432239		Hs.2936	matrix metalloproteinase 13 (collagenase	6.0
	435106	AA100847	Hs.193380	ESTs, Highly similar to AF174600 1 F-box	5.9
15		Al831297	Hs.123310		5.9
45		AW972512	Hs.20985	sin3-associated polypeptide, 30kD	5.9
		AW803341	He 11855/	gb:IL2-UM0079-090300-050-D03 UM0079 Ho CGI-83 protein	5.9
		Al793124	Hs.144479		5.9
				hypothetical protein FLJ22624	5.8
50	412022	Al005043	Hs.24143	Wiskott-Aldrich syndrome protein interac	5.8
	416636		Hs.42645	solute carrier family 16 (monocarboxylic	5.8
		A1375572	Hs.172634		5.8
		AA305599 AA306105	Hs.50785	hypothetical protein PRO2013 SEC22, veside trafficking protein (S. c	5.8 5.8
55		AI571940	Hs.7549	ESTs	5.8
	452281		Hs.28792	Homo sapiens cDNA FLJ11041 fis, done PL	5.8
	421281	Al299139	Hs.17517	ESTs	5.8
		AI033965		sterol-C4-methyl oxidase-like	5.8
60	400289		Hs.2258	matrix metalloproteinase 10 (MMP10; str	5.7
60		AV657117 AA831879	Hs.184164 Hs.136985	ESTs, Moderately similar to S65657 alpha	5.7 5.7
		W47595		transforming growth factor, beta 2	5.7
		NM_00711		tumor necrosis factor, alpha-induced pro	5.7
	448663	BE614599	Hs.106823	hypothetical protein MGC14797	5.7
65			Hs.122147		5.7
	446203	Z47553	Hs.14286	flavin containing monooxygenase 5	5.7
	428336	AA503115	HS.183/52	microseminoproteln, beta-	5.6

	430379	AF134149	Hs.240395	potassium channel, subfamily K, member 6	5.6
	422835	BE218705	Hs.121378	metallothionein-like 5, testis-specific	5.6
		AL044878		, , , , , , , , , , , , , , , , , , , ,	5.6
5		AF098158		chromosome 20 open reading frame 1	5.6
3		X03635	Hs.1657	estrogen receptor 1	5.6
	4470/8	AW885727	HS.3015/U	Homo sapiens mRNA; cDNA DKFZp5860072	5.6
	438691	AA906288	He 212184	FSTe	5.5
	439809	R41396		hypothetical protein FLJ23045	5.5
10		AW419196			5.5
	456373	BE247706	Hs.89751	membrane-spanning 4-domains, subfamily A	
	401645			C16001440*:gi]12330704 gb AAG52890.1 AF	35.5
		BE277414		mel transforming oncogene (derived from	5.5
15		A1734009		KIAA1603 protein	5.4
13		AI742605 NM_01598			5.4
		X91221	Hs.144465	cytokine receptor-like molecule 9	5.4 5.4
		R28363	Hs.24286	ESTs	5.4
		BE392914		Homo sapiens cDNA FLJ11344 fis, done PL	
20		H59846		ESTs, Moderately similar to ALU7_HUMAN A	
		AA319146		secretogranin II (chromogranin C)	5.4
		L32137	Hs.1584	cartilage oligomeric matrix protein (COM	5.4
		N34895	Hs.44648	ESTs	5.4
25		AW205168			5.4
23		AA576635		Opa-interacting protein 5 CGI-48 protein	5.3 5.3
		AA814100		ESTs	5.3
		U91616	Hs.91640	nuclear factor of kappa light polypeptid	5.3
	450701	H39960	Hs.288467	Homo sapiens cDNA FLJ12280 fis, clone MA	
30	445900	AF070526	Hs.13429	Homo sapiens clone 24787 mRNA sequence	5.2
	449051	AW961400	Hs.333526	HER2 receptor tyrosine kinase (c-erb-b2,	5.2
	418758	AW959311	Hs.172012	hypothetical protein DKFZp434J037	5.2
		U65590	Hs.81134	transcription factor 19 (SC1) interleukin 1 receptor antagonist	5.2 5.2
35				polyadenylate binding protein-interactin	5.2
-	428804	AK000713	Hs. 193736	hypothetical protein FLJ20706	5.2
		AF077345			5.2
	403485			C3001813*:gi 12737279 ref XP_012163.1 k	5.2
40				S100 calcium-binding protein A7 (psorias	5.1
40		Al878857		hematological and neurological expressed	5.1
		X69490 X70697	Hs.172004		5.1
		M81933	Hs.553 Hs.1634	solute carrier family 6 (neurotransmitte cell division cycle 25A	5.1 5.1
		AI810054	Hs.14119	ESTs	5.1
45				ESTs, Moderately similar to ALU7_HUMAN A	
	453931		Hs.25144	ESTs	5.1
	404347			Target Exon	5.1
		M30703		amphiregulin (schwannoma-derived growth	5.1
50	429113		Hs.5101	prostaglandin-endoperoxide synthase 2 (p	5.1
50	450603		Hs.12422	protein regulator of cytokinesis 1 ESTs	5.1 5.1
			Hs.4104	hypothetical protein	5.0
	435981		Hs.188620		5.0
	407376	AA993138	Hs.142287	ESTs, Weakly similar to ALUF_HUMAN !!!!	5.0
55			Hs.267695	UDP-Gal:betaGlcNAc beta 1,3-galactosyltr	5.0
	405348		11- 000400	C7001664:gi 12698061 db BAB21849.1 (AB	5.0
		AL036450		Homo sapiens cDNA FLJ10222 fis, clone HE	
			Hs.59838	hypothetical protein FLJ10808	5.0 5.0
60		NM_006235			5.0
- •		AU076643			4.9
	403329	NA		Target Exon	4.9
		BE623003		Homo sapiens clone TCCCTA00142 mRNA se	
65			Hs.129598		4.9
05		AW371048 AW966163	IS.33/58	H4 histone family, member H gb:EST378236 MAGE resequences, MAGI Ho	4.9
			Hs.182278		4.9
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				7.0

		AA650274		fibronectin leucine rich transmembrane p	4.9
		NM_00210 R10799	4HS.3066 Hs.191990	granzyme K (serine protease, granzyme 3;	4.9 4.8
				ESTs, Weakly similar to AT2A_HUMAN POTE	
5		Z45051	Hs,22920	similar to S68401 (cattle) glucose induc	4.8
		R38438	Hs.182575		4.8
		AF078849			4.8
		C18863	Hs.163443		
10		H93281	Hs.10710	hypothetical protein FLJ20417	4.8
10		Al571835	Hs.55468	GDNF family receptor alpha 1 ESTs	4.8 4.8
		AL135173		sorbitol dehydrogenase	4.8
		AL161999	Hs.77324	eukaryotic translation termination facto	4.8
	419078	M93119	Hs.89584	insulinoma-associated 1	4.8
15		AA233056			4.8
		Al357412	Hs.157601		4.8
		A1879148 X04430	Hs.26770	fatty acid binding protein 7, brain	4.7
			Hs.93913	interleukin 6 (interferon, beta 2) disintegrin protease	4,7 4,7
20			Hs,262823		4.7
				Homo sapiens cDNA; FLJ22463 fis, clone H	4.7
		AW192307		dolichyl-P-Glc:Man9GlcNAc2-PP-dolichylgl	4.7
		NM_015310		KIAA0942 protein	4.7
25		AI675749		nucleoponin 153kD	4.7
25		AF228704	Hs.121524	glutathione reductase	4.7 -4.0
	405801	BE218886	Hs.282070	NM_000390:Homo sapiens choroideremia (Ra	4.6 4.6
		W26354	Hs.28891	hypothetical protein FLJ11360; artemis p	4.6
		U62027		complement component 3a receptor 1	4.6
30	436027	AI864053	Hs.39972	ESTs, Weakly similar to I38588 reverse t	4.6
			Hs.337404		4.6
	403366	NA		Target Exon	4.6
	402542	AI916071	Hs.15607	Target Exon Homo sapiens Fanconi anemia complemental	4.6
35		Al907114	Hs.71465	squalene epoxidase	4.6
22		Al264155	Hs.152981		4.6
		Al459306	Hs.24908	ESTs	4.5
			Hs.245123		4,5
40		Al472209	Hs.323117		4.5
40		AW630534		Homo sapiens, clone MGC:9381, mRNA, com	
		AF146761 AI692181	Hs.49169	BCM-like membrane protein precursor KIAA1634 protein	4.5 4.5
		AW962128	115.43103	gb:EST374201 MAGE resequences, MAGG H	
			Hs.254881		4.5
45	428500	AI815395	Hs.184641	fatty acid desaturase 2	4.5
				ESTs, Weakly similar to 2109260A B cell	4.4
		A1377755	Hs.120695		4.4
		AA121673		Homo sapiens winged helix/forkhead trans zinc finger protein 281	4.4 4.4
50		Al815206	Hs.99395	ESTs	4.4
• •	401866	7.110 10200	. 10.0000	Target Exon	4.4
	418819	AA228776	Hs.191721		4.4
	406348			Target Exon	4.4
E E		AW895387		gb:QV4-NN0038-300300-157-c10 NN0038 Ho	
55		AW297880	Hs.98661	ESTS	4.4
		AW862214	He 283037	gb:QV4-CT0361-301299-074-b05 CT0361 Ho HSPC039 protein	4.4
				guanylate cyclase 1, soluble, beta 2	4.4
				DKFZP586D0824 protein	4.4
60	452190		Hs.91668	Homo sapiens clone PP1498 unknown mRNA	4.4
				low density lipoprotein-related protein	4.3
		AA706003		ESTs	4.3
	429922			H1 histone family, member 0	4.3 4.3
65	421379 400300		ms. 103982	small inducible cytokine subfamily B (Cy HER2 receptor tyrosine kinase (c-erb-b2,	4.3 4.3
55		AL041243	Hs.174104		4.3
	446595		Hs.15467	hypothetical protein FLJ20725	4.3
				•	

	403011	ATA		ENCOCOCCATOCO Destable assis (the see	40
		Al365384	Hs.11571	ENSP00000215330*:Probable serine/threoni	
		NM_00194		Homo sapiens cDNA FLJ11570 fis, clone HE	
		AA687538		E2F transcription factor 3 tetraspan 1	4.3 4.3
5				KIAA0704 protein	4.3
		AW188551		hypothetical protein FLJ14007	4.3
			Hs.179246	ESTs	4.3
		Al694413		olfactory receptor, family 2, subfamily	4.3
		M63835	Hs.77424	Fc fragment of IgG, high affinity la, re	4.2
10			Hs.279727	Homo sapiens cDNA FLJ14035 fis, done HE	4.2
		T47667	Hs.28005	Homo sapiens cDNA FLJ11309 fis, done PL	4.2
	442007	AA301116	Hs.142838	nucleolar phosphoprotein Nopp34	4.2
		AW953937		ESTs	4.2
15				ESTs, Weakly similar to T47184 hypotheti	4.2
13		A1085198 AW851980	Hs.164226	ESTs, Weakly similar to S72482 hypotheti	4.2 4.2
	446839	BE091926	Hs 16244	mitotic spindle coiled-coil related prot	4.2
				DEME-6 protein	4.2
	432116	AA902953	Hs.308538	ESTs	4.2
20		T97490	Hs.50002	small inducible cytokine subfamily A (Cy	4.2
	445625	BE246743	Hs.288529	hypothetical protein FLJ22635	4.2
				protease, serine, 23	4.2
		BE247676		E-1 enzyme	4.2
25		AK001376		hypothetical protein FLJ10514	4.1
25		AW779318		ESTs	4.1
			Hs.241551 Hs.132208	chloride channel, calcium activated, fam	4.1
		BE244074		regulator of Fas-induced apoptosis	4.1 4.1
			Hs.290585		4.1
30				matrix metalloproteinase 11 (MMP11; stro	4.1
		AF041163		Human T-cell receptor active alpha-chain	4.1
		BE562826		gb:601336534F1 NIH_MGC_44 Homo saplen	
		AK000136		asporin (LRR class 1)	4.1
25	426711	AA383471	Hs.180669	conserved gene amplified in osteosarcoma	4.1
35	405850		14 400400	Target Exon	4.1
		A1732892	Hs.190489	=	4.0
	400284		Hs.163484		4.0
		N91453	Hs.102987	estrogen receptor 1	4.0 4.0
40		U20158	Hs.2488	lymphocyte cytosolic protein 2 (SH2 doma	4.0
		AW797437		B-factor, properdin	4.0
	425704			Human clone 23948 mRNA sequence	4.0
	419594	AA013051		topoisomerase (DNA) II binding protein	4.0
4.5	419092		Hs.89603	mucin 1, transmembrane	4.0
45		Al034351	Hs.19030	ESTs	4.0
		AW963372		PRO2000 protein	4.0
	433404		Hs. 102720		4.0
		BE250127		thymldine kinase 1, soluble CDC20 (cell division cycle 20, S. cerevi	4.0 3.9
50		AW630088		Homo sapiens mRNA; cONA DKFZp564B126	
-		AW411479		FK506-binding protein 4 (59kD)	3.9
	404580		, 10.0 10	NM_014112*:Homo sapiens trichorhinophala	
		AB018345	Hs.27657	KIAA0802 protein	3.9
		AA031956		gb:zk15e04.s1 Soares_pregnant_uterus_NbH	
55	416658		Hs.79432	fibrillin 2 (congenital contractural ara	3.9
			Hs.294101	pre-B-cell leukemia transcription factor	3.9
		AL117406	Hs.200102	ATP-binding cassette transporter MRP8	3.9
			Hs.190325		3.9
60	418918		Hs.89476	CD2 antigen (p50), sheep red blood cell	3.9
50		W94197 Al201183	Hs.130251	ribosomal protein L26 homolog ESTs	3.9
					3.9 3.9
		AW935490	Hs.14658	Human chromosome 5q13.1 clone 5G8 mRNA	3.9
		BE019020		solute carrier family 16 (monocarboxyllc	3.9
65		NM_002543			3.9
		AA809875		ESTs	3.9
	419741	NM_007019	Hs.93002	1: "	3.9

	430017	AA263172 Hs.35	protein tyrosine phosphatase, non-recept	3.9	
	458814	Al498957 Hs.17086			
	428514	AW236861 Hs.19313	9 ESTs	3.8	
_		NM_002267Hs.3886	karyopherin alpha 3 (importin alpha 4)	3,8	
5		U40462 Hs.54452		3.8	
		BE565647 Hs.74899		3.8	
		AF055084 Hs.15369	2 Homo sapiens cDNA FLJ14354 fis, done Y7	3.8	
	400021	DE400000 Ha 04770	AFFX control - HUMISGF3A/M97935_MA	3.8	
10		BE466639 Hs.61779		3.8	
10		Al267371 Hs.17263 AA631739 Hs.33544		3.8 3.8	
		AW207206 Hs.13631		3.8	
			4 ESTs, Weakly similar to B28096 line-1 pr	3.8	
	401045		C11001883*:gi[6753278 ref NP_033938.1] c	3.8	
15	430178	AW449612 Hs.15247		3.8	
	423397	NM_001838Hs.1652	chemokine (C-C motif) receptor 7	3.8	
		Al660149 Hs.44865	, .	3.8	
		AJ227892 Hs.14627		3.8	
20		AW068115 Hs.821	biglycan	3.8	
20		AI767949 Hs.17983		3.8	
		NM_003512Hs.28777 M81057 Hs.18088		3.8 3.8	
		AA165232 Hs.22206		3.8	
		AL353944 Hs.50115			3.8
25			0 HER2 receptor tyrosine kinase (c-erb-b2,	3.7	•
	400286		C16000922:gi 7499103[pirl[T20903 hypothe	3.7	
		Al623693 Hs.19153		3.7	
		AW900992 Hs.93796		3.7	
20			0 hypothetical protein FLJ22439	3.7	
30		AA371307 Hs.12505		3.7	
		Al916662 Hs.21157 J03258 Hs.2062	7 kinectin 1 (kinesin receptor) vitamin D (1,25- dihydroxyvitamin D3) re	3.7 3.7	
	-	AW406878	gb:UI-HF-BL0-adg-g-06-0-UI.r1 NIH_MGC_37		
		NM_014737Hs.80905			
35			O Homo sapiens cDNA FLJ11489 fis, clone HE		
	430448	Al633553 Hs.13303		3.7	
			2 hypothetical protein FLJ20285	3.7	
		N49813 Hs.75615		3.7	
40			2 cell recognition molecule Caspr2	3.7	
40			2 normal mucosa of esophagus specific 1 6 ESTs, Weakly similar to (defline not ava	3.7 3.7	
	406153	AA037204 ITS.23033	Target Exon	3.7	
		AW873606 Hs.14900		3.7	
		Al884911 Hs.32989	receptor (calcitonin) activity modifying	3.7	
45	448918	AB011152 Hs.22572		3.7	
		AF113676 Hs.29768		3.6	
		U76248 Hs.20191	seven in absentia (Drosophila) homolog 2	3.6	
			6 hypothetical protein FLJ22490	3.6	
50		X98654 Hs.93837	9 ESTs, Weakly similar to I38022 hypotheti phosphatidylinositol transfer protein, m	3.6 3.6	
30		AF188625 Hs.18950	7 phospholipase A2, group IID	3.6	
	430378		tumor necrosis factor receptor superfami	3.6	
		AI800470 Hs.17194		3.6	
	426431	NM_000458Hs.16985	3 · transcription factor 2, hepatic; LF-B3;	3.6	
55			6 ESTs, Weakly similar to 138022 hypotheti	3.6	
		BE069341	gb:QV3-BT0381-270100-073-c08 BT0381 Ho		
		AW024973 Hs.28367		3.6	
		AV653264 Hs.13982		3.6	
60	452101		3 KIAA0129 gene product	3.6	
50		AW961434 Hs.31539		3.6	
		NM_000402Hs.80206		3.6	
		W26187 Hs.3327	Homo sapiens cDNA: FLJ22219 fis, clone H	3.6	
	440516	S42303 Hs.161	cadherin 2, type 1, N-cadherin (neuronal	3.6	
65		AW015415 Hs.12778		3.6	
		BE276891 Hs.19469		3.6	
	415079	R43179 Hs.22895	hypothetical protein FLJ23548	3.6	

3.4

	100010	41/00/00/5		2010 - 1-1-1-1	
		AK001015		BCL2-associated athanogene 2	3.6
			Hs.152812		3.6
			Hs.194024		3.6
5		AA380731		interleukin 2 receptor, gamma (severe co	3.6
5		AF088020		EST	3.6
		H63010	Hs.5740	ESTs	3.5
				eukaryotic translation elongation factor	3.5
		AI418055	Hs.161160		3.5
10		AF234882		suppression of tumorigenicity 7	3.5
10		AA284166		cyclin-dependent kinase inhibitor 3 (CDK	3.5
			Hs.222399		3.5
		AI907673		gb: L-BT152-080399-004 BT152 Homo sapier	
	403212	114000705	11- 50570	NM_019595:Homo sapiens Intersectin 2 (IT	3.5
15		AK000725		hypothetical protein FLJ20718	3.5
15				Homo sapiens, clone IMAGE:3351295, mRNA	
		W92147	Hs.118394		3.5
	422890		Hs.75893	ankyrin 3, node of Ranvier (ankyrin G)	3.5
		A1827248		Homo sapiens cDNA FLJ11469 fis, done HE	
20		AA641836		hypothetical protein FLJ23186	3.5 3.5
20		AK002135		hypothetical protein FLJ11273	3.5
			Hs.137007	poly(A)-binding protein, cytoplasmic 1-l	3.4
		BE311926	Hs.15830	hypothetical protein FLJ12691	3.4
		AW881145	NS. 13030	gb:QV0-OT0033-010400-182-a07 OT0033 Ho	
25		BE390551	Hs.77628	steroidogenic acute regulatory protein r	3.4
23		W29092	Hs.7678	cellular retinoic acid-binding protein 1	3.4
		AI167877	Hs.143716		3.4
	402470		115.145710	Target Exon	3.4
			Hs.192249		3.4
30		AW875237		ESTs	3.4
50		AI681545		hypothetical protein FLJ13117	3.4
		U61412	Hs.51133	PTK6 protein tyrosine kinase 6	3.4
		AA158177		fucosyltransferase 8 (alpha (1,6) fucosy	3.4
		M90516	Hs.1674	glutamine-fructose-6-phosphate transamin	3.4
35		AA447492		ESTs, Weakly similar to AF164793 1 prote	3.4
	402359		, 10.20100	C19001991*:gij12656111 gbjAAK00751.1 AF:	
		AA284267	Hs.221504		3.4
	415208		Hs.172004		3.4
		AA812633		ESTs	3.4
40	429345	R11141		hypothetical protein	3.4
	449027	AJ271216	Hs.22880	dipeptidylpeptidase III	3.4
	412115	AK001763	Hs.73239	hypothetical protein FLJ10901	3.4
	432180	Y18418	Hs.272822	RuvB (E coli homolog)-like 1	3.4
	428977	AK001404	Hs.194698		3.4
45		U58766	Hs.264428	tissue specific transplantation antigen	3.4
	418286	AA622528	Hs.319825	Homo sapiens, clone IMAGE:3616574, mRN/	
		AF037335		carbonic anhydrase XII (tumor antigen H	3.4
	443378	AW392550	Hs.9280	proteasome (prosome, macropain) subunit,	3.4
~ 0				KIAA0175 gene product	3.3
50	449571	AW016812	Hs.200266		3.3
		Al335773	Hs.270123		3.3
		NM_000505		coagulation factor XII (Hageman factor)	3.3
		AW160375		amyloid beta (A4) precursor-like protein	3.3
~ ~		U70370	Hs.84136	paired-like homeodomain transcription fa	3.3
55		AI627393		ESTs, Weakly similar to high mobility gr	3.3
				ESTs, Weakly similar to I38022 hypotheti	3.3
		AA361258		interleukin 7 receptor	3.3
		AA161071	Hs.71465	squalene epoxidase	3.3
60				glutamic-oxaloacetic transaminase 2, mit	3.3
60		AI086138	Hs.204044		3.3
				ras-related C3 botulinum toxin substrate	3.3
	426429			myosin-binding protein C, slow-type	3.3
		AA026880	Hs.25252	prolactin receptor	3.3
65	428566			clathrin, heavy polypeptide-like 1	3.3
65		BE243136	Hs.86947	a disintegrin and metalloproteinase doma	3.3
	436293	AI601188	Hs.120910		3.3
	411257	AA628967	ms.1152/4	ESTs, Highly similar to IHH_HUMAN INDIAN	3.3

	430253	AK001514		hypothetical protein FLJ10652	3.3
	430066	AI929659	Hs.237825	signal recognition particle 72kD	3.3
	436469	AK001455	Hs.5198	Down syndrome critical region gene 2	3.3
_		BE142681	Hs.155573	polymerase (DNA directed), eta	3.3
5		H09048	Hs.23606	ESTs	3.3
		H91882	Hs.118569	Dvl-binding protein IDAX (inhibition of	3.3
		AA496078		Human DNA sequence from clone RP11-2180	
		AA446932		ret finger protein 2	3.3
10			Hs.193804		3.3
10		R43409	Hs.6829	Homo sapiens mRNA for KIAA1644 protein,	3.3
		AW978484		Homo sapiens cDNA: FLJ22554 fis, clone H	3.3
		AI015709		Homo sapiens mRNA; cDNA DKFZp586i2022	
				ESTs, Weakly similar to A47582 B-cell gr	3.3 3.3
15		BE614387	Hs.118725	selenophosphate synthetase 2 c-Myc target JPO1	3.3
13		U24683		immunoglobulin heavy constant mu	3.3
		AA907734	Hs.124895		3.3
		AA479033		ESTs, Weakly similar to A47582 B-cell gr	3.3
		C01765	Hs.38750	hypothetical protein FLJ11526	3.3
20 -		AA912183	Hs.47447	ESTs	3.3
		U46258	Hs.339665		3.3
	404755			Target Exon	3.3
	451871	AI821005	Hs.118599		3.2
		AW406289		hypothetical protein	3.2
25	430580	AA806105	Hs.300697	immunoglobulin heavy constant gamma 3 (G	3.2
	400202			NM_002795*:Homo sapiens proteasome (pros	s3.2
	400222			NM_002082*:Homo sapiens G protein-couple	
		BE045897		ESTs, Weakly similar to l38022 hypotheti	3.2
20		BE550224	Hs.74170	metallothionein 1E (functional)	3.2
30		AJ002744		UDP-N-acetyl-alpha-D-galactosamine:polyp	3.2
		AI027643	Hs.120912		3.2
		BE379594	Hs.49136	ESTs, Moderately similar to ALU7_HUMAN A	
		U79745 AI793257	Hs.128151	solute carrier family 16 (monocarboxylic	3.2
35		AA640891	Hs.102406		3.2
<i>J J</i>		H04588	Hs.30469	ESTs	3.2
		AI244459		trinucleotide repeat containing 9	3.2
		AI821926	7.0	gb:nt78f05.x5 NCI_CGAP_Pr3 Homo sapiens	
			Hs.110857	polymerase (RNA) III (DNA directed) poly	3.2
40		NM_015156		KIAA0071 protein	3.2
		AI472078	Hs.303662		3.2
	448030	N30714	Hs.325960	membrane-spanning 4-domains, subfamily A	3.2
	418739	AA310964	Hs.88012	SHP2 interacting transmembrane adaptor	3.2
		R35343	Hs.24968	Human DNA sequence from clone RP1-233G	
45	434747	AA837085	Hs.220585	ESTs	3.2
		AW292593		Homo sapiens, clone MGC:17333, mRNA, con	
		AW503785		complement component (3d/Epstein Barr vi	3.2
		AA025386		ESTs, Weakly similar to S10590 cysteine	3.2
50		AW408337		CD7 antigen (p41)	3.2
50		D50915	Hs.38365	KIAA0125 gene product	3.2
		AL047586	Hs.10283	RNA binding motif protein 8B	3.2 3.2
			Hs.112157		3.2
		W20128 AA319233	Hs.296039 Hs.5521	ESTs	3.2
55		AA418204		ESTs natural killer-tumor recognition sequenc	3.2
55		AW966728		methionine adenosyltransferase II, beta	3.2
		AL118668		gb:DKFZp761I0310_r1 761 (synonym: hamy2)	
	417793	AW405434	Hs 82575	small nuclear ribonucleoprotein polypept	3.2
	428027	U22029	Hs.334345	cytochrome P450, subfamily IIA (phenobar	3.2
60	441197	BE244638	Hs.166	sterol regulatory element binding transc	3.2
~~	424634		3Hs.151407	cartilage intermediate layer protein, nu	3.2
	419986	AI345455	Hs.78915	GA-binding protein transcription factor,	3.2
	416714	AF283770	Hs.79630	CD79A antigen (immunoglobulin-associated	3.2
	449465	NM_004380	OHs.23598	CREB binding protein (Rubinstein-Taybi s	3.2
65	422166	W72424	Hs.112405	S100 calcium-binding protein A9 (calgran	3.2
	409079	W87707	Hs.82065	interleukin 6 signal transducer (gp130,	3.2
	420EE4	A A 3 2 7 5 0 R	He 233785	ESTe	32

		AA036849	Hs.61829	Homo sapiens cDNA FLJ12763 fis, clone NT	3.2
		AI733682	Hs.130239		3.2
		AI796870	Hs.54277	DNA segment on chromosome X (unique) 992	
5		AF076292 BE122762		forkhead box H1 ESTs	3.2 3.2
5	407104			v-erb-b2 avian erythroblastic leukemia v	3.2
		AI703172		ESTs, Weakly similar to 2109260A B cell	3.1
	430271			DnaJ (Hsp40) homolog, subfamily B, membe	3.1
4.0	425317	AW205118	Hs.210546	interleukin 21 receptor	3.1
10		AI278023	Hs.89986	ESTs	3.1
		BE388898		hypothetical protein FLJ11307	3.1
		AL137589 BE379335		hypothetical protein DKFZp434K0410 proteasome (prosome, macropain) 26S subu	3.1 3.1
				ESTs, Weakly similar to KIAA1074 protein	3.1
15				hypothetical protein dJ434O14.3	3.1
		Al124756	Hs.5337	isocitrate dehydrogenase 2 (NADP), mitoc	3.1
	405017			Target Exon	3.1
		AA706910			3.1
20		AL353957		hypothetical protein DKFZp434P0531	3.1
20	430105	NM_001141	Hs.2540	cholinergic receptor, nicotinic, alpha p arachidonate 15-lipoxygenase, second typ	3.1 3.1
	413507			ESTs, Weakly similar to I38022 hypotheti	3.1
		Al267700	Hs.317584		3.1
	422907	AI879263	Hs.6986	Human glucose transporter pseudogene	3.1
25		AA890023	Hs.1906	prolactin receptor	3.1
		BE387202		non-metastatic cells 1, protein (NM23A)	3.1
		AW247529 Al638516	Hs.22630	platelet-activating factor acetylhydrola cofactor required for Sp1 transcriptiona	3.1 3.1
		Al885190		ESTs, Weakly similar to repressor protei	3.1
30		U38945	Hs.1174	cyclin-dependent kinase inhibitor 2A (me	3.1
	400814			Target Exon	3.1
	402327			Target Exon	3.1
		AA190712		gb:zp87f09.r1 Stratagene HeLa cell s3 93	3.1
35		AL355722 Al571514	Hs.1068/5 Hs.133022	Homo sapiens EST from clone 35214, full	3.1 3.1
55		NM_000579		chemokine (C-C motif) receptor 5	3.1
		AJ245210	71 10.0 7 7 70	gb:Homo sapiens mRNA for immunoglobulin	3.1
		AF052762		gb:Homo sapiens clone csneg8-1 immunoglo	3.1
40		BE514514		coronin, actin-binding protein, 1A	3.1
40		AU076633	Hs.76353	serine (or cysteine) proteinase inhibito	3.1
	416379		Hs.203933		3.1
		D89974 Al399956	Hs.121102 Hs.208956		3.1 3.1
		BE143533		hypothetical protein FLJ20035	3.1
45		AW899713			3.1
	436043	AW963838	Hs.168830	Homo saplens cDNA FLJ12136 fis, clone MA	3.1
		AB012124	Hs.30696	transcription factor-like 5 (basic helix	3.1
	405381		LI= 4000C4	Target Exon	3.1
50	428746	AW503820 AL133731	Hs.4774	Spi-B transcription factor (Spi-1/PU.1 r Homo sapiens mRNA; cDNA DKFZp761C171	3.1 2.193.1
30	425782			cell growth regulatory with EF-hand doma	3.1
		W88562	Hs.108198		3.1
	419123	AA234276		ESTs	3.1
	438581			ESTs, Moderately similar to 178885 serin	3.1
55		X60992	Hs.81226	CD6 antigen	3.0
	428361 417880	NM_015905 BE241595		transcriptional intermediary factor 1 selectin L (lymphocyte adhesion molecule	3.0 3.0
	402606	DE241353	H5.02040	NM_024626:Homo sapiens hypothetical prot	
	401451			NM_004496*;Homo sapiens hepatocyte nucle	
60		AA299652	Hs.111496	Homo saplens cDNA FLJ11643 fis, clone HE	
		BE384836	Hs.3454	KIAA1821 protein	3.0
		BE561850	Hs.80506	small nuclear ribonucleoprotein polypept	3.0
		Y14768 X74794	Hs.890	lymphotoxin beta (TNF superfamily, membe minichromosome maintenance deficient (S.	3.0 3.0
65	425081 401519	A1 41 34	Hs.154443	C15000476*:gi 12737279 ref XP_012163.1	3.0
33		AI499220	Hs.71573	hypothetical protein FLJ10074	3.0
		AL135623		KIAA0575 gene product	3.0

	428423	AU076517	Hs.184276	solute carrier family 9 (sodium/hydrogen	3.0	
	413835	AI272727	Hs.249163	fatty acid hydroxylase	3.0	
	412600	L28824	Hs.74101	spleen tyrosine kinase	3.0	
	410491	AA465131	Hs.64001	Homo sapiens done 25218 mRNA sequence	3.0	
5	433658	L03678	Hs.156110	immunoglobulin kappa constant	3.0	
	427666	AI791495		calmodulin-like skin protein	3.0	
	452514	AI904898	-	gb:RC-BT068-130399-085 BT068 Homo sapi	en3.0	
	429500	X78565	Hs,289114	hexabrachion (tenascin C, cytotactin)	3.0	
	432485	N90866		CDW52 antigen (CAMPATH-1 antigen)	3.0	
10	437400	AB011542	Hs.5599	EGF-like-domain, multiple 5	3.0	
	452234	AW084176	Hs.223296	ESTs, Weakly similar to I38022 hypotheti	3.0	
	413269	BE167526		gb:CM4-HT0509-080300-107-g07 HT0509 Ho	omo	3.0
	453216	AL137566	Hs.32405	Homo sapiens mRNA; cDNA DKFZp586G032	21 (f	3.0
	400929			ENSP00000252232*:Sterol regulatory eleme	3.0	
15	445145	AI961702	Hs.147434	ESTs	3.0	
	432615	AA557191	Hs.55028	ESTs, Weakly similar to I54374 gene NF2	3.0	
	423279	AW959861	Hs.290943	ESTs	3.0	
	429392	AL109712	Hs.296506	Homo saplens mRNA full length insert cDN	3.0	
	408548	AA055449	Hs.63187	ESTs, Weakly similar to ALUC_HUMAN !!!!	3.0	
20	451346	NM_006338	3Hs.26312	glioma ampiffied on chromosome 1 protein	3.0	
	413109	AW389845	Hs.110855	ESTs	3.0	
	401714	NA		ENSP00000241802*:CDNA FLJ11007 FIS, C	LON	3.0
	421462	AF016495	Hs.104624	aquaporin 9	3.0	
	421750	AK000768	Hs.107872	hypothetical protein FLJ20761	3.0	
25	453293	AA382267	Hs.10653	ESTs	3.0	
	457085	AA412446	Hs.98138	ESTs	3.0	
	438930	AWR43633	Hs 306163	hypothetical protein Al 110115	3.0	

TABLE 22A

10

425331 250199 1

Table 22A shows the accession numbers for those pkeys lacking unigeneID's for Table 22. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

Pkey: CAT number: Unique Eos probeset Identifier number Gene cluster number Accession: Genbank accession numbers 15 CAT number Accessions 407980 103087_1 AA046309 Al263500 AA046397 AW803341 AW803265 AW803403 AW803466 AW803402 AW803413 AW803268 AW803396 AW803334 AW803355 410785 1221055_1 20 411743 1256098_1 AW862214 AW859811 AW862215 412138 1279172_1 AW895387 AW895547 AW895564 AW895323 AW895405 AW895539 AW895538 413269 1356961_1 BE167526 BE167651 BE076401 R24654 416935 163179_1 AA190712 AA190665 AA252564 AW881145 AA490718 M85637 AA304575 T06067 AA331991 422128 211994_1 25 AA410943 AW948953 AA334202 AA332882 423945 233566_1 AW406878 AW966560 AW966151 AW966496 AA336174 AA335376 AA335537 424109 235506_1 424128 235728 1 AW966163 AA335983 AA336011 AA335668 AA335973

BE069341 AW748403 AL044891 AI908240 AA393080 426878 273265_1 AI821926 AA658826 AA564492 AA635129 AI791191 30 432745 353673_1 441153 51084_2 BE562826 BE378727 448212 755099_1 Al475858 AW969013 451128 859865_1 AL118668 D78823 AI762176 452514 920172_1 AI904898 AI904849 AI904899 35 456207 165078_-1 AA193450

AW962128 AA355353 AA427363

TABLE 22B

Table 22B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 22. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank identifier (GI) numbers. *Dunham I. et al.* refers to the publication entitled 'The DNA sequence of human chromosome 22.* Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons,

15				
	Pkey	Ref	Strand	Nt_position
	400814	8569925	Minus	72840-72924,74761-74849
	400929	7651921	Minus	122033-122241,123483-124028
20	401045	8117619	Plus	90044-90184,91111-91345
	401451	6634068	Minus	119926-121272
	401519	6649315	Plus	157315-157950
	401645	7657839	Minus	34986-35133
	401714	6715702	Plus	96484-96681
25		8018106	Plus	73126-73623
	402327	7656695	Minus	108675-108770,109801-109910
		9211204	Minus	40403-41961
•	402408	9796239	Minus	110326-110491
•		9797107	Plus	195129-195776
30		9801558	Minus	67076-67594
		9884928	Plus	66350-66496
		9909429	Minus	81747-82094
		6693597	Minus	3468-3623
~ -		7630897	Minus	156037-156210
35		8516120	Plus	96450-96598
		8783692	Minus	49323-49652
		9966528	Plus	2888-3001,3198-3532,3655-4117
		9838195	Plus	74493-74829
40		6539738	Minus	240588-241589
40		7706327	Minus	53729-53846
	405017		Plus	35551-35690
	405348		Minus	43310-43462
		6006920	Minus	7636-8054
4.5	405801		Plus	63469-63694
45		6164995	Plus -	13871-14110
		9929734	Minus	12902-13069
	406348	9255985	Minus	71754-71944

TABLE 23: 320 GENES DOWN-REGULATED IN BREAST CANCER COMPARED TO NORMAL ADULT BREAST

Table 23 shows 320 genes down-regulated in breast cancer compared to normal adult breast. 5 These were selected as for Table 22, except that the numerator was set to the median value for 12 non-malignant breast specimens, the denominator was set to the median value amongst the 73 breast cancers, the 90th percentile value amongst the 12 non-malignant breast specimens was greater than or equal 80 units, and the ratio was greater than or equal to 4.0 (i.e. 4-fold down-regulated in tumor vs. normal breast). 10

Unique Eos probeset identifier number

ExAcon: UnigeneID: Exemplar Accession number, Genbank accession number

15

Unigene number Unigene gene title

Unigene Title:

Ratio of 50th percentile normal body tissue to 75th percentile tumor

20	Pkey	ExAcon	UnigenelD	UnigeneTitle	Ratio
	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4	22.4
		NM_000230	Hs.194236	leptin (murine obesity homolog)	17.4
		H57646	Hs.42586	KIAA1560 protein	15.4
25	418935	T28499	Hs.89485	carbonic anhydrase IV	15.0
		M25079	Hs.155376	hemoglobin, beta	14.6
		AL049176	Hs.82223	chordin-like	14.6
		AL133916	Hs.172572	hypothetical protein FLJ20093	14.3
		AI983730	Hs.26530	serum deprivation response (phosphatidy)	13.6
30		AI446543	Hs.95511	ESTs	12.6
		AA934589	Hs.49696	ESTs	12.2
		H25642	Hs.133471	ESTs	12.0
		L34041	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	12.0
~ -		NM_000163	Hs.125180	growth hormone receptor	11.7
35		AF027208	Hs.112360	prominin (mouse)-like 1	10.8
		AW207175	Hs.106771	ESTs	10.6
		X72632		NM_021724*:Homo sapiens nuclear receptor	10.1
		AW088826	Hs.117176	poly(A)-binding protein, nuclear 1	9.8
		N32759	Hs.172944	chorionic gonadotropin, beta polypeptide	9.8
40	406791	Al220684	Hs.272572	hemoglobin, alpha 2	9.5
	447471	AF039843	Hs.18676	sprouty (Drosophila) homolog 2	9.5
	451533	NM_004657	Hs.26530	serum deprivation response (phosphatidyl	9.4
	419407	AW410377	Hs.41502	hypothetical protein FLJ21276	9.0
	411939	Al365585	Hs.146246	ESTs	9.0
45	410532	T53088	Hs.155376	hemoglobin, beta	8.9
	425707	AF115402	Hs.11713	E74-like factor 5 (ets domain transcript	8.8
	416585	X54162	Hs.79386	leiomodin 1 (smooth muscle)	8.7
	443060	D78874	Hs.8944	procollagen C-endopeptidase enhancer 2	8.6
	435265	AA779958	Hs.185932	ESTs	8.5
50	422511	AU076442	Hs.117938	collagen, type XVII, alpha 1	8.4
	433138	AB029496	Hs.59729	semaphorin sem2	8.3
	402195			NM_004497*:Homo sapiens hepatocyte nucle	8.1
	429350	AI754634	Hs.131987	ESTs	8.1
	445107	Al208121	Hs.147313	ESTs, Weakly similar to I38022 hypotheti	8.1
55	406643	N77976	Hs.272572	hemoglobin, alpha 2	8.0
	410199	AW377424	Hs.205126	Homo sapiens cDNA: FLJ22667 fls, clone H	8.0
	417225	AA815048	Hs.24078	hypothetical protein FLJ12649	7.8
	437569	AA760849	Hs.294052	ESTs	7.5
	436062	AK000027	Hs.98633	ESTs	7.5
60	425078	NM_002599	Hs.154437	phosphodiesterase 2A, cGMP-stlmulated	7.5
	430327	AW973636	Hs.55931	ESTs	7.4

		Al393693	Hs.183297	DKFZP566F2124 protein	7.4
		Al150491	Hs.90756	ESTs	7.2
		R20893 AA452006	Hs.325823 Hs.333199	ESTs, Moderately similar to ALU5_HUMAN A ESTs	7.2 7.1
5		AW956360	Hs.4748	adenylate cyclase activating polypeptide	7.1
		AI352340	Hs.131194	ESTs	7.0
		AI219304	Hs.283108	hemoglobin, gamma G	6.9
		Al446183	Hs.9572	ESTs, Highly similar to CYA5_HUMAN ADENY	6.8
10		AA346839	Hs.209100	DKFZP434C171 protein	6.7
10		AI478427 AB002058	Hs.43125 Hs.113275	esophageal cancer related gene 4 protein	6.7
		AA256395	Hs.88156	purinergic receptor P2X-like 1, orphan r ESTs	6.7 6.6
	404368		113.00130	ENSP00000241075*:TRRAP PROTEIN.	6.6
		NM_006691	Hs.17917	extracellular link domain-containing 1	6.5
15	417090	AA193282	Hs.85863	ESTs, Weakly similar to B34612 zinc fing	6.5
		NM_003278	Hs.65424	tetranectin (plasminogen-binding protein	6.5
		AL119796	Hs.174185	ectonucleotide pyrophosphatase/phosphodi	6.5
		AW963085	11- 70400	gb:EST375158 MAGE resequences, MAGH Hom	
20		S72043 BE250659	Hs.73133 Hs.15463	metallothionein 3 (growth inhibitory fac	6.4 6.4
20		AA701483	Hs.36341	Homo sapiens, clone IMAGE:2959994, mRNA ESTs	6.3
	402779		110.00041	Target Exon	6.3
		AA213626	Hs.136204	EST	6.3
	439335	AA742697	Hs.62492	ESTs, Weakly similar to B39066 proline-r	6.3
25		AA001732	Hs.173233	hypothetical protein FLJ10970	6.2
		BE143068		gb:MR0-HT0158-030200-003-b09 HT0158 Homo	
		BE004783 NM 012093	Un 40000	gb:MR2-BN0114-270400-004-e11 BN0114 Homo	
		NM_012093	Hs.18268 Hs.334688	adenylate kinase 5 KIAA0273 gene product	6.1 6.1
30		H15968	Hs.293845	Homo sapiens, clone IMAGE:3502329, mRNA,	6.1
		F08212	Hs.234898	ESTs, Weakly similar to 2109260A B cell	6.0
	400089	NA		Eos Control	6.0
		W07475	Hs.277101	cytochrome c oxidase subunit IV isoform	5.9
25		N92818	Hs.64754	ESTs, Weakly similar to potential CDS [H	5.9
35		BE067414	11- 44005ô	gb:MR4-BT0355-200100-201-e05 BT0355 Homo	
	436704	AA062610	Hs.148050	EST .	5.9 5.9
		AW451023	Hs.65848	Target Exon hypothetical protein DKFZp761O132	5.9 5.9
		AA843387	Hs.87279	ESTs	5.9
40		NM_001874	Hs.334873	carboxypeptidase M	5.8
	410882	AW809163		gb:MR4-ST0118-261099-012-a03 ST0118 Homo	5.8
		AB014533	Hs.33010	KIAA0633 protein	5.8
		AI372588	Hs.8022	TU3A protein	5.8
45	-	AA372052	Hs.334559	Homo sapiens cDNA FLJ14458 fis, clone HE	5.8
43		BE063555 AW876813	Hs.3343	gb:CM1-BT0283-081199-033-d09 BT0283 Homo phosphoglycerate dehydrogenase	5.8 5.7
		AW014486	Hs.22509	ESTs	5.7 5.7
		AW452355	Hs.256037	ESTs	5.7
		AL036557	Hs.95910		5.7
50		AI695473	Hs.298006		5.7
		AA181641	Hs.184907		5.6
	404689			•	5.6
	438887		Hs.265499		5.6
55	406082 449748		Hs.82927 Hs.32043		5.6 5.6
55	431048		Hs.249129		5.5
	452205		1.0.2.10.120		5.5
		AW444613	Hs.288809	·	5.5
		AB020629	Hs.38095		5.5
60		AI668605	Hs.60380		5.5
		AA345824	Hs.76688		5.5
	401665 436107	T00070	Hs.191194		5,5
		AI161428	Hs.75916		5.5 5.5
65		BE005346	Hs.116410		5.5 5.5
		BE617015	Hs.11006		5.5
		A1432652	Hs.42824		5.5
				•	

	454016	AW016806	Hs.233108	ESTs	5,5
	414913	R25621		9-7 · · · · · · · · · · · · · · · · · · ·	5.4
		AA017590	Hs.129907		5.4
5		BE172240	Hs.126379	ESTs, Weakly similar to I38022 hypotheti	5.4
5		N49826 AA994520	Hs.18602	ESTs gb:ou42g09.s1 Soares_NFL_T_GBC_S1 Homo s	5.4 5.4
	403612			Target Exon	5.3
		AA007629	Hs.9739	glycerol-3-phosphate dehydrogenase 1 (so	5.3
	410057	R66634	Hs.268107	multimerin	5.3
10		BE272452	Hs,183109	monoamine oxidase A	5.3
		AA620814	Hs.144959	ESTs	5.3
		R99530	Hs.272572	hemoglobin, alpha 2	5.3 5.3
		AF012023 BE261320	Hs.173274 Hs.158196	integrin cytoplasmic domain-associated p transcriptional adaptor 3 (ADA3, yeast h	5.3
15		AW613948	Hs.194915	ESTs	5.3
		AI809481	Hs.131227	ESTs	5.3
	402054	NA		Target Exon	5.3
		AF212829	Hs.272406	potassium channel, subfamily K, member 9	5.3
20		R59638	Hs.6181	ESTS	5.2
20		AI904646	Hs.173871	gb:QV-BT065-020399-103 BT065 Homo saplen KIAA1300 protein	5.2 5.2
		AB037721 BE467930	Hs.170381	ESTs	5.2
		Al285901	Hs.181297	ESTs	5.2
	402698			ENSP00000251335*:DJ1003J2.1 (sodium and	5.2
25	401810			Target Exon	5.2
		AA827674	Hs.189073	ESTs	5.2
		AA424074	Hs.76780	protein phosphatase 1, regulatory (inhib	5.2 5.1
		M26380 NM_006744	Hs.180878 Hs.76461	lipoprotein lipase retinol-binding protein 4, interstitial	5.1
30		AW023469	Hs.65256	ESTs, Weakly similar to leucine-rich gli	5.1
20		AI821324	Hs.100445	ESTs	5.1
	402583	NA		NM_021620:Homo saplens PR domain contain	5.1
		NM_006103	Hs.2719	HE4; WFDC2; putative ovarian carcinoma m	5.1
35		Al435179	Hs.126820	ESTS	5.1 5.1
33		R53467 BE143867	Hs.269122	ESTs, Weakly similar to ALU1_HUMAN ALU S gb:MR0-HT0164-070100-013-h02 HT0164 Homo	
		X03350	Hs.4	alcohol dehydrogenase 1B (class I), beta	5.1
		BE244537	Hs.167382	natriuretic peptide receptor A/guanylate	5.1
	407891	AA486620	Hs.41135	endomucin-2	5.0
40		AW026692	Hs.224829	ESTs	5.0
		D59597	Hs.118821	CGI-62 protein	5.0
		AI524307 AI076012	Hs.162870 Hs.121388	ESTs ESTs, Weakly similar to MDHC_HUMAN MALAT	5.0 5.0
		BE160229	П5.121300	gb:QV1-HT0413-090200-062-a12 HT0413 Homo	5.0
45		AF012626	Hs.54472	fragile X mental retardation 2	5.0
		AW502327		gb:Ul-HF-BR0p-aka-a-07-0-Ul.rl NIH_MGC_5	5.0
	405062			Target Exon	5.0
		AK000706	Hs.15125	hypothetical protein FLJ20699	5.0
50		AW298163	Hs.82318	WAS protein family, member 3	5.0 5.0
50		AJ243662 R62431	Hs.110196 Hs.12758	NICE-1 protein ESTs	5.0
		R35009	Hs.24903	ESTs	5.0
		R00348		gb:ye69e06.r1 Soares fetal liver spleen	5.0
		AJ243191	Hs.56874	heat shock 27kD protein family, member 7	5.0
55		AI768289	Hs.304389	ESTs	4.9
		BE550889	Hs.158491	ESTs	4.9 4.9
		AW341470 AI783600	Hs.144907 Hs.208052	ESTs ESTs	4.9
	432433	AW014734	Hs.157969	ESTs ESTs	4.9
60		Al989812	Hs.199850	ESTs	4.9
		N94587 -	Hs.55063	ESTs	4.9
		AW973716	Hs.13913	KIAA1577 protein	4.9
		AA682722	Hs.192725	ESTs	4.9
65		AF026263 AW137094	Hs.247920 Hs.97990	cholinergic receptor, muscarinic 5 ESTs	4.8 4.8
0.5		AA868510	Hs.112496	ESTs	4.8
		Al349351	Hs.118944	hypothetical protein FLJ22477	4.8
				,	

	404705	V0000			
		X63094	Hs.283822	Rhesus blood group, D antigen	4.8
	427138	N77624	Hs.173717	phosphatidic acid phosphatase type 2B	4.8
	413072	BE063965		gb:QV3-BT0296-140200-085-h01 BT0296 Homo	4.8
	443721	AW450451	Hs.266355	ESTs	4.8
5		AW139474	Hs.246862	ESTs	4.8
-	_	AA843716	Hs.177927	ESTs	4.7
		Al025499	Hs.132238	ESTs	4.7
		Al383475	Hs,171697	ESTs, Weakly similar to T13924 sdk prote	4.7
		BE386764		gb:601273249F1 NIH_MGC_20 Homo sapiens c	4.7
10	426893	AA398716	Hs.97418	ESTs	4.7
	434046	AW292618	Hs.113011	ESTs	4.7
	401590			Target Exon	4.7
		AW134679	Hs.242849	ESTs	4.7
1.5		AK000123	Hs.180479	hypothetical protein FLJ20116	4.6
15		AA045290	Hs.25930	ESTs, Weakly similar to 2109260A B cell	4.6
	407737	R49187	Hs.6659	ESTs	4.6
	441955	AA972327	Hs.142903	ESTs	4.6
	441499	AW298235	Hs.101689	ESTs	4.6
		Al382726	Hs.182434	ESTs	4.6
20		AIGGEFEG	113,102404		4.6
20	403017	N140007	11-45040	Target Exon	
		N40087	Hs.15248	ESTs	4.6
		H58589	Hs.35156	Homo sapiens cDNA FLJ11027 fis, done PL	4.6
	414831	M31158	Hs.77439	protein kinase, cAMP-dependent, regulato	4.6
	459290	NM_001546	Hs.34853	inhibitor of DNA binding 4, dominant neg	4.6
25		Al142027	Hs.146650	ESTs	4.6
		AL137698	Hs.46531	Homo saplens mRNA; cDNA DKFZp434C1915 (f	
		AW204277	Hs.250723	hypothetical protein MGC2747	4.6
		AF134707	Hs.278679	a disintegrin and metalloproteinase doma	4.6
•		Al375984	Hs.167216	ESTs	4.6
30	419583	F00312		gb:HSBB0D101 STRATAGENE Human skeletal i	m4.6
	440698	Al348455	Hs.147492 ·	Homo sapiens cDNA FLJ11777 fls, clone HE	4.6
	451199	A1290653	Hs.124758	ESTs	4.6
	438338	NM_014861	Hs.6168	KIAA0703 gene product	4.6
		AW015933	Hs.112654	Homo sapiens, clone MGC:9764, mRNA, comp	4.5
35					
55	423301		Hs.1645	cytochrome P450, subfamily IVA, polypept	4.5
	417237		Hs.81737	palmitoyl-protein thioesterase 2	4.5
	439745	AL389981	Hs.149219	Homo sapiens mRNA full length insert cDN	4.5
	424137	AA335769	Hs.16262	ESTs	4.5
	449338	H73444	Hs.394	adrenomedullin	4.5
40	434744		Hs.283828	Homo sapiens genomic DNA, chromosome 21q	4.5
-10		AF035303	1 13.200020	gb:Homo sapiens clone 23943 mRNA sequenc	4.5
			11-0500		
		NM_012190	Hs.9520	formyltetrahydrofolate dehydrogenase	4.5
		AA169114	Hs.12247	hypothetical protein FLJ11413	4.5
	415986	Z43619		gb:HSC1GE121 normalized infant brain cDN	4.5
45	457416	BE142052	Hs.62654	kringle-containing transmembrane protein	4.5
	418064	BE387287	Hs.83384	S100 calcium-binding protein, beta (neur	4.4
		Al356125	Hs.157767	ESTs, Weakly similar to HXA2_HUMAN HOMEO	4.4
		AA156998	Hs.211568	eukaryotic translation initiation factor	4.4
	401093	701130330	113.211000	C12000586*:gi[6330167[dbj]BAA86477.1] (A	4.4
50		A3M000404	Ha DEDECO		
50		AW206494	Hs.253560	ESTS	4.4
		AW842353	Hs.321717	ESTs, Weakly similar to S22765 heterogen	4.4
	428222	AL133112	Hs.183085	Homo sapiens mRNA; cDNA DKFZp434K098 (fr	4.4
	442705	Al264634	Hs.131127	ESTs	4.4
	437409	AL359599	Hs.283850	Homo sapiens mRNA; cDNA DKFZp547C126 (fr	4.4
55	458494	Al380906	Hs.158436	ESTs	4.4
•	410490			gb:yj42d08.r1 Soares placenta Nb2HP Homo	4.4
	416069		Hs.20982	ESTs	4.4
		AA807958	Hs.314232	ESTs	4.4
60		AI499723	Hs.135089	ESTs	4.4
60	438327		Hs.172944	chorionic gonadotropin, beta polypeptide	4.4
	457711	AF147401	Hs.23917	ESTs	4.3
	400870			C11000905:gi[11692565[gb]AAG39879.1]AF28	4.3
		AA933590	Hs.28937		4.3
		H45384		gb:yn99c10.r1 Soares adult brain N2b5HB5	4.3
65				gb:Human Ig rearranged H-chain mRNA VDJ4	
UJ		M12873	11- 404004		4.3
		AV654020	Hs.184261	ESTs, Weakly similar to T26686 hypotheti	4.3
	403263	NA		Target Exon	4.3

	410034	BE067414		gb:MR4-BT0355-200100-201-e05 BT0355 Home	04.3
		Al421645	Hs.139851	caveolin 2	4.3
		BE395260	Hs.309438	EST	4.3
_		D45371	Hs.80485	adipose most abundant gene transcript 1	4.3
5		NM_002666	Hs.103253	perilipin	4.3
	400973		11- 55000	ENSP00000236667*:Mucin 5B (Fragment).	4.3
		AW366194	Hs.55962	ESTs	4.3
	405016	NM_005100	Hs.788	A kinase (PRKA) anchor protein (gravin)	4.3 4.3
10		A)475671	Hs.88607	CY000171*:gij9280405 gb AAF86402.1 AF245 ESTs, Highly similar to F-box protein FB	4.3
10	406118	A141 301 1	113.00007	ENSP00000246632:CDNA FLJ20261 fis, clone	4.3
		T02850		gb:FB12A9 Fetal brain, Stratagene Homo s	4.3
		AA480818	Hs.221736	ESTs	4,3
		AW451206	Hs.115899	ESTs	4.3
15	444445	AA342329	Hs.115920	Homo sapiens cDNA: FLJ22816 fis, clone K	4.3
	453880	AI803166	Hs.28462	ESTs, Weakly similar to I38022 hypotheti	4.3
		Al377221	Hs.40528	ESTs	4.2
		BE293116	Hs.76392	aldehyde dehydrogenase 1 family, member	4.2
20		AV652165	Hs.182482	ESTs, Weakly similar to T00362 hypotheti	4.2
20	403921		H- 40740	C5000212*:gi 10047237 dbj BAB13407.1 (A	4.2
	406344	A1798425	Hs.42710	ESTS	4.2
		AA191201	Hs.35861	C5001660:gi 11611537 dbj BAB18935.1 (AB DKFZP586E1621 protein	4.2 4.2
		BE155866	Hs.25522	KIAA1808 protein	4.2
25		AW070634	Hs.144794	ESTs	4.2
_•	404682			C9001188*:gi 12738842 ref[NP_073725.1 p	4.2
	418089	N69913	Hs.6858	ESTs, Weakly similar to 178885 serine/th	4.2
	403433			NM_001622:Homo sapiens alpha-2-HS-glycop	4.2
••		AW975460	Hs.143563	ESTs	4.2
30		Al309298	Hs.279898	Homo sapiens cDNA: FLJ23165 fls, cione L	4.2
		AI871247	Hs.6262	hypothetical protein MGC8407	4.2
		AW973708	Hs.201925	Homo saplens cDNA FLJ13446 fis, clone PL	4.2
		AA397789 AF193807	Hs.161803	ESTs	4.2
35		Y09763	Hs.131835 Hs.22785	Rhesus blood group, B glycoprotein gamma-aminobutyric acid (GABA) A recepto	4.2 4.2
33		AI733098	Hs.130800	ESTs	4.2
		AF086410	113.100000	gb:Homo sapiens full length insert cDNA	4.2
		AA399975	Hs.274151	ligatin	4,2
	408932	AW594172	Hs.278513	TP53TG3 protein	4.2
40	436112	T77545	Hs.187559	ESTs	4.2
		Al144152	Hs.58246	ESTs	4.2
		AA318060	Hs,135121	hypothetical protein FLJ22415	4.2
		NM_015977	Hs.285681	Williams-Beuren syndrome chromosome regi	4.2
45		R57171	Hs.57975	calsequestrin 2 (cardiac muscle)	4.1
43	400545 403051			Target Exon	4.1 4.1
		NM_005357	Hs.95351	Target Exon lipase, hormone-sensitive	4.1
		AA007534	Hs.125062	ESTs	4.1
		AA034116	Hs.118494	ESTs	4.1
50		W52010	Hs.191379	ESTs	4.1
	414516	AI307802	Hs.135560	ESTs, Wealdy similar to T43458 hypotheti	4.1
	438232	Al150595	Hs.122226	ESTs	4.1
		AA082947		gb:zn10g07.s1 Stratagene hNT neuron (937	4.1
E E		BE270758	Hs.69428	hypothetical protein MGC3020	4.1
55		Al306150	Hs.153450	ESTs, Weakly similar to 1909123A Na gluc	4.1
		AK000708	Hs.169764	hypothetical protein FLJ20701	4.1
		AL110416 AW817177	Un 102558	gb:DKFZp434K0431_r1 434 (synonym: htes3) Homo sapiens, done MGC:5352, mRNA, comp	4.1
		AA203281	Hs.102558 Hs.21798	ESTs	4.1 4.1
60		AW118878	Hs.110835	ESTs	4.1
		AW807116		gb:MR4-ST0062-040100-024-b12 ST0062 Homo	
		AW631296		gb:hh83c09.y1 NCI_CGAP_GU1 Homo sapiens	
	435942	R06285	Hs.191215	ESTs	4.1
		T76945		gb:yc92c07.r1 Soares Infant brain 1NIB H	4.1
65	403593	NA		Target Exon	4.0
	402690	D40504	N= 070405	Target Exon	4.0
	418190	R49591	Hs.270425	ESTs	4.0

	408641 AW245207	Hs.5555	hypothetical protein MGC5347	4.0
	427899 AA829286	Hs.332053	serum amyloid A1	4.0
	445975 AI811536	Hs.145734	ESTs	4.0
	438831 BE263273	Hs.6439	synapsin II	4.0
5	455578 BE006350	Hs.14355	Homo saplens cDNA FLJ13207 fis, clone NT	4.0
	401840 NA		Target Exon	4.0
	413753 U17760	Hs.75517	taminin, beta 3 (nicein (125kD), kalinin	4.0
	445030 Al205925	Hs.147238	ESTs, Highly similar to AAC3_HUMAN ALPHA	4.0
	433873 AW156913	Hs.150478	ESTs. Weakly similar to A Chain A. Cryst	4.0
10	456736 AW248217	Hs.1619	achaete-scute complex (Drosophila) homol	4.0
	450112 BE047734	Hs.5473	ESTs. Moderately similar to ALU5_HUMAN A	4.0
	448906 AI589567	Hs 309719	FSTs	4.0

TABLE 23A

Table 23A shows the accession numbers for those pkeys lacking unigeneID's for Table 23. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10

Pkey: Unique Eos probeset identifier number

CAT number: Accession: Gene cluster number Genbank accession numbers

15

Pkey CAT number Accessions

```
AW502327 AW502488 AW501829 AW502625 AW502687
        409853 1156226_1
20
                            BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
        410034 1170594_1
                            AA082947 AA083036
        410233 118656_1
        410490 1205347_1
                            H03589 AW750687 AW750688
        410882 1225686_1
                            AW809163 AW809247 AW809177 AW809190 AW809225
                            BE143068 AW849143 AW848705 AW848569 AW848071 AW848475 AW848092 AW848005
        411478 1247073_1
25
                            BE063555 BE151321 BE151319 BE151657 BE151655 BE063556 BE151322
        413065 1347960_1
                            BE063965 BE063968 BE064034 BE064028 BE063874 BE063966 BE063869 BE064043 BE064033 BE063884
        413072 1348163_1
        414593 1464909_1
                            BE386764 BE387560
        414913 1506721_1
                            R25621 C03959 C04010
                            AW963085 AA159005 AW963073
        415011 151328_1
30
        415986 1564410_1
                            Z43619 R61274 H12206 R12883
        416267 1583547_1
                            H45384 H49125 H41699
        417574 1687770_1
                            R00348 R09593
        417629 1690392_1
                            T76945 R20210 R05755
        418556 1767866_-1
                            T02850
35
                            F00312 AA247490 F31427 AA383663 F22045
        419583 186198_1
        426328 264901_1
                            AW631296 AA375484
        439590 47413_1
                            AF086410 W94386 W74609
        442398 541271_1
                            AA994520 AW393574
        452205 90415_1
                            C15819 AA024741 AA024742
40
        452654 925931_1
                            BE004783 BE004947 AI911790
                            AL110416 AW876759
        453692 977825_1
                            AW807116 AW807569 AW807415 AW807338 AW807288 AW807263 AW807316 AW177402 AW807413 AW807068 BE141561
        454183 1049636_1
                            BE141569 AW807401 AW807310 BE141565 AW807318 AW807119 AW807299 AW807241 AW807225 AW807204 AW807345
                            AW807103 BE141615 AW807431 AW807393 AW807337 AW807406 AW807259 AW807375 AW845890 AW807220 AW807399
45
                            AW807064 AW807376 AW807024 BE141595 AW807236 AW807027 AW807112 AW807378 AW807202 BE141593 AW807216
                            AW807138 AW807244 AW807221 AW807297 AW807050 AW807248 AW807404 AW807075 AW807237 AW807212 AW807308
                            AW807110 AW807104 BE140912 AW807301 AW807382 AW807294 AW807026 AW807020 AW807108 AW807025 AW807433 AW807124 AW807419 AW807031 AW807264 AW807032 AW807029 AW807052 AW807391 AW807207 AW807215 AW807019
                            AW807238 AW807201 BE141590 AW807302 AW807323 AW807380 AW807109 BE141588 AW845877 AW807418 AW807407
50
                            AW807309 BE141614 AW845861 AW807396 AW807300 AW807348 AW807311 AW807214 AW807132 AW807402 AW807350
                            AW807028 AW807298 AW807291 AW807305 AW807217 AW807312 AW807261 AW807268 AW807260 AW807266 AW807198
                            AW807346 AW807315 BE140940 AW807351 AW807122 AW807235 AW807076 AW807314 AW807213 AW807143 AW807131
                            AW800079 AW807066 AW807077 AW845923 AW807421 BE141619 BE140943 AW807420 AW807381 BE141621 AW845921
                            BE141629 BE141625 BE141624 BE141636 BE141630 AW807405 AW807290 AW807353
55
        454404 1170594 1
                            BE067414 BE067958 BE067419 BE067963 AW577127 AW601412
                            BE160229 AW819879 AW820179 AW819882 AW819876 AW820169 BE153201 AW993736 BE152911
        454775 1234106_1
        455282 1273020_1
                            BE143867 AW935060 AW886684
        459159 919998_1
                            Al904646 BE179494 BE179421
```

TABLE 23B

Table 23B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 23. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

10	Pkey: Ref:	Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.
	Strand: Nt_position:	Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

15				
	Pkey	Ref	Strand	Nt_position
	400545	9800107	Minus	124618-124881
	400870	9838306	Minus	34081-35027
20	400973	7960452	Minus	98119-98253
	401093	8516137	Minus	22335-23166
	401590	9966320	Minus	33547-33649
	401665	7145001	Plus	121591-122537
	401810	7342191	Plus	129063-129476
25 ·	401840	7684597	Plus	56283-56439
	402054	8083691	Minus	8288-8806
	402195	7689778	Minus	147901-148884
	402583	7684486	Plus	94883-95003
	402690	8348058	Plus	13368-13998
30	402698	8570304	Minus	108641-108903
	402779	9588555	Minus	38173-39210
	403017	6693623	Plus	78630-79367
	403051	4827080	Minus	5269-5411
	403263	7770677	Plus	52431-52737
35	403433	9719611	Minus	72225-72437
	403593	6862650	Minus	62554-62712,69449-69602
	403612	8469060	Minus	94723-94859
	403921	7711590	Minus	3297-3536
	404368	7630956	Minus	102053-102199
40	404682	9797231	Minus	40977-41150
	404689	7534100	Plus	119461-119717
	405016	6524300	Plus	51997-53308
	405062	7657730	Plus	101283-101432
	406118	9143818	Plus	53997-54629
45	406344	9255974	Plus	20254-20374,20526-20659,20835-21097
	406563	7711604	Plus	34401-34538

TABLE 24:

Table 24 depicts Seq ID No., UnigeneID, UnigeneTitle, Pkey, Pred.Cell.Loc., and ExAccn
for all of the sequences in Table 25. The information in Table 24 is linked by Seq ID No. to Table 25.

10	Pkey: ExAccn: Unigene Unigene Pred.Ce Seq.ID.N	ID: I Title: I II.Loc.: I	Exemplar Access Unigene number Unigene gene title Predicted Cellular			·
15	Pkey	ExAccn	UnigenelD	Unigene Title	Pred.Cell.Loc.	Seq. ID. No.
20	407276 415539 400297 450375		Hs.326736 Hs.72472 Hs.334473 7 Hs.8850	ESTs, Weakly similar to CP4Y_HUMAN CYTC Homo sapiens breast cancer antigen NY-BR BMP-R1B hypothetical protein DKFZp564O1278 a disintegrin and metalloproteinase doma		Seq ID 1 & 2 Seq ID 3 & 4 Seq ID 5 & 6 Seq ID 7 & 8 Seq ID 9 & 10
25	429170 424399	NM_0013 AI905687 AL120862 N92293	94Hs.2359 94Hs.2359 Hs.2533 2 Hs.124165 Hs.206832 Hs.155956	dual specificity phosphatase 4 dual specificity phosphatase 4 aldehyde dehydrogenase 9 family, member ESTs ESTs, Moderately similar to ALU8_HUMAN A N-acetyltransferase 1 (arylamine N-acety	nuclear nuclear cytoplasm	Seq ID 11 & 12 Seq ID 11 & 12 Seq ID 13 & 14 Seq ID 15 & 16 Seq ID 17 & 18 Seq ID 19 & 20
30	439840 410102 429220	AW44921 AW24850	9 Hs.155223 1 Hs.105445 18 Hs.279727 16 Hs.136319	stanniocalcin 2 GDNF family receptor alpha 1 Homo sapiens cDNA FLJ14035 fis, clone HE ESTs		Seq ID 21 & 22 Seq ID 23 & 24 Seq ID 25 & 26 Seq ID 27 & 28 Seq ID 29 & 30
35	409079 442818 442082 444381	W87707 AK00174 R41823 BE38733	Hs.79136 Hs.82065 1 Hs.8739 Hs.7413 5 Hs.283713 0 Hs.25252	LIV-1 protein, estrogen regulated interleukin 6 signal transducer (gp130, hypothetical protein FLJ10879 ESTs ESTs, Weakly similar to S64054 hypotheti Homo sapiens cDNA FLJ13603 fis, clone PL		Seq ID 25 & 30 Seq ID 31 & 32 Seq ID 33 & 34 Seq ID 35 & 36 Seq ID 37 & 38 Seq ID 39 & 40
40	416636 442117 433043	N32536 AW66496 W57554 AL117406	Hs.42645 44 Hs.128899 Hs.125019 5 Hs.200102 Hs.91668	solute carrier family 16 (monocarboxylic ESTs lymphold nuclear protein (LAF-4) mRNA ATP-binding cassette transporter MRP8 Homo sapiens clone PP1498 unknown mRNA		Seq ID 41 & 42 Seq ID 43 & 44 Seq ID 45 & 46 Seq ID 47 & 48 Seq ID 49 & 50
45	446733 452747 423242 417433 432201	AA863360 BE153855 AL039402 BE270260 Al538613	0 Hs.26040 5 Hs.61460 2 Hs.125783 6 Hs.82128 Hs.298241	ESTs, Weakly similar to fatty acid omega Ig superfamily receptor LNIR DEME-6 protein 5T4 oncofetal trophoblast glycoprotein Transmembrane protease, serine 3		Seq ID 51 & 52 Seq ID 53 & 54 Seq ID 55 & 56 Seq ID 57 & 58 Seq ID 59 & 60
50	114480 404561 325372	AW60216 BE066778 NA	Hs.136348 66 Hs.222399 8 Hs.151678	osteoblast specific factor 2 (fasciclin CEGP1 protein UDP-N-acetyl-alpha-D-galactosamine:polyp NM_014112*:Homo sapiens trichorhinophala Phase 2 & 3 Exons	mitochodria nuclear	Seq ID 61 & 62 Seq ID 63 & 64 Seq ID 65 & 66 Seq ID 67 & 68 Seq ID 69 & 70
55	335824 424735 400289 427585	NA U31875 X07820 D31152	4 Hs.334806 Hs.272499 Hs.2258 Hs.179729	KIAA1238 protein ENSP00000249072*:DJ222E13.1 (N-TERMIN short-chain alcohol dehydrogenase family matrix metalloproteinase 10 (stromelysin collagen, type X, alpha 1 (Schmid metaph		Seq ID 71 & 72 Seq ID 73 & 74 Seq ID 75 & 76 Seq ID 77 & 78 Seq ID 79 & 80 Seq ID 81 & 82
60	429441 421155 420931 420813	AJ224172 H87879 AF044197	Hs.99949	cytochrome P450, 51 (lanosterol 14-alpha lipophilin B (uteroglobin family member) lysyl oxidase small inducible cytokine B subfamily (Cy prolactin-induced protein Homo sapiens mRNA; cDNA DKFZp434E082	ER extracellular nuclear (fr	Seq ID 81 & 82 Seq ID 83 & 84 Seq ID 85 & 86 Seq ID 87 & 88 Seq ID 89 & 90 Seq ID 91 & 92

		X78592	Hs.99915	androgen receptor (dihydrotestosterone r	cytoplasm	Seq ID 93 & 94
	424905	NM_00249	7Hs.153704	NIMA (never in mitosis gene a)-related k	nuclear	Seq ID 95 & 96
	429859	NM_00705	0Hs.225952	protein tyrosine phosphatase, receptor t		Seq ID 97 & 98
_	446921	AB012113	Hs.16530	small inducible cytokine subfamily A (Cy	extracellular	Seq ID 99 & 100
5	445537	AJ245671	Hs.12844	EGF-like-domain, multiple 6		Seq ID 101 & 102
	428227	AA321649	Hs.2248	small inducible cytokine subfamily B (Cy	extracellular	Seq ID 103 & 104
	424001	W67883	Hs.137476	paternally expressed 10		Seq ID 105 & 106
	421727	Y13153	Hs.107318	kynurenine 3-monooxygenase (kynurenine 3		Seg ID 107 & 108
	452838	U65011	Hs.30743	preferentially expressed antigen in mela	nuclear	Seq ID 109 & 110
10	419667	AU077005	Hs.92208	a disintegrin and metalloproteinase doma		Seq ID 111 & 112
	414812	X72755	Hs.77367	monokine induced by gamma interferon	extracellular	Seq ID 113 & 114
	426320	W47595	Hs.169300	transforming growth factor, beta 2	extracellular	Seq ID 115 & 116
	422867	L32137	Hs.1584	cartilage oligomeric matrix protein (pse	extracellular	Seq ID 117 & 118
	411558	AA102670	Hs.70725	gamma-aminobutyric acid (GABA) A recepto		Seq ID 119 & 120
15	417866	AW067903	Hs.82772	collagen, type XI, alpha 1		Seq ID 121 & 122
	428398	AI249368	Hs.98558	ESTs		Seq ID 123 & 124
	431958	X63629	Hs.2877	cadherin 3, type 1, P-cadherin (placenta	plasma membrane	Seq ID 125 & 126
	428722	U76456	Hs.190787	tissue inhibitor of metalloproteinase 4		Seq ID 127 & 128
	412970	AB026436	Hs.177534	dual specificity phosphatase 10		Seq ID 129 & 130
20	421379	Y15221	Hs.103982	small inducible cytokine subfamily B (Cy	extracellular	Seq ID 131 & 132
	415752	BE314524	Hs.78776	putative transmembrane protein		Seq ID 133 & 134
	444051	N48373	Hs.10247	activated leucocyte cell adhesion molecu		Sea ID 135 & 136
	451110	AI955040	Hs.265398	ESTs. Weakly similar to transformation-r		Sea ID 137 & 138

TABLE 24A

Table 24A shows the accession numbers for those pkeys lacking unigeneID's for Table 24. For each probeset, we have listed the gene cluster number from which the oligonucleotides were designed. Gene clusters were compiled using sequences derived from Genbank ESTs and mRNAs. These sequences were clustered based on sequence similarity using Clustering and Alignment Tools (DoubleTwist, Oakland California). The Genbank accession numbers for sequences comprising each cluster are listed in the "Accession" column.

10 Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number

Accession: Genbank accession numbers

15 Pkey CAT number Accession

335824 CH22_3197FG_619_11_LINK_E 325372 c12_hs

TABLE 24B

Table 24B shows the genomic positioning for those pkeys lacking unigene ID's and accession numbers in Table 24. For each predicted exon, we have listed the genomic sequence source used for prediction. Nucleotide locations of each predicted exon are also listed.

Pkey: Ref:

Unique number corresponding to an Eos probeset Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22." Dunham I. et al., Nature (1999) 402:489-495.

Strand:

Indicates DNA strand from which exons were predicted. Indicates nucleotide positions of predicted exons.

Nt_position:

15

10

Pkey Ref

Nt_position

404561 9795980 Minus

Strand

69039-70100


20

Table 25

Sea ID NO: 1 DNA sequence

The 69 gene sequences identified to be overexpressed in breast cancer may be used to identify coding regions from the public DNA databases (nr and htgs in Genbank). The sequences may be used to either identify genes that encode known proteins, or they may be used to predict the coding regions from genomic DNA using exon prediction algorithms, such as FGENESH (Salamov and Solovyev, 2000, Genome Res. 10:516-522)

FGENESH predicted ORF Nucleic Acid Accession #: 1-1518 (underlined sequences correspond to start and stop codons) Coding sequence: 10 31 41 51 ATGGAGCCCT CCTGGCTTCA GGAACTCATG GCTCACCCCT TCTTGCTGCT GATCCTCCTC 60 TGCATGTCTC TGCTGCTGTT TCAGGTAATC AGGTTGTACC AGAGGAGGAG ATGGATGATC 120 15 AGAGCCCTGC ACCTGTTTCC TGCACCCCCT GCCCACTGGT TCTATGGCCA CAAGGAGTTT 180 TACCCAGTAA AGGAGTTTGA GGTGTATCAT AAGCTGATGG AAAAATACCC ATGTGCTGTT 240
CCCTTGTGGG TTGGACCCTT TACGATGTTC TTCAGTGTCC ATGACCCAGA CTATGCCAAG 300
ATTCTCCTGA AAAGACAAGA TCCCAAAAGT GCTGTTAGCC ACAAAATCCT TGAATCCTGG 360 GTTGGTCGAG GACTTGTGAC CCTGGATGGT TCTAAATGGA AAAAGCACCG CCAGATTGTG 420 AAACCTIGGT TCAACATAG CATTCTGAAA ATATTCATCA CCATGATGTC TGAGAGTGTT 480
CGGATGATGC TGAACAAATG GGAGGAACGC ATTGCCCAAA ACTCACGTCT GGAGCTCTTT 540
CAACATGTCT CCCTGATGAC CCTGGACAGC ATCATGAGT GTGCCTTCAG CCACCAGGGC 600
AGCATCCAGT TGGACAGTAC CCTGGACTCA TACCTGAAAG CAGTGTTCAA CCTTAGCAAA 660 20 ATCTCCAACC AGCGCATGAA CAATTTTCTA CATCACAACG ACCTGGTTTT CAAATTCAGC 720 TCTCAAGGCC AAATCTTTTC TAAATTTAAC CAAGAACTTC ATCAGTTCAC AGAGAAAGTA 780 ATCCAGGACC GGAAGGAGTC TCTTAAGGAT AAGCTAAAAC AAGATACTAC TCAGAAAAGG 840 25 CGCTGGGATT TTCTGGACAT ACTTTTGAGT GCCAAAAGCG AAAACACCAA AGATTTCTCT 900 GAAGCAGATC TCCAGGCTGA AGTGAAAACG TTCATGTTTG CAGGACATGA CACCACATCC 960 AGTGCTATCT CCTGGATCCT TTACTGCTTG GCAAAGTACC CTGAGCATCA GCAGAGATGC 1020 CGAGATGAAA TCAGGGAACT CCTAGGGGAT GGGTCTTCTA TTACCTGGGA ACACCTGAGC 1080 CAGATGCCTT ACACCACGAT GTGCATCAAG GAATGCCTCC GCCTCTACGC ACCGGTAGTA 1140 30 AACATATCCC GGTTACTCGA CAAACCCATC ACCTTTCCAG ATGGACGCTC CTTACCTGCA 1200 GGAATAACTG TGTTTATCAA TATTTGGGCT CTTCACCACA ACCCCTATTT CTGGGAAGAC 1260 CCTCAGGTCT TTAACCCCTT GAGATTCTCC AGGGAAAAATT CTGAAAAAAT ACATCCCTAT 1320 GCCTTCATAC CATTCTCAGC TGGATTAAGG AACTGCATTG GGCAGCATTT TGCCATAATT 1380 GAGTGTAAAG TGGCAGTGGC ATTAACTCTG CTCCGCTTCA AGCTGGCTCC AGACCACTCA 1440 35 AGGCCTCCCC AGCCTGTTCG TCAAGTTGTC CTCAAGTCCA AGAATGGAAT CCATGTGTTT 1500 GCAAAAAAG TTTGCTAATT TTAAGTCCTT TCGTATAAGA ATTAATGAGA CAATTTTCCT 1560 ACCAAAGGAA GAACAAAAGG ATAAATATAA TACAAAATAT ATGTATATGG TTGTTTGACA 1620 AATTATATAA CTTAGGATAC TTCTGACTGG TTTTGACATC CATTAACAGT AATTTTAATT 1680 TCTTTGCTGT ATCTGGTGAA ACCACAAAA ACACCTGAAA AAACTCAAGC TGACTTCCAC 1740 40 TGCGAAGGGA AATTATTGGT TTGTGTAACT AGTGGTAGAG TGGCTTTCAA GCATAGTTTG 1800 ATCAAAACTC CACTCAGTAT CTGCATTACT TTTATCTCTG CAAATATCTG CATGATAGCT 1860 TTATTCTCAG TTATCTTTCC CCAATAATAA AAAA 45 Seq ID NO: 2 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted 50 31 MEPSWLQELM AHPFLLLILL CMSLLLFQVI RLYQRRRWMI RALHLFPAPP AHWFYGHKEF 60 YPVKEFEVYH KLMEKYPCAV PLWVGPFTMF FSVHDPDYAK ILLKRODPKS AVSHKILESW 120 VGRGLVTLDG SKWKKHRQIV KPGFNISILK IFITMMSESV RMMLNKWEER IAQNSRLELF 180 55 OHVSLMTLDS IMKCAFSHOG SIQLDSTLDS YLKAVFNLSK ISNQRMNNFL HHNDLVFKFS 240 SOGQIFSKFN QELHQFTEKV IQDRKESLKD KLKQDTTQKR RWDFLDILLS AKSENTKDFS 300 EADLQAEVKT FMFAGHDTTS SAISWILYCL AKYPEHQQRC RDEIRELLGD GSSITWEHLS 360 QMPYTTMCIK ECLRLYAPVV NISRLLDKPI TFPDGRSLPA GITVFINIWA LHHNPYFWED 420 PQVFNPLRFS RENSEKIHPY AFIPFSAGLR NCIGQHFAII ECKVAVALTL LRFKLAPDHS 480 RPPQPVRQVV LKSKNGIHVF AKKVC 60 Seq ID NO: 3 DNA sequence Nucleic Acid Accession #: NM 052997 100-4125 (underlined sequences correspond to start and stop codons) Coding sequence: 65 21 31 41 CTAGTCTATA CCAGCAACGA CTCCTACATC GTCCACTCTG GGGATCTTAG AAAGATCCAT 60 70 AAAGCTGCCT CCCGGGGGACA AGTCCGGAAG CTGGAGAAGA TGACAAAAGAG GAAGAAGACC 120
ATCAACCTTA ATATACAAGA CGCCCAGAAG AGGACTGCTC TACACTGGGC CTGTGTCAAT 180 GGCCATGAGG AAGTAGTAAC ATTTCTGGTA GACAGAAAGT GCCAGCTTGA CGTCCTTGAT 240
GGCGAACACA GGACACCTCT GATGAAGGCT CTACAATGCC ATCAGGAGGC TTGTGCAAAT 300
ATTCTGATAG ATTCTGGTGC CGATATAAAT CTCGTAGATG TGTATGGCAA CATGGCTCTC 360 75 CATTATGCTG TTTATAGTGA GATTTTGTCA GTGGTGGCAA AACTGCTGTC CCATGGTGCA 420 GTCATCGAAG TGCACAACAA GGCTAGCCTC ACACCACTTT TACTATCCAT AACGAAAAGA 480



LLSITKRSEQ IVEFLLIKNA NANAVNKYKC TALMLAVCHG SSEIVGMLLQ QNVDVFAADI 180

CGVTAEHYAV TCGFHHIHEQ IMEYIRKLSK NHQNTNPEGT SAGTPDEAAP LAERTPDTAE 240 SLVEKTPDEA APLVERTPDT AESLVEKTPD EAASLVEGTS DKIOCLEKAT SGKFEOSAEE 300 TPREITSPAK ETSEKFTWPA KGRPRKIAWE KKEDTPREIM SPAKETSEKF TWAAKGRPRK 360 IAWEKKETPV KTGCVARVTS NKTKVLEKGR SKMIACPTKE SSTKASANDQ RFPSESKQEE 420 5 DEEYSCDSRS LFESSAKIQV CIPESIYQKV MEINREVEEP PKKPSAFKPA IEMQNSVPNK 480 AFELKNEQTL RADPMFPPES KQKDYEENSW DSESLCETVS QKDVCLPKAT HQKEIDKING 540 KLEESPNKDG LLKATCGMKV SIPTKALELK DMQTFKAEPP GKPSAFEPAT EMQKSVPNKA 600 LELKNEOTWR ADEILPSESK OKDYEENSWD TESLCETVSQ KDVCLPKAAH QKEIDKINGK 660 LEGSPVKDGL LKANCGMKVS IPTKALELMD MQTFKAEPPE KPSAFEPAIE MQKSVPNKAL 720 10 ELKNEQTLRA DEILPSESKQ KDYEESSWDS ESLCETVSQK DVCLPKATHQ KEIDKINGKL 780 EESPDNDGFL KAPCRMKVSI PTKALELMDM QTFKAEPPEK PSAFEPAIEM QKSVPNKALE 840 LKNEQTLRAD QMFPSESKQK KVEENSWDSE SLRETVSQKD VCVPKATHQK EMDKISGKLE 900 DSTSLSKILD TVHSCERARE LQKDHCEQRT GKMEQMKKKF CVLKKKLSEA KEIKSQLENQ 960 KVKWEQELCS VRLTLNQEEE KRRNADILNE KIREELGRIE EQHRKELEVK QQLEQALRIQ 1020 15 DIELKSVESN LNQVSHTHEN ENYLLHENCM LKKEIAMLKL EIATLKHQYQ EKENKYFEDI 1080 DIELESVESH LIQVSHTHEN ENT LEHENOM EXCENDIBLE ENTERSTORE ENTERST 1000 KILKEKNAEL QMTLKLKEES LTKRASQYSG QLKVLIAENT MLTSKLKEKQ DKEILEAEIE 1140 SHIPRLASAV QDHDQIVTSR KSQEPAFHIA GDACLQRKMN VDVSSTIYNN EVLHQPLSEA 1200 QRKSKSLKIN LNYAGDALRE NTLVSEHAQR DQRETQCQMK EAEHMYQNEQ DNVNKHTEQQ 1260 ESLDQKLFQL QSKNMWLQQQ LVHAHKKADN KSKITIDIHF LERKMQHHLL KEKNEEIFNY 1320 20 NNHLKNRIYQ YEKEKAETEN S Seq ID NO: 5 DNA sequence Nucleic Acid Accession #: none found

273-1785 (underlined sequences correspond to start and stop codons) Coding sequence:

41 31

25

CGCGGGGCGC GGAGTCGGCG GGGCCTCGCG GGACGCGGGC AGTGCGGAGA CCGCGGCGCT 60 30 GAGGACGCGG GAGCCGGGAG COCACGCGCG GGGTGGAGTT CAGCCTACTC TTTCTTAGAT 120 GTGAAAGGAA AGGAAGATCA TTTCATGCCT TGTTGATAAA GGTTCAGACT TCTGCTGATT 180 CATAACCATT TGGCTCTGAG CTATGACAAG AGAGGAAACA AAAAGTTAAA CTTACAAGCC 240 TGCCATAAGT GAGAAGCAAA CTTCCTTGAT AACATGCTTT TGCGAAGTGC AGGAAAATTA 300 AATGTGGGCA CCAAGAAAGA GGATGGTGAG AGTACAGCCC CCACCCCCCG TCCAAAGGTC 360 TTGCGTTGTA AATGCCACCA CCATTGTCCA GAAGACTCAG TCAACAATAT TTGCAGCACA 420
GACGGATATT GTTTCACGAT GATAGAAGAG GATGACTCTG GGTTGCCTGT GGTCACTTCT 480 35 GGTTGCCTAG GACTAGAAGG CTCAGATTTT CAGTGTCGGG ACACTCCCAT TCCTCATCAA 540 AGAAGATCAA TTGAATGCTG CACAGAAAGG AACGAATGTA ATAAAGACCT ACACCCTACA 600 CTGCCTCCAT TGAAAAACAG AGATTTTGTT GATGGACCTA TACACCACAG GGCTTTACTT 660
ATATCTGTGA CTGTCTGTAG TTTGCTCTTG GTCCTTATCA TATTATTTTG TTACTTCCGG 720
TATAAAAGAC AAGAAACCAG ACCTCGATAC AGCATTGGGT TAGAACAGGA TGAAACTTAC 780
ATTCCTCCTG GAGAATCCCT GAGAGACTTA ATTGAGCAGT CTCAGAGCTC AGGAAGTGGA 840 40 TCAGGCCTCC CTCTGCTGGT CCAAAGGACT ATAGCTAAGC AGATTCAGAT GGTGAAACAG 900 ATTGGAAAAG GTCGCTATGG GGAAGTTTGG ATGGGAAAGT GGCGTGGCGA AAAGGTAGCT 960 GTGAAAGTGT TCTTCACCAC AGAGGAAGCC AGCTGGTTCA GAGAGACAGA AATATATCAG 1020 45 ACAGTGTTGA TGAGGCATGA AAACATTTTG GGTTTCATTG CTGCAGATAT CAAAGGGACA 1080 GGGTCCTGGA CCCAGTTGTA CCTAATCACA GACTATCATG AAAATGGTTC CCTTTATGAT 1140 TATCTGAAGT CCACCACCCT AGACGCTAAA TCAATGCTGA AGTTAGCCTA CTCTTCTGTC 1200 AGTGGCTTAT GTCATTTACA CACAGAAATC TTTAGTACTC AAGGCAAACC AGCAATTGCC 1260 CATCGAGATC TGAAAAGTAA AAACATTCTG GTGAAGAAAA ATGGAACTTG CTGTATTGCT 1320 50 GACCTGGGCC TGGCTGTTAA ATTTATTAGT GATACAAATG AAGTTGACAT ACCACCTAAC 1380 ACTCGAGTTG GCACCAAACG CTATATGCCT CCAGAAGTGT TGGACGAGAG CTTGAACAGA 1440 AATCACTTCC AGTCTTACAT CATGGCTGAC ATGTATAGTT TTGGCCTCAT CCTTTGGGAG 1500
GTTGCTAGGA GATGTGTATC AGGAGGTATA GTGGAAGAAT ACCAGCTTCC TTATCATGAC 1560
CTAGTGCCCA GTGACCCCTC TTATGAGGAC ATGAGGGAGA TTGTGTGCAT CAAGAAGTTA 1620 55 CGCCCCTCAT TCCCA AACCG GTGGAGCAGT GATGAGTGTC TAAGGCAGAT GGGAAAACTC 1680 ATGACAGAAT GCTGGGCTCA CAATCCTGCA TCAAGGCTGA CAGCCCTGCG GGTTAAGAAA 1740
ACACTTGCCA AAATGTCAGA GTCCCAGGAC ATTAAACTCT GATAGGAGAG GAAAAGTAAG 1800
CATCTCTGCA GAAAGCCAAC AGGTACTCTT CTGTTTGTGG GCAGAGCAAA AGACATCAAA 1860
TAAGCATCCA CAGTACAAGC CTTGAACATC GTCCTGCTTC CCAGTGGGTT CAGACCTCAC 1920 60


65 Seq ID NO: 6 Protein sequence: Protein Accession #: none found

21 5t 11 31 41 70 MLLRSAGKLN VGTKKEDGES TAPTPRPKVL RCKCHHHCPE DSVNNICSTD GYCFTMIEED 60 DSGLPVVTSG CLGLEGSDFQ CRDTPPHQR RSIECCTERN ECNKDLHPTL PPLKNRDFVD 120 GPIHHRALLI SVTVCSLLLV LIILFCYFRY KRQETRPRYS IGLEQDETYI PPGESLRDLI 180 EQSQSSGSG GLPLLVQRTI AKQIQMVKQI GKGRYGEVWM GKWRGEKVAV KVFFTTEEAS 240 75 WFRETEIYOT VLMRHENILG FIAADIKGTG SWTQLYLITD YHENGSLYDY LKSTTLDAKS 300 MLKLAYSSVS GLCHLHTEIF STQGKPAIAH RDLKSKNILV KKNGTCCIAD LGLAVKFISD 360 TNEVDIPPNT RVGTKRYMPP EVLDESLNRN HFQSYIMADM YSFGLILWEV ARRCVSGGIV 420

TCTGTTTGTA GGCGGAGAAA CCGTTGGGTA ACTTGTTCAA GATATGATGC AT

CTTTCAGGGA GCGACCTGGG CAAAGACAGA GAAGCTCCCA GAAGGAGAGA TTGATCCGTG 1980

EEYQLPYHDL VPSDPSYEDM REIVCIKKLR PSFPNRWSSD ECLRQMGKLM TECWAHNPAS 480 RLTALRVKKT LAKMSESQDI KL



PPONPRKLIL AGNIHSLMK SDLVEYFTLE MLHLGNNRIE VLEEGSFMNL TRLQKLYLNG 420
NHLTKLSKGM FLGLHNLEYL YLEYNAIKEI LPGTFNPMPK LKVLYLNNNL LQVLPPHIFS 480
GVPLTKVNLK TNQFTHLPVS NILDDLDLLT QIDLEDNPWD CSCDLVGLQQ WIQKLSKNTV 540
TDDILCTSPG HLDKKELKAL NSEILCPGLV NNPSMPTQTS YLMVTTPATT TNTADTILRS 600
LTDAVPLSVL ILGLLIMFIT IVFCAAGIVV LVLHRRRRYK KKQVDEQMRD NSPVHLQYSM 660
YGHKTTHHTT ERPSASLYEQ HMVSPMVHVY RSPSFGPKHL EEEEERNEKE GSDAKHLQRS 720
LLEQENHSPL TGSNMKYKTT NQSTEFLSFQ DASSLYRNIL EKERELQQLG ITEYLRKNIA 780
QLQPDMEAHY PGAHEELKLM ETLMYSRPRK VLVEQTKNEY FELKANLHAE PDYLEVLEQQ 840
T
Seq ID NO: 9 DNA sequence

Seq ID NO: 9 DNA sequence
Nucleic Acid Accession #: NM_003474
Coding sequence: 307-3036 (underlined sequences correspond to start and stop codons)

15 51 31 41 CACTAACGCT CTTCCTAGTC CCCGGGCCAA CTCGGACAGT TTGCTCATTT ATTGCAACGG 60 TCAAGGCTGG CTTGTGCCAG AACGGCGCGCGCGCGACGCA CGCACACAC CGGGGGGAAA 120 CTITITIAAA AATGAAAGGC TAGAAGAGCT CAGCGGGGG GCGGGCCCGTG CGCGAGGGCT 180
CCGGAGCTGA CTCGCCGAGG CAGGAAATCC CTCCGGTCGC GACGCCCGGC CCCGCTCGGC 240
GCCCGCGTGG GATGGTGCAG CGCTCGCCGC CGGGCCCGAG AGCTGCTGCA CTGAAGGCCG 300
GCGACGATGG CAGCGCCCC GCTGCCCGTG TCCCCCGCC GCGCCCTCCT GCTCGCCCTG 360 20 GCCGGTGCTC TGCTCGCGCC CTGCGAGGCC CGAGGGGTGA GCTTATGGAA CGAAGGAAGA 420 25 GCTGATGAAG TTGTCAGTGC CTCTGTTCGG AGTGGGGACC TCTGGATCCC AGTGAAGAGC 480 TTCGACTCCA AGAATCATCC AGAAGTGCTG AATATTCGAC TACAACGGGA AAGCAAAGAA 540 CTGATCATAA ATCTGGAAAG AAATGAAGGT CTCATTGCCA GCAGTTTCAC GGAAACCCAC 600 TATCTGCAAG ACGGTACTGA TGTCTCCCTC GCTCGAAATT ACACGGTAAT TCTGGGTCAC 660 TGTTACTACC ATGGACATGT ACGGGGATAT TCTGATTCAG CAGTCAGTCT CAGCACGTGT 720 TCTGGTCTCA GGGACTTAT TGTGTTTGAA AATGAAAGCT ATGTCTTAGA ACCAATGAAA 780
AGTGCAACCA ACAGATACAA ACTCTTCCCA GCGAAGAAG TGAAAAGCGT CCGGGGATCA 840
TGTGGATCAC ATCACAACAC ACCAAACCTC GCTGCAAAGA ATGTGTTTCC ACCACCCTCT 900
CAGACATGGG CAAGAAGGCA TAAAAGAGAG ACCCTCAAGG CAACTAAGTA TGTGGAGCTG 960 30 GTGATCGTGG CAGACAACCG AGAGTTTCAG AGGCAAGGAA AAGATCTGGA AAAAGTTAAG 1020 CAGCGATTAA TAGAGATTGC TAATCACGTT GACAAGTTTT ACAGACCACT GAACATTCGG 1080 35 ATCGTGTTGG TAGGCGTGGA AGTGTGGAAT GACATGGACA AATGCTCTGT AAGTCAGGAC 1140
CCATTCACCA GCCTCCATGA ATTTCTGGAC TGGAGGAAGA TGAAGCTTCT ACCTCGCAAA 1200 TCCCATGACA ATGCGCAGCT TGTCAGTGGG GTTTATTTCC AAGGGACCAC CATCGGCATG 1260 GCCCCAATCA TGAGCATGTG CACGGCAGAC CAGTCTGGGG GAATTGTCAT GGACCATTCA 1320 40 GACAATCCCC TTGGTGCAGC CGTGACCCTG GCACATGAGC TGGGCCACAA TTTCGGGATG 1380
AATCATGACA CACTGGACAG GGGCTGTAGC TGTCAAATGG CGGTTGAGAA AGGAGGCTGC 1440 ATCATGAACG CTTCCACCGG GTACCCATTT CCCATGGTGT TCAGCAGTTG CAGCAGGAAG 1500 GACTTGGAGA CCAGCCTGGA GAAAGGAATG GGGGTGTGCC TGTTTAACCT GCCGGAAGTC 1560 AGGGAGTCTT TCGGGGGCCA GAAGTGTGGG AACAGATTTG TGGAAGAAGG AGAGGAGTGT 1620 GACTGTGGGG AGCCAGAGGA ATGTATGAAT CGCTGCTGCA ATGCCACCAC CTGTACCCTG 1680 AAGCCGGACG CTGTGTGCGC ACATGGGCTG TGCTGTGAAG ACTGCCAGCT GAAGCCTGCA 1740 45 GGAACAGCGT GCAGGGACTC CAGCAACTCC TGTGACCTCC CAGAGTTCTG CACAGGGGCC 1800 AGCCCTCACT GCCCAGCCAA CGTGTACCTG CACGATGGGC ACTCATGTCA GGATGTGGAC 1860 GGCTACTGCT ACAATGGCAT CTGCCAGACT CACGAGCAGC AGTGTGTCAC ACTCTGGGGA 1920 CCAGGTGCTA AACCTGCCCC TGGGATCTGC TTTGAGAGAG TCAATTCTGC AGGTGATCCT 1980 TATGGCAACT GTGGCAAAGT CTCGAAGAGT TCCTTTGCCA AATGCGAGAT GAGAGATGCT 2040 50 AAATGTGGAA AAATCCAGTG TCAAGGAGGT GCCAGCCGGC CAGTCATTGG TACCAATGCC 2100 GTTTCCATAG AAACAAACAT CCCCTGCAG CAAGGAGGCC GGATTCTGTG CCGGGGGACC 2160 CACGTGTACT TGGGCGATGA CATGCCGGAC CCAGGGCTTG TGCTTGCAGG CACAAAGTGT 2220 GCAGATGGAA AAATCTGCCT GAATCGTCAA TGTCAAAATA TTAGTGTCTT TGGGGTTCAC 2280 55 GAGTGTGCAA TGCAGTGCCA CGGCAGAGGG GTGTGCAACA ACAGGAAGAA CTGCCACTGC 2340 GAGGCCCACT GGGCACCTCC CTTCTGTGAC AAGTTTGGCT TTGGAGGAAG CACAGACAGC 2400 GGCCCCATCC GGCAAGCAGA TAACCAAGGT TTAACCATAG GAATTCTGGT GACCATCCTG 2460 TGTCTTCTTG CTGCCGGATT TGTGGTTTAT CTCAAAAGGA AGACCTTGAT ACGACTGCTG 2520
TTTACAAATA AGAAGACCAC CATTGAAAAA CTAAGGTGTG TGCGCCCTTC CCGGCCACCC 2580 60 COTGGCTTCC AACCCTGTCA GGCTCACCTC GGCCACCTTG GAAAAGGCCT GATGAGGAAG 2640 COGCCAGATT CCTACCCACC GAAGGACAAT CCCAGGAGAT TGCTGCAGTG TCAGAATGTT 2700 GACATCAGCA GACCCCTCAA CGGCCTGAAT GTCCCTCAGC CCCAGTCAAC TCAGCGAGTG 2760 CTTCCTCCCC TCCACCGGGC CCCACGTGCA CCTAGCGTCC CTGCCAGACC CCTGCCAGCC 2820 AAGCCTGCAC TTAGGCAGGC CCAGGGGACC TGTAAGCCAA ACCCCCTCA GAAGCCTCTG 2880 65 CCTGCAGATC CTCTGGCCAG AACAACTCGG CTCACTCATG CCTTGGCCAG GACCCCAGGA 2940 CAATGGGAGA CTGGGCTCCG CCTGGCACCC CTCAGACCTG CTCCACAATA TCCACACCAA 3000 70 GCAGAATGTT GATTACAGTG CAGTGCGCTG TAGTAGGCAT TTTTACCATC ACTGAGTTTT 3300 CCATGGCAGG AAGGCTTGTT GTGCTTTTAG TATTTTAGTG AACTTGAAAT ATCCTGCTTG 3360 ATGGGATTCT GGACAGGATG TGTTTGCTTT CTGATCAAGG CCTTATTGGA AAGCAGTCCC 3420 CCAACTACCC CCAGCTGTGC TTATGGTACC AGATGCAGCT CAAGAGATCC CAAGTAGAAT 3480 75 CTCAGTTGAT TTTCTGGATT CCCCATCTCA GGCCAGAGCC AAGGGGCTTC AGGTCCAGGC 3540 TGTGTTTGGC TTTCAGGGAG GCCCTGTGCC CCTTGACAAC TGGCAGGCAG GCTCCCAGGG 3600

ACACCTGGGA GAAATCTGGC TTCTGGCCAG GAAGCTTTGG TGAGAACCTG GGTTGCAGAC 3660 AGGAATCTTA AGGTGTAGCC ACACCAGGAT AGAGACTGGA ACACTAGACA AGCCAGAACT 3720 TGACCCTGAG CTGACCAGCC GTGAGCATGT TTGGAAGGGG TCTGTAGTGT CACTCAAGGC 3780 GGTGCTTGAT AGAAATGCCA AGCACTTCTT TTTCTCGCTG TCCTTTCTAG AGCACTGCCA 3840 5 CCAGTAGGTT ATTTAGCTTG GGAAAGGTGG TGTTTCTGTA AGAAACCTAC TGCCCAGGCA 3900 CTGCAAACCG CCACCTCCCT ATACTGCTTG GAGCTGAGCA AATCACCACA AACTGTAATA 3960 CAATGATCCT GTATTCAGAC AGATGAGGAC TTTCCATGGG ACCACAACTA TTTTCAGATG 4020 TGAACCATTA ACCAGATCTA GTCAATCAAG TCTGTTTACT GCAAGGTTCA ACTTATTAAC 4080 AATTAGGCAG ACTCTTTATG CTTGCAAAAA CTACAACCAA TGGAATGTGA TGTTCATGGG 4140 10 TATAGTTCAT GTCTGCTATC ATTATTCGTA GATATTGGAC AAAGAACCTT CTCTATGGGG 4200 CATCCTCTTT TTCCAACTTG GCTGCAGGAA TCTTTAAAAG ATGCTTTTAA CAGAGTCTGA 4260 ACCTATTTCT TAAACACTTG CAACCTACCT GTTGAGCATC ACAGAATGTG ATAAGGAAAT 4320 CAACTTGCTT ATCAACTTCC TAAATATTAT GAGATGTGGC TTGGGCAGCA TCCCCTTGAA 4380 CTCTTCACTC TTCAAATGCC TGACTAGGGA GCCATGTTTC ACAAGGTCTT TAAAGTGACT 4440 15 AATGGCATGA GAAATACAAA AATACTCAGA TAAGGTAAAA TGCCATGATG CCTCTGTCTT 4500 CTGGACTGGT TTTCACATTA GAAGACAATT GACAACAGTT ACATAATTCA CTCTGAGTGT 4560 TTTATGAGAA AGCCTTCTTT TGGGGTCAAC AGTTTTCCTA TGCTTTGAAA CAGAAAAATA 4620 TGTACCAAGA ATCTTGGTTT GCCTTCCAGA AAACAAAACT GCATTTCACT TTCCCGGTGT 4680 TCCCCACTGT ATCTAGGCAA CATAGTATTC ATGACTATGG ATAAACTAAA CACGTGACAC 4740 20 AAACACACAC AAAAGGGAAC CCAGCTCTAA TACATTCCAA CTCGTATAGC ATGCATCTGT 4800 TTATTCTATA GTTATTAAGT TCTTTAAAAT GTAAAGCCAT GCTGGAAAAT AATACTGCTG 4860 AGATACATAC AGAATTACTG TAACTGATTA CACTTGGTAA TTGTACTAAA GCCAAACATA 4920 TATATACTAT TAAAAAGGTT TACAGAATTT TATGGTGCAT TACGTGGGCA TTGTCTTTTT 4980 AGATGCCCAA ATCCTTAGAT CTGGCATGTT AGCCCTTCCT CCAATTATAA GAGGATATGA 5040 25 ACCAAAAAA AAAAAAAAAA AA Seq ID NO: 10 Protein sequence: NP_003465.2 Protein Accession #: 30 11 21 31 41 51 MAARPLPVSP ARALLLALAG ALLAPCEARG VSLWNEGRAD EVVSASVRSG DLWIPVKSFD 60 SKNHPEV LNI RLQRESKELI INLERNEGLI ASSFTETHYL QDGTDVSLAR NYTVILGHCY 120 YHGHVRGYSD SAVSLSTCSG LRGLIVFENE SYVLEPMKSA TNRYKLFPAK KLKSVRGSCG 180 SHHNTPNLAA KNVFPPPSQT WARRHKRETL KATKYVELVI VADNREFQRQ GKDLEKVKQR 240 35 LIEIANHVDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300 LIEIANHYDK FYRPLNIRIV LVGVEVWNDM DKCSVSQDPF TSLHEFLDWR KMKLLPRKSH 300
DNAQLVSGVY FQGTTIGMAP IMSMCTADQS GGIVMDHSDN PLGAAVTLAH ELGHNFGMNH 360
DTLDRGCSCQ MAVEKGGCIM NASTGYPFPM VFSSCSRKDL ETSLEKGMGV CLFNLPEVRE 420
SFGGQKCGNR FVEEGEECDC GEPEECMNRC CNATTCTLKP DAVCAHGLCC EDCQLKPAGT 480
ACRDSSNSCD LPEFCTGASP HCPANVYLHD GHSCQDVDGY CYNGICQTHE QQCVTLWGFG 540
AKPAPGICFE RVNSAGDPYG NCGKVSKSSF AKCEMRDAKC GKIQCQGGAS RPVIGTNAVS 600
IETNIPLQQG GRILCRGTHV YLGDDMPDPG LVLAGTKCAD GKICLNRQCQ NISVFGVHEC 660
AMQCHGRGVC NNRKNCHCEA HWAPPFCDKF GFGGSTDSGP IRQADNQGLT IGILVTILCL 720
LAAGFVVYLK RKTLIRLLFT NKKTTIEKLR CVRPSRPPRG FQPCQAHLGH LGKGLMRKPP 780
DSYPPKDNPR RLLQCQNVDI SRPLNGLNVP QPQSTQRVLP PLHRAPRAPS VPARPLPAKP 840
ALBOAGGTCK NDRPOKED BA DRU ARTITUT II HAL ARTDGOW ETGLIN LA BA PADOVPHOVE 900 40 45 ALRQAQGTCK PNPPQKPLPA DPLARTTRLT HALARTPGQW ETGLRLAPLR PAPQYPHQVP 900 RSTHTAYIK 50 Seq ID NO; 11 DNA sequence Nucleic Acid Accession #: NM_001394 400-1584(underlined sequences correspond to start and stop codons) Coding sequence: 21 31 51 55 GGAGCCGCG GACCGGCAAA AATACACGGG AGGCCGTCGC CGAAAAGAGT CCGCGGTCCT 120 CTCTCGTAAA CACACTCTCC TCCACCGGCG CCTCCCCCTC CGCTCTGCGC GCCGCCCGGC 180 TGGGCGCCCG AGGCCGCTCC GACTGCTATG TGACCGCGAG GCTGCGGGAG GAAGGGGACA 240 60 GGGAAGAAGA GGCTCTCCCG CGGGAGCCCT TGAGGACCAA GTTTGCGGCC ACTTCTGCAG 300 GCGTCCCTTC TTAGCTCTCG CCTGCCCCTT TCTGCAGCCT AGGCGGCCCA GGTTCTCTTC 360 TCTTCCTCGC GCGCCCAGCC GCCTCGGTTC CCGGCGACCA TGGTGACGAT GGAGGAGCTG 420 CGGGAGAGTGG ACTGCAGTGT GCTCAAAAGG CTGATGAACC GGGACGAGAA TGGCGGCGGC 480 GCGGCGGCA GCGGCAGCA CGGCACCCTG GGGCTGCCGA GCGGCGGCAA GTGCCTGCTG 540 65 CTGGACTGCA GACCGTTCCT GGCGCACAGC GCGGGCTACA TCCTAGGTTC GGTCAACGTG 600 CGCTGTAACA CCATCGTGCG GCGGCGGGCT AAGGGCTCCG TGAGCCTGGA GCAGATCCTG 660 CCCGCCGAGG AGGAGGTACG CGCCCGCTTG CGCTCCGGCC TCTACTCGGC GGTCATCGTC 720 TACGACGAGC GCAGCCCGCG CGCCGAGAGC CTCCGCGAGG ACAGCACCGT GTCGCTGGTG 780 GTGCAGGCGC TGCGCCGCAA CGCCGAGCGC ACCGACATCT GCCTGCTCAA AGGCGGCTAT 840 GAGAGGTTTT CCTCCGAGTA CCCAGAATTC TGTTCTAAAA CCAAGGCCT GGCAGCATC 900
CCACCCCGG TTCCCCCCAG CGCCACAGAG CCCTTGGACC TGGGCTGCAG CTCTCTTGTGG 960
ACCCCACTAC ACGACCAGGG GGGTCCTGTG GAGATCCTTC CCTTCCTCTA CCTCGGCAGT 1020
GCCTACCATG CTGCCCGGAG AGACATGCTG GACGCCCTGG GCATCACGGC TCTGTTGAAT 1080
GTCTCCTCGG ACTGCCCAAA CCACTTTGAA GGACACTATC AGTACAAGTG CATCCCAGTG 1140 70 75 GAAGATA ACC ACA AGGCCGA CATCAGCTCC TGGTTCATGG AAGCCATAGA GTACATCGAT 1200 GCCGTGAAGG ACTGCCGTGG GCGCGTGCTG GTGCACTGCC AGGCGGGCAT CTCGCGGTCG 1260 GCCACCATCT GCCTGGCCTA CCTGATGATG AAGAAACGGG TGAGGCTGGA GGAGGCCTTC 1320

GAGTTCGTTA AGCAGCGCCG CAGCATCATC TCGCCCAACT TCAGCTTCAT GGGGCAGCTG 1380 GGACCCCTGC GGGAGCGGGG CAAGACCCCC GCCACCCCA CCTCGCAGTT CGTCTTCAGC 1500 TTTCCGGTCT CCGTGGGCGT GCACTCGGCC CCCAGCAGCCTGCCCTACCT GCACAGCCCC 1560 5 ATCACCACCT CTCCCAGCTG TTAGAGCCGC CCTGGGGGCC CCAGAACCAG AGCTGGCTCC 1620 CAGCAAGGGT AGGACGGGCC GCATGCGGCA GAAAGTTGGG ACTGAGCAGC TGGGAGCAGG 1680
CGACCGAGCT CCTTCCCCAT CATTTCTCCT TGGCCAACGA CGAGGCCAGC CAGAATGGCA 1740
ATAAGGACTC CGAATACATA ATAAAAGCAA ACAGAACACT CCAACTTAGA GCAATAACCG 1800 GTGCCGCAGC AGCCAGGGAA GACCTTGGTT TGGTTTATGT GTCAGTTTCA CTTTTCCGAT 1860 10 AGAAATTTCT TACCTCATTT TTTTAAGCAG TAAGGCTTGA AGTGATGAAA CCCACAGATC 1920 CTAGCAAATG TGCCCAACCA GCTTTACTAA AGGGGGAGGA AGGGAGGACA AAGGGATGAG 1980
AAGACAAGTT TCCCAGAAGT GCCTGGTTCT GGGTACTTGT CCCTTTGTTGT CCGTTGTTGT 2040
AGTTAAAGGA ATTTCATTTT TAAAAGAAAT CTTCGAAGGT GTGGTTTTCA TTTCTCAGTC 2100
ACCAACAGAT GAATAATTAT GCTTAATAAT AAAGTATTTA TTAAGACTTT CTTCAGAGTA 2160 15 TGAAAGTACA AAAAGTCTAG TTACAGTGGA TTTAGAATAT ATTTATGTTG ATGTCAAACA 2220 GCTGAGCACC GTAGCATGCA GATGTCAAGG CAGTTAGGAA GTAAATGGTG TCTTGTAGAT 2280 ATGTGCAAGG TAGCATGATG AGCAACTTGA GTTTGTTGCC ACTGAGAAGC AGGCGGGTTG 2340 GGTGGGAGGA GGAAGAAAGG GAAGAATTAG GTTTGAATTG CTTTTTAAAA AAAAAAGAAA 2400 AGAAAAAGAC AGCATCTCAC TATGTTGCCA AGGCTCATCT TGAGAAGCAG GCGGGTTGGG 2460 20 TGGGAGGAGG AAGAAAGGGA AGAATTAGGT TTGAATTGCT TTTTTAAAAA AAAA Seq ID NO: 12 Protein sequence:
Protein Accession #: NP_001385 25 MYTMEELREM DCSVLKRLMN RDENGGGAGG SGSHGTLGLP SGGKCLLLDC RPFLAHSAGY 60 ILGSVNVRCN TIVRRRAKGS VSLEQILPAE EEVRARLRSG LYSAVIVYDE RSPRAESLRE 120 DSTVSLVVOA LRRNAERTDI CLLKGGYERF SSEYPEFCSK TKALAAIPPP VPPSATEPLD 180 LGCSSCGTPL HDQGGPVEIL PFLYLGSAYH AARRDMLDAL GITALLNVSS DCPNHFEGHY 240 QYKCIPVEDN HKADISSWFM EAIEYIDAVK DCRGRVLVHC QAGISRSATI CLAYLMMKKR 300 VRLEEAFEFV KQRRSIISPN FSFMGQLLQF ESQVLATSCA AEAASPSGPL RERGKTPATP 360 30 TSOFVFSFPV SVGVHSAPSS LPYLHSPITT SPSC 35 Seq ID NO: 13 DNA sequence Nucleic Acid Accession #: none found
Coding sequence: 68-340(underlined sequences correspond to start and stop codons) 40 41 51 31 AGCGCCTTGC CTTCTCTTAG GCTTTGAAGC ATTTTTTGTCT GTGCTCCCTG ATCTTCAGGT 60 AGCACCATG AAGTTCTTAG CAGTCCTGGT ACTCTTGGGA GTTTCCAGT 100
CACCACCATG AAGTTCTTAG CAGTCCTGGT ACTCTTGGGA GTTTCCATCT TCTGGTCTC 120
TGCCCAGAAT COGACAACAG CTGCTCCAGC TGACACGTAT CCAGCTACTG GTCCTGCTGA 180
TGATGAAGCC CCTGATGCTG AAACCACTGC TGCTGCAACC ACTGCGACCA CTGCTGCTCC 240
TACCACTGCA ACCACCGCTG CTTCTACCAC TGCTCGTAAA GACATTCAG TTTTACCCAA 300
ATGGGTTGGG GATCTCCCGA ATGGTAGAGT GTGTCCCTGA GATGGAATCA GCTTGAGTCT 360 45 TCTGCAATTG GGTCACAACT ATTCATGCTT CCTGTGATTT CATCCAACTA CTTACCTTGC 420 CTACGATATC CCCTTTATCT CTAATCAGTT TATTTTCTTT CAAATAAAAA ATAACTATGA 480 50 GCGAGCTAAC AT Seq ID NO: 14 Protein sequence: Protein Accession #: 55 **31** 41 11 21 MKFLAVLVLL GVSIFLVSAQ NPTTAAPADT YPATGPADDE APDAETTAAA TTATTAAPTT 60 60 ATTAASTTAR KDIPVLPKWV GDLPNGRVCP Sea ID NO: 15 DNA sequence NM_016640.2 Nucleic Acid Accession #: 39-1358(underlined sequences correspond to start and stop codons) Coding sequence: 65 41 11 21 31 GCTTAAGTTG ACCTCTGGGT CCGGAATCGC GGGCAAAG<u>AT G</u>GCCGCGCC AGGTGTTGGA 60 GGCCTTAGCT ACCCGGTCCG AGGCTTTCAT TGCACACCGC GGCTAATGCC GCCGCACGG 120 CTACAGAAAC GACCTCCCAA GACGTCGCGG CGACCCCCGT CGCGGGTAC CCGCCGATTG 180 70 75 AGCCCGAACC CGAACCTGAA CCTGCGCTGG ACCTCGCGGC GCTGCGTGCG GTCGCCTGCG 480 ACTGCCTGCT GCAGGAGCAC TTCTACCTGC GGCGCAGGCG GCGCGTGCAC CGTTACGAGG 540

AGAGCGAGGT CATATCTTTG CCCTTCCTGG ATCAGCTGGT GTCAACCCTC GTGGGCCTCC 600
TCAGCCCACA CAACCCGGCC CTGGCCGCTG CCGCCCTCGA TTATAGATGC CCAGTTCATT 660
TTTACTGGGT GCGTGGTGAA GAAATTATTC CTCGTGGTCA TCGAAGAGGT CGAATTGATG 720 ACTTGCGATA CCAGATAGAT GATAAACCAA ACAACCAGAT TCGAATATCC AAGCAACTCG 780 5 CAGAGTTTGT GCCATTGGAT TATTCTGTTC CTATAGAAAT CCCCACTATA AAATGTAAAC 840 CAGACAAACT TCCATTATTC AAACGGCAGT ATGAAAACCA CATATTTGTT GGCTCAAAAA 900 CTGCAGATCC TTGCTGTTAC GGTCACACCC AGTTTCATCT GTTACCTGAC AAATTAAGAA 960 GGGAAAGGCT TTTGAGACAA AACTGTGCTG ATCAGATAGA AGTTGTTTTT AGAGCTAATG 1020 CTATTGCAAG CCTTTTTGCT TGGACTGGAG CACAAGCTAT GTATCAAGGA TTCTGGAGTG 1080 10 AAGCAGATGT TACTCGACCT TTTGTCTCCC AGGCTGTGAT CACAGATGGA AAATACTTTT 1140 CCTTTTTCTG CTACCAGCTA AATACTTTGG CACTGACTAC ACAAGCTGAT CAAAATAACC 1200 CTCGTAAAAA TATATGTTGG GGTACACAAA GTAAGCCTCT TTATGAAACA ATTGAGGATA 1260 ATGATGTGAA AGGTTTTAAT GATGATGTTC TACTTCAGAT AGTTCACTTT CTACTGAATA 1320 GACCAAAAGA AGAAAAATCA CAGCTGTTGG AAAAC<u>TGA</u>AA AAGCATATTT GATTGAGAAC 1380 TGTGGGAATA TTTAAATTTT ACTGAAGGAA CAATAATGAT GAGATTTGTA ACTGTCAACT 1440 15 ATTAAATACA TTGATTTTTG AGACAAATAT TTCTTATGTC AACCTGTTAT TAGATCTCTT 1500 ACTCTGCTCA AATTCATCAC TGAAAGATTT AATTTTAGTT ACCTTTTGTT GATTTAAAAA 1560 TAATTGCATT TGTATATTGC TAACTGATAA GACAAATTGA GTTATTGAGC TATTAAATGC 1620 ACATTTTAAT ATAAATGCAG AAATCCCAAA TAAAATGCTA ACATACTGAA TTCAGTAATT 1680 20 AAAAGAACCC ACTGC Seq ID NO: 16 <u>Protein sequence;</u> Protein Accession #: NP_057724.1 25 31 MAAARCWRPL LRGPRLSLHT AANAAATATE TTSODVAATP VARYPPIVAS MTADSKAARL 60 MAAARCWRFL EROPRESENT AANAANATE ITSQDVAATE VARYFIVAS MITASSAARE 00
RRIERWQATV HAAESVDEKL RILTKMQFMK YMVYPQTFAL NADRWYQYFT KTVFLSGLPP 120
PPAEPEPEPE PEPEPALDLA ALRAVACDCL LQEHFYLRRR RRVHRYEESE VISLPFLDQL 180
VSTLVGLLSP HNPALAAAAL DYRCPVHFYW VRGEEIIPRG HRRGRIDDLR YQIDDKPNNQ 240
IRISKQLAEF VPLDYSVPIE IPTIKCKPDK LPLFKRQYEN HIFVGSKTAD PCCYGHTQFH 300 30 LLPDKLRRER LLRQNCADQI EVVFRANAIA SLFAWTGAQA MYQGFWSEAD VTRPFVSQAV 360 ITDGKYFSFF CYQLNTLALT TQADQNNPRK NICWGTQSKP LYETIEDNDV KGFNDDVLLQ 420 35 IVHFLLNRPK EEKSQLLEN Sea ID NO: 17 DNA sequence Nucleic Acid Accession #: NM_025059.1 3-2150 (underlined sequences correspond to start and stop codons) Coding sequence: 40 21 41 31 GCATGAGCCT GGACTGCACC AGCCATATCG CGCTGGGTGC CGCTTCGCCA GCGCCCGAGG 60 AAACTTACGA TCATCTTTCG GAAGTCCCGG TCACGCGGGGA GCAGTTAAAC CACTATCGGA 120
ATGTGGCTCA AAATGCTCGA AGTGAACTTG CAGCAACTTT GGTCAAATTT GAATGTGCTC 180 45 AGTCTGAGCT TCAAGACCTC CGATCCAAGA TGCTTTCTAA AGAAGTCTCC TGTCAAGAAC 240 TGAAAGCTGA AATGGAGAGC TACAAGGAAA ACAATGCCAG AAAATCATCT CTCCTTACCT 300 CTTTGAGAGA CAGAGTTCAG GAACTAGAAG AAGAATCAGC AGCACTTTCC ACTTCTAAAA 360 TCAGAACAGA AATCACAGCT CACGCTGCAA TCAAGGAGAA CCAGGAATTA AAGAAGAAAG 420 TTGTAGAGTT AAATGAAAAA TTACAAAAGT GTTCAAAAGA AAATGAGGAG AATAAGAAAC 480 50 AAGTTTCAAA GAATTGCAGG AAACATGAGG AATTTCTGAC TCAACTGCGT GACTGCTTGG 540 ATCCAGATGA GAGGAATGAC AAGGCATCAG ATGAAGATTT AATTTTAAAG CTTAGAGACC 600 TGCGCAAAGA AAATGAATTC GTGAAAGGAC AAATTGTTAT TCTTGAAGAG ACTATAAATG 660 TCCATGAGAT GGAAGCAAAA GCTAGCAGAG AAACGATCAT GAGGCTGGCT TCAGAAGTCA 720 ACAGAGAGCA GAAAAAAGCT GCCTCCTGTA CTGAAGAGAA AGAGAAGCTG AACCAGGACC 780 55 TGCTCAGTGC TGTAGAAGCA AAAGAAGCTC TTGAAAGGGA AGTTAAGATC TTCCAAGAAA 840 GGCTGCTTGC TGGCCAGCAG GTCTGGGATG CCTCAAAGCA GGAAGTGAGC CTCCTGAAGA 900
AAAGCTCTTC TGAGTTGGAG AAGAGTTTGA AGGCCAGTCA GGATGCAGTC ACAACCTCAC 960
AAAGCCAGTA CTCCTCATTT AGGGAGAAAA TCGCAGCCCT CCTTAGGGGC AGATTGAGCA 1020
TGACTGGGTC CACTGAGGAC ACCATTTTGG AGAAGATTCG AGAAATGGAC AGCCGGGAAG 1080 60 TOTTGGAGA CAACTTGAAT TITTGGAGAAAC AAAAATATCT TAAATTTCTG GATCAGCTT 1320 65 CTCAGAAAAT GAAGTTGGAC CAGATGGCTG CCGAACTTGG CTTTGACACG CGGCTGGACG 1380 TGGTTTTAGC TCGAACAGAG CAGCTGGTTC GTCTTGAGAG CAATGCAGTC ATTGAGAACA 1440 AGACCATTGC CCACAATTTG CAGAGAAAGC TAAAGACACA GAAAGAGAGA CTGGAGAGCA 1500 AAGAATTACA CATGAGCCTC CTCCGGCAGA AAATAGCCCA GCTGGAGGAG GAGAAGCAGG 1560 70 CACGCACGGC CTTGGTGGTT GAGAGGGACA ACGCGCATCT TACCATCAGG AACTTGCAGA 1620 AGAAGGTGGA GAGGCTGCAG AAAGAGCTGA ACACGTGTCG AGACTTGCAC ACCGAGCTCA 1680 AAGCCAAACT GGCCGACACC AATGAACTGA AGATTAAAAC TTTGGAACAG ACTAAAGCCA 1740 TTGAAGATCT AAACAAATCC AGAGACCAAC TGGAGAAGAT GAAGGAGAAA GCTGAGAAAA 1800 AGCTCATGTC TGTCAAGTCA GAACTGGATA CCACAGAACA TGAGGCTAAG GAGAATAAAG 1860 75 AAAGGCCAG AAACATGATA GAAGTGGTAA CCAGTGAAAT GAAGACACTA AAAAAATCTC 1920 TGGAAGAAGC AGAAAAGAGA GAAAAGCAGC TGGCAGACTT CAGGGAGGTG GTGTCGCAGA 1980

TGCTAGGCTT GAACGTGACC AGCCTTGCTC TTCCTGATTA TGAAATCATC AAGTGTCTTG 2040

AAAGATTGGT CCATTCACAT CAGCATCACT TTGTTACCTG TGCCTGCCTC AAAGATGTGA 2100 CTACTGGGCA AGAGAGGCAC CCACAAGGCC ATTTACAGCT TCTTCATTGA ACACTGTATC 2160 TCTTGAGAGA GGTGGCCATA AGACATGGCA CACAATTCCC AATTTCACAA ATTCCTCATG 2220 TCTTTGAGAT TTGATCAGTT TGTGAATATT TTATGCTTTG ATGATATAGT GAGAATGCAT 2280 5 CACTTGCAAA AACGATCTCA AAAGTGTCAG CCTTAGATAA ACGTCAGCAT TAAAAAACGC 2340 CAAAAAAAA AAAAAAAAGC ATTTTAGGAT CCAGAAGAAT TCCACCAGAT TGCATGAGTT 2400 AGATTGGGAA ATGGGAGTGG GAGATAATAT TGGGAGGTAT CTATTTTAAG TCAGGGGCTT 2460 TACTAGCCGA TITAGTTCTC ACAATAACCA TGTGGAGAAG CTGTGACATT TTTAATTTAC 2520 AACCTTTCTG GGGCTCAGAC ATAAAGTTAC CTATCCAAGG TTGCAGTTGG GTAGTGGTGG 2580 10 GACCAGGATG GACAACTCAT TGGCCCTGCC TCAAAAGCCA TACCTCTTCT CCTGCTATGC 2640 AGAATCTGTT TCTCCTGAAT CTCTGTGATG CTGGTGGGAA TTGTTTGCAT AGAGGAAGGA 2700 CAATAACCCT GCCATCGTGA GTTAATGTCC GGGCTGGTCA CAGTGGTTCA TGCCTGTAAT 2760 CCCAGCACTT TGGGAGTCCA AGGCAGGCAT ATCATTTGAG GTCAGGAGTT TAAGACCAGC 2820 CTGGCTAACA TAGTGAGACC CTGTTTCTAC TAAAAATACA AAAATAAGCC AGGTGTGGTG 2880 15 GTGCATGACT GTAATCCCAA CTACTCAGCA GGAGAAGCAC TTGAACCCAG GAGACGGAGG 2940 CGGCAGTGAG CCAAGATTGT GCCACTGCAC TCCAGCCTGG GCGACAGAGT GAAACTACAT 3000 CTCAGAAAAA AAAAAAAAAA AAAAAAAAAA AAGTTAATGT CCAAAAATGA CAGATTTACA 3060 AGTGTAAGCT ATATGATTTC TTCAAAAAGC AAAAGCAATA TACCTAATTC ATTTGGATCA 3120 AACTTACATA GGTCTCAGGT CCTGTAAGAA ACTTGCCTGT TCTAACTGTT GCTACCAGAT 3180 20 TATATCTGGT GGTAATTGTT AATGTTTCAG CAGGGCTGGT CTCAGTCCTT TAAAATGGAA 3240 AGCTTTATTT GGAGCCCAAC CCTATAAGAT GAAGAAATCC TATATAGTCT TATTCACCAA 3300 TATATCCAAT ACACCCACAG CAATGGTACC TTTTTAAGAT CAGGATTTTA TTATGAATTC 3360 CTGTCACTTT CTGTTTTCCA TTTAAATTTC TATTTTACAA ATTTTTCAGG GAATCATATT 3420 CTTAACTTCA CTGAGAAAAA TGTGTTACTC TTTTGGACAA TTTATCTTAT TTCTATCATA 3480 25 TAAGATGTAT TITTITATTG TCCTTAAAAG AAGCTCTAGC ATGAAATTAA AGGAAAGGGA 3540 AAGAAATAGA TCTGGTGCAC CCGAACATTA GGAGAAAATG AAAAATATAC AACCAACCGT 3600 TCGTGAGTCA TCAAAAAGTC AAAGTCAGCC TGGCCAACAT GGCAAAACTC CGTCTCTGCA 3660 AAAAATACAA AAATGAGCCC GGTATGTTGG CATATGCCTG TAATCCCAGC TACTCGAGAG 3720 GCTGAGACAC GAAAATTGCT TGAACCTGGG AGGCGGAGGT TGCAATGAGC CGAGATCGCG 3780 30 CTACTGCACT CCAGCCTGGG CAACAGAGAG AGACCTTGTC TCAAAAAACA ACAACAACAA 3840 AAAGTCAAAG TCATAATAAG CAAATTATTG GCTTCTTTCT TCTAGACYAA AAGAAATTAA 3900 AGAGATGAAA CAATCAATTG CAAGGGTCAA AACTAGATTG GATCTTGGTT TGAATGAAAA 3960 AAAGCATAAA ATATTCTTGC AATAATTGTA AAAATTTGAA TGTGGACTAA GTCCTAGATT 4020 ATATTAAAAT ATTITTAATT TITTAAGCTT GACAAATGCA CTGATTGTTA TACTTTAAAT 4080 35 AACTAAAAAT CTGAGAATCC ACAGTGCTAC AGACAATAAA TGATAAAATG GGAAAAAAA 4140 AAAAAAAAA A Seq ID NO: 18 <u>Protein sequence:</u>
Protein Accession #: NP_079335.1 40 31 MSLDCTSHIA LGAASPAPEE TYDHLSEVPV TREQLNHYRN VAQNARSELA ATLVKFECAQ 60 SELQDLRSKM LSKEVSCQEL KAEMESYKEN NARKSSLLTS LRDRVQELEE ESAALSTSKI 120 45 RTEITAHAAI KENOELKKKV VELNEKLOKC SKENEENKKO VSKNCRKHEE FLTQLRDCLD 180 PDERNDKASD EDLILKLRDL RKENEFVKGQ IVILEETINV HEMEAKASRE TIMRLASEVN 240 REQKKAASCT EEKEKLNQDL LSAVEAKEAL EREVKIFQER LLAGQQVWDA SKQEVSLLKK 300
SSSELEKSLK ASQDAVTTSQ SQYSSFREKI AALLRGRLSM TGSTEDTILE KIREMDSREE 360
SRDRMVSQLE AQISELVEQL GKESGFHQKA LQRAQKAENM LETLQGQLTH LEAELVSGGV 420
LRDNLNFEKQ KYLKFLDQLS QKMKLDQMAA ELGFDTRLDV VLARTEQLVR LESNAVIENK 480 50 TIAHNLORKL KTOKERLESK ELHMSLLROK IAQLEEEKQA RTALVVERDN AHLTIRNLOK 540 KVERLQKELN TCROLHTELK AKLADTNELK IKTLEQTKAI EDLNKSRDQL EKMKEKAEKK 600 LMSVKSELDT TEHEAKENKE RARNMIEVVT SEMKTLKKSL EEAEKREKQL ADFREVVSQM 660 LGLNVTSLAL PDYEIIKCLE RLVHSHQHHF VTCACLKDVT TGQERHPQGH LQLLH 55 Seq ID NO: 19 DNA sequence AF071552, NM_000662 Nucleic Acid Accession #: 60 Coding sequence: 441-1313 (underlined sequences correspond to start and stop codons) 51 21 31 41 65 CTTTGTATAA GGCTCAGCTA AAAGGGAAAT TGAGTGGGTC AGGTACCACG GATACTATAC 60 ACTCTATTGC ATGATTCTCC TGCCTACATC AGAAGACGTT TATAAGCCTA TTTTAAAGGA 120 TACCAGTTIGG AATCTICTCTT TTATTAATCA CCAAGAGAACAAC CATGAACAAG CTGTTTATCA 180
TTTGACTCAT CATTTAATCT TGATTTCCAG CTTCTCACAC TTGAAAGAAG ACATAATACA 240
TTTCTCACAG GATTCTGGGA CTATTAACTG AACTTATGTG TGTAAAAGGA ATTCATACAA 300
TGAAAGCACT AGAAATAATT ATTATACTTA TAACCATTGT ATTTTTACAT GTTTAAAATA 360 70 TAGCCATAAT TAGCCTACTC AAATCCAAGT GTAAAAGTAA AATGATTIGATTTTG 420
TAGCCATAAT TAGCCTACTC AAATCCAAGT GTAAAAGTAA AATGATTIGC TTTCGTTTTG 420
AGTCTAGGAA CAAATTGGACTTGGAAACATT AACTGACAT TCTTCAACAC CAGATCCGAG 540
CTGTTCCCTT TGAGAACCTT AACATCCATT GTGGGGATGC CATGGACTTA GGCTTAGAGG 600
CCATTTTTGA TCAAGTTGTG AGAAGAAATC GGGGTGGATG GTGTCTCCAG GTCAATCATC 660

TTCTGTACTG GGCTCTGACC ACTATTGGTT TTGAGACCAC GATGTTGGGA GGGTATGTTT 720 ACAGCACTCC AGCCAAAAAA TACAGCACTG GCATGATTCA CCTTCTCCTG CAGGTGACCA 780

75

TTGATGGCAG GAACTACATT GTCGATGCTG GGTTTGGACG CTCATACCAG ATGTGGCAGC 840 CTCTGGAGTT AATTTCTGGG AAGGATCAGC CTCAGGTGCC TTGTGTCTTC CGTTTGACGG 900 AAGAGAATGG ATTCTGGTAT CTAGACCAAA TCAGAAGGGA ACAGTACATT CCAAATGAAG 960 AATTTCTTCA TTCTGATCTC CTAGAAGACA GCAAATACCG AAAAATCTAC TCCTTTACTC 1020 5 TTAAGCCTCG AACAATTGAA GATTTTGAGT CTATGAATAC ATACCTGCAG ACATCTCCAT 1080 CATCTGTGTT TACTAGTAAA TCATTTTGTT CCTTGCAGAC, CCCAGATGGG GTTCACTGTT 1140
TGGTGGGCTT CACCCTCACC CATAGGAGAT TCAATTATAA GGACAATACA GATCTAATAG 1200
AGTTCAAGAC TCTGAGTGAG GAAGAAATAG AAAAAGTGCT GAAAAATATA TTTAATATTT 1260
CCTTGCAGAG AAAGCTTGTG CCCAAACATG GTGATAGATT TTTTACTATT TAGAATAAGG 1320
AGTAAAAACAA TCTTGTCTAT TTGTCATCCA GCTCACCAGT TATCAACTGA CGACCTATCA 1380 10 TGTATCTTCT GTACCCTTAC CTTATTTTGA AGAAAATCCT AGACATCAAA TCATTTCACC 1440 TATAAAAATG TCATCATATA TAATTAAACA GCTTTTTAAA GAAACATAAC CACAAACCTT 1500 TTCAAATAAT AATAATAATA ATAATAATAA ATGTATTTTA AAGATGGCCT GTGGTTATCT 1560 TGGAAATTGG TGATTTATGC TAGAAAGCTT TTAATGTTGG TTTATTGTTG AATTC 15 Seq ID NO: 20 Protein sequence: NP_000653.1 Protein Accession #: 20 21 31 MDIEÁYLERI GYKK SRNKLD LETLTDILQH QIRAVPFENL NIHCGDAMDL GLEAIFDQVV 60 RRNRGGWCLQ VNHLLYWALT TIGFETTMLG GY VYSTPAKK YSTGMIHLLL QVTIDGRNYI 120 VDAGFGRSYQ MWQPLELISG KDQPQVPCVF RLTEENGFWY LDQIRREQYI PNEEFLHSDL 180 25 LEDSKYRKIY SFTLKPRTIE DFESMNTYLQ TSPSSVFTSK SFCSLQTPDG VHCLVGFTLT 240 HRRFNYKDNT DLIEFKTLSE EEIEKVLKNI FNISLQRKLV PKHGDRFFTI Sea ID NO: 21 DNA sequence Nucleic Acid Accession #: NM 003714 30 Coding sequence: 123-1031 (underlined sequences correspond to start and stop codons) 51 CGGCACGAGC AAAAAGGAAG AGTGGGAGGA GGAGGGGAAG CGGCGAAGGA GGAAGAGGAG 60
GAGGAGGAAG AGGGGAGCAC AAAGGATCA GGTCTCCCGA CGGGAGGTTA ATACCAAGAA 120
CCATGTGTGC CGAGCGGCTG GGCCAGTTCA TGACCCTGGC TTTGGTGTTG GCCACCTTTG 180 35 ACCCGGCGCG GGGGACCGAC GCCACCAACC CACCCGAGGG TCCCCAAGAC AGGAGCTCCC 240 AGCAGAAAGG CCGCCTGTCC CTGCAGAATA CAGCGGAGAT CCAGCACTGT TTGGTCAACG 300 40 CTGGCGATGT GGGGTGTGGC GTGTTTGAAT GTTTCGAGAA CAACTCTTGT GAGATTCGGG 360
GCTTACATGG GATTTGCATG ACTTTTCTGC ACAACGCTGG AAAATTTGAT GCCCAGGGCA 420
AGTCATTCAT CAAAGACGCC TTGAAATGTA AGGCCCACGC TCTGCGGCAC AGGTTCGGCT 480 GCATAAGCCG GAAGTGCCCG GCCATCAGGG AAATGGTGTC CCAGTTGCAG CGGGAATGCT 540 ACCTCAAGCA CGACCTGTGC GCGGCTGCCC AGGAGAACAC CCGGGTGATA GTGGAGATGA 600 TCCATTTCAA GGACTTGCTG CTGCACGAAC CCTACGTGGA CCTCGTGAAC TTGCTGCTGA 660 CCTGTGGGGA GGAGGTGAAG GAGGCCATCA CCCACAGCGT GCAGGTTCAG TGTGAGCAGA 720 45 ACTGGGGAAG CCTGTGCTCC ATCTTGAGCT TCTGCACCTC GGCCATCCAG AAGCCTCCCA 780 CGGCGCCCC CGAGCGCCAG CCCCAGGTGG ACAGAACCAA GCTCTCCAGG GCCCACCACG 840 GGGAAGCAGG ACATCACCTC CCAGAGCCCA GCAGTAGGGA GACTGGCCGA GGTGCCAAGG 900 50 GTGAGCGAGG TAGCAAGAGC CACCCAAACG CCCATGCCCG AGGCAGAGTC GGGGGCCTTG 960 GGGCTCAGGG ACCTTCCGGA AGCAGCGAGT GGGAAGACGA ACAGTCTGAG TATTCTGATA 1020 TCCGGAGGTG AAATGAAAGG CCTGGCCACG AAATCTTTCC TCCACGCCGT CCATTTTCTT 1080 ATCTATGGAC ATTCCAAAAC ATTTACCATT AGAGAGGGGG GATGTCACAC GCAGGATTCT 1140 GTGGGGACTG TGGACTTCAT CGAGGTGTGT GTTCGCGGAA CGGACAGGTG AGATGGAGAC 1200 55 CCTGGGGCC GTGGGGTCTC AGGGGTGCCT GGTGAATTCT GCACTTACAC GTACTCAAGG 1260
GAGCGCGCCC GCGTTATCCT CGTACCTTTG TCTTCTTTCC ATCTGTGGAG TCAGTGGGTG 1320 TCGGCCGCTC TGTTGTGGGG GAGGTGAACC AGGGAGGGGC AGGGCAAGGC AGGGCCCCCA 1380
GAGCTGGGCC ACACAGTGGG TGCTGGGCCT CGCCCCGAAG CTTCTGGTGC AGCAGCCTCT 1440 GGTGCTGTCT CCGCGGAAGT CAGGGCGGCT GGATTCCAGG ACAGGAGTGA ATGTAAAAAT 1500 AAATATCGCT TAGAATGCAG GAGAAGGGTG GAGAGGAGGC AGGGGCCGAG GGGGTGCTTG 1560 GTGCCAAACT GAAATTCAGT TTCTTGTGTG GGGCCTTGCG GTTCAGAGCT CTTGGCGAGG 1620 60 GTGGAGGGAG GAGTGTCATT TCTATGTGTA ATTTCTGAGC CATTGTACTG TCTGGGCTGG 1680 GGGGGACACT GTCCAAGGGA GTGGCCCCTA TGAGTTTATA TTTTAACCAC TGCTTCAAAT 1740 CTCGATTTCA CTTTTTTAT TTATCCAGTT ATATCTACAT ATCTGTCATC TAAATAAATG 1800 65 GCTTTCAAAC AAAAAAAAA AAAAAAAAAA AAAAAAA Seq ID NO: 22 Protein sequence: NP_003705 Protein Accession #: 70 21 31 MCAERLGOFM TLALVLATFD PARGTDATNP PEGPODRSSQ OKGRLSLONT AEIQHCLVNA 60 GDVGCGVFEC FENNSCEIRG LHGICMTFLH NAGKFDAQGK SFIKDALKCK AHALRHRFGC 120 ISRKCPAIRE MVSQLQRECY LKHDLCAAAQ ENTRVIVEMI HFKDLLLHEP YVDLVNLLLT 180 75 CGEEVKEAIT HSVQVQCEQN WGSLCSILSF CTSAIQKPPT APPERQPQVD RTKLSRAHHG 240

EAGHHLPEPS SRETGRGAKG ERGSKSHPNA HARGRVGGLG AQGPSGSSEW EDEQSEYSDI 300


PCT/US02/02242 WO 02/059377

RR

5

Seq ID NO: 23 DNA sequence

Nucleic Acid Accession #:



NM_005264.1

5 TCCCGTGCCC ACCTCCGAGC ACGTGGCCGA GATCGTGGGC AGGCAAGGCT GCAAGATTAA 480 GGCCTTGAGG GCCAAGACCA ACACCTACAT CAAGACACCG GTGAGGGGCG AGGAACCAGT 540 GTTCATGGTG ACAGGGCGAC GGGAGGACGT GGCCACAGCC CGGCGGGAAA TCATCTCAGC 600 AGCGGAGCAC TTCTCCATGA TCCGTGCCTC CCGCAACAAG TCAGGCGCCG CCTTTGGTGT 660 GGCTCCTGCT CTGCCCGGCC AGGTGACCAT CCGTGTGCGG GTGCCCTACC GCGTGGTGGG 720 10 GCTGGTGGTG GGCCCCAAAG GGGCAACCAT CAAGCGCATC CAGCAGCAAA CCAACACATA 780 CATTATCACA CCAAGCCGTG ACCGCGACCC CGTGTTCGAG ATCACGGGTG CCCCAGGCAA 840 CGTGGAGCGT GCGCGCGAGG AGATCGAGAC GCACATCGCG GTGCGCACTG GCAAGATCCT 900 CGAGTACAAC AATGAAAACG ACTTCCTGGC GGGGAGCCCC GACGCAGCAA TCGATAGCCO 960 CTACTCCGAC GCCTGGCGGG TGCACCAGCC CGGCTGCAAG CCCCTCTCCA CCTTCCGGCA 1020 15 GAACAGCCTG GGCTGCATCG GCGAGTGCGG AGTGGACTCT GGCTTTGAGG CCCCACGCCT 1080 GGGTGAGCAG GGCGGGGACT TTGGCTACGG CGGGTACCTC TTTCCGGGCT ATGGCGTGGG 1140 CAAGCAGGAT GTGTACTACG GCGTGGCCGA GACTAGCCCC CCGCTGTGGG CGGGCCAGGA 1200
GAACGCCACG CCCACCTCCG TGCTCTTCTC CTCTGCCTCC TCCTCCTCCT CCTCTTCCGC 1260
CAAGGCCCGC GCTGGGCCCC CGGGCGCACA CCGCTCCCT GCCACTTCCG CGGGACCCGA 1320 20 GCTGGCCGGA CTCCCGAGGC GCCCCCGGG AGAGCCGCTC CAGGGCTTCT CTAAACTTGG 1380 TGGGGGCGGC CTGCGGAGCC CCGGCGGCGG GCGGGATTGC ATGGTCTGCT TTGAGAGCGA 1440 AGTGACTGCC GCCCTTGTGC CCTGCGGACA CAACCTGTTC TGCATGGAGT GTGCAGTACG 1500 CATCTGCGAG AGGACGGACC CAGAGTGTCC CGTCTGCCAC ATCACAGCCA CGCAAGCCAT 1560 CCGAATATTC TCCTAA 25 Seq ID NO: 26 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted 30 21 31 41 FCFAMPSLVV SGIMERNGGF GELGCFGGSA KDRGLLEDER ALOLALDOLC LLGLGEPPAP 60 RAGEDGGGG GGAPAQPTAP PQPAPPPPPA APPAAPTTAP AAQTPQPPTA PKGASDAKLC 120 ALYKEAELRL KGSSNTTECV PVPTSEHVAE IVGRQGCKIK ALRAKTNTYI KTPVRGEEPV 180 35 FMVTGRREDV ATARREIISA AEHFSMIRAS RNKSGAAFGV APALPGQVTI RVRVPYRVVG 240 LVVGPKGATI KRIQQQTNTY IITPSRDRDP VFEITGAPGN VERAREEIET HIAVRTGKIL 300 EYNNENDFLA GSPDAAIDSR YSDAWRVHQP GCKPLSTFRQ NSLGCIGECG VDSGFEAPRL 360 GEOGGDFGYG GYLFPGYGVG KQDVYYGVAE TSPPLWAGQE NATPTSVLFS SASSSSSSA 420 KARAGPPGAH RSPATSAGPE LAGLPRRPPG EPLQGFSKLG GGGLRSPGGG RDCMVCFESE 480 40 VTAALVPCGH NLFCMECAVR ICERTDPECP VCHITATQAI RIFS Seq ID NO: 27 DNA sequence Nucleic Acid Accession #: FGENESH predicted Coding sequence: 1-2070 (underlined sequences correspond to start and stop codons) 45 31 41 51 ATGAGCGGTG CGGGGGTGGC GGCTGGGACC CCCCCA GCTCGCCGAC CCCGGGCTCT 60
CGGCGCCGCG GCCAGCGCCC CTCTGTGGGC GTCCAGTCCT TGAGGCCGCA GAGCCCCCAG 120
CTCAGGCAGA GCGACCCGCA GAAACGGAAC CTGGACCTGG AGAAAAGCCT GCAGTTCCTG 180
CAGCAGCAGC ACTCGGAGAT CCTGGCCAAG CTCCATGAGG AGATCGAGCA TCTGAAGCGG 240
GAAAACAAGG GTGAGCCGGC GCGGGGCCCT AGGCCGGCC TGCCTCCCCA GGCACACTCA 300 50 ACACTGCCGC TCCCGCAGCA CAGAAACACA GCCATCAACT CCAGCACACG CCTGGGCTCA 360 GGGGGAACAC AGGACGGGA GCCCCTCCAG ACTGTCCTTG CCCACCTGGC TGCACTGGCC 420
CCTGTATGCC AACCCAGTGG GTACAGGTTC TGGGGGACCT GGACAGATGC CGCTACCTCT 480
AGCCGTGGCT GGACGATGTT ATGCAGCCAA GCACAGCACG TGCTGCTCTC GGGAAGCCCA 540 55 GGGCCTGAGG TCATTGCAGG GCGGCAGGTG GCCACAGGGT GCTCCCCAGA CCTCCCTCCT 600 60 GCAGCAACCA TGGGGACAAA GGGAGGAAGC AGAGTCCTGT TTCCTTGCCA CTTGTCCAAG 840 GCACTTCCCC ATCCTGACAG CGGCCCCAC CCAGCCCAGG ATCCTGGGCT GTGGTCTCAA 900 GCTCACTTCC CATTATCTTT GGGGCTGGGG CTGACATCAG GAGGACATCT GACTGGTGGA 960 TGGAGCCAGC CTGGGAACAT CGCAGCTGGG GCAGTGCCTA GGGCTCTCCC TTCCCAGGGA 1020 GACATGGAGA AGGGGGTTGA GGGAGGGCCC TTCCCTAGCC GCTGTGGCAA CTCCAGTGAG 1080 65 CTGTTCTGGG CAAAGTGTGG CCCAAGTCGG CAGCCCCAGC CCTGCAGTGC TGGGGACGCT 1140 GACAGGACAC GGGAAGAGGC CATGCTTTCC CTCGGGACCT GCTGTTCCAT GTGTCCCAAG 1200
CCCTCCTGCT TTCCAGATGG CCCCTCAGGA AACCACCTTT CCAGGGCCTC TGCTCCCTTG 1260
GCGCTCGCT GGGTCTGCAT CAACGGAGTG TGGGTAGAGC CGGGAGGACC CAGCCCTGCC 1320
AGGCTGAAGG AGGGCTCCTC ACCGGACACAC AGGCCAGGAG GCAAGCGTGG GCGTCTTGCG 1380 70 GGCGGTAGCG CCGACACTGT GCGCTCTCCT GCAGACAGCC TCTCCATGTC AAGCTTCCAG 1440 75 AGGCAGATGG GGGCGGGGC ACACCCCCCA ATGATCCTGC CCCTTCCCCT GCGAAAGCCC 1740 ACCACACTTA GGCAGTGCGA AGTGCTCATC CGCGAGCTGT GGAATACCAA CCTCCTGCAG 1800

CAGGGCGGC GAGGACGGGG GAGGTGGGGG GGGCGCGCC CCCGCGCAGC CGACAGCCCC 240

PCT/US02/02242 WO 02/059377

ACCCAAGAGC TGCGGCACCT CAAGTCCCTC CTGGAAGGGA GCCAGAGGCC CCAGGCAGCC 1860 CCGGAGGAAG CTAGCTTTCC CAGGGACCAA GAAGCCACGC ATTTCCCCAA GGTCTCCACC 1920 AAGAGCCTCT CCAAGAAATG CCTGAGCCCA CCTGTGGCGG AGCGTGCCAT CCTGCCCGCA 1980 CTGAAGCAGA CCCCGAAGAA CAACTTTGCC GAGAGGCAGA AGAGGCTGCA GGCAATGCAG 2040 AAACGCCCC TGCATCGCTC AGTGCTTTGA

Seq ID NO: 28 <u>Protein sequence:</u>
Protein Accession #: FGENESH predicted

10

5

25

MSGAGVAAGT RPPSSPTPGS RRRRQRPSVG VQSLRPQSPQ LRQSDPQKRN LDLEKSLQFL 60 QOOHSEMLAK LHEEIEHLKR ENKGEPARGP RPALPPQAHS TLPLPQHRNT AINSSTRLGS 120 15 GGTQDGEPLQ TVLAHLAALA PVCQPSGYRF WGTWTDAATS SRGWTMLCSQ AQHVLLSGSP 180 GPEVIAGRQV ATGCSPDLPP PSRAEMGRNP WDSPCPARSL PQIAAVARPR ISSPMALSPH 240 MLGAQGIWTH SIQGSLPAIW AATMGTKGGS RVLFPCHLSK ALPHPDSGPH PAQDPGLWSQ 300 AHFPLSLGLG LTSGGHLTGG WSQPGNIAAG AVPRALPSQG DMEKGVEGGP FPSRCGNSSE 360 LFWAKCGPSR QPQPCSAGDA DRTREEAMLS LGTCCSMCPK PSCFPDGPSG NHLSRASAPL 420 20 GARWYCINGV WYEPGGPSPA RLKEGSSRTH RPGGKRGRLA GGSADTYRSP ADSLSMSSFQ 480 GARWYCINGY WYEFOGPSPA KLKEGSSKIH KROUNKOKLA GUSADIYKSP ADSLESMESTQ 480
SYKSISNSAN SQGKARPQPG SFNKQDSKAD VSQKADLEEE PLLHNSKLAV VPGVQGQARK 540
EKAEASNAGA ACMGNSQHQG RQMGAGAHPP MILPLPLRKP TTLRQCEVLI RELWNTNLLQ 600
TQELRHLKSL LEGSQRPQAA PEEASFPRDQ EATHFPKVST KSLSKKCLSP PVAERAILPA 660
LKQTPKNNFA ERQKRLQAMQ KRRLHRSVL

Seq ID NO: 29 DNA sequence Nucleic Acid Accession #: NM_012319.2
Coding sequence: 138-2405 (underlined sequences correspond to start and stop codons)

30 41 51 CTCGTGCCGA ATTCGGCACG AGACCGCGTG TTCGCGCCTG GTAGAGATTT CTCGAAGACA CCAGTGGGCC CGTGTGGAAC CAAACCTGCG CGCGTGGCCG GGCCGTGGGA CAACGAGGCC 120 GCGGAGACGA AGGCGCAATG GCGAGGAAGT TATCTGTAAT CTTGATCCTG ACCTTTGCCC 180
TCTCTGTCAC AAATCCCCTT CATGAACTAA AAGCAGCTGC TTTCCCCCAG ACCACTGAGA 240
AAATTAGTCC GAATTGGGAA TCTGGCATTA ATGTTGACTT GGCAATTTCC ACACGGCAAT 300 35 ATCATCTACA ACAGCTTTTC TACCGCTATG GAGAAAATAA TTCTTTGTCA GTTGAAGGGT 360 TCAGAAAATT ACTTCAAAAT ATAGGCATAG ATAAGATTAA AAGAATCCAT ATACACCATG 420 ACCACGACCA TCACTCAGAC CACGAGCATC ACTCAGACCA TGAGCGTCAC TCAGACCATG 480
AGCATCACTC AGACCACGAG CATCACTCTG ACCATGATCA TCACTCTCAC CATAATCATG 540
CTGCTTCTGG TAAAAATAAG CGAAAAGCTC TTTGCCCAGA CCATGACTCA GATAGTTCAG 600 40 GTAAAGATCC TAGAAACAGC CAGGGGAAAG GAGCTCACCG ACCAGAACAT GCCAGTGGTA 660 GAAGGAATGT CAAGGACAGT GTTAGTGCTA GTGAAGTGAC CTCAACTGTG TACAACACTG 720 TCTCTGAAGG AACTCACTTT CTAGAGACAA TAGAGACTCC AAGACCTGGA AAACTCTTCC 780 CCAAAGATGT AAGCAGCTCC ACTCCACCCA GTGTCACATC AAAGAGCCGG GTGAGCCGGC 840 45 TGGCTGGTAG GAAAACAAAT GAATCTGTGA GTGAGCCCCG AAAAGGCTTT ATGTATTCCA GAAACACAAA TGAAAATCCT CAGGAGTGTT TCAATGCATC AAAGCTACTG ACATCTCATG 960 GCATGGGCAT CCAGGTTCCG CTGAATGCAA CAGAGTTCAA CTATCCTGTG CCAGCCATCA 1020
TCAACCAAAT TGATGCTAGA TCTTGTCTGA TTCATACAAG TGAAAAGAAG GCTGAAATCC 1080
CTCCAAAGAC CTATTCATTA CAAATAGCCT GGGTTGGTGG TTTTATAGCC ATTTCCATCA 1140
TCAGTTTCCT GTCTCTGCTG GGGGTTATCT TAGTGCCTCT CATGAATCGG GTGTTTTTCA 1200 50 AATTTCTCCT GAGTTTCCTT GTGGCACTGG CCGTTGGGAC TTTGAGTGGT GATGCTTTTT 1260 TACACCTTCT TCCACATTCT CATGCAAGTC ACCACCATAG TCATAGCCAT GAAGAACCAG 1320 CAATGGAAAT GAAAAGAGGA CCACTTTTCA GTCATCTGTC TTCTCAAAAC ATAGAAGAA 1380 GTGCCTATTT TGATTCCACG TGGAAGGGTC TAACAGCTCT AGGAGGCCTG TATTTCATGT 1440 55 TTCTTGTTGA ACATGTCCTC ACATTGATCA AACAATTTAA AGATAAGAAG AAAAAGAATC 1500 AGAAGAAACC TGAAAATGAT GATGATGTGG AGATTAAGAA GCAGTTGTCC AAGTATGAAT 1560 CTCAACTTTC AACAAATGAG GAGAAAGTAG ATACAGATGA TCGAACTGAA GGCTATTTAC 1620
GAGCAGACTC ACAAGAGCCC TCCCACTTTG ATTCTCAGCA GCCTGCAGTC TTGGAAGAAG 1680
AAGAGGTCAT GATAGCTCAT GCTCATCCAC AGGAAGTCTA CAATGAATAT GTACCCAGAG 1740 60 GGTGCAAGAA TAAATGCCAT TCACATTTCC ACGATACACT CGGCCAGTCA GACGATCTCA 1800 TTCACCACCA TCATGACTAC CATCATATTC TCCATCATCA CCACCACAA AACCACCATC 1860
CTCACAGTCA CAGCCAGCGC TACTCTCGGG AGGAGCTGAA AGATGCCGGC GTCGCCACTT 1920
TGGCCTGGAT GGTGATAATG GGTGATGGCC TGCACAATTT CAGCGATGGC CTAGCAATTG 1980 65 GTGCTGCTTT TACTGAAGGC TTATCAAGTG GTTTAAGTAC TTCTGTTGCT GTGTTCTGTC 2040 ATGAGTTGCC TCATGAATTA GGTGACTTTG CTGTTCTACT AAAGGCTGGC ATGACCGTTA 2100
AGCAGGCTGT CCTTTATAAT GCATGTCAG CCATGCTGGC GTATCTTGGA ATGGCAACAG 2160
GAATTTTCAT TGGTCATTAT GCTGAAAATG TTTCTATGTG GATATTTGCA CTTACTGCTG 2220
GCTTATTCAT GTATGTTGCT CTGGTTGATA TGGTACCTGA AATGCTGCAC AATGATGCTA 2280
GTGACCATGG ATGTAGCCGC TGGGGGTATT TCTTTTTTACA GAATGCTGGG ATGCTTTTTGG 2340 70 GTTTTGGAAT TATGTTACTT ATTTCCATAT TIGAACATAA AATGGTGTTTC GTATAAATT 2400
TCTAGTTAAG GTTTAAATGC TAGAGTAGCT TAAAAAGTTG TCATAGTTTC AGTAGGTCAT 2400
AGGGAGATGA GTTTGATGC TGTACTATGC AGCGTTTAAA GTTAGTGGGT TTTGTGATTT 2520
TTGTATTGAA TATTGCTGTC TGTTACAAAG TCAGTTAAAA GTTAGTGGGT TTTTTAAGT 2580 75 TATTCTATCT TGGAGATAAA ATCTGTATGT GCAATTCACC GGTATTACCA GTTTATTATG 2640

TTTTCAAGAA CTAACACAGT TATTCCTATA CTGGATTTTA GGTCTCTGAA GAACTGCTGG 2760
TGTTTAGGAA TAAGAATGTG CATGAAGCCT AAAATACCAA GAAAGCTTAT ACTGAATTTA 2820
AGCAAAGAAA TAAAGGAGAA AAGAGAAGAAT CTGAGAATT GGGGAGGCAT AGATTCTTAT 2880
AAAAATCACA AAATTTGTTG TAAAATTAGAG GGGAGAAATT TAGAATTAG TATAAAAAGG 2940
CAGAATTAGT ATAGAGTACA TTCATTAAAC ATTTTTGTCA GGATTATTTC CCGTAAAAAC 3000
GTAGTGAGCA CTCTCATATA CTAATTAGTG TACATTTAAC TTTGTATAAT ACAGAAATCT 3060
AAATATATTT AATGAATTCA AGCAATATAC ACTTGACCAA GAAATTGGAA TTTCAAAATG 3120
TTCGTGCGGG TTATATACCA GATGAGTACA GTGAGTAGTT TATGTATCAC CAGACTGGGT 3180
TATTGCCAAG TTATATACCA CCAAAAGCTG TATGACTGGA TGTTCTGGTT ACCTGGTTTA 3240
CAAAATTATC AGAGTAGTAA AACTTTGATA TATATGAGGA TATTAAAACT ACACTAAGTA 3300
TCATTTGATT CGATTCAGAA AGTACTTTGAT TATATCAG CCTTCAGTG CTATCATTGT 3360
GAGCAATTGT CTTTATATACACAA TAAATTCCTT ATATCAGCCTT G

Seq ID NO: 30 Protein sequence:
Protein Accession #: NP_036451.2

1 11 21 31 41 51

20 MARKLSVILI LTFALSVTNP LHELKAAAFP QTTEKISPNW ESGINVDLAI STRQYHLQQL 60 FYRYGENNSL SVEGFRKLLQ NIGIDKIKRI HIHIDHDHHS DHEHHSDHER HSDHEHHSDH 120 EHHSDHDHHS HINHAASGKN KRKALCPDHD SDSSGKDPRN SQGKGAHRPE HASGRRNVKD 180 SVSASEVTST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSK RVSRLAGRKT 240 NESVESBPKG EMVSRUTNEN DEGEMASKI TSHGMGOV PLINATEENVL CHAINNOID A 300

SVSASEVIST VYNTVSEGTH FLETIETPRP GKLFPKDVSS STPPSVTSKS RVSRLAGRKT 240
NESVSEPRKG FMYSRNTNEN PQECFNASKL LTSHGMGIQV PLNATEFNYL CPAIINQIDA 300
RSCLIHTSEK KAEIPPKTYS LQIAWVGGFI AISIISFLSL LGVILVPLMN RVFFKFLLSF 360
LVALAVGTLS GDAFLHLLPH SHASHHHSHS HEEPAMEMKR GPLFSHLSSQ NIEESAYFDS 420
TWKGLTALGG LYFMFLVEHV LTLIKQFKDK KKKNQKKPEN DDDVEIKKQL SKYESQLSTN 480
EEKVDTDDRT EGYLRADSQE PSHFDSQQPA VLEEEEVMIA HAHPQEVYNE YVPRGCKNKC 540
HSHFHDTLGQ SDDLIHHHD VHHILHHHHH QNHIPHSHSQ RYSREELKDA GVATLAWMVI 600
MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY 660

MGDGLHNFSD GLAIGAAFTE GLSSGLSTSV AVFCHELPHE LGDFAVLLKA GMTVKQAVLY 660 NALSAMLAYL GMATGIFIGH YAENVSMWIF ALTAGLFMYV ALVDMVPEML HNDASDHGCS 720 RWGYFFLQNA GMLLGFGIML LISIFEHKIV FRNF

35 Seq ID NO: 31 DNA sequence Nucleic Acid Accession #:

Nucleic Acid Accession #: NM_002184.1

31

41

Coding sequence: 256-3012(underlined sequences correspond to start and stop codons)

40 GAGCAGCCAA AAGGCCGCG GAGTCGCGCT GGGCCGCCC GGCGAGCTG AACCGGGGGC 60
CGCGCCTGCC AGGCCGACGG GTCTGGCCCA GCCTGGCGCC AAGGGGTTCG TGCGCTGTGG 120
AGACGCGGAG GGTCGAGGCG GCGCGGCCTG AGTGAAACCC AATGGAAAAA GCATGACATT 180
TAGAAGTAGA AGACTTAGCT TCAAATCCCT ACTCCTTCAC TTACTAATTT TGTGATTTGG 240
AAATATCCGC GCAAGATGTT GACGTTGCAG ACTTGGGTAG TGCAAGCCTT GTTTATTTTC 300
CTCACCCACTG AATCTACAGG TGAACTTCTA GATCATGTG GTTATATCAGT TCCTGAATCT 360
CCAGTTGTAC AACTTCATTC TAATTTCACT GCAGTTTTGTG TGCTAAAGGA AAAATGTATG 420
GATTATTTTC ATGTAAATGC TAATTACATT GTCTGGAAAA CCAATCT TACTATTCCT 480
AAGGAGCAAT ATACTATCAT AAACAGAACA GCATCCAGTG TCACCTTTAC AGATATAGCT 540

AAGGAGCAAT ATACTATCAT AAACAGAACA GCATCCAGTG TCACCTTTAC AGATATAGCT 540
TCATTAAATA TTCAGCTCAC TTGCAACATT CTTACATTCG GACAGCTTGA ACAGAATGTT 600
TATGGAATCA CAATAATTTC AGGCTTGCCT CCAGAAAAAAC CTAAAAATTT GAGTTGCATT 660
GTGAACGAGG GGAAGAAAT GAGGTGTGAG TGGGATGGT GAAAGGAAAC ACACTTGGAG 720
ACAAACTTCA CTTTAAAATC TGAATGGGCA ACACACAAGT TTGCTGATTG CAAAGCAAAA 780
CGTGACACCC CCACCTCATG CACTGTTGAT TATTCTACTG TGTATTTTTG CAAACTTGAA 840

55 GTCTGGGTAG AAGCAGAGAA TGCCCTTGGG AAGGTTACAT CAGATCATAT CAATTTTGAT 900
CCTGTATATA AAGTGAAGCC CAATCCGCCA CATAATTTAT CAGTGATCAA CTCAGAGGAA 960
CTGTCTAGTA TCTTAAAATT GACATGGACC AACCCAAGTTA TTAAGAGTGT TATAATACTA 1020
AAATAAACA TTCAATATAG GACCAAAAGAT GCCTCAACTT GGAGCCAGAT TCCTCCTGAA 1080
GACACAGCAT CCACCCGATC TTCATTCACT GTCCAAGACC TTAAACCTTT TACAGAATAT 1140
GTGTTTAGGA TTCGCTGTAT GAAGGAAGAT GGTAAGGGAT ACTGGAGTGAA 1200

60 GAAGCAAGTG GGATCACCTA TGAAGATAGA CCATCTAAAG CACCAAGTTT CTGGTATAAA 1260
ATAGATCCAT CCCATACTCA AGGCTACAGA ACTGTACAAC TCGTGTGGAA GACATTGCCT 1320
CCTTTTGAAG CCAATGGAAA AATCTTGGAT TATGAAGTGA CTCTCACAAG ATGGAAATCA 1380
CATTTACAAA ATTACACAGT TAATGCCACA AAACTGACAG TAAATCTCAC AAATGATCGC 1440

TATCTAGCAA CCCTAACAGT AAGAAATCTT GTTGGCAAAT CAGATGCAGC TGTTTTAACT 1500
ATCCTGCCT GTGACTTTCA AGCTACTCAC CCTGTAATGG ATCTTAAAGC ATTCCCCAAA 1560
GATACATGC TTTGGGTGGA ATGGACTACT CCAAGGGAAT CTGTAAAAGAA ATATATACTT 1620
GAGTGGTGTG TGTTATCAGA TAAAGCACCC TGTATCACAG ACTGGCAACA AGAAGATGGT 1680
ACCGTGCATC GCACCTATTT AAGAGGGAAC TTAGCAGAGA GCAAATGCTA TTTGATAACA 1740

70
GTTACTCCAG TATATGCTGA TGGACCAGGA AGCCCTGAAT CCATAAAGGC ATACCTTAAA 1800
CAAGCTCCAC CTTCCAAAGG ACCTACTGTT CGGACAAAAA AAGTAGGGAA AAACGAAGCT 1860
GTCTTAGAGT GGGACCAACT TCCTGTTGAT GTTCAGAATG GATTTATCAG AAATTATACT 1920
ATATTTTATA GAACCATCAT TGGAAATGAA ACTGCTGTGA ATGTGGATTC TTCCCACACA 1980
GAATATACAT TGTCCTCTTT GACTAGTGACACTTGTACA TGGTACGAAT GGCAGCATAC 2040
ACAGATGAAG GTGGGAAGGA TGGTCCACAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 2100

75
ACAGATGAAG GTGGGAAGGA TGGTCCAGAA TTCACTTTTA CTACCCCAAA GTTTGCTCAA 2100
GGAGAAATTG AAGCCATAGT CCTGCCTGTT TGCTTAGCAT TCCTATTGAC AACTCTTCTG 2160
GGAGTGCTGT TCTGCTTTAA TAAGCGAGAC CTAATTAAAA AACACATCTG GCCTAATGTT 2220
CCAGATCCTT CAAAGAGTCA TATTGCCCAG TGGTCACCTC ACACTCCTCC AAGGCACAAT 2280

TTTAATTCAA AAGATCAAAT GTATTCAGAT GGCAATTTCA CTGATGTAAG TGTTGTGGAA 2340 ATAGAAGCAA ATGACAAAAA GCCTTTTCCA GAAGATCTGA AATCATTGGA CCTGTTCAAA 2400 AAGGAAAAAA TTAATACTGA AGGACACAGC AGTGGTATTG GGGGGTCTTC ATGCATGTCA 2460 TCTTCTAGGC CAAGCATTTC TAGCAGTGAT GAAAATGAAT CTTCACAAAAA CACTTCGAGC 2520 ACTGTCCAGT ATTCTACCGT GGTACACAGT GGCTACAGAC ACCAAGTTCC GTCAGTCCAA 2580 5 GTCTTCTCAA GATCCGAGTC TACCCAGCCC TTGTTAGATT CAGAGGAGCG GCCAGAAGAT 2640 CTACAATTAG TAGATCATGT AGATGGCGGT GATGGTATTT TGCCCAGGCA ACAGTACTTC 2700 AAACAGAACT GCAGTCAGCA TGAATCCAGT CCAGATATTT CACATTTTGA AAGGTCAAAG 2760 CAAGTTTCAT CAGTCAATGA GGAAGATTTT GTTAGACTTA AACAGCAGAT TTCAGATCAT 2820 ATTTCACAAT CCTGTGGATC TGGGCAAATG AAAATGTTTC AGGAAGTTTC TGCAGCAGAT 2880 10 GCTTTTGGTC CAGGTACTGA GGGACAAGTA GAAAGATTTG AAACAGTTGG CATGGAGGCT 2940 GCGACTGATG AAGGCATGCC TAAAAGTTAC TTACCACAGA CTGTACGGCA AGGCGGCTAC 3000 CTAAAATGAT TTTATCTGTG AATTC 15 Seq ID NO: 32 Protein sequence: NP 002175.1 Protein Accession #: 41 20 MLTLQTWVVQ ALFIFLTTES TGELLDPCGY ISPESPVVQL HSNFTAVCVL KEKCMDYFHV 60 NANYIVWKTN HFTIPKEQYT IINRTASSYT FTDIASLNIQ LTCNILTFGQ LEQNYYGITI 120 ISGLPPEKPK NLSCIVNEGK KMRCEWDGGR ETHLETNFTL KSEWATHKFA DCKAKRDTPT 180 SCTVDYSTVY FVNIEVWVEA ENALGKVTSD HINFDPVYKV KPNPPHNLSV INSEELSSIL 240 25 KLTWTNPSIK SVIILKYNIQ YRTKDASTWS QIPPEDTAST RSSFTVQDLK PFTEYVFRIR 300 CMKEDGKGYW SDWSEEASGI TYEDRPSKAP SFWYKIDPSH TQGYRTVQLV WKTLPPFEAN 360 GKILDYEVTL TRWKSHLQNY TVNATKLTVN LTNDRYLATL TVRNLVGKSD AAVLTIPACD 420
FQATHPVMDL KAFPKDNMLW VEWTTPRESV KKYILEWCVL SDKAPCITDW QQEDGTVHRT 480
YLRGNLAESK CYLITVTPVY ADGPGSPESI KAYLKQAPPS KGPTVRTKKV GKNEAVLEWD 540
QLPVDVQNGF IRNYTIFYRT IIGNETAVNV DSSHTEYTLS SLTSDTLYMV RMAAYTDEGG 600 30 KDGPEFTFTT PKFAQGEIEA IVVPVCLAFL LTTLLGVLFC FNKRDLIKKH IWPNVPDPSK 660
SHLAQWSPHT PPRHNFNSKD QMYSDGNFTD VSVVEIEAND KKPFPEDLKS LDLFKKEKIN 720
TEGHSSGIGG SSCMSSSRPS ISSSDENESS QNTSSTVQYS TVVHSGYRHQ VPSVQVFSRS 780
ESTQPLLDSE ERPEDLQLVD HVDGGDGILP RQQYFKQNCS QHESSPDISH FERSKQVSSV 840 35 NEEDFVRLKQ QISDHISQSC GSGQMKMFQE VSAADAFGPG TEGQVERFET VGMEAATDEG 900 MPKSYLPQTV RQGGYMPQ Seg ID NO: 33 DNA sequence Nucleic Acid Accession #: NM_018255.1 40 11-2491 (underlined sequences correspond to start and stop codons) Coding sequence: 31 41 51 AGTTGGCGAC ATGGTGGCAC CCGTGCTGGA GACTTCTCAC GTGTTTTGCT GCCCAAACCG 60 45 GGTGCGGGGA GTCCTGAACT GGAGCTCTGG GCCCAGAGGA CTTCTGGCCT TTGGCACGTC 120 CTGCTCCGTG GTGCTCTATG ACCCCCTGAA AAGGGTTGTT GTTACCAACT TGAATGGTCA 180 CACCGCCCGA GTCAATTGCA TACAGTGGAT TTGTAAACAG GATGGCTCCC CTTCTACTGA 240 ATTAGTTTCT GGAGGATCTG ATAATCAAGT GATTCACTGG GAAATAGAGG ATAATCAGCT 300 TTTAAAAGCA GTGCATCTTC AAGGCCATGA AGGACCTGTT TATGCGGTGC ATGCTGTTTA 360 50 CCAGAGGAGG ACATCAGATC CTGCATTATG TACACTGATC GTTTCTGCAG CTGCAGATTC 420 TGCTGTTCGA CTCTGGTCTA AAAAGGGTCC AGAAGTAATG TGCCTTCAGA CTTTAAACTT 480
TGGAAATGGA TTTGCTTTGG CTCTCTGCTT ATCTTTTTTTG CCAAATACTG ATGTACCAAT 540 ATTAGCATGT GGCAATGATG ATTGCAGAAT TCACATATTT GCTCAACAAA ATGATCAGTT 600 55 CTTTGGTAGA GATCTTTTCC TAGCAAGCTG TTCACAAGAT TGCCTGATAA GAATATGGAA 720 GCTGTATATA AAGTCAACAT CTTTAGAAAC TCAGGATGAC GATAACATAA GACTGAAAGA 780 AAATACTTTT ACCATAGAAA ATGAAAGTGT TAAAATAGCA TTTGCTGTTA CTCTGGAGAC 840 AGTGCTAGCC GGTCATGAAA ACTGGGTAAA TGCAGTTCAC TGGCAACCTG TGTTTTACAA 900 AGATGGTGTC CTACAGCAGC CAGTGAGATT ATTATCTGCT TCCATGGATA AAACCATGAT 960 AGGTGGGAT CCAGATGAGA CATTAGATT THAT CAGGTAGAA CAGGTTCGAG TAGGTGAAGT 1020
AGGTGGGAAT ACTITGGGAT TITATGATTG CCAGTTCAAT GAAGATGCT CCATGATCAT 1080
TGCTCATGCT TTCCACGGAG CGTTGCACCT TTGGAAACAG AATACAGTTA ACCCAAGAGA 1140
GTGGACTCCA GAGATTGTCA TTTCAGGACA CTTTGATGGT GTCCAAGACC TAGTCTGGGA 1200 60 TOCAGAAGGA GAATTTATTA TCACTGTTGG TACTGATCAG ACAACTAGAC TTTTTGCTCC 1260 ATGGAAGAGA AAAGACCAAT CACAGGTGAC TTGGCATGAA ATTGCAAGGC CTCAGATACA 1320
TGGGTATGAC CTGAAATGTT TGGCAATGAT TAATCGGTTT CAGTTTGTAT CTGGAGCAGA 1380
TGAAAAAGTT CTTCGGGTTT TTTCTGCACC TCGGAATTTT GTGGAAAATT TTTGTGCCAT 1440
TACAGGACAA TCACTGAATC ATGTGCTCTG TAATCAAGAT AGTGATCTTC CAGAAGGAGC 1500 65 CACTGTCCCT GCATTGGGAT TATCAAATAA AGCTGTCTTT CAGGGAGATA TAGCTTCTCA 1560 CACITICCO GCATTGOGAT TATCAGATTA AGGIGITTT CAGGGAGGTA TAGCTICTCA 1560
GCCTTCTGAT GAAGAGGAGC TGTTAACTAG TACTGGTTTT GAGTATCAGC AGGTGGCCTT 1620
TCAGCCCTCC ATACTTACTG AGCCTCCCAC TGAGGATCAT CTTCTGCAGA ATACTTTGTG 1680
GCCTGAAGTT CAAAAACTAT ATGGGCACGG TTATGAAATA TTTTGTGTTA CTTGTAACAG 1740
TTCAAAGACT CTGCTTGCCT CAGCTTGTAA GGCAGCTAAG AAAGAGCATG CAGCTATCAT 1800 70 TCTTTGGAAC ACTACATCTT GGAAACAGGT GCAGAATTTA GTTTTCCACA GTTTGACAGT 1860 75 CACGCAGATG GCCTTCTCAC CTAATGAGAA GTTCTTACTA GCTGTTTCCA GAGATCGAAC 1920 CTGGTCATTG TGGAAAAAGC AGGATACAAT CTCACCTGAG TTCGAGCCAG TTTTTAGTCT 1980 TTTTGCCTTC ACCAACAAAA TTACTTCTGT GCACAGTAGA ATTATTTGGT CTTGTGATTG 2040

GAGTCCTGAC AGCAAGTATT TCTTCACTGG GAGTCGAGAC AAAAAGTGG TTGTCTGGGG 2100
TGAGTGCGAC TCCACTGATG ACTGTATTGA GCACAACATT GGCCCCTGGCT CCTCAGTCCT 2160
GGACGTGGGT GGGGCTGTGA CAGCTGTCAG CGTCTGCCCA GTGCTCCACC CTTCTCAACG 2220
ATACGTGGTT GCAGTAGGAT TGGAGTGTGG AAAGATTTGC TTATATACCT GGAAAAAGAC 2280
TGATCAAGTT CCAGAAATAA ATGACTGGAC CCACTGTGTA GAAACAAGTC AAAGCCAAAG 2340
TCATACACTG GCTATCAGAA AATTATCCTG GAAGAATTGC AGTGGAAAAA CTGAACAGAA 2400
GGAAGCAGAA GGTGCTGAGT GGTTACACTT TGCAAGCTGT GGTGAAGATC ACACTGTGAA 2460
GATACACAGA GTCAATAAAT GTGCACTGTAATGG

Seq ID NO: 34 <u>Protein sequence:</u> Protein Accession #: NP_060725.1

1 11 21 31 41 51

15 MVAPVLETSH VFCCPNRVRG VLNWSSGPRG LLAFGTSCSV VLYDPLKRVV VTNLNGHTAR 60
VNCIQWICKQ DGSPSTELVS GGSDNQVIHW EIEDNQLLKA VHLQGHEGPV YAVHAVYQRR 120
TSDPALCTLI VSAAADSAVR LWSKKGPEVM CLQTLNFGNG FALALCLSFL PNTDVPILAC 180
GNDDCRIHIF AQQNDQFQKV LSLCGHEDWI RGVEWAAFGR DLFLASCSQD CLIRIWKLYI 240
KSTSLETQDD DNIRLKENTF TIENESVKIA FAVTLETVLA GHENWVNAVH WQPVFYKDGV 300
LQQPVRLLSA SMDKTMILWA PDEESGVWLE QVRVGEVGGN TLGYDCQFN EDGSMIIAHA 360
FHGALHLWKQ NTVNPREWTP EIVISGHFDG VQDLVWDPEG EFIITVGTDQ TTRLFAPWKR 420
KDQSQVTWHE IARPQIHGYD LKCLAMINRF QFVSGADEKV LRVFSAPRNF VENFCAITGQ 480

25

KOUSQVI WHE JARPQIHOYD LRCLAMINAR QIVSGADEKV LRVISARNAY VENCAIIQU 480
SLNHVLCNQD SDLPEGATVP ALGLSNKAVF QGDIASQPSD EEELLTSTGF EYQQVAFQPS 540
ILTEPPTEDH LLQNTLWPEV QKLYGHGYEI FCVTCNSSKT LLASACKAAK KEHAAIILWN 600
TTSWKQVQNL VFHSLTVTQM AFSPNEKFLL AVSRDRTWSL WKKQDTISPE FEPVFSLFAF 660
TNKITSVHSR IIWSCDWSPD SKYFFTGSRD KKVVVWGECD STDDCIEHNI GPCSSVLDVG 720

GAVTAVSVCP VLHPSQRYVV AVGLECGKIC LYTWKKTDQV PEINDWTHCV ETSQSQSHTL 780 AIRKLCWKNC SGKTEQKEAE GAEWLHFASC GEDHTVKIHR VNKCAL

30 Seq ID NO: 35 DNA sequence

60

65

Nucleic Acid Accession #: NM_022131

Coding sequence: 11-2878 (underlined sequences correspond to start and stop codons)

35 | 11 | 21 | 31 | 41 | 51

TIGCTGCGAGG ATGCTGCCTG GGCGGCTGTG CTGGGTGCCG CTCCTGCTGG CGCTGGGCGT 60 GGGGAGCGGC AGCCGCCGGTG GCGGGACAG CCGGCAGCGC CCCCCCTCC CGGCTAAAGT 120 CAATAAGCAC AAGCCATGGA TCGAGACTTC ATATCATGGA GTCATAACTG AGAACAATGA 180 CACAGTCATT TTGGACCCAC CACTGGTAGC CCTGGATAAA GATGCACCGG TTCCTTTTTGC 240

40 AGGGGAATC TITGACCAC CATGGTAGC CCTGGATAG CATGGCCGGTTCA GAGCTGTGCTGGTGCT 300
CAACAAGACA TCAGGAGGGGCCCCCTTGAGGCCCCC TGAGTTGCA 360
GAAGGAGTAC ACATTCATCA TCCAGGCCTA TGACTGTGGTGCTGCGCCCC ACGAGACAGC 420
CTGGAAAAAG TCACACAAGG CCGTGGTCCA TATACAGGTG AAGGATGTCA ACGAGTTTGC 480
TCCCACCTTC AAAGAGCCAG CCTACAAGGC TGTTGTGACG GAGGGCAAGA TCTATGACAG 540

45
CATTCTGCAG GTGGAGGCCAT CTGACGAGGC TGTTGTGACG GAGGGCAAGA TCTTATGACAG 540
CATTCTGCAG GTGGAGGCCA TTGACGAGGA CTGCTCCCCA CAGTACAGCC AGATCTGCAA 600
CTATGAAATC GTCACCACAG ATGTGCCTTT TGCCATCGAC AGAAATGGCA ACATCAGGAA 660
CACTGAGAAG CTGAGCTATG ACAAACAACA CCAGTATGAG ATCCTGGTGA CCGCCTACGA 720
CTGTGGACAG AAGCCCGCTG CTCAGGACAC CCTGGTGCAG GTGGATGTGA AGCCAGTTTG 780

50 CAAGCCTGGC TGGCAAGACT GGACCAAGAG GATTGAGTAC CAGCCTGGCT CCGGGAGCAT 840
GCCCCTGTTC CCCAGCATCC ACCTGGAGAC GTGCGATGGA GCCGTGTTT CCCTCCAGAT 900
CGTCACAGAG CTGCAGCATA ATTACATTGG GAAGGGTTGT GACCGGGAGA CCTACTCTGA 960
GAAATCCCTT CAGAAGTTAT GTGGAGCCTC CTCTGGCATC ATTGACCTCT TGCCATCCCC 1020
TAGCGCTGCC ACCAACTGGA CTGCAGGACT GCTGGTGGAC AGCAGTGAGA TGATCTTCAA 1080

55
GTTTGACGGC AGGCAGGGTG CCAAAAATCCC CGATGGGATT GTGCCCCAAGA ACCTGACCGA 1140
TCAGTTCACC ATCACCATGT GGATGAAACA CGGCCCCAGC CCTGGTGTGA GAGCCGAGAA 1200
GGAAACCATC CTCTGCAACT CAGACAAAAAC CGAAATGAAC CGGCATCACT ATGCCCTGTA 1260
TGTGCACAAC TGCCGCCTCG TCTTTCTCTT GCGGAAGGAC TTCGACCACGT T1320
TCGCCCCGCG GAGTTCCACT GGAAGCTGGA TCAGATTTGT GACAAAGAGT GGCACTACTA 1380

TGTCATCAAT GTGGAGTTTC CTGTGGTAAC CTTATACATG GATGGAGCAA CATATGAACC 1440
ATACCTGGTG ACCAACGACT GGCCCATTCA TCCATCTCAC ATAGCCATGC AACTCACAGT 1500
CGGCGCTTGT TGGCAAGGAG GAGAAGTCAC CAAACCACAG TTTGCTCAGT TCTTTCATGG 1560
AAGCCTGGCC AGTCTCACCA TCCGCCCTGG CAAAATGGAA AGCCAGAAGG TGATCTCCTG 1620

CCTGCAGGCC TGCAAGGAAG GGCTGGACAT TAATTCCTTG GAAAGCCTTG GCCAAGGAAT 1680
AAAGTATCAC TTCAACCCCT CGCAGTCCAT CCTGGTGATG GAAGGTGACG ACATTGGGGAA 1740
CATTAACCGT GCTCTCCAGA AAGTCTCCTA CATCAACTCC AGGCAGTTCC CAACGGCGG 1800
TGTGCGGCGC CTCAAAGTAT CCTCCAAAGT CCAGTGCTTT GGGAAGACG TATGCATCAG 1860
TATCCCTGAG GTAGATGCCT ATGTGATGGT CCTCCAGGCC ATCGAGCCCC GGATCACCCT 1920


70 CCGGGGCACA GACCACTTCT GGAGACCTGC TGCCCAGTTT GAAAGTGCCA GGGGAGTGAC 1980 CCTCTTCCCT GATATCAAGA TTGTGAGCAC CTTCGCCAAA ACCGAAGCCC CCGGGGACGT 2040 GAAAACCACA GACCCCAAAAT CAGAAGTCTT AGAGGAAATG CTTCATAACT TAGATTTCTG 2100 TGACATTTTG GTGATCGGAG GGGACTTGGA CCCAAAGGCAG GAGTGCTTGG AGCTCAACCA 2160 CAGTGAGCTC CACCAACGAC ACCTGGATGC CACTAATTCT ACTGCAGGCT ACTCCATCTA 2220


75
CGGTGTGGGC TCCATGAGCC GCTATGAGCA GGTGCTACAT CACATCCGCT ACCGCAACTG 2280
GCGTCCGGCT TCCCTTGAGG CCCGGCGTTT CCGGATTAAG TGCTCAGAAC TCAATGGGCG 2340
CTACACTAGC AATGAGTTCA ACTTGGAGGT CAGCATCCTT CATGAAGACC AAGTCTCAG 2400
TAAGGAGCAT GTCAATCATC TGATTGTGCA GCCTCCCTTC CTCCAGTCTG TCCATCATCC 2460
TGAGTCCCGG AGTAGCATCC AGCACAGTTC AGTGGTCCCA AGCATTGCCA CAGTGGTCAT 2520




CACTICTICT GTGGAAGGAC TTTGTGAAGG AATTGGTGCT GGATTAGTGG ATGTTGCTAT 780 CTGGGTTGGC ACTTGTTCAG ATTACCCAAA AGGAGATGCT TCTACTGGAT GGAATTCAGT 840 TICTICGCATC ATTATTGAAG AACTACCAAA A<u>TAA</u>ATGCTT TAATTITCAT TIGCTACCTC 900
TITTTTATT ATGCCTTGGA ATGGTTCACT TAAATGACAT TITAAATAAG TITATGTATA 960
CATCTGAATG AAAAGCAAAG CTAAATATGT TTACAGACCA AAGTGTGATT TCACACTGTT 1020 5 TITAAATCTA GCATTATTCA TTTTGCTTCA ATCAAAAGTG GTTTCAATAT TTTTTTTAGT 1080 TGGTTAGAAT ACTTTCTTCA TAGTCACATT CTCTCAACCT ATAATTTGGA ATATTGTTGT 1140 GGTCTTTGT TTTTTCTCTT AGTATAGCAT TTTTAAAAAA ATATAAAAGC TACCAATCTT 1200 10. TGTACAATTT GTAAATGTTA AGAATTTTTT TTATATCTGT TAAATAAAAA TTATTTCCAA 1260 **CAACCTTAAA AAAAAAAAAAA AAAA** Seq ID NO: 38 Protein sequence: 15 51 31 MRPQGPAASP QRLRGLLLLL LLQLPAPSSA SEIPKGKQKA QLRQREVVDL YNGMCLQGPA 60 GVPGRDGSPG ANGIPGTPGI PGRDGFKGEK GECLRESFEE SWTPNYKQCS WSSLNYGIDL 120 GKIAECTFTK MRSNSALRVL FSGSLRLKCR NACCQRWYFT FNGAECSGPL PIEAIIYLDQ 180 GSPEMNSTIN IHRTSSVEGL CEGIGAGLVD VAIWVGTCSD YPKGDASTGW NSVSRIIIEE 240 20 Seq ID NO: 39 DNA sequence 25 NM 000949 Nucleic Acid Accession #: 285-2153(underlined sequences correspond to start and stop codons) Coding sequence: 30 CTCCCTCTTT CTGGATTTTA CCGACCGTTC GCGAAACAGC TTTCCACACA ATGGAGCTTC 120 ATGTCCTCGT GCAGGAAGTA CTCATCGACT GATGTGGCAG ACTTTGCTCC CTGACAAAAC 180 TAAAGAACTC TCCTATTCAT GGAGGCGAAC ACTGAGGATG CTTTCCACAT GAACCCTGAA 240 GTGAACTTCT GATACATTTC CTGCAGCAAG AGAAGGCAGC CAACATGAAG GAAAATGTGG 300 CATCTGCAAC CGTTTTCACT CTGCTACTTT TTCTCAACAC CTGCCTTCTG AATGGACAGT 360 35 TACCTCCTGG AAAACCTGAG ATCTTTAAAT GTCGTTCTCC CAATAAGGAA ACATTCACCT 420 GCTGGTGGAG GCCTGGGACA GATGGAGGAC TTCCTACCAA TTATTCACTG ACTTACCACA 480 GGGAAGGAGA GACACTCATG CATGAATGTC CAGACTACAT AACCGGTGGC CCCAACTCCT 540
GCCACTTTGG CAAGCAGTAC ACCTCCATGT GGAGGACATA CATCATGATG GTCAATGCCA 600
CTAACCAGAT GGGAAGCAGT TTCTCGGATG AACTTTATGT GGACGTGACT TACATAGTTC 660 40 AGCCAGACCC TCCTTTGGAG CTGGCTGTGG AAGTAAAACA GCCAGAAGAC AGAAAACCCT 720 ACCTGTGGAT TAAATGGTCT CCACCTACCC TGATTGACTT AAAAACTGGT TGGTTCACGC 780
TCCTGTATGA AATTCGATTA AAACCCGAGA AAGCAGCTGA GTGGGAGATC CATTTTGCTG 840
GGCAGCAAAC AGAGTTTAAG ATTCTCAGCC TACATCCAGG ACAGAAATAC CTTGTCCAGG 900
TTCGCTGCAA ACCAGACCAT GGATACTGGA GTGCATGGAG TCCAGCGACC TTCATTCAGA 960 45 TACCTAGTGA CTTCACCATG AATGATACAA CCGTGTGGAT CTCTGTGGCT GTCCTTTCTG 1020 CTGTCATCTG TTTGATTATT GTCTGGGCAG TGGCTTTGAA GGGCTATAGC ATGGTGACCT 1080 GCATCTTTCC GCCAGTTCCT GGGCCAAAAA TAAAAGGATT TGATGCTCAT CTGTTGGAGA 1140 AGGGCAAGTC TGAAGAACTA CTGAGTGCCT TGGGATGCCA AGACTTTCCT CCCACTTCTG 1200 50 ACTATGAGGA CTTGCTGGTG GAGTATTTAG AAGTAGATGA TAGTGAGGAC CAGCATCTAA 1260 TGTCAGTCCA TTCAAAAGAA CACCCAAGTC AAGGTATGAA ACCCACATAC CTGGATCCTG 1320 ACACTGACTC AGGCCGGGGG AGCTGTGACA GCCCTTCCCT TTTGTCTGAA AAGTGTGAGG 1380 AACCCCAGGC CAATCCCTCC ACATTCTATG ATCCTGAGGT CATTGAGAAG CCAGAGAATC 1440 CTGAAACAAC CCACACCTGG GACCCCCAGT GCATAAGCAT GGAAGGCAAA ATCCCCTATT 1500 55 TTCATGCTGG TGGATCCAAA TGTTCAACAT GGCCCTTACC ACAGCCCAGC CAGCACAACC 1560 CCAGATCCTC TTACCACAAT ATTACTGATG TGTGTGAGCT GGCTGTGGGC CCTGCAGGTG 1620
CACCGGCCAC TCTGTTGAAT GAAGCAGGTA AAGATGCTTT AAAATCCTCT CAAACCATTA 1680
AGTCTAGAGA AGAGGGAAAG GCAACCCAGC AGAGGGAGGT AGAAAGCTTC CATTCTGAGA 1740 CTGACCAGGA TACGCCCTGG CTGCTGCCCC AGGAGAAAAC CCCCTTTGGC TCCGCTAAAC 1800 60 CCTTGGATTA TGTGGAGATT CACAAGGTCA ACAAAGATGG TGCATTATCA TTGCTACCAA 1860 AACAGAGAGA GAACAGCGGC AAGCCCAAGA AGCCCGGGAC TCCTGAGAAC AATAAGGAGT 1920 ATGCCAAGGT GTCCGGGGTC ATGGATAACA ACATCCTGGT GTTGGTGCCA GATCCACATG 1980 CTAAAAACGT GGCTTGCTTT GAAGAATCAG CCAAAGAGGC CCCACCATCA CTTGAACAGA 2040 ATCAAGCTGA GAAAGCCCTG GCCAACTTCA CTGCAACATC AAGCAAGTGC AGGCTCCAGC 2100 ATGAGCTGA GAAAGCCCTG GCAACTTCAACTTCAACTTCAACTTCAAGCTGCAAGCTCAACTTCCAACTTCAACTT 65 AACTGTGATT TGTAGATTTA CTTTTTGCTG TTAGTTATAA AACTATGTGT TCAATGAAAT 2400 AAAAGCACAC TOCTTAGTAT TCTTGAGGGA CAATGCCAAT AGGTATATCC TCTGGAAAAG 2460 GCTTTCATGA TTTGGCATGG GACAGACGGA AATGAAATTG TCAAAATTGT TTACCATAGA 2520 AAGATGACAA AAGAAAATTT TCCACATAGG AAAATGCCAT GAAAATTGCT TTTGAAAAAC 2580 70 AACTGCATAA CCTTTACACT CCTCGTCCAT TTTATTAGGA TTACCCAAAT ATAACCATTT 2640 AAAGAAAGAA TGCATTCCAG AACAAATTGT TTACATAAGT TCCTATACCT TACTGACACA 2700 75 TIGCTGATAT GCAAGTAAGA AAT

AGCTATAATT TATTTGGACC AAGGAAGCCC TGAAATGAAT TCAACAATTA ATATTCATCG 720








QDQAPDESPK LKSSSETSVH CTSYRGVPAS KPEPARAKAK LSKFSIPKQG EESRSGETNS 300 CVEEIIREMT WLPPLSAIOA PGKVEPTKFP FPNKDSQLVS SGHNNPKKGD AEPESPDNGT 360 SNTSMLEDDL KLSSDEEENE QQAAQRTALR ALSDSAVVQQ PNCRTSVPSS KGSSSSSSS 420
TSSSSDSES SSGSDSETES SSSESEGSKP PHFSSPFAEP ASSNKWQLDK WLNKVNPHKP 480
PILIQNESHG SESNQYYNPV KEDVQDCGKV PDVCQPSLRE KEIKSTCKEE QRPRTANKAP 540
GSKGVKQKSP PAAVAVAVSA AAPPPAVPCA PAENAPAPAR RSAGKKPTRR TERTSAGDGA 600
NCHRPEEPAA ADALGTSVVV PPEPTKTRPC GNNRASHRKE LRSSVTCEKR RTRGLSRIVP 660 5 KSKEFIETES SSSSSSSDSD LESEQEEYPL SKAQTVAASA SSGNDQRLKE AAANGGSGPR 720 APVGSINART TSDIAKELEE QFYTLVPFGR NELLSPLKDS DEIRSLWVKI DLTLLSRIPE 780 10 HI.PQEPGVLS APATKDSESA PPSHTSDTPA EKALPKSKRK RKCDNEDDYR EIKKSQŒKD 840 SSSRLATSTS NTL SANHCNM NINSVAIPIN KNEKMLRSPI SPLSDASKHK YTSEDLTSSS 900 RPNGNSLFTS ASSSKKPKAD SQLQPHGGDL TKAAHNNSEN IPLHKSRPQT KPWSPGSNGH 960 RDCKRQKLVF DDMPRSADYF MQEAKRMKHK ADAMVEKFGK ALNYAEAALS FIECGNAMEQ 1020 GPMESKSPYY LMYSETVELI RYAMRIKTHS GPNATPEDKQ LAALCYRCLA LLYWRMFRIK 1080 RDHAVKYSKA LIDYFKNSSK AAQAPSPWGA SGKSTGTPSP ISPNPFPGSS VGSQGSLSNA 1140 SALSPSTIVS IPQRIHQMAA NHVSITNSIL HSYDYWEMAD NLAKENREFF NDLDLLMGPV 1200 15 TLHSSMEHLV OYSOOGLHWL RNSAHLS Seq ID NO: 47 DNA sequence 20 Nucleic Acid Accession #: NM_033151 351-4499(underlined sequences correspond to start and stop codons) Coding sequence: 25 ACTGGGATAA AGCAAGAAGA CTGATTTTAT GAGCAGGGGT TTGATACATC AAAGGAGATT 60 GCCCAGGATC AAGGGTGCGG TGTTGGGGGT GGGTTGGGGA GGGTGGTTAG AGAAGGTTTC

ACTAAGTGAT TTGGGCCTGA GGCCTGAGAA GATGTTTAAA AAGAGGGATC AAGCACAGC 180
TAAGGAGAGG AAAGAGCAGG CACCCAAACC TCTGCATGC CCCAATATGC TCCCTGCAGG 240
GTAGTGCCCC CTCTTCTGGC TGCTCAAGGC GAGATCTAAG CTTCTTCTAA CTCCTGCTGT 300
CTTTTCATAT TCTCTGATTC TGGGAAACGA AGAATTGGCA GGAACTGAAA ATGACTAGGA 360 30 AGAGGACATA CTGGGTGCCC AACTCTTCTG GTGGCCTCGT GAATCGTGGC ATCGACATAG 420 GCGATGACAT GGTTTCAGGA CTTATTTATA AAACCTATAC TCTCCAAGAT GGCCCCTGGA 480 GTCAGCAAGA GAGAAATCCT GAGGCTCCAG GGAGGGCAGC TGTCCCACCG TGGGGGAAGT 540
ATGATGCTGC CTTGAGAACC ATGATTCCCT TCCGTCCCAA GCCGAGGTTT CCTGCCCCC 600
AGCCCCTGGA CAATGCTGGC CTGTTCTCCT ACCTCACCGT GTCATGGCTC ACCCCGCTCA 660 35 TGATCCAAAG CTTACGGAGT CGCTTAGATG AGAACACCAT CCCTCCACTG TCAGTCCATG 720 ATGCCTCAGA CAAAAATGTC CAAAGGCTTC ACCGCCTTTG GGAAGAAGAA GTCTCAAGGC 780
GAGGGATTGA AAAAGCTTCA GTGCTTCTGG TGATGCTGAG GTTCCAGAGA ACAAGGTTGA 840
TTTTCGATGC ACTTCTGGGC ATCTGCTTCT GCATTGCCAG TGTACTCGGG CCAATATTGA 900 40 TTATACCAAA GATCCTGGAA TATTCAGAAG AGCAGTTGGG GAATGTTGTC CATGGAGTGG 960 GACTCTGCTT TGCCCTTTTT CTCTCCGAAT GTGTGAAGTC TCTGAGTTTC TCCTCCAGTT 1020
GGATCATCAA CCAACGCACA GCCATCAGGT TCCGAGCAGC TGTTTCCTCC TTTGCCTTTG 1080
AGAAGCTCAT CCAATTTAAG TCTGTAATAC ACATCACCTC AGGAGAGGCC ATCAGCTTCT 1140
TCACCGGTGA TGTAAACTAC CTGTTTGAAG GGGTGTGCTA TGGACCCCTA GTACTGATCA 1200 45 CCTGCGCATC GCTGGTCATC TGCAGCATTT CTTCCTACTT CATTATTGGA TACACTGCAT 1260 TTATTGCCAT CTTATGCTAT CTCCTGGTTT TCCCACTGGC GGTATTCATG ACAAGAATGG 1320 CTGTGAAGGC TCAGCATCAC ACATCTGAGG TCAGCGACCA GCGCATCCGT GTGACCAGTG 1380 AAGTTCTCAC TTGCATTAAG CTGATTAAAA TGTACACATG GGAGAAACCA TTTGCAAAAA 1440 TCATTGAAGA CCTAAGAAGG AAGGAAAGGA AACTATTGGA GAAGTGCGGG CTTGTCCAGA 1500 50 GCCTGACAAG TATAACCTTG TTCATCATCC CCACAGTGGC CACAGCGGTC TGGGTTCTCA 1560 TCCACACATC CTTAAAGCTG AAACTCACAG CGTCAATGGC CTTCAGCATG CTGGCCTCCT 1620 TGAATCTCCT TCGGCTGTCA GTGTTCTTTG TGCCTATTGC AGTCAAAGGT CTCACGAATT 1680 CCAAGTCTGC AGTGATGAGG TTCAAGAAGT TTTTCCTCCA GGAGAGCCCT GTTTTCTATG 1740 TCCAGACATT ACAAGACCCC AGCAAAGCTC TGGTCTTTGA GGAGGCCACC TTGTCATGGC 1800 55 AACAGACCTG TCCCGGGATC GTCAATGGGG CACTGGAGCT GGAGAGGAAC GGGCATGCTT 1860 CCCAGGGGAT GACCAGGCCT AGAGATGCCC TOGGGCCAGA GGAAGAAGGG AACAGCCTGG 1920
GCCCAGAGTT GCACAAGATC AACCTGGTGG TGTCCAAGGG GATGATGTTA GGGGTCTGCG 1980
GCAACACGGG GAGTGGTAAG AGCAGCCTGT TGTCAGCCAT CCTGGAGGAG ATGCACTTGC 2040
TCGAGGGCTC GGTGGGGGTG CAGGGAAGCC TGGCCTATGT CCCCCAGCAG GCCTGGATCG 2100 60 TCAGCGGGAA CATCAGGGAG AACATCCTCA TGGGAGGCGC ATATGACAAG GCCCGATACC 2160 TCCAGGTGCT CCACTGCTGC TCCCTGAATC GGGACCTGGA ACTTCTGCCC TTTGGAGACA 2220
TGACAGAGAT TGGAGAGCGG GGCCTCAACC TCTCTGGGGG GCAGAAACAG AGGATCAGCC 2280
TGGCCCGCGC CGTCTATTCC GACCGTCAGA TCTACCTGCT GGACGACCCC CTGTCTGCTG 2340 65 TGGACGCCCA CGTGGGGAAG CACATTTTTG AGGAGTGCAT TAAGAAGACA CTCAGGGGGA 2400 AGACGTCGT CCTGGTGACC CACCAGCTGC AGTACTTAGA ATTTTGTGGC CAGATCATTT 2460
TGTTGGAAAA TGGGAAAATC TGTGAAAATG GAACTCACGG TGAGTTAATG CAGAAAAAAGG 2520
GGAAATATGC CCAACTTATC CAGAAGATGC ACAAGGAAGC CACTTCGGAC ATGTTGCAGG 2580
ACACAGCAAA GATAGCAGAG AAGCCAAAGG TAGAAAGTCA GGCTCTGGCC ACCTCCCTGG 2640 ACACAGCARA GATAGCAGAG ARGCCAAAGG TROATAGTCA GCACAGGAG ACTICCOS 2640
AAGAGTCTCT CAACGGAAAT GCTGTGCCGG AGCATCAGCT CACACAGGAG GAGGAGATGG 2700
AAGAAGGCTC CTTGAGTTGG AGGGTCTACC ACCACTACAT CCAGGCAGCT GGAGGTTACA 2760
TGGTCTCTTG CATAATTTC TTCTTCGTGG TGCTGATCGT CTTCTTAACG ATCTTCAGCT 2820
TCTGGTGGCT GAGCTACTGG TTGGAGCAGG GCTCGGGGAC CAATAGCAGC CGAGAGAGCA 2880 70 ATGGAACCAT GGCAGACCTG GGCAACATTG CAGACAATCC TCAACTGTCC TTCTACCAGC 2940 75 TGGTGTACGG GCTCAACGCC CTGCTCCTCA TCTGTGTGGG GGTCTGCTCC TCAGGGATTT 3000 TCACCAAAGT CACGAGGAAG GCATCCACGG CCTGCACAA CAAGCTCTTC AACAAGGTTT 3060 TCCGCTGCCC CATGAGTTTC TTTGACACCA TCCCAATAGG CCGGCTTTTG AACTGCTTCG 3120

CAGGGGACTT GGAACAGCTG GACCAGCTCT TGCCCATCTT TTCAGAGCAG TTCCTGGTCC 3180 TGTCCTTAAT GGTGATCGCC GTCCTGTTGA TTGTCAGTGT GCTGTCTCCA TATATCCTGT 3240 TAATGGGAGC CATAATCATG GTTATTTGCT TCATTTATTA TATGATGTTC AAGAAGGCCA 3300 TCGGTGTGTT CAAGAGACTG GAGAACTATA GCCGGTCTCC TTTATTCTCC CACATCCTCA 3360 ATTCTCTGCA AGGCCTGAGC TCCATCCATG TCTATGGAAA AACTGAAGAC TTCATCAGCC 3420 AGTTTAAGAG GCTGACTGAT GCGCAGAATA ACTACCTGCT GTTGTTTCTA TCTTCCACAC 3480 GATGGATGGC ATTGAGGCTG GAGATCATGA CCAACCTTGT GACCTTGGCT GTTGCCCTGT 3540 TCGTGGCTTT TGGCATTTCC TCCACCCCT ACTCCTTTAA AGTCATGGCT GTCAACATCG 3600 TGCTGCAGCT GGCGTCCAGC TTCCAGGCCA CTGCCCGGAT TGGCTTGGAG ACAGAGGCAC 3660 10 AGTTCACGGC TGTAGAGAGG ATACTGCAGT ACATGAAGAT GTGTGTCTCG GAAGCTCCTT 3720 TACACATGGA AGGCACAAGT TGTCCCCAGG GGTGGCCACA GCATGGGGAA ATCATATTTC 3780
AGGATTATCA CATGAAATAC AGAGACAACA CACCCACCGT GCTTCACGGC ATCAACCTGA 3840 CCATCCGCGG CCACGAAGTG GTGGGCATCG TGGGAAGGAC GGGCTCTGGG AAGTCCTCCT 3900 TGGGCATGGC TCTCTTCCGC CTGGTGGAGC CCATGGCAGG CCGGATTCTC ATTGACGGCG 3960 15 TGGACATTTG CAGCATCGGC CTGGAGGACT TGCGGTCCAA GCTCTCAGTG ATCCCTCAAG 4020 ATCCAGTGCT GCTCTCAGGA ACCATCAGAT TCAACCTAGA TCCCTTTGAC CGTCACACTG 4080 ACCAGCAGAT CTGGGATGCC TTGGAGAGGA CATTCCTGAC CAAGGCCATC TCAAAGTTCC 4140 CCAAAAAGCT GCATACAGAT GTGGTGGAAA ACGGTGGAAA CTTCTCTGTG GGGGAGAGGC 4200 AGCTGCTCTG CATTGCCAGG GCTGTGCTTC GCAACTCCAA GATCATCCTT ATCGATGAAG 4260 CCACAGCCTC CATTGACATG GAGACAGACA CCCTGATCCA GCGCACAATC CGTGAAGCCT 4320 TCCAGGGCTG CACCGTGCTC GTCATTGCCC ACCGTGTCAC CACTGTGCTG AACTGTGACC 4380 20 ACATCCTGGT TATGGGCAAT GGGAAGGTGG TAGAATTTGA TCGGCCGGAG GTACTGCGGA 4440 AGAAGCCTGG GTCATTGTTC GCAGCCCTCA TGGCCACAGC CACTTCTTCA CTGAGATAAG 4500 GAGATGTGGA GACTTCATGG AGGCTGGCAG CTGAGCTCAG AGGTTCACAC AGGTGCAGCT 4560 TCGAGGCCCA CAGTCTGCGA CCTTCTTGTT TGGAGATGAG AACTTCTCCT GGAAGCAGGG 4620 GTAAATGTAG GGGGGTGGG GATTGCTGGA TGGAAACCCT GGAATAGGCT ACTTGATGGC 4680 25 TCTCAAGACC TTAGAACCCC AGAACCATCT AAGACATGGG ATTCAGTGAT CATGTGGTTC 4740 TCCTTTTAAC TTACATGCTG AATAATTTTA TAATAAGGTA AAAGCTTATA GTTTTCTGAT 4800 CTGTGTTAGA AGTGTTGCAA ATGCTGTACT GACTTTGTAA AATATAAAAC TAAGGAAAAC 4860 30 Seq ID NO: 48 Protein sequence: Protein Accession #: NP_149163.2 MTRKRTYWVPNSSGGLVNRGIDIGDDMVSGLIYKTYTLQDGPWSQQERNPEAPGRAAVPPWGKYDAALRT MIPFRPKPRFPAPQPLDNAGLFSYLTVSWLTPLMIQSLRSRLDENTIPPLSVHDASDKNVQRLHRLWEEE VSRRGIEKASVLLVMLRFQRTRLIFDALLGICFCIASVLGPILIIPKILEYSEEQLGNVVHGVGLCFALF 35 40 VNGALELERNGHASEGMTRPRDALGPEEGNSLGPELHKINLVVSKGMMLGVCGNTGSGKSSLLSAILEE
MHLLEGSVGVQGSLAYVPQQAWIVSGNIRENILMGGAYDKARYLQVLHCCSLNRDLELLPFGDMTEIGER
GLNLSGGQKQRISLARAVYSDRQIYLLDDPLSAVDAHVGKHIFEECIKKTLRGKTVVLVTHQLQYLEFCG
QIILLENGKICENGTHSELMQKKGKYAQLIQKMHKEATSDMLQDTAKIAEKPKVESQALATSLEESLNGN
AVPEHQLTQEEEMEEGSLSWRYYHHYIQAAGGYMVSCIIFFFVVLIVFLTIFSFWWLSYWLEQGSGTNSS 45 AVPEHQLTQEEEMEEGSLSWRVYHHYIQAAGGYMVSCIIFFFVVLIVFLTFSFWWLSYWLEQGSGTNSS RESNGTMADLGNIADNPQLSFYQLVYGLNALLLICVGVCSSGIFTKVTRKASTALHNKLFNKVFRCPMSF FDTPIGRLLNCFAGDLEQLDQLLPIFSEQFLVLSLMVIAVLLIVSVLSPYILLMGAIMVICFTYYMMF KKAIGVFKRLENYSRSPLFSHILNSLQGLSSIHVYGKTEDFISQFKRLTDAQNNYLLLFLSSTRWMALRL EIMTNLVTLAVALFVAFGISSTPYSFKVMAVNIVLQLASSFQATARIGLETEAQFTAVERILQYMKMCVS EAPLHMEGTSCPQGWPQHGEIIFQDYHMKYRDNTPTVLHGINLTIRGHEVVGIVGTGSGKSSLGMALFR LVEPMAGRILIDGVDICSIGLEDLRSKLSVIPQDPVLLSGTIRFNLDPFDRHTDQQIWDALERTFLTKAI SKFPKKLHTDVVENGGNFSVGERQLLCIARAVLRNSKIILIDEATASIDMETDTLIQRTIREAFQGCTVL VIAHRVTTVLNCDHILVMGNGKVVEFDRPEVLRKKPGSLFAALMATATSSLR 50 55 Seq ID NO: 49 DNA sequence Nucleic Acid Accession #: NM_033419 18-980 (underlined sequences correspond to start and stop codons) Coding sequence: 60 31 41 CGAGCCAGGG AGAAAGG<u>ATG</u> GCCGGCCTGG CGGCGCGGTT GGTCCTGCTA GCTGGGGCAG 60 CGGCGCTGGC GAGCGGCTCC CAGGGCGACC GTGAGCCGGT GTACCGCGAC TGCGTACTGC 120 AGTGCGAAGA GCAGAACTGC TCTGGGGGGC CTCTGAATCA CTTCCGCTCC CGCCAGCCAA 180 65 TCTACATGAG TCTAGCAGGC TGGACCTGTC GGGACGACTG TAAGTATGAG TGTATGTGGG 240 TCACCGTTGG GCTCTACCTC CAGGAAGGTC ACAAAGTGCC TCAGTTCCAT GGCAAGTGGC 300
CCTTCTCCCG GTTCCTGTTC TTTCAAGAGC CGGCATCGGC CGTGGCCTCG TTTCTCAATG 360
GCCTGGCCAG CCTGGTGATG CTCTGCCGCT ACCGCACCTT CGTGCCAGCC TCCTCCCCCA 420
TGTACCACAC CTGTTGTGCC TTCGCCTGGT TGTCCCTCAA TGCATGGTTC TGGTCCACAG 480 70 TTTTCCACAC CAGGGACACT GACCTCACAG AGAAAATGGA CTACTTCTGT GCCTCCACTG 540 TCATCCTACA CTCAATCTAC CTGTGCTGCG TCAGGACCGT GGGGCTGCAG CACCCAGCTG 600
TGGTCAGTGC CTTCCGGGCT CTCCTGCTGC TCATGCTGAC CGTGCACGTC TCCTACCTGA 660
GCCTCATCCG CTTCGACTAT GGCTACAACC TGGTGGCCAA CGTGGCTATT GGCCTGGTCA 720
ACGTGGTGTG GTGGCTGGCC TGGTGCCTGT GGAACCAGCG GCGGCTGCCT CACGTGCGCA 780 75 AGTGCGTGGT GGTGGTCTTG CTGCTGCAGG GGCTGTCCCT GCTCGAGCTG CTTGACTTCC 840

CACCGCTCTT CTGGGTCCTG GATGCCCATG CCATCTGGCA CATCAGCACC ATCCCTGTCC 900
ACGTCCTCTT TTTCAGCTTT CTGGAAGATG ACAGCCTGTA CCTGCTGAAG GAATCAGAGG 960




Nucleic Acid Accession #: NM_030916 Coding sequence: 1-1533 (underlined sequences correspond to start and stop codons) 5 31 41 ATGCCCCTGT CCCTGGGAGC CGAGATGTGG GGGCCTGAGG CCTGGCTGCT GCTGCTGCTA 60 CTGCTGGCAT CATTTACAGG CCGGTGCCCC GCGGGTGAGC TGGAGACCTC AGACGTGGTA 120
ACTGTGGTGC TGGGCCAGGA CGCAAAACTG CCCTGCTTCT ACCGAGGGGA CTCCGGCGAG 180
CAAGTGGGGC AAGTGGCATG GGCTCGGGTG GACGCGGGCG AAGGCGCCCA GGAACTAGCG 240 10 CTACTGCACT CCAAATACGG GCTTCATGTG AGCCCGGCTT ACGAGGGCCG CGTGGAGCAG 300 CCGCCGCCCC CACGCAACCC CCTGGACGGC TCAGTGCTCC TGCGCAACGC AGTGCAGGCG 360 GATGAGGGCG AGTACGAGTG CCGGGTCAGC ACCTTCCCCG CCGGCAGCTT CCAGGCGCGG 420 CTGCGGCTCC GAGTGCTGGT GCCTCCCCTG CCCTCACTGA ATCCTGGTCC AGCACTAGAA 480 GAGGGCCAGG GCCTGACCCT GGCAGCCTCC TGCACAGCTG AGGGCAGCCC AGCCCCCAGC 540 15 GTGACCTGGG ACACGGAGGT CAAAGGCACA ACGTCCAGCC GTTCCTTCAA GCACTCCCGC 600 TOTGCTGCCG TCACCTCAGA GTTCCACTTG GTGCCTAGCC GTTCCATGAA TGGGCAGCCC 660
CTGACTTGTG TGGTGTCCCA TCCTGGCCTG CTCCAGGACC AAAGGATCAC CCACATCCTC 720
CACGTGTCT TCCTTGCTGA GGCCTCTGTG AGGGCCTTG AAGACCAAAA TCTGTGGCAC 780
ATTGGCAGAG AAGGAGCTAT GCTCAAGTGC CTGAGTGAAG GGCAGCCCC TCCCTCATAC 840 20 AACTGGACAC GGCTGGATGG GCCTCTGCCC AGTGGGGTAC GAGTGGATGG GGACACTTTG 900 GGCTTTCCCC CACTGACCAC TGAGCACAGC GGCATCTACG TCTGCCATGT CAGCAATGAG 960 TTCTCCTCAA GGGATTCTCA GGTCACTGTG GATGTTCTTG ACCCCCAGGA AGACTCTGGG 1020
AAGCAGGTGG ACCTAGTGTC AGCCTCGGTG GTGGTGGTGG GTGTGATCGC CGCACTCTTG 1080
TTCTGCCTTC TGGTGGTGGT GGTGGTGCTC ATGTCCCGAT ACCATCGGCG CAAGGCCCAG 1140 25 CAGATGACCC AGAAATATGA GGAGGAGCTG ACCCTGACCA GGGAGAACTC CATCCGGAGG 1200 CTGCATTCCC ATCACACGGA CCCCAGGAGC CAGCCGGAGG AGAGTGTAGG GCTGAGAGCC 1260 GAGGGCCACC CTGATAGTCT CAAGGACAAC AGTAGCTGCT CTGTGATGAG TGAAGAGCCC 1320 GAGGGCCGCA GTTACTCCAC GCTGACCACG GTGAGGGAGA TAGAAACACA GACTGAACTG 1380 CTGTCTCCAG GCTCTGGGCG GGCCGAGGAG GAGGAAGATC AGGATGAAGG CATCAAACAG 1440 30 GCCATGAACC ATTTTGTTCA GGAGAATGGG ACCCTACGGG CCAAGCCCAC GGGCAATGGC 1500 ATCTACATCA ATGGGCGGGG ACACCTGGTC TGA Seq ID NO: 54 Protein sequence:
Protein Accession #: NP_112178.1 35 31 41 40 QVGQVAWARV DAGEGAQELA LLHSKYGLHV SPAYEGRVEQ PPPPRNPLDG SVLLRNAVQA 120 DEGEYECRVS TFPAGSFQAR LRLRVLVPPL PSLNPGPALE EGQGLTLAAS CTAEGSPAPS 180
VTWDTEVKGT TSSRSFKHSR SAAVTSEFHL VPSRSMNGQP LTCVVSHPGL LQDQRITHIL 240
HVSFLAEASV RGLEDQNLWH IGREGAMLKC LSEGQPPPSY NWTRLDGPLP SGVRVDGDTL 300
GFPPLTTEHS GIYVCHVSNE FSSRDSQVTV DVLDPQEDSG KQVDLVSASV VVVGVIAALL 360 45 FCLLVVVVVL MSRYHRRKAQ QMTQKYEEEL TLTRENSIRR LHSHHTDPRS QPEESVGLRA 420 EGHPDSLKDN SSCSVMSEEP EGRSYSTLTT VREIETQTEL LSPGSGRAEE EEDQDEGIKQ 480 AMNHFVQENG TLRAKPTGNG IYINGRGHLV Seq ID NO: 55 DNA sequence 50 AF007170.1 Nucleic Acid Accession #: Coding sequence: 73-1725 (underlined sequences correspond to start and stop codons) 31 41 55 AAGGAGGCGG CCTCCGGGAA AAGCGACCGC AGGACTCCTG AGAGCAGCCT CCATGAGGCC 60 CTGGACCAGT GCATGACCGC CCTGGACCTC TTCCTCACCA ACCAGTTCTC AGAAGCACTC 120
AGCTACCTCA AGCCCAGAAC CAAGGAAAGC ATGTACCACT CACTGACATA TGCCACCATC 180
CTGGAGATGC AGGCCATGAT GACCTTTGAC CCTCAGGACA TCCTGCTTGC CGGCAACATG 240 ATGAAGGAGG CACAGATGCT GTGTCAGAGG CACCGGAGGA AGTCTTCTGT AACAGATTCC 300 60 TTCAGCAGCC TGGTGAACCG CCCCACGCTG GGCCAATTCA CTGAAGAAGA AATCCACGCT 360 GAGGTCTGCT ATGCAGAGTG CCTGCTGCAG CGAGCAGCCC TGACCTTCCT GCAGGACGAG 420
AACATGGTGA GCTTCATCAA AGGCGGCATC AAAGTTCGAA ACAGCTACCA GACCTACAAG 480
GAGCTGGACA GCCTTGTTCA GTCCTCACAA TACTGCAAGG GTGAGAACCA CCCGCACTTT 540 GAAGGAGGAG TGAAGCTTGG TGTAGGGGCC TTCAACCTGA CACTGTCCAT GCTTCCTACT AGGATCCTGA GGCTGTTGGA GTTTGTGGGG TTTTCAGGAA ACAAGGACTA TGGGCTGCTG 660
CAGCTGGAGG AGGAGCGTC AGGGCACAGC TTCCGCTCTG TGCTCTGTGT CATCGTCCTG 720
CTGTGCTACC ACACCTTCCT CACCTTCGTG CTCGGTACTG GGAACGTCAA CATCGAGGAG 780
GCCGAGAAGC TCTTGAAGCC CTACCTGAAC CGGTACCCTA AGGGTGCCAT CTTCCTGTTC 840 65 TTTGCAGGGA GGATTGAAGT CATTAAAGGC AACATTGATG CAGCCATCCG GCGTTTCGAG 900
GAGTGCTGTG AGGCCCAGCA GCACTGGAAG CAGTTTCACC ACATGTGCTA CTGGGAGCTG 960
ATGTGGTGCT TCACCTACAA GGGCCAGTGG AAGATGTCCT ACTTCTACGC CGACCTGCTC 1020
AGCAAGGAGA ACTGCTGGTC CAAGGCCACC TACATTTACA TGAAGGCCGC CTACCTCAGC 1080 70 ATGTTTGGGA AGGAGGACCA CAAGCCGTTC GGGGACGACG AAGTGGAATT ATTTCGAGCT 1140 GTGCCAGGCC TGAAGCTCAA GATTGCTGGG AAATCTCTAC CCACAGAGAA GTTTGCCATC 1200 CGGAAGTCCC GGCGCTACTT CTCCTCCAAC CCTATCTCGC TGCCAGTGCC TGCTCTGGAA 1260 ATGATGTACA TCTGGAACGG CTACGCCGTG ATTGGGAAGC AGCCGAAACT CACGGATGGG 1320

Seq ID NO: 53 DNA sequence

75

ATACTTGAGA TTATCACTAA GGCTGAAGAG ATGCTGGAGA AAGGCCCAGA GAACGAGTAC 1380



PCT/US02/02242 WO 02/059377

Coding sequence: 1-1362(underlined sequences correspond to start and stop codons) 41 51 5 ATGGGGGAAA ATGATCCGCC TGCTGTTGAA GCCCCCTTCT CATTCCGATC GCTTTTTGGC 60 CTTGATGATT TGAAAATAAG TCCTGTTGCA CCAGATGCAG ATGCTGTTGC TGCACAGATC 120 CTGTCACTGC TGCCATTGAA GTTTTTTCCA ATCATCGTCA TTGGGATCAT TGCATTGATA 180 TTAGCACTGG CCATTGGTCT GGGCATCCAC TTCGACTGCT CAGGGAAGTA CAGATGTCGC 240
TCATCCTTTA AGTGTATCGA GCTGATAGCT CGATGTGACG GAGTCTCGGA TTGCAAAGAC 300
GGGGAGGACG AGTACCGCTG TGTCCGGGTG GGTGGTCAGA ATGCCGTGCT CCAGGTGTTC 360 10 ACAGCTGCTT CGTGGAAGAC CATGTGCTCC GATGACTGGA AGGGTCACTA CGCAAATGTT 420 GCCTGTGCCC AACTGGGTTT CCCAAGCTAT GTGAGTTCAG ATAACCTCAG AGTGAGCTCG 480 CTGGAGGGGC AGTTCCGGGA GGAGTTTGTG TCCATCGATC ACCTCTTGCC AGATGACAAG 540
GTGACTGCAT TACACCACTC AGTATATGTG AGGGAGGGAT GTGCCTCTGG CCACGTGGTT 600 15 ACCTTGCAGT GCACAGCCTG TGGTCATAGA AGGGGCTACA GCTCACGCAT CGTGGGTGGA 660 AACATGTCCT TGCTCTCGCA GTGGCCCTGG CAGGCCAGCC TTCAGTTCCA GGGCTACCAC 720 CTGTGCGGGG GCTCTGTCAT CACGCCCCTG TGGATCATCA CTGCTGCACA CTGTGTTTAT 780
GACTTGTACC TCCCCAAGTC ATGGACCATC CAGGTGGGTC TAGTTTCCCT GTTGGACAAT 840
CCAGCCCCAT CCCACTTGGT GGAGAAGATT GTCTACCACA GCAAGTACAA GCCAAAGAGG 900 20 CTGGGCAATG ACATCGCCCT TATGAAGCTG GCCGGGCCAC TCACGTTCAA TGAAATGATC 960 CAGCCTGTGT GCCTGCCCAA CTCTGAAGAG AACTTCCCCG ATGGAAAAGT GTGCTGGACG 1020 TCAGGATGGG GGGCCACAGA GGATGGAGGT GACGCCTCCC CTGTCCTGAA CCACGCGGCC 1080 GTCCCTTTGA TTTCCAACAA GATCTGCAAC CACAGGGACG TGTACGGTGG CATCATCTCC 1140 CCCTCCATGC TCTGCGCGGG CTACCTGACG GGTGGCGTGG ACAGCTGCCA GGGGGACAGC 1200 25 GGGGGGCCCC TGGTGTGTCA AGAGAGGAGG CTGTGGAAGT TAGTGGGAGC GACCAGCTTT 1260 GGCATCGGCT GCGCAGAGGT GAACAAGCCT GGGGTGTACA CCCGTGTCAC CTCCTTCCTG 1320 GACTGGATCC ACGAGCAGAT GGAGAGAGAC CTAAAAACCT GA Seq ID NO: 60 <u>Protein sequence</u> Protein Accession #: NP_076927 30 31 41 51 MGENDPPAVE APFSFRSLFG LDDLKISPVA PDADAVAAQI LSLLPLKFFP IIVIGIIALI 60 LALAIGLGIH FDCSGKYRCR SSFKCIELIA RCDGVSDCKD GEDEYRCVRV GGQNAVLQVF 120
TAASWKTMCS DDWKGHYANV ACAQLGFPSY VSSDNLRVSS LEGGFREEFV SIDHLLPDDK 180
VTALHHSVYV REGCASGHVV TLQCTACGHR RGYSSRIVGG NMSLLSQWPW QASLQFQGYH 240
LCGGSVITPL WIITAAHCVY DLYLPKSWTI QVGLVSLLDN PAPSHLVEKI VYHSKYKPKR 300 35 LGNDIALMKL AGPLTFNEMI QPVCLPNSEE NFPDGKVCWT SGWGATEDGG DASPVLNHAA 360 40 VPLISNKICN HRDVYGGIIS PSMLCAGYLT GGVDSCQGDS GGPLVCQERR LWKLVGATSF 420 GIGCAEVNKP GVYTRVTSFL DWIHEQMERD LKT Seq ID NO: 61 DNA sequence NM 006475 Nucleic Acid Accession #: 45 Coding sequence: 28-2538 (underlined sequences correspond to start and stop codons) 31 41 AACAGAACTG CAACGGAGAG ACTCAAGATG ATTCCCTTTT TACCCATGTT TTCTCTACTA 60 TTGCTGCTTA TTGTTAACCC TATAAACGCC AACAATCATT ATGACAAGAT CTTGGCTCAT 120
AGTCGTATCA GGGGTCGGGA CCAAGGCCCA AATGTCTGTG CCCTTCAACA GATTTTGGGC 180 50 ACCAAAAAGA AATACTTCAG CACTTGTAAG AACTGGTATA AAAAGTCCAT CTGTGGACAG 240 ACAACGACTG TITTATATGA ATGITGCCCT GGTTATATGA GAATGGAAGG AATGAAAGGC 300
TGCCCAGCAG TITTGCCCAT TGACCATGTT TATGGCACTC TGGGCATCGT GGAGCCACC 360
ACAACGCAGC GCTATTCTGA CGCCTCAAAA CTGAGGGAGG AGATCGAGGG AAAGGGATCC 420
TTCACTTACT TTGCACCGAG TAATGAGGCT TGGGACAACT TGGATTCTGA TATCCGTAGA 480
GGTTTGGAGA GCAACGTGAA TGTTGAATTA CTGAATGCTT TACATAGTCA CATGATTAAT 540 55 AAGAGAATGT TGACCAAGGA CTTAAAAAAT GGCATGATTA TTCCTTCAAT GTATAACAAT 600 TTGGGGCTTT TCATTAACCA TTATCCTAAT GGGGTTGTCA CTGTTAATTG TGCTCGAATC 660
ATCCATGGGA ACCAGATTGC AACAAATGGT GTTGTCCATG TCATTGACCG TGTGCTTACA 720
CAAATTGGTA CCTCAATTCA AGACTTCATT GAAGCAGAAG ATGACCTTTC ATCTTTTAGA 780
GCAGCTGCCA TCACATCGGA CATATTGGAG GCCCTTGGAA GAGACGGTCA CTTCACACTC 840 60 TTTGCTCCCA CCAATGAGGC TTTTGAGAAA CTTCCACGAG GTGTCCTAGA AAGGTTCATG 900 GGAGACAAAG TGGCTTCCGA AGCTCTTATG AAGTACACA TCTCAAAATAC TCTCAGTGT 960
TCTGAGTCTA TTATGGGAGG AGCAGTCTTT GAGACGCTGG AAGGAAATAC TCTCAGTGT 960
GGATGTGACG GTGACAGTAT AACAGTAAAT GGAATCAAAA TGGTGAACAA AAAGGATATT 1080
GTGACAAATA ATGGTGTGAT CCATTTGATT GATCAGGTCC TAATTCCTGA TTCTGCCAAA 1140 65 GAGTTATTG AGCTGGCTGG AAAACAGCAA ACCACCTTCA CGGATCTTGT GGCCCAATTA 1200
GGCTTGGCAT CTGCTCTGAG GCCAGATGGA GAATACACTT TGCTGGCACC TGTGAATAAT 1260
GCATTTTCTG ATGATACTCT CAGCATGGTT CAGCGCCTCC TTAAATTAAT TCTGCAGAAT 1320
CACATATTGA AAGTAAAAGT TGGCCTTAAT GAGCTTTACA ACGGGCAAAT ACTGGAAACC 1380

70


75

ATCGGAGGCA AACAGCTCAG AGTCTTCGTA TATCGTACAG CTGTCTGCAT TGAAAATTCA 1440 ATCGGAGGCA AACAGCTCAG AGTCTTCGTA TATCGTACAG CTGTCTGCAT TOAAAATTCA 1440
TGCATGGAGA AAGGGAGTAA GCAAGGGAGA AACGGTGCGA TTCACACATATT CCGCGAGAGT 1500
ATCAAGCCAG CAGAGAAATC CCTCCATGAA AAGTTAAAAC AAGATAAGCG CTTTAGCACC 1560
TTCCTCAGCC TACTTGAAGC TGCAGACTTG AAAGAGCTCC TGACACAACC TGGAGACTGG 1620
ACATTATTTG TGCCAACCAA TGATGCTTTT AAGGGAATGA CTAGTGAAGA AAAAGAAATT 1680

CTGATACGGG ACAAAAATGC TCTTCAAAAC ATCATTCTTT ATCACCTGAC ACCAGGAGTT 1740

AAAATCTTTC TGAAAGAAGT AAATGATACA CTTCTGGTGA ATGAATTGAA ATCAAAAGAA 1860 TCTGACATCA TGACAACAAA TGGTGTAATT CATGTTGTAG ATAAACTCCT CTATCCAGCA 1920 GACACACCTG TTGGAAATGA TCAACTGCTG GAAATACTTA ATAAATTAAT CAAATACATC 1980 5 CAAATTAAGT TTGTTCGTGG TAGCACCTTC AAAGAAATCC CCGTGACTGT CTATACAACT 2040 AAAATTATAA CCAAAGTTGT GGAACCAAAA ATTAAAGTGA TTGAAGGCAG TCTTCAGCCT 2100 ATTATCAAAA CTGAAGGACC CACACTAACA AAAGTCAAAA TTGAAGGTGA ACCTGAATTC 2160 AGACTGATTA AAGAAGGTGA AACAATAACT GAAGTGATCC ATGGAGAGCC AATTATTAAA 2220 AAATACACCA AAATCATTGA TGGAGTGCCT GTGGAAATAA CTGAAAAAGA GACACGAGAA 2280 10 GAACGAATCA TTACAGGTCC TGAAATAAAA TACACTAGGA TTTCTACTGG AGGTGGAGAA 2340 ACAGAAGAAA CTCTGAAGAA ATTGTTACAA GAAGAGGTCA CCAAGGTCAC CAAATTCATT 2400 GAAGGTGGTG ATGGTCATTT ATTTGAAGAT GAAGAAATTA AAAGACTGCT TCAGGGAGAC 2460 ACACCCGTGA GGAAGTTGCA AGCCAACAAA AAAGTTCAAG GTTCTAGAAG ACGATTAAGG 2520 GAAGGTCGTT CTCAG<u>TGA</u>AA ATCCAAAAAC CAGAAAAAA TGTTTATACA ACCCTAAGTC 2580 AATAACCTGA CCTTAGAAAA TTGTGAGAGC CAAGTTGACT TCAGGAACTG AAACATCAGC 2640 15 ACAAAGAAGC AATCATCAAA TAATTCTGAA CACAAATTTA ATATTTTTTT TTCTGAATGA 2700 GAAACATGAG GGAAATTGTG GAGTTAGCCT CCTGTGGTAA AGGAATTGAA GAAAATATAA 2760 CACCTTACAC CCTTTTTCAT CTTGACATTA AAAGTTCTGG CTAACTTTGG AATCCATTAG 2820 AGAAAAATCC TTGTCACCAG ATTCATTACA ATTCAAATCG AAGAGTTGTG AACTGTTATC 2880 CCATTGAAAA GACCGAGCCT TGTATGTATG TTATGGATAC ATAAAATGCA CGCAAGCCAT 2940 20 TATCTCTCCA TGGGAAGCTA AGTTATAAAA ATAGGTGCTT GGTGTACAAA ACTTTTTATA 3000 TCAAAAGGCT TTGCACATTT CTATATGAGT GGGTTTACTG GTAAATTATG TTATTTTTTA 3060 CAACTAATTI TGTACTCTCA GAATGTTTGT CATATGCTTC TTGCAATGCA TATTTTTTAA 3120 TCTCAAACGT TTCAATAAAA CCATTTTTCA GATATAAAGA GAATTACTTC AAATTGAGTA 3180 ATTCAGAAAA ACTCAAGATT TAAGTTAAAA AGTGGTTTGG ACTTGGGAA 25 Seq ID NO: 62 Protein sequence: NP_006466 Protein Accession #: 30 MIPFLPMFSL LLLLIVNPIN ANNHYDKILA HSRIRGRDQG PNVCALQQIL GTKKKYFSTC 60 KNWYKKSICG QKTTVLYECC PGYMRMEGMK GCPAVLPIDH VYGTLGIVGA TTTQRYSDAS 120 KLREEIEGKG SFTYFAPSNE AWDNLDSDIR RGLESNVNVE LLNALHSHMI NKRMLTKDLK 180 35 NGMIIPSMYN NLGLFINHYP NGVVTVNCAR IIHGNQIATN GVVHVIDRVL TQIGTSIQDF 240 IGAEDDLSSF RAAAITSDIL EALGRDGHFT LFAPTNEAFE KLPRGVLERF MGDKVASEAL 300
MKYHILNTLQ CSESIMGGAV FETLEGNTIE IGCDGDSITV NGIKMVNKKD IVTNNGVIHL 360
IDQVLIPDSA KQVIELAGKQ QTTFTDLVAQ LGLASALRPD GEYTLLAPVN NAFSDDTLSM 420
VQRLLKLILQ NHILKVKVGL NELYNGQILE TIGGKQLRVF VYRTAVCIEN SCMEKGSKQG 480 RIGAHIFRE IIKPAEKSLH EKLKQDKRFS TFLSLLEAAD LKELLTQPGD WTLFVPTNDA 540
FKGMTSEEKE ILIRDKNALQ NILLYHLTPG VFIGKGFEPG VTNILKTTQG SKIFLKEVND 600
TLLVNELKSK ESDIMTINGV IHVVDKLLYP ADTPVGNDQL LEILNKLIKY IQIKFVRGST 660
FKEIPVTVYT TKIITKVVEP KIKVIEGSLQ PIKTEGPTL TKVKIEGEPE FRLIKEGETI 720 40 TEVIHGEPII KKYTKIIDGV PVEITEKETR EERIITGPEI KYTRISTGGG ETEETLKKLL 780 45 QEEVTKVTKF IEGGDGHLFE DEEIKRLLQG DTPVRKLQAN KKVQGSRRRL REGRSQ Sea ID NO: 63 DNA sequence Nucleic Acid Accession #: NM 020974 Coding sequence: 81-3080 (underlined sequences correspond to start and stop codons) 50 GGCGTCCGCG CACACCTCCC CGCGCCGCCG CCGCCACCGC CCGCACTCCG CCGCCTCTGC 60 CCGCAACCGCTGAGCCATCC ATGGGGGTCG CGGGCCGCAA CCGTCCCGGG GCGGCCTGGG 120 55 CGGTGCTGCT GCTGCTGCTG CTGCTGCCGC CACTGCTGCT GCTGGCGGGG GCCGTCCCGC 180 CGGGTCGGGG CCGTGCCGCG GGGCCGCAGG AGGATGTAGA TGAGTGTGCC CAAGGGCTAG 240 ATGACTGCCA TGCCGACGCC CTGTGTCAGA ACACACCCAC CTCCTACAAG TGCTCCTGCA 300 AGCCTGGCTA CCAAGGGGAA GGCAGGCAGT GTGAGGACAT CGATGAATGT GGAAATGAGC 360 TCAATGGAGG CTGTGTCCAT GACTGTTTGA ATATTCCAGG CAATTATCGT TGCACTTGTT 420 60 TTGATGGCTT CATGTTGGCT CATGACGGTC ATAATTGTCT TGATGTGGAC GAGTGCCTGG 480
AGAACAATGG CGGCTGCCAG CATACCTGTG TCAACGTCAT GGGGAGCTAT GAGTGCTGCT 540
GCAAGGAGGG GTTTTTCCTG AGTGACAATC AGCACACCTG CATTCACCGC TCGGAAGAGG 600 GCCTGAGCTG CATGAATAAG GATCACGGCT GTAGTCACAT CTGCAAGGAG GCCCCAAGGG 660 GCAGCGTCGC CTGTGAGTGC AGGCCTGGTT TTGAGCTGGC CAAGAACCAG AGAGACTGCA 720
TCTTGACCTG TAACCATGGG AACGGTGGGT GCCAGCACTC CTGTGACGAT ACAGCCGATG 780
GCCCAGAGTG CAGCTGCCAT CCACAGTACA AGATGCACAC AGATGGGAGG AGCTGCCTTG 840 65 AGCGAGAGGA CACTGTCCTG GAGGTGACAG AGAGCAACAC CACATCAGTG GTGGATGGGG 900 ATAAACGGGT GAAACGGCGG CTGCTCATGG AAACGTGTGC TGTCAACAAT GGAGGCTGTG 960 ACCGCACCTG TAAGGATACT TCGACAGGTG TCCACTGCAG TTGTCCTGTT GGATTCACTC 1020
TCCAGTTGGA TGGGAAGACA TGTAAAGATA TTGATGAGTG CCAGACCCGC AATGGAGGTT 1080
GTGATCATTT CTGCAAAAAC ATCGTGGGCA GTTTTGACTG CGGCTGCAAG AAAGGATTTA 1140 70 AATTATTAAC AGATGAGAAG TCTTGCCAAG ATGTGGATGA GTGCTCTTTG GATAGGACCT 1200 GTGACCACAG CTGCATCAAC CACCCTGGCA CATTTGCTTG TGCTTGCAAC CGAGGGTACA 1260 CCCTGTATGG CTTCACCCAC TGTGGAGACA CCAATGAGTG CAGCATCAAC AACGGAGGCT 1320 GTCAGCAGGT CTGTGTGAAC ACAGTGGGCA GCTATGAATG CCAGTGCCAC CCTGGGTACA 1380 75 AGCTCCACTG GAATAAAAA GACTGTGTGG AAGTGAAGGG GCTCCTGCCC ACAAGTGTGT 1440 CACCCCGTGT GTCCCTGCAC TGCGGTAAGA GTGGTGGAGG AGACGGGTGC TTCCTCAGAT 1500


TTCATTGGAA AAGGATTTGA ACCTGGTGTT ACTAACATTT TAAAGACCAC ACAAGGAAGC 1800





AGAGTGATGC TGCAGAACTA AATCATAAGG AGGAACATAG CTTGCATGTT CAAGATCCAT 840 CTTCTAGCAG TAAGAAGGAC TTGAAAAGCG CAGTTCTGAG TGAGAAGGCT GGCTTCAATT 900 ATGAAAGCCC CAGTAAGGGA GGAAACTTTC CCTCCTTTCC GCATGATGAG GTGACAGACA 960 GAAATATGTT GGCTTTCTCA TTTCCAGCTG CTGGGGGAGT CTGTGAGCCC TTGAAGTCTC 1020 5 CGCAAAGAGC AGAGGCAGAT GACCCTCAAG ATATGGCCTG CACCCCCTCA GGGGACTCAC 1080
TGGAGACAAA GGAAGATCAG AAGATGTCAC CAAAGGCTAC AGAGGAAACA GGGCAAGCAC 1140
AGAGTGGTCA AGCCAATTGT CAAGGTTTGA GCCCAGTTTC AGTGGCCTCA AAAAACCCAC 1200 AAGTGCCTTC AGATGGGGGT GTAAGACTGA ATAAATCCAA AACTGACTTA CTGGTGAATG 1260 ACAACCCAGA CCCGGCACCT CTGTCTCCAG AGCTTCAGGA CTTTAAATGC AATATCTGTG 1320 10 GATATGGTTA CTACGGCAAC GACCCCACAG ATCTGATTAA GCACTTCCGA AAGTATCACT 1380 TAGGACTGCA TAACCGCACC AGGCAAGATG CTGAGCTGGA CAGCAAAATC TTGGCCCTTC 1440
ATAACATGGT GCAGTTCAGC CATTCCAAAG ACTTCCAGAA GGTCAACCGT TCTGTGTTTT 1500
CTGGTGTGCT GCAGGACATC AATTCTTCAA GGCCTGTTTT ACTAAATGGG ACCTATGATG 1560 TGCAGGTGAC TTCAGGTGGA ACATTCATTG GCATTGGACG GAAAACACCA GATTGCCAAG 1620 15 GGAACACCAA GTATTTCCGC TGTAAATTCT GCAATTTCAC TTATATGGGC AACTCATCCA 1680 CCGAATTAGA ACAACATTTT CTTCAGACTC ACCCAAACAA AATAAAAGCT TCTCTCCCCT 1740 CCTCTGAGGT TGCAAAACCT TCAGAGAAAA ACTCTAACAA GTCCATCCCT GCACTTCAAT 1800 CCAGTGATTC TGGAGACTTG GGAAAATGGC AGGACAAGAT AACAGTCAAA GCAGGAGATG 1860 ACACTCCTGT TGGGTACTCA GTGCCCATAA AGCCCCTCGA TTCCTCTAGA CAAAATGGTA 1920 20 CAGAGGCCAC CAGTTACTAC TGGTGTAAAT TTTGTAGTTT CAGCTGTGAG TCATCTAGCT 1980 CACTTAAACT GCTAGAACAT TATGGCAAGC AGCACGGAGC AGTGCAGTCA GGCGGCCTTA 2040 ATCCAGAGTT AAATGATAAG CTTTCCAGGG GCTCTGTCAT TAATCAGAAT GATCTAGCCA 2100 AAAGTTCAGA AGGAGAGACA ATGACCAAGA CAGACAAGAG CTCGAGTGGG GCTAAAAAGA 2160 AGGACTTCTC CAGCAAGGGA GCCGAGGATA ATATGGTAAC GAGCTATAAT TGTCAGTTCT 2220 25 GTGACTTCCG ATATTCCAAA AGCCATGGCC CTGATGTAAT TGTAGTGGGG CCACTTCTCC 2280 GTCATTATCA ACACTCCAT AACATTCACA AGTGTACCAT TAAACACTGT CCATTCTGTC 2340
CCAGAGGACT TTGCAGCCCA GAAAAGCACC TTGGAGAAAT TACTTATCCG TTTGCTTGTA 2400
GAAAAAGTAA TTGTTCCCAC TGTGCACTCT TGCTTCTGCA CTTGTCTCCT GGGGCGGCTG 2460
GAAGCTCGCG AGTCAAACAT CAGTGCCATC AGTGTTCATT CACCACCCCT GACGTAGATG 2520 30 TACTCCTCTT TCACTATGAA AGTGTGCATG AGTCCCAAGC ATCGGATGTC AAACAAGAAG 2580 CAAATCACCT GCAAGGATCG GATGGGCAGC AGTCTGTCAA GGAAAGCAAA GAACACTCAT 2640 GTACCAAATG TGATTTTATT ACCCAAGTGG AAGAAGAGAT TTCCCGACAC TACAGGAGAG 2700 CACACAGCTG CTACAAATGC CGTCAGTGCA GTTTTACAGC TGCCGATACT CAGTCACTAC 2760 TGGAGCACTT CAACACTGTT CACTGCCAGG AACAGGACAT CACTACAGCC AACGGCGAAG 2820 35 AGGACGGTCA TGCCATATCC ACCATCAAAG AGGAGCCCAA AATTGACTTC AGGGTCTACA 2880 ATCTGCTAAC TCCAGACTCT AAAATGGGAG AGCCAGTTTC TGAGAGTGTG GTGAAGAGAG 2940 AGAAGCTGGA AGAGAAGGAC GGGCTCAAAG AGAAAGTTTG GACCGAGAGT TCCAGTGATG 3000 ACCTTCGCAA TGTGACTTGG AGAGGGGCAG ACATCCTGCG GGGGAGTCCG TCATACACCC 3060 AAGCAAGCCT GGGGCTGCTG ACGCCTGTGT CTGGCACCCA AGAGCAGACA AAGACTCTAA 3120 GGGATAGTCC CAATGTGGAG GCCGCCCATC TGGCGCGACC TATTTATGGC TTGGCTGTGG 3180 AAACCAAGGG ATTCCTGCAG GGGGCGCCAG CTGGCGGAGA GAAGTCTGGG GCCCTCCCCC 3240 40 AGCAGTATCC TGCATCGGGA GAAAACAAGT CCAAGGATGA ATCCCAGTCC CTGTTACGGA 3300 GGCGTAGAGG CTCCGGTGTT TTTTGTGCCA ATTGCCTGAC CACAAAGACC TCTCTCTGGC 3360 GAAAGAATGC AAATGGCGGA TATGTATGCA ACGCGTGTGG CCTCTACCAG AAGCTTCACT 3420
CGACTCCCAG GCCTTTAAAC ATCATTAAAC AAAACAACGG TGAGCAGATT ATTAGGAGGA 3480
GAACAAGAAA GCGCCTTAAC CCAGAGGCAC TTCAGGCTGA GCAGCTCAAC AAACAGCAG 3540
GGGGCAGCAA TGAGGAGCAA GTCAATGGAA GCCCGTTAGA GAGGAGGTCA GAAGATCATC 3600 45 TAACTGAAAG TCACCAGAGA GAAATTCCAC TCCCCAGCCT AAGTAAATAC GAAGCCCAGG 3660 GTTCATTGAC TAAAAGCCAT TCTGCTCAGC AGCCAGTCCT GGTCAGCCAA ACTCTGGATA 3720 TTCACAAAAG GATGCAACCT TTGCACATTC AGATAAAAAG TCCTCAGGAA AGTACTGGAG 3780 ATCCAGGAAA TAGTTCATCC GTATCTGAAG GGAAAGGAAG TTCTGAGAGA GGCAGTCCTA 3840 50 TAGAAAAGTA CATGAGACCT GCGAAACACC CAAATTATTC ACCACCAGGC AGCCCTATTG 3900 AAAAGTACCA GTACCCACTT TTTGGACTTC CCTTTGTACA TAATGACTTC CAGAGTGAAG 3960 CTGATTGGCT GCGGTTCTGG AGTAAATATA AGCTCTCCGT TCCTGGGAAT CCGCACTACT 4020 TGAGTCACGT GCCTGGCCTA CCAAATCCTT GCCAAAACTA TGTGCCTTAT CCCACCTTCA 4080 55 ATCTGCCTCC TCATTTTTCA GCTGTTGGAT CAGACAATGA CATTCCTCTA GATTTGGCGA 4140 TCAAGCATTC CAGACCTGGG CCAACTGCAA ACGGTGCCTC CAAGGAGAAA ACGAAGGCAC 4200 CACCAAATGT AAAAAATGAA GGTCCCTTGA ATGTAGTAAA AACAGAGAAA GTTGATAGAA 4260 GTACTCAAGA TGAACTTTCA ACAAAATGTG TGCACTGTGG CATTGTCTTT CTGGATGAAG 4320 TGATGTATGC TTTGCATATG AGTTGCCATG GTGACAGTGG ACCTTTCCAG TGCAGCATAT 4380 GCCAGCATCT TTGCACGGAC AAATATGACT TCACAACACA TATCCAGAGG GGCCTGCATA 4440 60 GGAACAATGC ACAAGTGGAA AAAAATGGAA AACCTAAAGA GTAAAACCTT AGCACTTAGC 4500 ACAATTAAAT AGAAATAGGT TTTCTTGATG GGAATTCAAT AGCTTGTAAT GTCTTATGAA 4560 GACCTATTAA AAAAATACTT CATAGAGCCT GCCTTATCCA ACATGAAATT CCCTTCTTTT 4620 GTTATTCTTT CTTTTGATGA GTAGGTTACC AAGATTAAAA AGTGAGATAA ATGGTCAATG 4680 65 AGAAAGAATG GAAGATGGTA AACAATCACT TTTTAAAACC TGTTAAGTCA AAACCATCTT 4740 GGCTAATATG TACTGGGGAA ATAATCCATA AGAGATATCA CCAGACTAGA ATTAATATAT 4800
TTATAAAGAA AGAGACCAAA ACTGTCTAGA ATTTGAAAGG GTTTACATAT TATTATACTA 4860
AAGCAGTACT GGACTGGCCA TTGGACCATT TGTTCCAAAA CCCATAAATT GTTGCCTAAA 4920 70 TTTATAATGA TCATGAAACC CTAGGCAGAG GAGGAGAAAT TGAAGGTCCA GGGCAATGAA 4980 AGAAAAATGG CGCCCTCTCA ATTTAGTCTT CTCTCATTGG CCATGTTTCA GATTTTGACC 5040 TAGAAATGCG AGCTGTGGTT AGGCTTGGTT AGAGTGCAGC AAGCAACATG ACAGATGGTG 5100
GCACGCTGTT TTTACCCAGC CCTGCCTGTA CATACACATG CACACCCTCT CTGATATTTT 5160
TGTCCTTTAG ATGTTCAAAT ACTCAGTAGT CCTTTTGTTT GCGGTTTAGA TTCATTTTGT 5220 75 CCACACATGT ACCCATTTTA AAAAACAATG TCCTCGATGC TTCTGTAGTG ATTTCATTTT 5280 AGCCAGGTAT TTCTTTCTTG TGTGTGATGA ACCAGTATGG ATTTGCTTTT CTAAGCCTCC 5340 TGTTGGTTAC TAATCTCACT TGGCACATTA TAACTAAAGG AATCCCCTCA ATTCAAAAGC 5400

ATAGATGGAT ACAAATGTCA GACCGTGGGT TTAATTTGTT TAGAACACAT GGCATTTCTT 5460 CACAAGGTAA CCTGCTGTAT TTATTTATTT TCTTTTGGTT AAATATAATT TCCAAACTTT 5520 GTGGTCAGGC AGCGTCTAAG GTTACGTTAC CACAGACTGA CAGTTGGTAT ATGTACCAGC 5580 CAATCCCTTC ATTAAATGTA TACAGATTTA GTTAAGTAGC ATTAAATAGG ATTCTTAGAA 5640 5 GTATGTCCTC ATAGAACTTT TAATACTTAA GGCTTTGTAA AAACTATCCA TGAAGGGAAA 5700 GCTCCTCAGC ATAACTGCTC AGGGAAATAG GGCTAAATAA CTGAACATTA AATAATTGGT 5760 TAAAGGTGCT GTTAGTCGAG CCTCAATGCT TGCTACAAGG ATGTATGTAC AAGGACTGAC 5820 TTTAATAATT TGCATTATAT TGTCCCAACC AGTAGTTTAT TTTTTGCCAC GGAGATGTAG 5880 AAGATATTAC AAGCTACTGG ATGCACTGTC AGATTAACTT ATTTCATTAA AGAAGTTGGG 5940 10 AGAACAAATA GGAAAAAAAA AACTTATTTT TCTAGTAAAT ATTAATGTAT TACATTTCAA 6000 ATAATGGTGC CTGACATATT GAATAATTAT TTTCTACAGT GTACGTATGC AACAAAGATA 6060 TTCCATCATG CATTAGAGTC AGTTCTGGCT CTGCCTAGCT GTTTACATTT GCAAATGTAG 6120 CAAACAAGGT AATGAAGCAA CTATTTCTAT TGCAGTAGAT ATCCTTTTGT GTGTGTGTGT 6180 GTGCATTAAA GTTGTAAACG GTAACATGAA ACAAATGAAA GTTCTTGCTA TAATGGTATG 6240 15 GAAAACAAGA AGGAAATGAA AATATTTTTA TGCCTACTTA GGAAAAAAAG GGTAGCACTT 6300 ATTICATTICA AGACTITITI TITTITTATA TITTIAAGCTC TIAACTCACA TIGITTATGCT 6360
TAAGATGATA AACATATATC CTCTTTTTAT TGCTTTGTCT ATGTTTCATA TGAAACATTT 6420 CAGAAATTAT TITGATAAGT GTTGCTGGAA TCTGCAACGC TGATTTTTTT TTGCATTCTG 6480 TAGTCGCATT TGCACTCCAT TTTTACATTA ATTCGCAGTT GCTTTGTATC ATTGTTTTGT 6540 20 TTGGGTTTTG TTTCTTTTTC ACAGTGCCGG GTCTTCGTTT CTTAAAGTTG GATGGCAGGT 6600 AGAGTTCAAC CAGTTCGTGA CTGTTGTAGC GAATGAAGTT AAAAAAATGT CTTTCTGATG 6660 TTGTGTTGTC ATTTTCATTT TTGCATTTTT TTGTTTGCAT ATTAAAAAAA GAGAAAAGAG 6720 AAAGCAAGAG ACAGAAATCA GGACTAAGTC CTCTGCTTCA GTTTCATTGT TAACGGGCCT 6780 TATTCTGATC TCACCTGTCG CGTAGCTCTA ATATTCACAT AAACTGAAAT AAAGAAGTGG 6840 25 AATGAGGAGC TITGACATTC AAATTATGTG ATGTAATITA TCTTCCTTAG GAATTTTGAT 6900 GGATGCATCT CAAAATGTAT AGCCAGACTT GAGAGGTGAC AATTAAAGAT CTAAAAAAGA 6960 GAGGAGATTC CCCCAAACAA CAATATTTAA TTTTCTTAGT AAAAAGAATA ACAGAATGCA 7020 TCGTGGCAAT CCTTAAGCAA CATTATCTAT GTGGACTGCT TAAATCAGCA AAACACCAGA 7080 AGTTTGGTTA ACTTGGGCAA TATGACAAGT ATTACTTTTT GGGCAAAACT ACTCATTAAG 7140 30 CAATTTCTCT AGTGTGTCGG ACACAAATAG GTTCTTTATT TTTGGCATGT ATGCCTTTTT 7200 ATTTTCATTC AATTTTTTT TTTTCTCAGA CAGACATAGT AGTATCAACT AGCATTGGAA 7260 AATACATATC ACTATTCTTG GAATATTTAT GGTCAGTCTA CTTTTTAGTA AAATATTTTT 7320 CATTTTTTGC TITCATTATT ATACATATTT TGGTGGAGAA GAGGTTGGGC TTTTTTGAAA 7440 GAGACAAAAA TTTATTATAA CACTAAACAC TCCTTTTTTG ACATATTAAA GCCTTTATTC 7500 CATCTCTCAA GATATATTAT AAAATTTATT TTTTTAATTT AAGATTTCTG AATTATTTTA 7560 35 TCTTAAATTG TGATTTTAAA CGAGCTATTA TGGTACGGAA CTTTTTTTAA TGAGGAATTT 7620 CATGATGATT TAGGAATTTT CTCTCTTGGA AAAGGCTTCC CCTGTGATGA AAATGATGTG 7680 CCAGCTAAAA TTGTGTGCCA TTTAAAAACT GAAAATATTT TAAAATTATT TGTCTATATT 7740 CTAAATTGAG CTTTGGATCA AACTTTAGGC CAGGACCAGC TCATGCGTTC TCATTCTTCC 7800 TTTTCTCACT CTTTCTCTCA TCACTCACCT CTGTATTCAT TCTGTTGTTT GGGATAGAAA 7860 40 AATCATAAAG AGCCAACCCA TCTCAGAACG TTGTGGATTG AGAGAGACAC TACATGACTC 7920 CAAGTATATG AGAAAAGGAC AGAGCTCTAA TTGATAACTC TGTAGTTCAA AAGGAAAAGA 7980 GTATGCCCAA TTCTCTCTAC ATGACATATT GAGATTTTTT TTAATCAACT TTTAAGATAG 8040 TGATGTTCTG TTCTAAACTG TTCTGTTTTA GTGAAGGTAG ATTTTTATAA AACAAGCATG 8100 45 GGGATTCTTT TCTAAGGTAA TATTAATGAG AAGGGAAAAA AGTATCTTTA ACAGCTCTTT 8160 GTTGAAGCCT GTGGTAGCAC ATTATGTTTA TAATTGCACA TGTGCACATA ATCTATTATG 8220 ATCCAATGCA AATACAGCTC CAAAAATATT AAATGTATAT ATATTTTAAA ATGCCTGAGG 8280 AAATACATTT TTCTTAATAA ACTGAAGAGT CTCAGTATGG CTATTAAAAT AATTATTAGC 8340 CTCCTGTTGT GTGGCTGCAA AACATCACAA AGTGACCGGT CTTGAGACCT GTGAACTGCT 8400 50 GCCCTGTTTA GTAAATAAAA TTAATGCATT TCTAGAGGGG GAATATCTGC CATCCAGTGG 8460 TGGAAATGTG GAGTAAAGAA GCTGGTGGTC TGCTTCTGTG CTGTATGCCA GCCTTTTGCC 8520 TTAAGTTGAG AGGAGGTCAA CTTTAGCTAC TGTCTTTGGT TTGAGAGCCA TGGCAAAAAA 8580 AAAAAAAGAA AAAAAGATCA AGTCGTCTTT GGTGAGCCAG TAAGGTGAAA GCTTGCTGAC 8640 55 TGTCCAAGGC ACAAGAGAAA ATTGAGGAAT TGAAATGCAA CCTGAGTATC AAACTAAATA 8700 TTCTAATCAA AGGTAGGTAC TGTTAGGTGG AATTCTATCA GCAGGCAACT GCAAATGAGA 8760 AGAAGATAGA AGGIACGCCCG TCGGGACTTT GGAGGGCATT GTTATTTCC CAAAGAAAGA 8820 CGGCCAAGGG CAGAGGCATG GATTCTTTGC AGAGCACTTC CTTTTGGTTT TTCAGTACTG 8880 TTTCATAGAC AGTGGGCTCA CATGTTCCTG ATAGTGCTGC AGTTGCTTAG AAAGCATCCC 8940 AGTTAATTGC AGTAATTAGA ACTTCTGGAA TATGCTAGGG CAGAAGTATG TCAAGTATOT 9000 60 CACATGAAGA AAATGTGAAA TTCAAGAGTA ATCCACACGT GAGAAACTAG ACAATGTACA 9060 TTCATGTGTT CTCTTGAAAG GAAAGGGAGA GCTGTAAGCT TCACTCTGTC CTACACCGGA 9120
GAAAAGCAGG AATAACTTTA CCGTGGAAAT AATGTTTAGC TTTTATCAGA GAAAATTGTC 9180
CTTCTAGAGC ATAGAGTCCC AAAACTCAAT TCTGGTTTTC CCCTGTTTTT TTTTTTTTT 9240 .65 TTTTTCCCAA CATATGAACT GCAGCATATC ACTTTTTCTT TTTGTGCCTC AGGTTCCTCA 9300 CCTGTAAAAT TGAAAAATAT ATGTATTAAT AATATTATTA ATAATAATAA TGGTAATGTA 9360
GTACTTGTTT GTAAAGCACT TTGAGATCCT TGGTTGAAAG GCACCATAGG AGTGCCAAGT 9420
ATTATTATGT GGCCAAGGGG GTTATTTAAA CTGTCAGTTC CCAAAGGCCA GGAAAGGTTG 9480
GGGTCATTTT TCTTAAAGAC GAGCTGTAAA TATCAACTAG GCAGCCAATA GTGTTGACTA 9540 70 TGAAGATGCA AAACTATTAC TAGGCTGATA AAATCATAGT TTCTTAATGG CTACCAATAA 9600 GGCAAATATC ACAATAATAA ACGCCAAATT CCTTAGGGCG GACTATTTGA CAACCACATG 9660
GAAAACTTTG GGGGAGGCAT GAGGGGGGAA CATCTCAAAA TGCCAATGTA AAATTTAACT 9720
TACAGCAATA TTCACCAGCA GAAAATGTCT TTCATATGGA ATGATTTCAT GTTGCTAAGA 9780
AAAAGAATTC AATTTGTAGT CCTGATTTGA ATACTAGAAT GTTGGCTATA ATAGTTCTGT 9840 75 TCITACAACA CATGAAATTT TTTCGTTTTA TTTTATTTTG TTTTCATAGT GCATGTTCAT 9900 TTCTACTCAC AAACATGTTC TTGGTGTATT TCTTATGCAA ACAATCTTCA GGCAGCAAAG 9960 ATGTCTGTTA CATCTAAACT TGAATAATAA AGTTTTACCA CCAGTTACAC A



	CCTCAAGCCA TCCTGAACTG CGTTAATAAG TTCTGGACAT TTCAAGAGTT GGCTGGCCAT 1200
	GGTGTTCCTC TGCCGGATAC TTTCTCTTAT GGTGGCCACG AAAATTTTGC TAAAATGATT 1260
	GATGAGGCTG AAGTTCTGGA GTTCCCAATG GTAGTAAAGA ATACGCGGGG TCACAGAGGT 1320 AAAGCTGTTT TCTTGGCTCG AGATAAGCAC CATTTGGCTG ATCTAAGCCA TCTTATTCGC 1380
5	CATGAAGCGC CATACCTGTT CCAGAAGTAT GTTAAAGAGT CTCATGGACG GGATGTACGT 1440
-	GTCATTGTCG TGGGAGGCCG TGTGGTTGGC ACCATGTTAC GTTGTTCAAC AGATGGGAGA 1500
	ATGCAAAGCA ACTGCTCATT AGGTGGTGTG GGGATGATGT GCTCATTGAG TGAACAAGGG 1560
	AAGCAGCTAG CTATCCAGGT GTCTAATATC CTGGGGATGG ATGTGTGTGG CATTGACCTG 1620
• •	CTGATGAAAG ATGACGGCTC CTTCTGCGTC TGTGAGGCCA ATGCAAATGT AGGTTTCATC 1680
10	GCCTTTGATA AGGCTTGTAA TCTAGATGTA GCTGGTATCA TAGCAGACTA TGCCGCCTCC 1740
	CTTCTACCCT CTGGCCGGCT CACCCGGCGT ATGTCCCTGC TCTCCGTGGT GTCCACTGCC 1800
	AGTGAGACTA GTGAGCCGGA GCTGGGTCCC CCAGCCAGCA CTGCTGTTGA CAACATGAGT 1860
	GCAAGTTCCA GCTCTGTTGA CAGCGACCCT GAAAGCACGG AGCGAGAGCT GCTCACCAAG 1920
15	CTCCCAGGGG GCCTGTTCAA CATGAACCAG CTGCTAGCCA ATGAAATCAA ACTACTGGTG 1980
13	GACTGACTCC ACTGGTAATT AACCAACAAA ACCCTTGTAA AACTTTCTTT CTTCTTTCT 2040
	ATTITITAAAA CCAACTIGCA ATGCTGTTCA TGGAGGATGC TCAGGAAGAT GAGAGAAAAAT 2100
	TAGTAGGATT AGTTGGAGAG AGTGGGAGAT AGATGAGACC TCTGCTAGTA AGATGTTACT 2160
	TTCATTTACA AATCCTACAA ATAGAGAGGC AGAATAGGTG GGGTATAGAA AAATGTCAGG 2220 CTCTCATAGT TACCCTTTTA AATTGCTAAA AAATGTGAT GCTCATAGGC CATGAGGAAC 2280
20	AAATACTITT TITTITICAT GGTCCCTTGC TITTGTTTTT GTACAAAAAA AAATGGTTTT 2340
20	GCTACAAATA TCCAAGTAGC ATAACTTCAC ATTGTGTTGG AAGATTTGTC ATCAGTGAGG 2400
	AAAACATCTG CTTAAATTAC AGGAATTTTT GTATTATACA GCTCTGAAAA TTCTGCCATT 2460
	TCCTTATTAA CTAGCAGCTT TAGTTTGTAG TTTATGAAAT CTTGAGGGGC TCTTTTACTG 2520
	GGATTICITA TTTTTTGTT TTTTCCCGCT TAATTTGGTG GGAGGTCAAA TTGAATATAA 2580
25	CCCAATAAAG GCTTCTTAAT GAGAAAATTG GCATGTTTGC ATGATGAAAT GGAAATGAAC 2640
	AGTATTGCAA TGTCCGGTAT ACAAAATAAC ATTAATTCAA TGTAGATAAA ATTACACTAG 2700
	TTTAAAATAT GTGCATTCAC TTGTATTTGT TAGTGTTTTA GTCTTTTTTG AAAGATGTGC 2760
	TCTGTTAATG TTGCTTTTTT TTTTTTTTT TAATACATGC TAGTCTAACA TTTCCTGCTC 2820
20	TATGCCTGCA TCTTTAACAA TGGCCAAAGT GAAGAAAATG CTACCTTTTT TGTTAACAAG 2880
30	ACACTGACTT GAAACATGTA CATTTAAAGC CTTTTATTTT TTCCCTTTTT GTTTTGGTAG 2940
	TTGGGCATTT AAATAAGGAC AAGGAAAAAT ATTTTTGGGG GCAAATCAAG AGCCTATGAG 3000
	TTCTAAGTAT AAAGCTGAAG TGATTTCGAA TGCCAGCGTT ATATATTTGC ATTTTTCACA 3060
	TTTTACGAGG GAGTATATGT GTATGTGTGT GCACGCATGC ATGTGTATGT GTTTTGCTTT 3120
35	TTGTTTCCAT CAACTAATCA AAAAGGATAA TTTAGAAAAT GGAGCATGAT GGGAAACAGA 3180 GTTTTTGACT TTAAAAAACA GATGAGTTGT TTTCATAAGT AGACTCCACT GGGGTAGAGG 3240
55	TATTCACCTT AAAACATAGG GTGAGTAGAT GCTTTTTTAG GCCTTTTTGT GTATATGTAC 3300
	GTTGTTTGTT TTTTTCCTTT TGTTTCTAGC CTGTTCAGTG TACAGTTTAT TCAAGGCTAC 3360
	ATGCTTTTCT TTAATGCTTC TGGCTATGCA TTTTCTCTTT TTACATATAG GATTTGGGAT 3420
	TGGGGGTGGG TTGGATGTTT TTGTTTGGGG ACTTATTTAG TAGTATTGAG TCTCTTATAG 3480
40	CCCTACTCTT AAGCCTTCAA TACTGTCCAC TCTTTATATT CCTTTACTTG CAGAATTTAT 3540
	AAAAGCCCC AAACTGCATA TAATATGAGC CTTTAAAACA TGGGTAAAAC TAATCCCATT 3600
	GATGGGTTTG GATGGTATGT TAAGAAATGG AGATGCTGCA GAGCCCAACG TAATTTTTTA 3660
	AACAGCAAGT TTTCCATCTC CCTACGAATC CTCTGAAGCT TTTACCCAAG CCCTTTCTTG 3720
45	CCTCTCCAGT GCTATTTTCC TTCAGATGGA CCTTAAACAT AATTTCTTGG ACACTACTAG 3780
43	AGAGACITCG AGGCAATAAT AAAAGATCAG TATTAACCAG CTATAACAGA GGTTTGATCA 3840
	TGCTTACITG TACAGTTTTT CCCCCGTTTT AAAAAGGAAT GTAATAAAAT TTGTTTTTTC 3900
	CATAGAATTA AATAATATTA AAATTGAGTG AAAGGTTGAT TGTTGATGAA TAGAATAGTA 3960 CCTCTCATCT GTGCAGTGTC TCATTTCACC TCAGAGAAAA GGATACATAA GAGGAGTTTG 4020
	TAATTTATCT TAGGATATTC TAATTGCATT TAAAAGAACT TATCTTGCGC AGGGTAAATG 4080
50	GGGGACTCAC ATACATATAT TAATACCTCT GACTCATTAA CAGAAAGAAA TACTTGGTAC 4140
	TTCTTTCGCT GAATGACCAT ACTGTGGAGG ATGCATACTA TTTGGTATAG AGAAATAAAT 4200
	GAGGAAGAAA GAACTGCTTA ATTAAATTAT CATTCATATG TTCATATAGA GACCATCTGG 4260
	TTGCCATGTG TATTATGACA CATACACTTT GAATAGTTAC ATATCACAAG TATGTAGTTC 4320
<i></i>	ATGTTTGTGT TGGTGGGGTA AGGCATCAGG AAAAATGTAG TTAGTCTTTT CTTAACTTAT 4380
55	ACCAAATTAA CCAACTATAT TATAGGAAAT ATGTGAAATT AGTTCATTAG CTTTATTCAC 4440
	TATTATGCAT TCACATGATA TTAAAACGTA CACTCACATG TTAGAATGAA AAGAGCAGTA 4500
	GTTATCTTAG ATTTTAAAAA CATGGATATC TTCTTGAATT CCTTCAAGAT TGAGGTAGAG 4560
	AATAAGAGCA AATCATTCTG GAAGTACCTT AAGGAAACAA ACAGCAGCAG ATATTTAGGT 4620
60	TAAACTTATT TTCATAATTG TTTAATAACT TTTGTATAAT CTTCATTGCT ATTATGAGAG 4680
OO	AGAATGTATA TATCAAATAT GTGTAATGAT AAAATCTGAA TTGTAAAATT TTTGTATATT 4740 GTTAAAATTG TAATTCTAAA TTGTATTTCA AAAATGATTA TTTCTGATAT TGTTTTTATG 4800
	TCACCCATGA TGAAAACTGG ACTTTATATA TCTAAACATA CAAGTATGAA CTATTCTATT
	TAAAATITIT AATAGTTITT TTCTITTTTG GTGCCTATAA TTGATTGGTC ATTTCTGCTG 4920
	GCTTTTCTCC AATGAACATT GAAATCTTCC TGTATATGTT ACCAATAAGA AAACTACCCT 4980
65	GGAACAGTAG AAAAACCCAA CAAGAGACTT GGCATTCATC AAGCACATTA TCAGACTTTG 5040
	AGAACATATT GAAGGCATTG ACTITGAAAA TCATCTCTTT TTCTCAAGAA GAAAGCAATG 5100
	GAGAAGCAAA TITGTTTCAT TCAGTGAATC CCCAGTTTGG GGCTTGTGGG GCTTAGAGAC 5160
	ATTGTGAAAT CAAATCTTGT GTTATACTTT TCTCCTGGCT CACTTTTTTT GAGAAGGTTT 5220
70	ATGGGCTATT TGGCTGGTGA GACACGATCC CCTCCTAAGA AAATGTAGGT GCTCAGACAG 5280
70	GTAACCACTG CTGCTACTGT TTTTATTTGT TIGTTTGTTC AATTTTATTT AAGATTTGTT 5340
	TTTGTTGTAC TAGGATTTTA AAAAATGTAA TATATTGCAG GATTTATAAC CAG
	G - ID NO. 72 Parties
	Seq ID NO: 72 Protein sequence: Protein Accession #: BAA86552
75	Protein Accession #: BAA86552
, ,	

75

1 11 21 31 41 51 | | | | | |


380

RINGELITAY PQVVVVRVPT PWVQSDSDIT VLRHLEKMGC RLMNRPQAIL NCVNKFWTFQ 120 ELAGHG VPLP DTFSYGGHEN FAKMIDEAEV LEFPMVVKNT RGHRGKAVFL ARDKHHLADL 180 SHLIRHEAPY LFQKYVKESH GRDVRVIVVG GRVVGTMLRC STDGRMQSNC SLGGVGMMCS 240 LSEQGKQLAI QVSNILGMDV CGIDLLMKDD GSFCVCEANA NVGFIAFDKA CNLDVAGIIA 300 5 DYAASLLPSG RLTRRMSLLS VVSTASETSE PELGPPASTA VDNMSASSSS VDSDPESTER 360 ELLTKLPGGL FNMNQLLANE IKLLVD Seq ID NO: 73 DNA sequence 10 XM 040080.2 Nucleic Acid Accession #: Coding sequence: 159-1104 (underlined sequences correspond to start and stop codons) 15 CTGAGTGGGG GCGGGGACTG CTGGAGTTGC GGGGCCTGCC TGGGGTAGGG CGGGGCAGGA 60 CAGCTTGGAG ATAGGGCCCG GAATTGCGGG CGTCACTCTG CTCCTGCGAC CTAGCCAGGC 120 GTGAGGGAGT GACAGCAGCG CATTCGCGGG ACGAGAGCGA TGAGTGAGAA CGCCGCACCA 180 GGTCTGATCT CAGAGCTGAA GCTGGCTGTG CCCTGGGGCC ACATCGCAGC CAAAGCCTGG 240
GGCTCCCTGC AGGGCCCTCC AGTTCTCTGC CTGCACGGCT GGCTGGACAA TGCCAGCTCC 300
TTCGACAGAC TCATCCCTCT TCTCCCGCAA GACTTTTATT ACGTTGCCAT GGATTTCGGA 360 20 GGTCATGGGC TCTCGTCCCA TTACAGCCCA GGTGTCCCAT ATTACCTCCA GACTTTTGTG 420 AGTGAGATCC GAAGAGTTGT GGCAGCCTTG AAATGGAATC GATTCTCCAT TCTGGGCCAC 480 AGCTTCGGTG GCGTCGTGGG CGGAATGTTT TTCTGTACCT TCCCCGAGAT GGTGGATAAA 540 CTTATCTTGC TGGACACGCC GCTCTTTCTC CTGGAATCAG ATGAAATGGA GAACTTGCTG 600 ACCTACAAGC GGAGACCAT AGAGCACGTG CTGCAGGTAG AGGCCTCCCA GGAGCCCTCG 660 25 CACGTGTTCA GCCTGAAGCA GCTGCTGCAG AGGTTACTGA AGAGCAATAG CCACTTGAGT 720 GAGGAGTGCG GGGAGCTTCT CCTGCAAAGA GGAACCACGA AGGTGGCCAC AGGTCTGGTT 780 CTGAACAGAG ACCAGAGGCT CGCCTGGGCA GAGAACAGCA TTGACTTCAT CAGCAGGGAG 840 CTGTGTGCGC ATTCCATCAG GAAGCTGCAG GCCCATGTCC TGTTGATCAA AGCAGTCCAC 900 GGATATTTTG ATTCAAGACA GAATTACTCT GAGAAGGAGT CCCTGTCGTT CATGATAGAC 960 30 ACGATGAAAT CCACCCTCAA AGAGCAGTTC CAGTTTGTGG AAGTCCCAGG CAATCACTGT 1020 GTCCACATGA GCGAACCCCA GCACGTGGCC AGTATCATCA GCTCCTTCTT ACAGTGCACA 1080 CACATGCTCC CAGCCCAGCT G<u>TAG</u>CTCTGG GCCTGGAACT ATGAAGACCT AGTGCTCCCA 1140 GACTCAACAC TGGGACTCTG AGTTCCTGAG CCCCACAACA AGGCCAGGGA TGGTGGGGAC 1200 AGGCCTCACT AGTCTTGAGG CCCAGCCTAG GATGGTAGTC AGGGGAAGGA GCGAGATTCC 1260 35 AACTTCAACA TCTGTGACCT CAAGGGGGAG ACAGAGTCTG GGTTCCAGGG CTGCTTTCTC 1320 CTGGCTAATA ATAAATATCC AGCCAGCTGG AGGAAGGAAG GGCAGGCTGG GCCCACCTAG 1380 CCTTTCCCTG CTGCCCAACT GGATGGAAAA TAAAAGGTTC TTGTATTCTC A 40 Seq ID NO: 74 Protein sequence: Protein Accession #: XP_040080.1 41 11 21 31 45 MSENAAPGLI SELKLAVPWG HIAAKAWGSL QGPPVLCLHG WLDNASSFDR LIPLLPQDFY 60 YVAMDFGGHG LSSHYSPGVP YYLQTFVSEI RRVVAALKWN RFSILGHSFG GVVGGMFFCT 120 FPEMVDKLIL LDTPLFLLES DEMENLLTYK RRAIEHVLQV EASQEPSHVF SLKQLLQRLL 180 KSNSHLSEEC GELLLQRGTT KVATGLVLNR DQRLAWAENS IDFISRELCA HSIRKLQAHV 240 LLIKAVHGYF DSRQNYSEKE SLSFMIDTMK STLKEQFQFV EVPGNHCVHM SEPQHVASII 300 50 SSFLQCTHML PAQL Seq ID NO: 75 DNA sequence Nucleic Acid Accession #: NM 005794 Coding sequence: 434-1276 (underlined sequences correspond to start and stop codons) 55 GGTTCCCTTC CACGCTGTGA AGCTTTGTTC TTTTGGTCTT CATGATAAAT CTTGCTGCTG 60 CTCACTCGTT GGGTCCGTGC CACCTTTAAG AGCTGTAACA CTCACCGCGA AGGTCTGCAA 120 60 CTTCACTCCT GGGGCCAGCA AGACCACGAA TGCACCGAGA GGAATGAACA ACTCTGGACA 180 CACCATCTTT AAGAACCGTA ATACTCACCG CAAGGGTCTG CAACTTCATT CTTGAAGTCA 240 GTGAGGCCAA GAACCCATCA ATTCCGTACA CATTTTGGTG ACTTTGAAGA GACTGTCACC 300 TATCACCAAG TGGTGAGACT ATTGCCAAGC AGTGAGACTA TTGCCAAGTG GTGAGACCAT 360 CACCAAG IGGIGAGACI ATTGCCAAGC AGTGAGACIA TIGCCAAGG GIGAGACCAT 360
CACCAAGCGG TGAGACTATC ACCTATCGCC AAGTGGCCTG ATTCAGCAGG AAGCATCTCA 420
GACACCAACC ACTATGCTGT CAGCAGTTGC CCGGGGCTAC CAGGGCTGGT TTCATCCCTG 480
TGCTAGGCTT TCTGTGAGGA TGAGCAGCAC CGGGATAGAC AGGAAGGGCG TCCTGGCTAA 540
CCGGGTAGCC GTGGTCACGG GGTCCACCAG TGGGATCGGC TTTGCCATCG CCCGACGTCT 600
GGCCCGGGAC GGGGCCCACG TGGTCATCAG CAGCCGGAAG CAGCAGAACG TGGACCGGC 660 65 CATGGCCAAG CTGCAGGGGG AGGGGCTGAG TGTGGCGGGC ATTGTGTGCC ACGTGGGGAA 720 70 CATGAGGAC CGGGAGCAGC TGGTGGCCAA GGCCCTGGAG CACTGTGGGG GCGTCGACTT 780
CCTGGTGTGC AGCGCAGGGG TCAACCCTCT GGTAGGAGC ACTCTGGGGA CCAGTGAGCA 840
GATCTGGGAC AAGATCCTAA GTGTGAACGT GAAGTCCCCA GCCCTGCTGC TGAGCCAGTT 900
GCTGCCCTAC ATGGAGAACA GGAGGGGTGC TGTCATCCTG GTCTCTTCCA TTGCAGCTTA 960 TAATCCAGTA GTGGCGCTGG GTGTCTACAA TGTCAGCAAG ACAGCGCTGC TGGGTCTCAC 1020

75

MCSSVAAKLW FLTDRRIRED YPQKEILRAL KAKCCEEELD FRAVVMDEVV LTIEQGNLGL 60

TAGAACACTG GCATTGGAGC TGGCCCCCAA GGACATCCGG GTAAACTGCG TGGTTCCAGG 1080 AATTATAAAA ACTGACTTCA GCAAAGTGTT TCATGGGAAT GAGTCTCTCT GGAAGAACTT 1140 CAAGGAACAT CATCAGCTGC AGAGGATTGG GGAGTCAGAG GACTGTGCAG GAATCGTGTC 1200



CAGTTCTTCA TTCCCTACAC CATAAAGAGT AAAGGTATAG CAGTAAGAGG AGAGCAAGGT 180 ACTCCTGGTC CACCAGGCCC TGCTGGACCT CGAGGGCACC CAGGTCCTTC TGGACCACCA 240 GGAAAACCAG GCTACGGAAG TCCTGGACTC CAAGGAGAGC CAGGGTTGCC AGGACCACCG 300 GGACCATCAG CTGTAGGGAA ACCAGGTGTG CCAGGACTCC CAGGAAAACC AGGAGAGAGA 360
GGACCATATG GACCAAAAGG AGATGTTGGA CCAGCTGGCC TACCAGGACC CCGGGGCCCA 420
CCAGGACCAC CTGGAATCCC TGGACCGGCT GGAATTTCTG TGCCAGGAAA ACCTGGACAA 480
CAGGGACCAC CAGGAGCCCC AGGACCCAGG GGCTTTCCTG GAGAAAAGGG TGCACCAGGA 540 5 GTCCCTGGTA TGAATGGACA GAAAGGGGAA ATGGGATATG GTGCTCCTGG TCGTCCAGGT 600 GAGAGGGGTC TICCAGGCCC TCAGGGTCCC ACAGGACCAT CTGGCCCTCC TGGAGTGGGA 660
AAAAGAGGTG AAAATGGGGT TCCAGGACAG CCAGGCATCA AAAGTGATAG AGGTTTTCCG 720
GGAGAAATGG GACCAATTGG CCCACCAGGT CCCCAAGGCC CTCCTGGGGA ACGAGGGCCA 780
GAAGGCATTG GAAAGCCAGG AGCTGCTGGA GCCCCAGGCC AGCCAGGGAT TCCAGGAACA 840 10 AAAGGTCTCC CTGGGGCTCC AGGAATAGCT GGGCCCCCAG GGCCTCCTGG CTTTGGGAAA 900 CCAGGCTTGC CAGGCCTGAA GGGAGAAAGA GGACCTGCTG GCCTTCCTGG GGGTCCAGGT 960 GCCAAAGGGG AACAAGGGCC AGCAGGTCTT CCTGGGAAGC CAGGTCTGAC TGGACCCCCT 1020 GGGAATATGG GACCCCAAGG ACCAAAAGGC ATCCCGGGTA GCCATGGTCT CCCAGGCCCT 1080 15 AAAGGTGAGA CAGGGCCAGC TGGGCCTGCA GGATACCCTG GGGCTAAGGG TGAAAGGGGT 1140 TCCCCTGGGT CAGATGGAAA ACCAGGGTAC CCAGGAAAAC CAGGTCTCGA TGGTCCTAAG 1200 GGTAACCCAG GGTTACCAGG TCCAAAAGGT GATCCTGGAG TTGGAGGACC TCCTGGTCTC 1260
CCAGGCCCTG TGGGCCCAGC AGGAGCAAAG GGAATGCCCG GACACAATGG AGAGGCTGGC 1320
CCAAGAGGTG CCCCTGGAAT ACCAGGTACT AGAGGCCCTA TTGGGCCACC AGGCATTCCA 1380
GGATTCCCTG GGTCTAAAGG GGATCCAGGA AGTCCCGGTC CTCCTGGCCC AGCTGGCATA 1440 20 GCAACTAAGG GCCTCAATGG ACCCACCGGG CCACCAGGGC CTCCAGGTCC AAGAGGCCCC 1500 TCTGGAGAGC CTGGTCTTCC AGGGCCCCCT GGGCCTCCAG GCCCACCAGG TCAAGCAGTC 1560 ATGCCTGAGG GTTTTATAAA GGCAGGCCAA AGGCCCAGTC TTTCTGGGAC CCCTCTTGTT 1620 AGTGCCAACC AGGGGGTAAC AGGAATGCCT GTGTCTGCTT TTACTGTTAT TCTCTCCAAA 1680 25 GCTTACCCAG CAATAGGAAC TCCCATACCA TTTGATAAAA TTTTGTATAA CAGGCAACAG 1740 CATTATGACC CAAGGACTGG AATCTTTACT TGTCAGATAC CAGGAATATA CTATTTTCA 1800 TACCACGTGC ATGTGAAAGG GACTCATGTT TGGGTAGGCC TGTATAAGAA TGGCACCCCT 1860 GTAATGTACA CCTATGATGA ATACACCAAA GGCTACCTGG ATCAGGCTTC AGGGAGTGCC 1920 ATCATCGATC TCACAGAAAA TGACCAGGTG TGGCTCCAGC TTCCCAATGC CGAGTCAAAT 1980 30 GGCCTATACT CCTCTGAGTA TGTCCACTCC TCTTTCTCAG GATTCCTAGT GGCTCCAATG 2040 TGAGTACACC CCACAGAGCT AATCTAAATC TTGTGCTAGA AAAAGCATTC TCTAACTCTA 2100
CCCCACCCTA CAAAATGCAT ATGGAGGTAG GCTGAAAAGA ATGTAATTT TATTTTCTGA 2160
AATACAGATT TGAGCTATCA GACCAACAAA CCTTCCCCCT GAAAAGTGAG CAGCAACGTA 2220
AAAACGTATG TGAAGCCTCT CTTGAATTTC TAGTTAGCAA TCTTAAGGCT CTTTAAGGTT 2280 35 TTCTCCAATA TTAAAAAATA TCACCAAAGA AGTCCTGCTA TGTTAAAAAC AAACAACAAA 2340 AAACAAAGCA ACAAAAAAA AAATTAAAAA AAAAAACAGA AATAGAGCTC TAAGTTATGT 2400 GAAATTTGAT TTGAGAAACT CGGCATTTCC TTTTTAAAAA AGCCTGTTTC TAACTATGAA 2460 TATGAGAACT TCTAGGAAAC ATCCAGGAGG TATCATATAA CTTTGTAGAA CTTAAATACT 2520 40 TGAATATTCA AATTTAAAAG ACACTGTATC CCCTAAAATA TTTCTGATGG TGCACTACTC 2580 TGAGGCCTGT ATGGCCCCTT TCATCAATAT CTATTCAAAT ATACAGGTGC ATATATACTT 2640 GTTAAAGCTC TTATATAAAA AAGCCCCAAA ATATTGAAGT TCATCTGAAA TGCAAGGTGC 2700 TTTCATCAAT GAACCTTTTC AAAACTTTTC TATGATTGCA GAGAAGCTTT TTATATACCC 2760 AGCATAACTT GGAAACAGGT ATCTGACCTA TTCTTATTTA GTTAACACAA GTGTGATTAA 2820 45 TTTGATTTCT TTAATTCCTT ATTGAATCTT ATGTGATATG ATTTTCTGGA TITACAGAAC 2880 ATTAGCACAT GTACCTTGTG CCTCCCATTC AAGTGAAGTT ATAATTTACA CTGAGGGTTT 2940 CAAAATTCGA CTAGAAGTGG AGATATATTA TTTATTTATG CACTGTACTG TATTTTTATA 3000 TTGCTGTTTA AAACTTTTAA GCTGTGCCTC ACTTATTAAA GCACAAAATG TTTTACCTAC 3060 50 TCCTTATTTA CGACACAATA AAATAACATC AATAGATTTT TAGGCTGAAT TAATTTGAAA 3120 CATCAATAGA TTTTTAGG Seq ID NO: 80 <u>Protein sequence:</u>
Protein Accession #: NP_000484.1 55 21 31 41 60 MLPQIPFLLL VSLNLVHGVF YAERYQTPTG IKGPLPNTKT QFFIPYTIKS KGIAVRGEQG 60 TPGPPGPAGP RGHPGPSGPP GKPGYGSPGL QGEPGLPGPP GPSA VGKPGV PGLPGKPGER 120
GPYGPKGDVG PAGLPGPRGPP GPPPGIPGPA GISVPGKPGQ QGPTGAPGPR GFPGEKGAPG 180
VPGMNGQKGE MGYGAPGRPG ERGLPGPQGP TGPSGPPGVG KRGENGVPGQ PGIKGDRGFP 240
GEMGPIGPPG PQGPPGERGP EGIGKPGAAG APGQPGIPGT KGLPGAPGIA GPPGPPGFGK 300 PGLPGLKGER GPAGLPGGPG AKGEQGPAGL PGKPGLTGPP GNMGPQGPKG IPGSHGLPGP 360
KGETGPAGPA GYPGAKGERG SPGSDGKPGY PGKPGLDGPK GNPGLPGPKG DPGVGGPPGL 420
PGPVGPAGAK GMPGHNGEAG PRGAPGIPGT RGPIGPPGIP GFPGSKGDPG SPGPPGPAGI 480
ATKGLNGPTG PPGPPGPRGP SGEPGLPGPP GPPGPPGQAV MPEGFIKAGQ RPSLSGTPLV 540
SANQGVTGMP VSAFTVILSK AYPAIGTPIP FDKILYNRQQ HYDPRTGIFT CQIPGIYYFS 600 65 70 YHVHVKGTHV WVGLYKNGTP VMYTYDEYTK GYLDQASGSA IIDLTENDQV WLQLPNAESN 660 GLYSSEYVHS SFSGFLVAPM Seg ID NO: 81 DNA sequence NM_000786 Nucleic Acid Accession #:

Coding sequence: 332-1861 (underlined sequences correspond to start and stop codons)

51


75


11


21


31

41










AAGAAAGCAC AATAAAAATG AGTAACAGAA AAAGCACATA TACTAGCCTA ACAGATTGGC 1020




TTGTTGGCAC ACCTTATTAC ATGTCTCCTG AACAAATGAA TCGCATGTCC TACAATGAGA 720 AATCAGATAT CTGGTCATTG GGCTGCTTGC TGTATGAGTT ATGTGCATTA ATGCCTCCAT 780
TTACAGCTTT TAGCCAGAAA GAACTCGCTG GGAAAATCAG AGAAGGCAAA TTCAGGCGAA 840
TTCCATACCG TTACTCTGAT GAATTGAATG AAATTATTAC GAGGATGTTA AACTTAAAGG 900
ATTACCATCG ACCTTCTGTT GAAGAAATTC TTGAGAACCC TTTAATAGCA GATTTGGTTG 960 5 CAGACGAGCA AAGAAGAAAT CTTGAGAGAA GAGGCCGACA ATTAGGAGAG CCAGAAAAAT 1020 CGCAGGATTC CAGCCCTGTA TTGAGTGAGC TGAAACTGAA GGAAATTCAG TTACAGGAGC 1080 GAGAGCGAGC TCTCAAAGCA AGAGAAGAAA GATTGGAGCA GAAAGAACAG GAGCTTTGTG 1140 TTCGTGAGAG ACTAGCAGAG GACAAACTGG CTAGAGCAGA AAATCTGTTG AAGAACTACA 1200 10 GCTTGCTAAA GGAACGGAAG TTCCTGTCTC TGGCAAGTAA TCCAGAACTT CTTAATCTTC 1260 CATCCTCAGT AATTAAGAAG AAAGTTCATT TCAGTGGGGA AAGTAAAGAG AACATCATGA 1320 GGAGTGAGAA TTCTGAGAGT CAGCTCACAT CTAAGTCCAA GTGCAAGGAC CTGAAGAAAA 1380
GGCTTCACGC TGCCCAGCTG CGGGCTCAAG CCCTGTCAGA TATTGAGAAA AATTACCAAC 1440
TGAAAAGCAG ACAGATCCTG GGCATGCGC<u>T AG</u>CCAGGTAG AGAGACACAG AGCTGTGTAC 1500
AGGATGTAAT ATTACCAACC TTTAAAGACT GATATTCAAA TGCTGTAGTG TTGAATACTT 1560 15 GGCCCCATGA GCCATGCCTT TCTGTATAGT ACACATGATA TTTCGGAATT GGTTTTACTG 1620 TTCTTCAGCA ACTATTGTAC AAAATGTTCA CATTTAATTT TTCTTTCTTC TTTTAAGAAC 1680 ATATTATAAA AAGAATACTT TCTTGGTTGG GCTTTTAATC CTGTGTGTGA TTACTAGTAG 1740 GAACATGAGA TGTGACATTC TAAATCTTGG GAGAAAAAAT AATATTAGGA AAAAAATATT 1800 20 TATGCAGGAA GAGTAGCACT CACTGAATAG TTTTAAATGA CTGAGTGGTA TGCTTACAAT 1860 TGTCATGTCT AGATTTAAAT TTTAAGTCTG AGATTTTAAA TGTTTTTGAG CTTAGAAAAC 1920 CCAGTTAGAT GCAATTTGGT CATTAATACC ATGACATCTT GCTTATAAAT ATTCCATTGC 1980 TCTGTAGTTC AAATCTGTTA GCTTTGTGAA AATTCATCAC TGTGATGTTT GTATTCTTTT 2040 TTTTTTTCTG TTTAACAGAA TATGAGCTGT CTGTCATTTA CCTACTTCTT TCCCACTAAA 2100 TAAAAGAATT CTTCAGTTA 25 Seq ID NO: 96 Protein sequence: NP_002488 Protein Accession #: 30 GIREFNPNIM ANEVERINMI TOSISGENEA RELATEDKIN ASEHOMOSAP IENSMPSRAE 60 DYEVLYTIGT GSYGRCOKIR RKSDGKILVW KELDYGSMTE AEKOMLVSEV NLLRELKHPN 120 IVRYYDRIID RTNTTLYIVM EYCEGGDLAS VITKGTKERQ YLDEEFVLRV MTQLTLALKE 180 35 CHRRSDGGHT VLHRDLKPAN VFLDGKQNVK LGDFGLARIL NHDTSFAKTF VGTPYYMSPE 240 QMNRMSYNEK SDIWSLGCLL YELCALMPPF TAFSQKELAG KIREGKFRRI PYRYSDELNE 300 IITRMLNLKD YHRPSVEEIL ENPLIADLVA DEQRRNLERR GRQLGEPEKS QDSSPVLSEL 360 KLKEIQLQER ERALKAREER LEQKEQELCV RERLAEDKLA RAENLLKNYS LLKERKFLSL 420 ASNPELLNLP SSVIKKKVHF SGESKENIMR SENSESQLTS KSKCKDLKKR LHAAQLRAQA 480 40 LSDIEKNYQL KSRQILGMR Seq 1D NO: 97 DNA sequence NM_007050.2 Nucleic Acid Accession #: Coding sequence: 185-4576 (underlined sequences correspond to start and stop codons) 45 11 31 41 51 CCTCCCGCCT CAGTTCGCGC CGCGCCTCGG CTTGGAACGC AGGAGCGCCG GCTCCGGGAG 60 CCCGAGCGGA GCAGCCGCG CGCAGCCA GCGGCGCGC CGGCGATGGC GGGCACCCC 120
GCGCCCGCCC CAGTCCCGCC CCCGCCCC CGGGGAAGGG GCTGAGCTGC CCGCCGCCC 180
CCGGATGGCG AGCCTCGCCC CGCCGCCCT CAGCCTGCTC CTGAGGCTGC AGCTGCCGC 240
ACTGCCCGGC GCCCGGGCTC AGAGCGCCCC AGGTGGCTGT TCCTTTGATG AGCACTACAG 300 50 CAACTGTGGT TATAGTGTGG CTCTAGGGAC CAATGGGTTC ACCTGGGAGC AGATTAACAC 360 AACGGAGAAA CCAATGCTGG ACCAGGCAGT CACCACAGGA TCTTCATGA TGGTGAACAG 420
CTCTGGGAGA GCCTCTGGCC AGAAGGCCCA CCTTCTCCTG CCAACCCTGA AGAGAAATGA 480
CACCACTGC ATCGACTTCC ATTACTACTT CTCCAGCCGT GACAGGTCCA GCCCAGGGGC 540
CTTGAACGTC TACGTGAAGG TGAATGGTGG CCCCCAAGGG AACCCTGTGT GGAATGTGTC 600 55 CGGGGTCGTC ACTGAGGGCT GGGTGAAGGC AGAGCTCGCC ATCAGCACTT TCTGGCCACA 660 TTTCTATCAG GTGATATTTG AATCCGTCTC ATTGAAGGGT CATCCTGGCT ACATCGCCGT 720
GGACGAGGTC CGGGTCCTTG CTCATCCATG CAGAAAAGCA CCTCATTTTC TGCGACTCCA 780
AAACGTGGAG GTGAATGTGG GGCAGAATGC CACATTTCAG TGCATTGCTG GTGGGAAGTG 840 60 GTCTCAGCAT GACAAGCTTT GGCTCCAGCA ATGGAATGGC AGGGACACGG CCCTGATGGT 900 CACCCGTGTG GTCAACCATC AGGCGCTTCTC AGCCACAGTC AGTGTGGCAG ACACTGCCCA 960
CGGGAGCGTC AGCAACACAC GCCGCTTCTC AGCCACAGTC AGTGTGGCAG ACACTGCCCA 960
CTACGCGGAG CTGATCGTGA AAGAGCCTCC CACGCCCATT GCTCCCCCAG AGCTGCTGGC 1080
TGTGGGGGGCC ACATACCTGT GGATCAAGCC AAATGCCAAC TCCATCATCG GGGATGGCCC 1140
CATCATCCTG AAGGAAGTGG AATATCGCAC CACCACAGGC ACGTGGGCAG AGACCCACAT 1200 65 AGTCGACTCT CCCAACTATA AGCTGTGGCA TCTGGACCCC GATGTTGAGT ATGAGATCCG 1260
AGTCGCTCT CCCAACTATA AGCTGTGGCA TCTGGACCCC GATGTTGAGT ATGAGATCCG 1260
AGTGCTCCTC ACACGACCAG GTGAGGGGGG TACGGGACCG CCAGGGGCTC CCCTCACCAC 1320
CAGGACCAAG TGTGCAGATC CGGTACATGG CCCACAGAAC GTGGAAATCG TAGACATCAG 1380
AGCCCGGCAG CTGACCCTGC AGTGGGAGCC CTTCGGCTAC GCGGTGACCC GCTGCCATAG 1440 70 CTACAACCTC ACCGTGCAGT ACCAGTATGT GTTCAACCAG CAGCAGTACG AGGCCGAGGA 1500 GGTCATCCAG ACCTCCTCCC ACTACACCCT GCGAGGCCTG CGCCCCTTCA TGACCATCCG 1560 GCTGCGACTC TTGCTGTCTA ACCCCGAGGG CCGAATGGAG AGCGAGGAGC TGGTGGTGCA 1620 GACTGAGGAA GACGTTCCAG GAGCTGTTCC TCTAGAATCC ATCCAAGGGG GGCCCTTTGA 1680 GGAGAAGATC TACATCCAGT GGAAACCTCC CAATGAGACC AATGGGGTCA TCACGCTCTA 1740 75 CGAGATCAAC TACAAGGCTG TCGGCTCGCT GGACCCAAGT GCTGACCTCT CGAGCCAGAG 1800

GGGGAAAGTG TTCAAGCTCC GGAATGAAAC CCACCACCTC TTTGTGGGTC TGTACCCAGG 1860 GACCACCTAT TCCTTCACCA TCAAGGCCAG CACAGCAAAG GGCTTTGGGC CCCCTGTCAC 1920 CACTCGGATT GCCACCAAAA TTTCAGCTCC ATCCATGCCT GAGTACGACA CAGACACCCC 1980 ATTGAATGAG ACAGACACGA CCATCACAGT GATGCTGAAA CCCGCTCAGT CCCGGGGAGC 2040
TCCTGTCAGT GTTTATCAGC TGGTTGTCAA GGAGGAGCGA CTTCAGAAGT CACGGAGGGC 2100
AGCTGACATT ATTGAGTGCT TTTCGGTGCC CGTGAGCTAT CGGAATGCCT CCAGCCTCGA 2160
TTCTCTACAC TACTTTGCTG CTGAGTTGAA GCCTGCCAAC CTGCCTGTCA CCCAGCCATT 2220 5 TACAGTGGGT GACAATAAGA CATACAATGG CTACTGGAAC CCTCCTCTCT CTCCCCTGAA 2280 AAGCTACAGC ATCTACTTCC AGGCACTCAG CAAAGCCAAT GGAGAGACCA AAATCAACTG 2340 TGTTCGTCTG GCTACAAAAG CACCAATGGG CAGCGCCCAG GTGACCCCGG GGACTCCACT 2400 CTGCCTCCTC ACCACAGGTG CCTCCACCCA GAATTCTAAC ACTGTGGAGC CAGAGAAGCA 2460 10 GGTGGACAAC ACCGTGAAGA TGGCTGGCGT GATCGCTGGC CTCCTCATGT TCATCATCAT 2520 TCTCCTGGGC GTGATGCTCA CCATCAAAAG GAGAAGAAAT GCTTATTCCT ACTCCTATTA 2580 CTTGTCCCAA AGGAAGCTGG CCAAGAAGCA GAAGGAGACC CAGAGTGGAG CCCAGAGGGA 2640 15 GATGGGGCCT GTGGCCTCTG CCGACAAACC CACCACCAAG CTCAGCGCCA GCCGCAATGA 2700 TGAAGGCTTC TCTTCTAGTT CTCAGGACGT CAACGGATTC ACAGATGGCA GCCGCGGGGA 2760 GCTTTCCCAG CCCACCCTCA CGATCCAGAC TCATCCCTAC CGCACCTGTG ACCCTGTGGA 2820 GATGAGCTAC CCCCGGGACC AGTTCCAACT CGCCATCCGG GTGGCTGACT TGCTGCAGCA 2880 CATCACGCAG ATGAAGAGAG GCCAGGGCTA CGGGTTCAAG GAGGAATACG AGGCCTTACC 2940 AGAGGGGCAG ACAGCTTCGT GGGACACAGC CAAGGAGGAT GAAAACCGCA ATAAGAATCG 3000 ATATGGGAAC ATCATATCCT ACGACCATTC CCGGGTGAGG CTGCTGGTGC TGGATGGAGA 3060 20 CCCGCACTCT GACTACATCA ATGCCAACTA CATTGACGGA TACCATCGAC CTCGGCACTA 3120 CATTGCGACT CAAGGTCCGA TGCAGGAGAC TGTAAAGGAC TTTTGGAGAC GTCGCACTTA 3180
GGAGAACTCC GCCAGCATCA TGCAGGAGAC TGTAAAAGGAC TTTTTGGAGAA TGATCTGGCA 3180
GGAGAACTCC GCCAGCATCC TCATGGTCAC AAACCTGGTG GAAGTGGGCA GGGTGAAATG 3240
TGTGCGATAC TGGCCAGATG ACACGGAGGT CTACGGAGAC ATTAAAGTCA CCCTGATTGA 3300
AACAGAGCCC CTGGCAGAAT ACGTCATACG CACCTTCACA GTCCAGAAGA AAGGCTACCA 3360 25 TGAGATCCGG GAGCTCCGCC TCTTCCACTT CACCAGCTGG CCTGACCACG GCGTTCCCTG 3420 CTATGCCACT GGCCTTCTGG GCTTCGTCCG CCAGGTCAAG TTCCTCAACC CCCCGGAAGC 3480 TGGGCCCATA GTGGTCCACT GCAGTGCTGG GGCTGGGCGG ACTGGCTGCT TCATTGCCAT 3540
TGACACCATG CTTGACATGG CCGAGAATGA AGGGGTGGTG GACATCTTCA ACTGCGTGCG 3600
TGAGCTCCGG GCCCAAAGGG TCAACCTGGT ACAGACAGAG GAGCAATATG TGTTTGTGCA 3660 30 CGATGCCATC CTGGAAGCGT GCCTCTGTGG CAACACTGCC ATCCCTGTGT GTGAGTTCCG 3720 TTCTCTCTAC TACAATATCA GCAGGCTGGA CCCCCAGACA AACTCCAGCC AAATCAAAGA 3780 TGAATTTCAG ACCCTCAACA TTGTGACACC CCGTGTGCGG CCCGAGGACT GCAGCATTGG 3840 GCTCCTGCCC CGGAACCATG ATAAGAATCG AAGTATGGAC GTGCTGCCTC TGGACCGCTG 3900 CCTGCCCTTC CTTATCTCAG TGGACGGAGA ATCCAGCAAT TACATCAACG CAGCACTGAT 3960 GGATAGCCAC AAGCAGCCTG CCGCCTTCGT GGTCACCCAG CACCCTCTAC CCAACACCCGT 4020 GGCAGACTTC TGGAGGCTGG TGTTCGATTA CAACTGCTCC TCTGTGGTGA TGCTGAATGA 4080 GATGGACACT GCCCAGTTCT GTATGCAGTA CTGGCCTGAG AAGACCTCCG GGTGCTATGG 4140 GCCCATCCAG GTGGAGTTCG TCTCCGCAGA CATCGACGAG GACATCATCC ACAGAATATT 4200 40 CCGCATCTGT AACATGGCCC GGCCACAGGA TGGTTATCGT ATAGTCCAGC ACCTCCAGTA 4260 CATTGGCTGG CCTGCCTACC GGGACACGCC CCCCTCCAAG CGCTCTCTGC TCAAAGTGGT 4320 CCGACGACTG GAGAAGTGGC AGGAGCAGTA TGACGGGAGG GAGGGACGTA CTGTGGTCCA 4380 CTGCCTAAAT GGGGGAGGCC GTAGTGGAAC CTTCTGTGCC ATCTGCAGTG TGTGTGAGAT 4440 GATCCAGCAG CAAAACATCA TTGACGTGTT CCACATCGTG AAAACACTGC GTAACAACAA 4500 45 ATCCAACATG GTGGAGACCC TGGAACAGTA TAAATTTGTA TACGAGGTGG CACTGGAATA 4560 TTTAAGCTCC TTT<u>TAG</u>CTCA ATGGGATGGG GAACTGCCGG AGTCCAGAGG CTGCTGTGAC 4620 CAAGCCCCCT TTTGTGTGAA TGGCAGTAAC TGGGCTCAGG AGCTCTGAGG TGGCACCCTG 4680 CCTGACTCCA AGGAGAAGAC TGGTGGCCCT GTGTTCCACG GGGGGCTCTG CACCTTCTGA 4740 GGGGTCTCCT GTTGCCGTGG GAGATGCTGC TCCAAAAGGC CCAGGCTTCC TTTTCAACCT 4800 50 AACCAGCCAC AGCCAAGGGC CCAAGCAGAA GTACACCCAC AAGCAAGGCC TTGGATTTCT 4860 GGCTCCCAGA CCACCTGCTT TTGTTCTGAG TTTGTGGATC TCTTGGCAAG CCAACTGTGC 4920 AGGTGCTGGG GAGTGGGAGG CTCCCCTGCC CTCCTTCTCC TTAGGAGTGG AGGAGATGTG 4980 TGTTCTGCTC CTCTACGTCA TGGAAAAGAT TGAGGCTCTT GGGGGTCACT GCTCTGCTGC 5040 55 CCCCTGCAAC CTCCTTCAGG GGCCTCTGGC ACCAGACATT TGCAGTCTGG ACCAGTGTGA 5100 CCTTACGATG TTCCCTAGGC CACAAGAGAG GCCCCCCATC CTCACACCTA ACCTGCATGG 5160 GGCTTCGCCC ACAACCATTC TGTACCCCTT CCCCAGCCTG GGCCTTGACC GTCCAGCATT 5220 CACTGGCCGG CCAGCTGTGT CCACAGCAGT TTTTGATAAA GGTGTTCTTT GCTTTTTTGT 5280 GTGGTCAGTG GGAGGGGGTG GAACTGCAGG GAACTTCTCT GCTCCTCGTT GTCTTTGTAA 5340 60 AAAGGGACCA CCTCCCTGGG GCAGGGCTTG GGCTGACCTG TAGGATGTAA CCCCTGTGTT 5400 TCTTTGGTGG TAGCTTTCTT TGGAAGAGAC AAACAAGATA AGATTTGATT ATTTTCCAAA 5460 GTGTATGTGA AAAGAAACTT TCTTTTGGAG GGTGTAAAAT CTTAGTCTCT TATGTCAAAA 5520 AGAAGGGGC GGGGAGTTT GAGTATGTAC CTCTAAGACA AATCTCTCGG GCCTTTTATT 5580 TTTTCCTGGC AATGTCCTTA AAAGCTCCCA CCCTGGGACA GCATGCCACT GAGCAAGGAG 5640 65 AGATGGGTGA GCCTGAAGAT GGTCCCTTTG GTTTCTGGGG CAAATAGAGC ACCAGCTTTG 5700 TGCATAATTT GGATGTCCAA ATTTGAACTC CTTCCTAAAG AAACCCAGCA GCCACCTTGA 5760 AAAAGGCCAT TGTGGAGCCC ATTATACTTT GATTTAAAAT AGGCCAAGAG AATCAGGCCT 5820 GGAGATCTAG GGTCTTGTCC AAAGTGTGAG TGAGTCAATG AGAGGGAACC AACATTTGCT 5880 AAGTCTCTAC TGTATGCCAG GGATCATGCT TGGCACTTTC CATAGGACAT TTCACACAGT 5940 70 CCTTAGAACC CCCAGGAGAG AGCTACTGAC TTGTTATCAT CTCCATTTGA TCATCTCCTC 6000 CAATGAGGAA ACCACGCAC CTTCCTTAGT AATGAAATCC TGGGTTCCAA AGGGGCAGGT 6060
AATGGCAATG AGACTTCTCC GTGCTGTTTT CTTCATCTTC TCTAAGCCAA GCAATTATTT 6120
TATGGAGGGA AAATAAGGCC AGAAACTTCT GAGCAGATAA CTCCACAAAT GGAAATTAG 6180
TACTTTCTTC CTGATGCCAG TTCTTCTGGG AAGCGCAGAA TTTCAGATAT ATTTTAGTAA 6240 75 CACATTCCCA GCTCCCCAGG AAAGCCAGTC TCATCTAATT TCTTAGTCAG TAAAAACAAT 6300 TCCCTGTTCC TTCAGGCTAT GAATGGACCA GCCAGGGAAA CTCTCGACCT TGATCTCTAG 6360 CCAGTGCTTA GGCCCAATAT CTGACAGCCT CAGGTGGGCT GGGACCTAGG AAGCTCCATC 6420

TTGAAGGCTG GTCTAGCCCC AGACAGGGCA TGAGGGGCAG AGAATTCAAG AAGGTACAGC 6480 TTTGGCCCTC AAGAGCCCAC TGTATGCTGG GGAAATGGAA CCATGGTGCA GTAGTGTGGA 6540 GTGGATGAGT GTTCCATGAG CCTAGGAGCA AGAAAGTCTC TTCGGCCTCG GGCTTCCTGG 6600 AGAAGGGGAC GTCCATTCCT GCTGGGTCTT AACAAGCATA AAAAGGAAAA AAAGGAAACT 6660 5 CAGGCAAAGG GATCCATATG TGCAATGGCA AAGAAATGTG AAAAGGCATT GGGAGAAGCA 6720 GTCTGGGGGA GGCCAGCCCA GTGCGGGCAC AGCACAACAC GGGGAGCAGC AAGAGATGAG 6780 CCAGGGTCCA GGAGACAGAT GCCCATCGCG AGTACAGACT TTGTCCTATT GGCAACAAGG 6840 AGTCCATGGA GCTTTAGAGA GATGCACTCA GCTTCGTGTT GGCCAAGACT CCTTCTGGGC 6900 CAATGGGGCT GCCTCTTTTC CTTTCATCAG ACACTGTGAA AACATTCCCT TAAGCGTGCA 6960 10 CTITITAATA TCACATCTAT TTGTCTGTCT GCTCATTGTT TTGTTGCTGG AACTAAATAT 7020 GCAATGGATC ATGAGACTCA GATTCTATGA GAAACCCAGG GTCTCTGCTT TACCACGGAG 7080 CAGGGTCACC AACCCAGATC TCCAGGCCCA TGAGGATGGA ACATGAAAGG AGCCGACAAA 7140 AGTTGCTTCC ATTGGCATGG GCTCTGGAGC TGTCCAGAAG TCCAGGGACA CCAGACTTGA 7200 TCAAGGAAGG GCTGTCACTT TAGAGGTTCA AAAGGAAGTG CCTCAAAGCA AAGGCAAGCA 7260 15 AAGGAACCCC ACGATGAACT TGCTCTTTTC CTTTGATGAG CCTCTCCCCA GGTGTATTTC 7320 AGCAGACCCC GGGGACCCAC CCCCACTGGG CCTGCTGGCC TCCCTCGGCT CCAGCCCAAT 7380
GCCCCAGCTG GCCTTCCCCA GCCTGCAAGG AGCCTGTAGC ATGGCAAATC TGCCTGCTGT 7440
ATGCTATTTT CTTAGATCTT GGTACATCCA GACAGGATGA GGGTGGAGGG AGAGCTATTT 7500 AACACAAATC CTAAGATTTT TTTCTGCTCA GGAAGGGGTG AAATAGCTGG CAGATACAAA 7560 20 AGACAGTGGC TTTTATCATT TTAAATGGTA GGAATTTAAG GTGTGACTTC AGGGAGAAAC 7620 AAACTTGCAA AAAAAAAAA TCTCAGGCCA TGTTGGGGTA ACCCAGCAAG GGCCAGTGAT 7680 GATTTCCCCC AGCTCATCCC CTTATTTTCC CACAACCCAA CCATTCTCTA AAGCAGGACA 7740 GTGAATAGGT CTTAGGCCAG TGCACACAGG AAGAAATTGA GGCTTATGGA TGGGGATGAC 7800 TTCCCTAAGA TCCCATGGGA CAAGGATGTG GCAAGGCTTG GATGAGATGG GGCACCAGTG 7860 25 CCCAGGAATT TGAACATTTT CCTTTACCCA GGAAATCTCC GGAGCCAACA CCACCACCC 7920 CAGGGGGTCT CCCCACCCCA CCCCATTTAC AGGGTGAGCT CAGCCTGTCA TGAGCAGAGG 7980
AAAATATTAT TAATGCTCTC TGAGTCTTTA CAACAGGAGC TCTTACCTCA TAGATGTGGG 8040
CTCTGTTTGG GGAAGATGCA AGGAAGTAAT GAGAAGCCCA GGAAATTTCT CCACCTGTGT 8100 TTATGGCCTA AATAGCTTCA GGATGTATCT TAGCTGCACT CCAACATTGC ATCCTTTCTG 8160' 30 GGGTGAAGAA TCTGGGCCAA CCAGGGGTCC TTGGGCCTCT AGAAGGCCAC AGTAGGCCTC 8220 TCTTTGTGGG AATGGAAGGG GACAGTTTGC TTTTAGTGCT GGCCCTCTCT GTGGGTGTGG 8280 CCTGCAAAGG AACCAACAGA CCCTATGCTG GGGACTCTAA CATGTGAGCT CATTAAATTC 8340 TTCCAGCATT CTAAAGGAGG GTTTGTGATT GTCACCATTT ACTGATGAGG AAACTAAGGC 8400 TCCTAGGGGA GAAATCACTT GCCCACAGTT CCACAGCTAG TGAGTGAATG AACCAGGATT 8460 35 TAAACCGGTT TTTTCTCACT ACAGAGACAA TATTTTTCCA CCATTGTATC TCACATTTTT 8520
CCCAGGAGGT TACCCATAAC AGAAGAGACT AGAGTGGAAC AGATACGTCA GTGGATAAAG 8580
CTCAAAGCAA ACAACAGTAA GCTTAAAATT CCTTCATAGT CTCATGTTTT ACGTTCACAA 8640 TTCATGCAAA ATTTGCATTC CACTTTCTGA TTTAGCCTTG TTGGTTTTAA TATGACTCTA 8700 TATGACGGAC CCTAGGTCAG CTGGTCTTCA GCTTGACCT AGAATTGACT CTAGGAGCAG 8820
TGACCCTGCT GCCTCCCAGA GCCAGTTATA GGCTCAAGAT CAAGACCAAC TGACCTTCTC 8880
CTAGGCAGCT CCTTTGGTGT GTGGGTGCTC TGACCTCACT GTTCATGAGG GGACCTCAAC 8940 40 TAAGGCATCT TCCAGTTGGG TGCTGGAAGG AACCCATTAA CTCACACTAG AATGATGAGG 9000 ATTTGCTCAT CTGGCGTGGA GAAGGATGAG CCCACAAAAC CCTAAAGGGA AAAGAGAAGC 9060 TGGACACAGC TGTACTCAGC AGATTCCTGA ATGCTAGGCT GGAAAGTGGT GCCTGTTGTC 9120 CAAGTGGAGT CACATGGTTG CTAATGTGGG CAAGTCTGAG GACACACTTC ATGAGCAGCT 9180 45 GGGGTCTGGA AGGCTCCTCA CTTTACCCTA GCCACACATA ATTACTGGGT GCCTACAGCA 9240 CCTAGCACCT TGGAGGGGGC ACTATTAGGA AATCGAGATT ACTATGGCAC AATTAATTCC 9300 TGGGTAAGGC ATGGGGTTGT GGTGGACAGA GCTCAGTCTT TAGTTTGAAC GAAAACATAC 9360 ATACATGAAA AACATACATG AAAAAAGGAC CCTCATCAAC ATTAGAAGGG GTAGATTTGG 9420 AGCACTTTAG GCAGGAAAAC AGGAACGCAA GGCCAGGAAA CTGGAACCCA GTGAATACTC 9480 50 AGAACCGAGG ATGCAGATGA CTTATTTAGC AAAATGGTCA CTTCTGTGAC ATAGCTGGAG 9540 AAAGGATGGG TAACAGCTTG CCAGAGCCAC TTGGAACAAG GGCAAATCTC AGTGTCTGGG 9600 GCAAAAGATG ATGCATTTCC CTCTGACCCA TCATGTTTAT TCATCCTCCA CTCCCCATTG 9660 CCACACTAGC TCTTGCTGTA AGTCCTCACC AGGATCTACA TTTCCTCGTC GCTGGTGGGA 9720 ACCCCTTAGA GTACATAGAG GTATCAGTCC AGTAAGACTG CTCTACACAA CAGAAGTGAG 9780 55 GCCCAGGGAG TAGCAGCCAG GCCCTTATCC TGTTACCTCT GCAGGAGTGA CTGCCCAACC 9840 CAGATCCAGA GACATTGAAG GAAATGATAA TTCCTTGGTA CCTCACTGCC TTGGGACAAA 9900
ATGAAGAAAG CCACCCTTCC TTAGGCTGCA GCTTGCCACT CCTGGGCTGG GTAAACAGGT 9960
CATCAGCACC AGGCTCAACC AGGAGTAACA TTCTGGAAGA CATGGGTGAG CCCAAGAGGA 10020
AGCATGAACA GGACGCTGTT CCTAAGTCAT GTCAACAGGT TGTGCTGGGC CAGGATCCCC 10080 60 AGGGAAAAA ATGGTCAACC CAACTGGAGG GTAGGTTAGA AGAAAAAAA CATAAACGTG 10140 GATAGTCATG TCATCTCAAA TCCCTGACTT GGCTTCCCCA TTACTTGACA GTCTGAGCTC 10200 CTTCTTAGCC TGTGACCAGC TTCAAATCAC AGCCAAGTAA AACAAGGAAA TAGGAAAAGT 10260 AAATCCAACT AGAAGAGACA AGCTGAGATT CAGATTTGTT TACTCCTCCC ATGCAAAGTT 10320 65 TCCCTGTTGG AGGTTTTCCA TGTATACATG TCTAGAAGTG ATAGAATGCA AGGCCTTGGC 10380 TTTGTCTTGC AGGGATCTGC CTTTGAGGTC ATAGACTGAA CAGCAGGGAG AGAGGTTAGT 10440 GGTGGAGTGT GGGGGGAGCT GTTCTAGCTC CAGTTTCTTC TGACACATTT TTCAGGATCA 10500
TGGATCTGAT CCTCCGAAGC ACAGCAGAGA TATCTAAGCC ATATTTTGTGC ACATGAGCAG 10560
ACTCTTCTAG TTTTTTAGTA ACCAGGGATG GGCTTTTGCA TGGCACTGAC TATAGAGATG 10620 70 TCTTGTAGAG ATCAAGCCAG TCTTTTGCAT CCCACCTGCC CACCTCCAGA AGAGATGGGA 10680 AAAGGTCATC AAAGGGCATT CACCACCTGA AATCCACCTCA TGAATGTTAG GTCTCTAAAA 10740
GGAGGCATCA ACACTCACAA TGGTAGCCTC CAAACCTAGC ATCCCACCTA TCTAAGAGCT 10800
CAGGGGTGGT CCACTGGGGC AGATACAAGG GAAGTGCAAG GGCTCAGGAT GAAAGAAAAT 10860
CTATTGGGAA GAGTTTTAGG GGCTTGATCA TTATTGGGGCT TCCTTCTATA TCTGAGAACT 10920
GCTCTGGGTG GTGAGATGTG GACTCTGATC CTTAATTGGA ATGTTCGGAG AATGAGTGTC 10980 75 TGGTGGCCTT GAAGTGTTGG ACAGAAAAGT ATCAGTATAA AAGCCTGGAG CTCAGGGTAA 11040





Seq ID NO: 103 DNA sequence

31 51 5 GAGACATTCC TCAATTGCTT AGACATATTC TGAGCCTACA GCAGAGGAAC CTCCAGTCTC 60 AGCACCATGA ATCAAACTGC GATTCTGATT TGCTGCCTTA TCTTTCTGAC TCTAAGTGGC 120 ATTCA AGGAG TACCTCTCTC TAGAACCGTA CGCTGTACCT GCATCAGCAT TAGTAATCAA 180 CCTGTTAATC CAAGGTCTTT AGAAAAACTT GAAATTATTC CTGCAAGCCA ATTTTGTCCA 240 10 CGTGTTGAGA TCATTGCTAC AATGAAAAAG AAGGGTGAGA AGAGATGTCT GAATCCAGAA 300 TCGAAGGCCA TCAAGAATTT ACTGAAAGCA GTTAGCAAGG AAATGTCTAA AAGATCTCCT 360 TAAAACCAGA GGGGAGCAAA ATCGATGCAG TGCTTCCAAG GATGGACCAC ACAGAGGCTG 420 CCTCTCCCAT CACTTCCCTA CATGGAGTAT ATGTCAAGCC ATAATTGTTC TTAGTTTGCA 480 GTTACACTAA AAGGTGACCA ATGATGGTCA CCAAATCAGC TGCTACTACT CCTGTAGGAA 540 15 GGTTAATGTT CATCATCCTA AGCTATTCAG TAATAACTCT ACCCTGGCAC TATAATGTAA 600 GCTCTACTGA GGTGCTATGT TCTTAGTGGA TGTTCTGACC CTGCTTCAAA TATTTCCCTC 660 ACCTTTCCCA TCTTCCAAGG GTACTAAGGA ATCTTTCTGC TTTGGGGTTT ATCAGAATTC 720 TCAGAATCTC AAATAACTAA AAGGTATGCA ATCAAATCTG CTTTTTAAAG AATGCTCTTT 780 ACTTCATGGA CTTCCACTGC CATCCTCCCA AGGGGCCCAA ATTCTTTCAG TGGCTACCTA 840 20 CATACAATTC CAAACACATA CAGGAAGGTA GAAATATCTG AAAATGTATG TGTAAGTATT 900 CTTATTTAAT GAAAGACTGT ACAAAGTATA AGTCTTAGAT GTATATATTT CCTATATTGT 960 TTTCAGTGTA CATGGAATAA CATGTAATTA AGTACTATGT ATCAATGAGT AACAGGAAAA 1020 TTTTAAAAAT ACAGATAGAT ATATGCTCTG CATGTTACAT AAGATAAATG TGCTGAATGG 1080 TTTTCAAATA AAAATGAGGT ACTCTCCTGG AAATATTAAG 25 Seq ID NO: 104 <u>Protein sequence:</u>
Protein Accession #: NP_001556.1 41 21 31 30 MNQTAILICC LIFLTLSGIQ GVPLSRTVRC TCISISNQPV NPRSLEKLEI IPASQFCPRV 60 EIIATMKKKG EKRCLNPESK AIKNLLKAVS KEMSKRSP Seq ID NO: 105 DNA sequence 35 NM 015068.1 Nucleic Acid Accession #: Coding sequence: 1170-2243 (underlined sequences correspond to start and stop codons) 41 40 GTAACAACCG TCACCCTGGG TCCCGACTGC CCACCTCCTC CTCCTCCCCC TCCCCCCAAC 60 AACAACAACA ACAACACTC CAAGCACACC GGCCATAAGA GTGCGTGTGT CCCCAACATG 120 ACCGAACGAA GAAGGGACGA GCTCTCTGAA GAGATCAACA ACTTAAGAGA GAAGGTCATG 180 AAGCAGTCGG AGGAGAACAA CAACCTGCAG AGCCAGGTGC AGAAGCTCAC AGAGGAGAAC 240 ACCACCCTTC GAGAGCAAGT GGAACCCACC CCTGAGGATG AGGATGATGA CATCGAGCTC 300 CGCGGTGCTG CAGCAGCTGC TGCCCCACCC CCTCCAATAG AGGAAGAGTG CCCAGAAGAC 360 45 CTCCCAGAGA AGTTCGATGG CAACCCAGAC ATGCTGGCTC CTTTCATGGC CCAGTGCCAG 420 ATCTTCATGG AAAAGAGCAC CAGGGATTTC TCAGTTGATC GTGTCCGTGT CTGCTTCGTG 480 ACAAGCATGA TGACCGGCCG TGCTGCCCGT TGGGCCTCAG CAAAGCTGGA GCGCTCCCAC 540 TACCTGATGC ACAACTACCC AGCTTTCATG ATGGAAATGA AGCATGTCTT TGAAGACCCT 600 CAGAGGCGAG AGGTTGCCAA ACGCAAGATC AGACGCCTGC GCCAAGGCAT GGGGTCTGTC 660 50 ATCGACTACT CCAATGCTTT CCAGATGATT GCCCAGGACC TGGATTGGAA CGAGCCTGCG 720 CTGATTGACC AGTACCACGA GGGCCTCAGC GACCACATTC AGGAGGAGCT CTCCCACCTC 780 GAGGTCGCCA AGTCGCTGTC TGCTCTGATT GGGCAGTGCA TTCACATTGA GAGAAGGCTG 840
GCCAGGGCTG CTGCAGCTCG CAAGCCACGC TCGCCACCC GGGCGCTGGT GTTGCCTCAC 900
ATTGCAAGCC ACCACCAGGT AGATCCAACC GAGCCGGTGG GAGGTGCCCG CATGCGCCTG 960 55 ACGCAGGAAG AAAAAGAAAG ACGCAGAAAG CTGAACCTGT GCCTCTACTG TGGAACAGGA 1020 GGTCACTACG CTGACAATTG TCCTGCCAAG GCCTCAAAGT CTTCGCCGGC GGGAAACTCC 1080
CCGGCCCCGC TGTAGAGGGA CCTTCAGCGA CCGGCCAGA AATAATAAGG TCCCCACAAG 1140
ATGATGCCTC ATCTCCACAC TTGCAAGTGA TGCTCCAGAT TCATCTTCCG GGCAGACACA 1200
CCCTGTTCGT CCGAGCCATG ATCGATTCTG GTGCTTCTGG CAACTTCATT GATCACGAAT 1260 60 ATGTTGCTCA AAATGGAATT CCTCTAAGAA TCAAGGACTG GCCAATACTT GTGGAAGCAA 1320 ATTGATGGGCG CCCCATAGCA TCGGGCCCAG TTGTCCACGA AACTCACGAC CTGATAGTTG 1380
ACCTGGGAGA TCACCGAGAG GTGCTGTCAT TTGATGTGAC TCAGTCTCCAT TTCTTCCCTG 1440
TCGTCCTAGG GGTTCGCTGG CTGAGCACAC ATGATCCCAA TATCACATGG AGCACTCGAT 1500
CTATCGTCTT TGATTCTGAA TACTGCCGCT ACCACTGCCG GATGTATTCT CCAATACCAC 1560 65 CATCGCTCCC ACCACCAGCA CCACAACCGC CACTCTATTA TCCAGTAGAT GGATACAGAG 1620 TTTACCAACC AGTGAGGTAT TACTATGTCC AGAATGTGTA CACTCCAGTA GATGAGCACG 1680
TCTACCCAGA TCACCGCCTG GTTGACCCTC ACATAGAAAT GATACCTGGA GCACACAGTA 1740
TTCCCAGTGG ACATGTGTAT TCACTGTCCG AACCTGAAAT GGCAGCTCTT CGAGATTTTG 1800 70 TGGCAAGAAA TGTAAAAGAT GGGCTAATTA CTCCAACGAT TGCACCTAAT GGAGCCCAAG 1860 TTCTCCAGGT GAAGAGGGGG TGGAAACTGC AAGTTTCTTA TGATTGCCGA GCTCCAAACA 1920 ATTTTACTAT CCAGAATCAG TATCCTCGCC TATCTATTCC AAATTTAGGAA GACCAAGCAC 1980
ACCTGGCAAC GTACACTGAA TTCGTACCTC AAATACCTGG ATACCAAACA TACCCCACAT 2040
ATGCCGCGTA CCCGACCTAC CCAGTAGGAT TCGCCTGGTA CCCAGTGGGA CGAGACGGAC 2100 75 AAGGAAGATC ACTATATGTA CCTGTGATGA TCACTTGGAA TCCACACTGG TACCGCCAGC 2160 CTCCGGTACC ACAGTACCCG CCGCCACAGC CGCCGCCTCC ACCACCACCA CCGCCGCCGC 2220 CTCCATCTTA CAGTACCCTG TAAATACCTG TCATGTCCTT CAGGATCTCT GCCCTCAAAA 2280

NM 001565.1 Coding sequence: 67-363 (underlined sequences correspond to start and stop codons)

Nucleic Acid Accession #:

TTTATTCCTG TTCAGCTTCT CAATCAGTGA CTGTGTGCTA AATTTTAGGC TACTGTATCT 2340 TCAGGCCACC TGAGGCACAT CCTCTCTGAA ACGGCTATGG AAGGTTAGGG CCACTCTGGA 2400 CTGGCACACA TCCTAAAGCA CCAAAAGACC TTCAACATTT TCTGAGAGCA ACAGAGTATT 2460 TGCCAATAAA TGATCTCCA TTTTTCCACC TTGACTGCCA ATCTAACTAA AATAATTAAT 2520 AAGTTTACTT TCCAGCCAGT CCTGGAAGTC TGGGTTTTAC CTGCCAAAAC CTCCATCACC 2580 ATCTAAATTA TAGGCTGCCA AATTTGCTGT TTAACATTTA CAGAGAAGCT GATACAAACG 2640 5 CAGGAAATGC TGATTTCTTT ATGGAGGGGG AGACGAGGAG GAGGAGGACA TGACTTTCT 2700 TGCGGTTTCG GTACCCTCTT TTTAAATCAC TGGAGGACTG AGGCCTTATT AAGGAAGCCA 2760 AAATTATCGG TGCAGTGTGG AAAGGCTTCC GTGATCCTCT CGCTGCACCC TTAGAAACTT 2820 CACCGTCTTC AAACTCCATT TCCATGGTTC TGTTAATTCT CAAGGAGCAG CAACTCGACT 2880 GGTTCTCCCA GGAGCAGGAA AAACCCTTGT GACATGAAAC ATCTCAGGCC TGAAAAGAAA 2940 10 GTGCTCTCTC AGATGGACTC TTGCATGTTA AGACTATGTC TTCACATCAT GGTGCAAATC 3000 ACATGTACCC AATGACTCCG GCTTTGACAC AACACCTTAC CATCATCATG CCATGATGGC 3060 TTCCACAAAG CATTAAACCT GGTAACCAGA GATTACTGGT GGCTCCAGCG TTGTTAGATG 3120 TTCATGAAAT GTGACCACCT CTCAATCACC TTTGAGGGCT AAAGAGTAGC ACATCAAAAG 3180 15 GACTCCAAAA TCCCATACCC AACTCTTAAG AGATTTGTCC TGGTACTTCA GAAAGAATTT 3240 TCATGAGTGT TCTTAATTGG CTGGAAAAGC ACCAGCTGAC GTTTTGGAAG AATCTATCCA 3300 TGTGTCTGCC TCCATATGCA TCTGGGCATT TCATCTTCAG TCCCCTCATT AGACTGTAGC 3360 ATTAGGATGT GTGGAGAGAG GAGAAATGAT TTAGCACCCA GATTCACACT CCTATGCCTG 3420 GAAGGGGGAC ATCTTTGAAG AAGAGGAATT AGGGCTGTGG ACACTGTCTT GAGGATGTGG 3480 20 ACTTCCTTAG TGAGCTCCAC ATTACTTGAT GGTAACCACT TCAAAAGGAT CAGAATCCAC 3540 GTAATGAAAA AGGTCCCTCT AGAGGATGGA GCTGATGTGA AGCTGCCAAT GGATGAAAAG 3600 CCTCAGAAAG CAACTCAAAG GACTCAAAGC AACGGACAAC ACAAGAGTTG TCTTCAGCCC 3660
AGTGACACCT CTGATGTCCC CTGGAAGCTT TGTGCTAACC TGGGACTGCC TGACTTCCTT 3720
TAGCCTGGTC CCTTGCTACT ACCTTGAACT GTTTTATCTA ACCTCTCTT TTCTGTTTAA 3780
TTCTTTGCTA CTGCCATTGA CCCTGCTGCA GGATTTGTGT CATTTTCCTG CCTGGTTGCT 3840 25 GAGACTCCAT TTTGCTGCCA CACACAGAGA TGTAAGAGGC AGGCTTTAAT TGCCAAAGCA 3900 CAGTTTGAGC AGTAGAAAAC AACATGGTGT ATATCTCAAA TTGCCTGACA TGAAGAGGAG 3960 TCTAACGGTG AAGTTTCACT TTTCATCAGC ATCATCTTTC ACATGTTCAT TATCATCCGC 4020 TCTTATTCTT GCATGTTTAA ACACTTAAAA TTTTTAGTAT AATTTTTAGT GTGTTTTGAA 4080 30 GTGGTGACTA GGCTTTCAAA AACTTCCATT GAATTACAAA GCACTATCCA GTTCTTATTG 4140 TTAAACTAAG TAAAAATGAT AAGTAACATA GTGTAAAATA TTCCTTTACT GTGAACTTCT 4200 TACAATGCTG TGAATGAGAG GCTCCTCAGA ACTGGAGCAT TTGTATAATA ATTCATCCTG 4260 TTCATCTTCA ATTITAACAT CATATATAAT TTCAATTCTA TCAATTGGGC CTTTAAAAAT 4320 CATATAAAAG GATATAAAAT TTGAAAAGAG AAACCTAATT GGCTATTTAA TCCAAAACAA 4380 35 CTTTTTTTT TCCTTCAATG GAATCAGAAA GCTTGTCAAT CACTCATGTG TTTTAGAGTA 4440 ATTACTTTTA AAATGGTGCA TTTGTGCTTC TGAACTATTT TGAAGAGTCA CTTCTGTTTA 4500 CCTCAAGTAT CAATTCATCC TCCATACATT TGAATTCAAG TTGTTTTTTG TCAAATTTAC 4560 AGTTGTCAAT TGATCTTCAA GCTGCAGGGT GCCTAGAAAT GGGCCGTTGT CTGTAGCCCT 4620 40 GGCATGTGCA CACGGACATT TGCCACCACT GCAAGCAAAA GTCTGGAGAA GTTCACCAAC 4680 GACAAGAACG ATTAGGGAAA ATATGCTGCT GTGGGTTAAC AACTCAGAAA GTCCCTGATC. 4740 CACATTTGGC TGTTTACTAA AGCTTGTGAT TAACTTTTTG GCAGTGTGTA CTATGCTCTA 4800 TTGCTATATA TGCTATCTAT AAATGTAGAT GTTAAGGATA AGTAATTCTA AATTTATTAT 4860 TCTATAGTTT TGAAGTTTGG TTAAGTTTCC TTTCACTCAA TTGATTTATT TTGTTGTTAA 4920 TCAAATTTAT GTTAATTGGA TCCTTTAAAT TTTTTTTGGC ATTTTCCAAC AAAAATGGCT 4980 45 TTATTCATAA GAAAGGAAAA AAATCAATGG AATTTGATAT CTAAAGAAGT TAGAAAGGGA 5040 GCAAAATAAA AAACATAAAG GAGATAGATG AATTAGTAAG CAAATCAGTA GTCGAGTTTT 5100 TCAAACTGGC AAAATTAATT AATTGACTTT TAGCCCAAAT TTACATTGTT AATTAAATCA 5160 AGAAGGAAGA AGATCTAAGA GCTCCCATTG ATAGGCAAGC CTAGAGAGAA CTAGCTAAAT 5220 50 TTATCATGCT AGGATATTGA AACACAGAAA GTTTACATAC ATTTATGAAG GGTCAATTTA 5280 GTTTGGACAG TGAGGTATTT GTCTTAGTGG AAAAAAGGAG AATTAGTCTG ATCAAATCGT 5340 GAAGTAATAC AGTGAACTTG CAGGTGCACA AAATAAGAGG GCCACATCTA TATGGTGCAG 5400 TCTGGAATTC TGTTTAAGTT TGTAGGTACC TCTTGGACTT CTGAATTGAT CCAGTTGTCA 5460 TCCACCACAG ACATCTCACA TCAGATACAG ACAGTTCCAA GATTGACAAC AGAGAACAAC 5520 55 CTGCTGGAAA GACCTGGGCA GAAATGGAGA GCCCTGCGGG AACCATGCTA CATTTTCATC 5580 TAAAGAGAGA ATGCACATCT GATGAGACTG AAAGTTCTTT GTTGTTTTAG ATTGTAGAAT 5640 GGTATTGAAT TGGTCTGTGG AAAATTGCAT TGCTTTTATT TCTTTGTGTA ATCAAGTTTA 5700 AGTAATAGGG GATATATAAT CATAAGCATT TTAGGGTGGG AGGGACTATT AAGTAATTTT 5760 AAGTGGGTGG GGTTATTTAG AATGTTAGAA TAATATTATG TATTAGATAT CGCTATAAGT 5820 60 GGACATGCGT ACTTACTTGT AACCCTTTAC CCTATAATTG CTATCCTTAA AGATTTCAAA 5880 TAAACTCGGA GGGAACTGCA GGGAGACCAA CTTATTTAGA GCGAATTGGA CATGGATAAA 5940 AACCCCAGTG GGAGAAAGTT CAAAGGTGAT TAGATTAATA ATTTAATAGA GGATGAGTGA 6000 CCTCTGATAA ATTACTGCTA GAATGAACTT GTCAATGATG GATGGTAAAT TTTCATGGAA 6060 GTTATAAAAG TGATAAATAA AAACCCTTGC TTTTACCCCT GTCAGTAGCC CTCCTCCTAC 6120 65 CACTGAACCC CATTGCCCCT ACCCCTCCTT CTAACTTTAT TGCTGTATTC TCTTCACTCT 6180 ATATTTCTCT CTATTTGCTA ATATTGCATT GCTGTTACAA TAAAAATTCA ATAAAGATTT 6240 AGTGGTTAAG TGC Seq ID NO: 106 <u>Protein sequence:</u>
Protein Accession #: NP_055883.1 70 51 MTERRADELS EEINNLREKV MKQSEENNNL QSQVQKLTEE NTTLREQVEP TPEDEDDDIE 60 75 LRGAAAAAP PPPIEEECPE DLPEKFDGNP DMLAPFMAQC QIFMEKSTRD FSVDRVRVCF 120 VTSMMTGRAA RWASAKLERS HYLMHNYPAF MMEMKHVFED PQRREVAKRK IRRLRQGMGS 180 VIDYSNAFQM IAQDLDWNEP ALIDQYHEGL SDHIQEELSH LEVAKSLSAL IGQCIHIERR 240

LARAAAARKP RSPPRALVLP HIASHHQVDP TEPVGGARMR LTQEEKERRR KLNLCLYCGT 300 GGHYADNCPA KASKSSPAGN SPAPL

NM 003679.1

Seq ID NO: 107 DNA sequence


Nucleic Acid Accession #:


5

Coding sequence: 47-1507(underlined sequences correspond to start and stop codons) 51 10 GGCACGAGCA GAAGCAACAA TAATTGTGAA AAATACTTCA GCAGTT<u>ATG</u>G ACTCATCTGT 60 CATTCAAAGG AAAAAAGTAG CTGTCATTGG TGGTGGCTTG GTTGGCTCAT TACAAGCATG 120 CITTCTTGCA AAGAGGAATT TCCAGATTGA TGTATATGAA GCTAGGGAAG ATACTCGAGT 180 GGCTACCTTC ACACGTGGAA GAAGCATTAA CTTAGCCCTT TCTCATAGAG GACGACAAGC 240 CCCCAATGTG AAAATGCACT TTAACCACAG GCTGTTGAAA TGTAATCCAG AGGAAGGAAT 480 15 GATCACAGTG CTTGGATCTG ACAAAGTTCC CAAAGATGTC ACTTGTGACC TCATTGTAGG 540
ATGTGATGGA GCCTATTCAA CTGTCAGATC TCACCTGATG AAGAAACCTC GCTTTGATTA 600
CAGTCAGCAG TACATTCCTC ATGGGTACAT GGAGTTGACT ATTCCACCTA AGAACGGAGA 660
TTATGCCATG GAACCTAATT ATCTGCATAT TTGGCCTAGA AATACCTTTA TGATGATTGC 720 20 ACTTCCTAAC ATGAACAAAT CATTCACATG TACTTTGTTC ATGCCCTTTG AAGAGTTTGA 780 AAAACTTCTA ACCAGTAATG ATGTGGTAGA TTTCTTCAG AAATACTTTC CGGATGCCAT 840 CCCTCTAATT GGAGAGAAAC TCCTAGTGCA AGATTTCTTC CTGTTGCCTG CCCAGCCCAT 900 GATATCTGTA AAGTGCTCTT CATTTCACTT TAAATCTCAC TGTGTACTGC TGGGAGATGC 960 25 AGCTCATGCT ATAGTGCCGT TTTTTGGGCA AGGAATGAAT GCGGGCTTTG AAGACTGCTT 1020 GGTATTTGAT GAGTTAATGG ATAAATTCAG TAACGACCTT AGTTTGTGTC TTCCTGTGTT 1080 CTCAAGATTG AGAATCCCAG ATGATCACGC GATTTCAGAC CTATCCATGT ACAATTACAT 1140 AGAGATGCGA GCACATGTCA ACTCAAGCTG GTTCATTTTT CAGAAGAACA TGGAGAGATT 1200 TCTTCATGCG ATTATGCCAT CGACCTTTAT CCCTCTCTAT ACAATGGTCA CTTTTTCCAG 1260 30 AATAAGATAC CATGAGGCTG TGCAGCGTTG GCATTGGCAA AAAAAGGTGA TAAACAAAGG 1320 ACTCTTTTTC TTGGGATCAC TGATAGCCAT CAGCAGTACC TACCTACTTA TACACTACAT 1380 GTCACCACGA TCTTTCCTCT GCTTGAGAAG ACCATGGAAC TGGATAGCTC ACTTCCGGAA 1440
TACAACATGT TTCCCCGCAA AGGCCGTGGA CTCCCTAGAA CAAATTTCCA ATCTCATTAG 1500
CAGGTGATAG AAAGGTTTTG TGGTAGCAAA TGCATGATTT CTCTGTGACC AAAATTAAGC 1560 35 ATGAAAAAA TGTTTCCATT GCCATATTTG ATTCACTAGT GGAAGATAGT GTTCTGCTTA 1620 TAATTAAACT GAATGTAGAG TATCTCTGTA TGTTAATTGC AATTACTGGT TGGGGGGTGC 1680 ATTITAAAAG ATGAAACATG CAGCTTCCCT ACATTACACA CACTCAGGTT GAGTCATTCT 1740 AACTATAAAA GTGCAATGAC TAAGATCCTT CACTTCTCTG AAAGTAAGGC CCTAGATGCC 1800 40 TCAGGGAAGA CAGTAATCAT GCCTTTTCTT TAAAAGACAC AATAGGACTC GCAACAGCAT 1860 TGACTCAACA CCTAGGACTA AAAATCACAA CTTAACTAGC ATGTTAACTG CACTTTTCAT 1920 TACGTGAATG GAACTTACCT AACCACAGGG CTCAGACTTA CTAGATAAAA CCAGAAATGG 1980 AAATAAGGAA TTCAGGGGAG TTCCAGAGAC TTACAAAATG AACTCATTTT ATTTTCCCAC 2040 CTTCAAATAT AAGTATTATC ATCTATCTGT TTATCGTCTA TCTATCTATC ATCTATCTAT 2100 45 TCTATTTATT TATGTATTTA GAGATCAGGT CTCACTCTGT TGACCAGGCT GGAGTGCAGT 2220 GGTGAGATCT GGGTTCACTG CAACCTCTGC CTCCTGGGCT CAAGCAATCC TCCCACTTCA 2280 GCCTCCCAAA TAGCTGGGGC TACCATGGTA TTTTTCAGTA GAGACCGGT CTTGCCATGC 2340
TGCCCAGGCC AGTCTCAAAC TCCTGGCCTC ATGTGATCTG CCCACCTCAG CCTCCCAAAG 2400 50 TACAGGGATT AGAGTTGTGA GCCACCGCTG CCAGCCCAGA GTTACCCTCT AAAGATAAGA 2460 AAAAGGCTAT TAATATCATA CTAAGTGAAG GACAGGAAAG GGTTTTATTC ATAAATTAAA 2520
TGTCTACATG TGCCAGAATG GAAAGGAAAC AAGGGGAGAC AACTTTTATA GAAATACAAA 2580
GCCATTACTT TATTCAATTT CAGACCCTCA GAAGCAATTT ACTAATTTAT TCTTCGACTA 2640
CATACTGCAG CAGAACCAGC AATACACTTG ATTTTTAAAA GCACATTTAG TGAAATGTTT 2700 55 TCTTTGGTTC ATCCTTCTTT AACAGGCTGC TGAGTCACTC AGAAATCCTT CAAACATGAT 2760 GGGCCCCTAT AACAAAAGAC AGATTGACAA GAGAAAAACA AACATAAATT TATTAGCGGG 3000 60 TATATGTAAT ATATATGTGG GAAATACAGG GGAATGAGCA AATCTCAAAG AGCTGGCGTC 3060 TTAGAACTCC CTGGCTTATA TAGCATCGAC AAAGAACAGT AAATTTTTAG AGAAACAACA 3120 AAACAAAGAA AAAGAGCTTT GAGTCTGTAG GGGCAGCAAT TTGGGGGAG CAAATATATG 3180
GGAGTTTGCC TTGTAGATTC CTCTGGTGGT GGTCTCCAGG CTGACAAGGA TTCAAAGTTG 3240
TCTCTGAAAC TCCTCTTTGT CATACTGCAC ATATAAAACG TCTTTTGTT CCAACAAGAG 3300 65 GATTTCTTTT TCATTCTAGA ATTATCTCCT TGATAACTTG ATCAGATATA GGACATGACA 3360 CTGAATAGAG TCCAACAGTA CAAAAAAAAT TCAGTATGTT CTAGCTACTT CACACATGTG 3420 TACGCGACAG TTATTTTTAC AGTAAGGTAT TTTCGAGAAA AATGCATTAC GTGTTTTGGA 3480 AAATAGAGTA ATTTAAAAAA TATATTTGAA ATGAAAATCT CCAACACATT AGAAGATGAT 3540 GATGTTAGAT GCCCATCGTG TGCCACAAGT GGTTTTTTCA TTATGTAAAG CACCCGTTGA 3600 70 ATTAAAAGAA TTTGTTTTTG TTCAACCTCT TCCTGAGGCC CAAGAGCATA TGGGCAATTC 3660 GGATTTCCTG CTGGACCACA AGGTTCTGTT GATATTACAT AGAAACGGGT ATTCCAGACA 3720 CTTCTTATGA TGAAAGTCCA AAAGTGGCAT CCAATTTAAG GCCCCATCTT TCGTTGCCAT 3780 TCTTCATTCC TACAAAGGAC GAACTTGGAT TACATCAACT TTGGACCCAT TGGTTTTGTC 3840 GCTGTCGTCA ACTGACAGTG ATTCACCACT GGTGATGATA AAAATGATGG AAGAAGAGTT 3900 75 GAAAGTCACT TTTTTCTTTG GCCTGTCCCC ATCTTTCTGT GACATCACAA TGGGTCTGAT 3960 CTGCATTTCA CTTCCAGCTG CTGGTAGGTC TTTAGCAGGC CTCTGGCACC TCAGCAGTCG 4020 GAGGCACAGA AGCTGCAAAA GGGATCTTCG AAACTGGGCA GAGAAAAAAT AAAGTGGAAT 4080

ATTAAGTAAA AGTTGGGCAC TAATCTGGAT TAACATTCGA GGAAATCAGT TGAGCTGATT 4140 TAAGTTGTTT TTTGTTTGTT AGCAGGTGTG GATGTGGGGT TATGTGGTCA TGCTCAGATC 4200 TACCTAAATC ACCCCAGAGC TTTATGTCTT TTATTCATTC TAAATCTTAT TAACCGGAAT 4260 ATGTAGGACC ATTTCAATAC CTTGTAATCC TCCAAGCTTC AATCTGCACA CACTTTCTAT 4320 5 GAGGGCAGGT ACAACTATTA AGAGATTTTG AACATTAAGT TAGTCCACAA ATATTCAGTG 4380 GGCATCTACT AGGTGACAGC CACTGTGCTA TAATTAGAGA CTTTTTACTA TAAGCATCAA 4440 AAACAGATAA GGCTCTTCCT GGCAGAGTTT ACAGCCTGGT GTACTTGCTA ATGTCTCTTT 4500 AATTAGGTGA AGAATTTTTT TTTTCTATCG AAATTACTAA TCAGTTGGGG AAAAAAATAC 4560 TATAGCAGAC AGCACTA ATG TCATCA ACAA ACATTGTTCT TCTCCGTGTC CTGGGTACAA 4620 10 CATCGAATAA TATTTCTTGG CCTCCTTTCC GCTTCTCCTC TCTGCTGTTC CTCTCTACAA 4680 GAACCTGGGA GGCCAACGCC TAAAGATCAT AATATCACAA TGGAAGGAAC CTAGATTCCT 4740 AAATGACTGC ATAGGACAGA TCCCATCTCC TCCACCCAAT ACATTATTAG ACTGAACTGT 4800 GACCTGAAAT GAGCAATAAA CTCTGTATTA ATTCACTGAA ATGTTGGGGT TGCTTGTTAT 4860 AGTAGTCGGT CCATCATGAC CAGTAAAACA TAAATCAAAA GTTAATGTAA TTGTTATCCC 4920 15 ATTATTTAGA GCGAAATAAA TGTTGAATAT ATGGACTTTC TCAGATTAGG AAATACCAAT 4980 ТАААААТАТА АТАААТАССТ Seq ID NO: 108 Protein sequence: Protein Accession #: NP_003670.1 20 31 41 MDSSVIQRKK VAVIGGGLVG SLQACFLAKR NFQIDVYEAR EDTRVATFTR GRSINLALSH 60 RGRQALKAVG LEDQIVSQGI PMRARMIHSL SGKKSAIPYG TKSQYILSVS RENLNKDLLT 120 25 AAEKYPNVKM HFNHRLLKCN PEEGMITVLG SDKVPKDVTC DLIVGCDGAY STVRSHLMKK 180 PRFDYSQQYI PHGYMELTIP PKNGDYAMEP NYLHIWPRNT FMMIALPNMN KSFTCTLFMP 240 FEEFEKLLTS NDVVDFFQKY FPDAIPLIGE KLLVQDFFLL PAQPMISVKC SSFHFKSHCV 300 LLGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFSNDLSL CLPVFSRLRI PDDHAISDLS 360 MYNYIEMRAH VNSSWFIFQK NMERFLHAIM PSTFIPLYTM VTFSRIRYHE AVQRWHWQKK 420 30 VINKGLFFLG SLIAISSTYL LIHYMSPRSF LCLRRPWNWI AHFRNTTCFP AKAVDSLEQI 480 SNLISR Seq ID NO: 109 DNA sequence Nucleic Acid Accession # NM_006115.1 35 Coding sequence: 236-1765 (underlined sequences correspond to start and stop codons) 31 21 41 51 GCTTCAGGGT ACAGCTCCCC CGCAGCCAGA AGCCGGGCCT GCAGCCCCTC AGCACCGCTC 60 40 CGGGACACCC CACCCGCTTC CCAGGCGTGA CCTGTCAACA GCAACTTCGC GGTGTGGTGA 120 ACTCTCTGAG GAAAAACCAT TTTGATTATT ACTCTCAGAC GTGCGTGGCA ACAAGTGACT 180 GAGACCTAGA AATCCAAGCG TTGGAGGTCC TGAGGCCAGC CTAAGTCGCT TCAAAATGGA 240 ACGAAGGCGT TTGTGGGGTT CCATTCAGAG CCGATACATC AGCATGAGTG TGTGGACAAG 300 CCCACGGAGA CTTGTGGAGC TGGCAGGGCA GAGCCTGCTG AAGGATGAGG CCCTGGCCAT 360 TGCCGCCCTG GAGTTGCTGC CCAGGGAGCT CTTCCCGCCA CTCTTCATGG CAGCCTTTGA 420 CGGGAGACAC AGCCAGACCC TGAAGGCAAT GGTGCAGGCC TGGCCCTTCA CCTGCCTCCC 480 45 TCTGGGAGTG CTGATGAAGG GACAACATCT TCACCTGGAG ACCTTCAAAG CTGTGCTTGA 540 TGGACTTGAT GTGCTCCTTG CCCAGGAGGT TCGCCCCAGG AGGTGGAAAC TTCAAGTGCT 600 GGATTTACGG AAGAACTCTC ATCAGGACTT CTGGACTGTA TGGTCTGGAA ACAGGGCCAG 660 TCTGTACTCA TTTCCAGAGC CAGAAGCAGC TCAGCCCATG ACAAAGAAGC GAAAAGTAGA 720 TGGTTTGAGC ACAGAGGCAG AGCAGCCCTT CATTCCAGTA GAGGTGCTCG TAGACCTGTT 780 50 CCTCAAGGAA GGTGCCTGTG ATGAATTGTT CTCCTACCTC ATTGAGAAAG TGAAGCGAAA 840 GAAAAATGTA CTACGCCTGT GCTGTAAGAA GCTGAAGATT TTTGCAATGC CCATGCAGGA 900
TATCAAGATG ATCCTGAAAA TGGTGCAGCT GGACTCTATT GAAGATTTTGG AAGTGACTTG 960
TACCTGGAAG CTACCCACCT TGGCGAAATT TTCTCCTTAC CTGGGCCAGA TGATTAATCT 1020
GCGTAGACTC CTCCTCCCC ACATCCATGC ATCTTCCTAC ATTTCCCCGG AGAAGGAAGA 1080 55 GCAGTATATC GCCCAGTTCA CCTCTCAGTT CCTCAGTCTG CAGTGCCTGC AGGCTCTCTA 1140 TGTGGACTCT TTATTTTTCC TTAGAGGCCG CCTGGATCAG TTGCTCAGGC ACGTGATGAA 1200 CCCCTTGGAA ACCCTCTCAA TAACTAACTG CCGGCTTTCG GAAGGGGATG TGATGCATCT 1260 GTCCCAGAGT CCCAGCGTCA GTCAGCTAAG TGTCCTGAGT CTAAGTGGGG TCATGCTGAC 1320 60 CGATGTAAGT CCCGAGCCCC TCCAAGCTCT GCTGGAGAGA GCCTCTGCCA CCCTCCAGGA 1380 CCTGGTCTTT GATGAGTGTG GGATCACGGA TGATCAGCTC CTTGCCCTCC TGCCTTCCCT 1440
GAGCCACTGC TCCCAGCTTA CAACCTTAAG CTTCTACGGG AATTCCATCT CCATATCTGC 1500
CTTGCAGAGT CTCCTGCAGC ACCTCATCGG GCTGAGCAAT CTGACCCACG TGCTGTATCC 1560
TGTCCCCCTG GAGAGTTATG AGGACATCCA TGGTACCCTC CACCTGGAGA GGCTTGCCTA 1620 65 TCTGCATGCC AGGCTCAGGG AGTTGCTGTG TGAGTTGGGG CGGCCCAGCA TGGTCTGGCT 1680 TAGTGCCAAC CCCTGTCCTC ACTGTGGGGA CAGAACCTTC TATGACCCGG AGCCCATCCT 1740 GTGCCCCTGT TTCATGCCTA ACTAGCTGGG TGCACATATC AAATGCTTCA TTCTGCATAC 1800 TTGGACACTA AAGCCAGGAT GTGCATGCAT CTTGAAGCAA CAAAGCAGCC ACAGTTTCAG 1860 ACAAATGTTC AGTGTGAGTG AGGAAAACAT GTTCAGTGAG GAAAAAACAT TCAGACAAAT 1920 70 GTTCAGTGAG GAAAAAAAGG GGAAGTTGGG GATAGGCAGA TGTTGACTTG AGGAGTTAAT 1980

Seq ID NO: 110 Protein sequence; Protein Accession #: NP_006106.1





AQLVTGTSFS GPTVGMAIQN SICSPDFSGG VNMDHSTSIL GVASSIAHEL GHSLGLDHDL 360

AATGCACTAC TGTGTGCTGA GCGCTTTTCT GATCCTGCAT CTGGTCACGG TCGCGCTCAG 240 CCTGTCTACC TGCAGCACAC TCGATATGGA CCAGTTCATG CGCAAGAGGA TCGAGGCGAT 300 CCGCGGGCAG ATCCTGAGCA AGCTGAAGCT CACCAGTCCC CCAGAAGACT ATCCTGAGCC 360 5 CGAGGAAGTC CCCCCGGAGG TGATTTCCAT CTACAACAGC ACCAGGGACT TGCTCCAGGA 420 GAAGGCGAGC CGGAGGGCGG CCGCCTGCGA GCGCGAGAGG AGCGACGAAG AGTACTACGC 480 CAAGGAGGTT TACAAAATAG ACATGCCGCC CTTCTTCCCC TCCGAAAATG CCATCCCGCC 540
CACTTTCTAC AGACCCTACT TCAGAATTGT TCGATTTGAC GTCTCAGCAA TGGAGAAGAA 600 TGCTTCCAAT TTGGTGAAAG CAGAGTTCAG AGTCTTTCGT TTGCAGAACC CAAAAGCCAG 660 10 AGTGCCTGAA CAACGGATTG AGCTATATCA GATTCTCAAG TCCAAAGATT TAACATCTCC 720 AACCCAGCGC TACATCGACA GCAAAGTTGT GAAAACAAGA GCAGAAGGCG AATGGCTCTC 780 CTTCGATGTA ACTGATGCTG TTCATGAATG GCTTCACCAT AAAGACAGGA ACCTGGGATT 840 TAAAATAAGC TTACACTGTC CCTGCTGCAC TTTTGTACCA TCTAATAATT ACATCATCCC 900 AAATAAAAGT GAAGAACTAG AAGCAAGATT TGCAGGTATT GATGGCACCT CCACATATAC 960 15 CAGTGGTGAT CAGAAAACTA TAAAGTCCAC TAGGAAAAAA AACAGTGGGA AGACCCCACA 1020 TCTCCTGCTA ATGTTATTGC CCTCCTACAG ACTTGAGTCA CAACAGACCA ACCGGCGGAA 1080 GAAGCGTGCT TTGGATGCGG CCTATTGCTT TAGAAATGTG CAGGATAATT GCTGCCTACG 1140 TCCACTTTAC ATTGATTTCA AGAGGGATCT AGGGTGGAAA TGGATACACG AACCCAAAGG 1200 GTACAATGCC AACTTCTGTG CTGGAGCATG CCCGTATTTA TGGAGTTCAG ACACTCAGCA 1260 20 CAGCAGGGTC CTGAGCTTAT ATAATACCAT AAATCCAGAA GCATCTGCTT CTCCTTGCTG 1320 CGTGTCCCAA GATTTAGAAC CTCTAACCAT TCTCTACTAC ATTGGCAAAA CACCCAAGAT 1380 TGAACAGCTT TCTAATATGA TTGTAAAGTC TTGCAAATGC AGC<u>TAA</u>AATT CTTGGAAAAG 1440 TGGCAAGACC AAAATGACAA TGATGATGAT AATGATGATG ACGACGACAA CGATGATGCT 1500 TGTAACAAGA AAACATAAGA GAGCCTTGGT TCATCAGTGT TAAAAAAATTT TTGAAAAAGC 1560 25 GGTACTAGTT CAGACACTTT GGAAGTTTGT GTTCTGTTTG TTA AAACTGG CATCTGACAC 1620 AAAAAAAGTT GAAGGCCTTA TTCTACATTT CACCTACTTT GTAAGTGAGA GAGACAAGAA 1680 GCAAATTTTT TTAAA Seq ID NO: 116 Protein sequence: 30 Protein Accession #: NP_003229.1 31 41 MHYCVLSAFL ILHLVTVALS LSTCSTLDMD QFMRKRIEAI RGQILSKLKL TSPPEDYPEP 60 35 EEVPPEVISI YNSTRDLLQE KASRRAAACE RERSDEEYYA KEVYKIDMPP FFPSENAIPP 120 TFYRPYFRIV RFDVSAMEKN ASNLVKAEFR VFRLQNPKAR VPEQRIELYQ ILKSKDLTSP 180 TQRYIDSKVV KTRAEGEWLS FDVTDAVHEW LHHKDRNLGF KISLHCPCCT FVPSNNYIIP 240 NKSEELEARF AGIDGTSTYT SGDQKTIKST RKKNSGKTPH LLLMLLPSYR LESQQTNRRK 300 KRALDAAYCF RNVQDNCCLR PLYIDFKRDL GWKWIHEPKG YNANFCAGAC PYLWSSDTQH 360 40 SRVLSLYNTI NPEASASPCC VSQDLEPLTI LYYIGKTPKI EQLSNMIVKS CKCS Sea ID NO: 117 DNA sequence Nucleic Acid Accession #: NM_000095.1 Coding sequence: 26-2299 (underlined sequences correspond to start and stop codons) 45 31 51 CAGCACCCAG CTCCCCGCCA CCGCCATGGT CCCCGACACC GCCTGCGTTC TTCTGCTCAC 60 CCTGGCTGCC CTCGGCGCGT CCGGACAGGG CCAGAGCCCG TTGGGCTCAG ACCTGGGCCC 120 50 GCAGATGCTT CGGGAACTGC AGGAAACCAA CGCGGCGCTG CAGGACGTGC GGGACTGGCT 180
GCGGCAGCAG GTCAGGGAGA TCACGTTCCT GAAAAACACG GTGATGGAGT GTGACGCGTG 240
CGGGATGCAG CAGTCAGTAC GCACCGGCCT ACCCAGCGTG CGGCCCCTGC TCCACTGCGC 300 GCCCGGCTTC TGCTTCCCCG GCGTGGCCTG CATCCAGACG GAGAGCGGCG GCCGCTGCGG 360 CCCCTGCCC GCGGGCTTCA CGGGCAACGG CTCGCACTGC ACCGACGTCA ACGAGTGCAA 420 CGCCCACCCC TGCTTCCCCC GAGTCCGCTG TATCAACACC AGCCCGGGGT TCCGCTGCGA 480 GGCTTGCCCG CCGGGGTACA GCGGCCCCAC CCACCAGGGC GTGGGGCTGG CTTTCGCCAA 540 55 GGCCAACAAG CAGGTTTGCA CGGACATCAA CGAGTGTGAG ACCGGGCAAC ATAACTGCGT 600 CCCCAACTCC GTGTGCATCA ACACCCGGGG CTCCTTCCAG TGCGGCCCGT GCCAGCCCGG 660 CTTCGTGGGC GACCAGGCGT CCGCTGCCA GCGCGCGCA CAGCGCTTCT GCCCCGACGG 720 CTCGCCCAGC GAGTGCCACG AGCATGCAGA CTGCGTCCTA GAGCGCGATG GCTCGCGGTC 780 GTGCGTGTGT CGCGTTGGCT GGGCCGGCAA CGGGATCCTC TGTGGTCGCG ACACTGACCT 840 60 AGACGGCTTC CCGGACGAGA AGCTGCGCTG CCCGGAGCCG CAGTGCCGTA AGGACAACTG 900 GGTGACTGTG CCCAACTCAG GGCAGGAGGA TGTGGACCGC GATGGCATCG GAGACGCCTG 960
CGATCCGGAT GCCGACGAGGA CCGGGGTCCC CAATGAAAAG GACAACTGCC GCTGGTGCG 1020
GAACCCAGAC CAGCGCAACA CGGACGAGGA CAAGTGGGGC GATGCGTGCG ACAACTGCCG 1080
GTCCCAGAAG AACGACGACC AAAAGGACAC AGACCAGGAC GGCCGGGGCG ATGCGTGCGA 1140 65 CGACGACTC GACGGCGAC GGATCCGCAA CCAGGCCGAC AACTGCCCCTA GGGTACCCAA 1200
CTCAGACCAG AAGGACAGTG ATGGCGATGG TATAGGGGAT GCCTGTGACA ACTGTCCCCA 1260
GAAGAGCAAC CCGGATCAGG CGGATGTGGA CCACGACTTT GTGGGAGATG CTTGTGACAG 1320
CGATCAAGAC CAGGATGGAG ACGGACATCA GGACTCTCGG GACAACTGTC CCACGGTGCC 1380
TAACAGTGCC CAGGAGGACT CAGACCACGA TGGCCAGGGT GATGCCTGCG ACGACGACGA 70 CGACAATGAC GGAGTCCCTG ACAGTCGGGA CAACTGCCGC CTGGTGCCTA ACCCCGGCCA 1500 GGAGGACGCG GACAGGGACG GCGTGGGCGA CGTGTGCCAG GACGACTTTG ATGCAGACAA 1560 GGTGGTAGAC AAGATCGACG TGTGTCCGGA GAACGCTGAA GTCACGCTCA CCGACTTCAG 1620 75 GGCCTTCCAG ACAGTCGTGC TGGACCCGGA GGGTGACGCG CAGATTGACC CCAACTGGGT 1680 GGTGCTCAAC CAGGGAAGGG AGATCGTGCA GACAATGAAC AGCGACCCAG GCCTGGCTGT 1740 GGGTTACACT GCCTTCAATG GCGTGGACTT CGAGGGCACG TTCCATGTGA ACACGGTCAC 1800

TTGATTTCTT TTTTTTATT CTGACTTTTA AAAACAACTT TTTTTTCCAC TTTTTTAAAA 180

GGATGACGAC TATGCGGGCT TCATCTTTGG CTACCAGGAC AGCTCCAGCT TCTACGTGGT 1860
CATGTGGAAG CAGATGGAGC AAACGTATTG GCAGGCGAAC CCCTTCCGTG CTGTGGCCGA 1920
GCCTGGCATC CAACTCAAGG CTGTGAAGTC TTCCACAGGC CCCGGGGAAC AGCTGCGGAA 1980
CGCTCTGTGG CATACAGGAG ACACAGAGTC CCAGGTGCGG CTGCTGTGGA AGGACCCGCG 2040
AAACGTGGGT TGGAAGGACA AGAAGTCCTA TCGTTGGTTC CTGCAGCACC GGCCCCAAGT 2100
GGGCTACATC AGGGTGCGAT TCTATGAGGG CCCTGAGCTG GTGGCCGACA GCAACGTGGT 2160
CTTGGACACA ACCATGCGGG CTGCCCCCT GGGGTCTTC TGCTTCTCCC AGGAACAT 2220
CATCTGGGCC AACCTGCGTT ACCGCTGCAA TGACACCATC CCAGAGGACT ATGAGACCCA 2280
TCAGCTGCGG CAAGCCTAGG GACCAGGGTG AGGACCCC GGATGACAGC CACCCTCACC 2340
GCGGCTGGAT GGGGGCTCTG CACCCAGCCC AAGGGGTGGC CGTCCTGAGG GGGAAGTGAG 2400
AAGGGCTCAG AGAGGACAAA ATAAAGTGTG TGTGCAGGG

Seq ID NO: 118 Protein sequence:
Protein Accession #: NP_000086.1

15

30

35

55

60

65

70

75

20
WYPDTACVLL LTLAALGASG QGQSPLGSDL GPQMLRELQE TNAALQDVRD WLRQQVREIT 60
FLKNTVMECD ACGMQQSVRT GLPSVRPLLH CAPGFCFPGV ACIQTESGGR CGPCPAGFTG 120
NGSHCTDVNE CNAHPCFPRV RCINTSPGFR CEACPPGYSG PTHQGVGLAF AKANKQVCTD 180
INECETGQHN CVPNSVCINT RGSFQCGPCQ PGFVGDQASG CQRGAQRFCP DGSPSECHEH 240
ADCVLERDGS RSCVCRVGWA GNGILCGRDT DLDGFPDEKL RCPEPQCRKD NCVTVPNSCQ 300
EDVDRDGIGD ACDPDADGDG VPNEKDNCPL VRNPDQRNTD EDKWGDACDN CRSQKNDDQK 360
DTDQDGRGDA CDDDIDGDRI RNQADNCPRV PNSDQKDSDG DGIGDACDNC PQKSNPDQAD 420
VDHDFVGDAC DSDQDQDGDG HQDSRDNCPT VPNSAQEDSD HDGQGDACDD DDDNDGVPDS 480
RDNCRLVPNP GQEDADRDGV GDVCQDDFDA DKVVDKIDVC PENAEVTLTD FRAFQTVVLD 540
PEGDAQIDPN WVVLNQGREI VQTMNSDPGL AVGYTAFNGV DFEGTFHVNT VTDDDYAGFI 600
FGYQDSSSFY VVMWKQMEQT YWQANPFRAV AEPGIQLKAV KSSTGPGEQL RNALWHTGDT 660

ESQVRLLWKD PRNVGWKDKK SYRWFLQHRP QVGYIRVRFY EGPELVADSN VVLDTTMRGG 720

Seq ID NO: 119 DNA sequence
Nucleic Acid Accession #: NM_014211
Coding sequence: 157-1479 (underlined sequences correspond to start and stop codons)

RLGVFCFSQE NIIWANLRYR CNDTIPEDYE THQLRQA

31

ACCTACGTTC CTTCCACTTT CCTGGTGGTG TIGTCCTGGG TTTCATTTTG GATCTCTCC 960
GATTCAGTCC CTGCAAGAAC CTGCATTGGA GTGACGACCG TGTTATCAAT GACCACACTG 1020
ATGATCGGGT CCCGCACTTC TCTTCCCAAC ACCAACTGCT TCATCAAGGC ACTCGATGTG 1080
TACCTGGGGA TCTGCTTTAG CTTTGTTTT GGGGCCTTGC TAGAATATGC AGTTGCTCAC 1140
TACAGTTCCT TACAGCAGAT GCCAGCCAAA GATAGGGGGA CAACAAAGGA AGTAGAAGAA 1200
GTCAGTATTA CTAATATCAT CAACAGCTCC ATCTCCAGGCT TTAAACGGAA GATCAGCTTT 1260
GCCAGCATTG AAATTTCCAG CGACAACGTT GACTACAGTG ACTTGACAAT GAAAACCAGC 1320
GACAAGTTCA AGTTTGTCTT CCGAGAAAAG ATGGGCAGGA TTGTTGACTAT TTTTACACATT 1380
CAAAACCCCA GTAATGTTGA TCACTATTCC AAACTACTGT TTCCTTTGAT TTTTATGCTA 1440
GCCAATGTAT TTTACTGGGC ATACTACATG TATTTTTAGG TCAATGTTAA ATTTCTTGCA 1500

TACACTAGAT TGGTCTTACA GTTTGAGCTT CGGAGGAATG TTCTGTATTT CATTTTGGAA 900

CAAAACCCCA GTAATGTTGA TCACTATTCC AAACTACTGT TITCCTTTGAT TITTATGCTA 1440
GCCAATGTAT TTTACTGGGC ATACTACATG TATTITTGAG TCAATGTTAA ATTITCTTGCA 1500
TGCCATAGGT CTTCAACAGG ACAAGATAAT GATGTAAATG GTATTITAGG CCAAGTGTGC 1560
ACCCACATCC AATGGTGCTA CAAGTGACTG AAATAATATT TGAGTCTTTC TGCTCAAAGA 1620
ATGAAGCTCC AACCATTGTT CTAAACTGTG TAGAAGTCCT AGCATTATAG GATCTTGTAA 1680
TAGAAACATC AGTCCATTCC TCTITCATCT TAAATCAAGGA CATTCCATG GAGCCCAAGA 1740
TTACAAATGT ACTCAGGGCT GTTTATTCGG TGGCTCCCTG GTTTGCATTT ACCTCATATA 1800
AAGAATGGGA AGGAGCCAT TGGGTAACCC TCAAGTGTCA GAAGTTGTTT CTAAAAGTAAC 1860
TATACATGTT TTTTACTAAA TCTCTGCAGT GCTTATAAAA TACATTGTTG CCTATTTAGG 1920
GAGTAACATT TTCTAGTTTT TGTTTCTGGT TAAAATGAAA TATGGGCTTA TGTCAATTCA 1980
TTGGAAGTCA ATGCACTAAC TCAATACCAA GATGAGTTTT TAAATAATGA ATATTATTTA 2040

GAGTAACATT TTCTAGTTTT TGTTTCTGGT TAAAATGAAA TATGGGCTTA TGTCAATTCA 1980
TTGGAAGTCA ATGCACTAAC TCAATACCAA GATGAGTTTT TAAATAATGA ATATTATTA 2040
ATACCACAAC AGAATTATCC CCAATTTCCA ATAAGTCCTA TCATTGAAAA TTCAAATATA 2100
AGTGAAGAAA AAATTAGTAG ATCAACAATC TAAACAAATC CCTCGGTTCT AAGATACAAT 2160
GGATTCCCCA TACTGGAAGG ACTCTGAGGC TTTATTCCC CACTATGCAT ATCTTATCAT 2220
TTTATTATTA TACACACATC CATCCTAAAC TATACTAAAG CCCTTTTCCC ATGCATGGAT 2280

TTTATTA TACACACATC CATCCTAAAC TATACTAAAG CCCTTTTCCC ATGCATGGAT 2280 GGAAATGGAA GATTTTTTTG TAACITGTTC TAGAAGTCTT AATATGGGCT GTTGCCATGA 2340 AGGCTTGCAG AATTGAGTCC ATTITCTAGC TGCCTTTATT CACATAGTGA TGGGGTACTA 2400


AAAGTACTGG GTTGACTCAG AGAGTCGCTG TCATTCTGTC ATTGCTGCTA CTCTAACACT 2460 GAGCAACACT CTCCCAGTGG CAGATCCCCT GTATCATTCC AAGAGGAGCA TTCATCCCTT 2520 TGCTCTAATG ATCAGGAATG ATGCTTATTA GAAAACAAAC TGCTTGACCC AGGAACAAGT 2580 GGCTTAGCTT AAGTAAACTT GGCTTTGCTC AGATCCCTGA TCCTTCCAGC TGGTCTGCTC 2640 5 TGAGTGGCTT ATCCCGCATG AGCAGGAGCG TGCTGGCCCT GAGTACTGAA CTTTCTGAGT 2700 AACAATGAGA CACGTTACAG AACCTATGTT CAGGTTGCGG GTGAGCTGCC CTCTCCAAAT 2760 CCAGCCAGAG ATGCACATTC CTCGGCCAGT CTCAGCCAAC AGTACCAAAA GTGATTTTTG 2820 AGTGTGCCAG GGTAAAGGCT TCCAGTTCAG CCTCAGTTAT TTTAGACAAT CTCGCCATCT 2880 TTAATTTCTT AGCTTCCTGT TCTAATAAAT GCACGGCTTT ACCTTTCCTG TCAGAAATAA 2940 10 ACCAAGGCTC TAAAAGATGA TTTCCCTTCT GTAACTCCCT AGAGCCACAG GTTCTCATTC 3000 CTTTTCCCAT TATACTTCTC ACAATTCAGT TTCTATGAGT TTGATCACCT GATTTTTTTA 3060 ACAAAATATT TCTAACGGGA ATGGGTGGGA GTGCTGGTGA AAAGAGATGA AATGTGGTTG 3120
TATGAGCCAA TCATATTTGT GATTTTTTAA AAAAAGTTTA AAAGGAAATA TCTGTTCTGA 3180 AACCCCACTT AAGCATTGTT TTTATATAAA AACAATGATA AAGATGTGAA CTGTGAAATA 3240 15 AATATACCAT ATTAGCTACC CACC Seq ID NO: 120 Protein sequence: Protein Accession #: 20 31 MNYSLHLAFV CLSLFTERMC IQGSQFNVEV GRSDKLSLPG FENLTAGYNK FLRPNFGGEP 60 VQIALTLDIA SISSISESNM DYTATIYLRQ RWMDQRLVFE GNKSFTLDAR LVEFLWVPDT 120
YIVESKKSFL HEVTVGNRLI RLFSNGTVLY ALRITITVAC NMDLSKYPMD TQTCKLQLES 180 25 WGYDGNDVEF TWLRGNDSVR GLEHLRLAQY TIERYFTLVT RSQQETGNYT RLVLQFELRR 240 NVLYFILETY VPSTFLVVLS WYSFWISLDS VPARTCIGVT TVLSMTTLMI GSRTSLPNTN 300 CFIKAIDVYL GICFSFVFGA LLEYAVAHYS SLQQMAAKDR GTTKEVEEVS ITNIINSSIS 360 SFKRKISFAS IEISSDNVDY SDLTMKTSDK FKFVFREKMG RIVDYFTIQN PSNVDHYSKL 420 LFPLIFMLAN VFYWAYYMYF 30 Sea ID NO: 121 DNA sequence NM 001854 Nucleic Acid Accession #: Coding sequence: 163-5582 (underlined sequences correspond to start and stop codons) 35 AACCATCAAA TTTAGAAGAA AAAGCCCTTT GACTTTTTCC CCCTCTCCCT CCCCAATGGC 60 TGTGTAGCAA ACATCCCTGG CGATACCTTG GAAAGGACGA AGTTGGTCTG CAGTCGCAAT 120 TTCGTGGGTT GAGTTCACAG TTGTGAGTGC GGGGCTCGGA GATGGAGCCG TGGTCCTCTA 180 40 GGTGGAAAAC GAAACGTGG CTCTGGGATT TCACCGTAAC AACCCTCGCA TTGACCTTCC 240
TCTTCCAAGC TAGAGAGGGTC AGAGGAGCTG CTCCAGTTGA TGTACTAAAA GCACTAGATT 300
TTCACAATTC TCCAGAGGGA ATATCAAAAA CAACGGGATT TTGCACAAAC AGAAAGAATT 360 CTAAAGGCTC AGATACTGCT TACAGAGTTT CAAAGCAAGC ACAACTCAGT GCCCCAACAA 420 AACAGTTATT TCCAGGTGGA ACTITICCCAG AAGACTITIC AATACTATTT ACAGTAAAAC 480
CAAAAAAAG AATTCAGTCT TTCCTTTTAT CTATATATAA TGAGCATGGT ATTCAGCAAA 540
TTGGTGTTGA GGTTGGGAGA TCACCTGTTT TTCTGTTTGA AGACCACACT GGAAAACCTG 600
CCCCAGAAGA CTATCCCCTC TTCAGAACTG TTAACATCGC TGACGGGAAG TGGCATCGGG 660 45 TAGCAATCAG CGTGGAGAAG AAAACTGTGA CAATGATTGT TGATTGTAAG AAGAAAACCA CGAAACCACT TGATAGAAGT GAGAGAGCAA TTGTTGATAC CAATGGAATC ACGGTTTTTG 780 50 GAACAAGGAT TTTGGATGAA GAAGTTTTTG AGGGGGACAT TCAGCAGTTT TTGATCACAG 840 GTGATCCCAA GGCAGCATAT GACTACTGTG AGCATTATAG TCCAGACTGT GACTCTTCAG 900 CACCCAAGGC TGCTCAAGCT CAGGAACCTC AGATAGATGA GTATGCACCA GAGGATATAA 960 CACCCAAGG IGCICAAGGI CAGGAACCIC AGATAGATGA GIATGAACACA GAGGAITAA 960
TCGAATATGA CTATGAGTAT GGGGAAGCAG AGTATAAAAGAG GGCTGAAAGT GTAACAGAGG 1020
GACCCACTGT AACTGAGGAG ACAATAGCAC AGACGGAGGC AAACATCGTT GATGATTTTC 1080
AAGAATACAA CTATGGAACA ATGGAAAGTT ACCAGACAGA AGCTCCTAGG CATGTTTCTG 1140
GGACAAATGA GCCAAATCCA GTTGAAGAAA TATTTACTGA AGAATATCTA ACGGGAGAG 1200 55 ATTATGATTC CCAGAGGAAA AATTCTGAGG ATACACTATA TGAAAACAAA GAAATAGACG 1260 GCAGGGATTC TGATCTTCTG GTAGATGGAG ATTTAGGCGA ATATGATTTT TATGAATATA 1320 AAGAATATGA AGATAAACCA ACAAGCCCC CTAATGAAGA ATTTGGTCCA GGTGTACCAG 1380 CAGAAACTGA TATTACAGAA ACAAGCATAA ATGGCCATGG TGCATATGGA GAGAAAGGAC 1440 60 AGAAAGGAGA ACCAGCAGTG GTTGAGCCTG GTATGCTTGT CGAAGGACCA CCAGGACCAG 1500 CAGGACCTGC AGGTATTATG GGTCCTCCAG GTCTACAAGG CCCCACTGGA CCCCCTGGTG 1560 ACCCTGGCGA TAGGGGCCCC CCAGGACGTC CTGGCTTACC AGGGGCTGAT GGTCTACCTG 1620
GTCCTCCTGG TACTATGTTG ATGTTACCGT TCCGTTATGG TGGTGATGGT TCCAAAGGAC 1680
CAACCATCTC TGCTCAGGAA GCTCAGGCTC AAGCTATTCT TCAGCAGGCT CGGATTGCTC 1740 65 TGAGAGGCCC ACCTGGCCCA ATGGGTCTAA CTGGAAGACC AGGTCCTGTG GGGGGGCCTG 1800 GTTCATCTGG GGCCAAAGGT GAGAGTGGTG ATCCAGGTCC TCAGGGCCCT CGAGGCGTCC 1860 AGGGTCCCCC TGGTCCAACG GGAAAACCTG GAAAAAGGGG TCGTCCAGGT GCAGATGGAG 1920 GAAGAGGAAT GCCAGGAGAA CCTGGGGCAA AGGGAGATCG AGGGTTTGAT GGACTTCCGG 1980 GTCTGCCAGG TGACAAAGGT CACAGGGGTG AACGAGGTCC TCAAGGTCCT CCAGGTCCTC 2040 70 CTGGTGATGA TGGAATGAGG GGAGAAGATG GAGAAATTGG ACCAAGAGGT CTTCCAGGTG 2100 AAGCTGGCCC ACGAGGTTTG CTGGGTCCAA GGGAACTCC AGGAGCTCCA GGCAGCCTG 2160 GTATGGCAGG TGTAGATGGC CCCCCAGGAC CAAAAGGGAA CATGGGTCCC CAAGGGAGC 2220 CTGGGCCTCC AGGTCAACAA GGGAATCCAG GACCTCAGGG TCTTCCTGGT CCACAAGGTC 2280 CAATTGGTCC TCCTGGTGAA AAAGGACCAC AAGGAAAACC AGGACTTGCT GGACTTCCTG 2240 GTGCTGATGG GCCTCCTGGT CATCCTGGGA AAGAAGGCCA GTCTGGAGAA AAGGGGGCTC 2400 75 TGGGTCCCCC TGGTCCACAA GGTCCTATTG GATNNCCGGG CCCCCGGGGA GTAAAGGGAG 2460

CAGATGGTGT CAGAGGTCTC AAGGGATCTA AAGGTGAAAA GGGTGAAGAT GGTTTTCCAG 2520 GATTCAAAGG TGACATGGGT CTAAAAGGTG ACAGAGGAGA AGTTGGTCAA ATTGGCCCAA 2580 GAGGGNAAGA TGGCCCTGAA GGACCCAAAG GTCGAGCAGG CCCAACTGGA GACCCAGGTC 2640 CTTCAGGTCA AGCAGGAGAA AAGGGAAAACTTGGAGTTCC AGGATTACCA GGATATCCAG 2700 5 GAAGACAAGG TCCAAAGGGT TCCACTGGAT TCCCTGGGTT TCCAGGTGCC AATGGAGAGA 2760 AAGGTGCACG GGGAGTAGCT GGCAAACCAG GCCCTCGGGG TCAAGGTGC 2820
CTCGAGGTTC AAGAGGTGCA AGAGGTCCCA CTGGGAAACC TGGGCCAAAG GGCACTTCAG 2880
GTGGCGATGG CCCTCCTGGC CCTCCAGGTG AAAGAGGTCC TCAAGGACCT CAGGGTCCAG 2940 TTGGATTCCC TGGACCAAAA GGCCCTCCTG GACCACCAGG AAGGATGGGC TGCCCAGGAC 3000 10 ACCCTGGGCA ACGTGGGGAG ACTGGATTTC AAGGCAAGAC CGGCCCTCCT GGGCCAGGGG 3060 GAGTGGTTGG ACCACAGGGA CCAACCGGTG AGACTGGTCC AATAGGGGAA CGTGGGTATC 3120 CTGGTCCTCC TGGCCCTCCT GGTGAGCAAG GTCTTCCTGG TGCTGCAGGA AAAGAAGGTG 3180 CAAAGGGTGA TCCAGGTCCT CAAGGTATCT CAGGGAAAGA TGGACCAGCA GGATTACGTG 3240 GTTTCCCAGG GGAAAGAGGT CTTCCTGGAG CTCAGGGTGC ACCTGGACTG AAAGGAGGGG 3300 15 AAGGTCCCCA GGGCCCACCA GGTCCAGTTG GCTCACCAGG AGAACGTGGG TCAGCAGGTA 3360 CAGCTGGCCC AATTGGTTTA CGAGGGCGCC CGGGACCTCA GGGTCCTCCT GGTCCAGCTG 3420 GAGAGAAAGG TGCTCCTGGA GAAAAAGGTC CCCAAGGGCC TGCAGGGAGA GATGGAGTTC 3480 AAGGTCCTGT TGGTCTCCCA GGGCCAGCTG GTCCTGCCGG CTCCCCTGGG GAAGACGGAG 3540 ACAAGGGTGA AATTGGTGAG CCGGGACAAA AAGGCAGCAA GGGTGGCAAG GGAGAAAATG 3600 20 GCCCTCCCGG TCCCCCAGGT CTTCAAGGAC CAGTTGGTGC CCCTGGAATT GCTGGAGGTG 3660 ATGGTGAACC AGGTCCTAGA GGACAGCAGG GGATGTTTGG GCAAAAAGGT GATGAGGGTG 3720 CCAGAGGCTT CCCTGGACCT CCTGGTCCAA TAGGTCTTCA GGGTCTGCCA GGCCCACCTG 3780 GTGAAAAAGG TGAAAATGGG GATGTTGGTC CATGGGGGCC ACCTGGTCCT CCAGGCCCAA 3840 GAGGCCCTCA AGGTCCCAAT GGAGCTGATG GACCACAAGG ACCCCCAGGT TCTGTTGGTT 3900 25 CAGTTGGTGG TGTTGGAGAA AAGGGTGAAC CTGGAGAAGC AGGAAACCCA GGGCCTCCTG 3960 GGGAAGCAGG TGTAGGCGGT CCCAAAGGAG AAAGAGGAGA GAAAGGGGAA GCTGGTCCAC 4020 CTGGAGCTGC TGGACCTCCA GGTGCCAAGG GGCCGCCAGG TGATGATGGC CCTAAGGGTA 4080 ACCCGGGTCC TGTTGGTTTT CCTGGAGATC CTGGTCCTCC TGGGGAACTT GGCCCTGCAG 4140 GTCAAGATGG TGTTGGTGGT GACAAGGGTG AAGATGGAGA TCCTGGTCAA CCGGGTCCTC 4200 30 CTGGCCCATC TGGTGAGGCT GGCCCACCAG GTCCTCCTGG AAAACGAGGT CCTCCTGGAG 4260 CTGCAGGTGC AGAGGGAAGA CAAGGTGAAA AAGGTGCTAA GGGGGAAGCA GGTGCAGAAG 4320 GTCCTCCTGG AAAAACCGGC CCAGTCGGTC CTCAGGGACC TGCAGGAAAG CCTGGTCCAG 4380 AAGGTCTTCG GGGCATCCCT GGTCCTGTGG GAGAACAAGG TCTCCCTGGA GCTGCAGGCC 4440 AAGATGGACC ACCTGGTCCT ATGGGACCTC CTGGCTTACC TGGTCTCAAA GGTGACCCTG 4500 ACTICCAAGGG TGAAAAGGGA CATCCTGGTT TAATTGGCCT GATTGGTCCT CCAGGAGAAC 4560
AAGGGGAAAA AGGTGACCGA GGGCTCCCTG GAACTCAAGG ATCTCCAGGA GCAAAAGGGG 4620
ATGGGGGAAT TCCTGGTCCT GCTGGTCCCT TAGGTCCACC TGGTCCTCCA GGCTTACCAG 4680 35 GTCCTCAAGG CCCAAAGGGT AACAAAGGCT CTACTGGACC CGCTGGCCAG AAAGGTGACA 4740 GTGGTCTTCC AGGGCCTCCT GGGCCTCCAG GTCCACCTGG TGAAGTCATT CAGCCTTTAC 4800 CAATCTTGTC CTCCAAAAAA ACGAGAAGAC ATACTGAAGG CATGCAAGCA GATGCAGATG 4860 ATAATATTCT TGATTACTCG GATGGAATGG AAGAAATATT TGGTTCCCTC AATTCCCTGA 4920 AACAAGACAT CGAGCATATG AAATTTCCAA TGGGTACTCA GACCAATCCA GCCCGAACTT 4980 40 GTAAAGACCT GCAACTCAGC CATCCTGACT TCCCAGATGG TGAATATTGG ATTGATCCTA 5040 ACCAAGGTTG CTCAGGAGAT TCCTTCAAAG TTTACTGTAA TTTCACATCT GGTGGTGAGA 5100 CTTGCATTTA TCCAGACAAA AAATCTGAGG GAGTAAGAAT TTCATCATGG CCAAAGGAGA 5160 45 AACCAGGAAG TTGGTTTAGT GAATTTAAGA GGGGAAAACT GCTTTCATAC TTAGATGTTG 5220 AAGGAAATTC CATCAATATG GTGCAAATGA CATTCCTGAA ACTTCTGACT GCCTCTGCTC 5280 GGCAAAATTT CACCTACCAC TGTCATCAGT CAGCAGCCTG GTATGATGTG TCATCAGGAA 5340 GTTATGACAA AGCACTTCGC TTCCTGGGAT CAAATGATGA GGAGATGTCC TATGACAATA 5400 ATCCTTTTAT CAAAACACTG TATGATGGTT GTACGTCCAG AAAAGGCTAT GAAAAAACTG 5460 TCATTGAAAT CAATACACCA AAAATTGATC AAGTACCTAT TGTTGATGTC ATGATCAGTG 5520 50 ACTITGGTGA TCAGAATCAG AAGTTCGGAT TTGAAGTTGG TCCTGTTTGT TTTCTTGGCT 5580 AAGATTAAGA CAAAGAACAT ATCAAATCAA CAGAAAATGT ACCTTGGTGC CACCAACCCA 5640
TTTTGTGCCA CATGCAAGTT TTGAATAAGG ATGTATGGAA AACAACGCTG CATATACAGG 5700
TACCATTTAG GAAATACCGA TGCCTTTGTG GGGGCAGAAT CACAGACAAA AGCTTTGAAA 5760 55 ATCATAAAGA TATAAGTTGG TGTGGCTAAG ATGGAAACAG GGCTGATTCT TGATTCCCAA 5820 TICTCAACTC TCCTTTTCCT ATTTGAATTT CTTTGGTGCT GTAGAAAACA AAAAAAGAAA 5880 AATATATT CATAAAAAT ATGGTGCTCA TTCTCATCCA TCCAGGATGT ACTAAAACAG 5940 TGTGTTTAAT AAATTGTAAT TATTTTGTGT ACAGTTCTAT ACTGTTATCT GTGTCCATTT 6000 CCAAAACTTG CACGTGTCCC TGAATTCCGC TGACTCTAAT TTATGAGGAT GCCGAACTCT 6060 GATGGCAATA ATATGTAT TATGAAAATG AAGTTATGAT TTCCGATGAC CCTAAGTCCC 6120 60 TTTCTTTGGT TAATGATGAA ATTCCTTTGT GTGTGTTT


Seq ID NO: 122 Protein sequence:
Protein Accession #: NP_001845

31

GADGLPGPPG TMLMLPFRYG GDGSKGPTIS AQEAQAQAIL QQARIALRGP PGPMGLTGRP 540 GPVGGPGSSG AKGESGDPGP QGPRGVQGPP GPTGKPGKRG RPGADGGRGM PGEPGAKGDR 600 GFDGLPGLPG DKGHRGERGP QGPPGPPGDD GMRGEDGEIG PRGLPGEAGP RGLLGPRGTP 660 GAPGQPGMAG VDGPPGPKGN MGPQGEPGPP GQQGNPGPQG LPGPQGPIGP PGEKGPQGKP 720 5 GLAGLFGADG PPGHPGKEG SGEKGALGPP GPGPIGXPG PRGVKGADGV RGLKGSKGEK 780
GEDGFFGFKG DMGLKGDRGE VGQIGPRGXD GPEGPKGRAG PTGDPGPSGQ AGEKGKLGVP 840
GLPGYPGRQG PKGSTGFPGF PGANGEKGAR GVAGKPGPRG QRGPTGPRGS RGARGPTGKP 900
GPKGTSGGDG PPGPPGERGP QGPQGPVGFP GPKGPPGPPG RMGCPGHPGQ RGETGFQGKT 960 GPPGPGGVVG PQGPTGETGP IGERGYPGPP GPPGEQGLPG AAGKEGAKGD PGPQGISGKD 1020 10 GPAGLRGFPG ERGLPGAQGA PGLKGGEGPQ GPPGPVGSPG ERGSAGTAGP IGLRGRPGPQ 1080 GPPGPAGEKG APGEKGPQGP AGRDGVQGPV GLPGPAGPAG SPGEDGDKGE IGEPGKGSK 1140
GGKGENGPPG PPGLQGPVGA PGIAGGDGEF GPRGQQGMFG QKGDEGARGF PGPPGPIGLQ 1200
GLPGPPGEKG ENGDVGPWGP PGPPGPRGPQ GPNGADGPQG PPGSVGSVGG VGEKGEPGEA 1260
GNPGPPGEAG VGGPKGERGE KGEAGPPGAA GPPGAKGPPG DDGPKGNPGP VGFPGDPGPP 1320 15 GELGPAGQDG VGGDKGEDGD PGQPGPPGPS GEAGPPGPPG KRGPPGAAGA EGRQGEKGAK 1380 GEAGAEGPPG KTGPVGPQGP AGKPGPEGLR GPGPVGEQG LPGAAGQDGP PGPMGPPGLP 1440 GLKGDPGSKG EKGHPGLIGL IGPPGEQGEK GDRGLPGTQG SPGAKGDGGI PGPAGPLGPP 1500 GPPGLPGPQG PKGNKGSTGP AGQKGDSGLP GPPGPPGPPG EVIQPLPILS SKKTRRHTEG 1560 MQADADDNIL DYSDGMEEIF GSLNSLKQDI EHMKFPMGTQ TNPARTCKDL QLSHPDFPDG 1620 20 EYWIDPNQGC SGDSFKVYCN FTSGGETCIY PDKKSEGVRI SSWPKEKPGS WFSEFKRGKL 1680 LSYLDVEGNS INMVQMTFLK LLTASARQNF TYHCHQSAAW YDVSSGSYDK ALRFLGSNDE 1740 EMSYDNNPFI KTLYDGCTSR KGYEKTVIEI NTPKIDQVPI VDVMISDFGD QNQKFGFEVG 1800 **PVCFLG** 25 Seq ID NO: 123 DNA sequence Nucleic Acid Accession #: NM_015886 Coding sequence: 485-1261 (underlined sequences correspond to start and stop codons) 30 GAATTCCCCC CCCCCCCCC TCACTTGGTG TGTCTATATG TCTGGCAGAC ATTATCAGCA 60 CATTCTCTGT TGTTACCTGT GATTCATTTT TTCTTCACTC TCCAGGTGAA TTTCAATTGC 120 TGAAAATTTC CCACTGAAAA TATGCAGTAA TATATTTTGT GGTTCAGACA TTTGGGGCAA 180 ATGGTTCACA TTCATTTTAG GGTTAGTGGT CATGCTGTTT ATTTTTCTCT GCTATACAAA 240 35 GTTCCTCTTA GGGGTCTGCC TCATGACACT AAAAAATGAA TAGAGATTCT ACTGTAGGTT 300 ATCTCCTAGG CTTGAGTTCA ACATTTGTTT GGATTTTTGA AGAAAGTCAA ATCAAGCAAT 360 GCTCCCAAAT GATGTCTTTG TAAATTCATA CCCTCTGGCC CTATTTTTTT TCATAGACCC 420 TAACTCTACC TTTCTGCTTT AAAGCAAAGT AAACTCGGTG GCCTCTTCTT CTCCACCCCT 480 CAAAATGATA GCAATCTCTG CCGTCAGCAG TGCACTCCTG TTCTCCCTTC TCTGTGAAGC 540 40 AAGTACCGTC GTCCTACTCA ATTCCACTGA CTCATCCCCG CCAACCAATA ATTTCACTGA 600
TATTGAAGCA GCTCTGAAAG CACAATTAGA TTCAGCGGAT ATCCCCAAAG CCAGGCGGAA 660
GCGCTACATT TCGCAGAATG ACATGATCGC CATTCTTGAT TATCATAATC AAGTTCGGGG 720 CAAAGTGTTC CCACCGGCAG CAAATATGGA ATATATGGTT TGGGATGAAA ATCTTGCAAA 780 ATCGGCAGAG GCTTGGGCGG CTACTTGCAT TTGGGACCAT GGACCTTCTT ACTTACTGAG 840 45 ATTTTTGGGC CAAAATCTAT CTGTACGCAC TGGAAGATAT CGCTCTATTC TCCAGTTGGT 900 CAAGCCATGG TATGATGAAG TGAAAGATTA TGCTTTTCCA TATCCCCAGG ATTGCAACCC 960 CAGATGTCCT ATGAGATGTT TTGGTCCCAT GTGCACACAT TATACGCAGA TGGTTTGGGC 1020 CACTTCCAAT CGGATAGGAT GCGCAATTCA TGCTTGCCAA AACATGAATG TTTGGGGATC 1080 50 AGTTTACCTT TTCCTCCAGG AAATATAATG ATTTCTGGGA ACATGGGCAT GTATATATAT 1320 ATATGGAGAG AGAATTITGC ACATATTATA CATATTITGT GCTAATCTTG TTTTCCTCTT 1380 AGTATTCCTT TGTATAAATT AGTGTTTGTC TAGCATGTTT GTTTAATCCT TTGGGAATTC 55 Seq ID NO: 124 Protein sequence: NP_056970.1 Protein Accession #: 31 60 MIAISAVSSA LLFSLLCEAS TVVLLNSTDS SPPTNNFTDI EAALKAQLDS ADIPKARRKR 60 YISQNDMIAI LDYHNQVRGK VFPPAANMEY MVWDENLAKS AEAWAATCIW DHGPSYLLRF 120 LGQNLSVRTG RYRSILQLVK PWYDEVKDYA FPYPQDCNPR CPMRCFGPMC THYTQMVWAT 180 SNRIGCAIHA CQNMNVWGSV WRRAVYLVCN YAPKGNWIGE APYKVGVPCS SCPPSYGGSC 240 TDNLCFPGVT SNYLYWFK 65 Seq ID NO: 125 DNA sequence Nucleic Acid Accession #: NM 001793 70 Coding sequence: 54-2543 (underlined sequences correspond to start and stop codons) 31 GCGGAACACC GGCCGCCGT CGCGGCAGCT GCTTCACCCC TCTCTCTGCA GCCATGGGGC 60 75 TCCCTCGTGG ACCTCTCGCG TCTCTCCTCC TTCTCCAGGT TTGCTGGCTG CAGTGCGCGG 120 CCTCCGAGCC GTGCCGGGCG GTCTTCAGGG AGGCTGAAGT GACCTTGGAG GCGGGAGGCG 180 CGGAGCAGGA GCCCGGCCAG GCGCTGGGGA AAGTATTCAT GGGCTGCCCT GGGCAAGAGC 240



CAGCTCTGTT TAGCACTGAT AATGATGACT TCACTGTGCG GAATGGCGAG ACAGTCCAGG 300



PCT/US02/02242 WO 02/059377

MEYNKSHIQG AVHINCADKI SRRRLQQGKI TVLDLISCRE GKDSFKRIFS KEIIVYDENT 240 NEPSRVMPSO PLHIVLESLK REGKEPLVLK GGLSSFKONH ENLCDNSLQL QECREVGGGA 300 SAASSLLPQP IPTTPDIENA ELTPILPFLF LGNEQDAQDL DTMQRLNIGY VINVTTHLPL 360 YHYEKGLFNY KRLPATDSNK QNLRQYFEEA FEFIEEAHQC GKGLLIHCQA GVSRSATIVI 420 5 AYLMKHTRMT MTDAYKFVKG KRPIISPNLN FMGQLLEFEE DLNNGVTPRI LTPKLMGVET 480 Seq ID NO: 131 DNA sequence Nucleic Acid Accession #: NM_005409.3 10 Coding sequence: 94-378 (underlined sequences correspond to start and stop codons) 31 TTCCTTTCAT GTTCAGCATT TCTACTCCTT CCAAGAAGAG CAGCAAAGCT GAAGTAGCAG 60
CAACAGCACC AGCAGCAACA GCAAAAAACA AACATGAGT TGAAGGGCAT GGCTATAGCC 120
TTGGCTGTGA TATTGTGTGC TACAGTTGTT CAAGGCTTCC CCATGTTCAA AAGAGGACGC 180 15 TGTCTTTGCA TAGGCCCTGG GGTAAAAGCA GTGAAAGTGG CAGATATTGA GAAAGCCTCC 240 ATAATGTACC CAAGTAACAA CTGTGACAAA ATAGAAGTGA TTATTACCCT GAAAGAAAAT 300 AAAGGACAAC GATGCCTAAA TCCCAAATCG AAGCAAGCAA GGCTTATAAT CAAAAAAGTT 360 GAAAGAAAGA ATTTT<u>TAA</u>AA ATATCAAAAC ATÄTGAAGTC CTGGAAAAGG GCATCTGAAA 420 AACCTAGAAC AAGTTTAACT GTGACTACTG AAATGACAAG AATTCTACAG TAGGAAACTG 480 20 AGACTTTTCT ATGGTTTTGT GACTTTCAAC TTTTGTACAG TTATGTGAAG GATGAAAGGT 540 GGGTGAAAGG ACCAAAAACA GAAATACAGT CTTCCTGAAT GAATGACAAT CAGAATTCCA 600 CTGCCCAAAG GAGTCCAGCA ATTAAATGGA TTTCTAGGAA AAGCTACCTT AAGAAAGGCT 660 GGTTACCATC GGAGTTTACA AAGTGCTTTC ACGTTCTTAC TTGTTGTATT ATACATTCAT 720 25 GCATTTCTAG GCTAGAGAAC CTTCTAGATT TGATGCTTAC AACTATTCTG TTGTGACTAT 780 GAGAACATTT CTGTCTCTAG AAGTTATCTG TCTGTATTGA TCTTTATGCT ATATTACTAT 840 CTGTGGTTAC AGTGGAGACA TTGACATTAT TACTGGAGTC AAGCCCTTAT AAGTCAAAAA 900 CATCTATGTG TCGTAAAGCA TTCCTCAAAC ATTTTTTCAT GCAAATACAC ACTTCTTTCC 960 CCAAATATCA TGTAGCACAT CAATATGTAG GGAAACATTC TTATGCATCA TTTGGTTTGT 1020 30 TTTATAACCA ATTCATTAAA TGTAATTCAT AAAATGTACT ATGAAAAAAA TTATACGCTA 1080 TGGGATACTG GCAACAGTGC ACATATTTCA TAACCAAATT AGCAGCACCG GTCTTAATTT 1140 GATGTTTTTC AACTTTTATT CATTGAGATG TTTTGAAGCA ATTAGGATAT GTGTGTTTAC 1200 TGTACTTTTT GTTTTGATCC GTTTGTATAA ATGATAGCAA TATCTTGGAC ACATTTGAAA 1260 TACAAAATGT TTTTGTCTAC CAAAGAAAAA TGTTGAAAAA TAAGCAAATG TATACCTAGC 1320 35 AATCACTTTT ACTTTTTGTA ATTCTGTCTC TTAGAAAAAT ACATAATCTA ATCAATTTCT 1380 TTGTTCATGC CTATATACTG TAAAATTTAG GTATACTCAA GACTAGTTTA AAGAATCAAA 1440 Seq ID NO: 132 <u>Protein sequence:</u> Protein Accession #: NP_005400.1 40 11 21 31 41 51 45 MSVKGMAIAL AVILCATVVQ GFPMFKRGRC LCIGPGVKAV KVADIEKASI MYPSNNCDKI 60 EVIITLKENK GQRCLNPKSK QARLIIKKVE RKNF Seq ID NO: 133 DNA sequence NM_012342 Nucleic Acid Accession #: 50 Coding sequence: 373-1155 (underlined sequences correspond to start and stop codons) 41 51 CTGGCGCGGG CGGGAGCTGC GGCGGATACC CTTGCGTGCT GTGGAGACCC TACTCTCTTC 60 CTGGCGCGGG CGGGAGCTGC GGCGGATACC CTTGCGTGCT GTGGACCC TACCTCTCT 80 GCTGAGAACG GCCGCTAGCG GGGACTGAAG GCCGGGGGCC CACTCCCGAC CCGGGGCTAG 120 CGTGCGTCCC TAGAGTCGAG CGGGGCAAGG GAGCCAGTGG CCGCCGACGG GGGACCGGGA 180 AACTTTTCTG GGCTCCTGGA GAGCCCTGTA GCCGCGCTCC ATGCTCCGGC AGCGGCCCGA 240 AACCCAGCCC CGCCGCTGAC GGAGCCCGCC GCTCCGGGCA GGGCCCATGC CCTGCGCGCT 300 55 CCGGGGGTCG TAGCTGCCGC CGAGCCGGGG CTCCGGAAGC CGGCGGGGGC GCCGCGGCCG 360 60 ACAGACATCT GCCAAGCCAA ACAGGCCCGA AACCACTCTG GCACCACCAT ACCCACATTG 660
GAATGCTGTC ATGAAGACAT GTGCAATTAC AGAGGGCTGC ACGATGTTCT CTCTCCTCCC 720
AGGGGTGAGG CCTCAGGACA AGGAAACAGG TATCAGCATG ATGGTAGCAG AAACCTTATC 780
ACCAAGGTGC AGGAGCTGAC TTCTTCCAAA GAGTTGTGGT TCCGGGCAGC GGTCATTGCC 840
GTGCCCATTG CTGGAGGGCT GATTTTAGTG TTGCTTATTA TGTTGGCCCCT GAGGATGCTT 900 65 GTGCCATTG CTGGAGGGCT GATTTTAGTG TTGCTTATTA TGTTGGCCCT GAGGATGCTT 900
CGAAGTGAAA ATAAGAGGCT GCAGGATCAG CGGCAACAGA TGCTCTCCCG TTTGCACTAC 960
AGCTTTCACG GACACCATTC CAAAAAGGGG CAGGTTGCAA AGTTAGACTT GGAATGCATG 1020
GTGCCGGTCA GTGGGCACGA GAACTGCTGT CTGACCTGTG ATAAAATGAG ACAGCAGAC 1080
CTCAGCAACG ATAAGATCCT CTCGCTTGTT CACTGGGGCA TGTACAGTGG GCACGGGAAG 1140
CTGGAATTCG TATGACGGAG TCTTATCTGA ACTACACTTA CTGAACAGCT TGAAGGCCTT 1200
TTGAGTTCTG CTGGACAGGA GCACTTTATC TGAAGACAAA CTCATTTAAT CATCTTTGAG 1260
AGACAAAATG ACCTCTGCAA ACAGAATCTT GGATATTTCT TCTGAAGGAT TATTTGCACA 1320
GACTTAAATA CAGTTAAAATG TGTTATTTGC ATCCAAGGGA GCTGGAATTG AGTACCTAAA 1440

70

75

TTTGTACACA CTGTCACCAG GGTTATTTGC ATCCAAGGGA GCTGGAATTG AGTACCTAAA 1440

TAAACAAAAA TGTGCCCTAT GTAAGCTTCT ACATCTTGAT TTATTGTAAA GATTTAAAAG 1500 AAATATATAT ATTTTGTCTG A

Seq ID NO: 134 Protein sequence: 5 Protein Accession #: NP 036474.1 21 31 41 MDRHSSYIFI WLQLELCAMA VLLTKGEIRC YCDAAHCVAT GYMCKSELSA CFSRLLDPQN 60 10 SNSPLTHGCL DSLASTTDIC QAKQARNHSG TTIPTLEOCH EDMCNYRGLH DVLSPPRGEA 120 SGQGNRYQHD GSRNLITKVQ ELTSSKELWF RAAVIAVPIA GGLILVLLIM LALRMLRSEN 180 KRLQDQRQQM LSRLHYSFHG HHSKKGQVAK LDLECMVPVS GHENCCLTCD KMRQADLSND 240 KILSLVHWGM YSGHGKLEFV 15 Seq ID NO: 135 DNA sequence Nucleic Acid Accession #: NM_001627.1 Coding sequence: 64-1815 (underlined sequences correspond to start and stop codons) 20 CGGGACGACG CCCCTCCTG CGGCGTGGAC TCCGTCAGTG GCCCACCAAG AAGGAGGAGG 60
AATATGGAAT CCAAGGGGGC CAGTTCCTGC CGTCTGCTCT TCTGCCTCTT GATCTCCGCC 120
ACCGTCTTCA GGCCAGGCCT TGGATGGTAT ACTGTAAATT CAGCATATGG AGATACCATT 180 ATCATACCTT GCCGACTTGA CGTACCTCAG AATCTCATGT TTGGCAAATG GAAATATGAA 240
AAGCCCGATG GCTCCCCAGT ATTTATTGCC TTCAGATCCT CTACAAAGAA AAGTGTGCAG 300 25 TACGACGATG TACCAGAATA CAAAGACAGA TTGAACCTCT CAGAAAACTA CACTTTGTCT 360
ATCAGTAATG CAAGGATCAG TGATGAAAAG AGATTTGTGT GCATGCTAGT AACTGAGGAC 420
AACGTGTTTG AGGCACCTAC AATAGTCAAG GTGTTCAAGC AACCATCTAA ACCTGAAATT 480 GTAAGCAAAG CACTGTTTCT CGAAACAGAG CAGCTAAAAA AGTTGGGTGA CTGCATTTCA 540 30 GAAGACAGTT ATCCAGATGG CAATATCACA TGGTACAGGA ATGGAAAAGT GCTACATCCC 600 CTTGAAGGAG CGGTGGTCAT AATTTTTAAA AAGGAAATGG ACCAGTGAC TCAGCTCTAT 660 ACCATGACTT CCACCCTGGA GTACAAGACA ACCAAGGCTG ACATACAAAT GCCATTCACC 720 TGCTCGGTGA CATATTATGG ACCATCTGGC CAGAAAACAA TTCATTCTGA ACAGGCAGTA 780 TTTGATATTT ACTATCCTAC AGAGCAGGTG ACAATACAAG TGCTGCCACC AAAAAATGCC 840 ATCAAAGAAG GGGATAACAT CACTCTTAAA TGCTTAGGGA ATGGCAACCC TCCCCCAGAG 900
GAATTTTTGT TTTACTTACC AGGACAGCCC GAAGGAATAA GAAGCTCAAA TACTTACACA 960 35 CTGATGGATG TGAGGCGCAA TGCAACAGGA GACTACAAGT GTTCCCTGAT AGACAAAAA 1020 AGCATGATTG CTTCAACAGC CATCACAGTT CACTATTTGG ATTTGTCCTT AAACCCAAGT 1080 GGAGAAGTGA CTAGACAGAT TGGTGATGCC CTACCCGTGT CATGCACAAT ATCTGCTAGC 1140 40 AGGAATGCAA CTGTGGTATG GATGAAAGAT AACATCAGGC TTCGATCTAG CCCGTCATTT 1200 TCTAGTCTTC ATTATCAGGA TGCTGGAAAC TATGTCTGCG AAACTGCTCT GCAGGAGGTT 1260 GAAGGACTAA AGAAAAGAGA GTCATTGACT CTCATTGTAG AAGGCAAACC TCAAATAAAA 1320 ATGACAAAGA AAACTGATCC CAGTGGACTA TCTAAAACAA TAATCTGCCA TGTGGAAGGT 1380 TITICCAAAGC CAGCCATTCA GTGGACAATT ACTGGCAGTG GAAGCGTCAT AAACCAAACA 1440
GAGGAATCTC CTTATATTAA TGGCAGGTAT TATAGTAAAA TTATCATTTC CCCTGAAGAG 1500
AATGTTACAT TAACTTGCAC AGCAGAAAAC CAACTGGAGA GAACAGTAAA CTCCTTGAAT 1560
GTCTCTGCTA TAAGTATTCC AGAACACGAT GAGGCAGACG AGATAAGTGA TGAAAAACAGA 1620 45 GAAAAGGTGA ATGACCAGGC AAAACTAATT GTGGGAATCG TTGTTGGTCT CCTCCTTGCT 1680 GACATAGATGA ATGACCAGGC AAAACTAATT GTGGGAATGA THOTHGGTG TECETTOT 1080
GCCCTTGTTG CTGGTGTCGT CTACTGGCTG TACATGAAGA AGTCAAAGAC TGCATCAAAA 1740
CATGTAAACA AGGACCTCGG TAATATGGAA GAAAACAAAA AGTTAGAAGA AAACAATCAC 1800
AAAACTGAAG CC<u>TAA</u>GAGAG AAACTGTCCT AGTTGTCCAG AGATAAAAAT CATATAGACC 1860
AATTGAAGCA TGAACGTGGA TTGTATTTAA GACATAAACA AAGACATTGA CAGCAATTCA 1920 50 TIGGTTCAAGT ATTAAGCAGT TCATTCTACC AAGCTGTCAC AGGTTTTCAG AGAATTATCT 1980
CAAGTAAAAC AAATGAAATT TAATTACAAA CAATAAGAAC AAGTTTTGGC AGCCATGATA 2040
ATAGGTCATA TGTTGTGTTT GGTTCAATTT TTTTTCCGTA AATGCTCGCA CTGAGGATTT 2100
CTTTTTGGTT TGCCTTTTAT GTAAATTTTT TACGTAGCTA TTTTTATACA CTGTAAGCTT 2160 55 ATOMATATE 19ADCAGGIA CALLICIDAL ICLUALIGET ATCAGCAATG CUCCAAACTT 2280
TCTCATAAGC ACCTAAAACC CAAAAGGTGGC AGCTTGTGAA GATTGGGGAC ACTCATATTG 2340
CCCTAATTAA AAACTGTGAT TTTTATCACA AGGGAGGGA GGCCGAGAGT CAGACTGATA 2400
GACACCATAG GAGCCGACTC TTTGATATGC CACCAGCGAA CTCTCAGAAA TAAATCACAG 2460
ATGCATATAA ACCACATAC ATAATGGTAC TCCCAAACTG ACAATTTTAC CTATTCTGAA 2520 60 AAAGACATAA AACAGAATT 65 Seq ID NO: 136 Protein sequence: Protein Accession #: NP 001618.1 70 MESKGASSCR LLFCLLISAT VFRPGLGWYT VNSAYGDTII IPCRLDVPQN LMFGKWKYEK 60 PDGSPVFIAF RSSTKKSVQY DDVPEYKDRL NLSENYTLSI SNARISDEKR FVCMLVTEDN 120
VFEAPTIVKV FKQPSKPEIV SKALFLETEQ LKKLGDCISE DSVPDGNITW YRNGKVLHPL 180
EGAVVIIFKK EMDPVTQLYT MTSTLEYKTT KADIQMPFTC SVTYYGPSGQ KTIHSEQAVF 240
DIYYPTEQVT IQVLPPKNAI KEGDNITLKC LGNGNPPPEE FLFYLPGQPE GIRSSNTYTL 300
MDVRRNATGD YKCSLIDKKS MIASTAITVH YLDLSLNPSG EVTRQIGDAL PVSCTISASR 360

NATVVWMKDN IRLRSSPSFS SLHYQDAGNY VCETALQEVE GLKKRESLTL IVEGKPQIKM 420 TKKTDPSGLS KTIICHVEGF PKPAIQWTIT GSGSVINQTE ESPYINGRYY SKIIISPEEN 480

VTLTCTAENQ LERTVNSLNV SAISIPEHDE ADEISDENRE KVNDQAKLIV GIVVGLLLAA 540 LVAGVVYWLY MKKSKTASKH VNKDLGNMEE NKKLEENNHK TEA

5 Seq ID NO: 137 DNA sequence Nucleic Acid Accession #: XM_030559 Coding sequence: 1-119 (underlined sequences correspond to start and stop codons) 41 10 ATGAACCGCA GCCACCGGCA CGGGGCGGC AGCGGCTGCC TGGGCACTAT GGAGGTGAAG 60 AGCAAGTTTG GAGCTGAATT TCGTCGGTTT TCGCTGGAAA GATCAAAACT TGGAAAATTT 120
GAGGAGTTTT ATGGATTACT ACAACATGTT CATAAAATA ATGATGATAA TTATCACAAA 240
GCTATGCAG ACATCCATGG AGACTTACTA CCTATAAATA ATGATGATAA TTATCACAAA 240
GCTGTTTCAA CGGCCAATCC ACTGCTTAGG ATATTTATAC AAAAGAAGGA AGAAGCAGAC 300 15 TACAGTGCCT TTGGTACAGA CACGCTAATA AAGAAGAAGA ATGTTTTAAC CAACGTATTG 360 CGTCCTGACA ACCATAGAAA AAAGCCACAT ATAGTCATTA GTATGCCCCA AGACTTTAGA 420
CCTGTGCTT CTATTATAGA CGTGGATATT CTCCCAGAAA CGCATCGTAG GGTACGTCTT 480
TACAAATACG GCACGGAGAA ACCCCTAGGA TTCTACATCC GGGATGGCTC CAGTGTCAGG 540
GTAACACCAC ATGGCTTAGA AAAGGTTCCA GGGATCTTTA TATCCAGGCT TGTCCCAGGA 600
GGTCTGGCTC AAAGTACAGG ACTATTAGCT GTTAATGATG AAGTTTTAGA AGTTAATGGC 660 20 ATAGAAGTTT CAGGGAAGAG CCTTGATCAA GTAACAGACA TGATGATTGC AAATAGCCGT 720
AACCTCATCA TAACAGTGAG ACCGGCAAAC CAGAGGAATA ATGTTGTGAG GAACAGTCGG 780
ACTTCTGGCA GTTCCGGTCA GTCTACTGAT AACAGCCTTC TTGGCTACCC ACAGCAGATT 840
GAACCAAGCT TTGAGCCAGA GGATGAAGAC AGCGAAGAAG ATGACATTAT CATTGAAGAC 900
AATGGAGTGC CACAGCAGAT TCCAAAAGCT GTTCCTAATA CTGAGAGCCT GGAGTCATTA 960 25 ACACAGATAG AGCTAAGCTT TGAGTCTGGA CAGAATGGCT TTATTCCCTC TAATGAAGTG 1020 AGCTTAGCAG CCATAGCAAG CAGCTCAAAC ACGGAATTTG AAACACATGC TCCAGATCAA 1080 AAACTCTTAG AAGAAGATGG AACAATCATA ACATTA<u>TGA</u> 30 Seq ID NO: 138 <u>Protein sequence:</u> Protein Accession #: XP_030559 21 41 31 35 MNRSHRHGAG SGCLGTMEVK SKFGAEFRRF SLERSKPGKF EEFYGLLQHV HKIPNVDVLV 60 GYADHGDLL PINNDDNYHK AVSTANPLLR IFIQKKEEAD YSAFGTDTLI KKKNVLTNVL 120 RPDNHRKKPH IVISMPQDFR PVSSIIDVDI LPETHRRVRL YKYGTEKPLG FYIRDGSSVR 180 VTPHGLEKVP GIFISRLVPG GLAQSTGLLA VNDEVLEVNG IEVSGKSLDQ VTDMMIANSR 240 40 NLIITVRPAN QRNNVVRNSR TSGSSGQSTD NSLLGYPQQI EPSFEPEDED SEEDDIIIED 300 NGVPQQIPKA VPNTESLESL TQIELSFESG QNGFIPSNEV SLAAIASSSN TEFETHAPDQ 360 KILLEEDGTII TL

It is understood that the examples described above in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All publications, sequences of accession numbers, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

WHAT IS CLAIMED IS:

ī	1. A method of detecting a breast cancer-associated transcript in a cen		
2	from a patient, the method comprising contacting a biological sample from the patient with	ιa	
3	polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence		
4	as shown in Tables 1-25.		
1	2. The method of claim 1, wherein the biological sample comprises		
2	isolated nucleic acids.		
1	3. The method of claim 2, wherein the nucleic acids are mRNA.		
1	4. The method of claim 2, further comprising the step of amplifying		
2	nucleic acids before the step of contacting the biological sample with the polynucleotide.		
1	5. The method of claim 1, wherein the polynucleotide comprises a		
2	sequence as shown in Tables 1-25.		
1	6. The method of claim 1, wherein the polynucleotide is immobilized o		
2	6. The method of claim 1, wherein the polynucleotide is immobilized o a solid surface.	П	
۷.	a solid surface.		
1	7. The method of claim 1, wherein the patient is undergoing a therapeur	ti	
2	regimen to treat breast cancer.		
1	8. The method of claim 1, wherein the patient is suspected of having		
2	breast cancer.		
1	9. An isolated nucleic acid molecule consisting of a polynucleotide		
2	sequence as shown in Tables 1-25.		
۷	sequence as shown in Tables 1-23.		
1	10. The nucleic acid molecule of claim 9, which is labeled.		
l	11. An expression vector comprising the nucleic acid of claim 9.		
ı	12. A host cell comprising the expression vector of claim 11.		

1	13.	An isolated polypeptide which is encoded by a nucleic acid molecule	
2	having polynucleotide sequence as shown in Tables 1-25.		
1	14.	An antibody that specifically binds a polypeptide of claim 13.	
1	15.	The antibody of claim 14, further conjugated to an effector component.	
1	16.	The antibody of claim 15, wherein the effector component is a	
2	fluorescent label.		
1	17.	The antibody of claim 15, wherein the effector component is a	
2	radioisotope or a cytotoxic chemical.		
1	18.	The antibody of claim 15, which is an antibody fragment.	
1	19.	The antibody of claim 15, which is a humanized antibody	
1	20.	A method of detecting a breast cancer cell in a biological sample from	
2	a patient, the method comprising contacting the biological sample with an antibody of claim		
3	14.		
1	21.	The method of claim 20, wherein the antibody is further conjugated to	
2	an effector component.		
1	22.	The method of claim 21, wherein the effector component is a	
2	fluorescent label.		
1	23.	A method for identifying a compound that modulates a breast cancer-	
2	associated polypeptide, the method comprising the steps of:		
3	(i) contacting the compound with a breast cancer-associated polypeptide, the		
4	polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least		
5	80% identical to a sequence as shown in Tables 1-25; and		
6	(ii) determining the functional effect of the compound upon the polypeptide.		
1	24.	A drug screening assay comprising the steps of	

2 (i) administering a test compound to a mammal having breast cancer or a cell
3 isolated therefrom;
4 (ii) comparing the level of gene expression of a polynucleotide that selectively
5 hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-25 in a
6 treated cell or mammal with the level of gene expression of the polynucleotide in a control
7 cell or mammal, wherein a test compound that modulates the level of expression of the
8 polynucleotide is a candidate for the treatment of breast cancer.